﻿   Table of Contents
Title Page
Introduction
About the book
PSYCHIATRY
Integrative Psychiatry | J Luke
DSM-5 and the Fight for the Heart of Psychiatry | S Novella
Scientology’s War on Medicine | H Hall
Treating Pain Psychologically | S Novella
The Debate Is Over: Antidepressants DO Work Better Than Placebo | H Hall
“Postnatal depression blood test breakthrough” or Churnalism? | J Coyne
New Drug Is Effective for Post-Partum Depression, But There Are Drawbacks | H Hall
Depression Re-examined: A New Way to Look at an Old Puzzle | H Hall
Is Addiction a Disease? Yes and No | H Hall
Video Games and the Brain | S Novella
Is Gaming Addiction a Thing? | S Novella
Mental Illness Denial | S Novella
Psychology and Psychotherapy: How Much Is Evidence-Based? | H Hall
Improving mental health is a walk in the park (but mind the volcanoes) | J Bellamy
Psychodermatology? | H Hall
How To Approach Psychogenic Symptoms | S Novella
Standards in Behavioral Science | S Novella
Wearables and Wellness Populism: How Smart Watches Got MAHA’d | S Gavura
NEUROLOGY
Undermining the regulation of stem cell therapies in Italy: A warning for the future? | D Gorski
A Skeptic’s Guide to the Mind | H Hall
Brain Research in the 21st Century | S Novella
A New Collaborative in Neuroscience | S Novella
Your Brain In Space | S Novella
Neuroscience and Destiny | S Novella
Left Brain – Right Brain Myth | S Novella
Male and Female Brains are Different | S Novella
Mapping the Brain | S Novella
Hacking the Brain – A New Paradigm in Medicine | S Novella
The Brain is a Composite Organ | S Novella
Integrative Neurology – More Bait and Switch | S Novella
Preventing Traumatic Brain Injury | S Novella
The NFL and Brain Injury | S Novella
ALZHEIMERS
Declining Dementia | S Novella
FTC Slaps Down “Brain Training” Claims | S Novella
Fraud, Scientific Rigor, and Alzheimer’s Research | S Novella
FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab | S Zakaria
No evidence, no problem: A closer look at the aducanumab approval | S Gavura
FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s | S Novella
Another Controversial Alzheimer’s Drug | S Novella
FDA Approves Leqembi for Alzheimer’s | S Novella
Yet Another Alzheimer’s Drug | S Novella
New Review Casts Doubt On Alzheimers Drugs But Is Controversial | S Novella
MEND Protocol For Alzheimer’s Disease | S Novella
Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab) | S Gavura
Enbrel for Stroke and Alzheimer’s | S Novella
Vitamin E for Alzheimer’s | H Hall
Lithium and Alzheimer’s Disease | S Novella
What Is Brain Death? | S Novella
Exercise and Memory | S Novella
FDA Approves Controversial ALS Drug – Relyvrio | S Novella
ALS and the market for false hope | S Gavura
Real Time Computer Communication | S Novella
Mini-Brains for Disease Research | S Novella
MUTIPLE SCLEROSIS
Liberation Procedure for Multiple Sclerosis | S Novella
The First Multiple Sclerosis Patient | R Killeen
Venous Insufficiency in Multiple Sclerosis. Steven Novella.
The End for CCSVI | S Novella
Update on CCSVI and Multiple Sclerosis | S Novella
Brian Clement claims Hippocrates treatments “reverse” multiple sclerosis | J Bellamy
Brain Stimulation for Memory | S Novella
Paralyzed Patient Communicates with Brain Implant | S Novella
Helping the Paralyzed Walk | S Novella
In Animal Study, Nanobots Repair Spinal Cords | S Novella
Communicating with the Locked In (update) | S Novella
Cyborg Therapeutics | S Novella
Brain-Machine Interface | S Novella
Adding Sensation to Robotic Limbs | S Novella
Is there a natural treatment for tinnitus? | S Gavura
Daniel and Tana Amen’s Book The Brain Warrior’s Way: Standard Health Advice Mixed with Misinformation and Fanciful Ideas | H Hall
Mind Over Matter: The Brain’s Way of Healing | H Hall
The Limits of Neuroplasticity | S Novella
Neuroplasticity Nonsense Is Full of Red Flags | H Hall
Stem Cell Stroke Therapy | S Novella
The Bobath Concept for Cerebral Palsy and Stroke Rehabilitation | H Hall
Mirror Neurons and the Pitfalls of Brain Research | H Hall
Debunking Sleep Myths | S Novella
PET Scans Predict Coma Outcome | S Novella
Detecting Consciousness in the Vegetative | S Novella
A PANDAS Story | S Novella
ADHD
The ADHD Controversy | S Novella
Why Is ADHD On The Rise | S Novella
More questions about acetaminophen: Does it cause ADHD? | S Gavura
Music for ADHD? | S Novella
Redefining Dyslexia | S Novella
TIC’D OFF | G Richey
Use of Dental Appliances in the Management of Tourette Syndrome | G Ritchey & C Jones
More False Hope for People with Tourette Syndrome | C Jones
The Parasympathetic State | H Hall
Some essential oils may trigger seizures | S Gavura
Keto Diet for Neurological Disorders | S Novella
Reflex Integration Therapy | H Hall
Dubious Autonomic Nervous System Claims | S Novella
Gyrostim and the Infrastructure of Quackery | S Novella
Reader’s Digest Promotes Prevagen | H Hall
Vertigo Voodoo: A Crazy-Sounding Cure That Actually Works | H Hall
Leaky Brain, Leaky Gut: Are They Real? | H Hall
Zap Your Way to Learning? | S Novella
Brain Research in the 21st Century | S Novella
The PIED Piper of Nootropics | S Novella
Creatine Supplements for Brain Function | S Novella
Brain Wave Pseudoscience | S Novella
Vision Therapy Quackery | S Novella
The Evidence for Rehabilitation Robots | S Novella
Parkinson’s Disease: A Detective Story | H Hall
Body Integrity Dysphoria – A Rare and Informative Condition | S Novella
HEADACHES
CAM and Headaches | S Novella
Treating Migraines | S Novella
How Not to Treat Migraine | S Novella
New Study Questions fMRI Validity | S Novella
Carotid Artery Stenosis: Surgery, Stent, or Nonsurgical Stroke Prevention? | H Hall
Bad Reporting about Uploading Memories | S Novella
Brain Stimulation for the Masses | S Novella
EMDR Is Still Dubious | S Novella
Dynamic Neural Retraining | S Novella
Does Brain Training Work? | S Novella
Auditory Integration Training | S Novella
Is There a Treatment for Tinnitus | S Novella
Quantum Neurology | S Novella
Brainwashed: Neuroscience and Its Perversions | H Hall
Conscious Discipline – More Dubious Neuroscience | S Novella
Frontal Lobotomy: Zombies Created by One of Medicine’s Greatest Mistakes | H Hall
Different Strokes for Different Folks: Assessing Risk in Women | H Hall
Premature Claims for Neurotrophic Factors | S Novella
Irlen Syndrome | S Novella
Why the Brain is the Most Interesting Organ | J Howard
Science-Based Medicine Reviews: Real Medicine
A Critical Guide for the Health Practitioner and Consumer 
2024 Edition

Executive Editor Steven Novella MD
Managing Editor David Gorski MD PhD
Series Editor Mark Crislip MD

   Introduction
Steven Novella
The world of health care is becoming an increasingly complex and challenging place. The internet is changing the way we generate and access information, and health information is one of the most popular uses of the internet. It represents an unprecedented democratization of information and opinion. 
While there are many advantages and benefits to such information access, there are also many challenges to health professionals, regulators, academics, and consumers. There is a proliferation of health related products and services, with many provocative health claims. Regulations are generally not keeping up, and often have been watered down, in the face of this onslaught of claims and products. 
The consumer is left with an overwhelming array of health claims, many of which challenge and even directly oppose the traditional experts and institutions. 
The mission of Science-Based Medicine (SBM) is to be a source of reliable information and analysis to help navigate the wild west of health information on the internet and elsewhere. The authors who contribute to this series of e-books are all physicians and other health care professionals who have a great deal of experience educating the public about complex medical issues. We especially take on controversial issues and try to expose pseudoscience and fraud wherever possible.
The Philosophy of Science-Based Medicine
The philosophy of SBM, at its core, is simple: Safe and effective health care is critical to everyone’s quality of life; so much so that it is generally considered a basic human right. Therefore, health care products and services that work and are safe are better than those that do not work or are unsafe. 
The best method for determining which interventions and health products are safe and effective is, without question, good science. Therefore it is in everyone’s best interest for health care to be systematically evaluated by the best science available.
Too often the nature of science itself is misunderstood or misrepresented to the public. Science is not an arcane and privileged discipline. By its very nature it is meant to be transparent and public. Science is nothing more than a systematic and careful use of evidence and logic to evaluate factual claims. And good science possesses certain virtues that are not unique to science but generic to all intellectual endeavors: fairly accounting for all available evidence, using valid and internally consistent logic, using unambiguous concepts and language, proper use of statistics, being quantitatively precise and accurate, and above all being honest.
And yet there are numerous and powerful influences in society that strongly appose the scientific basis of medicine. Driven by some combination of ideology or the desire for profit they wish to eliminate standards of science in health care, or (often under the guise of “health care freedom”) create a double standard in which unscientific methods and products can thrive unchecked. Others simply lack the training or knowledge to achieve minimal standards of quality for scientific medicine. And even the best traditions of scientific medicine can benefit from more critical analysis.
Recognition of the need for careful scientific analysis in medicine partly stems from a recognition that it is very difficult (almost impossible) to reliably assess treatments anecdotally. Human perception, memory, and cognition are prone to a host of flaws, weaknesses, and biases that will tend to mislead us, especially towards conclusions that we wish to be true. Placebo effects, confirmation bias, and simple statistics can make any intervention seem effective, even when they are worthless or harmful. 
Science-Based Medicine vs Evidence-Based Medicine
Within the practice of medicine there is already a recognition of the need to raise the standards of evidence and the availability of the best evidence to the practitioner and the consumer – formalized in the movement known as evidence-based medicine (EBM). 
EBM is a vital and positive influence on the practice of medicine, but it has its limitations. EBM tends to focus on clinical trial results to the exclusion of scientific plausibility. The focus on trial results (which, in the EBM lexicon, is what is meant by “evidence”) has its utility, but fails to properly deal with medical modalities that are highly implausible, or seem to defy well-established findings in science.
All of science describes the same reality, and therefore it must (if it is functioning properly) all be mutually compatible. Collectively, science builds one cumulative model of the natural world. This means we can make rational judgments about what is likely to be true based upon what is already well established. This does not necessarily equate to rejecting new ideas out-of-hand, but rather to adjusting the threshold of evidence required to establish a new claim based upon the prior scientific plausibility of the new claim. Failure to do so leads to conclusions and recommendations that are not reliable, and therefore medical practices that are probably not safe and effective.
The SBM Series
This is why the authors of this series strongly advocate for science based medicine – the use of the best scientific evidence available, in the light of our cumulative scientific knowledge from all relevant disciplines, in evaluating health claims, practices, and products. 
Some of the articles here will analyze individual studies, and explore the strengths and weaknesses of their methods, separating what the study really tells us from how it may be represented in the media. Other articles will summarize what many studies tell us about a specific medical question. 
We will also explore health information on the internet, separating out which information is reliable from that which is misleading, erroneous, or possibly even fraudulent. Likewise we will critique mainstream media coverage of health topics, giving the reader specific tools for to critically analyze health information for themselves.
Other articles will explore topics related to health regulation and academia. Regulations have struggled to keep up with the rapidly changing health care market place, with critical gaps that leave the health care consumer responsible for their own protection. Academic institutions themselves, long the defenders of high standards of scholarship in all fields, including medicine, have been infiltrated by promoters of pseudoscientific belief systems. The result is that there is no longer any single reliable guarantee of scientific integrity. 
The SBM series of e-books is organized by topic, such as acupuncture, chiropractic, homeopathy, and many others. The books are collections of essays, not intended to be a systematic reference, but rather to explore the various scientific issues related to each topic. The goal is to give the reader critical thinking skills and a deeper understanding of, not just the current findings of science, but the process of science, specifically how it relates to health care and the topic of each book. 
Science-based medicine can serve as your pocket guide through the wilderness of health information.

As of 5000, there are over 5000 essays on the Science Based Medicine website. I do no know about you, but I find it difficult to find any post I wrote, much less one written by another contributor. 

So I have updated the books and include almost all the articles through ??. The volumes are

CAM Concepts
Chiropractic
COVID 
Critical Thinking
Diet and Nutrition
Ethics and CAM
Herbs, Supplements, and Diet
Homeopathy
Infections and Immunity
Law and CAM
Media and Internet
Medicine, Public Health, Dentistry and Pediatrics
Miscellaneous CAM
Naturopathy
Neurology and Psychiatry
Placebo
Quackademic Medicine
Regulation. FDA and FTC
SBM or EBM
Stem Cells, Genetics, AI and Gender
Supplements, Vitamins and Herbs
Vaccine & Anivax
Vaccines and Autism
Vaccines and Preventable Infections

The articles are roughly organized by publication date and topic. Many articles will be in multiple volumes as an essay of, for example, chiropractic and law will be found in both the chiropractic volume and the law volume.

You may find the organization a bit odd. I do. But 4700 plus articles are difficult to organize and I have more to do in my retirement than work of these volumes.

Still, if you find I have missed a nentry or some glaring error, drop me a note and I will fix it for the next edition.

About the authors
Steven P. Novella, MD – Founder and Executive Editor Science Based Medicine.
Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD.
David H. Gorski, MD, PhD – Managing Editor. Science Based Medicine.
Mark A. Crislip, MD. Editor, Science Based Medicine Guides. 
He did he editing of all the volumes so is to blame for any mistakes.
As to all the other contributors, if you are interested click on the ‘Link’ at top of each essay to go the SBM site, where further information about each author can be found.
A Note On References

The chapters in this book were originally blog entries at ScienceBasedMedicine.org.
Blog and web pages lend themselves to hyperlinks to sources and references that are tedious to translate into footnotes for this ebook.
Under the title of each essay is a hyperlink, cleverly titled ‘Link’, to the original blog entry with all the hyperlinks and references, as well as the comments to the blogs, which often have interesting and thoughtful insights by our readers, as well as some curious comments by the not so thoughtful.
Graphs, tables and links to videos are not in included these essays due to issues of copyright and permission. However, thanks to the ‘Link’, the graphics are a click away.
Thanks for reading the site.
Mark Crislip 


Psychiatry

Integrative Psychiatry
Alternative medicine is not just restricted to physical health. Practitioners have insinuated themselves into mental health as well, to the detriment of patients and science.
Jesse Luke on August 4, 2017
Link


Psychiatry hasn’t had the best reputation for a long time. The practice has sat under a cloud made up of poor understanding, stigma and many dangerous, often cruel treatments. Psychiatric patients are truly among the most vulnerable and underserved in the field of medicine, and many struggle on a daily basis. To make matters worse, there is a massive cadre of integrative practitioners, proponents, and related companies who are promoting and practicing what they call integrative psychiatry.
(Note that integrative psychiatry should not be confused with integrated psychiatry, which is merely the placement of psychiatrists into other patient care environments to increase access.)
A (very) brief history of mental illness

From ancient times until the middle of the 20th century there have been numerous pseudo-psychiatric treatments based upon religion, superstition and/or poor science. These include trepanation – drilling holes in the skull to release evil spirits (still practiced by some, believed to increase blood flow); exorcisms – also to rid the body of spirits; insulin shock therapy that would induce hypoglycemic comas; and the infamous lobotomy (leucotomy), which surgically isolated the prefrontal cortex. Antonio Moniz controversially received the Nobel Prize for the latter in 1949. However, for many conditions, the only treatments were psychoanalysis and far too often, long-term confinement in institutes across countries, some used for centuries (a few still exist as modern hospitals).
In the 1950s major psychiatric medications were introduced to the field: chlorpromazine, the first anti-psychotic, and imipramine, the first antidepressant; many others followed quickly. Through this new- found ability to control conditions, patients gained better control of their lives. A large movement of deinstitutionalization followed in the 60s, moving care from institutes to local centers and private practice. Psychiatry became more mainstream very quickly, consultations occurred more, and people became less afraid of the profession and its treatments. In the following decades further advances were made with the increased usage of the more recent benzodiazepines to replace the more dangerous barbiturates, and SSRIs to replace tricyclics and MAO-inhibitors, that often came with severe side effects and sometimes severe lifestyle restrictions, to treat depression. The asylum and lobotomy days are fortunately behind us, though there still exists a need for psychiatric hospitals and in unique, resistant cases the use of older drugs, electro-convulsive therapy, and sometimes involuntary admittance.
Though compared to the past the contemporary treatment of mental illness is far more advanced and humane, there are still major issues. The medications available are far from perfect. Research funding in the field typically falls far behind that of other diseases, and undertreatment is still a significant problem. The WHO estimates that more than 300 million people suffer from depression worldwide. With less than 50% treated (imagine that for other possibly fatal diseases), it is the current leading cause of disability worldwide. That is just depression though; if we were to factor in the number of people suffering from other mental illness in the world the number would likely be over a billion. With these numbers it must also be noted that the suffering endured is truly immeasurable; as a result, a patient’s desire for help is often just as great as those with cancer or other serious illnesses. Their mental states, often already fragile, unfamiliarity with mental illness, and desperation will allow predispose them to grasp at any hope, and integrative medicine stands ready to offer the illusion of a helping hand. Psychiatric illness is serious and should be taken seriously by society. Patients need science-based psychiatry, not more delusions.
Integration of CAM I – The nonsense
The methods employed by integrative psychiatry, like integrative medicine, can be roughly divided into two types: re-branding conventional advice as “alternative”, and promoting unproven and unscientific treatment options. Many of the purported treatments will be familiar to regular readers and well-researched medical sceptics, but there are a few that are quite rare and fringe, even in CAM. Integrative psychiatry doesn’t have any true centralization by itself like functional medicine does. As a result, practitioners fall under the broad aegis of integrative medicine, each choosing any point on the spectrum they like and defining the practice as they see fit.
The 2015 copy of Kaplan & Sadock’s Synopsis of Psychiatry (not to be confused with their Comprehensive Textbook of Psychiatry) has a chapter on CAM treatments. The book, and its ten prior editions, are mainstream and commonly used for education and reference. In the chapter devoted to CAM and integrative psychiatry, it has an extensive list of CAM options, and here I have excerpted some of the more obscure interventions, with a brief description:
    • Anthroposophically extended medicine: using “wisdom of life” to perform mental exercises that balance mind and body
    • Bates method: purportedly cures vision problems by splashing warm and cold water on the eyes, swaying, focusing on objects and thinking happy thoughts
    • Trager method: sitting in a chair for an hour or so and being guided through the unconscious mind choosing its own better movements
    • Environmental medicine: concerns about hypersensitivity and disease caused by electricity, wifi, etc. (note that there is also science-based environmental medicine and this ain’t it)
    • Ozone therapy: introducing ozone (O3) to the body in order to treat everything from cancer to AIDS. It includes drinking ozonated water and “…insufflations, in which a catheter is inserted into the rectum or vagina with ozone administered at a slow flow rate; and autohemotherapy, in which a person’s own ozonized blood is reintroduced into the body.”
    • Past life medicine: Using hypnosis to regress a person to a past life and “…the healing process is aided by contact with spiritual beings that are believed to have the ability to reverse illness and maintain health”; according to the text it is up to the psychiatrist to take the actual regression literally or figuratively
The list also includes many more, like acupuncture, chelation, chiropractic, colonic irrigation, homeopathy, naturopathy, therapeutic touch, and even shamanism.
Integration of CAM II – The rebranding
As far as rebranding is concerned, there is quite a bit – such as listing exercise as a CAM modality, as is often seen in similar writing. Tai chi and yoga are also listed separately even though they are just other forms of exercise. Nutrition is also listed as alternative, but criticizes the USDA guidelines and gives fad diets like the Atkins and Ornish diets as examples of “alternative diets”. Strikingly, the use of B-vitamins in alcoholics is also listed as alternative when it has been standard care for a while.
Biofeedback and hypnosis were not on the full list because these “modalities” are now “incorporated into standard psychiatric practice.” Both are umbrella terms that can cover many things, but neither are truly commonplace in psychiatry. Biofeedback has been experimented with by multiple fields of medicine, including psychiatry for some time now. It is, put simply, using a machine interface to provide perceptible readings on normally imperceptible bodily processes (such as blood pressure, skin conductance, or brainwaves) in an attempt to help patients monitor and control them in some way. There is evidence both for and against the intervention but considering the many different forms it can take it seems inappropriate to give such a blanket endorsement of the practice.
Hypnosis, on the other hand, is partly approved of by both the American Psychiatric Association [PDF] and the American Psychological Association. These endorsements are not, however, a blanket approval of all forms of the therapy. In fact, along with other medical organizations they condemn the practice of regression therapy with the aim of recovering repressed memories, because the likely result is actually the implantation of false memories, many taking the form of alien abductions, satanic ritual abuse, and sexual abuse. Integrative psychiatry, on the other hand, considers it to be a useful tool and encourage its use.
It may appear that the list of interventions was put in place simply to inform readers of the various forms of CAM and wasn’t an approval, but the sentence that follows the section implies otherwise:
Any of the complementary methods described in this section can be integrated into standard psychotherapeutic practice, although some lend themselves better than others.
These treatments don’t simply reside in ink though, they are in actual practice. A quick google search will reveal a tremendous number of doctors offering integrative psychiatric care, many offering phone consultations. It is likely that you can shop around for just about any alternative treatment you would like and get someone with a medical degree to condone it. This movement isn’t confined to small and individual practices, though; the Wellness Institute at the Cleveland Clinic (yes, that Cleveland Clinic) offers holistic psychotherapy that may consist of regression hypnosis, breath therapy that utilizes vibrational energy, guided imagery, and rebirthing breath that can help overcome the previous trauma of birth. UCSF offers acupuncture and ayurvedic massage among other things. It also seems that integrative psychiatry is buying into unproven diagnoses: ILADS (yes, that ILADS) has produced its own pamphlet for psychiatrists, in which it shows that nearly all psychiatric symptoms can be caused by chronic Lyme disease (yes, that chronic Lyme disease!) and mentions of it can be found on many websites.
Keeping with the forward march of CAM into mainstream medicine, the American Psychiatric Association has a dedicated “sub-specialty” devoted to integrative psychiatry. They offer a CME course through their online education center, and various webinars, and their publishing arm offers multiple books on the subject (this is the same organization that publishes the DSM).
Conclusion: Psychiatry needs more science, not less
It isn’t unfair to say that psychiatry is far from the most science-based specialty in medicine (a problem it shares with psychology and psychotherapy). The causes of many conditions are not known, and most hypotheses as to what does cause them are largely based on what effects psychiatric medications have inside the body. Researchers are working diligently in multiple fields to understand the genetic, environmental, and social causes of mental illness. Amazing progress has been made and there is a lot to come, but just because the train of science moves slowly does not give a reason to hang off the side and pick up magical cures along the track. Mental illness can often be severe and debilitating. It contributes greatly to shortened life spans, poverty, and global economic loss. It therefore must be taken extremely seriously. It is difficult now to get even basic treatment to half the people that require it. The solution requires a massive expansion of funding, outreach, and social awareness.
Adding unrealistic and fictional interventions to the field will only cause harm, and in my opinion it seems cruel for psychiatrists to be putting delusions into the heads of patients with mental illnesses. This can only be stopped through the work of an informed public. If these treatments were to enter the mainstream in significant amounts, it would be extremely difficult to push them back out. Nothing is without risk, and the risks present are simply too large. It is easy to imagine a patient with schizophrenia or depression that gets the idea their conditions can be treated simply and without medications that often come with adverse effects, especially when medication compliance is already a serious challenge in the field. Modern psychiatry isn’t great, but it helps and it is far better than what we used to have — but that’s the direction integrative psychiatry moves, towards pseudo-science and superstition harkening back to a time when psychiatrists treated their patients on personal whims and theories with no true regard for the patient. As a patient with depression and anxiety I want real science-based psychiatry, not to be propped up by a placebo that could shatter at any moment with possibly disastrous results.

DSM-5 and the Fight for the Heart of Psychiatry
The new DSM is out, what are people saying about it?
Steven Novella on May 22, 2013
Link
The fifth edition of the Diagnostics and Statistical Manual (DSM-5) was recently released. This is the standard reference of mental disorders and psychiatric illnesses released by the American Psychiatric Association (APA).
As with previous editions there is a great deal of discussion and wringing of hands over the details – which disorders were created or eliminated. For example hoarding is now considered its own disorder, rather than part of obsessive compulsive disorder (it has its own reality TV show, why not its own DSM diagnosis?).
This time around, however, the debate over the DSM goes much deeper than the particulars of specific diagnoses. The real debate is about the very existence of the DSM – its validity and utility. While this discussion is nothing new, it has taken on an unprecedented dimension with the rejection of the DSM by the National Institutes of Mental Health (NIMH). Director Thomas Insel wrote:
The goal of this new manual, as with all previous editions, is to provide a common language for describing psychopathology. While DSM has been described as a “Bible” for the field, it is, at best, a dictionary, creating a set of labels and defining each. The strength of each of the editions of DSM has been “reliability” – each edition has ensured that clinicians use the same terms in the same ways. The weakness is its lack of validity. Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure. In the rest of medicine, this would be equivalent to creating diagnostic systems based on the nature of chest pain or the quality of fever. Indeed, symptom-based diagnosis, once common in other areas of medicine, has been largely replaced in the past half century as we have understood that symptoms alone rarely indicate the best choice of treatment.

Categorization in science and medicine
The debate is largely about how we categorize mental disorders (I will use the term mental disorders as a non-specific catchall in this article for mental illness, disease, psychiatric conditions, etc.). This will likely turn out to be bigger than the demotion of Pluto to a dwarf planet.
As with the categorization of planets, this is more than just an issue of definition. In planetary astronomy the issue was with how we understand planetary formation and solar system dynamics. With mental disorders the real debate is about our understanding of underlying cause.
Insel may be overstating the case, but historically he is correct- the DSM is mainly a dictionary of terms, so that psychiatrists can talk to each other and publish using a consistent lexicon. The DSM gives specific diagnoses an operational definition based upon a list of signs and symptoms.
While this approach has been criticized, it is almost universal in medicine as a starting point for our exploration of any new disease. I disagree with Insel in his implication that symptom-based diagnosis is inherently flawed and largely abandoned in the rest of medicine.
When we first identify a new disease or disorder it is almost always first recognized by its symptoms, signs, and course. This is the purely descriptive phase of our understanding. Epidemiology comes next – who gets it, how, and when. Scientists then hunt for an underlying cause – the pathophysiology. It takes years to decades to fully understand a disease, and for many we still lack a full understanding even after decades of active research.
In ALS, for example (motor neuron disease) we know that motor neurons are dying, but we don’t know why. So the diagnosis is defined largely clinically, although based upon exam findings and test results. The diagnosis is not based upon any understanding of cause, however. Further, this means that ALS is likely not one disease but many, that have the same manifestation because the same cell population is dying.
Migraine is another example. Headaches are entirely classified by a list of symptoms (frequency and location of headache and association with other symptoms).
Multiple sclerosis is a mixture, like many diseases. We understand a great deal about pathophysiology, and diagnosis is based upon hard findings. But we don’t know the ultimate cause, and there are subtypes of MS that are entirely clinically based (mostly on the course of the disease – relapsing remitting, chronic progressive, etc.). We don’t know why the different subtypes are different.
In reality, the degree to which medical diagnoses are clinical – based upon signs, symptoms, and course – vs based upon pathophysiology is entirely dependent upon our current understanding of pathophysiology.
Criticizing a diagnostic scheme on this criterion, therefore, seems odd. What is the alternative? If we lack a sufficient understanding of pathophysiology, we need to categorize based upon what we do now (how patients present). These diagnostic labels are placeholders. We expect and hope to replace them one day with a categorization based upon a deeper understanding of the disease.
The reality is that medical diagnoses today are a mishmash of clinical features (signs, symptoms, disease course, age of onset), biological markers, pathology, response to treatment, and pattern of inheritance if any. Psychiatric diagnoses are no different – except that we largely lack biological markers and pathology. This reflects the complexity of mental disorders and the current state of our understanding.
The NIMH, however, is now saying that it also, and predominantly, reflects a flawed approach.
The biological model of mental illness
The NIMH is taking what critics call the extreme biological approach to mental disorders – that all mental disorders are brain disorders, and properly studied we should be able to figure out those biological causes.
What Insel is saying is that the DSM is not just a convenient list of placeholder diagnoses, but it is a straitjacket. Researchers have been forced to base their studies into biological causes on DSM labels that may not (and probably don’t) reflect underlying reality.
This situation would then be similar to doing biological research based upon classic Linnaen taxonomy rather than evolution-based cladistic categorization. Linnaeus based his categorization of life upon often superficial features. Now that we understand the origin of the diversity of life, evolution, we can re-categorize all of life in a way that reflects true evolutionary relationships.
Insel is in essence saying that the NIMH has failed to find biological markers for mental illness because they have been forced to labor under a false categorization system, the DSM. A cynic might say that he is blaming the DSM for the failures of the NIMH. A charitable interpretation is that Insel is responding to disappointing progress appropriately by rethinking basic strategy.
Some critics have essentially said, a pox on both houses (the DSM and NIMH).
The DSM is criticized as being “cynically pragmatic” – for putting a practical clinical approach above scientific evidence in drawing DSM diagnoses. At the very least, the DSM needs an evidence-base overhaul, and it probably won’t get it until the old-guard releases its iron grip.
Meanwhile, the NIMH claim that all mental disorders are biological is overly simplistic. Mental disorders are a complex combination of brain function and environmental factors. We will therefore never get completely away from clinical criteria, even if they are better informed by biological information.
As with many disputes, reality is likely in the middle of these two extremes (the pragmatic clinical approach and the biological approach). One area that should have complete agreement, however, is that scientific evidence should be the ultimate determining factor.
The new approach
Meanwhile, neuroscientists seem to be taking their research into mental disorders away from the DSM and more in the direction indicated by the NIMH. The new emphasis is on genetics and functional brain imaging. This is partly driven by technological development – they are researching in these areas because they have the tools to do so.
Researchers are therefore stepping back from classic clinical diagnoses and trying to think about mental disorders in a more fundamental way. They are trying to identify networks or modules in the brain that correlate to specific fundamental behaviors or experiences. Rather than thinking about full clinical syndromes, neuroscientists are trying to reduce them to specific and well-defined neurological phenomena.
In a recent interview on the SGU with one such researcher, Heather Berlin, she described how in her research on obsessive compulsive disorder she is looking at the brain responses to disgust. OCD patients, it turns out, have an increased disgust response. Perhaps, then, we may eventually understand a subset of what are now called OCD patients as individuals with hyperactive disgust response disorder.
Researchers are also building on the genome project to identify genes that correlate with mental disorders. No one expects to find a single gene that equates to a specific mental disorder, but we are finding gene variants that correlate to increased risk. Autism researchers, for example, have been very successful in identifying genes that correlate with risk of ASD.
Here is where Insel’s complaint about the DSM comes in. He is arguing that genetic research might be doomed to failure if researchers are forced to correlate genetic variants to disease labels that don’t reflect biological reality. Such research is set up to fail from the beginning. It remains to be seen if stepping back from the DSM will yield greater success.
Conclusion: Controversy, but not necessarily useful discussion
Psychiatry’s critics have been having a field day spinning all of this controversy as the death knell for psychiatry. Rather, I see it all as a very healthy sign of growth. Psychiatry has had a prolonged infancy as a scientific discipline, stuck for decades in the descriptive clinical phase of understanding illness.
This phase is necessary and does have some practical utility. But it can also be a mental straitjacket, if the placeholder labels are mistaken for necessarily real biological entities (they may or may not be). This straitjacket effect is not unique to psychiatry (nothing here is) – I teach students frequently that they need to understand the nature of various diagnoses. Some are specific pathophysiological entities, others are vague clinical syndromes that exist for purely practical purposes. Don’t confuse the two.
All medical specialties are trying to advance their field by deepening their understanding of pathophysiology. All need to practice medicine in the meantime, with imperfect knowledge.
Psychiatry might be suffering from a bit of a complex since it is lagging behind most other medical fields. I don’t think this can be entirely blamed on the DSM, however. Perhaps it is partly due to the fact that the DSM has had a disproportionate effect on categorization in psychiatry. The profession made a bargain with the DSM, trading flexibility for consistency.
Medical practice can have it both ways – we can (and do) use labels as placeholders, but not as iron-clad entities that constrain our thinking or research. The problem, however, is that regulatory agencies take the placeholder labels as iron-clad. The FDA, insurance companies, and research funding agencies use them as constraints.
In this regard perhaps the NIMH had to back away from the DSM.
Part of the lag of psychiatry, however, is that the subject matter is genuinely complex, and there are strong non-biological influences. I don’t think we will ever get to a pure biological categorization of mental disorders. I do think that neuroscience and genetics research will transform the field and our thinking of mental disorders, as all successful scientific research should do.
If I am being hopeful I see this current controversy as a sign that psychiatry is ready to push through to the next level – more evidence-based, and more biologically informed categories and diagnoses.
The DSM is a necessary placeholder, but that means its reign must end one day, and that will not represent failure, but progress.

Scientology’s War on Medicine
Scientology is famously anti-psychiatry, teaching its believers that psychiatry is not only bogus, but downright evil, and in its place promotes a variety of unscientific and pseudoscientific practices. However, Scientology’s war on medicine goes beyond just psychiatry.
Harriet Hall on March 24, 2015
Link

Note: The film Going Clear: Scientology and the Prison of Belief will be available on HBO starting March 29th. I haven’t seen it yet, but apparently it profiles former members who reveal details that have elicited a very angry response from the Church of Scientology. I thought I would use the occasion to reprint a SkepDoc column that originally appeared in Skeptic magazine (Volume 18: Number 3) titled “Scientology’s War on Medicine.”
Scientology has openly declared war on psychiatry and is ambivalent if not openly hostile towards the rest of medicine. Its “mind over matter” philosophy promises that attaining the “Clear” state will eliminate illness.
Recently there has been a spate of exposés of Scientology, ably reviewed by Jim Lippard on eSkeptic. They offer some shocking revelations. Defectors from Scientology have described kidnappings, deliberate lying, unnecessary deaths, human trafficking, thought control (“brainwashing”), coercion, violations of labor standards, violations of human and civil rights, and other crimes. Scientology has been protected from prosecution by its designation as a religion and its vast wealth and influence; but if even a fraction of these accusations are true, Scientology has much to answer for.
Initially people are attracted to Scientology because it provides answers. Your problems are due to past experiences holding you back. Scientology can help you deal with those problems and the upper levels will reveal the secret of life itself.
Members are audited with an E-Meter (similar to a lie detector) and one-on-one attention. The auditing process is similar to psychotherapy in that it encourages people to think about their problems and work to overcome them. In Scientology, ideas are not immaterial: they have weight and solidity. The E-Meter locates and discharges mental masses that are blocking the free flow of energy. Memories are blamed and traced back in time even into past lives. Patients keep repeating the details of the experience until they are drained of any emotional charge. Once the painful experiences and associations are drained off, there are astonishing results: asthma, headaches, arthritis, menstrual cramps, astigmatism, and ulcers simply disappear. The reactive mind is replaced by the rational mind. In one case a boy’s IQ supposedly rose from 83 to 212.
Scientology believes no memory is ever erased: every sound and smell can be completely recaptured. Even prenatal memories and past life memories remain. The fetus remembers if the mother attempted to abort it and develops psychological problems because it knows it is living with murderers. Cells are sentient and remember painful emotions. “Engrams” become a physical part of cellular structure, controlling behavior like a post-hypnotic suggestion. This understanding of memory is incompatible with current scientific knowledge.
Then there is a second stage of Scientology where people pay for ever more expensive classes, are indoctrinated into the mythology, progress up the church’s ladder of OT (Operating Thetan) levels, and may even join the elite Sea Org, signing a billion year contract.
The Scientology myth was originally a secret revealed only to those who reached the OT III level, but it is now public knowledge. The universe began 4 quadrillion years ago. Evil lord Xenu and his psychiatrist co-conspirators froze individuals (thetans), sent them to the planet Earth, dropped them into volcanoes and blew them up with hydrogen bombs. Freed from their bodies, the thetans were trapped in an electronic ribbon and subjected to brainwashing with a colossal motion picture device which implanted them with all the world religions. Free-floating thetans attach themselves to living people, as many as millions of them in a single body. These “body thetans” have to be eliminated to achieve spiritual progress. If not cleared by Scientology, these thetans will blow themselves up and destroy civilization as they have done many times before. Only Scientology can save humanity from the cycle of self-destruction.
We are all thetans (Scientology’s term for the soul), immortal spiritual beings that are incarnated in innumerable lifetimes. Auditing is not just to resolve psychological problems but to “recall to the thetan his immortality and help him relinquish his self-imposed limitations” – to emancipate a person from the laws of matter, energy, space and time (MEST). Bored thetans had created MEST universes and then forgot they weren’t real.
When you become “clear” of body thetans, you have a flawless memory able to recall anything you have ever studied; are less susceptible to diseases; rarely have accidents; and are free of neuroses, compulsions, and psychosomatic illnesses. As you progress to the higher OT levels you will be able to levitate, travel through time, control the thoughts of others by telepathy, and have total command over the material universe. With these superhuman powers you can make a traffic light turn green or emit an electric shock that can put out someone’s eyes or cut him in half.
Only one problem: there never were any “clears.” Attempted demonstrations of these powers consistently failed. When auditing was independently tested, it failed (Hubbard claimed they didn’t do it right). Auditing may indeed help people, but its results have never been validated.
As in other cults, confession and re-education are used to control thought. Past lives provide misdeeds to confess. Instead of providing consolation, confession exploits vulnerabilities and steers people into thinking about their faults. The cult keeps its victims in a suggestible state and vigorously suppresses questions and doubts. Exit costs make the prospect of leaving more painful than staying.
Scientology was invented by a science fiction writer, L. Ron Hubbard. He was a liar, fantasist, bigamist, and adulterer; charismatic, vindictive, with sexual and psychological problems that he revealed in the Affirmations, a secret memoir which the church now claims is a forgery. One ex-lover described him as manic-depressive with paranoid tendencies and delusions of grandeur. At one point, concerned that divorce would hurt his reputation, he proposed that if his wife really loved him, she should kill herself.
Hubbard began to develop his ideas in Dianetics, a book that Nobel physicist Isidor Isaac Rabi said “probably contains more promises and less evidence per page than has any publication since the invention of printing.” The book empowered people to become practitioners themselves. Hubbard said, “I’d like to start a religion. That’s where the money is.” A religion could maintain control of devotees permanently with a series of veiled revelations and levels.
Scientology discourages any use of medication. Pain and other symptoms are treated by “Assists.” For the Contact Assist you repeatedly press the injured part of the body against the object that hurt it until the pain goes away. There is also the Touch Assist; one person who was treated as a child said her mother wouldn’t stop prodding her with a finger until she said she felt better. So of course she said she did. John Travolta once did an Assist on Marlon Brando at a party; he touched Brando’s leg, both closed their eyes, and Brando said it helped.
Assists can supposedly awaken unconscious persons, eliminate boils, reduce earaches and back pain, and make a drunk sober.
At age 7, Jenna Miscavige was assigned the post of Medical Liaison Officer, responsible for treating sick children and providing vitamins to the healthy. Scientology allowed vaccinations but didn’t permit the use of medicine for the treatment of pain or fever. The church doesn’t believe in comforting children, believing they are adults in young bodies and can handle pain like an adult.
Hubbard chastised subordinates for wearing eyeglasses, tried to convince them they could see without them, and said needing them was a transgression against Scientology.
OTs should not have accidents and illnesses; when one woman developed a cold sore, she was consigned to a condition of Treason.
Hubbard had his own (untrained) medical officer. He was afraid of doctors. When a motorcycle accident left him in severe pain from broken ribs and other injuries, he refused to go to the hospital and even refused pain pills, complaining that they slowed down his heart.
Operating Thetans supposedly didn’t get sick, but L. Ron Hubbard had poor hearing, poor vision, was obese, and had numerous physical and psychological problems. His lame excuse was that he was at such a high level he couldn’t get down to the power level of a body. When he died following a stroke, they said that he didn’t die, but intentionally dropped his body to move on to a higher level of existence. He is expected to return some day. Every Scientology facility maintains an office furnished exactly as he liked, even down to a pair of slippers.
Hubbard theorized that one wealthy Scientologist was not making progress because he had taken LSD and it must still be in his system. He put him to work swabbing the decks on the Sea Org ship to sweat it out of his system. That was the beginning of the Scientology drug treatment program, Narconon.
A fundamental feature of Narconon is the Purification Rundown, a 3 week program to eliminate toxins. Patients spend up to 8 hours a day in a sauna; they exercise and take massive doses of vitamins, especially niacin. Niacin causes skin flushing and tingling sensations which they interpret as evidence of toxins being purged. One woman said Novocaine from previous dental work began to surface and her mouth went numb for 90 minutes.
Psychotic episodes were treated with the Introspection Rundown: solitary confinement, vitamins, calcium and magnesium. 1995 Lisa McPherson suffered a mental breakdown and died following 17 days of this treatment under guard in a Florida hotel. She lapsed into a coma and died en route to a hospital where there was a doctor affiliated with the church (the ambulance bypassed several closer hospitals). Church officials lied in sworn statements to police, claiming that she hadn’t been subject to an Introspection Rundown. A defector later confessed that he had destroyed incriminating documents. The medical examiner determined that the cause of death was a pulmonary embolus: a clot had formed due to the worst case of dehydration she had ever seen, following 5 days without any liquids. Church lawyers pressured her attorney, threatening a legal battle, and she changed her ruling to say the death was “accidental.” Shortly thereafter she retired and became a recluse.
One former Sea Org member said he went psychotic on OT III. He said he lost his sense of identity when he found out that thousands of individual alien beings were struggling for control of his body, trying to give him cancer or drive him insane.
One auditor was declared a “Suppressive Person” and had a nervous breakdown. Instead of treatment he was punished and made to do manual labor. He escaped, killed his wife, and committed suicide.
Anyone who questions Scientology doctrine is sent to RPF (Rehabilitation Project Force). There they are subjected to terrible living conditions and an inadequate diet, and are made to do manual labor; it has been compared to the prison camps of the Soviet Gulag. One Sea Org man was forced to shovel up asbestos in a renovation project with no protective gear, not even a mask. A woman was made to weld without protective glasses; she burned her eyes and got no medical attention at all. A severely handicapped MS patient who was unable to talk was sent to RPF.
Medical treatment is often cruel and inadequate. A woman who had incapacitating migraines kept auditing herself on the E-Meter in lieu of treatment, because she felt responsible for her pain. A little deaf mute girl was isolated in the Sea Org ship’s chain locker for a week because Hubbard thought it might cure her deafness. Yvonne Gillham, a Sea Org member, died of a brain tumor that would have been operable with earlier diagnosis. She blamed herself for her symptoms and refused to take pain meds because it might interfere with her auditing.
Scientologists are persuaded to wean themselves off any medications. John Travolta’s son was taken off his seizure meds, which may have contributed to his death. A young man taking Lexapro was labeled as a drug addict and his father was ordered to lock his son’s Lexapro in the trunk of his car. The patient killed himself with his father’s pistol. The case was dismissed for lack of evidence.
Brooke Shields got through post-partum depression with the help of antidepressants. Tom Cruise erupted with fury on a talk show, dissing psychiatry and saying she should have treated her depression with diet and exercise.
Despite their aversion to prescription drugs, Scientologists are curiously gullible about alternative medicine. John Travolta is enthusiastic about bee pollen. David Miscavige, the current president, follows the Blood Type Diet and takes his personal chiropractor along when he travels. Hubbard invented Dianazene, a mixture of nicotinic acid and vitamins taken daily with milk and chocolate to cure cancer and sunburns. He recommended a baby formula of boiled barley and corn syrup that he picked up in Roman days in a former lifetime. He was fanatical about taking vitamins.
Hubbard blamed psychiatrists for helping Xenu commit genocide 5 billion years ago. Scientologists hold psychiatrists responsible for modern wars, racism, ethnic cleansing, and terrorism, including the Holocaust, apartheid, and 9/11. Hubbard called psychiatry the sole cause of decline in the universe. He said if psychiatrists “had the power to torture and kill everyone, they would do so…they are psychotic criminals…” He accused them of trying to institute world government by manipulating human behavior. Scientologists accused Osama bin Laden’s deputy, a “psychiatrist,” (actually a general surgeon) of controlling his thoughts. Another “psychiatrist” who allegedly masterminded the Madrid train bombings was actually a used-car salesman who had nothing to do with the incident. Scientology maintains the exhibit “Psychiatry: An Industry of Death” in Hollywood, featuring errors of psychiatry like madhouses, lobotomies, electric shock, and drugs for spurious diagnoses. Scientology aims to eliminate psychiatry in all its forms, claiming that no mental diseases have ever been proven to exist.
When TIME magazine criticized Scientology, they claimed Eli Lilly had ordered the article in retribution for the damage Scientology had caused to their “killer drug Prozac,” which supposedly causes people to commit mass murder and suicide.
Scientology lobbyists even got legislation passed in Florida that would hold schoolteachers criminally liable for just suggesting to parents that kids might have a mental health condition such as ADD. Fortunately the governor vetoed it.
Hubbard claimed to have obtained a perfect understanding of human nature by self-examination and to have an exact science. Nonsense! There is no science in Scientology. Crispian Jago has created The Venn Diagram of Irrational Nonsense: overlapping circles for quackery bollocks, religious bollocks, pseudoscientific bollocks, and paranormal bollocks; he put Scientology at the center where all these overlap. I agree: that’s exactly where it belongs.
Note: My source for much of this information is Going Clear: Scientology, Hollywood, and the Prison of Belief by Lawrence Wright. Further details and full references can be found in the book.

Treating Pain Psychologically
Steven Novella on February 5, 2014
Link
One of the goals of rigorous science is to disentangle various causes so we can establish exactly where the lines of cause and effect are. In medicine this allows us to then optimize the real causes (what aspect of treatments actually work) and eliminate anything unnecessary.
Eliminating the unnecessary is more than just about efficiency – every intervention in medicine has a potential risk, so this is also about risk reduction.
It often seems to me that the goal of “alternative” medicine is to blur the lines of cause and effect, to exploit non-specific effects in order to promote a useless but profitable ritual (acupuncture comes to mind).
Pain is the area most susceptible to such blurring of lines. Pain is a complex combination of physiological and psychological effects. Physiologically pain is produced by tissue damage or pathology provoking pain signals in sensing nerves (nociceptive pain). This type of pain serves a protective purpose, and does not last beyond the pathology itself. There is also neuropathic pain, in which pain arises abnormally from within the nervous system itself. This type of pain is chronic and not protective.
Pain signals are conducted to the brain where they are perceived. There are two components to this perception, with their own neuroanatomical correlates. The first type localizes the pain – where exactly in the body the pain originates. The second adds emotional context to the pain – it makes it hurt. Pain would not serve its function if it didn’t really bother us or force us to pay attention.
Interestingly, opiates are more effective at suppressing the emotional aspect of pain. Therefore it is common for patients on opiates for severe pain to report that they can still feel the pain, it just doesn’t bother them.
At every step in the process, pain intensity can be modulated. Further, pain is closely tied with attention – the pain hurts more when we attend to it, and less when we attend to something else. Anxiety and depression also increase the subjective experience of pain.
Therefore, a multidisciplinary or total approach to treating pain can address treating the underlying pathology (always the first priority), inhibiting the physiological and neurological production and conduction of pain, reducing the brain’s perception of pain, and modulating all of the psychological aspects of attending to pain and its emotional comorbidities.
When doing pain research it is critical to isolate, as much as possible, all of these various effects. Otherwise no conclusions can be drawn about the effect of any one aspect of the treatment. The kind attention of the practitioner and the hope of a treatment effect alone will likely result in the reporting of reduced pain.
This is all closely related to the concept of “placebo effects.” Operationally, in medical research “placebo effects” are everything other than a physiological response to the active treatment being studied. However, when treating pain these other effects could not only be useful, but already be part of multidisciplinary pain treatment. These non-specific effects, however, do not justify the active treatment, unless the active treatment is shown to independently contribute to the overall pain reduction.
Again taking acupuncture as an example – the point by proponents is often made that even if acupuncture is no more effective than placebo (it isn’t), that’s OK, because placebo effects are useful in treating pain. But acupuncture is not delivering these placebo effects, it is the ritual surrounding acupuncture that is primarily doing so. The sticking of needles into specific points does not appear to add anything to the overall effect.
If we want to maximize the utility of the psychological aspects of pain treatment, then let’s optimize those and dispense with the elements that are adding nothing. There are attempts to do just that. Some methods already in use include biofeedback, stress management, and cognitive-behavioral therapy (CBT).
A recent study looks at combining such methods into a protocol the researchers call “Mindfulness-Oriented Recovery Enhancement (MORE).” The technique is described as:
Mindfulness involves training the mind to increase awareness, gain control over one’s attention and regulate automatic habits.Reappraisal is the process of reframing the meaning of a stressful or adverse event in such a way as to see it as purposeful or growth promoting.Savoring is the process of learning to focus attention on positive events to increase one’s sensitivity to naturally rewarding experiences, such as enjoying a beautiful nature scene or experiencing a sense of connection with a loved one.
In other words, meditation and CBT, so it seems like a new spin on these established techniques. That is not necessarily a criticism, however, if the goal is to optimize the effectiveness of non-pharmacological techniques in managing chronic pain.
One of the biggest complications in treating chronic pain is opiate overuse. This occurs because of tolerance, the drugs work less and less well over time so doses have to increase. Also opiates are psychologically addicting, and patient often self-medicate with them to treat the anxiety and depression that goes along with the pain.
The researchers in the above study also looked at opiate overuse as an outcome. They found:
MORE participants reported significantly greater reductions in pain severity (p = .038) and interference (p = .003) than [support group (SG)] participants, which were maintained by 3-month follow-up and mediated by increased nonreactivity and reinterpretation of pain sensations. Compared with SG participants, participants in MORE evidenced significantly less stress arousal (p = .034) and desire for opioids (p = .027), and were significantly more likely to no longer meet criteria for opioid use disorder immediately following treatment (p = .05); however, these effects were not sustained at follow-up.
This is a preliminary, but reasonably designed and powered study. The results are encouraging, but all the caveats apply until it is properly replicated.
The one discouraging result is that reduction in opiate overuse was not sustained. One rule of thumb in pain research is that what patients do is likely more significant than what they say. If they report less pain but use the same amount of pain medication, their report is likely biased.
Conclusion
It’s time to move past the empty rhetoric and deceptive shell-game of “placebo medicine.” Non-specific effects of a positive therapeutic intervention, combined with specific psychological interventions, can reduce the experience of pain and improve quality of life. This should not be used to justify useless rituals and the magical thinking (and risks, however small) that go along with them.
Rather, researchers interested in such effects should study them directly and figure out how to maximize their usefulness and free them from the pre-scientific rituals in which they are often embedded.

The Debate Is Over: Antidepressants DO Work Better Than Placebo
The idea that antidepressants are no more effective than placebo has been put to rest. They clearly work when used appropriately, although the effect size is not as large as the published studies have suggested.
Harriet Hall on March 6, 2018
Link


A meme that continues to appear regularly in the media and in the comments section of this blog is “antidepressants are no better than placebo.” It is a false belief based on a faulty interpretation of the evidence. A new study has just come out that should put the final nail in its coffin. Antidepressants are indisputably effective when prescribed appropriately for moderate-to-severe major depression. Part of the confusion is that they have often been prescribed inappropriately for mild depression or sadness, where there is no evidence to support their use. They are serious drugs for a serious illness, not “happy pills.”
The “antidepressants are placebos” meme may have originated with Irving Kirsch. In a 1998 meta-analysis, he found that 75% of the apparent effects of antidepressants were placebo effects, and he suggested that the other 25% probably were too.
Selective publication
A 2008 New England Journal of Medicine article by Erick Turner et al. “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy” caused quite a stir. They did a systematic review of both published and unpublished antidepressant trials. Overall, only 51% of studies were positive, but 94% of published studies were positive. Because of publication bias, the published literature overestimated the benefits of antidepressants; it conveyed an effect size of 0.31, nearly one third larger than the effect size derived from the data as a whole.
They concluded:
Selective reporting deprives researchers of the accurate data they need to estimate effect size realistically. Inflated effect sizes lead to underestimates of the sample size required to achieve statistical significance. Underpowered studies — and selectively reported studies in general — waste resources and the contributions of investigators and study participants, and they hinder the advancement of medical knowledge. By altering the apparent risk–benefit ratio of drugs, selective publication can lead doctors to make inappropriate prescribing decisions that may not be in the best interest of their patients and, thus, the public health.
Commenters on that article tended to overlook one important fact: each drug, when subjected to meta-analysis, was shown to be superior to placebo. All the evidence agreed that antidepressants were better than placebo, just not as much better as the published literature would lead us to believe.
Effect size
Kirsch et al. re-evaluated the data for four of the drugs covered in the Turner analysis, and they calculated an effect size of 0.32, almost identical to the 0.31 found by Turner. Despite this initial agreement, they reached opposite conclusions about efficacy based on different understandings of what these effect size numbers mean in terms of clinical significance. I wrote about their disagreement previously. As Turner elegantly explained, the published studies posited a glass containing 0.41 liters, and Turner found that the glass contained 0.31 liters, which he sees as a partially full glass, whereas Kirsch considers a glass containing 0.31 liters to be equivalent to an empty glass. For comparison, psychotherapy has an effect size of only 0.22.
A more definitive study
The new study was published February 21, 2018, in The Lancet. The lead author is Cipriani, but both Erick Turner and John Ioannidis (another familiar name, the author of “Why Most Published Research Findings Are False“) are among the co-authors. They looked at published data from 522 randomized double-blind controlled trials testing 21 different antidepressants, and they sought out unpublished data. In all, the data covered 116,477 subjects who had been properly diagnosed with major depressive disorder and were treated for at least eight weeks. Their criterion for “effectiveness” was a reduction of depressive symptoms of at least 50% on an observer-rating scale (better than subjective self-reporting). They found that each of the 21 antidepressant drugs was more effective than placebo.
The accompanying Forest plot (AKA “blobbogram”) is impressive:
The blue squares indicate the average odds ratio from studies of each drug, with amitriptyline leading the pack with an OR of 2.13 times compared to placebo and reboxetine in last place with an OR of 1.37. The black horizontal lines indicate the 95% confidence intervals. That means that while the measured value can’t be guaranteed to be precisely accurate, they are 95% confident that the actual value lies somewhere within that range. Note that none of the confidence intervals crosses the vertical 1.0 line that would indicate an equal response to placebo and drug. This is about as good a Forest plot as you could hope to see.
While all antidepressant drugs were effective, some were more effective than others. Fluoxetine (Prozac) was one of the less effective ones. They also looked at dropout rates to gauge acceptability. Clomipramine was the least acceptable. They have made their entire dataset available to the public. The information may help clinicians decide which drugs to choose for their patients.
Conclusion: A blow to antidepressant denialism
This new evidence is impressive. Only the most perversely recalcitrant antidepressant denialists will continue to say that the drugs are no more effective than placebo. The debate is over. Questions remain about effect size and prescription guidelines, but it has been satisfactorily established that antidepressants (all of them) work better than placebo. Depression kills; antidepressants can help prevent suicides, relieve suffering, and improve quality of life and functioning. Thanks for that, Big Pharma.

“Postnatal depression blood test breakthrough” or Churnalism?
James Coyne on August 2, 2013
Link
“Postnatal depression blood test breakthrough” proclaimed the headline. The UK Guardian article then declared:
British doctors reveal ‘extremely important’ research that could help tens of thousands of women at risk.
Here it comes. Readers were going to be fed a press release generated by the study’s authors and forwarded undigested by the media but disguised as writings of a journalist. If only the journo had asked someone in the know about the likelihood of a single study yielding such breakthrough blood test for risk of depression in new mothers.
The story echoed earlier churnalism from Sky News, British satellite television news service:
There is evidence that if you can identify women at risk early you could treat early or introduce measures to prevent or stop the process of the disease.
A study of 200 pregnant women, published in the Journal of Psychiatric Research, found two molecular “signatures” in the genes that increased the risk of postnatal depression by up to five times. One in seven new mothers suffer from depression.
Prof Grammatopoulos has claimed he could test women for the genetic changes for £30-£40, but the cost could be reduced to £10 if the screening system is automated.
By the time the story got to the Telegraph, it was embellished further:
Experts hope that the test will be available within two years, with results showing it to be at least 85 per cent accurate in early trials carried out by psychiatrists.
In the face of the considerable interest in the test being generated by the media coverage, the UK National Health Service (NHS) provided a critical evaluation from Bazian. The NHS coverage made good points but stopped short of blasting the media coverage and the author of the JPR article for their hype and hokum:
While the potential for inexpensive screening of postnatal depression is genuinely exciting, the limitations of the study – such as its size and the fact that it did not assess associations with diagnosed postnatal depression – should have been made more explicit by the papers.
Nothing in the existing literature prepares us for a study of 200 pregnant women yielding a clinic-ready £10 test for risk of postpartum depression. But further evaluation of these claims requires a detailed analysis of the original article in the context of the larger literature. The article is behind a pay wall, but if you cannot retrieve it from your university library, you can find an abstract here and request a copy from the senior author at d. grammatopoulos @ warwick.ac.uk.
A closer look
My examination confirmed the press coverage was nonsense and the article was not much better. There were far too few patients to identify genes associated with depression, and depression was not even measured. Any results would be unlikely to replicate. The authors went about it all wrong if their goal was make even a tiny step toward the distant goal of having a genetic test for depression. The conduct and reporting of the study was quite inconsistent with best practices for candidate gene studies. Finally, it is not clear how clinically useful and appropriate a blood test for risk of postpartum depression would be, which this decidedly is not, anyway.
Oh, but what a tale spun for the gullible. The press coverage and the article itself provide a good opportunity to hone the skills needed to detect hype and hokum. Especially, if you believe like I do that there is going to be a lot of it ahead with the search for biomarkers of depression having become such a hot topic.
    • The study did not involve 200 women, only 140. The number 200 is the number of women approached, not the number of women enrolled.
    • There was no diagnosis made of depression, neither while the women were pregnant nor after they had delivered.
    • Instead, women were designated as “at risk” solely on the basis of their scores on a screening questionnaire, the Edinburgh Postpartum Depression Scale (EPDS). You can find it here. Although widely used, the scale is crudely constructed and psychometrically poor. It draws howls when women hit the item 6: “Things are getting on top of me”. “Damn, that’s how I got here…” a woman laughed out loud while being screened in my study of low income pregnant women in inner city Philadelphia.
    • The EPDS yields a high rate of false positives when compared to a diagnostic interview. The investigators set a cutpoint of 10 for defining “at risk” rather than a more usual 13, which increases the yield of “at risk” women at the cost of sacrificing the positive predictive value of these designations.
    • At the prenatal assessment 111 women had low scores, leaving only 29 “at risk.” The postnatal assessment revealed 34 patients scored high. Of these, only 21 were new high scorers. The other 13 represented 44% of the women scoring high at the prenatal assessment continue to do so. If we require that to be considered “postnatal depression,” the elevated scores could not have first occurred during pregnancy, we have to go with the lower number of 21 at risk.
A biological test with a claimed “accuracy of 85%” is being proposed as the basis for initiating treatment for pregnant women who are asymptomatic and not otherwise appropriate for treatment with antidepressants. And the “validation” of this biological test is not in a sample with a carefully diagnosed target condition. Rather, it is on the basis of responses of a few women to a screening questionnaire with items suggesting they are engaged in an exercise with all the scientific status of filling out a questionnaire that might be taken from a tabloid.
Yet somehow the press coverage made the startling claim that gene ‘signatures’ had been found carrying five times the risk of depression.
These small numbers mitigate not only against a valid genetic study, but even the use of suitable statistical controls. Note that the statistical power of a study to detect an effect is not a function of the overall sample size, but the size of the target group.
We can expect that such a grossly underpowered study:
    • Will require larger effect sizes to attain statistical significance. If statistical significance is designated as the criterion for a discovery, any effect sizes will be inflated.
    • Any use of statistical controls for potential confounds or to rule out alternative hypotheses is ridiculous and invalid.
    • Reports of “discoveries” are likely to be false positives and to go unreplicated.
    • Whatever is “discovered” is not about depression, because we do not have an adequate measure of depression.
We are at high risk of nonsense.
The investigators claim to have tested only five single-nucleotide polymorphisms (SNPs). We cannot know whether they actually tested hundreds, but are only reporting five. The rationale for testing only these five is weak, but let’s suspend skepticism for now. Still, the individual five SNPS were tested against three patterns of high risk and then combinations of SNPs were tested. And finally, haplotype distributions were globally and individually tested. Bottom line: the number of statistical tests approached the number of high risk women.
If you are still interested in the actually mixed results of this study, you can access the summary provided by the NHS here.
Authors as spin masters
Journalists at risk of becoming churnalists sometimes check a press release against the abstract of a journal article. Unfortunately, hyped press releases are associated with abstracts that spin the presentation and interpretation of results. To discover this, one usually needs to compare the abstract to the results actually reported in the text. But more basic spin can begin in the introduction, where the existing literature is given a biased summary in order to frame the importance of the research question that is being studied and the results that are obtained.
Abstract
The abstract opens with a stronger statement of the consistency of the existing literature that is justified. Only confirmatory findings from the study are presented, with null findings ignored. The abstract ends with an exaggerated declaration of this study being “the first evidence.”
Introductions
Introductions can be spun with a puffer fish strategy, exaggerating the prevalence and importance of a problem and with the creation of false authority by selective citation of the past literature. This introduction exhibits both.
The puffer fish strategy involves selectively citing and combining evidence so that the phenomenon under study is construed as highly prevalent with significant and long-lasting public health consequences. Authors thus puff up the importance of what they are studying by combining high estimates of prevalence with high estimates obtained from studies that actually tap different phenomena of the consequences of a condition going untreated.
In this case, high estimates of normally occurring postpartum blues (30-50%) are combined with studies of postpartum clinical depression (prevalence ~9%) which has more public health consequences, as well as the dangers associated with rare and entirely distinct phenomenon, postpartum psychosis (0.1 to 0.2%). The three distinct phenomena are treated as “depression,” establishing that the study is important because it is investigating a common condition having serious consequences for the mother and infant, including the possibility of maternal suicide and infanticide.
Selective citation creating false authority involves emphasizing positive studies and suppressing negative ones. But it also involves distorting what is cited so that the existing literature seems more uniformly consistent with the overall characterization of the literature, the framing of the research question, and the results that are obtained. Investigating the creation of false authority, one looks for missing null findings, citations for empirical claims that turn out to be not actually empirical studies, and citations of studies that upon examination turn out to have findings different than how they are cited or to be simply irrelevant.
There are lots of instances in this introduction, only a few of which I will cite.
Puzzlement is expressed that screening for postpartum depression is not universal, especially given the public health importance of it. What is ignored is a lack of evidence that routine screening would improve depression outcomes. There have also been large demonstrations that mandating implementation of screening for postpartum depression in specific settings such as the State of New Jersey Ob settings or Head Start programs, has not lead to women having lower depression scores.
The strong impression is created that postpartum depression is a distinctive condition, with an identified hormonal and perhaps genetic basis. The actual clinical epidemiological data suggest that women are no more likely to be clinically depressed immediately after giving birth than other comparably aged women who have not given birth. Much of the depression that is identified as postpartum actually began during pregnancy.
The introduction suggests that postnatal depression is likely to be associated with abnormalities in the hypothalamic pituitary adrenal (HPA) axis. That is a hypothesis with lots of contradictory data. One of the key problems is that postpartum depression is extremely heterogeneous. Depression identified by screening and interviewing, rather than from women seeking psychiatric services is likely to yield women in whom HPA axis abnormalities cannot be found.
Women identified on the basis of screening and interviewing will often meet criteria for major depression with the minimum number of symptoms and of only mildest severity. They are more likely to be suffering from personal and social difficulties than identifiable HPA axis abnormalities.
Think of it: are we really willing to assume that there has to be a genetically-based biological abnormality for a woman to endorse being sad, fatigued, lacking sleep, diminished concentration, and having recently lost 5% body weight in two weeks after giving birth?
The search for candidate genes for risk of depression involves tracking weak and inconsistent signals. These are likely to be lost in the static of including a considerable proportion of women lacking in distinct biological abnormalities.
The authors give particular attention to the hypothesis that postpartum depression is a result of increased production of placental corticotropin-releasing hormone (pCRH) during pregnancy that is abruptly withdrawn with the passing of the placenta during birth. This is another attractive hypothesis that has yielded lots of contradictory data. The bulk of the research has been conducted with small samples of women who have not assessed for clinical depression, but are designated “depressed” solely on the basis of a screening instrument.
The literature concerning pCRH and mood is also characterized by considerable confirmatory bias with negative findings either spun as positive in the original studies or selectively ignored and subsequent studies.
See, for instance, the study in the Archives of General Psychiatry that claimed finding “midpregnancy pCRH [placental CRH] is a sensitive and specific early diagnostic test for PPD symptoms” in a sample with 16 women identified by scores on the EPDS with more statistical tests than “depressed” women. And positive results emerged only with quadratic analyses, not linear ones. And only with statistical controls derived from an inappropriate automatic selection process. My group wrote the first author several times to get her to explain exactly how she claimed positive results. She did not reply.
The strength of evidence for genetic aspects of major depression is exaggerated. If you Google genetics and depression, the many links you will get will demonstrate wild fluctuations over time in declarations of breakthrough discoveries and disappointments, followed by more discoveries and disappointments. The consensus is now that single genes with great explanatory power are unlikely to be identified. Hope is now for small numbers of genes explaining small proportion of variance in distinctly different types of “depression.”
I could go on, but I think you can get the picture that the introduction misconstrues the existing literature as supporting this study as the next step. I could similarly analyze the discussion for the creation of a false consensus with the past literature. I was particularly impressed with the connecting of this study from a sample of Caucasian women to a study of Han Chinese patients not specifically selected for postpartum depression.
What are journos to do?
Journalists would garner a lot of attention if they were the first to report a true breakthrough study yielding an inexpensive blood test for risk of depression. But the overwhelming hype, false discoveries, and confirmatory bias in both the scientific literature and media coverage should caution against accepting claims by authors that single studies represent a breakthrough or that their claims will hold up in subsequent studies. As John Ioannidis has demonstrated, most claims of discoveries are either false or greatly exaggerated. In hot areas of research like this one, lower standards are set for declaring discoveries and so there are even more false discoveries and exaggerations that will not replicate.
Journalists cannot be expected to develop much expertise in biostatistics, clinical epidemiology, psychiatry or psychometrics. They cannot be expected to have the time or expertise to check for puffer fish strategies or the creation of false authority with selective citation.
But it is reasonable to expect that when authors approach them with press releases, journalists should maintain appropriate skepticism until they have checked out the press release with someone with relevant expertise, unconnected to the author.
Who else has responsibility to address misleading medical information being made available to consumer clinicians and patients? Are researchers only responsible for how their research is disseminated? Do others with relevant expertise have no responsibility to speak out?
As in a lot of areas of professionalism, an ethic of mutually avoiding critical commentary prevails: ‘Don’t criticize me and I won’t criticize you…Don’t call me on my hype and hokum and I won’t call you on yours.”
Special thanks to Marcus Munafo for encouragement and helpful feedback on earlier drafts and to Paul Ingraham for his editorial suggestions and from saving me from WordPress hell. However, all inaccuracies and excesses are the sole responsibility of James C. Coyne.

New Drug Is Effective for Post-Partum Depression, But There Are Drawbacks
A new drug promises to cure postpartum depression, but it is restricted and patients must be hospitalized for a 60-hour IV infusion.
Harriet Hall on June 25, 2019
Link

There’s a new cure for postpartum depression; but don’t celebrate just yet. It’s far from a panacea, and it’s not for everyone. The devil is in the details.
Post-partum depression (PPD) affects about 15% of women. It can have serious consequences for both mother and child, ranging from bonding issues to suicidal or infanticidal thoughts. Treatment with counselling, medication, and social support is not always successful. Antidepressants are often used, but it’s not clear which ones are likely to be effective or when they are preferable to non-drug options; and they may take several weeks to work. A more drastic remedy, electroconvulsive therapy (ECT), has helped some women who failed to respond to medication and counselling. Researchers have been looking for better options, and Sage Therapeutics thinks they have found one. In March, 2019, their new drug Zulresso (brexanolone) was approved by the FDA, the first drug to be specifically approved for PPD. It has a big advantage over antidepressants in that it works quickly, in just a couple of days.
It’s not available to just anybody. It carries a boxed warning. Because of concerns of serious risk, Zulresso was approved with a Risk Evaluation and Mitigation Strategy (REMS), which restricts its use to certified health care facilities and requires formal enrollment in a program. The drug is administered as a continuous IV infusion over 60 hours (2.5 days). Patients must be admitted to the hospital and monitored carefully for excessive sedation or sudden loss of consciousness. They must have continuous pulse oximetry monitoring. They can’t breastfeed, because there is no data on the drug’s safety during breastfeeding. They are not allowed to be alone with their children. Hospitalization is inconvenient and expensive. It means patients will be away from home and will have to disrupt family life and arrange childcare. And the cost is estimated to be $34,000 for the drug alone, a barrier to many new mothers who might benefit from the infusion.
What is it?
Brexanolone is not a typical antidepressant. It is a synthetic source of the neurosteroid allopregnanolone. It modulates the receptors for GABA, the primary inhibitory transmitter in the brain. Allopregnanolone is produced in the body from progesterone; levels rise during pregnancy and drop post-partum. There is some evidence that PPD patients may have lower levels than non-depressed women, and brexanolone is hypothesized to relieve depression by raising allopregnanolone levels. But it’s all speculation: we really don’t know how it works, and we don’t know what causes PPD.
The research
It’s not clear to me why they first decided to evaluate brexanolone for PPD or how they decided on the 60-hour infusion protocol. I will have to give them the benefit of the doubt and assume they had good reasons. There is evidence of effectiveness from blinded, placebo-controlled studies, but some may question the results because the studies were all funded by the manufacturer, and we know manufacturer-funded studies are more likely to be positive than independent studies.
Open-label, proof-of-concept study: four women with severe PPD received brexanolone titrated to a dose reflecting third-trimester allopregnanolone levels; all had remission of symptoms. With such small numbers and no controls, it’s uncertain what the results mean.
A phase 2 double-blind, randomized, placebo-controlled trial of patients with severe PPD measured an average decrease in the Hamilton Rating Scale for Depression of 21 points for 10 women who got a brexanolone infusion and a decrease of 8.8 points for 11 women who got a placebo infusion.
Two randomized double-blind, placebo-controlled phase 3 trials were reported in a single article in Lancet.
The first compared two different doses of brexanolone to placebo in patients with severe PPD and measured changes in the Hamilton Rating Scale for Depression.
Dose	Number of subjects	Decrease in depression scale
90 μg/kg per h	45	17.7
60 μg/kg per h	47	19.5
Placebo	46	14.0
The second compared the higher dose to placebo in patients with moderate PPD.
Dose	Number of subjects	Decrease in depression scale
90 μg/kg per h	54	14.6
Placebo	54	12.1
The authors said these were significant and clinically meaningful results. Yes, the drug consistently performed better than placebo, but it struck me as odd that the lower dose got a better response than the higher dose in the first trial and that the results for the 90 μg/kg per h dose in the second trial were worse than in the first trial and were essentially the same as the placebo results in the first trial. Why did they choose the higher dose for the second study? And in an appendix they reported the results of another, possibly more relevant tool, the EPDS, which showed significant results at 30 days only for the 60 μg/kg per h dose. And the results of the phase 3 study were less impressive than the phase 2 results. Something doesn’t add up; further trials are needed for clarification. Keep in mind that studies of antidepressants tend to have large placebo responses.
The reduction in the Hamilton scores was reported as clinically significant, but one of the researchers said that less than half (“nearly half”) of the brexanolone recipients were in remission and were no longer considered to be clinically depressed.
Preclinical testing in a mouse model was consistent with human studies, but that’s not entirely reassuring, since the model may not be valid and mice are different from humans.
There are some unanswered questions. Would it be safe to breastfeed? In the human studies, patients were only followed for 30 days; long-term results are not known. Did anyone relapse later? Could a second infusion be given for a relapse? How many patients were also taking antidepressant medication and how did that affect results?
Conclusion: Apparently effective, but problematic
Zulresso will probably not be used as a first-line treatment. The cost and the need for hospitalization will discourage many potential users. If it is used for patients who were treated first with antidepressants, counselling, and social support and failed to improve, that will mean a delay that will negate the advantage of a quick response.
The same company that sells Zulresso, Sage Therapeutics, is working on another drug for PPD, a pill that can be taken once daily. I’m going to go out on a limb here and predict that Zulresso will not last and will be supplanted by other drugs that are more user-friendly (and hopefully less expensive). Fingers crossed.

Depression Re-examined: A New Way to Look at an Old Puzzle
Harriet Hall on February 25, 2014
Link
Depression affects approximately 10% of Americans. It can be fatal; I found estimates of suicide rates ranging from 2-15% of patients with major depression. When it doesn’t kill, it impairs functioning and can make life almost unbearably miserable. It is a frustrating condition because there is no lab test to diagnose it, no good explanation of its cause, and the treatments are far from ideal.
Jonathan Rottenberg is a psychologist and research scientist who began to study depression after his own recovery from a major depressive illness. He teaches psychology at the University of South Florida, where he is the director of the Mood and Emotion laboratory. He has launched the Come Out of the Dark campaign to start a better, richer national conversation about depression. In a new book The Depths: The Evolutionary Origins of the Depression Epidemic, he reviews insights from recent experiments and asks a number of difficult questions, such as why humans evolved to be subject to incapacitating depressions. He comes up with some startling hypotheses, including the idea that evolution favored depression because of its survival value and that depression is essentially a good thing. He offers his ideas as the basis of a paradigm shift.
Is there an epidemic of depression? Rates of depression have been rising in most but not all countries. Is it a real epidemic, or might we be seeing the influence of increased awareness through the media and better diagnosis? I’m not sure we have enough evidence to be certain at this point.
What is depression? Is it:
    • A defect in brain chemistry? This is the basis of drug therapy. The chemistry imbalance hypothesis is simplistic, misleading, and essentially wrong. Antidepressants do indeed alter brain chemistry as they relieve symptoms, but that doesn’t necessarily mean that a chemical imbalance caused the problem, and it doesn’t explain what caused the imbalance or why it happened when it did.
    • A defect in thoughts? This is the basis of cognitive behavioral therapy (CBT). Is mere thinking enough to think yourself into a depression or out of one? The evidence suggests otherwise.
    • A defect in childhood experience? This is the basis of psychoanalysis. Freud’s theories have been largely discredited, and people with the most appalling childhoods can have normal adulthoods.
    • Not a defect at all? This is what Rottenberg proposes.
Evolution did not design us to be happy. It designed us to survive and reproduce. The function of mood is to integrate internal with external information to enhance fitness. Mood affects behavior: an anxious mood focuses attention on threats; a good mood broadens attention and leads people to seek out variety; and a negative mood first mobilizes effort, then eventually de-escalates effort when a task proves hopeless, conserving resources that can later be used to better purpose. Our moods occur first: we feel happy or sad, we feel a need to explain why we feel that way, and we think of a reason that would explain the mood. The reasons we come up with are not necessarily the right ones, and often they are mere confabulations.
Low mood has its benefits. Non-depressed people tend to overestimate their abilities, are prone to positive illusions, and demonstrate overconfidence and blindness to faults. When depressed, people are more realistic; they are more deliberate, skeptical, and careful in processing information from the environment.
Low mood can be triggered in animals and humans by factors such as separation from the group, removal to an unfamiliar environment, the inability to escape from a stressful situation, the death of a significant other, scarce food resources, prolonged bodily pain, and social defeat. Low mood serves as an alarm system. It gets our attention and lets us know something is wrong. Depression allows us to stop, retreat to an emotional cocoon, analyze what went wrong, and hopefully change course to avoid future calamities.
But low mood has its costs, too. Whatever the benefits, there are plenty of negative effects like distorted thinking, delusions, suicide, difficulty in concentrating and functioning, and weakened executive functions in the brain.
A shallow depression can be adaptive, but a deep depression is maladaptive. There’s a continuum, and any cut-off point to divide normal from abnormal is arbitrary. Rottenberg thinks low moods used to be helpful in the environment where humans evolved, but that the environment has changed in ways that make low moods less advantageous today.
He describes animal and human experiments that shed light on depression. Animals show signs of depression too. Animals often act as if they are mourning after they lose a significant other. In the “tail test,” rats suspended by their tails conserve their resources better if they give up quickly and stop struggling. Their low mood resolves quickly when the stress is over. Adolescent girls who had depressive symptoms became more disengaged from goals over time, but the more disengaged they were, the better off they were in later assessments, reporting lower levels of depression. In another study, a negative mood was found to enhance the quality and concreteness of persuasive arguments. In a starvation experiment, subjects developed the signs of depression as their bodies reacted to conserve the insufficient calories. Their energy and concentration diminished, they lost all interest in sex, and they ruminated obsessively about food. By preventing action they couldn’t afford, depression contributed to their survival on scanty rations. Their depression lasted longer than the experiment; Rottenberg hypothesizes that this strategy is effective because it holds behavior in place until depleted resources can be rebuilt.
How does this normally-resilient mood system fall into deep depression? Prolonged shocks produced helpless behavior in dogs, so they didn’t even try to escape from shocks when it was possible to escape. Chronic mild stress in rats reduces their pleasure-seeking behavior for months afterwards; their responsiveness to rewards returns when they are given antidepressants. Undergoing several stressors at once increases the likelihood of depression in both animals and humans. Not every animal shows prolonged depression, just as not every human becomes depressed under equivalent stresses. Genetic variation is likely the reason: it has been estimated that 30-40% of susceptibility to depression in humans is genetic.
Some kind of loss is always present in depression, whether it be the death of a child or an imagined loss of status. Bereavement is one kind of depression, once thought to be a separate entity but now considered to be part of the same continuum.
How long do minor depressions last? There are no good treatments for minor depression, and doctors often resort to “watchful waiting.” This may be a mistake: a study showed that after a month, only 6% of patients had recovered. Another study found that 72% of people who had a minor depression were still bothered by one or more symptoms of depression when interviewed a year later. At any given time, 22% of the population has at least one significant symptom of depression. Mild depressions outnumber deep ones six to one. Low-level sadness is so ordinary it is often overlooked. But having a mild depression quintuples the risk of a later major depression.
Depression can be triggered by events, temperaments, and routines such as sleep patterns, night shifts, and artificial light. Fish with different temperaments have different success in different environments; the bold fish are more likely to enter a trap, while wary fish are slower to adapt to changing conditions. Humans have an additional problem: Rottenberg says “Homo sapiens has the distinction of being a species that can become depressed without a major environmental insult.” We think our way into deeper depressions by rumination and self-flagellation. We worry about remote or nonexistent possibilities. When we are depressed we think we ought to be able to fix ourselves; but we can’t, and that makes us even more depressed.
Sometimes depressed people can’t even get out of bed. This reflects a lack of goals. They don’t see any good reasons that would motivate them to get up. Humans can set goals in abstract domains where progress is hard to measure. When they hold on to failing goals, they become depressed. They need to disengage from the failing goals. Self-help books and the ideals of happiness in our society create high expectations and perceived failures. In the West the idea of happiness usually involves high levels of arousal like enthusiasm and excitement; in general, those who place the highest values on that kind of happiness tend to be the least happy. Asians tend to place greater value on low arousal states like calm and serenity.
According to Rottenberg, depression arises not from a defect, but from what we do well: thinking, using language, holding onto ambitious goals, and even our drive to be happy. Rottenberg says “The picture of depression that emerges is richer, more interesting, and in some ways more troubling than defect-model approaches would allow.”
He offers clues about how low moods can be better managed: appreciating the costs of thinking, sometimes accepting a low mood with equanimity, aiming for goals that are high but not too high, knowing when it is time to give up on a goal, and realizing that happiness is not itself a goal but “a fleeting byproduct of progress towards other goals.” Despite the evolutionary directive to become depressed, we retain a margin of control to shape its course.
We have learned that depression comes on more gradually and lifts more gradually than we once thought. We can’t predict whether a patient will respond to any treatment, but that doesn’t mean we shouldn’t keep trying. We used to think antidepressants took 6 weeks to show an effect, but we often see patients improving in the first two weeks, even those taking a placebo! Early improvement doesn’t predict final outcome. Early improvers may face fewer life problems, have an innate resilience, or maybe they are just lucky. Recovered patients may still have some residual depression and fear that a relapse could happen any time. A deep depression can re-program our mood system so that it favors a return to low mood states; but the same brain plasticity also allows for re-re-programming to a more normal state with treatments like mindfulness-based cognitive therapy, which attempts to disconnect sad moods from negative thoughts about the self. Mood can be rebuilt by changing the way we think, our environment, our relationships, and our health habits like sleep, diet, and exercise.
“Just like hunger or pain, moods are survival-relevant mental states that can bind together thoughts, feelings, and memories [and] change our mental priorities.” But they lead to mood-congruent memory, where we retrieve memories that match our current mood and are unable to call up contradictory memories. This can fortify us to change our situation, but it also tends to deepen the depression and makes us mentally less nimble.
Depression can be viewed as an opportunity. Rottenberg describes a patient who used her depression as a lens to re-evaluate everything in her life and re-set her priorities. Her life was better after the depressive episode than before.
Conclusion
Rottenberg calls his ideas the “mood science approach” to depression. He says:
The evolutionary perspective asks us to be patient, to learn to tolerate some degree of low mood, and to listen to what it is that low mood can tell us.
I don’t think his approach qualifies as a “paradigm shift,” but he does provide some valuable insights about this frustrating condition. Some of these insights are speculative, but most are based on recent animal and human research.
I used to try to reduce the stigma and guilt of obesity by telling obese patients that their tendency to store calories as fat was not a bad thing per se: it would give them a survival advantage over thinner people in a starvation environment or an environment of alternating feast and famine. But in our modern environment, where food is plentiful, the survival advantage is with the non-obese. I don’t think what I said made them lose weight more successfully, but I hope it provided some degree of comfort and reduced guilt. In the same way, Rottenberg’s concepts may help destigmatize depression. Depressed patients may feel better about their condition if they are told that it is a result of evolutionary traits that are basically good for us but that sometimes overdo it. If nothing else, the ideas and the experimental evidence Rottenberg presents provide plenty of food for thought.

Is Addiction a Disease? Yes and No
Harriet Hall on December 1, 2015
Link

Addiction is a puzzling phenomenon. Why do addicts persist in self-destructive behavior even after it has lost them their jobs, their family, their health, and their self-respect? Do they have any control over their behavior? If so, why don’t they control it? If not, why not? Two recent books shed light on these questions: The Biology of Desire: Why Addiction Is Not a Disease, by Marc Lewis, and The Thirteenth Step: Addiction in the Age of Brain Science, by Markus Heilig.
Lewis is a neuroscientist and former addict; Heilig is a physician and addiction researcher. Lewis is convinced that addiction is not a disease, but a habit created by the neural circuitry of desire in the course of its normal functioning. Heilig is convinced that addiction is a chronic disease like diabetes that can’t be cured but that must be managed by lifelong treatment.
While they disagree about whether addiction is a disease, they actually agree about almost everything else. They agree that we should reject the stigma of addiction as a kind of moral failing. They reject the hypotheses that addiction is a matter of choice or self-medication. They think current diagnostic labels are inadequate. They both try to integrate two levels of information: the case histories of addicts and the scientific knowledge from research. They are both skeptical of AA and of conventional rehab programs. They both support evidence-based treatments. They both think addicts are not all alike and that individual addicts will respond better to individualized approaches.
Lewis: no, addiction is not a disease
Lewis argues that there is a developmental cascade, foreshadowed by difficulties in childhood, with a learning process about drugs or alcohol based more on desires than on pleasure, leading to ingrained habits and a restructuring of brain anatomy due to plasticity that unfortunately leads to a reduction of further plasticity. He tells the stories of five very different addicts to show what addiction feels like as he explains the neural changes underlying it. He sees recovery as a process of further development. He points out that the addicts who quit do so uniquely and inventively, through effort and insight, and he claims they end up stronger as a result. In his enthusiasm, he almost seems to be recommending addiction as a force for good, for personal growth. It’s a bit like cancer survivors who say they are better for it. They have made the best of a bad experience, but I hope they wouldn’t recommend it to others. They have grown, but there are other ways to grow.
The brain really does change with addiction; but he interprets this as learning, not brain disease. Similar brain changes occur with other types of goal-seeking, when people become absorbed in a sport or become obsessed by someone they fall in love with. The changes are not unique to drugs; people can become addicted to gambling, love objects, porn, food, sex, and other activities. Others argue that calling it a disease facilitates treatment, but he is convinced it can be harmful, damaging patients’ self-image and self-esteem and making them feel helpless.
Up to three quarters of drug and alcohol addicts recover without any treatment. 75% of the soldiers who became addicted to heroin in Viet Nam stopped using it when they returned to the US. In a rat study, rats raised in isolated cages were given a choice between water and morphine and they became addicted to morphine; but when they were moved to a large enclosure with other rats, they switched to water. That doesn’t sound like the way a disease works.
Drug abuse is irrational, but irrationality is an essential feature of human nature, not a disease. Addiction is a habit that is different from more benign habits in that it is mental rather than just behavioral, it involves strong feelings of desire, and it progresses from impulsive to compulsive behavior.
He discusses the role of adverse childhood experiences, ego depletion, distraction, having a coherent narrative of one’s life, re-directing desires to other goals, and empowerment.
People choose to stop when they have suffered more than enough. And when circumstances lend a hand. And when the possibility of self-control becomes as attractive – more attractive — than any other possibility, including temporary relief.
More arguments against calling addiction a disease:
    • The brain changes disappear when people stop using.
    • The loss of synaptic density is just the normal pruning that occurs with learning; it increases neural efficiency.
    • The medical profession emphasizes genetics and downplays the role of experience and environment.
    • Psychological and environmental predictors have more to do with how we experience our environment, but diseases are based on exposure, not experience
    • Attraction to addictive drugs is a response to suffering, social isolation, and recurring negative emotions.
    • Pharmaceutical drugs ease withdrawal symptoms and reduce addictive urges but only while they are still in the blood, often replacing addictive chemicals with related chemicals that can also be addictive.
    • Drugs that act by disrupting the dopamine system have unfortunate side effects.
    • Treatment centers start with drugs and then switch to 12-step programs that have nothing to do with medicine.
    • Addiction treatment targets cognitive and emotional processes; there is no disease that can be arrested by doing that.
    • Social processes like support and love are effective in addiction but not in any disease.
He advocates community-based programs and getting help for patients without delay as soon as their desire to change is ignited.
Heilig: yes, addiction is a chronic disease
…addiction is a malfunction of some of the most fundamental brain circuits that make us tick, and a disease that is not much different from other chronic, relapsing medical conditions.
Heilig begins with an appeal for compassion. He says
Drugs hook into brain circuitry we all rely on to obtain what we desire, avoid dangers, and make sensible decisions. Once you have realized that, it is impossible to look at a person with an addiction and escape the thought, “There, but for the grace of God, go I.”
He describes his own research and some of the amazing scientific advances he has seen during his career. He says the conventional medical model is painfully insufficient and “the system” interferes with the best treatment. The lessons from research have not been incorporated into standard addiction treatment. Patients are detoxed and treated briefly in inpatient facilities and then discharged with no systematic follow-up. They are handed off to AA, which may be comforting to some but has not been proven effective. They are usually not offered the treatments that are most likely to prevent relapse.
There is a double standard: relapse in diabetes and hypertension when patients go off their medications means the treatment is effective; relapse to drug or alcohol use following discharge from rehab is seen as treatment failure. Just as in any other chronic disease, addiction requires lifelong disease management with behavioral interventions and relapse-prevention medications.
Only a minority of active users of any substance will develop substance abuse and it may take many years. This is corroborated by rat studies where the pattern of compulsive use and relapse with re-exposure only develops in one-fifth of the animals, the same proportion that is seen in human epidemiological studies. Compulsive drug use reflects pathology of motivational brain circuits, and physical “dependence” on the drug is neither necessary nor sufficient.
The clinician should “walk with the patient” to build a thread of trust and empathy, and then should step back and apply the scientific perspective to the human situation. As in any other disease, treatment should be solidly evidence-based whenever possible.
Heilig explains in detail why he is skeptical that habit formation would be a major cause of continued drug use; he doesn’t reject that model, but stresses that we should let the utility of the model for developing successful treatments decide just how important it is. He shows that research does not support the self-medication model.
There are many routes to addiction. Our current diagnostic categories are inadequate; some day we may be able to identify sub-types like “impulsive alcoholism,” “opioid-reward dependent alcoholism,” or “socially anxious alcoholism.” There is a strong genetic component that accounts for 55–70% of addiction. Some day genetic analysis may inform our treatment, but for now he thinks that taking a good family history is more important than sequencing the genome.
He provides an enlightening tutorial on the three main categories of addictive drugs: opioids (like heroin), psychostimulants (like cocaine), and alcohol. The addictive properties of drugs are influenced by the characteristics of the individual. Only a few of the patients given morphine for post-op pain report pleasurable effects. And people differ in how effectively morphine relieves pain. That depends on the genetics of the mu-opioid receptor gene.
He describes the various medications used to treat the disease of addiction. Methadone maintenance programs help patients stay in treatment and avoid heroin; they have saved many lives. Buprenorphine is even more effective and safer.
For alcoholism, naltrexone has been shown to block relapse in response to alcohol cues; corticotrophin releasing factor has been shown to prevent stress-induced relapse. Naltrexone was slow to be adopted because meta-analyses showed only a small effect size, but clinicians observed that a minority of patients responded dramatically to it. It turned out that patients with a specific mu-opioid receptor gene variant benefited, but those with the more common gene variants didn’t.
Heilig’s research was aimed at figuring out what was going on here. He realized that association was not causation: the gene hadn’t been proven to be the culprit, because it might be an innocent gene traveling with another gene close to it on the chromosome. To determine causation, he did an ingenious experiment. They genetically modified mice, knocking out the mouse mu-opioid gene and replacing it with one or the other human gene variant. The mice with the less common variant released four times as much dopamine, consumed more alcohol, and had a much better response to naltrexone treatment. We don’t yet have access to every patient’s genetic profile, but we can do a pretty good job of identifying the variant by taking a good history. If the patient is male, has a strong family history of alcoholism, and had a stimulant-like response from alcohol when first beginning to drink, chances are he will respond to naltrexone. And there is little to lose from trying.
What matters is not what you call it, but how you treat patients
So is addiction a disease or not? It might be interesting to see these two authors duke it out in a debate, but I think it would be far more interesting to see them share their ideas in a productive discussion. I think they are both right. It’s like the blind men and the elephant — each has part of the truth — and much could be gained by combining their different insights. The bottom line: what matters is not what you call it; what matters is whether you can help patients.
The treatment and recovery community is a business that is entrenched in its ways and ignores recent scientific evidence. Addiction treatment lies largely outside the world of medicine, which has shown little interest in claiming responsibility for this field. For whatever reason, drug companies tend to be uninterested in investigating drugs for treating addiction.
Any approach to addiction should be based on science and tested for efficacy; quacks and outdated approaches should be eliminated. The focus should be on long-term management. We can do better, and the issues raised in these two books can help point the way.

Video Games and the Brain
A new article looked at the effect of playing video games on the brain.Its results confirm what was previously suspected from prior research. First, it is another demonstration of use-dependent plasticity in the brain. Further, it supports a direct relationship between the types of activity in which people engage and increases or decreases in the respective parts of the brain. And finally it supports the inverse relationship between the hippocampus and caudate nucleus with regard to different learning strategies.
Steven Novella on August 9, 2017
Link

In the last few decades there has been a rapid and profound change to the way people in industrialized countries interact with information and the world around them. We are now multi-media creatures. Children are more likely to spend time playing video games than playing ball.
It seems likely that this will have an effect on our brains, which is an adaptive organ especially when it comes to processing information. The question that has not yet been resolved definitively is whether or not these changes are a net positive or net negative.
A new study looking at the effect of playing video games on the gray matter of the brain suggests that the answer is – it depends. Prior research suggests that video-game players may derive a number of cognitive benefits from playing. The current researchers summarize these findings:
Action video game playing, in particular, has been shown to increase performance in cognitive tasks within several domains including visual attention, visual short-term memory, executive function and procedural learning abilities.
These findings are not surprising. The brain displays what is called plasticity – the ability to make new connections in response to specific activity. This can be significant enough to actually see an increase in the size of the part of the brain responsible for that function. For example, violin players will have increased gray matter in the part of the brain that controls the hand that works the frets. In fact the research on music is similar to the research on video games – those parts of the brain involved demonstrate plasticity.
The current researchers were looking at the hippocampus, which is part of the brain involved in short term memory and specifically spatial memory. They divided their subjects into those who tend to use a visual-spatial strategy while playing, and those who are more “response learners,” which relies on the reward system for procedural learning.
This division was not arbitrary. The hippocampus, as notes above, is involved in using a spatial strategy to navigate a video game environment. A separate structure in the brain, the caudate nucleus, is involved in the reward system and procedural learning. Interestingly, previous research has shown that in humans (and rodents) there is an inverse relationship between these two systems. If you increase the size of the hippocampus, you decrease the size of the caudate nucleus, and vice versa. The reason for this relationship is not clear, but research suggests that the optimal condition is to have a balance between the hippocampus and caudate.
The researchers also looked at two different types of games, first person shooters (like Call of Duty) and 3D platform games, like Super Mario 64. 3D platform games generally require a spatial strategy for playing, and unsurprisingly all players of these games showed an increase in the size of the hippocampus after 90 hours of play.
Players of first person shooter games could use either strategy, although 83% were response learners rather than spatial learners while playing these types of games. In those players who tended to be response learners playing first person shooter games resulted in a decrease in hippocampus size after 90 hours of play.
These results confirm what was previously suspected from prior research. First, it is another demonstration of use-dependent plasticity in the brain. Further, it supports a direct relationship between the types of activity in which people engage and increases or decreases in the respective parts of the brain. And finally it supports the inverse relationship between the hippocampus and caudate nucleus with regard to different learning strategies.
There are specific implications to this research beyond wonky neuroscience. Decreases in the size of the hippocampus are associated with a higher risk of psychiatric illness such as depression and PTSD, and also Alzheimer’s disease. Further, playing certain video games, as noted above, may have benefits for certain types of tasks. Playing video games, for example, improved the skills and outcomes of surgeons using laparoscopic techniques. So there are real-world implications at stake.
The bottom line of all of this is fortunately probably simple. The best advice remains – do stuff, do different kinds of stuff, and do new stuff. When you engage in any activity you are using your brain, and this will result in learning and plasticity. The brain responds to anything you do by reinforcing whatever connections and structures are necessary to do it.
Playing video games is therefore no different than anything else, it is just another type of activity. Playing a video game will increase whatever cognitive strategy you are using to play that game. Video games may have an advantage of having a rapid response because of the intensity of the interaction. They can also be tailored so that the difficulty increases as a player’s skill increases, so they can stay in the optimal range of difficulty for learning.
The potential disadvantage of video games is that they may encourage playing one type of game for many hours at the cost of other activity. This gets to the – do different kinds of stuff – recommendation. The old advice of everything in moderation seems to hold pretty well with this kind of neuroscience research. Engage in different kinds of activity, including different kinds of video games, and of course more physical activity. And try new things, which seem to be especially stimulating to the brain.
The result of engaging in a variety of cognitive activities and trying new things will be a decreased risk of mental illness and dementia. It will probably also be more fun and enjoyable.

Is Gaming Addiction a Thing?
The WHO has added gaming disorder as an official ICD diagnosis, and the APA is considering adding gaming disorder to the DSM. What is gaming disorder and how should it be diagnosed?
Steven Novella on June 20, 2018
Link

Full disclosure – I am an avid video gamer. I have been since Pong first came out in 1972, and I have enthusiastically indulged in video games all the way to the current virtual reality games. Playing video games has always been one of many recreational activities I engaged in, always in moderation, and has never taken over my life. OK – there was this one stretch in 1994 after Doom was released where I played more than I should have, and I had to delete the game from my computer. But otherwise, video games have been a fun and harmless pleasure.
For some, however, video games do take over their lives. For this reason the World Health Organization (WHO) recently added Gaming Disorder to their official list of health conditions in the International Classification of Diseases (ICD-11). Many are calling the disorder “gaming addiction,” although the term “addiction” should probably be reserved for biological addiction to substances. Gaming disorder, rather, is a pure compulsive behavior.
So what is gaming disorder?
Gaming disorder is defined in the draft 11th Revision of the International Classification of Diseases (ICD-11) as a pattern of gaming behavior (“digital-gaming” or “video-gaming”) characterized by impaired control over gaming, increasing priority given to gaming over other activities to the extent that gaming takes precedence over other interests and daily activities, and continuation or escalation of gaming despite the occurrence of negative consequences.
For gaming disorder to be diagnosed, the behaviour pattern must be of sufficient severity to result in significant impairment in personal, family, social, educational, occupational or other important areas of functioning and would normally have been evident for at least 12 months.
This is a pretty standard pattern for psychologically-based diagnoses. A “disorder” is defined as an impaired ability or function, a symptom, or a behavior that is persistent, perceived as negative, and causes demonstrable harm. There isn’t necessarily any pathology, and therefore there is no disease. That does not mean disorders are not real.
The brain is the organ of mood, thoughts, and behavior. The function of the brain is dependent upon not only the health of the various types of brain cells, but the pattern, strength, and function of connections. There are therefore many potential types of mental disorders that involve only the pattern of connections, without any classical cellular pathology.
The function of the brain is also dependent on biological as well as environmental factors. It’s complicated, and teasing apart the cause(s) of any identified problem behavior is also complex. For this reason mental disorders are primarily characterized by their clinical features – the pattern of mood, thoughts, and behaviors that typify them. Something as complex and chaotic as human behavior defies any attempt at unambiguous categorization, so there is a lot of overlap and fuzzy boundaries, but it is still possible to identify different basic types of disorders.
This is what the new WHO classification attempts to do. The other relevant document to this question is the DSM – the handbook of mental disorders. The American Psychiatric Association (APA) added “Internet Gaming Disorder” as a “condition for further study” in the DSM-V. So it is not yet an official diagnosis, but they want clinicians to give it a try and let them know how it goes. Is it a useful diagnosis, and should it be added to the DSM?
Here is their working definition:
1. Repetitive use of Internet-based games, often with other players, that leads to significant issues with functioning. Five of the following criteria must be met within one year:
     1.  Preoccupation or obsession with Internet games.
     2.  Withdrawal symptoms when not playing Internet games.
     3.  A build-up of tolerance–more time needs to be spent playing the games.
     4.  The person has tried to stop or curb playing Internet games, but has failed to do so.
     5.  The person has had a loss of interest in other life activities, such as hobbies.
     6.  A person has had continued overuse of Internet games even with the knowledge of how much they impact a person’s life.
     7.  The person lied to others about his or her Internet game usage.
     8.  The person uses Internet games to relieve anxiety or guilt–it’s a way to escape.
     9.  The person has lost or put at risk and opportunity or relationship because of Internet games.
I don’t know why they decided to limit the diagnosis to internet-based games. The exact same phenomenon can occur with offline games. I suspect the people involved were not gamers. But that nitpick aside, you can see that there is a reasonable operational definition that includes all the elements of a disorder – persistent, negative, and causing demonstrable harm.
As a compulsive type disorder, there is also an element of loss of control. Those with alleged gaming disorder persist in their behavior even when they know they shouldn’t, when it is causing them harm, even ruining their health and their lives. They engage in behavior that is otherwise not consistent with their personality, such as lying and manipulation – behavior typical of addiction.
Of course not all avid gamers have a disorder. Compulsive behavior is a typical human trait, and can be very adaptive. It can make us industrious, it is how musicians and artists master their craft, and athletes excel. Even if art or sports are for pure recreation (and not a person’s day job), we tend not to criticize avid artists or sports players. But being an avid gamer has a bit of an unfair stigma attached to it. That is not what makes it a disorder, however. Again – it has to have a demonstrable negative impact on your life, it has to cause harm.
Like all behavior-based disorders, there is a continuum, and no sharp demarcation line. But still, at one end of the spectrum there is a clear problem that may respond to intervention. So it makes sense to have a label to identify this harmful pattern of behavior, so we can talk about it and research it. There is also a practical angle in that professionals need to get reimbursed for their time, and insurance companies need to know what they are paying for, and so ICD codes are primarily used for billing.
In the end I think gaming disorder is a real thing, and the working definitions of the WHO and APA are reasonable. It is a type of compulsive behavior, like gambling, and is a harmless recreation in moderation, but can be ruinous if it takes on a life of its own. This may occur if there is an underlying disorder, like anxiety or depression, and someone is using the compulsive behavior to self-treat. Some people may have a compulsive personality type. Others may get into a compulsive pattern of behavior for a variety of non-specific reasons.
Perhaps it is often the case that gaming disorder, or another harmful compulsive behavior, is more of a symptom of deeper problems in someone’s life. It is still a useful entry point to address those deeper problems, and it has become a problem unto itself that needs to be addressed.
Like all such disorders that are one end of a spectrum of behavior, it is important to stick to strict diagnostic criteria, and be wary of diagnosis creep. That’s bound to happen, but it also does not mean that gaming disorder is not real.
        ◦ Finally, I don’t think that gaming disorder is a unique or entirely new phenomenon. It is simply a cultural manifestation of a more general compulsive behavior disorder. Humans, to an extent, are not much different than rats. We have a reward system wired into our brains. When we pull that lever and get a reward, something that gives us a pleasant shot of dopamine, we will pull that lever again and again. It’s built into the system. We just need to know when to stop pulling that lever. For some people it’s easier said than done, and they may need some help taking their hand off the lever.

Mental Illness Denial
This is really hard, and we have limited knowledge, but we have accumulated enough knowledge about mental health and illness to take a practical approach to many patients and to help them improve their lives. This should include the full range of options available, including medication and counseling. To deny the role of medication can do great harm to those who may need it.
Steven Novella on January 24, 2018
Link

I was recently pointed to an article by Johann Hari in The Guardian that takes a critical look at depression and the treatment for depression. Unfortunately, it turned out to be nothing more than the usual mental-illness denial talking points, misdirection, and obfuscation.
Mental illness denial is a well-worn topic for me. The basics are this – there are those, for various reasons, who are engaged in what I think qualifies as mental-illness denial. They include Scientologists, because they push their cult/religion as an alternative to psychiatry. There are also those who follow Szasz who saw psychiatry as a mechanism for political oppression. I also find denial at times among rival professions who want to take psychiatry down a peg or two (often they just confuse their experimental expertise for clinical expertise – always a problem).
They all tend to have in common the core claim that “mental illness” is a fiction. How can thoughts be diseased? This is ultimately a straw man that confuses different types of illness. Some illness is based in biological pathology – cells are damaged, deteriorating, poisoned, genetically flawed, or essentially not functioning within healthy parameters for some reason. You can often see the pathology in a biopsy or measure it with some physiological parameter.
But not all illness is pathological disease. There are also disorders in which some biological function is outside of healthy parameters without clear pathology. The brain in particular is prone to this type of illness, and that is because brain function depends on much more than just the health of its cells (neurons and glia). Even healthy brain cells can be organized in such a way that their neurological function is compromised.
Let’s say, for example, that the anxiety circuitry in the brain is hyperactive creating spontaneous, unfocused, and debilitating anxiety. Now of course, anxiety itself is part of our natural neurological function. It serves a purpose. But excessive and spontaneous anxiety no longer serves a functional purpose, it just inhibits the ability to function. It is a mental disorder, in the absence of biological pathology.
Mental health deniers, however, twist themselves into logical knots trying to deny that there could possibly be anything about excessive anxiety that we can properly call an illness or disorder.
Like all campaigns of denial, there is also a range of approaches to denying the existence and implications of mental illness. At the extreme end you will find pseudoscience and conspiracy theories. At the milder end you will find softer denial, and denial that they are deniers. At this end there is the attempt to sound reasonable, and to conceal that at the end of the day they are engaging in motivated reasoning to deny the topic they oppose for ideological or other reasons. They give themselves away, however, by using the tactics of denial, and always flirting with the more extreme arguments.
For example, climate change deniers trying to sound reasonable will often acknowledge that the Earth is warming, we just can’t be sure that humans are causing it. But if you back them into a corner with evidence, they will acknowledge this but just deny that we can do anything about it. There is evidence that this behavior is rooted in “solution aversion” – in the end they oppose proposed solutions to climate change, and will deny the science only as much as they need to in order to oppose those solutions.
With mental illness denial, sometimes the motivation is psychiatry denial – opposition to the psychiatric profession. Of course you can do this by denying mental illness, but for those trying to seem reasonable you can also say you accept that there is such a thing, but then deny that we understand it well enough to treat it. Or you can simply deny the approach to mental illness of the psychiatric profession.
At this point I want to be clear – there are legitimate criticisms of psychiatric science and practice. Just as there are legitimate criticisms of medicine in general, and any applied science, including climate science. There is also no sharp demarcation between fair and legitimate criticism and motivated denial. You need some knowledge and judgement to see the difference at the fuzzy border. That is why I tend to characterize denialism as a process, try to define and understand the process as best as possible, and then be vigilant about the intrusion of denialism strategies at any level.
So let’s get back to Johann Hari’s article and see where I think he veers into denialism. Hari is writing about the difference between a depression disorder and normal grief. He is commenting on the DSM (the manual psychiatrists use to make diagnoses – a popular target among deniers):
The authors conferred, and they decided that there would be a special clause added to the list of symptoms of depression. None of this applies, they said, if you have lost somebody you love in the past year. In that situation, all these symptoms are natural, and not a disorder. It was called “the grief exception”, and it seemed to resolve the problem.
So, in order to avoid confusing normal grief with a depressive disorder the DSM included a grief exception. This is common in defining mental illness. The brain interacts with the environment, so if we want to decide if a certain pattern of mood, thought, and behavior is due to a brain disorder we have to rule out that it is just responding to environmental triggers. Like with the anxiety example above – anxiety is normal if you have something to be anxious about, but a disorder if it is spontaneous or clearly out of proportion to the stimulus.
Hari continues his narrative:
Then, as the years and decades passed, doctors on the frontline started to come back with another question. All over the world, they were being encouraged to tell patients that depression is, in fact, just the result of a spontaneous chemical imbalance in your brain – it is produced by low serotonin, or a natural lack of some other chemical. It’s not caused by your life – it’s caused by your broken brain.
This is an oversimplification to the point of being wrong. See above – depression is caused by life, and when it is, that is not a disorder. But if an evaluation rules out reasonable life causes of depression, then we are left with the possibility that there is something about brain function that may be causing depression. Also keep in mind that the depression, in order to be considered a disorder, has to interfere with one’s life. It has to cause “demonstrable harm.”
And now here is where Hari goes entirely off the rails:
The grief exception seemed to have blasted a hole in the claim that the causes of depression are sealed away in your skull. It suggested that there are causes out here, in the world, and they needed to be investigated and solved there. This was a debate that mainstream psychiatry (with some exceptions) did not want to have. So, they responded in a simple way – by whittling away the grief exception. With each new edition of the manual they reduced the period of grief that you were allowed before being labelled mentally ill – down to a few months and then, finally, to nothing at all. Now, if your baby dies at 10am, your doctor can diagnose you with a mental illness at 10.01am and start drugging you straight away.
Is he really claiming that a competent psychiatrist practicing within the standard of care would diagnose a client with mental illness and prescribe medication one minute after their child dies? You might be tempted to say he was using an extreme example to illustrate a point – but that misses my point. Making such a diagnosis is all about context.
Hari creates a neat little narrative here that serves his purpose of mental illness denial. In his narrative, psychiatrists removed the grief exception from the DSM because it was inconvenient. However, here is a passage from the DSM-V that Hari neglects to mention:
Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgment based on the individual’s history and the cultural norms for the expression of distress in the contest of loss.
So what they really did was remove it from the list of criteria, which required putting a time limit on grief, and instead moved it to a note that was more open-ended and encouraged “clinical judgment.” Any fair and reasonable discussion of the psychiatric approach to mental illness and the evolution of the DSM should have contained this passage. But I guess it didn’t fit Hari’s neat little narrative.
After recounting his startling discovery that people are psychological beings with emotional needs (shocker), he finishes with this false dichotomy:
If you are depressed and anxious, you are not a machine with malfunctioning parts. You are a human being with unmet needs. The only real way out of our epidemic of despair is for all of us, together, to begin to meet those human needs – for deep connection, to the things that really matter in life.
This is a hopelessly simplistic approach to mental health, ironically as simplistic as the straw man “malfunctioning parts” approach he is criticizing. Rather, our mood, thoughts, and behavior are the net effect of a complex interaction between brain and environment. There are always a complex mix of psychological and psychiatric and sometimes neurological factors involved (rarely, it is a brain tumor). It takes care and clinical judgement to tease apart when someone just needs some counseling, or to make some practical changes to their life, or just time to process grief or other life events – and when they have a disorder that also needs to be treated in order to make it even possible for them to engage in therapy.
The DSM psychiatric approach to patients who have mental complaints, signs, or symptoms is to take a multi-tiered approach. First, rule out any underlying medical condition (make sure their anxiety isn’t due to hyperthyroidism, for example). Then assess their signs and symptoms in the context of their history to determine how much of it is likely to be due to life events. How much is personality. And how much, if any, may be due to some misfiring circuit in the brain.
This is really hard, and we have limited knowledge, but we have accumulated enough to take a practical approach to many patients and to help them improve their lives. This should include the full range of options available, including medication and counseling. To deny the role of medication can do great harm to those who may need it.

Psychology and Psychotherapy: How Much Is Evidence-Based?
Harriet Hall on March 31, 2015
Link

Despite all those Polish jokes, Poland has its share of good scientists and critical thinkers. A superb new book illustrates that fact in spades:
Psychology Gone Wrong: The Dark Side of Science and Therapy, by Tomasz Witkowski and Maciej Zatonski, Witkowski is a psychologist, science writer, and founder of the Polish Skeptics Club; Zatonski is a surgeon and researcher known for debunking unscientific therapies and claims in clinical medicine. Together, they turn a spotlight on research and treatment in the field of psychology. They uncover distressing flaws, show that many commonly accepted psychological principles are based on myths, argue that psychotherapy is a business and a kind of prostitution rather than an effective evidence-based medical treatment, and question whether psychotherapy should even exist, since in most cases it offers no advantage over talking to a friend about one’s problems, and in some cases can cause harm.
Research
They describe how disasters of social control like forced sterilizations and uncritical application of questionable IQ tests were instigated by psychologists who relied on their own flawed thinking rather than on empirical evidence from scientific studies. They tell horror stories about researchers who lied, plagiarized, distorted, falsified or even fabricated data, and got away with committing outright fraud over and over again. In some cases fraudulent studies were accepted as gospel and became the basis for ill-advised treatments.
They argue for transparency in research and show how difficult it is for others to obtain the raw data from studies even when the researchers say they are willing to provide it. They offer proposed solutions to increase transparency and promote data sharing. They discuss problems with peer review, editorial policy, poor research design, non-publication of negative studies, and failure to replicate positive studies. They show how these have created a situation where psychological theories are virtually unkillable.
They show how study results can get distorted and changed in re-telling. Remember the Little Albert experiment? An infant was conditioned to develop a fear of white rats by exposing him simultaneously to a white rat and a loud noise. This confirmed a popular theory, so it was immediately accepted as evidence that early childhood experiences could create lasting phobias that would extend to similar objects (in this case, to anything white and furry). Most psychology textbooks have misrepresented the facts about that experiment. They get the child’s age wrong, say he was conditioned with a white rabbit, and make up other stimuli that he supposedly reacted to, like a puppy and a teddy bear. Some textbooks even described how the researchers later “deconditioned” Little Albert, but that never happened. The research was done while he was in the hospital; they knew he would soon be leaving the hospital and it would be impossible to continue the research, and they deliberately decided not to decondition him. He died of hydrocephalus at age 6, so there is no way to know whether he would have had a lifelong phobia.
They uncover social control problems in the scientific community. Scientists who observed misconduct in their peers failed to report it in 36% of cases, and 69% of whistleblowers experienced negative consequences after reporting fraud.
Common yet questionable ideas
PsychoanalysisPsychoanalysis is a castle built on sand. Investigation has shown that Freud falsified or fabricated the details of every case he used to build his theory. His approach was not scientific. He never tested his ideas with experiments that might have falsified his beliefs, and he ignored facts that contradicted his beliefs. Many of his supposed original ideas came from other authors. How did he “discover” the Oedipus complex when none of his patients ever suggested they had such a problem? The answer is in a letter he wrote to a friend saying, “I found in myself a constant love for my mother, and jealousy of my father. I now consider this to be a universal event in early childhood.” Talk about projection and confirmation bias!
When tested, psychoanalysis was shown to be less effective than placebo. Its theories have been disproven, and no reasonable scientist or practitioner takes it seriously today. Yet it persists in popular opinion as one of the primary canons of practicing psychology.
Childhood experiencesWitkowsi and Zatonski provide ample evidence to debunk these myths about childhood experiences:
     1.  Personality is formed by early childhood experiences.
     2.  Mental disorders are caused by early childhood experiences.
     3.  Effective psychotherapy depends on the reconstruction of childhood experiences.
Delving into childhood memories often causes serious problems, and has led to terrible abuses such as the recovered memory movement. The idea of repressed and recovered memories is a creative invention of therapists. Patients are easily duped because it provides a convenient scapegoat to explain their problems and relieves them of responsibility for their inability to cope with their lives. Academic psychologists bear much of the blame for failing to subject pop trends to empirical verification and failing to speak out and denounce false theories.
Childhood sexual abuseThe typical consequence of childhood sexual abuse is not psychopathology but resilience. Studies have found no correlation with adult mental disorders, even when abuse is frequent or extreme. Less than 10% of victims experienced the abuse as traumatic or shocking at the time it occurred. Childhood sexual abuse is abhorrent enough in itself without tarring it with false claims that it causes adult mental illnesses. And those who point out the research findings (such as Bruce Rind) should not be accused of advocating crime.
PsychotherapyPsychotherapeutic interventions in general have been remarkably unsuccessful. Only one of the many varieties of psychotherapy is supported by acceptable evidence: cognitive-behavioral therapy. There is no correlation between a therapist’s training or experience and patient outcomes. Amateurs get equal results. The benefits of psychotherapy may be no better than the benefits of talking to a friend; in a sense, psychotherapists are paid to act as friends, which could be considered a sort of prostitution.
The harms of therapyTherapy can do real harm and can lead to suicide. It encourages dependence, false optimism, and externalized responsibility. Not one study of AA has ever shown it superior to any other approach for treating alcohol abuse, and in fact untreated patients have similar or better outcomes. Sexual misconduct by therapists has become so common that insurance companies have been refusing to insure them.
What are the alternatives?Can we replace psychotherapy with something else? Can a new “salutogenic” paradigm replace the pathogenic paradigm by focusing on human resilience and coping abilities? Mental health is characterized by commitment (a sense of purpose), by the belief that you have some control over your life, and by the understanding that change, not stability, is a natural element of reality. Hardiness is largely genetic but can be developed by exposure to stress.
Psychobusiness
Psychotherapy is more business than medicine. Bogus therapies abound. The authors devote two entire chapters to neurolinguistic programming (NLP), showing how it developed and flourished without any basis in reality, how the scientific literature served as theater decoration for a pseudoscientific farce, how it infiltrated academia, and how the scientific community irresponsibly failed to denounce it.
In another chapter, one of the authors describes how he perpetrated a psychological Sokal hoax. He got a bogus article published about a new therapy he invented based on Rupert Sheldrake’s pseudoscientific concept of “morphogenetic fields.” He invented and plagiarized outrageously, and offered clear hints about what he was doing, but the editors didn’t notice. They had some questions, but he made up nonsense answers and they bought his explanations. He accuses the editors of failing in their responsibility to protect their readers from false information and harmful recommendations. He conducted a test by having 172 people read the article: 77% said they would recommend the article to friends, and 61% would recommend the invented therapy to a person struggling with psychological problems. It’s scary to think how easily he could have marketed his new therapy and become rich at the expense of patients. In fact, after he disclosed that it was a hoax, he got a letter from a man who insisted that it was not a hoax; he said he had been thinking along the same lines and had reached the same conclusions.
Reacting to pseudoscience
In the concluding chapter, they describe the strategies employed by scientists with regard to pseudoscience:
     1.  Remaining indifferent and keeping silent.
     2.  Playing down the problem (Val Jones calls them “shruggies,” those who don’t feel the need to react because they think it’s no big deal and does little harm).
     3.  Attacking critics by questioning their competence and even their mental health rather than by engaging with the evidence.
     4.  Talking and giving the illusion of action without actually doing anything. Encouraging further debate, which is always a mistake.
     5.  Passive acceptance of criticism.
     6.  Arrogant hostility. Insulting pseudoscientific practitioners and using words like psychobabble, mumbo-jumbo, quackery, and flimflam.
     7.  Open, matter-of-fact criticism. The most fruitful strategy but the one least popular among psychologists.
Conclusion
You may find some of these ideas questionable or unpalatable. If so, I hope you will read the book and give the authors a fair chance to explain their thinking. This is a well-referenced, well-reasoned book that is chock-full of information about the state of psychology today. It exposes a lot of dirty linen that would be of interest to any reader. I agree with James Alcock, Professor of Psychology at York University, whose back-cover blurb says it should be required reading for every psychologist and psychology student and anyone contemplating psychotherapy.
I have only one criticism of the book – English is not the authors’ native language, and it shows. There are many infelicities of expression and even errors of grammar and usage. This does not interfere with understanding what the authors meant, but a good editor could have done a lot to improve their text.

Improving mental health is a walk in the park (but mind the volcanoes)
Using Twitter and geotagging, researchers add to the growing body of evidence demonstrating an association between contact with nature and improved mood.
Jann Bellamy on August 29, 2019
Link

A new study from researchers at the University of Vermont adds to the body of evidence suggesting that better mental health is right out your front door. [Schwartz, AJ, et al, “Visitors to urban greenspace have higher sentiment and lower negativity”, People and Nature, 2019; published by the British Ecological Society]
According to Christopher Danforth, one of the study’s co-authors,
Being in nature offers restorative benefits on dimensions not available for purchase in a store or downloadable on a screen.
That’s bad news for the wellness-industrial complex.
Noting “a growing interest in understanding the connection between mental health and exposure to biodiversity”, the researchers, funded by the National Science Foundation, turned to Twitter and geolocation technology to assess the association between park visits and changes in happiness, as expressed in tweets. In 2016, they collected all tweets (about 70,000 per day) geotagged with latitude and longitude in San Francisco, CA, for three months. San Francisco was selected because over 98% of its population live within walking distance of its top-ranked park system, which spans more than 220 sites and 3,400 acres. Parks were categorized based on vegetation cover in order to better understand how park type relates to the benefits of park visits. In other words, is bigger and greener better?
Using a complex process to collect and analyze Twitter user location and tweet content, the researchers compared user sentiment before, during, and after park visits. Lest you think “sentiment” too squishy a measure for science, you’ll be relieved to learn the researchers used the Hedonometer,
a word analysis tool that quantifies the sentiment of text based on the happiness values attributed to English words. The Hedonometer has been demonstrated to correlate with traditional survey metrics of subjective well-being at the city and state level, including Gallup’s well-being index and United Health Foundation’s America’s health ranking. The Hedonometer has also been deployed to analyse the discourse around climate change following hurricanes. [Citations omitted.]
How does this work?
The Hedonometer includes a sentiment dictionary for 10,022 of the most commonly used English words, merged from four distinct corpora . . . [and] performs favourably compared the other sentiment dictionaries . . . .The words were rated on a scale from 1 (least happy) to 9 (most happy). For example, “sunshine” has a score of 7.9 and “traffic” has a score of 3.3. [Citations omitted.]
To give context to their study, the authors catalogue some of the existing research on the mental health benefits of exposure to nature, including associations between
    • Subjective well-being and nearby natural areas,
    • Neighborhood greenness and lower levels of depression,
    • High levels of childhood exposure to greenspace and lower risk of developing psychiatric disorders,
    • Improved affect and cognition and walking through natural areas (as opposed to urban environments),
    • Walking in areas with greater biodiversity and subjective well-being,
    • Nature exposure and prosocial behavior,
    • At least 120 minutes of weekly nature exposure and enhanced self-reported health and well-being.
They note that “complementary theories from psychology and neurobiology suggest several mechanisms connecting nature exposure with mental state.” These include the “Biophilia hypothesis”, the idea that humans have an innate affinity for the natural environments like those in which we evolved, and “Attention Restoration Theory”, which predicts that time spent in nature gives us the opportunity to restore “directed attention capacity”, improving cognition. “Stress reduction theory” predicts a decrease in stress after contact with nature, “resulting in a variety of positive health outcomes”.
And the results are
In their research, the authors asked three questions.
What is the magnitude and duration of the change in sentiment (or, “happiness values”) from visiting urban parks?
Tweets posted within parks have a higher “happiness value” than tweets posted before or after park visits, and this elevated sentiment lasts from one to four hours. The mean change in sentiment for all parks was 0.229, which the authors compared to that of Christmas Day, 2016, the “happiest day” of that year, at least according to Twitter. They found that
tweets during visits to urban parks exhibited a similar increase in sentiment as the jump on Christmas Day for Twitter users as a whole.
What is the association of park type and vegetative cover with the change in sentiment from park visitation?
The bigger and greener the park, the greater the mean change in sentiment. Regional Parks have the highest mean change, followed by neighborhood parks and playgrounds (moderate mean change), then Plazas and Squares (lowest mean change).
What do word frequency patterns indicate about the mechanisms driving the change in sentiment from park visitation?
Park visits mean happy tweets.
Tweets in parks have higher sentiment than tweets prior to park visitation due to positive words with higher frequency, such as “beach”, “beautiful”, “festival”, “happy”, “young”, “fun”, and negative words with lower frequency, such as “not”, “no”, “don’t”, “can’t”, and “wait”. Of specific interest, negation words such as “not” and “don’t” fluctuate before and after park exposure but exhibit a marked drop (45% and 47%) in and around the park exposure. The word “beautiful” exhibits the opposite pattern, fluctuating around a baseline and then roughly doubling in frequency during park exposure. Finally, we examine the first person word “me” which has a neutral sentiment . . . . Use of “me” drops 38% from its mean use level during park visits. [Intra-article references omitted.]
That last stat leads me to infer that golf courses are no substitute for parks.
The authors note several limitations of their study: the difficulty of separating the roles of exercise and socialization from the contributions of nature to well-being and the inability to look at how age, gender, education levels, culture, socioeconomic status, and climate type may affect one’s response to nature.
On a policy level, they suggest that
Research further linking health with urban greenspace and biodiversity protection can help planners and public health officials build new strategies that support both goals. We suggest building or expanding parks near populations with limited access to greenspace and targeting funds towards the most effective types of parks for mental health benefits.
But, volcanoes
Despite the capacity for happy tweets, research tells us there are downsides to park visits. For example, you might want to think twice about making Yellowstone National Park your destination. Or, for that matter, any park in Colorado, Wyoming or Utah. According to a recent opinion piece in the New York Times, while it is “very, very, very unlikely” that the supervolcano beneath Yellowstone will erupt while you’re there, nevertheless, it has done exactly that three times over the past 2.1 million years, most recently 640,000 years ago.
First would come increasingly intense earthquakes, a sign that magma beneath Yellowstone was rushing toward the surface. The magma would burst through the ground in a titanic eruption, discharging the toxic innards of the earth to the air. It would continue for days, burying Yellowstone in lava within a 40-mile radius.
This would start a cascade of devastating events, which volcanologists estimate would bury large portions of Colorado, Wyoming and Utah in up to three feet toxic ash and, depending on the weather, dump a few inches on the Midwest and sprinkle the coasts. This supervolcano eruption would destroy crops, contaminate pastureland, and ruin power lines and transformers. Global temperatures might plummet due to blocked sunlight, rainfall would decline, perhaps killing off tropical forests, and farming could collapse, all making for what a 2015 European Science Foundation report on extreme geohazards called “the greatest catastrophe since the dawn of civilization”.
Whew!
But there is some good news. Although Bryan Walsh, the author of this op-ed, cheerfully titled “A Giant Volcano Could End Human Life on Earth as We Know It”, thinks we pay insufficient attention to existential risks like supervolcanos, the probability of a supereruption at Yellowstone in any given year is 1 in 730,000.
There are 20 of these supervolcanoes on earth. Mr. Walsh doesn’t say where the others are, something you may want to look up before choosing which park you might visit to improve your mental health. Whatever you decide, if you feel the earth trembling, be sure to tweet about it.

Psychodermatology?
A new specialty, psychodermatology, was invented to address the interaction of the mind and the skin. The effects of stress on the skin are not well defined, and the need for this new specialty is questionable.
Harriet Hall on April 17, 2018
Link


Psychodermatology has emerged as a new subspecialty of dermatology and psychiatry. It even has its own organization, the Association for Psychoneurocutaneous Medicine of North America. On their website you can locate a psychodermatologist in your area.
What exactly is psychodermatology? According to a review article in American Family Physician “A psychodermatologic disorder is a condition that involves an interaction between the mind and the skin.” They break it down into three categories:
     1.  Psychophysiologic disorders that become worse with emotional stress, like psoriasis and eczema
     2.  Primary psychiatric disorders that result in self-induced cutaneous manifestations like trichotillomania and delusions of parasitosis
     3.  Secondary psychiatric disorders where disfiguring skin disorders result in psychological problems such as decreased self-esteem, depression, or social phobia
They stress the importance of understanding the psychosocial, familial, and occupational context of skin disease. Yes, mainstream medicine is “holistic,” addressing everything about a patient that might affect diagnosis or treatment. This is true holistic medicine, not the kind of thing alternative medicine talks about.
Secondary psychiatric disorders
This is kind of a “well, duh!” thing. It goes without saying that if someone has a disfiguring skin disease it will have a psychological impact on his life in one way or another.
Primary psychiatric disorders
In addition to trichotillomania and delusions of parasitosis, there is dermatitis artefacta, where skin lesions are produced by the patient’s own actions. It’s also known as neurotic excoriations. It can be a form of emotional release in situations of distress. Patients will often deny scratching, but if they are prevented from touching the affected area (for instance, by a cast that covers a lesion on the arm) the lesion will heal.
Anecdote alert! I can’t vouch for this, but I heard it from the girlfriend of a dermatologist who told her about one of his patients. The patient had a skin lesion on his arm that he perpetuated by scratching. The dermatologist hypnotized him and gave him the post-hypnotic suggestion that whenever he felt the urge to scratch, he would resist the impulse and instead drop whatever he happened to be holding in his hand at the moment. At the dinner table, his wife would frequently say things that annoyed him, and he would respond to the stress by scratching. When he started dropping things instead of scratching, the wife stopped saying things that made him drop his fork or his drinking glass and make a mess on the table. She didn’t consciously realize what was happening, but she had become conditioned like Pavlov’s dogs. The man’s skin lesion was cured, and so was the wife’s nagging! If it’s not a true story, it should be.
Psychophysiologic disorders
No one would deny that a person’s psychological state can affect the skin. We blush when we are embarrassed or ashamed. Our hands sweat when we are anxious, afraid, in pain, or under stress. Strong emotions can produce goose bumps.
Stress is widely believed to cause or exacerbate a great many skin conditions, from psoriasis to alopecia areata. There are plausible physiological mechanisms; for instance, stress has been shown to affect skin permeability and the antimicrobial properties of the epidermal barrier. The role of stress is supported by numerous case reports and studies that not only show a correlation but sometimes report the success of psychotherapeutic interventions.
But there is a big problem with the research. In a 2013 article in Clinics in Dermatology, Orion and Wolf say “Although many data have been published, it appears that not enough good statistical evidence exists to support them.” It is difficult to measure stress; it is usually assessed retrospectively by self-reports on questionnaires. And patients may not be aware of stresses: in a study of alopecia areata in children, alopecia patients were more likely to be a member of a single-parent family and to perceive less expressiveness within their family than epileptic patients or healthy children, but they didn’t report more anxiety or depression.
It seems clear that stress can cause or exacerbate some skin disorders. What’s not so clear is what we can do about it. As Orion and Wolf went on to say:
Surprisingly, it appears that researchers show more enthusiasm in proving psychological difficulties to be an etiologic factor in the onset, exacerbation, or reoccurrence of skin diseases, but much less enthusiasm in finding whether psychological therapies can ameliorate them…To date, we still do not know enough about how to deal with this issue, although ironically this is the most important and practical question.
Conclusion: Do we really need this specialty?
I’m all in favor of raising awareness of the possible impact of stress and psychological factors on skin disorders. But do we really need a separate subspecialty to do that? I also found references to psychogynecology, psychopediatrics, psychocardiology, psychoorthopedics, psychourology, and psychoophthalmology. Do we need a “psycho-something” for every single branch and twig of medicine? I would argue that we don’t really need such terms because good clinical medicine already has a holistic approach that takes psychology into consideration. In an ideal world, when we said “dermatology” it would be understood that we include all the psychological, social, environmental and other factors that have a bearing on the diagnosis and treatment of skin diseases.

How To Approach Psychogenic Symptoms
Steven Novella on May 8, 2024
Link

Remember back in 1997, the Pokemon seizure episode? Hundreds of children reported symptoms, including seizures, after watching a specific episode of the Pokemon cartoon that includes a sequence of flashing alternating red and blue lights. The press reported the episode at face value, attributing the reaction to a known phenomenon of photosensitive epilepsy. However, later reviews found that the majority of cases were not seizures, and in fact occurred during later viewings of the episode, after the story was widely reported. In one survey, for example, about 15% of the children who reported symptoms reported having actual seizures.
The episode is a great example of a mass hysteria – a story spreading widely in the public that triggers some form of psychological reaction. This could involve a report of a UFO sighting leading to many further reported sightings, or the belief that something toxic is making people in a building sick leading to many people reporting symptoms, even if ultimately there is no underlying cause.
But we do need to keep in mind that, as with the Pokemon case, the original trigger of the mass hysteria was a real neurological reaction in some children. Photosensitive epilepsy is real. It is likely that the intensity and duration of the flashing lights was enough to trigger seizures in some susceptible children. Careful analysis also found that there were some specific conditions that contributed to the actual seizures – the frequency and duration of the flashing lights, viewing the program in a dark room and being closer to the screen.
As a neurologist this is a lesson we have to keep in the forefront of our clinical decision making. We typically use the term “psychogenic overlay” to describe apparently physical symptoms that may have a psychological origin. The “overlay” part is important, because most of the time the psychogenic symptoms are in addition to underlying neurological symptoms. We may also use the term “embellishment”, again to suggest that the psychological component is exacerbating a neurological phenomenon.
Even if we convincingly demonstrate that part of the patient’s symptoms are non-neurological and likely psychogenic, we need to avoid the temptation to conclude that the entire presentation is psychogenic. Most of the time, it isn’t. Very much like the Pokemon incident, something neurological happened which then triggered the psychogenic component. We have to make sure we don’t miss the neurological part because we are distracted by the psychogenic part.
What type of phenomena make up the psychogenic part? That is also an interesting and complex question, about which we should not make lazy assumptions. Sometimes psychological stress and anxiety do manifest as physical symptoms. This is not surprising, given that the brain is physical and part of the body, connected both neurologically and chemically to the rest of the body. Sometimes the connection is straightforward and easy to determine – anxiety leads to hyperventilation which leads to decreased blood CO2 levels which then causes tingling sensations and light-headedness. Sudden stress can also lead to a vasovagal response and fainting.
Other times the connection is a bit more complex. Sometimes sensory symptoms alter the complex sensory feedback mechanisms that are part of our voluntary muscle control. This can make it difficult for a patient to fully activate their muscles, or at least make it feel strange to them. On exam this can lead to decreased effort when testing muscle strength, and make is seem like psychogenic weakness. We can eventually get full strength from the patient, but it takes effort and maneuvering.
Sometimes the connection is still mysterious. Over time the language we use for such phenomena has shifted to better reflect the true state of our knowledge. It is best to avoid terminology that includes assumptions which have not been demonstrated, or that biases thinking in certain ways. For example, some people have events that look like seizures, but we do not see electrical activity on their EEGs (brain wave tests) that show seizure activity. These used to be called psychogenic seizures, but the truth is, we don’t always know if they are psychogenic or not, so now we simply call them non-epileptic seizures.
Also, it needs to be noted that as our technological ability to detect electrographic seizures improved, many cases that were previously thought to be “psychogenic” turned out to be epileptic. This was professionally humbling, and is what lead, in part, to the more cautious approach to other cases.
Some symptoms that are considered to be psychogenic may also result from what is called hypervigilance. These are physical symptoms, but they are likely not part of whatever new problem is going on. These can be chronic symptoms or mild symptoms that are largely unnoticed, until the new symptoms make the patient worried and they start to pay attention to every minor pain or muscle twitch.
Such background symptoms are so common we often refer to them as the “symptoms of life”. Especially as we get older, such symptoms are almost unavoidable. We all get some arthritis, or nerve compression like carpal tunnel syndrome, and may develop a host of symptoms that are difficult to diagnose specifically but extremely common with age.
All of this creates a lot of symptom noise – but again, there is often a signal hiding in that noise. The challenge is often disentangling what is new from what’s old, what is part of the core phenomenon and what is just hypervigilance or stress.
In such situations there are too types of error that clinicians can make. We can overdiagnose problems that are not discrete pathological entities, or we can fail to diagnose genuine new medical conditions. Both types of error carry significant risk, and we have to be careful to avoid both. Missing an acute problem, of course, means that we miss a possible opportunity to treat something, perhaps until it progresses further. Overdiagnosing, however, can lead to unnecessary testing and treatment. It can also create a false confidence in knowing the diagnosis, which can lead to missing other genuine conditions.
In short, the approach to possible psychogenic symptoms needs to be careful, thoughtful, and nuanced. Any simplistic approach is likely to miss important aspects of the what is actually happening, either with an individual patient or a medical phenomenon.

Standards in Behavioral Science
Steven Novella on July 2, 2025
Link
There is an excellent review in The Independent (by Helen Coffey) about the recent cultural shift within behavioral science. It reflects the exact same issues that we address here with medical science – identifying and eliminating shoddy scientific practices. It’s worth going over, providing examples from the medical side.
Perverse Incentives
The goal of science should be to discover the truth, regardless of what it is. This is especially important for an applied science like medicine – we want our interventions to be safe, effective, cost effective, efficient, and minimally invasive and disruptive. To achieve this we need to know what actually works – we need the best, most reliable science possible.
But there are other incentives that get in the way. Researchers want positive results that confirm their biases. Positive results are also more likely to be published and advance one’s career. It helps if the results are surprising and interesting, what Coffey calls “sexy”. Journal editors also like sexy results, because that increases the visibility, prestige, and impact factor of their journal. The press adores sexy results because they are very media friendly.
I would extend this idea of perverse incentives to include play to pay journals that just want to publish lots of stuff, regardless of quality. And of course there are ideologues who want to promote their particular world view. This gets entangled with the financial and career goals above as well. The result is that, if you, say, are an acupuncturist, you want to publish studies that show acupuncture works. You cite other studies that show acupuncture works. You can create in the literature an acupuncture fiction that has nothing to do with reality and is built on all the shoddy research that Coffey discusses.
It goes even further than Coffey realizes, because the sexy but shoddy research is not just a one-off. It can be part of a campaign promoting an entire false idea, even a false cultural institution. Things like homeopathy, acupuncture, Reiki, megavitamins, antioxidants, and chiropractic take on a life of their own. You get journals, institutions, and even entire professions dedicated to nonsense.
But at the core of all of it is the bad study. So let’s review Coffey’s points and even add some.
Fraudulent Studies
I don’t need to say much about fraudulent studies except that, unfortunately, they do exist. We can collectively do a better job of policing against fraud, detecting it, and weeding it out quickly, preferably before it ever gets published. This is mostly on journals and their editors, who need better fraud detection practices.
But perhaps the most important thing to realize about fraudulent scientific research is that this is not the main problem. It is a destructive and horrible thing, but relatively small compared to good-faith but sloppy research.
P-Hacking
P-hacking refers to superficially fine but ultimately questionable research practices that essentially amount to statistical cheating. The p-value is a rough statistic that is used to see if a study is even interesting – are the results likely to be a statistical fluke or the result of a real phenomenon. But the p-value is widely misunderstood and overused. Even worse, it has become too much of a focus of research, and has led to (sometimes inadvertent) hacking to get significant results.
Essentially these are methods that distort the statistical results by giving more throws of the dice (often without disclosing this fact). So, you can collect data until the results become significant, or make multiple comparisons, or look at multiple outcomes.
There are several basic fixes for p-hacking. One is to simply educate researchers about methods of p-hacking to make sure they don’t accidentally do it. But also editors can specific try to detect p-hacking and demand data from submissions that would help them do it. But there are two more definitive fixes. One is pre-registration of study methods. You cannot p-hack if you determine all research methods before collecting data. The other is replication, which follows the original methods to see if the same results occur.
Fragile Studies
Even if a study is honest and does not engage in p-hacking, the results may still not be reliable or generalizable because they are “fragile” (which you can think of as the opposite of being robust). A fragile study, for example, looks at a study population which is not representative for some reason. Coffey uses the example, common in behavioral psychology, of only using college students. But any study with narrow inclusion and exclusion criteria can also be fragile. Perhaps the results are only positive in certain cultures or subcultures (such as the fact that acupuncture studies are way more likely to be positive if conducted in an Asian country).
Another source of fragility is a small sample size. Fifty subjects in each arm of a study is generally considered to be a good minimum for a statistically robust study, and less than that should be immediately suspect. This depends on the outcome, however. More objective outcomes, like death, can get away with smaller sample sizes, while subjective outcomes like pain perception require even larger studies.
I would also consider another sign of fragility that only one laboratory or researcher can seem to generate positive results. Until a result reliably replicates, it is suspect.
Also, all the little details of studies that we often discuss in our specific reviews can be filed under fragility. A study may have a large drop-out rate, or not be properly blinded, or use dubious outcome measures, or a host of other weaknesses in the protocol.
Salami Slicing
Coffey uses the term “salami slicing” to refer to what is also called the sharpshooters fallacy, or more generically the problem of hypothesizing after you look at data. The sharpshooters fallacy refers to determining what a positive outcome is after seeing the result you already have, like shooting at the side of a barn and then drawing the target around your bullet hole, declaring who got a bullseye.
Ideally a research study would start with a clear hypothesis, and a specific method for gathering data that will test that hypothesis in a way that makes a-priori sense. Salami slicing is the practice of collecting a lot of data, then slicing and dicing up the data in different ways until you find some correlation that is significant, then backfilling some justification for why that’s the case.
Results of this approach often lack what we call face validity – they don’t seem to make sense on their face. But the results can be statistically significant, or at least appear significant if you don’t know and correct for the fact that multiple comparisons (slicing of the data) were done.
Importantly, the results can often be surprising and sexy – sure, because they also happen to be bullshit.
The Future
Coffey ends her piece on a positive note, saying that exposing all these dubious methods is having an impact, improving the overall rigor of the scientific literature. I agree that this is happening, although I would argue in needs to happen at least an order of magnitude more than we are currently seeing.
But there are also some counter-trends. At the same time we are trying to shore up the rigor of biomedical science, there are forces trying to weaken those standards, or at least carve out exceptions for their prefers beliefs. They have political allies, and lots of money.
Also, the media appears to be working against us. To make this point, just look at the ads below Coffey’s article. They represent the exact thing she is discussing. Social media seems to be designed, even more than mainstream media, to favor sexy results. There is now a cottage industry of influencers, self-help gurus, self-appointed pseudoexperts, contrarians, snake oil peddlers, and ideologues leveraging social media to spread the absolute worst shoddy science.
The fact that, behind the scenes, we are incrementally improving the rigor of our science is great. But it is overwhelmed by the deluge of misinformation and shoddy science out there. We need to tackle that realm as well. This requires increased standards not just for published studies, but for press releases, public communication, scientific journals, and academia. And we need to dramatically increase the amount and quality of our public science communication.
We also need to dramatically improve the quality of our regulations, which are steadily being ratcheted in the direction of snake oil. Don’t expect any improvement in the next four years, but this is an endless struggle we must keep up.

Wearables and Wellness Populism: How Smart Watches Got MAHA’d
Scott Gavura on July 3, 2025
Link
Here’s my watch telling me to try harder.
Fifteen years ago, then-contributor Peter Lipson wrote a short post on this blog that I’ve reflected on many times since. Titled Your Disease, Your Fault, Peter described a central theme that runs through nearly every variant of alternative medicine: That illness is preventable, and therefore, your fault. According to this worldview, disease isn’t a product of biology, inequity, or chance. It is a failure of your personal responsibility. If you’re sick, it’s because you didn’t exercise enough, take the right supplements, avoid all the vaccines, or do the correct detox.
Robert F. Kennedy Jr. doesn’t believe in germ theory. He is a proponent of miasmas, an abandoned 19th century medical idea that attributed disease to poor hygiene and inadequate ventilation. Miasma theory had moral overtones – lack of cleanliness was not only unhealthy, but a sign of failing or laziness. Under the banner of “Make America Healthy Again” (MAHA), RFK Jr. is translating this ideology into policy, reshaping health care in America.
Wearables, like smart watches, are part of this movement. Once used primarily by athletes, they’ve gone mainstream, and are now tools for health “optimization”, and personal accountability. It’s an appealing idea on the surface: that wearables can reduce health care costs and help Americans better manage their own health. However, this narrative risks stigmatizing illness, distracting from science-based interventions and programs, and ultimately, undermining public health.
The old new health ethos: Illness as moral failure
As Peter Lipson pointed out so succinctly fifteen years ago, the idea that all illness is preventable isn’t new – it’s long been a cornerstone of alternative medicine. But under MAHA, this fringe, unscientific belief has moved into the mainstream. RFK Jr. and his allies are promoting a vision of health that’s not just about personal habits, but also personal virtue. If you’re sick, it’s not bad luck, or bad genes – it’s your bad choices.
MAHA seems to be reworking public health as a series of moral decisions. RFK Jr. has claimed that nearly all chronic disease is preventable through diet and lifestyle alone, and his health policy proposals emphasize individual action over broader health system actions – particularly in areas of public health. Fluoride and vaccines are out. Take care of your health by rejecting “toxins”, eating organic, and tracking your own biology.
This kind of thinking is at odds with what is known about diseases and their causes. RFK Jr. downplays or ignores the role of aging, genetics, infection, environmental exposures, and structural inequities in influencing health. He frames illness into a moral failure—something you could have avoided if only you had tried harder. MAHA and RFK Jr. offers certainty instead of acknowledging complexity (just look at his messaging about autism) and it replaces compassion and science-based medicine with judgment and increasingly, pseudoscience.
MAHA’s embrace of wearables
Wearables are a growing theme among the MAHA evangelists and appear to be a key part of the “personal accountability” strategy. The new Commissioner of the Food and Drug Administration, Marty Makary, spoke about them during his Senate confirmation hearing, when he suggested that wearables like glucose monitoring devices, currently prescribed mainly for people with diabetes, should be available over-the-counter. He framed them as tools that could could address growing rates of obesity, and help prevent diabetes.
Casey Means, recently nominated to be US Surgeon General, is another proponent of wearables. Her book, Good Energy: The Surprising Connection Between Metabolism and Limitless Health argues that all chronic disease is a result of “metabolic dysfunction” and is effectively under your control. It ties in with the MAHA ethos – good health is your responsibility. Means is a cofounder of the company Levels, a which aims to “Bring Biowearables into the Mainstream and Improve Metabolic Health”. In a 2024 blog post, she wrote,
A CGM [continuous glucose monitor] is a biosensor that can alert us to early dysfunction, coach us on how to eat and live in a way that promotes Good Energy in our unique bodies, and promote accountability. My belief in the potential of this technology to reduce global metabolic suffering is why I cofounded Levels, which enables access to CGMs and software to understand and interpret the data.
Is a CGM useful for those with diabetes? Absolutely. It beats repeated pinpricks and diabetic test strips. But as a lifestyle device – the evidence isn’t there yet.
A few weeks ago, RFK Jr. spoke about how wearables are a central part of his MAHA vision:
We’re about to launch the biggest advertising campaign in HHS history to encourage Americans to use wearables…It’s a way people can take control over their own health. They can take responsibility. They can see, as you know, what food is doing to their glucose levels, their heart rates, and a number of other metrics, as they eat it…We think that wearables are a key to the MAHA agenda of making America healthy again and my vision is that every American is wearing a wearable in four years.
Data-driven discipline
The appeal of wearables lies in the promise of control. As I wrote two weeks ago, these devices have move from simple heart rate monitoring to collecting, analyzing and reporting an enormous amount of what looks like objective data. My Garmin smartwatch offers me real-time feedback on sleep, stress, workouts, recovery, and more. Other devices, like the Apple watch can give you an ECG. If you’re using a CGM, you can monitor your blood sugar on your phone in almost real-time. In theory, this information will help users make informed decisions about their health. And there is absolutely some potential for that to happen. But in practice, it also reinforces the idea that a deviation from “optimal” health is a personal failure, and any ill health is a consequence of something you didn’t do – but should have.
Shifting the focus from what’s effective
RFK Jr.’s vision of a nation where “every American is wearing a wearable in four years” doesn’t sound metaphorical. He is framing this as a central strategy to reduce healthcare costs and chronic disease burden. Importantly, notice what’s not on the policy table: It’s not improved access to health care professionals, investments in public health, or social programs that address known contributors to suboptimal health. Instead, this initiative offloads the responsibility for health to individuals, while minimizing the systemic factors that we know have an effect on health outcomes.
Rather than investing in evidence-based public health measures—like clean water, equitable care access, vaccination campaigns, or structural reform—the MAHA approach focuses on personal optimization. The message is clear: if you just track enough data, you can avoid disease. And if you don’t? That’s on you.
Could it work? As I noted two weeks ago, there is limited evidence that wearables can drive meaningful improvements in health outcomes. Early data is promising, but there’s (as yet) no persuasive evidence that these devices can eliminate (or even significantly reduce) chronic disease.
Then there are equity questions. A health system reshaped around wearables assumes everyone has the time, resources and digital literacy to use these technologies effectively. It ignores the needs of people who are uninsured, underhoused, chronically ill, elderly, or disabled – many of whom already face multiple health challenges.
By tying health outcomes to individual choices and digital self-surveillance, MAHA policies risk making healthcare less equitable and overall, less effective. They promote unproven technologies that may feel personally “empowering”, while diverting attention away from public health interventions that actually work, like vaccinations, nutrition assistance, and access to primary care.
Don’t blame the ill for their illness
Wearables are not inherently harmful. l like the feedback my Garmin gives me. Used appropriately, wearables can support healthier habits, offer helpful feedback, and (as my friend with new onset atrial fibrillation discovered,) even flag early signs of illness. But MAHA is positioning wearables as tools and instruments of personal virtue, part of an ideology that sees disease as personally preventable. This is a re-imagining of public health not as a collective responsibility with a key role for government, but as a personal responsibility, with wearables giving you feedback and keeping you virtuous. In doing so, it ignores the complexity of disease, overlooks social determinants of health, and ultimately, blames the sick for being sick. Your disease, your fault.


NEUROLOGY

Undermining the regulation of stem cell therapies in Italy: A warning for the future?
David Gorski on May 6, 2013
Link
Stem cells are magical.
At least, if you listen to what docs and “practitioners” who run stem cell clinics in various parts of the world, usually where regulation is lax and money from First World clientele is much sought after, that’s what you could easily come to believe. Unfortunately, it’s not just Third World countries in which “stem cell clinics” have proliferated. For instance, they are not nearly uncommon enough in Europe. The example that is most troubling right now is Italy, and the reason is that there is currently a law being considered that would greatly weaken the regulation of stem cell therapies, so much so that on Friday I saw something that’s fairly rare: a major scientific journal published a pointed editorial about this new law. Specifically EMBO Journal published a commentary by an international group of scientists warning about the path that the government of Italy is considering entitled Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
Stem cell quackery is a very popular form of quackery these days because, well, stem cells are so magical-seeming. You can now find stem cell treatments offered for autism (one of which, offered at a clinic in Costa Rica, I’ve discussed before and involves injecting “stem cells” into the cerebrospinal fluid of autistic children for a cool $15,000). Kent Heckenlively, the man who took his daughter to the aforementioned Costa Rica clinic for this treatment, is not alone in subjecting his autistic child to such unproven uses of stem cells. Just a couple of months ago, a broadcast journalist in the Philippines named Karen Davila took her autistic son to the Villa Medica Clinic in Germany, which offers variants of stem cell therapy. One is known as “fresh cell therapy” and involves harvesting cells from lamb fetuses and injecting them into the patient. The other is called fat stem cell repair therapy, which is claimed to involve harvesting fat from the patient’s abdomen or thigh and then isolating “stem cells” from them to be injected back into the patient’s body.
There’s also a variation on this “stem cell” theme in China, discussed by Steve Novella a few years ago, in which Dr. Hongyun Huang runs a clinic in which he injects “stem cells” claimed to be derived from olfactory sheath cells taken from aborted fetuses into the cerebrospinal fluid of patients suffering from spinal cord injury or motor neuron disease like amyotropic lateral sclerosis (Lou Gehrig’s disease), claiming what can only be referred to as miraculous cures, sadly credulously reported by the press. He’s a little more expensive, in that he charges $20,000 (or at least he did back in 2008, when Steve wrote his post).
It’s not just neurological diseases and conditions for which stem cell treatments are offered, though. Dubious “stem cell” treatments can be easily found for virtually any disease that is currently incurable, chronic, or only treatable with great effort and not-so-great success. The list of diseases and conditions include, in addition to developmental disorders such as autism, neurological injury, and degenerative neurological diseases such as multiple sclerosis, diseases as diverse as heart disease, autoimmune diseases, respiratory disease, HIV/AIDS, diabetes, hypertension, cancer, and, of course, anti-aging. Truly, there is seemingly no disease for which some clinic, somewhere in the world (usually in Central America and China, but sometimes in Germany and the former Soviet Union) won’t be claiming miraculous cures with “stem cells.”
One example, a clinic in the Ukraine called EmCell, advertises its wares with slickly-produced infomercials, chock full of impressive-appearing graphics and animations:
It’s hard not to note that 1994, the year that this clinic came into existence, was long before legitimate stem cell therapy, other than bone marrow transplantation, had progressed to anywhere near being a viable therapy. Notice the claims of patents, mostly in Russia and the Ukraine, but a few European patents and a couple of US patents as well. I looked at one of the US patents. All it is, is a method to prepare a “cell suspension” from human embryos that, or so it is claimed, is suitable for treating HIV. You know what you don’t see on the website? Solid evidence from randomized clinical trials. There are, however, many testimonials. It doesn’t help that well-known antivaccinationist and autism quack (in my opinion) Jeff Bradstreet is apparently the US contact for EmCell.
Of course, EmCell is far from alone; it’s just one of the older and slicker “stem cell” clinics. There are many others, such as the Stem Cell Institute in Panama, the Bio-Cellular Research Organization in Ireland, the Regenerative Medicine Institute in Tijuana, among many others. Astute readers might have noticed that I use scare quotes when I discuss stem cells in the context of these clinics. That’s because it’s very much in doubt in most of these clinics whether what is being administered actually consists of stem cells. That’s where the need for regulation comes in most acutely. It’s also why what is going on in Italy right now is of great concern.
Attacking regulation of stem cell therapies in Italy
It’s been a bad year for Italian science thus far. Just last month, animal rights activists broke into the animal facility at the University of Milan and occupied it. During the occupation, they stole animals and rearranged all the cage cards so that scientists didn’t know which group of animals were which anymore, rendering their work uninterpretable and ruining years of research. Now this. If you think that the “health freedom” movement is limited just to the US and its more libertarian-leaning groups, think again. The EMBO article, by Bianco et al, starts out describing how this proposed law came to be. Noting that this is the first case in which unproven “stem cell” treatments are recognized as legitimate therapy without having been tested in rigorous clinical trials and based only upon flimsy preclinical evidence, “to be made part of a publicly funded, public health care system,” Bianco et al write (note that “MSC” = “mesenchymal stem cell”):
Patients with disparate, severe neurological diseases were and are being treated, and will continue to be treated in a major public hospital in Italy, by intravenous and intrathecal infusions of ‘MSCs’, purportedly prepared according to a unique, novel method of isolation in culture, and in vitro differentiation into neurons. This activity had previously been taking place in Trieste. In Brescia, an official agreement had been stipulated between the public hospital and a private foundation, whereby the foundation was granted permission to prepare cells with the purportedly proprietary method. Cells for infusion into patients were prepared within a GLP lab (not stringent enough for growing cells in culture before use in patients), intended for the handling of bone marrow and cord blood-derived haematopoietic cells. Patients were being treated in the hospital. Patient care in public hospitals in Italy is paid for by the Government.
More information can be found in these news reports in Nature from March and April. Here’s what happened. Apparently, Italy’s health minister, Renato Balduzzi, has been impressed by the blandishments and claims regarding adult stem cell therapy and on March 21 decreed that that a controversial (actually, let’s be honest, a quack) stem cell therapy can continue in 32 terminally ill patients, mostly children, even though the stem cells were not isolated according to Italy’s safety standards. This decision followed a prolonged campaign and media pressure to authorize the compassionate use of the therapy. As noted in this Nature report, hundreds of people protested in Rome on March 23, including a naked woman with pro-stem cell slogans painted on her body.
This particular therapy is marketed by the Stamina Foundation and has been banned multiple times. However, this time the Stamina Foundation has found a winning public relations message, pushing for “compassionate use” of its unproven therapies:
Stamina Foundation president Davide Vannoni, a psychologist at the University of Udine, says that the publicity around the treatment has won him 9,000 new patients. He hopes that further modifications to the law will allow him to expand the therapy.
A month ago, an investigatory television programme, The Hyena, reported that children with incurable diseases such as spinal muscular atrophy were being denied supposedly important treatment, and Italian show-business personalities joined the call to relax rules on stem-cell treatment.
As is my wont, I wandered over to the Stamina Foundation website. Unfortunately, it’s in Italian, and I don’t speak Italian. However, a little Google Translate allowed me to get the gist of what the Stamina Foundation is selling. For instance, this page touts MSC for everything from heart disease, to Parkinson’s disease, to multiple sclerosis, to kidney damage, to type I diabetes, to Alzheimer’s disease, to Huntington’s chorea, to spinal injuries, and just about anything else you can think of. That, in and of itself, should be a massive red flag, of course, coupled with the fact that in the news reports Vannoni admits that he’s never published his outcomes. Moreover, the only published outcome, a small trial involving five babies with type I spinal muscular atrophy treated with Vannoni’s MSCs was published in October and was entirely negative, leading the authors to conclude:
More generally, our findings highlight the risk that the combination of newspaper ‘hype’ and parental ‘hope’, with the support of courts that are sympathetic to families with children with severe disorders, may produce shortcuts in the design of clinical studies that would need more rigorous preclinical information and more accurate safety and efficacy measures and may actually put patients at risk of potential side effects of therapy.
Vannoni’s response? He claimed that the therapy didn’t work because the clinicians did not use his exact cocktail of cells.
Indeed, I can’t help but compare Vannoni unfavorably to Stanislaw Burzynski, who at least has published a few papers and case reports. They might be crappy papers, case reports, and incomplete clinical trials that, when examined closely, don’t support his claims, but he has published. Vannoni, on the other hand, seems not to care about even the appearance of not being a quack.
One aspect that Vannoni does share with Burzynski, however, is his willingness to cynically use desperate patients to try to get approval for his unproven therapies. Indeed, public hospital Spedali Civili of Brescia has been permitting the Stamina Foundation to administer MSC treatment for various neurodegenerative treatments, despite it not being one of the 13 authorized Italian stem cell factories. After an inspection in 2012, the Italian version of the FDA ordered an immediate halt to these treatments, and that’s when the protests began:
But the halt sparked protests among patients’ families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country’s Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation’s treatments at the hospital.
The open letter urged Balduzzi not to succumb to the wave of emotion and pointed out that there was no evidence that MSCs can do what Vannoni and his patients’ parents claim they can do. They also argued that “compassionate use” exemptions shouldn’t be used as a means of weakening regulation of completely unproven therapies. Indeed, it’s worth citing a couple of passages, conveniently translated into English here:
The decision seems to be dictated by emotions raised by public opinion rather than by scientifically based reasons. No scientific evidence whatsoever has been produced suggesting that mesenchymal cells may have any effect on those diseases for which it is claimed they could be employed. Moreover, no scientific description has been given of the method by which it is claimed these cells may be obtained. This seems a real subversion of the scientific and moral foundations of medicine, denying both the dignity and the traumatic experiences of patients and their relatives. We are aware of these issues and they profoundly motivate the scientific community to generate and guarantee accepted, visible and public data that will change any potential scientific hypothesis into an accepted curative procedure.
The scientists also addressed the health freedom issue head on:
The freedom of any citizen to adopt any personal health decision, including the wish to refuse any cure, does not imply that the Government is obliged to authorize all medical procedures that anyone may suggest as appropriate. In fact, although the individual choice to use an imaginary or inappropriate therapy complies with the rights of individual citizens, such therapies should not necessarily be approved by the Government and provided by public or private health structures. It is not the Government’s role to respond to pressure from patients to translate an individual choice into a therapeutic option for ready use in any health structure. Media campaigns should not become instrumental in adopting decisions on medical or health procedures. The right of single individuals to adopt snake oil as a freely chosen drug does not mean that snake oil has to be prepared in hospital pharmacies as a result of Government-authorized procedures.
In other words, the Italian government is on the brink of giving free rein to stem cell quacks, but it’s worse than that. This order, as the scientists point out, in essence allows government-funded facilities to collaborate with stem cell quacks and facilitate their treating patients.
One point that the scientists didn’t really nail, and that’s the issue of informed consent. One notes that Vannoni’s stem cell quackery has no evidence for it published in the peer-reviewed biomedical literature nor any compelling clinical trial results. Consequently, if claims are being made for this treatment it is impossible to give informed consent because there is no evidence upon which to base even a rough estimate of the chances for success weighed against the risks of the treatment. Even worse, we don’t even know that these are really stem cells. Seriously. As the scientists point out, there is no transparency, and if there’s an area of clinical research where transparency is essential, it’s stem cell research.
Sadly, the scientists’ words fell on deaf ears. In fact, Balduzzi had called a scientific review committee to examine the cases and make recommendations. It recommended against authorizing further use of the Stamina Foundation’s stem cells in a public hospital, but Balduzzi ignored the recommendations of his own panel and permitted use of the Foundation’s procedure in a terminally ill three year-old. Indeed, Balduzzi signed the order allowing the bogus MSC therapy to continue at a public hospital. On April 10, the Italian Senate amended Balduzzi’s ministerial decree with a clause that would redefine stem cell therapy as tissue transplantation, thereby releasing it from any regulatory oversight by the government. If this decree is passed by the other parliamentary chamber in Italy, the Camera dei Deputati, then dubious stem cell therapies will be out of reach of Italian drug regulators. One notes that this will be in marked contrast to European Union and US standards, which treat cells removed, treated, and reinfused as drugs, although sadly one also has to note that the attempt to redefine cell therapies as not being drugs but surgical procedures or “tissue transplantation” is not unique to Italy. Regulations for stem cell therapies are in a perpetual state of catch-up.
It’s also hard not to note that the Catholic Church apparently played a role in this scientific debacle. As noted in Nature, Vannoni’s stem cell treatments are not embryonic stem cells; they are claimed to be MSCs; i.e., “adult stem cells.” Because of its opposition to the use of embryonic stem cells, the “scientifically naïve” Vatican is enamored of the sorts of treatments offered by the Stamina Foundation, and indeed even held its Second International Vatican Adult Stem Cell meeting from April 11 to 13, described as “a shamelessly choreographed performance” in which “sick children were paraded for television, sharing the stage with stem-cell companies and scientists desperate to hawk a message that their therapies must be speeded to clinical use” and was framed as a “fight for reason and fairness against an uncaring and intransigent scientific community.”
If you go to the Stem For Life website, you’ll find a lot of anecdotes, some preclinical science described, but not a whole lot of actual compelling evidence. One anecdote in particular is as manipulative as any I’ve ever seen anywhere else. Don’t get me wrong. I do believe that eventually that stem cells, be they adult or embryonic, will be used for more and more therapies and that they will eventually allow the treatment of diseases that we currently cannot treat, but we have to be realistic and understand what is and is not known about adult and embryonic stem cells before they are used as therapies.
Why the Stamina Foundation’s stem cell treatment is highly dubious
All of this brings us back to the EMBO article. I really do have to give the authors credit for a well-written, clear explanation of why MSCs are not ready for prime time yet and therefore why deregulating them, as the Italian government appears to be on the verge of doing, is madness. They pull no punches. First, they argue in a manner that I approve of heartily (and paraphrasing Tim Minchin) that “regenerative medicine must be medicine.” In other words:
Stem cells are not a homogeneous class of cells; ‘stem cells’ are not one-size-fits-all cures. There are different kinds of stem cells in different tissues, and even when the appropriate stem cell is selected for an indication it takes years of research to learn how to administer the stem cell safely and effectively, as demonstrated by the decades of research that was required to transplant bone marrow safely and effectively. The use of stem cells in medicine must remain cognizant not only of the true biological nature of the type of cells considered for use, but also of the biology of the diseases being targeted. Treating patients with disparate neurological diseases with intravenous or intrathecal infusion of MSCs, which is being done in Italy, has no medical rationale.
You can tell a lot about a purported stem cell therapy by how the “stem cells” are isolated and administered. If the physician doing the therapy can’t tell you what specific kind of stem cells he’s using, give a good technical description of how they are isolated and purified, show preclinical evidence demonstrating that they are, in fact, stem cells, and describe how he is going to target them to the correct area, then chances are good that the therapy is dubious. As Bianco et al point out:
In the case of systemic administration of mesenchymal stem cells (MSCs), cells are introduced into the bloodstream, which is not their natural environment. They are infused in the hope that they will reach target organs that do not normally contain MSCs. There is a wealth of knowledge about their function in their natural site (the bone marrow) and a wealth of knowledge on the properties they exhibit in a tissue culture dish. But it is not clear how exogenous MSCs will behave in the brain, kidney, or the lung. As inherently osteogenic and adipogenic cells, MSCs could generate bone or fat in the wrong organs if transplanted in sufficient numbers (Breitbach et al, 2007). MSCs can also embolize in the lungs and damage the local microcirculation. Allogeneic MSCs can trigger an adverse reaction (instant blood mediated inflammatory reaction, IBMIR; Moll et al, 2012), which leads to activation of the coagulation and complement cascades, and to the death of the infused cells. IBMIR can result occasionally in thromboembolism, but we were unaware until recently that IBMIR could be triggered by MSCs. This exemplifies why infusion of MSCs must necessarily be studied in rigorously controlled and monitored clinical trials before such therapies can be considered safe in patients.
In other words, you can’t just inject the cells either into the bloodstream or the cerebrospinal fluid, and hope like hell that they “home in” to the right place and know what to do. It’s not that simple, unfortunately. Adult stem cell therapy works for bone marrow transplantation because progenitor cells are made in the bone marrow and they tend naturally to stay there when the circulation takes them through the marrow. We also have 30 years of experience using adult stem cell therapy for bone marrow transplantation. Bianco et al recount a little history about this pointing out that the first trial using bone marrow transplant between unrelated patients resulted in the deaths of all the recipients in the trial. Indeed, Donnell Thomas, we are told, spent 14 additional years in the laboratory figuring out why donors had to be matched to recipients before transplant, observing that “This illustrates how even the simplest and most promising cell therapies must be studied in depth to be delivered safely and effectively to patients.” He also notes that the situation becomes much more complex for cell therapies in which the scientific rationale for whom they might work is not known, unclear, or unproven.
Basically, it turns out that to date there are very few examples of proven stem cell therapies. There is bone marrow transplantation, of course. There are also corneal resurfacing procedures with limbal stem cells and skin regeneration with epidermal stem cells. There is also decent preclinical evidence and a few case reports for bone regeneration, and it is not unreasonable to hypothesize the use of specific types of stem cells for cardiovascular disease, although progress in this area has been disappointing.
Then, as I’ve pointed out, there’s the whole issue of exactly what kind of cell is being used. Just because someone says they are isolating and using “stem cells” does not mean that what is being isolated and used are, in fact, stem cells. Indeed, Bianco et al get almost downright sarcastic (at least as sarcastic as I’ve seen in a scientific review article) and refer to mesenchymal stem cells as “most suspicious cells,” stating:
Cells that have become known as ‘MSCs’ are locally transplantable, system-specific and self-renewing perivascular progenitors of skeletal tissues, including the haematopoietic microenvironment (Sacchetti et al, 2007). They are found in the bone marrow and have significant potential in medicine and unique biological appeal. It is therefore perhaps not surprising that multiple cases of unauthorized stem cell treatments being offered directly to the public before any approval or evidence of efficacy are centred on the use of the so-called MSCs. Lack of scientific rigour, although not unique to the MSC subfield, has flourished therein. Loose definitions and poor assays have disseminated across the scientific community as ‘gold standards’ (Dominici et al, 2006), creating huge confusion and opening the way to the completely erroneous belief that any culture of cells from any kind of connective tissue is a culture of stem cells. The apparent ease of isolation and culture, and the conceptual confusion between a stem cell as a physical and functional entity, and a culture of cells originating from stem cells ex vivo (Caplan and Correa, 2011), have contributed to the widespread use of such cells worldwide. Their nature as ‘adult’ stem cells has granted license and exemption from unwanted ethical controversy. Pressure towards development of therapies from all funding bodies around the world, a general climate dominated by the need to develop treatments (‘translational medicine’, Zerhouni (2005)) and the very existence of multiple companies ready to commercialize ‘MSCs’ have contributed, in turn, to making this particular biological object prone to misuse in the clinic and user-friendly for ill-intentioned salesmen.
This cannot be repeated often enough. Whenever a stem cell clinic claims to be using “stem cells,” are they really? What is their scientific rationale? What are their preclinical data? Do they really support the use of these cells? In the vast majority of cases, including that of the Stamina Foundation, the answer is no.
Finally, we should think of these cells in the same way we think of any “complementary and alternative therapy”—or any therapy, for that matter—and I have yet to find a better paragraph, even one of mine, arguing for the importance of there being at least a plausible mechanism:
Complementary to empirical clinical trials, a number of studies have been conducted, claiming ‘beneficial effects’ of systemically infused MSCs in animal models. The conceptual design of these studies as ‘clinical trials in a mouse’ is often flawed, detracting from the power of such studies to highlight a robust rationale for subsequent clinical use. Typically, a pharmacological effect is measured, without measuring the dose, kinetics and dynamics of the active principle, unknown at the outset. A putative active principle is often identified ex post through ex vivo reductionistic experiments. These arbitrarily single out a putative ad hoc molecular mechanism out of a maze of possible, pleiotropic, interlocking mechanisms. An arbitrary hypothesis that fits the results is pursued and alternative hypotheses are ignored. In vivo effects are often interpreted in a biased way (e.g., in studies on ischaemic heart disease, size of post-infarct scars is equated to extent of necrosis; effects of cardiac remodelling are ignored). Even though these studies sometimes specifically record the vanishing of infused cells, they fail to relate any claimed effect to kinetics of cell survival. ‘Clinical data in the mouse’ are descriptive and insufficient to offer mechanistic insight. Mechanistic insight is not a dispensable intellectual luxury. It is specifically required to develop effective therapies. It is to this end that we need mechanisms and rationale. MSCs are thought to have a role in treating GvHD and arthritis alike (Keating, 2012), owing to their generic ‘known immune modulatory effects’. The specific immune modulatory effects are not known. We have no way to model and measure them effectively in vitro or in vivo. We have, therefore, no way to distinguish those operating in GvHD from those operating in arthritis, or to tell whether they are the same or different. We have no way to tell whether these effects are unique to MSCs or shared with other kinds of cells, and which ones. While potentially crucial to advance therapies that harness immune modulation, these issues are mostly neglected. Meanwhile repetitive, expensive, small, uncontrolled phase I–II trials with i.v. infusions of MSCs continue to be pursued as useful.
I love two of the sentences in that paragraph; so I will repeat them again: Mechanistic insight is not a dispensable intellectual luxury. It is specifically required to develop effective therapies. Live them. Learn them. Love them. I do, and I try to live by them in my research.
The same admonition could be directed at, say, acupuncture, except that at least MSCs have more plausible mechanisms. However, as Bianco et al point out, preclinical data and understanding are critical to designing clinical trials that can actually give the answer that is being sought. Just taking a bunch of ill-defined cells and willy-nilly injecting them into small groups of patients with wildly disparate conditions with wildly differing mechanisms of disease is likely to be no more informative than taking some needles and sticking them willy-nilly into patients with wildly disparate conditions with wildly differing mechanisms of disease and hoping we’ll gain therapeutic insight.
There can be no compassion without safety and efficacy
One of the most potent arguments for Balduzzi’s decision in Italy is an emotional one: Look at the suffering children! They are dying! How can we possibly deny them this therapy? My response would be to rephrase that a bit by adding specific therapies other than stem cell therapies.
For example: Look at the suffering children! They are dying! How can we possibly deny them MMS enema (bleach enema) therapy?
Or: Look at the suffering children! They are dying! How can we possibly deny them homeopathy?
Or: Look at the suffering children! They are dying! How can we possibly deny them bloodletting?
Sounds ridiculous when put in those terms, doesn’t it? But, even though some day they might turn out to be wonderful treatments, right now stem cells are in the same boat. We do not know if they are effective and safe, and there is an incredible paucity of preclinical evidence to show that they do anything for the deadly diseases for which they are being used in Italy. The argument is that these severely ill children have nothing else going for them, no other therapeutic alternatives; so safety concerns can be thrown out the window. However, terminally ill patients need more safety and protection, and exposing them to unknown risks in a therapy with no evidence of efficacy is, as Bianco et al, put it, ethically unacceptable. Most people would accept the contention that someone who is severely or terminally ill has the right to take risks in search of treatment, but their willingness to take such risks because “they have nothing to lose” makes them vulnerable to any number of unproven treatments or even outright quackery. Without some sound evidence that a treatment might be effective, they are in essence taking all risk with at best an unknown and likely very small chance of benefit and at worst no benefit at all for all the risk. While personal freedom might give them the right to “roll the dice” and take large risks for minimal chance of benefit, neither physicians nor the government are obligated to facilitate their taking such risks. In fact, quite the contrary for physicians, who are ethically bound to give proper informed consent and obligated not to provide treatments without evidence of efficacy. As Bianco et al put it, “There can be no compassion without safety and efficacy.”
One can only hope that the Italian government figures that out before the Camera dei Deputati takes up the minister’s decree.

A Skeptic’s Guide to the Mind
Harriet Hall on April 30, 2013
Link
In his first book, On Being Certain: Believing You Are Right Even When You’re Wrong, neurologist Robert Burton showed that our certainty that we are right has nothing to do with how right we are. He explained how brain mechanisms can make us feel even more confident about false beliefs than about true ones. Now, in a new book, A Skeptic’s Guide to the Mind: What Neuroscience Can and Cannot Tell Us About Ourselves, he investigates the larger question of how a brain creates a mind. There is no alternative to the scientific method for studying the physical world, but Burton thinks there are essential limitations to science’s ability to investigate conundrums like consciousness and free will. Brain scientists fall into error because:
…our brains possess involuntary mechanisms that make unbiased thought impossible yet create the illusion that we are rational creatures capable of fully understanding the mind created by these same mechanisms.
He has a bone to pick with neuroscientists. They are discovering fascinating information, but their interpretations often go beyond what the data can really tell us. They often draw questionable conclusions from imaging studies that could have other explanations.
There is a lot going on in our brains that we’re not aware of. Subconscious brain mechanisms are like a gigantic committee. Everything from your DNA to your past experiences to your political leanings to your emotions is given a vote, and only the result is passed on to your conscious awareness. If all the raw input to the committee were accessible to consciousness, it would be too much information and would hopelessly impair our ability to act. For the mind to function, mental sensations have to override contradictory evidence to create certainty and motivation.
The brain tries to make our experiences meaningful by tricks like re-ordering the temporal sequence of events. When the batter swings, he thinks he is seeing the ball and then reacting; but he initiates his swing before he could possibly be consciously aware of the ball’s trajectory.
Our minds are not truly individual and independent. We are subject to peer pressure and groupthink. Burton offers a non-woo-woo example of a “group mind” illustrated by exhibits from slime molds and locusts. Even the perception of visual illusions varies across cultures, and psychological studies may be misleading because 96% of behavioral science experiment subjects are from wealthy countries.
We have studied neurons because they are easier to study and are believed to be the basis of cognition. But glial cells are at least as numerous as neurons, and they may be vital to our understanding of the brain.
Burton questions some high-profile articles to show how good basic science has been used to advance unwarranted claims:
My goal isn’t to refute the observations but to question the degree of confidence in the conclusions.
Mirror neurons have been offered as an explanation for empathy, but the evidence is not sufficient to infer that. He questions research into the “neural correlates of consciousness” by investigators like Christof Koch, because the behavior of individual neurons can’t explain emergent properties with a higher level of complexity.
In an fMRI study, a patient in a persistent vegetative state was asked to imagine herself walking through her house and then to imagine playing tennis. Different patterns were identified on the fMRI scans when she was asked to think about these two different activities. The researchers concluded that she was conscious and was responding to their commands. Burton offers another possible explanation: that some degree of unconscious cognition was occurring without any conscious awareness.
The brain mapping project is misguided, according to Burton. One researcher believes his research marks a turning point in human history, and that we will eventually be able to read our memories from our neural circuitry and preserve them after death. Burton comments:
I cannot imagine a better example of faith-based magical thinking.
As infants develop into adults, they lose 50% of their neurons. A pruning process creates a more efficient brain. When a new skill is being developed, the volume of relevant parts of the brain increases, but once the skill is learned, brain volume returns to normal. A 2007 article from the Royal Society of England criticized 25 years of research on brain size and behavior, saying that while correlation doesn’t demonstrate causation, that is how results are invariably interpreted.
fMRI studies can show increased blood flow to areas of the brain, but they can’t distinguish between psychological and physical causes. In Burton’s analogy, if the fMRI lit up when subjects imagined three-legged Martians surfing on a sea of concrete, that wouldn’t make the Martians real. Scan findings in patients with fibromyalgia don’t prove their pain is “real” and may only indicate expectation of pain.
Burton says:
Neuroscientists must acknowledge that translations of scientific data into causal explanations about the mind are pure storytelling.
In physics, the speed of light can be measured without any influence from personal biases. In contrast, scientific data about the mind is filtered through personal perceptions. Burton feels that current neuroscience is teetering on the brink of an era of excess that will not be viewed kindly by history.
Instead of speculating about conscious “free will”, it would make more sense to focus on intention, which may be conscious or unconscious. Elegant studies have shown that brain activity demonstrates unconscious intention before conscious awareness of intent. He quotes Daniel Wegner:
The experience of consciously willing an action is not a direct indication that the conscious thought has caused the action.
Burton provides an overview of the latest research in neuroscience. He covers a wide variety of subjects, including out-of-body experiences, body image disorders (including people who want to have a limb amputated), feelings of causality, the alien hand syndrome, and the Dunning-Kruger effect, which describes how incompetent people not only often fail to recognize their incompetence but believe they are especially competent (sometimes paraphrased as “being too stupid to know that they’re stupid”).
This is heady stuff. It challenges our preconceptions. It is packed with the results of intriguing scientific experiments that raise more questions than they answer. The committee in my brain passed on a strong “thumbs up” vote to my conscious mind.

Brain Research in the 21st Century
Steven Novella on October 1, 2014
Link

In April 2013 President Obama announced the BRAIN initiative – Brain Research through Advancing Innovative Neurotechnologies – committing 100 million dollars to brain research. The goal of this initiative is to accomplish with the brain what the Human Genome Project accomplished with the human genome.
The BRAIN project came after a similar, and larger, initiative in Europe – the European Union’s Human Brain Project (HBP), which was given 1.3 billion dollars in funding. The HBP came under some controversy this summer when neuroscientists complained about how the money was being awarded.
The serious commitment to brain research on both sides of the Atlantic reflects the general recognition that the brain is an important and complex organ (arguably the most complex thing we know about in the universe) and there is tremendous opportunity to reap benefits from new research.
The comparison to the Human Genome Project is quite deliberate. The HGP is generally perceived to have been incredibly successful, the biological equivalent of announcing that we will send people to the moon by the end of the decade, then doing it.
There is also a PR downside to such big projects, however, and that is premature or unrealistic hype. The HGP came with it the promise (implied or explicit) that once we mapped the human genome countless disease cures would soon follow. That kind of translational research, however, is unpredictable and time consuming. We likely will see the benefits of the HGP, but they will come 1-2 decades later than the expectations created by the hype.
Also, now scientists are talking about mapping the proteome – a list of the proteins that the genes code for. Also, the field of epigenetics is exploding, studying the systems that regulate the expression of all those genes. Reality usually turns out to be more complicated than we think.
Right now we are also in the early-hype phase of the various projects to map the human brain, with most articles mentioning cures for Alzheimer’s and similar diseases. What emerges from efforts to map the brain will depend upon what kind of research is actually done. This was the focus of the recent HBP controversy.
Research might focus, for example, on neuroscientific studies to map specific circuits in the brain, literally mapping the “connectome.” Related to that are efforts to computer model the connectome, essentially creating a virtual human brain. Also related but distinct are efforts to understand human cognition, how those circuits we’re mapping actually function. The BRAIN project includes research focusing on neuroengineering, or machine-brain interfaces for research and to treat neurological injury or disability. Neurophysiology focuses on how the cells of the brain function biologically. Finally, translational research tries to take this basic knowledge and use it to cure diseases or enhance neurological function.
Whenever there are millions or billions of dollars to be awarded, there will be arguments over who is more deserving of the funding. The HBP protest was essentially from neuroscientists who feel that more money should be given to their research into mapping the brain. They felt that too much money was going to computer scientists to create a virtual model of the brain, and that the project was becoming more of an IT project than a neuroscience project.
While they are still working out this controversy, the BRAIN project has taken the approach of spreading out research funding in all of the above areas, including large and small innovating research projects. A recent editorial in Nature praises this approach:
The US BRAIN Initiative has the chance to get the concept back on its feet. Success will probably be down to a careful balance between focused order and innovative chaos — much like the organ itself.
Conclusion
It will probably come as no surprise that I (as a neurologist) am excited about the various brain-mapping initiatives. I also agree that success will depend on striking a careful balance.
In general, more funding for scientific research has a dramatic positive effect. However, there is always a delicate balance between funding research and controlling research. It is obviously reasonable to direct funding toward specific research goals, such as mapping the brain. If the funder, however, tries to micromanage how that goal is achieved, then this can distort the direction of research and actually be counterproductive.
In any massive research project like the various brain mapping initiatives, a balance between top-down order and bottom-up chaos does seem like the best approach. Part of this is balancing basic science and translational science. If research funding shifts research prematurely into finding a cure today, at the expense of basic science, then progress can actually slow. We also do not want to prematurely pick winners and losers, but fund a variety of valuable approaches and let the science sort itself out.
In brain mapping research in particular, I also think there is an interesting synergy between various approaches. Neuroscientists mapping circuits and neuroscientists understanding cognition need each other. We need to understand how the brain is wired up in order to fully understand the basic units and interactions of cognition, and we can only really understand the function of those circuits (which is partly used to map them) if we understand what circuits there are and how they connect. The functions of those circuits are also influenced by many physiological components.
Efforts to create a virtual brain depend largely on neuroscientists mapping the circuits (otherwise the computer scientists will have nothing to model). At the same time, computer simulations can be a valuable tool for mapping and understanding those circuits.
Any one aspect of brain mapping research is dependent on and will be enhanced by all the other aspects of brain research. And of course, at the end of the day we want therapeutic and practical applications, and that requires specific research.
Let the controlled chaos of innovation take hold in as many ways as possible.

A New Collaborative in Neuroscience
Steven Novella on November 9, 2016
Link

A recent comment in the journal Nature makes a bold proposal – to form a true multi-lab cooperative to perform collective research into the deep questions of neuroscience. There are two aspects of this proposal that are extremely interesting: the potential to make significant progress in answering the biggest questions in neuroscience, and the collaborative approach to research being proposed.
How does the brain work?
It is often difficult to answer questions about the current state of scientific knowledge to the general public because there is a lot of background knowledge about science itself that is necessary. As a result I find two common tropes – that scientific knowledge is binary (we either understand something or we don’t) and that we “have no idea” how something works, even when we have lots of ideas. Communicating about the brain almost always falls for these tropes.
Scientific knowledge is better understood using a metaphor of depth. The real question is not whether or not we understand how the brain works, but how deep is our knowledge about brain function. Because the brain is so complex we can simultaneously say that we know a great deal about brain function and there is a great deal we don’t understand.
We know basically how neurons work, how they communicate with each other, and how they store information. We understand how the brain is organized and mostly what different parts of the brain do. We have a very good idea how the organization in some parts of the brain relate to the information they store and process (the visual cortex, for example, is very well understood).
Using modern tools we are building a map of all the connections in the brain, the connectome. We already have low resolution connectomes, and as the research progresses our map of the human brain will get higher and higher resolution. So again this will not be a binary question, but one of detail and depth.
The authors of the current proposal want to take our understanding of neuroscience to the next level:
The plan now proposed by Zach Mainen, director of research at the Champalimaud Centre for the Unknown, in Lisbon, Portugal; Michael Häusser, professor of Neuroscience at University College London, United Kingdom; and Alexandre Pouget, professor of neuroscience at the University of Geneva, Switzerland, is inspired by the way particle physics teams nowadays mount their huge accelerator experiments to discover new subatomic particles and ultimately to understand the evolution of the Universe.
They propose that researchers focus on one very specific question, for example how the mouse brain forages for food. They will then try to understand this function at every level, from the neuron, to brain circuits, to behavior. Ultimately the researchers want to understand how the brain generates consciousness, which is probably the ultimate question of neuroscience.
Their approach is to work from the neuron up to try to understand how higher level phenomena emerge from lower level functions.
Collaborative science
As interesting as the neuroscience question, in my opinion, is the call for truly collaborative research:
To help push neuroscience research to take the leap into the future, the three neuroscientists propose some simple principles, at least in theory: “focus on a single brain function”; “combine experimentalists and theorists”; “standardize tools and methods”; “share data”; “assign credit in new ways”. And one of the fundamental premises to make this possible is to “engender a sphere of trust within which it is safe [to share] data, resources and plans”, they write.
They want to make researchers comfortable with sharing their data as it is gathered. They want experiments to be performed at different labs simultaneously, and for the creative process of research to be fully collaborative. They also want to combine different types of researchers so they can approach the problem from different perspectives while working together.
This all sounds great, but will require, as they say, new ways to assign credit. This means they will need buy in from the academic institutions at which the researchers work. I am curious to see how this will work out. I certainly hear a lot from academia about valuing collaboration, and this will be the ultimate test of that commitment.
I am excited about this idea because I think it has the potential to improve many of the current problems within the institutions of science. We write about these issues all the time here – the publish or perish environment encourages one-off studies of new ideas that are likely to be wrong, and does not sufficiently support the replications that are necessary to know if the results are reliable.
While the system grinds forward slowly, there is a lot of waste, in my opinion. In medicine this is particularly troubling because we have to decide what treatments to use while the research is going through this messy process, and our patients are hearing about exciting but probably wrong findings from the media on a regular basis.
It sounds like the current proposal will build replication into the research process itself. It is an attempt, it seems, to optimize the research infrastructure for actually answering questions, rather than getting published, advancing careers, bringing glory to institutions, and selling journals.
Further, as science advances and our questions get deeper and more complex, we may need a better approach to research in order to answer those questions. Medicine is a great example. It may simply be getting too complex for individual researchers or practitioners to fully grapple with that complexity. We need more collaborative models.
Humans in general perform better when they “crowd source” problems. One person will likely plug holes in the knowledge and vision of another person. Get many people together, and more holes will be plugged. Creativity can also be a collaborative process – people play off each other and the result is greater than the sum of the parts.
We often call such efforts a “Manhattan project” and I think the analogy is apt. The Manhattan project was a group of diverse theorists and experimentalists brought together for a common purpose, without regard for academic credit or anything other than achieving their goal. So, in a way, this is a proven model.
Author Mainen says:
“By collaboration, we don’t mean business as usual; we really mean it. We’ll have 10 labs doing the same experiments, with the same gear, the same computer programs. The data we will obtain will go into the cloud and be shared by the 20 labs. It’ll be almost as a global lab, except it will be distributed geographically.”
Punching through to the next level of understanding of how our brains work may just require this level of collaboration. Obviously, not every research question is this complex and will require such a model. The big questions of science, however, likely do.

Your Brain In Space
Steven Novella on November 20, 2024
Link

Amid all the shocking and depressing news regarding the future of American healthcare and medicine, at least over the next four years, I thought I would tackle something a bit lighter today. What happens to the brains of astronauts aboard the ISS? Space medicine is a field of study, if fairly niche, and will likely have increasing implications as humanity increases its occupation of the solar system.
Space is an incredibly hostile environment for humans and all living things. However, we can build habitats, like the International Space Station (ISS), to provide a pressurized breathable atmosphere at a comfortable temperature. But there are two aspects of space that are challenging for us to handle with out current technology – microgravity and radiation. Astronauts aboard the ISS receive between 80 and 160 mSv of radiation in a 6 month mission, with a career limit of 600 mSv. Typical exposure on the surface of Earth is 2mSv per year.
We also evolved in 1G of gravity and our physiology has adapted to that. While in orbit astronauts experience what is called microgravity because they are in freefall. While there are theoretical ways to deal with this, through rotation, NASA has no plans to tackle this engineering feat anytime soon. There are private companies with plans for rotating modules as early as the 2030s, but that may be ambitious. Even when we manage a rotating space station, for deep space missions there will be no artificial gravity likely anytime this century.
So studying the effects of prolonged microgravity is essential for future space exploration and missions. We know already that prolonged microgravity causes bone and muscle loss and redistribution of body fluids, causing swelling, changes in the eyes, and other effects. There is also cardiovascular deconditioning. But what about the brain – how does that handle microgravity?
A recent study seeks to characterize the effects on cognitive function of being aboard the ISS. They studies 25 astronauts:
“Cognitive performance data were collected at five mission phases: pre-flight, early flight, late flight, early post-flight, and late post-flight. We calculated speed and accuracy scores, corrected for practice effects, and derived z-scores to represent deviations in cognitive performance across mission phases from the sample’s mean baseline (i.e., pre-flight) performance.” 
And here is what they found:
“There was no evidence for a systematic decline in cognitive performance for astronauts on a 6-month missions to the ISS. Some differences were observed for specific subtests at specific mission phases, suggesting that processing speed, visual working memory, sustained attention, and risk-taking propensity may be the cognitive domains most susceptible to change in Low Earth Orbit for high performing, professional astronauts.”
That’s good news. There were some minimal effects early on, but nothing long term. Of course, longer durations would need to be studied to see if there are effects that take longer to appear. This study was not designed to determine the cause of any detected effect. Some early cognitive slowing could simply be due to the stress of launching into space and acclimating to a cramped and unfamiliar environment. Fluid shifts from microgravity or higher radiation levels may have an effect. They specifically looked at sleep and did not see any correlation, so that was likely not a strong effect.
It is good news that there was no significant effect, at least for a six month mission. Being an astronaut is a cognitively demanding job and we wouldn’t want them to be compromised just from being in space. It is also preferable that prolonged stays in low Earth orbit do not cause permanent harm to the health of astronauts.
This is a question that NASA and other space agencies will continue to explore. I had the opportunity to ask a NASA scientist what their overall plan was for dealing with the harsh environment of space. They don’t think there are many technological fixes, at least in the near future. Radiation and prolonged microgravity (or reduced gravity on the Moon or Mars) will continue to be a reality of space travel for the foreseeable future. NASA’s strategy, rather, is two things – get there fast, and study ways to mitigate any health effects.
This is why NASA continues to research the health of ISS astronauts. The ISS is essentially a test bed for all future crewed space missions. We need to understand as much as possible about the health effects of space and to figure out ways to limit or fix any negative effects.
Hopefully this study reflects an underlying reality that the brain does fine in microgravity, so at least we have one fewer things to worry about.

Neuroscience and Destiny
Steven Novella on January 7, 2015
Link

A newly-published review of neuroscience research looking at the predictive value of functional and anatomical imaging raises interesting questions about the role of such studies in learning, psychiatric treatment, and even the treatment of criminals. “Prediction as a Humanitarian and Pragmatic Contribution from Human Cognitive Neuroscience” by Gabrieli, Ghosh, and Whitfield-Gabrieli and published in Neuron, does a thorough job of explaining the current state of the research and pointing to where future research is needed.
The basic idea is to use noninvasive imaging to look at the structure or function of the brain as a way of predicting future behavior, and then using those predictions to help guide treatment and education interventions, and perhaps decisions regarding parole or further treatment of criminal behavior. This concept raises many issues, including the technology being used, the state of the research, the ultimate potential for this line of research, and ethical considerations.
The major question underlying this entire endeavor is, to what extent is brain anatomy and function destiny? 
The technology
There are two basic ways to look at the brain to determine its functional potential with regard to specific tasks (such as reading, impulse control, tendency toward depression, etc.). The first is to look at anatomy independent of any current task being performed. Essentially this approach uses MRI scanning to measure the thickness or overall size of gray matter regions or of white matter tracks. If, for example, the “cable” that connects the two main language processing areas (called the arcuate fasciculus) is thicker, this may correlate with a greater ability to learn a new language or improve reading skills.
The advantage of this approach is that the technology is highly reliable and precise. This is simply a physical measurement.
The second approach is to look at brain activity during a specific task. There are several options for this approach: fMRI scanning (which measures blood flow) has a good spatial resolution but a poor temporal resolution, while looking at electrical or magnetic activity through EEG or MEG respectively has better temporal resolution, but worse spatial resolution.
These approaches have the advantage of looking at actual brain activity – seeing which parts of the brain are active during a specific task. They are currently less precise than purely anatomical techniques. They also have the added difficulty of being dependent on the subject performing the task that they are being instructed to perform (such as attempting to match words that rhyme). The researchers cannot know for sure how focused a subject is on the target task, or what mental method they are using to achieve the task.
Taken together, these techniques are relative new and powerful tools for looking at brain anatomy and function. They are detailed enough to be useful, but still have significant limitations.
The research
The authors do an excellent job of reviewing the logic and methods behind research looking into using imaging technology to predict future outcomes (although their paper can get very technical at times). I will give a simplified summary here. Essentially, the first phase of such research is to look for correlations between some brain attribute and some outcome measure (such as reading skill or level of depression). Researchers can look for correlations within a group, between groups, or with change from baseline.
They correctly caution that correlations do not necessary equal causation. They further point out that such correlations are always overestimates, and that the more variability there is in the brain regions and markers being measured, the greater the ability to tease out some correlation (to find some apparent signal in the noise). Correlations therefore need to be confirmed by making predictions with a fresh data set.
They outline various statistical methods for creating a model based on correlations and then testing the model by using it to make predictions about a different data set.
The bulk of the paper then reviews existing research in various areas. Overall existing research is mostly preliminary. Most studies are small in size and look mainly at correlations. Few have done the follow up of testing their models with predictions using fresh data. Therefore, while this may be an exciting area of research, the published studies have not yet matured to the point where we can make practical use of the results.
What the current research does show is that there is a modest but real correlation between brain imaging and various cognitive outcomes. The data is most robust and convincing with respect to language. This makes sense, since there are brain structures dedicated to language processing, and the robustness of this processing is likely to correlate to language ability.
Another area where the authors point out the research is fairly solid is depression, for example looking at brain responses to depressed faces and outcomes of treatment for depression. I also assess the research looking at impulse control and the frontal lobe structures that correlate with such control as being fairly solid.
However, even in these areas where there is a clear correlation, the amount of predictive value tends to be fairly modest. In many of the studies reviewed, positive imaging predicts only 20% or so of later variability. In a study of reading outcomes, traditional ability measures predicted 65% of later outcome, while brain imaging predicted 57%. However, when the two types of information were combined, predictive value increased to 81%.
Future research and applications
The authors correctly point out that if this line of research is to be useful clinically then the research needs to progress to much larger studies which look at the predictive value of models based on correlations. In addition, we need to get more and more detailed in terms of correlating specific brain structures or activity and specific clinical outcomes.
I do wonder, however, what the ultimate limit will be for this line of research. The brain is a complex system, with many different tasks and abilities interacting in a complex way to yield an end result. There may be some low-hanging fruit to pick, such as with reading and language skill. With such tasks there may be a tight correlation between the organization of the brain and ultimate ability. For other more complex outcomes, such as criminality, there may be significant limits on how predictive such approaches can be.
It may be necessary to take the research farther still – looking at many different parts of the brain and then computer modeling their interaction. We may still get to the limits predicted by chaos theory, however. We can’t predict weather accurately beyond 5 days or so, and we may not be able to predict human behavior and outcomes beyond a certain limit also.
In addition there is the issue of the relative contribution of brain anatomy compared to plasticity (the ability of the brain to change its wiring), environment and learning. We are likely only looking at potential by looking at the brain. This of course will have a statistical predictive value, but this does not mean that brain anatomy is destiny for an individual. If we can’t apply this data to an individual (only statistically to groups) then perhaps the vision of the authors will never be fully realized.
This issue blends into the ethics of looking at the brain in order to determine future outcomes. Should a criminal be denied parole because his brain imaging shows relatively-low impulse control, which predicts a higher probability of recidivism?
Where this type of information can be useful (and the authors do point this out) is adding predictive information to help guide treatment decision in certain psychiatric disorder and education interventions. If we can identify at an early age those students who will have difficulty with language and reading, then they can be given greater resources in that area to help them keep up with their peers. This is already being done, using standard testing, but the evidence suggests brain imaging might add to the predictive power of such testing.
In the clinical setting brain imaging may help predict who will respond better to one type of drug over another, or to cognitive behavior therapy. Medical interventions are largely based on statistical data with large groups, and this approach would be no different.
Conclusion
I largely agree with the authors that the new wave of brain anatomical and function imaging has brought with it a new age of understanding the brain. I also agree that there is tremendous potential to use this type of imaging to guide interventions for education and psychiatry. Applications to criminal justice are more complex and fraught with ethical considerations.
We are, however, still years away from practical applications. We need, as the authors suggest, to do large studies of predictive value. But then we also need, in my opinion, to do clinical outcomes research – looking at the net outcomes from employing this type of data in real world situations.
One fear that I have (and the authors also point this out) is that the allure of such data will give it a mystique that goes beyond its real world applicability. If people think we can peer into someone’s brain and predict their future, there would be the strong temptation to treat brain scans as if they were destiny, and short circuit more thorough and nuanced methods for evaluating individuals and optimizing interventions.
In the end I think that this approach will be one more tool in our toolbox, and it can be a powerful tool. Such data will still need to be used thoughtfully, with a full appreciation of its limitations.

Left Brain – Right Brain Myth
Steven Novella on August 6, 2014
Link

Years of analyzing popular but dubious claims leads to the impression that just about all knowledge that filters down to the popular consciousness is essentially wrong, at least as a first approximation. This may sound cynical, but think about any area in which you have specialized knowledge and compare that to what the average person believes about that area. Now extrapolate that to every other area of specialized knowledge.
I may be skeptical, but I am not a nihilist. I do think the situation can be and is being improved by popularizing science and other areas of knowledge. Experts need to be directly involved in teaching the public about their area, and when they are, popular beliefs can be corrected.
One example is the myth that we only use 10% of our brain. This is still fairly popular, and was recently a central plot element to the blockbuster movie, Lucy. However, Google “10% brain” and you will find nothing but links to sites debunking this myth, at least in the first few pages.
Another popular but baseless myth is the notion that people are either dominantly left-brained or right-brained in their personality and cognitive style. Google “left brain right brain” and you get more of a mix of credulous sites, like this personality testing site, which states:
We go through life attached to a lot of personality-related labels – introverted, optimistic, strong but silent, drama queen, etc. But left-brain or right-brain? These are not so well-known. Interestingly however, whether it is our left hemisphere that is more dominant or our right one, the distinction can impact our personality and the decisions we make. For example, left-brain people are more organized and systematic. Right-brain people are more creative and intuitive. So which side of your brain do you wake up on in the morning? Find out with this test!
Popular culture seems to latch onto ideas that are sexy or meet some psychological need. The idea that we only use 10% of our brains means we have massive untapped potential. The left brain-right brain thing feeds into our fascination with ourselves and the feeling of control and understanding we get by attaching simple, all-encompassing labels to people.
A recent study directly addresses the question of whether or not there is a neurological basis to hemisphere-dominant cognitive styles, but before we review the study let’s go through a little background on the brain.
It is certainly true that the brain is divided into two hemispheres, right and left. These hemispheres also carry out some different tasks. Specific cognitive abilities localize in one of three basic patterns. They can be bilateral or diffuse, so they do not localize to one hemisphere. Much of what our frontal lobes do, such as attention, are bilaterally redundant in this fashion.
Other abilities localize to both hemispheres for the opposite side. For example, each hemisphere processes vision for the opposite side of the universe.
Still other abilities are localized and lateralize to one hemisphere. For left-hemisphere-dominant people (which is most people) language and math localize to the left hemisphere, while music and visual-spatial processing localize to the right hemisphere. It is this fact which seems to have led to the right brain-left brain idea.
However, just because there are specific abilities that localize to a specific part of the brain in one hemisphere, that does not mean that our general personality or cognitive style also localizes to one hemisphere or displays hemispheric dominance. Many basic cognitive functions just don’t localize in this way.
Further, the two hemispheres have massive interconnectedness. The corpus callosum, for example, is a thick cable running between the two hemispheres, and there are other, smaller cables. There are many networks in the brain that span the two hemispheres. Both sides of our brain work together seamlessly to produce one consciousness.
There is no significant basis in neuroscience for the hypothesis that people have hemisphere-dominant cognitive styles. This is just a popular made-up myth. I could only find one psychology researcher, Morton, supporting this notion in the published literature, calling the phenomenon “hemisity.”
If we take “hemisity” as a serious proposal, what does the evidence show?
A 2013 study directly addressed this question with functional MRI scanning of different subjects.
Lateralization of brain connections appears to be a local rather than global property of brain networks, and our data are not consistent with a whole-brain phenotype of greater “left-brained” or greater “right-brained” network strength across individuals. Small increases in lateralization with age were seen, but no differences in gender were observed.
What they found when they looked at thousands of regions in the brain is that there were localized hubs of activity associated with specific tasks, but no global pattern of hemisphere dominance. Despite Morton’s claims and popular belief that people sort into a binary system of left- or right-brained, looking at brain activity did not support this claim.
Conclusion
Another popular myth bites the dust. The notion that people are dominantly left- or right-brained never had a solid foundation in neuroscience, and now the best evidence we have is convincingly negative.
As myths go, this one is fairly benign, but not completely. Any time our understanding of the world is muddied with simplistic and incorrect notions, there is the potential for mischief. In this case, attempting to pigeonhole with a false binary label can be extremely counterproductive in interpersonal relationships and especially psychology.
Such notions also are sometime applied to education with the belief that children have different learning styles that need to be catered to. This also does not appear to be true.
Labeling people as left or right brained is no better than approaching people according to their astrological sign or blood type, except that it has the patina of neuroscience that may cause some otherwise-rational people to take the idea seriously.

Male and Female Brains are Different
Steven Novella on May 15, 2024
Link

Neuroanatomical research has long established that there are statistical differences at the macroscopic level in male and female brains. There are also functional differences in terms of memory and cognition. However, these differences are largely statistical, and exist in a mosaic of different traits. This means that, if we look at specific features (whether anatomical or functional) there are male-female differences, but individuals each have their own mosaic pattern of more male or more female characteristics. There is no one typical female or typical male brain.
One additional important caveat to this research is that it generally focuses on unambiguously cis male or cis female subjects. This is necessary to address the questions at hand, but is says nothing about people who do not fit into this paradigm. Studies are beginning to apply what we have learned about male and female brains to nonbinary individuals, but that is a separate line of research.
There is also a meta-question we can ask about this research – as our technology to image and analyze the brain improves, are male-female differences coming into sharper focus, or getting more blurry? If there are truly neurological differences based on biological sex, then as our technology improves these differences should not only hold up scientifically, we should get a more clear and accurate picture of them. That seems to be what is happening.
A recent study is a great example of where this research is heading. There are three features of interest to this study. The first is that it uses advanced MRI scanning technology to look at the microstructure of living brains. It relies on diffusion MRI scanning, which measures how quickly water molecules move through different tissues in various directions to differentiate different tissues and create detailed images. This technique reflects differences in the microstructure of tissues and is especially useful in imaging brain tissue, where the connections between brain cells create a very specific tissue microstructure. All those axons running in the same direction allow for directional water diffusion.
In fact this study mainly looks at the white matter part of the brain – the part where all the axons are running, making connections. Further, they placed the diffusion maps onto a standard brain template, so that the AI did not know how big the brain was or other gross details like cortical thickness. This way the AI algorithms could not use those details to determine biological sex, and had to rely only on the pattern of white matter connections.
The second advanced technology leveraged by this study is artificial intelligence (AI). I know there has been a lot of hype surrounding recent advances in AI, but don’t let the hype distract you. AI algorithms are powerful, and are increasingly a boon to many different types of research. There is a genuine AI revolution in research taking place, and this study is just one example.
The researchers used three main AI models, 2D convolutional neural networks, 3D convolutional neural networks and Vision Transformer, in order to analyze thousands of MRI scans from 471 male and 560 female healthy subjects (age range, 22–37 years). The AI models were first told which biological sex the scans were from and learned the diffusion patterns that were more likely to be associated with each. Then they were given unlabeled scans and asked to predict if they were from a male or female subject.
Across the different AI models, they were all able to accurately tell the difference between male and female brains between 92% and 98% of the time. That is remarkable accuracy. This is not the first study to use AI to examine biological sex differences in brain function, but so far it is the most accurate.
This latest crop of studies also differ from older studies (not using AI) in that they can actually tell individual male and female brains apart. Older studies mostly were able to determine statistical differences only. This is likely saying that men are taller than women on average, but knowing a person’s height does not tell you if they are biologically male or female. But AI can look at a suite of these statistical differences and learn to make accurate predictions about the sex of an individual.
This research, however, does not tell us what the ultimate causes of these differences are. Because brain development is strongly influenced by the environment and the experience and learning of an individual, even clear anatomical and functional differences can be due in part to socialization, for example. It’s also highly likely that hormonal differences strongly influence brain development. It’s difficult to determine the relative balance of biological vs environmental influences on brain structure, and this balance likely varies considerably among individuals.
Developing functional maps of male and female brains is incredibly useful for further research. It has long been established, for example, that many neurological and psychiatric conditions differ between males and females. Men are more likely to have autism while women are more likely to have depression, for example. If we have a detailed map of male-female brain differences, this can shed light on not only why these condition risks differ, but on the nature of these conditions themselves.
These same tools can also be used to tell the difference between a schizophrenic brain and a neurotypical brain. But of course, we first have to determine what a neurotypical brain looks like, and that means knowing what a typical male and typical female brain looks like. It would also be fascinating to use this technique to look at trans or non-binary individuals to help us understand this phenomenon better as well.
In other words – this research goes far beyond the basic question of male-female brain differences. It’s critical to neuroscience research in general, and is likely to inform our understanding of many neurological conditions.

Mapping the Brain
Steven Novella on April 16, 2025
Link
I think it’s important to recognize not only how fake science can degrade medicine and exploit health care consumers, but also how real science can benefit medicine and consumers. It’s also important to separate hype from reality, because there often is science-based snake oil, meaning that there are fake treatments based on the hype of real science.
We are near the beginning of some real and exciting medical science and it’s important to track where we are. We are just beginning to see the benefits, for example, of CSRISPR technology. Genetic engineering in general is poised to transform many areas of medicine. Another important emerging area is our ability to map, interface with, and alter brain function. Neuromodulation is a legitimate area of treatment, but also ripe for exploitation.
An exciting area of research is the large collaborations trying to map the human brain in detail – the connectome. This is often likened to the genome project, but it is a much greater undertaking. The ultimate goal is to create a complete wiring diagram of the entire human brain. Of course, such a diagram, if represented in computer hardware or even virtually in software, can be functional. A complete wiring diagram could be a functional digital brain.
In fact, it is difficult to have the first without the second (at least in pieces, if not all together). In order to know if a wiring diagram is accurate we need to know that it functions like a brain. A recent series of publications illustrates the process nicely.
This is the work of The Machine Intelligence from Cortical Networks (MICrONS) Project, a collaboration t of more than 150 scientists and researchers from the Allen Institute, Princeton, Harvard, Baylor College of Medicine, Stanford and many others. Their goal is to create a “dense reconstruction of the structural connections and functions” of the human brain.
Recently they have accomplished this for a small piece of the mouse visual cortex. They have created the largest functional wiring map of a mammalian brain to date “containing more than 200,000 cells, four kilometers of axons (the branches that reach out to other cells) and 523 million synapses (the connection points between cells).”
The process they used was to take a cubic millimeter of mouse brain and sliced it into 25,000 layers, each 1/400th the thickness of a human hair (which always seems to the be standard metric by which such things are communicated to the public). Another team then used artificial intelligence (AI) to reconstruct these layers into a 3D model.
As an aside, AI is yet another area where it is important to separate hype from reality, but I see both kinds of error being made. It is easy to overhype what AI can currently accomplish, but just as often I see dismissing the power of current AI applications as hype. Meanwhile, AI is transforming research in many areas, and neuroscience is one. AI is great at making sense of massive sets of data, so it is ideally suited for areas of research such as genetics and neuroscience.
The result of this collaborative effort was a details map of a piece of the visual cortex of the mouse brain. But they needed that map also to be functional, to see not only how the cells were connected together but how they functioned. So they trained AI on information from mice whose brain activity was being recorded while they were watching action movies.
This enabled the scientists to see how the wiring worked, which lead to new discoveries, such as the role of certain type of inhibition in brain function. They found that inhibitory cells were not just downgrading overall neuronal activity, but some were highly selective in which neurons they inhibited, meaning they were a functional part of the information processing (not just brakes).
To test their new model they used it to predict how the mouse visual cortex would respond to specific stimuli, and it was able to do so. Crucially, it was able to predict the response to novel visual stimuli, meaning different than the training data.
In essence we now have a working digital model of a piece of the mouse visual cortex. This is an important proof of concept. Their plan is to keep going, and to progress from sensory cortex to higher level processing, abstraction, planning, and other functions. The ultimate goal, of course, is to create a fully function digital mouse brain. And once that is done, to complete the same project for a human brain.
But even with just a mouse brain, that can serve as a model for a generic mammalian brain, and allow us to study virtually many types of neurological disease. We can compare healthy brains to diseased brains and see what’s different. How is the wiring pattern of an autistic brain or schizophrenic brain different than a typical brain?
Imagine having fully functional digital mouse brains – this could enable us to run psychological and neurological experiments “in silico” orders of magnitude faster and cheaper than having to deal with live animals.
Of course, replicating this project for a human brain introduces very tricky ethical considerations. We need to think carefully and work out these ethical implications now, before the technology is upon us, which will likely be sooner than many people think.
    • 

Hacking the Brain – A New Paradigm in Medicine
Steven Novella on February 19, 2014
Link
The word “paradigm” is over misused and overused, diluting its utility. Thomas Kuhn coined the term in The Structure of Scientific Revolutions to refer to an overarching explanatory system in science. Scientists, according to Kuhn, work within a paradigm during periods of “normal science,” punctuated by occasional “paradigm shifts” when the old explanatory model no longer sufficed, and a radically new explanatory system was required. The term has since come into colloquial use to mean any scientific breakthrough, which marketers quickly overused to refer to just about any new product.
I am therefore cautious about using the term, but I think it is appropriate in this case. In medicine I would consider a new paradigm to be an entirely new approach to some forms of illness. Common treatment paradigms include nutrition, physical therapy, surgery, and pharmacology. A new paradigm is emerging in my field of neurology – directly affecting brain function through electromagnetic stimulation.
The brain is a chemical organ, with many receptors for specific neurotransmitters. This has allowed us to use a pharmacological approach in treating brain disorders – using drugs that are agonists (activators) or antagonists (blockers) of various neurotransmitter receptors, or that affect the production or inactivation of the neurotransmitters themselves. There are limits to this approach, however. First, neurotransmitters are not the only factor affecting brain function. The brain is also a biological organ like any other, and so all the normal physiological factors are in play. Further, there is only so much evolved specificity to the neurotransmitters and their receptors.
If the brain were designed top-down it might have made sense to have each specific function or circuit in the brain use a unique neurotransmitter and a unique receptor. If this were the case, then we could design drugs that would have only one desired effect. But this is not the brain we have. Our brains evolved from the bottom-up, resulting in the use of a few neurotransmitters in various circuits in the brain, with receptors that are related because they are evolutionarily derived from common receptor ancestors. Therefore, when we design a dopamine agonist to treat Parkinson’s disease, they can cause psychotic side effects because similar receptors are used in other parts of the brain.
In some cases we are already pushing up against the limits of specificity to the pharmacological paradigm in neurology. If we are going to have treatments that are dramatically more effective or specific, we need a “paradigm shift.”
Fortunately the brain is also an electrical organ. Neuron firing can be affected by electrical stimulation or magnetic fields. There is no theoretical limit to the specificity of this approach, only practical technological limits. If we could target specific neurons and directly affect their firing, we could have any level of control over brain function.
Using electrical stimulation to affect brain function is actually decades old. The first use of this approach I am aware of is electroconvulsive therapy. In its infancy, this was the crudest of interventions – shocking the whole brain to cause a generalized seizure in order to treat depression. The treatment is effective, but the side effects, including memory loss, were severe. Over the years the technique has been refined, with less and less stimulation to produce the same results.
The cutting edge of “hacking the brain” with direct stimulation is still relatively crude compared to the potential of this approach, but with very promising results. Examples include deep brain stimulation (DBS) for Parkinson’s disease. Wires are placed into specific structures in the brain, the ventral intermediate nucleus of the thalamus, the subthalamic nucleus, or the internal segment of the globus pallidus. Stimulation at specific frequencies can reduce tremors or other motor symptoms of Parkinson’s disease. This is an invasive procedure, and there are side effects, but the results can be very good for patients who are at the limit of what pharmacology can do.
Various types of stimulation, including DBS but also vagal nerve stimulation, are being used to treat epilepsy. Epilepsy might be particularly amenable to this approach, as seizures are, in fact, electrical events.
Transcranial magnetic stimulation (TMS) is another approach – using a magnetic field to disrupt specific brain circuits. TMS is being studied for a variety of applications, including epilepsy and movement disorders, but also migraines, chronic pain, anxiety, post-traumatic stress disorder, and more.
The age of electrically hacking the brain is already here, but what interests me most is the ultimate potential for this approach. Right now there are several technological limitations to this approach: the specificity of targeting smaller and smaller circuits with either external fields or implanted wires, the safety of having wires penetrating the body and entering the brain, powering and cooling implantable devices, and overall computer technology. There is also the knowledge base of which neuroanatomical structures will produce what effects and side effects.
None of these technological challenges will likely prove an absolute limit to this approach, and there is no theoretical limit. We are finding new ways to power and cool small devices. There is plenty of waste energy in a human body – more than enough to power a small, efficient electronic device.
Electronics themselves are advancing at an incredible pace. The promise of carbon nanotube circuits, for example, would use much less power and generate much less waste heat than current electronics. There is also no reason to think that advances in computer technology will not continue at their current pace for the foreseeable future.
It only requires a reasonable extrapolation from current technology and research to imagine a not-too-distant future with implantable computer chips that are capable of targeted machine-brain interface, self-powered and sufficiently cooled, that can alter brain function in precise ways to produce a host of therapeutic effects.
This does raise one other question: are there any theoretical limits to the computer-brain interface? I have discussed this question at length on my other blog, Neurologica. The short answer is that there does not appear to be any significant theoretical limits to such an interface. Brain plasticity seems to allow for a seamless integration of computer and brain, and all the proofs of concept have already been achieved.
Just this week scientists at Harvard reported that they were able to implant a computer chip into the brain of one monkey that allowed it to control the movements of a second sedated monkey (two monkeys were used so that they did not have to paralyze one monkey for the experiment). The implanted chip read the activity of about 100 neurons and learned their activity in relation to physical movements. The second monkey had 36 electrodes implanted in their spinal cord, and when connected the “master” monkey could control the movements of the second sedated monkey.
Conclusion
Opposing pseudoscience in medicine is often a negative endeavor — pointing out that claims are not based upon adequate science or evidence. We have collectively made a conscious effort not to fall into the trap of being naysayers and only focusing on the negative. Science-based medicine is a positive endeavor, promoting good science in medicine. But science itself has a huge negative component: when you separate the wheat from the chaff, you have to discard the chaff.
It is important to occasionally focus on what does work in medicine, and on legitimate scientific advances. Claiming that we are on the threshold of a new paradigm in medicine, one in which we can use a variety of technologies to manipulate brain function to treat a variety of neurological diseases and disorders, may sound like the very kind of hype we generally deconstruct on this blog. This one, however, turns out to be true.
No one can predict exactly how much time it will take to develop specific applications, but the pathway seems clear and we are making steady progress.

The Brain is a Composite Organ
A new study published in Nature Neuroscience shows evidence that our brains are actually two organs combined into one composite organ.
Steven Novella on September 23, 2026
Link

A new study published in Nature Neuroscience shows evidence that our brains are actually two organs combined into one composite organ. You may be thinking that I am referring to the two hemispheres of the brain, but I am not. The notion that our two brain hemispheres function independently is largely a myth—they are massively interconnected with many neural circuits spanning both hemispheres.
Rather, the study was looking at the earliest embryonic origins of the forebrain, midbrain, and hindbrain. The forebrain is the cerebral cortex, the most recently evolved thinking part of the brain. It also contains the thalamus, hypothalamus, and basal ganglia. The midbrain is a small region at the top of the brainstem that includes the substantia nigra, periaqueductal gray, red nucleus, and other structures. They are the interconnection between the brain and the cerebellum and the cortex and brainstem. The hindbrain is essentially the brainstem, which contains primitive circuits for breathing, autonomic function, and connections to the spinal cord. The anterior hindbrain also contains the cerebellum, which acts as a separate brain for coordination.
Up until now, it was thought that the brain develops from one common neuroectoderm stem cell—one stem cell that becomes the entire nervous system. This makes intuitive sense since the nervous system functions as an integrated whole and is comprised of the same kind of cells and tissue.
What this new study finds, however, is that the forebrain and midbrain derive from an anterior neural ectoderm stem cell, while the hindbrain derives from a posterior neural ectoderm stem cell. These two lineages never overlap, meaning that they emerge at the same time during gastrulation, but they do not share common neural stem cells. Therefore, it seems that evolutionarily they represent two independent parallel nervous systems that were later fused into one composite organ.
This study was done on the mouse brain, but they then demonstrated the same two-origin system in chickens, zebrafish, and acorn worms, showing that this split goes back 550 million years to hemichordates.
While all this is fascinating, why is this medically relevant? Well, researchers commonly use stem cells and then coax them to develop into specific cell types, so that they can study them and use them to model different diseases. Up until now, it has been difficult for researchers to derive hindbrain cells from these neural stem cells, which has frustrated research. Now the reason appears to be clear: those stem cells can only become forebrain and midbrain cells—they cannot become hindbrain cells. These two developmental paths are already committed, with different gene expression, and cannot cross over.
This new study opens up the possibility of creating hindbrain cell lines for study. In fact, the researcher did coax posterior neural stem cells to become hindbrain motor neurons, with all the characteristics of those cells. For basic science research like this, it is easy to speculate or claim that it might lead to medical breakthroughs in the future, and of course this is no exception. This is no guarantee, but historically such basic science findings do lead to downstream benefits.
In this case, there is a strong case to be made that the ability to develop authentic hindbrain cell lines will be a boon to research, including research looking into the causes and potential treatments for specific diseases, like motor neuron diseases that affect hindbrain motor neurons. It will take years, perhaps decades, to realize these downstream benefits, but they will likely come. This research (if it holds up, which seems likely) does relieve a significant frustration for those studying the hindbrain and diseases that affect it.

Integrative Neurology – More Bait and Switch
Integrative medicine is a marketing concept still rife with pseudoscience.
Steven Novella on June 9, 2021
Link

What, exactly, is “integrative medicine?” In science having a precise definition of terms is critical. It is a necessary starting point for investigation. In fact, we often refer to an “operational definition” which is not just a description, but a concrete specific set of procedures and outcomes with clear delineation. For example, a general definition of Type II diabetes might include insulin resistance resulting in poor glucose control. An operational definition would include, a 2-hour glucose tolerance test of >200.
A recent commentary on Medscape about integrative medicine in neurology defined it as, “healing-oriented practice with a focus on lifestyle interventions, offering patient-centered care addressing physical, mental, and spiritual well-being.” That is a vague definition. In my opinion, it is deliberately vague, specifically so that it can sound useful but in practice can include or exclude any intervention. The problem gets even deeper when we consider that the term “integrative medicine” is meant to distinguish certain practices and approaches from regular medicine. So it is not just defining a field, but also a demarcation line between integrative medicine and medicine. As lines go, this one is as fuzzy as it gets.
Being as charitable as possible, it seems there are four potential operational features of integrative medicine outlined in this quote: healing-oriented practice, lifestyle interventions, patient-centered care, and addressing physical, mental, and spiritual well-being. The problem is that none of these actually can be distinguished from medicine in general. “Healing-oriented practice” is extremely vague. Again, being charitable, in medicine we generally divide treatments into curative, functional, or symptomatic. The former is designed to alter the course of a disease, heal an injury, or cure a disease. Symptomatic treatments are intended to reduce symptoms and improve quality of life. Functional treatments, like physical therapy, improve function (so they are more than symptomatic) without necessarily curing the underlying condition. Many interventions combine aspects of two or three of these outcomes, but it’s important to understand the purpose of any treatment.
So, given that, what does “healing-oriented practice” mean? Does integrative medicine not include symptomatic or functional interventions? That would be odd, because the vast majority of their interventions are actually symptomatic. In the Medscape commentary, which reviews an integrative medicine conference, almost every intervention discussed is symptomatic, with the main outcome measure being quality of life or a subjective symptom like pain. Invoking “healing” is all about marketing, flipping reality onto its head. Reductionist science-based medicine combines all treatment goals, and cures illness whenever possible. Yet is has long been part of the alt med propaganda that mainstream medicine treats only symptoms, while magic-based medicine heals. This marketing claim does not hold up to even the slightest scrutiny.
The problem with the other three components, lifestyle interventions, patient-centered care, and addressing physical, mental, and spiritual well-being, is that they are already part of mainstream medicine, where the concepts originated. Integrative medicine (under any of its evolving marketing slogans) did not develop these concepts. They just stole them for their own. Research into the effect of lifestyle factors on health and illness has long been a part of scientific medicine.
Patient-centered care goes back at least 40 years in mainstream medicine, with increasing popularity as a term starting in the 1980s. The idea is to focus not just on treatment, but the total patient experience. This was a reaction to the reality of modern medicine, which requires increasingly complex systems to manage all components of health care. The concern was that the patient was getting lost in the mix, with the logistical, technical, and administrative needs of the system getting in the way. We needed to re-center the entire process around the patient to optimize their healthcare experience. Integrative medicine had nothing to do with this entire process – they just adopted the language because it sounds good.
In medical school in the late 1980s I learned about the “biopsychosocial” model of medicine. The term goes back to George Engel in the early 1980s, and you can see how quickly it became popular as within a few years it was being incorporated into medical school teaching. Similar to patient-centered practice, the idea was to make sure that the entire patient was being addressed, not just their biology. You are not treating a disease – you are treating a patient with a disease. This is a subtle but critical shift in attitude, and was meant to make sure the medicine profession was not so distracted by the advancing science of medical interventions that we lost focus on the whole patient. Mind-body-spirit is just a new-age version of biopsychosocial. The latter is actually much more appropriate to medicine. It is decidedly unprofessional and even unethical for a healthcare provider to intrude on their patient’s religious beliefs. We should be respectful but neutral, and certainly not impose any spiritual or religious beliefs onto our patients. We should understand their beliefs, their culture, and their psychology in order to address how that might impact their health and their care, but that is very different from basing an intervention on a spiritual belief.
By their own definition, therefore, there doesn’t seem to be any legitimate purpose for integrative medicine. It’s just repackaging and rebranding concepts that already exist within mainstream medicine. But any examination of the interventions that go under the integrative banner reveals what we have called here at SBM the “Trojan Horse” of alt med. The definition of integrative medicine is not what it is actually about, it’s just the branding designed to gain entry into mainstream medicine. It is the Trojan Horse. What spills out of that horse, however, is the real purpose of alt med – an eclectic collection of pseudoscience and magic-based treatments. The real purpose of the alt med/complementary/integrative brand is to eliminate the science-based standard of care in medicine, or at least carve out an exception, so that a variety of treatments previously considered to be health fraud can flourish.
Reviews have shown that the most common integrative medicine practices include: herbal medicine, homeopathy, chiropractic, acupuncture, and reflexology. Herbal medicine is simply pharmacology, but with poorly studied and regulated products. Homeopathy is 100% pure pseudoscience. Chiropractic is a mixed bag, but I think the best summary is – what chiropractors do that works is not unique to chiropractic, and what they do that is unique to chiropractic doesn’t work. Acupuncture is demonstrably nothing more than an elaborate placebo. Reflexology is also pure pseudoscience. How is any of this patient-centered or even holistic?
The review of the neurological presentations during the integrative medicine conference includes such insights as – pain is a brain processing phenomenon. Do tell. Loneliness has a negative impact on quality of life. Exercise is good for you. This is hardly a revolution in medicine. The author admits she was not impressed by the evidence presented for specific supplements, but overall “I left impressed by the depth and commitment to scientific rigor by the majority of presenters”. I don’t know if there was any straight-up pseudoscience, like homeopathy, at the conference. The list of topics [PDF] does not include references to specific interventions, so a lot of nonsense can be tucked away in specific talks. Some talks, such as those referring to thyroid testing, are very suspicious for common “functional medicine” pseudoscience. I also have to wonder about the qualifier “the majority of presenters,” which could be 51%. So there were some that were not committed to scientific rigor?
In any case, the review did leave me with a question. Perhaps integrative medicine is getting trapped in its own marketing (the pseudoscience is getting trapped inside the Trojan Horse). In order to get into mainstream medicine, they have to pretend to just be focusing on lifestyle and patient-centered medicine, but still be scientifically rigorous. This might attract some practitioners who actually believe the marketing. My question is – is there any chance that integrative medicine will evolve into a redundant but at least reasonably science-based philosophy within mainstream medicine? If they just repackage stuff we are doing already, and can’t really let loose the pseudoscience without contradicting their own marketing, then perhaps integration will change them more than it changes medicine.
That’s a very optimistic view, and I’m not willing to bet on it. It’s necessary to continue to expose integrative medicine for what it is – a thinly disguised conduit for pseudoscience into medicine. If proponents disagree, then fine – let’s all dedicate the practice of medicine, regardless of practice philosophy, to rigorous standards of science-based medicine. Our job is to make sure they don’t just pay it lip service, and that everyone understands what SBM standards really mean, and why they are necessary. They will have no choice but to fall into the trap, or admit they are not scientifically rigorous. In practice this means we will conflict over what SBM standards should be, and what the scientific evidence actually says. That is the risk – they are trying to change medicine, to water down the scientific standards, to distort research, and to weaken regulations. Unless we elevate them to rigorous standards, they will drag down all of medicine into pseudoscience.O

Preventing Traumatic Brain Injury
Steven Novella on August 19, 2026
Link

Traumatic brain injury (TBI) affects tens of millions of people worldwide each year with about 5 million deaths. For those who survive there is often permanent neurological impairment. TBI is therefore a serious public health issue that needs to be addressed. The largest international study of TBI was recently published in Nature Medicine, providing some insight into how best to approach the issue.
For background, TBI is exactly what it sounds like – traumatic injury to the brain. This is mostly from external forces to the head, rather than something happening inside the skull, resulting from either something hitting the head or the head hitting something. The brain is a soft jelly-like organ essentially floating in cerebrospinal fluid inside the skull. When such an injury occurs the brain impacts the inside of the skull on the side of the injury, but then can whip back and hit the other side as well (so-called coup contrecoup injury). This can cause surface bruising on the brain.
Perhaps worse, however, is the shearing forces on the entire brain, which as you might imagine is a delicate structure. These forces can cause diffuse axonal injury – a tearing of the axonal connections within the brain. This can result in widespread disruption of the brain’s connections with itself, impairing brain function.
Typical symptoms of TBI include headaches, impaired memory, impaired concentration, persistent dizziness, and difficulty processing sensory information. Patients often feel overwhelmed by everyday situations, like being in a room with multiple people, riding in a car with rapidly moving scenery, or having to keep track of daily activity.
Management of TBI focuses on speeding recovery, avoiding anything that might exacerbate it, and treating symptoms. One important intervention is called neurological rest – avoiding any activity or environment that causes stress or worsens symptoms. There are some neurorehabilitation techniques, and some medications may be helpful. What we do not have is any curative intervention – there is currently no way to reverse the diffuse axonal injury, other than the brain’s own healing ability. This means that symptoms are often permanent.
Getting to the recent study – they looked at over 2,000 TBI patients from 100 hospitals in 29 countries. The most common cause of TBI was automobile accidents, especially in countries with low human developmental index (HDI) tier. In the highest HDI tier ground level falls were more common. This may partly be artifactual as people are less likely to even make it to a hospital (where the data was gathered) in low HDI countries.
The overwhelming conclusion of the study was that the most effective public health measure in order to limit the morbidity and mortality of TBI is to prevent the injuries in the first place. This in turn means that we need to find ways to reduce head injuries from traffic accidents, and we need to prevent falls in the elderly. Second, we need to improve the healthcare infrastructure available so that people with TBI get treated quickly and effectively.
How do we prevent TBIs from traffic accidents? First – wear a helmet, if you are riding a bike, motorcycle, or scooter. Helmets reduce the force on the skull, reducing the risk of TBI by 65-88%. They also reduce the severity of the TBI if one occurs. In a car, wear your seat belt, and place children in appropriate car seats. Air bags are also very effective, and in the US most new cars have not only the front air bags but the side curtain air bags to protect the head.
Preventing ground-level falls in the elderly is also a critical public health measure. This can be as simple as using a cane, which unfortunately many people resist. This can progress to a walker or even scooter when necessary. A home safety evaluation is also useful – removing any tripping hazards, for example. This often falls to family members as often people who are at risk of falling do not recognize the risk or may be resistant to intervention.
The study highlights that simple common-sense interventions are often the most effective public health interventions we have at our disposal. For TBI, prevention is the best approach, as there is unlikely to be any effective restorative treatment anytime soon.

The NFL and Brain Injury
Steven Novella on August 26, 2026
Link

Last week I wrote about traumatic brain injury (TBI). By coincidence, the BMJ just published a study looking at a type of TBI called chronic traumatic encephalopathy (CTE), which is caused by repeated head injuries over a long period of time, even those not severe enough to cause an acute TBI. They were looking specifically at former NFL football players, because that sport is known to cause multiple minor head traumas, especially over a long career. The findings, while not surprising, are alarming.
The researchers looked at the medical histories of 1,712 former NFL players who died during 2008-21. They were all players after 1949, when hard helmets came into standard use. Of these players, 338 had donated their brains for examination after death, and so they were available for pathological examination.
The fact that these brains were voluntarily donated is the biggest caveat in this study, because it means that this is a self-selective group. The obvious potential bias is that those players who were motivated to donate their brains were concerned that they might have CTE. Players who were asymptomatic may not have even been aware of the option, let alone be motivated to do so. The authors attempt to account for this factor, as you will see.
They found:
“Among 1712 NFL players who died, 338 (19.7%) players’ brains were studied, 315 (93.2%) of whom had a diagnosis of CTE; thus, among all 1712 NFL players who died, the possible CTE prevalence at death ranged between 18.5% and 98.7%.”
The range is so large because of the potential for biased selection. In other words, if there were a 100% selection bias, meaning every player with CTE donated their brains, then you get the maximally conservative estimate of 18.5% of all the players having CTE. If everyone who did not donate their brain had CTE, then you get the 98.7%. Likely the number is somewhere in between, but probably closer to the lower end.
Of note, CTE can only be diagnosed pathologically, meaning at autopsy. The diagnosis can be suspected clinically, but cannot be confirmed without examining the brain directly. The diagnosis is confirmed by the presence of tau protein buildup microscopically. This is not visualized by MRI scans. Clinical examination can diagnose dementia, and MRI scan can visualize some of the damage, but these cannot distinguish CTE from other causes on dementia. Only microscopic examination can. This is why this study is important to understanding CTE, because it examined so many brains to confirm CTE.
Of the brain donors in the study, about 60% had clinically diagnosable dementia. Disappointingly, they did not do an assessment for dementia in the non-donors, so we don’t really know what this means about the total dementia risk for these NFL players. The range of possible incidence is from 11.8–92.1%, which doesn’t really tell us much.
They also looked at deaths during the period from 1016-2021, when brain donation was most common. During that period the minimum CTE risk was 24.5%, which is why you might see headlines that at least a quarter of NFL players develop CTE.
What does this mean for the NFL? Defenders will argue that the NFL has already made adjustments to reduce CTE risk, which is true. The data in this study are from older players, those that dies between 2008 and 2021. We won’t have definitive data on recent players for decades. But we do have some indicators.
Modern helmet design does continue to improve, reducing the forces on the heads of players. There have also been numerous rules changes, limiting head impacts during play. What we can look at is concussion rates. In this study NFL concussion rates decreased by 38% after rules changes implemented in 2018.
However, concussions may or may not be a good indicator or CTE risk. There is evidence that CTE results from repeated forces to the brain that are below the threshold for causing concussion. In other words, you can get CTE without ever suffering a single acute concussion. Further, modern helmets, while good at reducing concussion risk, may not reduce the risk of these lesser traumas, which can result from rapid acceleration of the head without the blow necessary to cause concussion.
So essentially, we don’t know if these recent interventions have actually reduced CTE risk, and if so by how much. It is plausible that the risk is lower, but lower than 18-25% (and remember, this is at the low end) is not very encouraging. That could still mean a very high risk of this severe neurological outcome for players.

ALZHEIMERS

Declining Dementia
Steven Novella on November 23, 2016
Link


Dementia is a significant health burden of increasing significance as our population ages. Worldwide the prevalence of dementia is 5-7% in people 60 years and older, with risk doubling every 5 years after age 60. About 5.4 million Americans are living with dementia.
Dementia is a general category referring to a chronic decline in overall cognitive function. The most common cause of dementia is Alzheimer’s disease, accounting for about half of cases. There is also a category of mild cognitive impairment (or cognitive impairment not dementia) that is milder and does not meet the diagnostic criteria for full dementia.
Declining prevalence
There is some good news, however. A recent study published in JAMA finds that in the US the prevalence of dementia in those 65 and older declined between 2000 and 2012, from 11.6 to 8.8%. This is both statistically significant and clinically significant.
This also mirrors evidence from other countries also showing a decline in dementia prevalence over the last 20 years, including the UK, Denmark, and Sweden.
The big question, of course, is what is causing this decline? If we can determine the major factors then perhaps we could use that knowledge to further decrease dementia risk.
The JAMA study was not designed to answer that question, but it did collect basic demographic information that provides at least some clues. They found a correlation between years of education and decreased risk of dementia, enough to explain part but not all of the decline. Overall the average years of education in the study cohort increased from 11.8 to 12.7 from 2000 to 2012.
This is not a new finding. Overall the evidence strongly suggests that anything you do to make your brain work harder has a protective effect against developing dementia. For example, one study found those who were bilingual presented with dementia on average three years older than those who are monolingual.
A 2016 systematic review looking at mental leisure activity and cognitive decline found an overall significant protective effect.
However, brain training games specifically have not fared well. Despite controversial claims by companies selling brain training, the evidence has not found a significant protective effect. A 2014 consensus statement by researchers concluded:
We object to the claim that brain games offer consumers a scientifically grounded avenue to reduce or reverse cognitive decline when there is no compelling scientific evidence to date that they do. The promise of a magic bullet detracts from the best evidence to date, which is that cognitive health in old age reflects the long-term effects of healthy, engaged lifestyles. In the judgment of the signatories below, exaggerated and misleading claims exploit the anxieties of older adults about impending cognitive decline. We encourage continued careful research and validation in this field.
A study published this year (the ACTIVE trial) has been getting a lot of press because it reports a protective effect for a specific type of video game, one that trains speed of processing (but not ones that train memory). They found:
At mean age of 82 years, about 60% of trained participants compared to 50% of controls (p<.05) were at or above their baseline level of self-reported IADL function at 10 years. The reasoning and speed-of-processing interventions maintained their effects on their targeted cognitive abilities at 10 years (reasoning: effect size, 0.23 [99% CI, 0.09-0.38]; speed-of-processing: effect size, 0.66 [99% CI, 0.43-0.88]). Memory training effects were no longer maintained for memory performance. Booster training produced additional and durable improvement for the reasoning intervention for reasoning performance (effect size, 0.21 [99% CI, 0.01-0.41]) and the speed-of-processing intervention for speed-of-processing performance (effect size, 0.62 [99% CI, 0.31-0.93]).
While interesting, this is one study, subject to all the sources of bias and p-hacking that we frequently discuss on SBM. It is not enough to reverse the consensus of prior research, but it does indicate that more research is needed.
There is also good evidence that physical activity is associated with improved cognitive health.
My take-home summary of all this research is that it is good to be physically and mentally active. The details of what type of activity don’t seem to matter much, when it comes to mental activity it is best to challenge yourself. Do something new, and work your brain in new ways. There is no magic in any particular task or game, but there is a preliminary suggestion that activity which engages executive function may be particularly useful.
Other factors
Are there other factors that could also be responsible for the decline in dementia prevalence? Probably, but there are so many possible factors at present we cannot nail down which ones are important.
Overall good health is likely a factor. This is an easy recommendation to make, because there are obvious wide-ranging advantages to overall good health. If it also reduces dementia risk, that’s just the icing on the cake. So, don’t smoke, get plenty of sleep, drink in moderation, exercise regularly, treat your chronic conditions like hypertension and diabetes, and take good care of yourself.
What about nutrition? Generally good nutrition is always a good idea, but what about specific supplements? Vitamin E and C (the anti-oxidants) get a lot of attention, but a 2013 systematic review concluded:
Overall, findings do not consistently show habitual intakes of dietary antioxidants are associated with better cognitive performance or a reduced risk for dementia. Future intervention trials are warranted to elucidate the effects of a high intake of dietary antioxidants on cognitive functioning, and to explore effects within a whole dietary pattern.
The evidence, however, remains mixed and I would say this is still a bit of an open question, but clearly there is no home-run here. Other specific nutrients, like folic acid, B12, and B6, also have not shown a consistent benefit when taken routinely.
However, elevated homocysteine levels does appear to be a risk factor for vascular disease and Alzheimer’s disease, and these B vitamins reduce homocysteine levels. Some researchers believe that current studies are inadequate because they mix in subjects who are healthy and don’t need B vitamins, which is a fair point.
At present, at the very least, older patients should be routinely tested for B vitamin and homocysteine levels and supplemented appropriately. Targeted supplementation may be better than routine or blind supplementation. It is easy, for example to oversupplement and have B6 levels that are too high, and even toxic.
Best advice: stay active, eat well, like your doctor tells you to
It is somewhat reassuring that dementia prevalence has declined in the US and other developed countries. Dementia remains a serious public health issue and anything to reduce its burden is welcome.
The recent study only provides evidence that years of education seem to have a protective effect, but this is also not the whole picture.
The best current advice for those who wish to minimize their dementia risk is to remain physically and mentally active, have overall good nutrition, and overall good health. There does not appear to be any magic bullet.

FTC Slaps Down “Brain Training” Claims
Steven Novella on January 6, 2016
Link
Lumosity is a company that provides online and mobile games that it claimed are scientifically designed to enhance memory, focus, mental flexibility, and even stave off dementia. In a recent decision, the Federal Trade Commission (FTC) concluded that Luminosity’s claims are not based on adequate scientific evidence. They imposed a $50 million judgement against Lumos Labs, the company who sells Lumosity, and allowed them to settle for $2 million.
Being mentally active
The idea behind “brain training” is not a bad one, it’s just easy to misrepresent as something it isn’t. The basic notion is that using your brain makes it function better. It is better to be mentally and physically active than inactive. This overview summarized the evidence:
Given the complexity of the dynamic reciprocal relationships between stimulating activities and cognitive function in old age, additional research will be needed to address the extent to which observed effects validate a causal influence of an intellectually engaged lifestyle on cognition. Nevertheless, the hypothesis that an active lifestyle that requires cognitive effort has long-term benefits for older adults’ cognition is at least consistent with the available data.
While the evidence is less than definitive, the current evidence suggests that being mentally active does improve cognitive function. The effect appears to be most robust for activity that involves the frontal lobes (planning and executive function), integrates multiple areas of the brain, and that is novel or new.
As with dietary advice, all of the complex research can currently be boiled down to rather simple advice – be mentally active, try new things and engage in different types of mental activity. Also get regular physical exercise. Such simple advice does not sell many self-help books or subscriptions to brain-training services.
“Brain training”
The very term “brain training,” in my opinion, is inherently deceptive. It implies that something more than just learning or practice is going on. This is the crux of the FTC decision against Lumosity – they claimed that their games were scientifically designed to train your brain and thereby confer some generalizable cognitive benefits. They were, however, getting ahead of the research, and their claims happened to land on the wrong side of reality.
This was, and to some extent remains, a legitimate research question: when you engage in a specific mental activity do you get better at just that specific activity, or does your cognitive function improve in general (do you get “smarter”)?
Another way to state this question is this: how generalizable are the skills improved by engaging in a specific activity. In other words – if I engage in a word game, like a crossword puzzle, do I get better at just crossword puzzles, at similar word-based games, at all language-based games, or at all cognitive tasks? Products like Lumosity imply or directly claim that the answer is close to the extreme of generalizability – that playing specific games make you smarter.
The answer from current research, however, is close to the extreme narrow end; playing a mental-training game makes you better at that specific game, and maybe very similar games, but that’s it. Skills do not seem to transfer to untrained tasks, general cognitive function, or daily activities. They may, however, make people feel smarter.
The research is somewhat plagued by a lack of adequate control groups in many studies. The best studies do have adequate controls, which are absolutely necessary. In one study, for example, researchers compared three groups: one group was trained on programs designed to enhance reasoning, planning, and problem solving. The second group was trained on memory, attention, visuospatial processing, and mathematical calculations. The third group, the control, was given five obscure knowledge questions and asked to use the internet to find the answers.
They found no difference in outcomes for all three groups; they all improved slightly in the assessment tasks, reflecting a generic training effect, and perhaps also an observational effect and confidence effect.
I do need to emphasize this is complex research and there is some room for a range of opinions about what it says. For example, there are studies that show that playing certain video games may enhance a surgeon’s ability with virtual reality endoscopic procedures. This implies some transfer of skills, specifically visual processing. It may reflect comfort level with navigating a virtual world on a computer screen.
However, what is true for visual processing may not be true for memory, language, math, or other cognitive skills. This is part of the challenge for this research – there are countless ways to parse the specific claims.
Conclusion: Stay mentally active, there are no panaceas
The current consensus based upon existing research is that engaging in cognitive tasks is overall a good thing. Stay mentally active and engaged, and try to engage in a variety of activities and in novel activities. Video games can be part of this.
However, the evidence so far does not support the claim that specific skills learned in one task are transferable to other tasks (with the possible exception of visual processing and perhaps task switching), or are generalizable to overall cognitive function, memory, focus, or mental quickness.
There is also no evidence that games “scientifically designed” for “brain training” are any better than regular games.
The bottom line is that you will improve at whatever task you practice, and perhaps closely related tasks.
There is no evidence to support spending any amount of money on specific products. Do what interests you, challenges you, and engages you. Don’t believe the “brain training” hype.
Hopefully, the FTC decision against Lumosity will take the wind out of the sales of brain training products, and reduce the hype somewhat.

Fraud, Scientific Rigor, and Alzheimer’s Research
A stunning case of possible fraud in Alzheimer’s research reinforces the need for scientific rigor at every level.
Steven Novella on August 10, 2022
Link

Several recent science news items that I have discussed here and on my other blog, NeuroLogica, have a common thread weaving through them – the need for medical science to have high standards of rigor and to weed out both sloppy science and fraud at every level. The stakes for modern biomedical research are simply too high, and the costs of fraud and error too great.
Most dramatically there is the case of probable exposure of more than a decade of fraud in Alzheimer’s research. To quickly summarize this case, in 2006 neuroscientist Sylvain Lesné, published a paper in which he and his coauthors alleged to show that “A specific amyloid-β protein assembly in the brain impairs memory”. This had a large impact on Alzheimer’s (AD) research. One of the main competing theories for the ultimate cause of AD is that the brain degeneration results from the buildup of a toxic form of the amyloid-β protein. The controversy is over whether amyloid-β is simply a marker of AD or is it actually causing AD. This has significant implications for finding an effective treatment.
In his paper Lesné apparently showed that transferring amyloid-β to rats would impair their memory. This strongly suggests that the amyloid-β is causing the impairment. At the time this was taken as powerful support for the amyloid-β proponents, and certainly had an influence on the next decade and a half of AD research, including NIH and other funding.
However, a recent Science article and investigation details the accusations of another neuroscientist, Matthew Schrag, who claims to have found evidence of manipulated images in the Lesné paper, and in other Lesné research over the years. Images in scientific papers are often data, and manipulating images is therefore manipulating, or even manufacturing, data. It’s a giant no-no – it’s scientific fraud. So these allegations are extremely serious. This is why Science launched their own independent investigation, bringing in many experts in image analysis. Their conclusion is that they found “blatant” evidence of image manipulation. At present it seems that Lesné is solely responsible for the fraud as he was personally responsible for all images in his research, but his co-authors should have been more careful themselves.
Lesné’s original 2006 paper was published in Nature, who has not yet retracted the study, but did add this warning:
The editors of Nature have been alerted to concerns regarding some of the figures in this paper. Nature is investigating these concerns, and a further editorial response will follow as soon as possible. In the meantime, readers are advised to use caution when using results reported therein.
Unless they come to a very different conclusion from the Science investigators, I suspect a retraction is coming soon. This kind of fraud is devastating on many levels, and represents a massive waste of biomedical research resources. But if we want to look on the bright side it is also true that Lesné’s claims were met with initial skepticism (especially from those supporting competing theories of AD causality) and his findings were difficult to replicate. In the end the system did manage to discover the alleged fraud, mainly because the one thing you cannot fool with fraudulent research is reality itself. This case also reinforces why replication is so critical in scientific research.
This case also has implications for the underlying scientific question – is amyloid-β responsible for AD? This certainly undercuts the case for amyloid-β, but it does not mean that it is wrong. It can be true despite any fraud by Lesné. But it does put a controversial decision by the FDA which I discussed last year in a harsh light. In 2021 the FDA approved Aduhelm as a treatment for AD. The approval was controversial because it was based entirely on improving a marker for the disease rather than a traditional clinical outcome.
The FDA justified the approval by stating:
Patients receiving the treatment had significant dose-and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta plaque.
The approval is contingent on later clinical trials showing clinical benefit. Ten of the 11 neuroscientists on the FDA advisory panel recommended not approving the drug, and the eleventh abstained. The FDA approved the drug anyway. Those neuroscientists understood that basing approval on a marker alone is highly problematic, and that amyloid-β as a marker for AD is still controversial. They likely feel now that the FDA has a huge “I told you so” coming.
In April of 2022 the US Centers for Medicaid and Medicare Services decided not to cover Aduhelm treatment, and many private insurers followed suit. Biogen, the maker of Aduhelm, has no choice but to proceed with their blinded clinical trials to prove efficacy – which is what should have happened in the beginning.
This entire saga also can be seen to support a recent initiative by the NIH to fund the development of educational modules for researcher, to teach high levels of scientific rigor. The modules would cover:
…biases in research; logical fallacies around causality; how to develop hypotheses; designing literature searches; identifying experimental variables; and reducing confounding variables in research.
These are all phenomena we discuss at length here at SBM, and they are indeed major problems in scientific research. It does seem that many researchers commit errors, such as p-hacking, simply because they are insufficiently aware of the problem and how to avoid it. It’s unclear if this kind of education would prevent fraud such as Lesné is alleged to have committed, but it wouldn’t hurt. It may make it easier for colleagues to detect fraud. And of course, there is no one solution to the problems of fraud and sloppy research, which is why we need filters in the system at every level.
The NIH’s efforts are definitely a step in the right direction. In fact, I would hope that not only do they make these educational materials available, but that funding eventually becomes dependent on certification in scientific rigor. The point of this is to reduce waste – waste of time, resources, and NIH funding. The Lesné affair shows how extreme the cost of bad research can be, estimated in the hundreds of millions of research dollars.
The institutions of science are imperfect, but strive to be self-corrective. While this is a sad and frustrating case, the response is appropriate – weed out the fraud, make corrections, and figure out how best to reduce similar fraud in the future. The NIH initiative is one method. But journals also need to add better filters prior to publication as well.

FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab
If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.
Saami Zakaria on June 23, 2024
Link

On June 10th, the FDA convened an advisory panel to discuss the status of donanemab, drug maker Eli Lilly’s latest beta-amyloid targeting monoclonal antibody for Alzheimer’s disease. The hours-long meeting included slides early on specifying that discussion points would include whether the advisory committee thought donanemab was effective, dosing considerations, and whether the benefits of the drug outweighed the risks. At the end of the meeting, the panel voted unanimously 11-0 that donanemab is effective at slowing Alzheimer’s in early-stage disease and that the benefits outweigh the risks. While this decision alone does not represent approval of the drug, the FDA is expected to act on the recommendation of its advisory panel in the coming months.
Presenting the evidence
In March the FDA had originally announced it would put off a decision regarding approval to further study and ask for additional information regarding trial data. Arguably the biggest trial in question, the TRAILBLAZER-ALZ 2 trial, came out last year. It concluded that donanemab statistically significantly slowed clinical progression at 76 weeks in those with baseline low/medium tau and in the combined low/medium and high tau pathology population.
The advisory panel was convened in June to discuss a number of issues, including the high rates of side effects (24% brain swelling and 31% brain bleeding in the donanemab groups). Patients in the donanemab group were only treated until amyloid plaque levels reached a pre-specified set point at which point treatment was stopped, representing the “limited-duration dosing regimen” referred to. Baseline tau levels were used to stratify patients.
In the trial results, clinical progression of Alzheimer’s was slowed in those in the low/medium tau group and in the combined low/medium and high tau group. But the “high” tau group alone did not have an improved integrated Alzheimer Disease Rating Scale score (iADRS), the primary outcome measure in the trial (though participants did show improvement with a secondary outcome measure, the clinical dementia rating scale sum of boxes or CDR-SB score). Patients with higher tau burdens would be more at risk for developing Alzheimer’s to begin with. If the drug were to be approved, questions surrounding who to offer it to and how to offer them the drug need to be addressed.
The meeting included presentations on efficacy and safety results by officials at Eli Lilly, opportunities for clarifying questions from the committee, and an open public hearing with speakers unaffiliated with the FDA having the opportunity to chime in. At the end of the session, each of the 11 advisory committee members had an opportunity to share their thoughts briefly when discussing their votes.
Reservations
Although the votes of affirmation for donanemab were unanimous, not all committee members shared an unbounded enthusiasm. For example, Dr. Nilufer Ertekin-Taner from the Mayo Clinic gave her vote of affirmation with the understanding that the data aren’t clear for all populations of interest, including those with two copies of the APOE4 gene (a strong Alzheimer’s risk factor), and in African American and Latin American patients.
If approved, donanemab would join fellow beta-amyloid targeting monoclonal antibody lecanemab (Leqembi™) as the third FDA approved disease-modifying Alzheimer’s treatment while seeking to avoid the fate of the first approved therapy, aducanumab (Aduhelm™), which has since been pulled from the market by maker Biogen due to difficulties generating enthusiasm and obtaining insurance coverage for their drug. Both lecanemab and aducanumab were approved under the FDA’s accelerated approval pathway, where drug approval is based not on clinical efficacy but on showing efficacy in achieving a surrogate endpoint. In these cases, the endpoint was a reduction of beta-amyloid plaques. Critically, however, the link between beta-amyloid and cognitive decline is far from certain.
The amyloid hypothesis and the tau hypothesis
The hypothesis that beta-amyloid is linked to cognition, or the amyloid hypothesis, posits that the accumulation of beta-amyloid fibrils under pathological conditions (such as with Alzheimer’s disease) leads to the development of plaques that are neurotoxic and lead to cognitive decline. Initial excitement for this hypothesis was linked to the fact that individuals with Down syndrome who have three copies of the amyloid precursor protein gene instead of the regular two have a higher rate of developing Alzheimer’s Disease. This protein is involved in the generation of beta-amyloid peptides.
However, not everyone with Down syndrome who develops beta-amyloid plaques has gone on to develop Alzheimer’s disease. Additionally, in other experiments using genetically modified mice with increased beta-amyloid production, nerve cell death was not observed as anticipated. Also, with the more recent advent of imaging for amyloid plaques in humans, many patients without known cognitive decline have extensive amyloid deposits, while many patients with Alzheimer’s Disease have few amyloid deposits. There are however mutations in amyloid genes identified which are linked to early onset familial Alzheimer’s, though these represent no more than 10% of Alzheimer’s cases.
Altogether, though the initial enthusiasm for the amyloid hypothesis was high, there are holes. Another protein called tau has also been implicated in the development of Alzheimer’s disease. Specifically, when tau is hyperphosphorylated (termed neurofibrillary tangles if they are formed in neuronal cell bodies), it is strongly correlated with the development of cognitive symptoms. Imaging techniques to study the patterns of tau pathology as well as post-mortem studies of patients showed much better correlation between tau pathology and cognitive status. The tau hypothesis has today garnered more support for direct correlation with cognitive decline in Alzheimer’s disease.
Regardless, interpretation of trial data for all three amyloid targeting drugs purported to show not just clearance of beta-amyloid but also less cognitive decline compared to placebo. These observations raised many questions, including the extent to which beta-amyloid is directly related to cognition, the extent to which modulation of beta-amyloid modulates tau, and – crucially — the extent to which the trials showing benefit were run well and had their data interpreted correctly.
What happened with aducanumab?
In the case of aducanumab, only one of the phase 3 trials showed slight benefit, but only in males over the age of 70 with a copy of the APOE4 gene. Though the other trial did not show benefit, a post-hoc analysis that studied only those receiving at least 14 treatment sessions with a “high” dose of the drug did show some benefit.
Although an FDA advisory committee voted heavily against recommending aducanumab via the traditional pathway based on clinical efficacy, the FDA switched its review to that of the accelerated approval pathway based on the surrogate endpoint that showing removal of beta-amyloid on its own was good enough and then approved the drug. This was done without consultation with the advisory committee, leading 3 members of the advisory committee to resign. A congressional probe later found atypical collaboration between Biogen and the FDA. Biogen eventually discontinued development of aducanumab in January of this year.
The devils in the details
The “Lecanemab in early Alzheimer’s Disease” trial was published in late 2022 and concluded that lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months. Not widely publicized was that per the trial data, lecanemab did not slow cognitive decline in women, and in fact enhanced decline in those with 2 APOE4 genes. Interestingly, trial data for aducanumab, lecanemab, and donanemab do show reduction in phosphorylated tau levels, keeping open the question of a threshold level of amyloid which influences tau pathology.
Another issue plaguing the trials had been the nagging question of functional unblinding which may be contributing to the positive results. In phase 3 trials of amyloid-targeting drugs, 21% to 44% of patients on active treatment developed brain bleeding or swelling, given the acronym ARIA for amyloid-related imaging abnormalities. A recent analysis postulated that the development of ARIA would have triggered protocol changes that may have unblinded patients and those around them to their treatment. This same analysis found a positive correlation between the incidence of ARIA-E (E for edema; brain swelling) and reported efficacy of the drugs in question.
An additional point of criticism was how a sensitivity analysis aimed to account for functional unblinding in the TRAILBLAZER ALZ-2 Trial, in which patients with ARIA-E had their post ARIA data points replaced with extrapolated data points from the average course of patients receiving donanemab who did not develop ARIA-E. It is also well known that ARIA are more likely to occur in those with the APOE4 gene mutation and, as previously mentioned, that APOE4 is more likely to lead to Alzheimer’s. This would have effectively removed individuals most at risk for developing Alzheimer’s disease from the donanemab group.
Finally, while levels of statistical significance have been hit in the aforementioned trials, an additional point of contention is when these changes become clinically meaningful. It’s been suggested that the threshold for a meaningful difference is a within-patient change of CDR-SB score of 1. With this in mind, neither donanemab nor lecanemab during their respective trial periods improved scores this much. However, the CDR-SB scale may also not capture one’s cognition very well.
So, is it worth it?
Now that the FDA advisory committee panel has unanimously voted to give donanemab the green light, it seems close to a sure bet that donanemab will be approved in the next few months. However, with the above reservations in mind, there remains uncertainty. To drill this down properly and instill public confidence, more transparency is needed. This includes more data on within-trial subject level records. Without increased transparency, it’s hard to ignore the reservations regarding donanemab and its predecessors.
If, as is the case with donanemab, patients with higher baseline tau pathology do not see a benefit in their iADRS, then those most at risk of developing cognitive decline stand to benefit the least. A big question would be if it is worth it to pre-emptively suggest a drug like donanemab to patients with suspected early Alzheimer’s disease before symptoms progress.
With the reservations discussed above, the side effect profile, and the tenuous nature of the amyloid hypothesis on which the premise of clinical efficacy is based, it should not be suggested to patients at this time. Nevertheless, if already approved, it’s also hard for clinicians to put a full stop on offering the drug to patients asking for it. In this case, as long as clinicians are open about the uncertainties, the remainder of the decision-making should fall to the patient.

No evidence, no problem: A closer look at the aducanumab approval
Why did the FDA approve aducanumab, a drug that hasn’t been shown to work?
Scott Gavura on June 10, 2021
Link


In exchange for the financial costs and risk of side effects, we expect prescription drugs to do something useful. It may be reducing the likelihood of death, eliminating an infection, or improving the quality of our life in some way. But the expected benefits should be understood and they should be meaningful. Depending on the condition being treated, measuring “clinically meaningful” endpoints can be time consuming and difficult, but they are the only way we can determine whether a drug is actually delivering a real benefit – or not.
Sometimes researchers choose to measure “surrogates”, instead of clinically meaningful endpoints. Surrogates are not themselves clinically meaningful or relevant to patients, but are assumed to be a proxy or substitute for the real thing. While some surrogates are good predictors of relevant endpoints, some have proven over time to be useless. A cautionary tale comes from the Cardiac Arrhythmia Suppression Trial which studied drugs that did a good job at improving a surrogate marker (premature heart beats) but were eventually found to increase the risk of death, not reduce it. Another example might be cancer drugs that improve a surrogate such as “progression free survival” which is the time until the cancer reappears based on imaging or laboratory measures, but subsequently are found to have no effect on when you actually die (overall survival). That is, they improved the surrogate, but not a measure that is relevant to cancer patients. The main reason to measure surrogates is because of convenience. If you are studying a drug or other intervention when the relevant endpoint can take years to appear, a surrogate, if it correlates well, can reduce the time needed to complete a clinical trial. But it’s risky.
Given the mixed history with surrogates, there is tremendous hesitation among science-based health professionals to accept surrogate markers as relevant when those measures have not themselves been proven to correlate with endpoints that are actually meaningful to patients and their families. Whether or not regulators like the FDA should accept surrogates in clinical trials as evidence of efficacy is a point of controversy and debate. Regulators must balance what may be promising preliminary evidence, and the potential for a drug to offer some benefit, against the possibility that the drug is actually ineffective or even harmful.
All of this gives some context for reaction to the FDA’s approval this week of aducanumab, the first drug in decades approved to treat Alzheimer’s disease. Aducanumab failed in clinical trials – yet it was approved for sale. Why?
The challenge of Alzheimer’s disease
Alzheimer’s disease (AD) is a neurological disease that is the most common cause of dementia. AD tends to be a disease of the elderly that commonly presents initially as memory impairment (particularly of recent events) and progresses to include greater deficits including inability to problem solve and impaired judgement. Overtime, AD can include psychiatric and other behavioural symptoms. Progressive disease is inevitable, but the rate of decline can range from a few years to decades. AD is common, and affects an estimated 6 million Americans, with that prevalence expected to increase based on population trends.
How AD develops is not known, but it produces changes in the brain that are destructive, progressive, and irreversible. A common feature of AD is the accumulation of protein called “beta amyloid” in the form of plaques that are thought to interfere with signalling and eventually cause cell death. Another feature is called “tau tangles,” where tau protein fibers twist and collapse, which are also thought to cause cell death.
Despite decades of research there has been little progress in developing medications or therapies that can improve symptoms or slow the progression of the disease. A class of drugs called cholinesterase inhibitors provide modest benefit for some of the symptoms of the disease, but do not affect its progressive nature. Memantine, another drug, works differently from the cholinesterase inhibitors and may provide some benefit in moderate AD. However, there is no treatment that has been shown to have any meaningful effect on the disease itself.
The unimpressive history of aducanumab
For over twenty years, researchers have pursued treatments against beta amyloid after trials in mice showed promising results. No treatments have ever shown benefit in phase 3 clinical trials, however. Biogen has been studying aducanumab, an antibody which targets beta amyloid, for years. Two large Phase 3 clinical trials called ENGAGE and EMERGE were established to evaluate the efficacy of the drug in patients with mild AD. These were 18 month trials that measured the effect of aducanumab in early AD. Patients were randomized 1:1:1 to low-dose aducanumab, high-dose aducanumab, or placebo, and the drug was given as an intravenous infusion every 4 weeks. The primary endpoint measured was the Clinical Dementia Rating Scale Sum of Boxes test (CDR-SB), which can assess the severity of Alzheimer’s dementia. In March 2019 both ENGAGE and EMERGE were discontinued after an independent data safety monitoring board concluded that the trials were unlikely to meet their primary endpoint. That is, in the language of clinical trials, they were discontinued “for futility”. Given no drug with a similar mechanism of action had ever been shown to be successful, this was not surprising. However, in analyses done after the trials were stopped (i.e., a “post-hoc” analysis), the manufacturer suddenly claimed that the drug was in fact effective, and it intended to pursue regulatory approval. (Post-hoc analysis can be important to generate hypotheses but are the statistical equivalent of shooting at a wall and painting the bullseye afterwards.) In short, the manufacturer claimed that after the futility analysis, additional data was made available that provided sufficient evidence of efficacy to merit moving forward with seeking approval. Notably, Biogen did not launch another trial to actually confirm their post-trial hypothesis. It filed for FDA approval.
It should be noted that the drug is not free of harms. It can cause swelling of the brain called amyloid-related imaging abnormalities (ARIA), common to this category of drugs, which can cause symptoms like headache.
Aducanumab was reviewed in November 2020 at an FDA advisory committee meeting. The briefing documents are here if you wish to peruse them. Among those documents included endorsements from FDA staff members supporting the manufacturer’s contention that the drug is effective. The report also contained comments from other FDA staff members criticizing the efficacy statements and the manufacturer’s reliance on post-hoc analyses, which were (justifiably) described as biased. Ultimately the panel votes on the evidence were strongly negative. While the FDA is not required to follow its advisory committee recommendations, these recommendations are typically important.
On June 8, 2021 the FDA granted accelerated approval for aducanumab, now branded Aduhelm, while requiring Biogen to do a confirmatory clinical trial over the next nine years. Incredibly, it did not even limit approval to patients similar to those in the clinical trial, who had mild disease and confirmed amyloid plaques. Instead, it put no restrictions on its use. There is no evidence whatsoever to suggest that aducanumab is effective in patients with advanced Alzheimer’s disease, but the drug can now be used in those patients.
In the meantime, Biogen can start marketing this product immediately, while clinicians, patients, and families are left wondering if the drug actually works at all. Notably the FDA approval states that the basis of approval is not a clinically meaningful endpoint – it was ultimately approved based on a surrogate :
“approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).” Additionally, “drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.”
So for the next several years, this drug is expected to be used in millions of Alzheimer’s patients, generating tens of billions of dollars in revenue (STAT says it may be the most lucrative drug product in history), without any clear evidence that the drug is actually doing anything beneficial at all.
A travesty of a mockery of a sham of an approval
FDA drug approval is a worldwide gold-standard that establishes that a drug is effective and has an acceptable safety profile. With aducanumab, the FDA has approved a drug that failed its Phase 3 clinical trials, and its own advisory committee recommended against approval. And the basis of approval was a surrogate endpoint that has not been shown to correlate with any clinically meaningful outcome for patients. With this approval, it may have done serious damage to its own reputation as a regulator.
Alzheimer’s is a devastating disease and there will be immediate demand for a drug which offers even a glimmer of hope. But is hope worth the $56,000 per patient, per year, price tag? Is the risk of brain swelling worth $56,000 per year, if the drug provides no benefit? A drug that meaningfully affects the course of Alzheimer’s disease justifiably should be a multi-billion dollar drug. But Biogen hasn’t shown this. Maybe we will find out in 2030, if Biogen completes the required trial, and after billions of dollars have been spent on treatments. Alzheimer’s patients and their families deserve better.

FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s
Criticism of the FDA’s decision to approve aducanumab for Alzheimer’s disease.
Steven Novella on July 7, 2021
Link

Alzheimer’s disease (AD) is a complex neurodegenerative disease that causes progressive dementia. Patients have impaired memory and as the disease progresses they have increasing impairment of all cognitive function. Life expectancy is typically 3-11 years following diagnosis. Worldwide more than 25 million people suffer from AD, with a prevalence of 4.4% in those over 65. In the US for those over 70 the prevalence is 9.7%.
At present there are no treatments which are generally considered to be disease modifying, and nothing approaching a cure. Existing treatments are considered symptomatic in that they reduce the severity of impairment but do not prevent progression. It is clear there is a great need for an effective treatment for AD, and this has apparently driven the decision by the FDA (discussed by Scott Gavura last month) to give “fast track” approval to a new drug, aducanumab (brand name Aduhelm), based on preliminary evidence. But the decision has proven to be highly controversial.
In the FDA announcement they report:
Researchers evaluated Aduhelm’s efficacy in three separate studies representing a total of 3,482 patients. The studies consisted of double-blind, randomized, placebo-controlled dose-ranging studies in patients with Alzheimer’s disease. Patients receiving the treatment had significant dose-and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta plaque.
They also explain that, given the great need, they allowed for approval based upon a biomarker only, without clinical data. They argue this is because there is a plausible connection between the biomarker (reduction in amyloid beta plaque) and clinical disease. Further, they now require the company, Biogen, to conduct a clinical trial to prove benefit. If the trial does not show clinical benefit, then the FDA will withdraw approval.
That all sounds reasonable, or at least they give a justifiable reason for their decision. However, they leave out many details, such as the fact that out of their 11 member advisory panel of neurologists, 10 voted not to approve aducanumab and one abstained. There are several reasons offered for their advice to reject the application. One is the fact that of the two clinical trials, one did not show a significant reduction in amyloid plaque while the other did. The results were mixed at best.
The majority of FDA reviewers (outside the neurology advisory panel) did recommend approval of the drug (which is why it was approved). This included the pharmacological review and the clinical review. However, the statistical review recommended denial, because the statistical results were weak. One of the members of the advisory panel, Dr. Aaron Kesselheim, who resigned in protest after the approval, said:
If the FDA allows companies to get drugs approved on the basis of trials that are stopped early, trials that are reanalyzed, that sets a precedent.
An independent statistical analysis published in March in JAMA also took issue with the statistical analysis, concluding that the results were not statistically significant. Therefore, we have two clinical trials, one negative, the other mixed with questionable statistical significance at best. That seems like a low bar, especially if we are relying entirely on a marker for AD rather than net clinical outcomes.
Further, use of that biomarker, amyloid beta plaque, has also been criticized. This has been one of the challenging aspects of AD science – researchers find lots of biomarkers that correlate with disease progression. However, as is always the challenge with biomarkers, it is unclear if this is contributing to progression of the disease or is just a consequence of it. Specifically, we cannot assume that simply reducing the presence of the amyloid beta plaque will reduce progression of the disease.
As other critical experts have pointed out, there have been prior monoclonal antibody treatments which demonstrably reduce amyloid beta plaque in AD but which failed to produce any clinical improvement, specifically bapineuzumab and solanezumab (monoclonal antibody drug names all end in “mab”). While there is still debate on this issue, the evidence so far does not clearly support reduction in amyloid beta plaque as a predictive biomarker for clinical improvement.
Scientifically, therefore, aducanumab may not even work as advertised in terms of meaningful reduction in amyloid beta plaque in AD, and even if it does this may not result in clinical improvement. But there are some pragmatic considerations as well. One is that the company announced that the cost of the drug will be $56,000 per year. Monoclonal antibodies are not chemicals, as the name implies they are specifically created antibodies with a therapeutic target. They are expensive to make, hence the high price tag just for the drug (although critics claim the company is including a hefty profit in that price tag) but also are expensive to give. They are delivered through intravenous infusions. A reasonable estimate for total cost, therefore, is about double the drug cost, or over $100k per year.
Given the prevalence of AD this is a hefty price tag for a treatment based on such thin evidence. Further, there are likely to be inequities in availability and reimbursement.
Another concern (one we often point to with questionable medical treatments) is that treatment with aducanumab, because it is FDA approved, may displace other experimental treatments. Patients in clinical trials (and who may be getting a placebo) may want to pull in order to get aducanumab, or may never enter a clinical trial in the first place. If aducanumab truly worked, this would be OK, it would become the standard of care and the baseline with which further research would be compared. But given the dim view that many experts have for this treatment, the fear it the only net effect, in addition to wasting a lot of health care dollars, will be to slow further AD clinical research.
The one good thing about the aducanumab controversy is that the public debate on the topic has been nuanced and well-informed. The principles I have outlined above are all important concepts that are broadly applicable. We invoke them frequently in many contexts at SBM: biomarkers may not predict clinical outcome, statistical rigor is critical, preliminary results are poor predictors of ultimate efficacy, and diverting resources based on false hope can cause much harm. Let’s hope these lessons are learned well. They can be applied to just about the entire supplement industry and much of the alternative medicine industry, for example.

Another Controversial Alzheimer’s Drug
A new treatment for Alzheimer’s Disease is promising, but we’re not there yet.
Steven Novella on November 30, 2022
Link

A recent study in The New England Journal of Medicine presents data, for the first time, showing a treatment that slows down the progression of Alzheimer’s dementia. The study – “Lecanemab in Early Alzheimer’s Disease” – tests a monoclonal antibody that is given as an IV infusion every two weeks. While this should be viewed as a legitimate breakthrough, it also shows the continued challenge of understanding and treating this complex disease.
Alzheimer’s (AD) is the most common form of dementia, which is a chronic global cognitive impairment. Usually memory is affected early and most significantly, but all cognitive functions can be affected. AD is considered a neurodegenerative disease, in which cells of the nervous system progressively die of. This entire category of diseases has proven extremely challenging. One of the challenges is that research discovers that lots of things are happening when nervous system cells die, but it is hard to know which things are driving the progression of cell death and which are themselves just downstream effects or markers. Is that inflammation killing the cells or just cleaning up already damaged cells?
Another challenge is that many of the neurodegenerative diseases are likely multiple diseases. They are clinically defined by which cell populations are being affected, but there may be multiple processes that are killing those cells, and each one would require a different treatment. Even a single neurodegenerative disease may have multiple causes, with the cumulative effects leading to cell death.
For AD there are two main contenders for the ultimate cause of degeneration, both abnormal proteins. One protein is called amyloid-beta (Aβ), which is a misfolded protein that aggregates outside of neurons, creating what are called plaques. The other is tau, which is also a misfolded protein, but this one aggregates inside neurons and causes neurofibrillary tangles. Tau is normally a protein that is part of microtubules, which transport nutrients throughout the cell. Further, Aβ and tau seem to work together, described as the “trigger and bullet” that causes neuronal degeneration.
Further complicating attempts at treating AD is the fact that Aβ and tau build up may occur for years and even decades prior to the onset of clinical symptoms – so the disease is fairly advanced pathophysiologically before we know it exists. Treatments aimed at Aβ and tau may therefore be too late to stop significant damage. There are screening tests for these proteins, in the blood, CSF, or through PET scanning, but these suffer from relatively low sensitivity and specificity. This means that many people with AD test negative, while many people without AD test positive. For this reason their clinical use is limited (although they are very helpful in research), mainly to atypical cases, and only 1-2% of people with AD get such protein tests.
I am glossing over a lot of complexity, but that is the basic picture. It’s no wonder that the last few decades of clinical research into treating AD has essentially been a string of failures. We may need to give multiple treatments to the right patients early enough in the disease process to make a clinically significant difference. Misfolded proteins are also not the whole picture, as other processes, such as inflammation, are playing a role.
With that background, we can understand why a treatment aimed solely at Aβ in patients who already have clinical AD may have limited utility. But that is the new treatment presented in the NEJM – lecanemab. These antibodies bind to Aβ, directing immune cells to them and leading to the breakdown of the Aβ plaques. The study itself is very rigorous:
We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing.
The primary outcome measure was change from baseline to 18 months in clinical dementia rating. Several other dementia scales were used as secondary outcomes, as well as the amount of amyloid seen on PET scanning in the brain. Here is the main result:
The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001).
That is, by all accounts, a modest effect size, about a 25% difference in outcome over 18 months. I previously wrote about another drug, aduhelm, which is also a monoclonal antibody that targets amyloid plaques. The controversy with aduhelm was that it was approved by the FDA based on preliminary data of reduction in amyloid only, without proof of clinical benefit. That data for lecanemab is better, and the FDA approval process is underway. This study, however, does lend some support to the potential for aduhelm to also work, since it works by the same mechanism.
The “controversy” with lecanemab is primarily about the ultimate utility of this approach. Monoclonal antibodies are expensive products, and this one would have to be given every two weeks as an IV infusion, presumably over years. That could represent a huge health care burden, for a modest effect. I am not saying it’s not worth it, and I imagine anyone facing AD or a loved-one with AD would take the 25% slowing down of progression. But we do need to think of the potentially massive effects such a treatment could have on health care systems.
Further, lecanemab was not without side effects, which were significant in 26.4% of patients. There was a 17% incidence of brain bleeds, and a 13% incidence of brain swelling in the treatment group (with few in the placebo group). It’s possible these side effects may be more detrimental than the benefit of the drug.
What we need to know at this point is how well lecanemab will work in the clinical setting. Will every patient need to get a PET scan or antibody study to qualify for treatment? How many years, on average, will patients be getting a regular IV treatment with the drug? Will the side effects get worse over longer treatment periods? On the optimistic side, researchers report that the average patient with AD lives at home for 6 years before going into a nursing home. Over that 6 years treatment with lecanemab can extend their independence by 19 months.
Perhaps the most useful thing about this study is that it is a proof of concept – treating amyloid beta early in the disease can have clinical benefits. Lecanemab (or aduhelm) may not transform AD treatment, because of the modest effects and side effect profile. But we now know we can make a clinical difference with this treatment approach. Next generation treatments may be more effective and safer. Also, we may need to combine amyloid treatments with tau treatments. We may also need better screening tests to tell early on, even before symptoms begin, who can benefit from such treatments. Hopefully we are just seeing the beginning of effective treatments for AD.

FDA Approves Leqembi for Alzheimer’s
FDA upgrades Leqembi for AD from accelerated to traditional approval based on latest clinical data.
Steven Novella on July 12, 2023
Link

The FDA has just given its first traditional approval for a disease-modifying drug to treat Alzheimer’s disease (AD). This is a significant milestone with serious implications for AD treatment. But as always some clinical context is helpful.
In January of 2023 the FDA gave accelerated approval to the drug, Leqembi (lecanemab-irmb). The accelerated approval pathway was created, as the FDA says:
“…to approve drugs for serious conditions where there is an unmet medical need, based on clinical data demonstrating the drug’s effect on a surrogate endpoint, that is reasonably likely to predict a clinical benefit to patients.”
This was a departure for the FDA, who previously required evidence of clinical benefit in excess of risk. The accelerated pathway has also been controversial. Proponents argue that it gives practitioners the ability to prescribe drugs that have a good chance of working years earlier than they otherwise would. For diseases that are progressive and irreversible, this time can be extremely valuable. It also allows academic clinicians to conduct research more easily, since they can simply prescribe the drug and get it paid for.
Further, many clinicians already do this with off-label use. If a drug is approved and on the market, and may be of benefit in a different disease, you can just prescribe it off-label. The belief that a drug may work for a new indication is often based on its mechanism of action. The accelerated pathway would essentially allow the exact same practice but with drugs not already approved for a separate indication.
Critics, however, argue that using biomarkers to predict clinical efficacy is tricky business, with a fairly low hit-rate. This has been particularly true in neurodegenerative disorders, which are complex diseases involving many biological markers. Research into such diseases, like AD, ALS, and Parkinson’s disease, have been characterized by a string of disappointments, as one biomarker after another does not translate into a disease-modifying treatment. These are the very diseases the FDA is focusing on with their accelerated approval pathway.
The challenge is that when cells are dying, a lot of things are happening biologically. It seems that no matter what aspect of cell function we look at, it’s different in disease cells compared to healthy cells. Almost anything, therefore, can be a biomarker of the disease state. But that does not mean that every biomarker is actually driving the disease. It could just be a consequence of the disease. Treating a biomarker, therefore, may be like getting cosmetic surgery to look younger. It may alter some of the effects of aging, but It doesn’t change one’s biological age.
This is why the Leqembi approval is so important. It is the first time researchers have definitively tied a biomarker of AD with a demonstrable clinical outcome. Perhaps even more important than the availability of a new treatment for AD is the clinical confirmation that the Aβ proteins and the soluble protofibrils they create are pathogenic in AD, and not just a downstream marker.
Two years ago I wrote about another AD drug, similar to Leqembi, approved through the accelerated approval pathway – Aduhelm. There were other issues with this drug, namely that the data regarding beta amyloid reduction was not that clear, with critics arguing the data was not even statistically significant. The company was given three years to provide clinical confirmation of benefit, and those studies are still under way. Meanwhile Leqembi beat Aduhelm to the punch.
What is the data that Leqembi actually works? The study involved 1795 participant with early dementia and confirmation of amyloid plaques on either PET scanning or by cerebrospinal fluid analysis. Leqembi is a humanized monoclonal antibody that binds to beta amyloid and reduces plaque formation in the brain. The multicenter study was a double-blind placebo controlled trial with a 1:1 ratio of treatment to placebo. Subjects were followed for 18 months with a standardized measure of dementia, and several secondary measures of function. The study showed:
The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In a substudy involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, −59.1 centiloids; 95% CI, −62.6 to −55.6). 
Leqembi reduced brain amyloid burden and moderately reduce progression of dementia compared to placebo. All secondary measures were also improved in the treatment group. This is well above the threshold for full regular approval by the FDA, so it’s not surprising that an FDA panel approved the drug unanimously. These fairly clear clinical results are and important confirmation of the amyloid hypothesis of AD, and also is likely to be taken as validation of the FDA accelerated approval pathway. But what will it mean for AD patients?
Given that AD is a progressive, irreversible, and otherwise untreatable disease, any treatment that slows the progression of the disease is potentially hugely useful. On average people live about 10-11 years after diagnosis with AD (depending on severity at time of diagnosis), but there is a long tail with some people living up to 20 years. Even if we take an average survival, a 20% or so reduction means 2-3 years likely greater survival, and some of this time can have meaningful function. If treatment is started early in the disease, this could mean several years more of independent living and meaningful interactions with loved-ones.
And of course the hope is that the longer survival will give more time for research to develop further treatments which also slow down the disease. We may ultimately develop a cocktail of several treatments addressing different aspects of the disease. The ultimate goal is that the disease is slowed so much that people generally die with AD rather than from AD.
But there are significant downsides to this treatment as well. Because it is a monoclonal antibody it has to be given in an IV infusion, which is given every other week. The total cost is estimated at $26,500 per year, which would mean a typical Medicare copay of $5,000 per year. And there are side effects:
Lecanemab resulted in infusion-related reactions in 26.4% of the participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%.
The amyloid-related imaging abnormalities (ARIA) result from swelling and bleeding caused by the inflammatory reaction of the antibodies attaching to the amyloid. Often this is minor and asymptomatic, but ARIA can be symptomatic in some patients causing headaches and dizziness. In severe cases there can be actual brain bleeds, even to the point of being life-threatening. For this reason patient on blood thinners should probably not take Leqembi.
There are about 6.7 million patients with AD in the US at this time. Let’s say about 1 million of them will be in the early stages and qualify for treatment. If all of them were treated, that would cost 26.5 billion dollars a year. Also, with the availability of treatment, the diagnosis of early AD is likely to increase. That cost does not include the treatment of side effects. In terms of cost effectiveness, that would have to be weighed against the cost of traditional AD care, including nursing home care. Would treatment only delay entry into nursing home care, or would it potentially reduce it (as some patients may die before getting to that point)?
The availability of expensive drugs providing moderate benefit for horrible diseases is something we need to confront as a society. It is technology like this that has been mostly driving up the costs of healthcare. The monoclonal antibody revolution has accelerated this effect.
From the perspective of the patient and their loved-ones, this is not much of a dilemma. Facing the reality of AD or a similar neurodegenerative disease, any effective treatment is welcome. Further I would think of treatments like Leqembi as a likely (hopefully) transitional phase. The most significant thing, arguably, about Leqembi is that we finally have clinical confirmation that our basic science understanding of AD is on to something. We are not just looking at shadows on the wall – we actually understand something about how this awful disease works.
The hope is that this is the first baby step on what will become a steady journey of improvement, even if incremental. We may be getting the first peak of a future in which neurodegenerative diseases are no longer destiny, but are simply managed chronically.

Yet Another Alzheimer’s Drug
A third drug either FDA approved or showing clinical benefit for Alzheimer’s disease confirms that the world of AD treatment has changed forever.
Steven Novella on July 19, 2023
Link

I would not have guessed that a mere week after writing about FDA approval for leqembi for Alzheimer’s disease, I would feel compelled to write about another drug that also shows incredible promise for treating the disease. This makes three drugs that have either gained some form of FDA approval or shown clinical efficacy in a phase III trial. This has caused a flood of calls to my colleagues who specialize in treating dementia, so a review of where things stand could be helpful. It is also interesting to review how things have seemed to change so quickly after decades of disappointment.
To review, in June 2021 the FDA gave accelerated approval to Aduhelm (aducanumab) for the treatment of Alzheimer’s disease (AD), which is a progressive dementia caused by a neurodegenerative process. As I wrote at the time, this decision was somewhat controversial. First, it was one of the early tests for the FDA’s new accelerated pathway, which can approve a drug for an unmet need based entirely on improvement in a biomarker without evidence of actual clinical benefit. Further, there was good reason to be cautious about the amyloid hypothesis of AD on which the approval was based. The evidence itself also had some issues – an independent analysis questioned the statistical significance of the results.
All things considered, it was not looking good for Aduhelm or the FDA’s new accelerated pathway. Biogen, the manufacturer of Aduhelm, was given three years to provide clinical evidence that their drug actually works, and studies are still ongoing. Meanwhile, Aduhelm now appears to have been beaten to the finish line by two other similar drugs, answering many of the thorny questions about this entire approach to AD.
Early in 2023 leqembi (lecanemab) was given the same accelerated approval by the FDA based on the same kind of data, that the drug binds to and reduces amyloid. Last week, based on a large clinical trial, that approval was upgraded to full regular approval. Leqembi reduces the progression of clinical measures of AD by 27%. Now, a mere week later, a large clinical trial shows that a third drug, donanemab, reduces AD progression by 35%.
Before I discuss further what all this means, let’s review the new data. First, this was a very large trial:
Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021.
Of the 24 clinical outcomes measured in the trial, 23 were statistically significant. The effect size is also robust:
The least-squares mean (LSM) change in iADRS score at 76 weeks was −6.02 (95% CI, −7.01 to −5.03) in the donanemab group and −9.27 (95% CI, −10.23 to −8.31) in the placebo group (difference, 3.25 [95% CI, 1.88-4.62]; P < .001)
Tau is another protein implicated in AD, and the group that did the best were the low-tau group. The mixed tau group also saw improvement, but not as much. Also, there was a correlation between early treatment and benefit. Like lecanemab, about 24% of subjects had changes on their MRI scan shows edema or effusion, 6% symptomatic. Three patients in the treatment group died of a treatment reaction, while one died in the placebo arm. The FDA is likely to have a decision by the end of the year, but given this data it is very likely that donanemab will gain full approval.
How is it that after three decades of failure, we now have three drugs in two years showing such promise? There are several factors. It is interesting to note that until these three drugs there was considerable controversy over the amyloid hypothesis of AD. It is clear that beta amyloid and other forms of amyloid and tau proteins build up in the brains of AD patients. These proteins become toxic when they form complexes, including plaque and fibrillary tangles. However, it was never fully clear if the plaque and tangles were the consequence of the disease or the cause of neurodegeneration. If the former, then targeting amyloid would cause cosmetic changes but not be disease-modifying. Many amyloid targeting drugs have been tested over the years, and none have worked, casting doubt on the notion that amyloid is the culprit.
Perhaps the most significant thing to come out of lecanemab and now donanemab showing clinical benefit is that these drugs are the first clinical confirmation of the amyloid hypothesis. Of note, lecanemab and donanemab target different forms of amyloid. Donanemab targets plaques directly, while lecanemab targets forms of amyloid before they form into plaques. Donanemab shows that clearing plaques themselves is beneficial. The data also show that the benefits last even after treatment stops, at least for 18 months.
So what was the breakthrough? Researchers give several reasons. First, these three drugs are all monoclonal antibodies (that is why they all end in “mab”). These are antibodies that bind to certain type of amyloid and target the immune system after them, which then breaks them down and clears them. This approach likely just works better than previous drugs.
Second, researchers have been more aggressive at dosing. It is almost a cliché that when a drug fails to show benefit in a clinical trial, proponents always argue that we simply need to give it in a higher dose, or perhaps there is a subgroup for whom the treatment works. It turns out, both are true when it comes to anti-amyloid treatments. You need to significantly reduce amyloid build up to see clinical benefit. Also, researchers started studying patients with early disease, and that seems to have made a big difference.
What, then, is the current state of treatment for AD and what can we expect in the future? First, studies of Aduhelm need to be completed to show clinical benefit. This is looking much more likely, given the results from lecanemab and donanemab. Assuming it works, and the FDA gives final approval to it and donanemab, we may soon have three FDA approved disease-modifying treatments for AD. It is a new world, and an exciting time for the field of AD research and treatment.
Patients now have interesting options. Of the three drugs, donanemab looks the most promising, both because it has the largest effect size, and because treatment does not necessarily need to be indefinite. Researchers think that a one year treatment phase followed by occasional maintenance treatments may be enough. Meanwhile, lecanemab requires treatments every other week indefinitely.
But it’s always good to have options. Not every patient may tolerate or respond to donanemab, and could cross over to one of the other drugs if necessary. Also, it is possible that combining lecanemab and donanemab (and eventually aducanumab) may have added benefit, since they target different versions of amyloid.
These treatment seem to work best, and may be only worth the risk and expense, in early disease. So it is important for patients with very mild or early symptoms to be evaluated by a specialist and start treatment as early as possible. Also, the availability of treatments tends to light a fire under diagnostic interventions. We generally don’t bother (outside clinical trials) with expensive, risky, or invasive diagnostic procedures for a disease that isn’t treatable anyway. But now that AD is treatable, early diagnosis becomes critical.
This will even cause a push for better diagnostic technology to identify AD earlier and earlier, perhaps even before clinical symptoms. The hope is that very early treatment will slow progression enough that people will not live long enough to ever develop severe dementia. This may lead to screening for AD in asymptomatic individuals, especially if there is a family history of AD.
Now that we know targeting amyloid can alter the disease, this will help focus future research. There are many subquestions about exactly which form of amyloid or tau to target, and in which combinations. The three approved drugs may be eventually considered to be just the crude beginning of this process – important proofs of concept, but not the mature treatments we will eventually have. The success of these drugs is likely to spawn and guide years of subsequent research.

New Review Casts Doubt On Alzheimers Drugs But Is Controversial
Steven Novella on April 22, 2026
Link

I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the progression of Alzheimer’s disease (AD). The benefits are modest, and come with the potential for serious side effects and a high price tag, but after decades of disappointment it was good to at least have a proof of concept that some application of our understanding of AD can help.
But now a Cochrane review casts doubt on the efficacy of these drugs. It is being widely reported as showing the drugs do not work, and is being used to justify not paying for treatments. The BBC, for example, reports, “Breakthrough £90,000 Alzheimer’s drugs unlikely to benefit patients, report suggests.”
The authors of the review looked at 17 studies involving over 20 thousand patients who were followed for at least 18 months. They concluded:
“The effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive function and dementia severity at 18 months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease is trivial, while on functional ability, it is small at best. Amyloid‐beta‐targeting monoclonal antibodies increase the risk of amyloid‐related imaging abnormalities. Both desirable outcomes and adverse events were inconsistently reported in the studies included in the review.
Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Future research on disease‐modifying treatments for Alzheimer’s disease should focus on other mechanisms of action.”
That is pretty devastating. But the fact that they looked at 17 studies was an immediate red flag for me – I didn’t think there were 17 studies of the currently two approved drugs. There isn’t. The authors looked at every monoclonal antibody that targets amyloid, including those that have previously been shown not to work. They included aducanumab, bapineuzumab, crenezumab, donanemab, gantenerumab, lecanemab, ponezumab, remternetug, and solanezumab (the “mab” stands for monoclonal antibody).
These are all drugs that are antibodies which target some form of amyloid protein, which is the protein that builds up in neuron in AD and is a significant marker for the disease. The longstanding question has been, however, is amyloid driving AD or is it just a downstream effect? If the latter than removing it might do nothing to alter the course of the disease or treat its symptoms.
That is really what is at the core of this evidence – is amyloid the target we should be focusing on? Or is AD more of an inflammatory disease? Inflammation is something else that can be primary (causing the disease) or secondary (just cleaning up the damage caused by the disease). There is also tau protein, which can also build up in some patients with AD. In fact the research is progressing to distinguishing patients in terms of how much amyloid vs tau they have. We can also distinguish patients who have familial forms of AD from those who don’t, so AD is really a category of multiple specific diseases.
It’s important to understand that the precise role of amyloid in AD vs other potential mechanisms is a decades-long heated debate among AD researchers. After decades of negative clinical trials, many researchers were pushing for the conclusion that amyloid is simply a dead end therapeutically. Then lecanemab and donanemab showed clear (but modest) clinical benefit, and it was the turn of the amyloid theory promoters to do their victory dance. Even though the clinical benefits might be small, it was taken as a proof of concept – the amyloid hypothesis must be onto something.
In this context, this latest review might be seen as a counterattack by the anti-amyloid brigade. That might explain why the researcher chose to include all anti-amyloid monoclonal antibodies, not just the ones that have been previously shown to work. It also explains their rather pointed conclusion – “Future research on disease‐modifying treatments for Alzheimer’s disease should focus on other mechanisms of action.” Should it, really?
Amyloid researchers are not taking this sitting down. They are quick to point out that this review does not clarify the data, it deliberately muddies it by mixing in older failed drugs with newer successful ones. In essence, critics claim, they have deliberately diluted out the evidence for efficacy then falsely claimed the entire class of drugs is a failure, and used that to deny the underlying mechanism.
I tend to be persuaded by this argument – I immediately found it extremely odd that they would do a review that combines drugs which don’t work with drugs that do and treat them as one class.
I think this 2025 review takes a more nuanced and appropriate clinical approach to this evidence. They found:
“Anti-amyloid mAbs consistently demonstrated robust amyloid clearance and modest slowing of clinical decline in early symptomatic AD. Differences emerged across agents in efficacy signals, safety profiles, and regulatory outcomes. Lecanemab and donanemab showed more consistent cognitive benefits, while aducanumab yielded mixed findings, leading to its withdrawal.”
and concluded…
“Anti-amyloid mAbs provide proof of concept for AD modification, with the greatest benefit in early disease stages and moderate tau burden. Optimal use requires biomarker confirmation of the amyloid, careful tau staging, and genetic risk assessment. While limitations remain, these therapies represent a pivotal step toward precision neurology and may serve as a foundation for multimodal strategies targeting tau, neuroinflammation, and vascular pathology.”
Exactly. I have heard several grand rounds by leading AD researchers, and this conclusion seems spot on to what they are saying. AD is a complex set of diseases, which is why it has proven so difficult to treat. No simple approach is likely going to have any significant impact. It took decades to develop treatments targeting amyloid that show clinical benefit, partly because monoclonal antibody technology has allowed more precise targeting and higher doses. They are just the beginning, however.
Going forward we need to do several things. First, continue to advance our screening efforts and ability to diagnose AD early, because the earlier the treatment the more effective it is, and this can be a massive factor. Second, we need to separate AD into various subtypes – as the above study concludes, we need to confirm the role of amyloid and determine how much of a role tau is likely playing also. We need to combine this with genetic data and family history. Together we can then target a suite of specific treatments towards individual patients. But of course, we have to develop the individual treatments first, and the anti-amyloid mabs are just the first step.
Finally, we need to continue to explore other mechanisms at work in AD and target them as well, not just amyloid and tau, but inflammation and vascular pathology. Perhaps in 20-30 years, or even sooner, we will have a cocktail of treatments, each of which individually has a modest benefit, but together have a significant benefit for slowing down AD. Since AD tends to present in older age, slowing down progression can mean that many patients die with AD rather than from AD, and while still highly functional.
In the end, I am not even sure what role this latest review plays. By mixing older drugs that don’t work with newer ones that do it seems designed to muddy the waters, and to have a negative outcome. This is likely just to confuse the public, and is being used by regulators to justify not paying for these newer treatments.


MEND Protocol For Alzheimer’s Disease
Steven Novella on June 22, 2016
Link

The medical profession is currently engaged in a simmering debate about what is the best overall approach to take toward the relationship between science and health care. I would say that the current dominant model is Evidence-Based Medicine (EBM). We, of course, advocate for a number of tweaks to EBM we call Science-Based Medicine (SBM).
SBM essentially advocates for an ironic-sounding holistic approach to scientific evidence. All evidence should be considered in its proper context with an eye toward the strengths and weaknesses of each kind of evidence, and in the context of the institutions of science and medicine. SBM represents a higher standard of overall evidence, which we feel is justified given the degree to which medical interventions are adopted prematurely (as evidenced by later reversals).
At the same time there are those, in the minority but with an established presence, who are essentially arguing for lowering the standard of science in health care. They exist on a spectrum, at one end including those who would abandon science entirely in favor of spirituality and philosophy-based medicine. At the other end are those who claim to endorse science but want to change the rules of scientific medicine to include a much lower standard of evidence. This is more pseudoscience than antiscience. Chief among them, in my opinion, are proponents of what they call “functional medicine.” Functional medicine essentially uses science incorrectly, but still cloaks itself with the imprimatur of science.
The MEND Protocol
As an example of how functional medicine uses scientific evidence incorrectly, we have the MEND Protocol for Alzheimer’s disease (AD).
AD is a complex neurodegenerative disease that results in the death and dysfunction of neurons in the brain, causing a slow global cognitive decline over years. This is one of those diseases where we have a great deal of research and knowledge about what is happening in the disease, but we have not been able to put it all together and determine what the ultimate cause is.
The problem with neurodegenerative diseases in general is that a series of complex changes occur in the cells and we don’t know what is cause and what is effect. A lot of things happen when neurons die, but are those things causing the neurons to die or just a result of the dying process?
In AD, for example, we see the buildup of certain proteins, causing plaques and neurofibrillary tangles. We also see that some proteins have changed their conformation, similar to what happens in Creutzfeldt-Jakob disease (the human version of bovine spongiform encephalopathy or mad cow disease). Perhaps oxidative stress is playing a role, or neurotoxic neurotransmitters. Some gene variants present a higher risk of developing AD. There is impaired axonal transport, and there is inflammation.
Inflammation is always tricky because it is virtually ubiquitous when cells are dying, and is also part of the healing process. The immune system is the clean-up crew, which reacts to damaged and unhealthy cells. So when we see markers of inflammation we don’t know if the inflammation is causing the damage or a reaction to it, or both. The inflammation may also be reactive, but then accelerate the damage.
As a result of this complexity we have lots of clues but few clear answers. There have been many clinical trials which essentially fix one of the markers for AD, but they so far have not altered the course of the disease.
In general we need high quality clinical trials, with proper blinding, to know if a specific intervention actually works, regardless of how plausible it seems based on the basic science. When dealing with a disease as biologically complex as AD, it is especially necessary because the number of false leads is massive.
The Functional Medicine approach
The MEND Protocol is a functional medicine approach to AD. According to the website of Muses labs, which owns the rights to the protocol (as evidenced by the “TM” after name – always a red flag):
MEND Protocol is designed to address the active underlying pathways for Alzheimer’s disease including metabolic issues, toxicity, inflammation, and mitochondrial damage. The therapeutics recommended by the MEND™ Protocol offer a way to bring these mechanisms into a state of enhancing a participant’s cognitive health – and maintaining that control over time. These factors and their complex interrelationships must be personalized based on an individual’s specific needs.
Due to the complexity of the personalization process, the Protocol is created via health management software. Our algorithms are able to process a wide range of data on an individual’s health status and recommend specific interventions matched to each individual.
Essentially their approach is to address all the markers in AD, all the things that basic science studies show might be off, without addressing the issue of whether or not these markers actually cause or drive AD. They then add the further layer of complexity of “personalized” medicine.
Personalized medicine is similar to functional medicine, except that it is reasonable in theory. If we can learn how to predict (with genetics, mostly) how an individual patient will respond to a treatment, we will be able to have a better outcome then just applying population-based data.
The challenge is, we need a lot of data about how individual factors affect the response to interventions. Many people promising personalized medicine currently, in my opinion, are skipping this important step. It becomes pseudoscience because it is massively premature, trading on the hype and promise of the personalized approach, but skipping over all the tedious science.
The result of their function and personalize approach is a salad of technobabble:
The analysis algorithm recommends both pharmacological and non-pharmacological components. For example, if synaptic reconstruction and maintenance is needed, then multiple biological mechanisms may require normalization, enhancement, or administration. Examples of these underlying biological mechanisms include: periodically activating autophagy, blocking prionic tau amplification, increasing beta-amyloid clearance, inhibiting beta-amyloid oligomerization, minimizing inflammation, normalizing neurotrophic factors, reducing ApoE Ɛ4- mediated signals, reducing stress, reducing tau phosphorylation, restoring cholinergic neuro- transmission, and reversing memory loss. Assessing the status of these biological mechanisms involves quantifying and observing hormonal balance, citicoline, C-reactive protein and other inflammation-related markers, diet, exercise, homocysteine, omega-3 acids, sleep, and so on. Interventions targeting specific biological mechanisms are then prioritized and prescribed to optimize key biological mechanisms. Medication doses are specified to an individual’s needs. Individuals are re-tested periodically and the protocol is updated as necessary.
How, exactly, do they know if a patient requires “synaptic reconstruction” and what evidence do they have that there is an effective treatment? It sounds very sciencey and impressive, and that is apparently the idea, but they are getting at least several steps ahead of the science.
A recent study
A study looking at the clinical effects of the MEND protocol was just published: “Reversal of cognitive decline in Alzheimer’s disease.” Despite the suggestive title, the methods of the study are preliminary.
The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neurodegeneration (MEND).
Essentially this is an observational study, a case series of 10 patients. This is reasonable as a preliminary study design, but it should not be used to support claims of efficacy – it is not an efficacy trial. All 10 patients improved in the trial.
The data, of course, is unblinded, meaning that it is very unreliable. In my experience as a neurologist, cognitive function can be very subjective. It is affected by mood, by transient things such as sleep, and there is also a huge element of subjective perception.
Some of the subjects did better on neuropsychological testing, but there is a known practice effect to such standardized tests. Patients always do better on the second taking.
They present 10 cases, but there is no mention of how these 10 cases were selected and if they are representative.
I also note that the authors refer to patients as having “Alzheimer’s disease” when in fact they should have referred to them as “Alzheimer’s type dementia.” AD is a pathological diagnosis, and there is no mention of brain biopsy on any of the cases. They met clinical criteria for Alzheimer’s type dementia, which is not the same as confirming AD.
Therefore, it is quite possible that some of these patients had a self-limiting process in the first place. This is exactly why randomization and blinding are necessary.
Conclusion: Dubious science, based on questionable theory
The approach of the MEND protocol is highly dubious in that it extrapolates wildly from basic science to clinical application, in a disease known for its horrific complexity. They further add another layer so complexity by claiming to “personalize” the protocol.
While the current case series is certainly provocative, I do not think it is reasonable to use this level of evidence to make clinical claims. This is especially true given the extraordinary nature of those claims.
What we need now is a randomized double-blind placebo controlled trial. They can still use their personalization – just do the protocol on every subject, while giving half actual treatment and the others placebos.

Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)
An important decision has been made about a controversial new drug to treat Alzheimer’s disease.
Scott Gavura on January 20, 2022
Link


Alzheimer’s disease (AD) is a neurological disease that is the most common cause of dementia, affecting an estimated 6 million Americans. Despite decades of research there has been little progress in developing medications or therapies that can improve symptoms or slow the progression of the disease. In its early stages, there was enthusiasm for a new drug, aducanumab, that targets beta-amyloid which is a plaque-like protein that accumulates in the brain and is thought to interfere with signalling and function.
Steven Novella and I both blogged about aducanumab when it was approved in the United States in 2021. Now branded Aduhelm, it was a very controversial approval which was based on the effect of the drug on a surrogate, or proxy for the disease. Importantly the drug has not yet been shown to actually give any meaningful clinical benefit. While ten out of eleven members of an advisory committee to the FDA voted against approving Aduhelm, the FDA did approve the product, requiring a clinical trial to show benefit.
Both Steven and I also raised the issue of the cost of Aduhelm when it was approved. The drug alone costs $56,000 per year, plus infusion and delivery costs. Given the prevalence of AD and the absence of effective treatments, there could be substantial demand and costs for a product. How insurers would react was a question. Now we have an answer from the biggest insurer in the United States, the Centers for Medicare & Medicaid Services (CMS) which recently released a proposed “National Coverage Determination” decision memorandum on the drug.
What is the CMS and why does this matter?
The CMS is the single largest payer for health care in the United States, covering almost 90 million Americans. A national coverage determination (NCD) is a statement regarding whether or not Medicare will pay for a specific service or treatment. These decisions are binding on Medicare contractors. In short, CMS has proposed it Medicare will only provide coverage for Aduhelm when it is administered as part of a clinical trial. Clinical trials will be reviewed to determine if they meet CMS standards. If they do, then recipients will be eligible to have the cost of the drug and the administration covered.
What did the CMS say?
The CMS decision memo provides an overview of AD and a good summary of the evidence for and against amyloid:
Alzheimer’s disease (AD) is a currently irreversible brain disorder that progressively degrades memory, cognitive function, and ability to carry out tasks of daily living. AD is the number one cause of dementia in older Americans, contributing to 60-80% of cases. Over 6 million older Americans are believed to have AD. This prevalence is expected to rise to 14 million by 2060 barring effective interventions (such as lifestyle changes, treatment of risk factors, and possibly combinations of Alzheimer’s drugs). AD is the sixth leading cause of death in the United States, but may rank from fifth to as high as third (after heart disease and cancer) as a cause of death for older Americans.
With respect to amyloid, it notes (I will cut and paste from the detailed but very readable summary):
The role of amyloid in Alzheimer’s disease remains complicated for at least three reasons. First, amyloid plaques are seen in other diseases, such as dementia with Lewy bodies, cerebral amyloid angiopathy, Parkinson’s disease, Huntington’s disease, and inclusion body myositis….Second, amyloid is associated with normal physiologic processes. …. Third, amyloid plaques can be detected in cognitively normal older adults. Autopsy studies demonstrate that approximately one-third of older individuals (20-65% depending on age) who are cognitively normal have amyloid accumulation at levels consistent with AD pathology.
CMS then summarizes the evidence it considered. It noted that beyond aducanumab, there are at least three other monoclonal antibodies in clinical trials. This guidance is applicable to all anti-amyloid monoclonal antibodies, as the drugs all have a similar function in the brain. It posed a specific question to answer:
Is the evidence sufficient to conclude that the use of monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease improves health outcomes for Medicare beneficiaries?
CMS searched different medical databases like Ovid Medline and PubMed for relevant articles, and then summarized all the trials and results into two tables. it discussed the two aducanumab clinical trials (EMERGE and ENGAGE) in detail:
Our conclusion is that Biogen’s secondary analysis cannot overturn, definitively confirm, or substitute for, the RCT evidence. With conflicting results from two RCTs (EMERGE and ENGAGE), and a secondary analysis that did not resolve the difference between the two RCTs, CMS believes that the available evidence is insufficient to establish that the treatment is reasonable and necessary under section 1862(a)(1)(A) of the Social Security Act.
Acknowledging the need for better data and the current insufficient evidence to support the use of this product and related monoclonal antibodies for AD, CMS is proposing “coverage with evidence development” or CED which means that it will fund the products when part of a clinical trial that is seeking to provide better evidence to inform a permanent funding decision. As no trial has yet been able to show that aducanumab (or a related drug) provides a clinically meaningful improvement in outcomes that are relevant to patients, a trial must be able to answer the following if it is to be considered eligible for inclusion (and funding):
    • Does use of monoclonal antibodies directed against amyloid for the treatment of AD result in both a statistically significant and clinically meaningful difference in decline in cognition and function?
    • What is the frequency and clinical impact of adverse events associated with the use of monoclonal antibodies directed against amyloid for the treatment of AD?
What does this mean for patients?
        ◦ Without well designed clinical trials, we will not be able to determine if aducanumab or related monoclonal antibodies provides any benefit for patients with AD. While the FDA approved aducanumab without any evidence of patient benefit, CMS’s bold decision will ensure that any funding put towards the drug will help answer this crucial efficacy question. This decision is a good one. It considers the needs of patients who want access to promising treatment, while ensuring that data is collected, rigorously and systematically, to bring us better evidence about these expensive therapies.

Enbrel for Stroke and Alzheimer’s
Steven NovellaonMay 8, 2013
Link
A recent article in the LA times tells of a husband’s quest to find a treatment for his wife’s Alzheimer’s disease. This is a narrative that journalists know and love—the brave patient or loved-one who won’t accept the nihilism of the medical establishment, who finds a maverick doctor willing to buck the system.
The article itself at least was not gushing, it tended toward a neutral tone, but such articles do tend to instill in the public a very counterproductive attitude toward science and medicine. I would have preferred an exposé of a dubious clinic exploiting desperate patients by peddling false hope. That is a narrative in which journalists rarely engage.
The story revolves around Dr. Edward Tobinick and his practice of perispinal etanercept (Enbrel) for a long and apparently growing list of conditions. Enbrel is an FDA-approved drug for the treatment of severe rheumatoid arthritis. It works by inhibiting tumor necrosis factor (TNF), which is a group of cytokines that are part of the immune system and cause cell death. Enbrel, therefore, can be a powerful anti-inflammatory drug. Tobinick is using Enbrel for many off-label indications, one of which is Alzheimer’s disease (the focus of the LA Times story).
The Dubious Health Clinic
Before I go into the details of Tobinick’s claims, let’s review the typical features of what we commonly call the “quack clinic” or the dubious health clinic. I wrote about this in 2009, and listed the following features:
    • The clinic often has an impressive name, such as “The Institute Of,” but lacks any formal affiliation with an established institution, like a university or hospital, and was founded and may even continue to be operated by one person.
    • The clinic claims to treat or cure one or more diseases that is currently believed to be incurable. Their claims sound too good to be true.
    • There is only one clinic in the world that can perform their special procedure or that uses their proprietary treatment. Sometimes the treatment offered is new and experimental.
    • The clinic claims to cure a variety of diseases, all with different causes and pathophysiology, with a single treatment – the “one cure for all diseases” approach.
    • The clinic is often located in a country with little or no regulation.
    • The clinic claims that it is the victim of repression. Typically they will say that either Big Pharma, the medical establishment, the insurance industry – or some other convenient villain—is trying to suppress their revolutionary treatment. Alternatively, the “medical establishment” is simply closed-minded to their paradigm-shifting ideas.
    • Testimonials are used to promote the treatments offered by the clinic, but they have not published appropriate research in legitimate peer-reviewed journals.
    • When challenged by professional organizations, the clinic defends itself by appealing to politicians, using the testimonies of previous patients who believe they have been helped by the clinic and the accusation of a conspiracy of those trying to protect their monopoly.
The Institute of Neurological Recovery
Now let’s take a look at Tobinick’s clinic. It has an impressive name—a one-man institute.1 The website proclaims:
The Institute of Neurological Recovery (INR®) is pleased to provide this introduction to its pioneering medical concepts, research, and treatment programs. INR designates a group of separate medical practices that utilize innovative, patented, off-label medical treatments developed by Edward Tobinick M.D. These treatment methods are designed to target a number of neuroinflammatory conditions with unmet medical need.
Many of the features of a dubious clinic are right there—the impressive name, claim to treat many conditions with one treatment, emphasis on how innovative the treatments are. The website also claims that his treatments are patented.
This is an interesting side issue, worthy of its own post. There has been a surge in the US in recent years in medical procedure patents. However, the first (and I think only) infringement lawsuit lost its case. Medical procedure patents are generally opposed by medical organizations as counterproductive profiteering and are banned in 80 countries. They are still legal in the US but there has been a number of legislative effort recently to limit or ban them.
The patented procedure (even if not enforced) seems like just another way to market the uniqueness of the treatments offered by the dubious clinic.
The list of conditions for which Tobinick claims or even has patented use of Enbrel include Alzheimer’s, stroke, traumatic brain injury, Parkinson’s disease, carpal tunnel syndrome, brain tumor, spinal cord injury, and back pain. That quite impressive for a doctor who isn’t even a neurologist. Tobinick is an internist who, prior to curing a long list of neurological diseases, specialized in laser hair removal.
The LA Times reports:
But his claims about the back treatment led to an investigation by the California Medical Board, which placed him on probation for unprofessional conduct and made him take classes in prescribing practices and ethics.
Tobinick has since moved his practice to Florida,2 which is a very quack-friendly state.3 Its “health care freedom” law effectively shields dubious practitioners from pesky medical boards.
Plausibility and evidence
When considering just the notion that Enbrel, a TNF inhibitor, might have a broad range of applications, this is entirely plausible. It is common for immunosuppressive drugs to gain an FDA approved indication for one specific condition, such as transplant rejection or rheumatoid arthritis, and then to be used off-label for many other autoimmune conditions.
This is very tricky, however, as the immune system is complex. There are different components to the immune system, and different aspects of immunity are involved in different auto-immune conditions. Therefore there is no one immunosuppressant drug or treatment for all auto-immune conditions.
When a new immune-suppressing drug comes on the market it is common for it to be tried in a variety of conditions—but practice then follows evidence. Initially we might see some case reports, followed by a case series. If the drug shows promise, then a double-blind placebo-controlled trial would ultimately determine its effectiveness.
This is definitely a gray area of off-label use. How much evidence is necessary to justify an off-label use of a drug—and how far off label? Sometimes the popularity of a new off-label use of a drug gets ahead of the evidence. In most cases, however, eventually the research is done and practice conforms to the evidence.
The claims of Tobinick, however, are not in the gray area—they are leaps and bounds ahead of the evidence. Further, the conditions he claims to treat are not clearly immune-mediated diseases. It’s one thing to use an immune-suppressing drug to treat a disease that is known to be caused by immune activity, and probably the kind of immune activity suppressed by the drug.
Tobinick, however, is claiming that a wide range of neurological conditions not known to be immune mediated are treated by a specific immunosuppressant.
On his website he cites many studies, but none of them establish the effectiveness of Enbrel for any of the conditions he is treating. Most of them are simply identifying that TNF is increased in the condition. This is very weak evidence, however, as markers of immune activity are frequently increased in diseases that are not caused by immune activity. The immune system is very reactive — it reacts to disease with inflammation (often what we refer to as the cleanup crew). The inflammation is not causing the disease, it is simply the body’s reaction to it.
Tobinick has also started to publish case series — little more than retrospective case series reporting on his own patients. This is weak evidence even when coming from an established researcher within their own area of expertise. It is all but worthless coming from clinic like Tobinick’s.
This is where his lack of expertise is especially relevant. Such arguments are often portrayed as elitist, as if a mere internist cannot have a valuable insight into how to treat neurological disease. But medicine and research are complex and there are many pitfalls. Unless you have expertise dealing with strokes or dementia, including how to properly research these conditions, you are likely to fall for these pitfalls.
For example, in his recent case series he writes:
Significant improvement was noted irrespective of the length of time before treatment was initiated; there was evidence of a strong treatment effect even in the subgroup of patients treated more than 10 years after stroke and TBI.
This, if anything, is evidence that the observed treatment effect is mere placebo. It is very implausible that stroke or TBI deficits will be equally responsive to an anti-inflammatory treatment (or any treatment) regardless of time since the stroke or trauma.
Stroke researchers are also very familiar with what is known as the “cheerleader effect.” Take any patient with chronic deficits, give them any intervention and then encourage them to function better, and they will function better. This can result simply from trying harder, or even just the incidental physical therapy benefit of engaging in a treatment and being evaluated.
Unless all these factors are controlled for with proper blinding, no conclusions about the treatment effect are possible. Tobinick is providing the kind of evidence that is guaranteed to be positive, but not the kind of evidence that would determine if his treatments are effective or not.
Conclusion
If you strip away the gratuitous narrative in the LA Times story and just look at the facts presented, a very different narrative emerges. Ken Chiate brought his wife to Tobinick’s clinic for 165 injections of Enbrel over four years, at a cost of $800 each (that’s $132,000).4 During that time there were questionable subjective effects from the treatment, typical of placebo-only effects. Meanwhile his wife continued to relentlessly progress, as is typical of the disease, until she finally died in 2011.
According to the article, the treatments gave Chiate a sense of purpose and of hope — a false hope, it turned out. He still clings to the idea that Enbrel may be an effective treatment for Alzheimer’s disease — even though Tobinick himself has apparently moved on to treating stroke.
In my opinion, the story documents exploitation of a well-meaning and desperate husband at the hands of a dubious practitioner, practicing at the fringes of medical ethics and evidence, making bold claims without adequate justification. The story also documents the utter failure of the regulatory system to prevent (or even properly react to) such exploitation. Florida in particular appears to be a haven for such activity.

Update April 2, 2015
1 Dr. Tobinick objects to this characterization on the basis that his practice includes multiple staff and other physicians. I maintain that this characterization is appropriate because his “institute” is merely his private practice of which he is the only significant component. The “institute’s” websites are found at tobinick.com, strokebreakthrough.com, nrimed.com, painbreakthrough.com, and alzheimerbreakthrough.com. Despite having several websites, his is the only bio that appears on any of them (and he so testified in court). No other physicians are featured on the INR website, nor any of the “Institute”’s other websites.
2 Tobinick objects to the fact that the original text stated that he moved his clinic to Florida. However, the clinic did not move to Florida, Dr. Tobinick himself moved to Florida where he opened an additional clinic, where he now works, but kept his a California clinic open also.
3 Dr. Tobinick objects to my characterization of Florida as “Quack Friendly.” However, as I pointed out in the text, Florida has a healthcare freedom law that specifically shields practitioners from having action taken against their license simply because they are practicing below the standard of care. In fact I was involved in a case where the court concluded a neurologist was practicing below the standard of care, but they appealed based upon Florida’s health care freedom law and the claim that they could not be held to the standard of care, and they won on appeal.
4 Dr. Tobinick disputes this figure, claiming that the LA Times story is incorrect. He claims that he charged Chiate a total of $71,000 for the treatments. However, other news sources state that he charges thousands of dollars for the initial treatment.

Vitamin E for Alzheimer’s
Harriet Hall on January 7, 2014
Link
Recently you may have seen headlines like “Vitamin E slows decline in patients with mild Alzheimer’s” or “There’s still no cure for Alzheimer’s disease, but the latest hope for slowing its progression is already on drugstore shelves.” They were referring to an article in the January 1, 2014 issue of the Journal of the American Medical Association (JAMA) announcing the results of the TEAM-AD VA Cooperative Randomized Trial of vitamin E and memantine (Namenda) for Alzheimer’s disease (AD).
The study attracted a lot of media attention. Most of the news reports I have seen were accurate and cautious, explaining the nuances of the study rather than suggesting that everyone should run out and buy vitamin E; but I wouldn’t be surprised to learn that a lot of readers ignored the fine print and did just that. It would be interesting to track sales of vitamin E and see if there was a bump following the publicity.
We know of no treatment that will delay, prevent or cure Alzheimer’s disease, or that affects the underlying disease process. It’s a tragic, frustrating disease that takes away the very things that make us who we are: memory and personality. It is affecting more and more people as the numbers of elderly increase. Available prescription medications are only modestly effective in slowing functional decline and delaying the need for institutionalization. They are expensive, they don’t help everyone, and when they do help, they only help for a limited time. It is very exciting to think an inexpensive vitamin could help patients with mild to moderate AD, but we must resist the temptation to read too much into this study.
Study design
The study was a large, rigorous, multicenter randomized placebo-controlled trial with 33 authors, carried out at 14 Veterans Affairs (VA) medical centers. It enrolled 613 patients age 53 to 96 with a diagnosis of possible or probable AD of mild to moderate severity who were already taking an acetylcholinesterase inhibitor (AChEI). 65% were on Donepezil, 32% on Galantamine, and 3% on Rivastigmine); 97% were male, 86% were white, 13% black, and 11% Hispanic. (Note: these were classified as possible or probable cases, since definitive diagnosis of AD is only possible at autopsy.)
Participants were randomized to one of four groups:
    • Alpha tocopherol (vitamin E) 1,000 IU twice a day + memantine-matching placebo
    • Memantine 10 mg twice a day + vitamin E-matching placebo
    • Both vitamin E and memantine
    • Two placebos
Primary outcome measure was the Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory (ADCS-ADL), a validated questionnaire that assesses functional abilities to perform activities of daily living. A difference of 2 points on this scale is generally considered significant because it potentially represents, for example, a loss of dressing or bathing independently. Secondary outcome measures included tests of cognitive function and dementia severity, memory, language and praxis functions, assessment of psychological and behavioral problems, the time required for caregivers to assist patients in major areas of daily activities, and a measure of functional dependence.
Annual assessments included physical exams, review of concomitant medications, blood concentrations of the study drugs to assess adherence, and careful questioning about adverse experiences. 42% of subjects failed to complete the trial, most commonly due to death (50%), withdrawal of consent (30%) and adverse events possibly related to the study medication (1%). Mean follow-up time was 2.27 years.
Findings
All participants got worse over the period of the study. Subjects in the vitamin E group had a significantly slower decline than those in the placebo group (3.15 units less on the ADCS-ADL Inventory, annual rate of decline 19% less, delay in progression of 6.2 months). There was no significant difference between the placebo group and the memantine or memantine + vitamin E groups. The group taking both vitamin E and memantine did significantly worse than the group taking vitamin E alone.
Adherence was estimated at 65-68%, which isn’t all that bad considering the age of patients and the effects of Alzheimer’s.
Secondary outcomes showed no significant differences between the four groups except that caregiver hours increased less in the vitamin E group than in the memantine group.
Safety: there were no significant differences between groups for serious adverse events. The annual mortality rate was 7.3% for vitamin E, 11.3% for memantine, 9% for vitamin E + memantine, and 9.4% for placebo.
Discussion
They concluded that 2,000 IU of vitamin E significantly delayed clinical progression in activities of daily living in patients with mild to moderate AD who were also taking AChEI. Paradoxically, the combination of memantine and vitamin E had less effect than either drug alone; the authors could not think of a plausible mechanism for this finding. No significant changes were seen in cognition or memory, but the researchers considered the 6.2-month delay in progression of functional loss to be of more practical importance. Mortality rate was reduced with vitamin E, in contrast to a previous meta-analysis of vitamin E studies that had showed an increase in all-cause mortality with doses typically lower than the 2,000 IU used in this study. Interestingly, only one study in that meta-analysis involved Alzheimer’s patients, and that one also showed a decrease in mortality.
Editorial
An accompanying editorial praised the study as reflecting the best in trials of AD therapy, especially because of its size, duration, and separation from commercial motivation; but it characterized the therapeutic effect as “modest” and more relevant to functional disability than to any effect on the disease process itself. They pointed out that functional ability is non-specific (decreasing with age as well as with disease), that the primary outcome was not confirmed by any of the secondary outcomes, and that the mechanism of vitamin E in AD is uncertain. Memantine is only approved for moderate to severe AD, and this study confirms that it is not indicated for milder disease. The results for vitamin E are encouraging, but can’t be extrapolated to situations other than the specific ones in the study.
Another opinion
An ND quoted on one website said “This new study demonstrates that scientists seeking to slam the door on vitamins, and new vitamin research, is the antithesis of what science is all about.” He is responding to a straw man. Several recent studies and editorials have discouraged indiscriminate use of multivitamins in healthy populations, especially as a substitute for a nutritious diet. But no one has recommended we stop studying individual vitamins for new indications where there is preliminary evidence that they might be helpful in specific populations or diseases.
Conclusion
This study is encouraging, but it doesn’t mean everyone should start taking high doses of vitamin E to ward off Alzheimer’s. And it would be premature to incorporate vitamin E into routine treatment of Alzheimer’s patients on the basis of this one study. There are too many unanswered questions. Women and minority groups were underrepresented, the interaction with memantine is puzzling, the secondary outcomes didn’t support the primary outcome, the beneficial effect on mortality may not be generalizable to all AD patients, and interactions with other medications or illnesses have not been studied.
I agree with the Alzheimer’s Association’s call for caution:
No one should take vitamin E to treat Alzheimer’s disease except under the supervision of a physician. Vitamin E — especially at the high doses used in the ADCS study — can negatively interact with other medications, including those prescribed to keep blood from clotting or to lower cholesterol.

Lithium and Alzheimer’s Disease
Steven Novella on August 13, 2025
Link
This is an interesting story, which has been all over the news so worthy of covering here. Alzheimer’s disease (AD), the major cause of dementia in humans, is a very complex disease. We have been studying it for decades, revealing numerous clues as to what kicks it off, what causes it to progress, and how to potentially treat it. This has lead to a lot of knowledge about the disease, but only recently resulted an effective disease-modifying treatments – the anti-amyloid treatments.
Another line of investigation has focused on lithium – that’s right, the element, and a major component of EV batteries. Lithium has long been recognized as a treatment for various mood and mental disorders, and was approved in 1970 in the US for the treatment of bipolar disorder. That is what I learned about it in medical school – it was the standard of care for BD but no one really new how it worked. It was the only “drug” that was just an element. It had a certain mystery to it, but it clearly was effective.
Now lithium is emerging as a potential treatment for AD. A recent study of lithium in mice has brought the treatment into the mainstream press, so it’s worth a review. Because of lithium’s benefit for BD it was studied for its effects on the brain. But also, it was observed that patients getting lithium treatment for BD had a lower risk of AD. Other observational data, such as levels of lithium in drinking water, also appeared to have this protective association. This kind of observational data is never definitive, but it was interesting enough to warrant further research.
Also, research started finding many potential mechanisms by which lithium could affect brain function. It is a cofactor for some enzymes, meaning it makes them work more efficiently. It also can affect gene expression and therefore certain protein levels. It can also silence the activity of some proteins. It’s always hard to extrapolate from these kinds of effects to a net clinical outcome, so at best they were further clues that need to be followed up.
Over this same time lithium’s potential role in AD was being further explored. It turns out that lithium levels tend to be lower in patients with minimal cognitive impairment, which can be an early sign of AD. Further still the amyloid plaques that are a hallmark of AD bind up lithium to reduce levels in the brain. Reduced lithium also contributes to more plaques, creating a vicious loop. Earlier studies with lithium and animal models of dementia showed mixed results. But it’s possible this is because forms of lithium that get bound up in amyloid are not effective, while other forms of lithium that are resistant to so-called amyloid sequestration are effective. This includes lithium orotate.
This brings us to the new study. Researchers looked at the effect of lithium orotate in a mouse model of dementia. First they found the depleting lithium from the brains of mice increased both amyloid and tau plaques, a hallmark of AD. It also led to “pro-inflammatory microglial activation, the loss of synapses, axons and myelin, and accelerated cognitive decline.” They then found that supplementing lithium orotate not only slowed but reversed memory loss and brain changes in the mice.
They also discovered a potential mechanism: “These effects were mediated, at least in part, through activation of the kinase GSK3β. Single-nucleus RNA-seq showed that Li deficiency gives rise to transcriptome changes in multiple brain cell types that overlap with transcriptome changes in AD.”
Taken together, this is a nice story, with lots of circumstantial evidence but mostly pointing towards a consistent conclusion. Low brain lithium levels may contribute to the onset and progression of AD, exacerbated by amyloid plaques further sequestering lithium. Supplementation with lithium orotate, which is not sequestered by amyloid, may therefore restore brain function and slow or even reverse the anatomical changes that result from the disease.
It is also worth pointing out that animal models of AD, while very useful in studying the disease, is a very poor predictor of treatment effects. In one review animal models of AD failed to predict treatment effects in humans 99.6% of the time. That is the biggest reason not to get too excited here, and to essentially wait for the human trials.
I certainly hope this treatment turns out to be effective, but we have been here many times before – with a nice story about how AD works pointing toward a potential treatment, which then fails in human clinical trials. So here we are again. Of course, past history does not means things will not work out this time, and this is a reasonably good story. The next step, obviously, are clinical trials in humans. These are in the works. It helps that lithium is already an established treatment, so it already has a known safety profile.
The hope is that we will complete several clinical trials over the next 5-6 years and that lithium orotate will prove effective in treating AD. It is also nice that lithium as a treatment is dirt cheap. It cannot be patented and it is cheap to make. There is some concern that this means, however, pharmaceutical companies will therefore not want to invest millions of dollars in clinical research.
But that is exactly why we have the NIH and federal funding of medical research, for treatments that are not commercially profitable. This is also why it is so painful that Trump is attacking this funding. He has cancelled more than 1800 NIH grants, a move that is probably illegal, but meanwhile has dramatically decreased funding of research and threatens our medical research infrastructure. His budget bill also cut NIH funding by 40% ($18 billion). The senate, thankfully, rejected this and has since proposed a funding bill that will restore NIH’s funding and increase it by 1%. Now we have to wait to see what the House does and what the final compromise will be. The future of research like this will depend upon what they do.


What Is Brain Death?
Steven Novella on March 25, 2015
Link

Of course, any story illustrating the issues surrounding brain death is going to be a sad and tragic tale. In December of 2013, Jahi McMath suffered bleeding complications following a tonsillectomy and tissue removal for sleep apnea. This resulted in a cardiac arrest with an apparent prolonged period of lack of blood flow to the brain. While her heart function was brought back, Jahi suffered severe brain anoxia (damage due to lack of oxygen) and was declared brain dead on December 12, 2013.
Jahi’s tragic story is not over, however, because her family refused to accept the diagnosis of brain death. They took legal action to keep the hospital from pulling life support, and eventually worked out a compromise where the family was able to remove Jahi to their own care. At present Jahi is apparently being cared for in an apartment in New Jersey, on a ventilator and fed through a feeding tube.
There is often some confusion as to what brain death actually is. The term is unfortunately often used to refer to a persistent vegetative state or other severe impairment of consciousness, but this is not accurate. Brain death refers to a complete lack of function of the brain, including basic reflexes in the brain stem. There is a specific protocol for declaring a person brain dead, requiring detailed examination by at least two attending physicians to document the complete absence of any brain function. If the slightest pupillary reflex is present, then the patient cannot be declared brain dead. The criteria also include provisions that there are no medications in the person’s system that can suppress neurological function and their core body temperature is sufficiently high (being too cold can also suppress neurological function).
There are also several types of supporting evidence that can be used when appropriate. These include electroencephalogram, which reads the electrical activity of the brain. A complete absence of electrical activity supports the diagnosis of brain death. Tests looking at blood flow to the brain can also be performed. A complete absence of blood flow to the brain also supports the diagnosis of brain death. These laboratory criteria are not necessary if the patient meets the clinical criteria for brain death, but they can be used if some parts of the exam cannot be done for practical reasons.
Overall the criteria are very conservative. They are designed to minimize the chance of declaring someone brain dead when they aren’t. These are universally-accepted criteria, established in 1995 by the American Academy of Neurology. Since then there hasn’t been a single case of a patient who was declared brain dead by the standard criteria who later recovered.
Legally a patient who is brain dead can be declared dead. They are then legally no longer a living person.
In the case of Jahi the hospital doctors declared her dead based upon brain death criteria, even though her heart was still beating. At that point no further medical intervention is warranted. In fact many consider it unethical and abusive to perform any medical interventions on a dead body. Because of the family’s protests, however, the judge in the case assigned an independent doctor, Graham Fisher, M.D., the chief of Child Neurology at Stanford University School of Medicine, to examine Jahi and make his own determination. He agreed with the diagnosis of brain death.
The family requested that their own doctor also independently examine Jahi, but the judge refused. They wanted Paul Byrne to examine Jahi. Byrne, however, is hardly an objective physician. He is a crusader against the very notion of brain death. He is a neonatologist, past president of the Catholic Medical Association, and an outspoken critic of organ donation based upon the concept of brain death.
As is often the case when declarations of either persistent vegetative state or brain death are controversial, the family or those opposing the diagnosis often claim that there are signs of brain activity the doctors say are not present. In this case the family, sometimes through their lawyer, claim that Jahi has moved her limbs in response to commands. They are also now claiming that independent examination has revealed electrical activity and blood flow to the brain, however this information is not available for independent review.
It is common for there to be spinal reflexes that can cause even dramatic movements in someone who is brain dead. These types of reflexes have been termed the “Lazarus effect” because they may create the impression of someone rising from the dead. Activity in the spinal cord, however, is compatible with brain death, and may be triggered either spontaneously or through mechanical stimulation (such as when a patient is turned or moved during care).
Jahi was moved from California to New Jersey for a specific reason. New Jersey allows for religious exemptions to the legal declaration of brain death. Jahi’s family claims that according to their religious beliefs, as long as her heart is beating she is still alive.
Similar issues arose in the Terri Schiavo case, which came to national attention in 2005. In that case Schiavo was in a persistent vegetative state (not brain dead) and her husband wanted to withdraw life support, while her family refused, resulting in a prolonged court battle. The husband eventually prevailed. At autopsy it was found that Schiavo’s brain weighed about half of what a healthy brain for someone her size should have weighed, evidence of the diffuse and catastrophic brain damage she had suffered.
In that case, as with this one, the family tried to appeal to a cherry-picked expert to give them the answer they sought, and they also claimed that Schiavo was exhibiting signs of brain activity that multiple independent experts concluded was not present.
Reporting on the Schiavo case was also particularly bad. A review found that only 1% of mass media reporting defined a persistent vegetative state, while 21% of articles falsely claimed that Schiavo had the potential to recover.
Conclusion
It is understandable that there would be ethical discussions and disagreements over how best to balance the rights of patients, the demands of dignity, the responsibilities of health care professionals and the state, and the religious freedoms of patients and their families. At the very least, however, such discussions, and their application to individual cases, should be informed by reliable scientific and medical information. Media reporting should also strive to be as scientifically accurate as possible.
Distorting the science and cherry picking evidence are unfortunately common when strongly-held ideological beliefs are at stake.
In the case of Jahi there is also a legal matter at stake. The family is suing the hospital for malpractice. In California there is a legal cap of $250,000 for the wrongful death of a child. There is no cap if the child is injured but still alive, which the suit is claiming. It is therefore likely that a California court will have to officially rule on whether or not Jahi is alive or dead.

Exercise and Memory
Steven Novella on November 25, 2015
Link

There is no escaping the evidence that regular moderate exercise is associated with a host of medical benefits. Among those benefits are perhaps improved memory and cognition, and questionably a decreased risk of developing dementia.
The latest study to show this correlation involved younger and older adults who wore a step-monitor. The number of steps they took during the study interval was then correlated with their performance on neuropsychological testing. The researchers found that for the older adults, but not younger adults, more physical activity correlated with better overall cognitive performance, but especially for face-name recognition.
This is a small study, with 60 subjects total. Also, the study is correlational only. It is possible that healthier older adults are both more physically active and cognitively nimble, because of underlying biological fitness. More cognitively active older adults may also be more physically active – the lines of cause and effect are plausible in multiple ways.
However, we do have a fairly large literature to draw upon to explore this question further. For example, studies looking at the acute effects of aerobic exercise find that it improves some types of cognitive function immediately.
There is complexity in interpreting the research due to the fact that there are many subquestions to sort through. Studies can look at all adults, only older adults, healthy adults, adults with minimal cognitive impairment, or with dementia. They can look at any exercise, or at aerobic fitness. And there are a large number of cognitive outcomes they can measure.
A literature review
A 2008 Cochrane review concluded:
There is evidence that aerobic physical activities which improve cardiorespiratory fitness are beneficial for cognitive function in healthy older adults, with effects observed for motor function, cognitive speed, delayed memory functions and auditory and visual attention. However, the majority of comparisons yielded no significant results.
They go on to recommend greater standardization among researchers, focusing on a few cognitive tests so results can be more comparable.
A more recent 2015 review found:
Results indicated that physical exercise may benefit cognitive function among older adults who have MCI [mild cognitive impairment], including improvements in global cognition, executive function, memory, attention, and processing speed. Physical exercise may also positively impact the physiology of the aging brain. However, evidence surrounding the characteristics of effective physical exercise interventions in terms of exercise type, intensity, duration, and frequency remains limited.
Newer studies continue to find a correlation, and even causation with intervention trials, in which some type of physical activity improves some cognitive measures.
A 2014 review concluded:
The studies on older subjects with MCI reported some positive effects of physical exercise on cognition, mainly on global cognition, executive function, attention and delayed recall.
They also call for more rigorous trials with prospective intervention designs to better establish cause and effect.
The reviews make several consistent points:
    • There does appear to be a consistent association between physical activity and some kinds of improved cognitive function in older adults who are either healthy or who have minimal cognitive impairment. The data for adults with Alzheimer’s disease is trending negative.
    • Because of the large number of variables, the literature is a bit challenging to interpret, and everyone agrees that more rigorous trials are needed to clarify which types of exercise yield benefit (if the benefits are specific to any types of exercise).
The bigger picture
The meta-lesson here is understanding how challenging it is to answer a specific clinical question with high quality research. Even a question that seems rather straightforward at first – does exercise improve memory or cognitive function? – turns out to be very complex and difficult to answer.
We also see a very familiar pattern emerge: the preliminary literature shows results that are highly variable, but are trending in one direction. This preliminary literature is most useful for indicating if more rigorous research is worth the effort, and also helps clarify how to design more rigorous studies.
Eventually, over years and many studies looking at the question in different ways, a clearer picture begins to emerge. Still, the results need to be interpreted with caution and with an understanding of the limitations of clinical research.
Even with a highly plausible and uncontroversial putative effect, such as the effects of exercise on cognition, we can see this familiar pattern. These lessons need to be remembered with more controversial, ideological, and emotional medical questions.
Conclusion: Regular exercise probably helps you think
At this point I would say that there is probably a beneficial effect from physical activity for cognitive function in older adults who are either healthy or have mild cognitive symptoms. Benefits for full-blown dementia are less clear, but have not been ruled out.
Given what we know about exercise physiology, a benefit is highly plausible. In addition, there are a host of well-established other benefits, and that the risks of getting regular moderate exercise are low. Therefore, it seems obvious to recommend regular exercise for both overall and mental fitness.
Further research may or may not clarify which types of exercise have the most benefit. It may not make a significant difference – it may just turn out that any exercise is better than being sedentary.
Finally, for those interested in science-based medicine in general, it is a good practice to pick a very narrow and uncontroversial question and then carefully examine the research to see how the experts address a question, how the literature evolves over time, and the strengths and weaknesses of different kinds of studies.
These are basic critical thinking skills to have, and may be easier to learn when not clouded with the emotional blur of a highly charged issue.

FDA Approves Controversial ALS Drug – Relyvrio
A close look a the FDA approval of Relyvrio.
Steven Novella on October 5, 2022
Link

The good news is that the FDA recently approved for use in ALS (amyotrophic lateral sclerosis) only the third drug meant to slow the progression of the disease – Relyvrio. However, the approval was highly controversial, because the data for the efficacy of this drug combination is questionable. The approval raises critical questions for what it means to take a science-based approach to medicine.
ALS is a neurodegenerative disease, similar to Alzheimer’s disease and Parkinson’s disease. These have proved to be a challenging class of diseases to understand and treat. In ALS motor neurons (both upper and lower motor neurons – the nervous system cells that allow for voluntary movement) die over time, causing weakness and the atrophy and death of muscle tissue. This is a fatal disease, with survival being between 2-5 years from time of first symptom. It is also relentlessly progressive, spreading throughout the body until eventually patients are not strong enough to breath on their own. At that point they are either placed permanently on a ventilator to help them breath, or they will die from the ALS.
More precisely, ALS is a type of disease, defined as degeneration of the motor neurons. But there are at least several, and perhaps many, specific pathophysiological diseases that cause ALS. It can be inherited, for example, or sporadic. It can be caused by a neurotoxin in some cases, and can occur with other neurodegenerative symptoms. But most patients with ALS are sporadic (no family history), idiopathic (no known cause), and follow a typical pattern of progression. It is a challenging disease to understand because many things happen at the cellular level on the way to these neurons dying, and it is difficult to know which processes are causing the progression and which are just a result of the cause. There also may be many causes working together, and when the cumulative stress gets beyond a certain point, the cells start to die.
There are currently three drugs approved to slow the progression of ALS, riluzole, edaravone, and now Relyvrio. The first two have a modest effect, prolonging survival by a few months. This can be significant for ALS patients, however, and the hope is that eventually we will build up a cocktail of drugs, each perhaps with modest effect but cumulatively with a significant effect. The ultimate goal, of course, is a “cure” which can be defined in this case as stopping progression (hopefully early enough to prevent functional decline). Reversing existing muscle loss is a different problem.
Relyvrio is a combination of two drugs, sodium phenylbutyrate and taurursodiol. The mechanism of action in ALS of the two drugs is currently unknown. However, phenylbutyrate enhances a pathway by which nitrogen is removed through the kidneys. It may also have effects on misfolded proteins, which can be a contributor to progression of ALS. Taurursodiol is a bile acid that may interfere with apoptosis – cellular death. These are speculative mechanisms, but not implausible.
Why is the FDA approval of this combination controversial? It’s because the data they relied on for approval is preliminary and not very convincing. It is, in fact, a phase II trial that focusses mainly on safety and only preliminarily at efficacy. Typically the FDA relies on two or more phase III trials, which are larger and more rigorous than a phase II. The study, called the CENTAUR trial, was published in the NEJM. The study enrolled 137 patient with ALS, with two-thirds in the treatment group and one-third in the placebo group. That is a relatively small trial for a clinical study, but not uncommon for ALS studies as it is a rare disease with short survival. Here are the results:
In a modified intention-to-treat analysis, the mean rate of change in the ALSFRS-R score was −1.24 points per month with the active drug and −1.66 points per month with placebo (difference, 0.42 points per month; 95% confidence interval, 0.03 to 0.81; P=0.03). Secondary outcomes did not differ significantly between the two groups. Adverse events with the active drug were mainly gastrointestinal.
The effect size is small and the statistical significance is slight. But actually, the results are much more suspect than that if you delve into the details. Here is a nice analysis published in a blog post on the Science website, which I will summarize. First, there were problems with randomization. The first 18 patients were all assigned to treatment, because the placebos had not yet shipped when the trial started. The next nine were then assigned to placebo, and then normal randomization took over from there. This is a small problem, but it partially unblinded the study and given the small numbers of subjects, small anomalies can be significant.
In my opinion the most significant issue is that 12 patients in the treatment group were on either riluzole or edaravone, the other approved drugs for ALS, while only two patients in the placebo group were. This is a critical asymmetry. Further, the primary outcome of the study is changes to a scale used to assess neurological function in ALS patients (the ALSFRS-R scale). The question is, do patients with ALS progress linearly along this scale as their disease worsens, or does progression follow another pattern? The study assumed a linear progression, but this may not be true.
Does all this matter? Absolutely. In fact, the FDA’s own analysis showed that if you make any changes to the choices made by the researchers in terms of how to analyze the data, the results become non-significant. If this sounds like p-hacking, that’s because it is. The company running the trial, Amylyx, chose the one analysis that showed a barely significant result.
Looked at from this perspective, the results don’t look good. If you ask – should SBM support the FDA approval of a drug combination with unknown mechanism of action based on a single preliminary study that is barely statistically significant and only as a result of clear p-hacking, the answer might seem obvious. But there is another layer to this case that makes it more complicated.
In a letter to the FDA [PDF], ALS clinicians asked them to approve Relyvrio for ALS. They write:
There is no cure for ALS, and most people with the disease die within 2-5 years of diagnosis. The unmet need is critical and pressing. That means that therapies that provide benefit, even if the effect is incremental, need to be available to ALS specialists and neurologists who are in the front lines providing care and treatment to people with ALS.
I actually know some of the people who signed this letter and worked with them. They are all serious and dedicated scientists and clinicians, and their opinion should be taken seriously. Because ALS is an almost universally fatal disease with few treatment options that are not very effective, we need to consider the risk-vs-benefit of using speculative treatments based on preliminary data. This drug combination is not magic – it has some reasonable plausibility. It is relatively safe. So the risk vs benefit, even if the possibility of benefit is small, is reasonable. What they are saying is – give us as clinicians treating these patients the option to decide if this is worth it for our patients.
I would consider Relyvrio to be an experimental treatment for ALS, despite the FDA approval, and its use to be compassionate care, not proven therapy. This is all well-established and ethically valid practice. The question is – how should the FDA have handled this? They have clearly moved recently to the position of approving treatments for neurodegenerative diseases at a lower standard than normal because of the seriousness of these diseases.
Also – there is a phase III trial in the works for Relyvrio, with results likely available in 2024. A larger and more rigorous trial should answer the question. I would not be surprised if the new trial shows no efficacy, although of course I hope that it confirms a clinical benefit. If it does prove with better data to be worthless, then the FDA should withdraw approval. In the end, that is a reasonable approach, as long as the more rigorous trials are done and the results affect approval and practice.
However, there is a final concern – whether it will be possible to recruit patients for a placebo-controlled trial when they can get prescribed the drug. Why take a chance on getting the placebo? If that turns out to be the case, then that would cast the FDA’s decision in a much more problematic light.

ALS and the market for false hope
Scott Gavura on December 18, 2025
Link

Amyotrophic lateral sclerosis (ALS) is probably one of the most devastating diagnoses that we should all hope to never hear. Also known as Lou Gehrig’s disease, or motor neuron disease, ALS is a progressive neurodegenerative disorder that affects the nerve cells in the brain and spinal cord that are responsible for controlling voluntary muscles. As the disease advances, both upper and lower motor neurons degenerate and die, leading to muscle weakness, twitching, atrophy, stiffness, and eventually paralysis of the muscles involved in movement, speech, swallowing, and breathing.
There is no known cure for ALS. Treatments are limited to managing symptoms, improving quality of life, and in some cases, modestly slowing progression. Science-based or evidence-based medicine is limited to what the evidence actually shows. In contrast there is no lack of “innovative” therapies, supplements, and other treatments that are marketed as supportive, restorative, or even disease-modifying. Many are sold directly to patients, often at significant cost, and in the absence of robust, credible published evidence that they offer meaningful benefits to patients.
Recent media coverage in Canada has highlighted just how vulnerable people with ALS can be to these claims. A CBC investigation reported on an American patient who sought treatment at a private clinic in Saskatchewan, spending thousands on unproven interventions after selling her home to pay for treatment. According to the CBC, her condition continued to deteriorate, and she later died after returning to the United States. The details are tragic, but the story itself is sadly not unique. It illustrates the desperation that accompanies ALS diagnosis, like many terminal diagnoses, and the persistent market for treatments that promise more than a review of the evidence can support.

Recognized Treatments
Despite decades of research, and many millions of dollars invested, evidence-based treatment options for ALS remain very limited. No treatment has been shown to reverse motor neuron loss or stop disease progression. However, a small number of therapies have been show to offer modest benefits.
Riluzole was the first medication (approved in 1995) shown to actually alter the course of the disease. ALS involves progressive motor neuron degeneration, with glutamate-mediated excitotoxicity believed to be one possible mechanism. Excess glutamate overstimulates neurons, causing cellular damage. Riluzole’s exact mechanism of action is unclear, but it appears to reduce this excitotoxicity. Clinical trials and long-term observational studies suggest that riluzole modestly prolongs survival, typically by several months. It does not improve muscle strength or reverse established disability. Riluzole is a standard, first-line treatment of ALS.
Edaravone has been shown to provide a modest slowing of functional decline in a subset of patients with ALS by slowing the loss of physical function, and helping some patients live longer. Edaravone does not stop ALS, but in some patients it can modestly slow the disease’s progression. Its benefits in the broader ALS population is unclear.
Other more recently approved therapies have generated headlines but their role remains uncertain. Some have been approved under accelerated or conditional pathways based on surrogate endpoints or limited clinical data. As I have discussed recently, there are significant risks in approving drugs based on surrogate endpoints. Based on the accumulated evidence, benefits from these new therapies are expected to be modest, and ongoing studies will eventually determine if these products actually provide meaningful benefits.
Supportive care
For most people with ALS, the greatest improvements in survival and quality of life come not from disease-modifying drugs, but from comprehensive supportive care delivered through multidisciplinary ALS clinics.
Key components include:
    • Non-invasive ventilation, which improves survival and reduces symptoms of respiratory failure
    • Nutritional support, including timely placement of feeding tubes when appropriate
    • Management of symptoms such as spasticity, pain and muscle cramps
    • Physical, occupational, and speech therapy to preserve function and communication for as long as possible
These specialized ALS clinics are associated with longer survival compared with fragmented or generalist care.
What ALS treatments can offer
This section is brief, because the number of proven therapies is maddeningly small. Existing treatments may slow progression, ease symptoms, and extend life modestly. To date nothing has been proven to cure ALS, regenerate motor neurons, or restore function once it has been lost.
This large gap between what medicine can realistically offer today, and what patients and their families understandably want creates the perfect environment for treatments that offer and promise hope. When hope isn’t backed by good evidence, it may result in lost time, disappointment, wasted resources, and even harm.
Supplements and ALS
When faced with a disease like ALS, and the limited medication options, it is understandable that patients and their families will look for anything that might help. Supplements are especially appealing. They are widely marketed (often with few restrictions on claims) and generally perceived to be “natural” and “safe”.
Many supplements have been studied in clinical trials. As is common in dietary supplement research, positive trials are usually small, short-term, and poorly designed. When larger or better-designed trials have been conducted, results have generally been negative or unclear.
Examples include:
    • Antioxidants such as vitamin E and vitamin C do not slow disease progression or improve survival in randomized trials, suggesting that targeting oxidative stress is not an effective approach.
    • Vitamin B12, particularly in high doses. Limited studies have not demonstrated clear, consistent benefit.
    • Omega-3 fatty acids, often promoted for neuroprotection, look promising in observational research. However, based on prospective trials, they remain unproven.
    • Herbal products and “proprietary blends” are frequently marketed with vague statements about “cellular support” or “neuroprotection,” but usually have no evidence to support them.
No supplement has been shown to meaningfully slow disease progression, improve survival, or restore function in ALS. However, clinicians may also feel uncomfortable discouraging their use, particularly when patients are highly motivated, the proven treatments are modestly effective and the perceived risks seem low. This may unintentionally reinforce the idea that supplements are at least potentially helpful.
The idea that supplements are harmless is often wrong, as has been noted many times on this blog. Product regulation is so weak in many countries that labels may not reliably tell you the actual contents. Even if what’s on the label is actually in the bottle, supplements can cause adverse effects, interact with prescription medications, or interfere with nutrition and metabolism. Financial toxicity is a known side effect too. Supplement regimens can be expensive.
Conclusion: False hope can be compelling
ALS remains a disease with few effective treatment options. This has driven interest in anything else that might offer benefit. Evidence‑based treatments may provide only modest improvements, but these gains are measurable, clinically meaningful, and have been proven in clinical trials. In contrast, dietary supplements have been used for decades and continue to be widely marketed without demonstrating any ability to alter the trajectory of ALS in any substantive way. The appeal of unproven approaches is understandable, but without credible evidence, they continue to divert attention and resources from treatments that can genuinely help, and, as recent reporting illustrated, drive expectations that ultimately cannot be met.
    • 

Real Time Computer Communication
Steven Novella on June 18, 2025
Link
For those with advanced ALS (amyotrophic lateral sclerosis) or certain brainstem strokes, they can be what is referred to as “locked in”. They are mostly paralyzed. A tip of the basilar artery brainstem stroke, for example, can leave one only able to move their eyes. Many with ALS, long before they get to this point, lose the ability to speak because of bulbar weakness – weakness in the tongue and muscles in their throat.
The resulting inability to communicate can be devastating. Even simple needs, such as asking someone to scratch their nose or reposition them in bed, can be laborious. There are various methods to improve communication. For those with any remaining hand control, there are communication devices. For those with only eye control, there are eye-tracking systems that can allow them to spell out their messages. Stephen Hawking famously used such a device, with the computer voice being recognized as “his” voice. These techniques are extremely useful, but also can be slow and laborious.
The ultimate goal for treating the inability to communicate because of some form of paralysis, while the mind is still relatively spared, is the brain-machine interface (BMI). A sufficiently robust and trained interface could theoretically allow for patients to simply think what they want to say while the computer “reads” their thoughts and converts them to text or to speech.
This technology goes back to 1970 with the first animal research. In 1998, the first invasive BMI was performed on a human with implanted electrodes on the brain’s surface. This allowed for the control of a cursor on a computer screen. The technology has incrementally advanced since then, including three main components: the electrodes that provide for the interface, the computer hardware that runs the algorithms, and the computer software that interprets the signals.
A recent demonstration shows where the technology currently is. Researchers at UC Davis Health have implanted a BMI on a patient with ALS who has lost the ability to speak. With that interface, they were able to train the patient and the software to produce real-time computer speech based on the patient’s intentions with 97% accuracy. This is an amazing accomplishment and could be life-changing for those with similar disabilities.
This advance is also, in my opinion, more than incremental. I have been following this technology closely for the last couple of decades, and this achievement is about 15-20 years ahead of where I thought we would be based on my assessment from about 5 years ago. What has changed? Simply put – AI.
The latest crop of artificial intelligence applications or machine learning is very good at finding subtle patterns, such as the patterns in electrical signals from a patient’s brain. By adding such machine learning into the mix, BMI technology is able to be trained much faster and produce results much more quickly. The result, in this case, is real-time BMI-based communication. This would simply not be possible today without AI.
It is important to note that this is a single case, and there are some limitations, so let’s get into some details. First, the electrodes were placed in the brain tissue itself, meaning they required an invasive surgery. They used “256 intracortical electrodes” in four arrays on the motor cortex. So they were not recording his language cortex, but rather the muscles he intended to move in order to speak. So when he tries to speak (but cannot due to muscle paralysis) the software interprets the signals, determines the words he is trying to say, and then speaks them. Because there were recordings of his voice from prior to the onset of ALS the computer was able to speak in his voice. Here are the results in detail:
On the first day of use (25 days after surgery), the neuroprosthesis achieved 99.6% accuracy with a 50-word vocabulary. Calibration of the neuroprosthesis required 30 minutes of cortical recordings while the participant attempted to speak, followed by subsequent processing. On the second day, after 1.4 additional hours of system training, the neuroprosthesis achieved 90.2% accuracy using a 125,000-word vocabulary. With further training data, the neuroprosthesis sustained 97.5% accuracy over a period of 8.4 months after surgical implantation, and the participant used it to communicate in self-paced conversations at a rate of approximately 32 words per minute for more than 248 cumulative hours.
This is an incredibly rapid training period for a BMI. Also, 32 words per minute with 97.5% accuracy is essentially normal conversation (a bit on the slow side, but perfectly reasonable). And of course there are likely to be incremental advances from here.
The main limitation is the intracortical electrodes. These have a lifespan of 1-4 years. At some point within this time period their function will degrade until they are no longer functional. The two main limitations are slight movements of the electrodes in their relationship to the cortical tissue, and the formation of scar tissue that electrically isolates the electrodes.
For BMI technology there is currently a trade-off between fidelity on the one hand and longevity and invasiveness on the other. In this study they opted for maximal fidelity. In other words, the more intimately the electrodes interface with the brain, the better the signals you get, but the more invasive the procedure and the shorter the lifespan. Intracortical (embedded in brain tissue) electrodes give the best signals but are the most invasive, followed by brain surface, then inside the skull but not touching brain tissue, followed by scalp electrodes. You could also have a semi-invasive procedure of drilling holes in the skull beneath the scalp electrodes, or even place the electrodes through the skull but not touching the brain.
One intriguing technology is the stentrodes – which are placed inside veins within the skull, similar to stents used in cardiology. But these stents are electrodes, which can get close to brain tissue within the skull, but are not touching the brain.
Researcher are also working on nanowire electrodes, which go inside brain tissue, but the hope is they will be so small they will not cause scar tissue to form. They are also developing soft electrodes that can move with the brain, which can solve both technical problems – keeping a consistent relationship to brain tissue and not provoking inflammation and scar tissue.
Electrode technology is now the main limiting factor in BMI applications. As this latest study demonstrates, the computer hardware and AI-enabled software are highly functional. With high-quality enough signals they can quickly learn and then rapidly interpret those signals to essentially read the minds of patients in near real time.
Two potential paths forward include improving the software further so that it can make do with progressively lower quality (but less invasive) signals. If we can develop a system that functions nearly as well with scalp electrodes (not sure if this is even possible, but if it is) then this will make the technology vastly more accessible. Or, we need to make soft electrodes that are essentially permanent. Or we need some combination of the two – improve the AI so it can get by with progressively less invasive electrodes. Personally, I think the stentrodes may be the best compromise, but we’ll see.
In short, brain-machine interface technology is an exciting new area of medicine that has recently benefited from a huge functionality boost due to recent developments in AI. It is an example of what we can do when we invest in basic science and biomedical research.

Mini-Brains for Disease Research
New research on organoid “mini-brains” highlights the potential of this new kind of scientific research.
Steven Novella on October 27, 2021
Link

We often talk about the strengths and weaknesses of different kinds of medical research, a basic understanding of which is necessary for any meaningful Science-Based Medicine assessment of medical claims. For example, in vitro research allows for highly controlled environments and interventions and can use human cells, but mostly looks at cells in isolation, and therefore misses many potential factors. Meanwhile, animal research allows scientists to examine whole-organism responses to different interventions, and also allows detailed examination of tissue after the fact. The primary limitation, however, is that non-human animals are not humans, and biological differences can affect outcomes. Human research allows for a determination of results in actual people, but has significant ethical and pragmatic limitations. This is why medical researchers use a range of research options, to combine the strengths of different approaches to get the most reliable answers.
In recent years an entirely new category of medical research has been added to the list, something that combines some of the strengths of all three main approaches outlined above – use of organoids. An organoid can be studied in vitro like a cell culture, and can use human cells, but also can include some of the structure and interactions of whole organs. Organoid research therefore lies somewhere between in vitro and in vivo human research.
This type of research has been made possible by advances in stem cell research. Typically researchers will start with adult-derived stem cells, like fibroblasts from skin, and then induce them to become pluripotent, which can become every cell type in the body. The only stem cells with more potential are totipotent, derived from early embryos, which can become every cell type in the body and also the placenta and extraembryonic cell types. Adult-derived induced pluripotent stem cells are almost as good as embryonic stem cells in research, and has allowed the field to significantly advance without the ethical and political controversy surrounding embryonic cells.
Starting with induced pluripotent stem cells, researchers have figured out how to grow organoids, which are mini-organs with some of the architecture and range of cell types found in mature organs. This allows for a type of in vitro (not in a full living organism) research but better than just a culture of cells. Organoid research can look at the interactions among different cell types in an organ, and also how those cells form organ structures. Organoids are not fully functioning organs, but they are part of the way there, and allow researchers to ask questions they could not otherwise research with just cell cultures or even human research. Technically they are three-dimensional cell cultures replicating some of the structures in a mature organ.
Beyond just being able to research human cells and organ structures, researchers can make organoids from healthy or diseased cells, in order to replicate disease states and look for differences with healthy organ development. They can even take a cell sample from an individual patient to study their organoids. In addition to studying disease states, organoids can be used as models for screening drugs to see if they alter disease progression.
One recent organoid research study shows the potential of this approach – Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology. In this study the researchers made brain organoids from stem cells the most common mutation causing a neurodegenerative disease which combines motor neuron disease (ALS) and frontotemporal dementia (FTD). ALS causes degeneration of motor neurons resulting in progressive weakness. Meanwhile cortical brain cells also degenerate, mostly in the frontal and temporal lobes, causing progressive cognitive decline and personality change. Understanding exactly how the mutation causes changes in the development, functioning, and aging of the human brain is critical to understanding the disease and designing potential treatment.
They found that differences in brain organoid development are apparent from the early stages, indicating that patients suffering from ALS/FTD may have the beginning of the disease even at birth. Both neurons and astrocytes (the two main cell types in the brain) develop DNA damage and start to accumulate abnormal proteins. Build up of protein debris is a known mechanism, or at least a strong marker, of many neurodegenerative diseases, so this is not surprising.
This study also features an advance in the basic technology of brain organoids. Rather that growing spheres of brain tissue, they grew flatter slices of brain tissue. This allowed for better nutrition of all the cells. Typically cells in the center of a brain organoid will die, limiting the total time that they can be maintained. This was a significant limitation on research, because scientists could only model short-term changes and effects. In the current study researchers were able to maintain their brain organoid slices for 240 days, and report (although not yet published) that their lab has maintained brain organoids for 340 days. This opens the door to much longer-term effects and responses to possible treatment interventions.
In fact, in this study the researchers also tested a potential drug (GSK2606414) on their organoid model. The drug reduced the accumulation of toxic proteins and some cell death. This highlights another potential feature of organoid research, that it can serve as a type of translational research – research designed to take basic science findings and test them clinically. While not fully translational, because it is not done in living humans, organoid research can take potential treatments discovered by cell-culture research and test them in disease organoid models.
        ◦ Two decades ago, when stem cell hype was taking off, use of stem cells to create organoids for research was not even discussed. The first organoid was not made until 2013. But this may turn out to be an unanticipated, and yet the most impactful, use of stem cells (at least for now). Organoid research has opened up an entirely new middle ground of medical research and we are likely to hear a lot more about this type of research in the future.

MS

Liberation Procedure for Multiple Sclerosis
Steven Novella on June 13, 2012
Link

It has been very instructive, from a science-based medicine perspective, to watch the story of alleged chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS) unfold over the last three years. In 2009 Dr. Paolo Zamboni, an Italian vascular surgeon, published a paper in which he claimed that 100% of MS patients he investigated showed signs of blockage in the veins that drain blood from the brain, a condition he named CCSVI. This paper sparked immediate controversy. This controversy has been in the news again recently with the making public of the results of an observational study of the liberation procedure to treat CCSVI.
Existing research over the last half century strongly indicate that MS is primarily a disease of immune dysfunction (an autoimmune disease), resulting in inflammation in the brain that causes damage, specifically to the myelin, the insulation around nerve fibers that allows them to conduct signals efficiently. Zamboni is suggesting that MS is primarily a vascular disease causing back pressure on the veins in the brain and iron deposition which secondarily results in inflammation. This would be a significant paradigm shift in MS. It would also not be the first time such a dramatic shift in MS science has been proposed but failed in replication.
The MS community did not give much credence to the notion of CCSVI, but despite this there has been an incredible amount of research on the idea over the last three years (a PubMed search on “CCSVI” gives 103 results). Most of the research has simply attempted to replicate Zamboni’s findings, with mixed but generally unimpressive results. No one has found the 100% results that Zamboni originally reported. The studies have found a range of venous insufficiency in MS patients, down to 0%, but many finding results in the range of 20-40%. However, patients with other neurological disease and healthy controls have also been found to have similar rates of venous insufficiency. Some studies have found a positive correlation with MS, others have not.
A faint signal in the noise, but what is it saying?
Systematic reviews of CCSVI have mostly concluded that, while there is a weak signal there, it is buried in the noise of variability of study results, which seem to be dominated by variability in the techniques used. There are several ways to assess venous function (MRI scan, doppler studies, venography) and these produce different results. At this time the consensus of reviews seems to be that: Zamboni’s results have not been replicated, there may or may not be any association between CCSVI and MS, if there is any association it is only in a subset of MS patients and much smaller than Zamboni suggests. Some have suggested that perhaps the inflammation in MS (and in some other conditions) can secondarily cause venous anomalies, but this is incidental and not pathogenic in MS.
One recent study tied off the jugular veins in mice, which would be functionally analogous to severe CCSVI, and found no inflammation, changes to the blood brain barrier, or clinical signs – in other words, no signs or markers for an MS like response to a reasonable clinical model of CCSVI. This seems to undercut the plausibility of the CCSVI hypothesis.
The bottom line is that CCSVI seems to be yet another failed hypothesis attempting to change everything we thought we knew about MS.
The “liberation procedure”, the internet, and conspiracy
Yet, over the last three years there has been significant interest in treatment of CCSVI on the part of MS patients, especially those who are not responding to proven therapy. This is understandable – any potential for a new treatment or cure would be of interest to a patient with a chronic debilitating disease. The treatment is called the liberation procedure, and is essentially angioplasty to open up the veins draining the brain and relieve the alleged back pressure. Clinics are already offering the treatment to patients, despite the fact that CCSVI remains controversial at best and there is no convincing scientific evidence that the liberation procedure works.
Part of the CCSVI phenomenon is that it has been happening in the post-social media world. Perhaps that is why the controversy has exploded and seems to be playing itself out so quickly. Part of this social media phenomenon is the divisive venom with which believers in CCSVI have attacked the medical mainstream. Conspiracy theories to explain away mainstream skepticism seemed to have already been in place and were taken out, fully formed, at the first sign of scientific skepticism.
Every online article about CCSVI is full of comments from supporters claiming that neurologists are engaged in a conspiracy to suppress CCSVI, in which the government is complicit, and “Big Pharma” (of course) is behind it all. It has been instructive to listen to conspiracy theories about various medical treatments. Believers simply invent villains as needed, without any consistency of logic. In the chronic Lyme disease controversy, for example, the treatment is a pharmaceutical – antibiotics. So Big Pharma can’t be the villain in that story, therefore believers simply made the insurance companies wear the black hats. At other times proponents of alternative treatments rail against mainstream medicine’s over-reliance on invasive procedures, but now the treatment they want is an invasive procedure, so neurologists (who treat MS medically) are the villains, and the surgeons are the heroes. Somehow evidence and scientific plausibility gets left behind in all the conspiracy mongering.
Treatments, evidence, and risks
The evidence, however, is what ultimately drives mainstream thinking about a disease and its treatment. In the case of CCSVI we now have the results of a large observational study. Zamboni’s group has also published a study of the liberation procedure, with weakly positive results, but given his role in this controversy few find the results compelling.
Dr. William Pryse-Phillips, a Canadian neurologist, followed the results of patients from Newfoundland and Labrador who went overseas to have the liberation procedure done. This was not a randomized trial, although the assessments were blinded. They followed 30 patients who had the procedure, and 10 controls who did not. They found no benefits from the procedure – there was no improvement in standard measures of MS severity and no difference between treated and untreated patients. Further, several patients developed clots in their jugular veins after the procedure. If the underlying concept of CCSVI is correct then these patients should have become significantly worse – but they didn’t.
Reports of the study also indicate that two Canadians have died from the procedure, but it was not clear if they were in this study or not (probably not, considering how it was reported). In any case, the point is that the procedure is not risk free. A risk vs benefit analysis of the liberation procedure for MS does not justify the treatment, which has dubious plausibility in addition.
In the US the FDA has issued a warning that the liberation procedure is not safe and has no proven benefit. In addition to rare deaths, there are other serious complications reported. There are no reliable statistics, however, on what percentage of patients are having serious complications.
Conclusion: Enthusiasm outpaces science
CCSVI is a radical proposal seeking to fundamentally change our understanding of MS. Proponents of this new hypothesis have failed to meet the burden of evidence for such a radical change. Results of the burst of research that has taken place over the last three years display the typical variability and noise for a null hypothesis – that the notion is not true. There is no convincing evidence that CCSVI exists, and now there is no convincing evidence that treatments based upon the CCSVI theory are effective. Further, these treatments are invasive and pose serious risks.
Despite low (but not zero) prior plausibility, the medical community has dedicated a significant amount of time and effort to doing serious research into the question of CCSVI. If it has any legitimacy, they want to know about it. They also want to back up their opinions with reliable evidence. Despite this, believers in CCSVI are enthusiastically weaving conspiracy theories to explain away legitimate scientific skepticism toward this new hypothesis.

The First Multiple Sclerosis Patient
Twenty years before Charcot described the nerve-destroying disease multiple sclerosis, an illegitimate British noble spent much of his adult life describing the disease and its effects.
Robert Killeen on August 28, 2020
Link

Multiple sclerosis (MS) is a neurodegenerative malady characterized by recurrent neural attacks that are followed by a partial waning of symptoms. The disease is chronic and, over time, the patient accumulates neuronal damage manifest by a gradual loss of physical capacities. There is no cure for MS and the common causes of death are infections such as pneumonia or urinary tract infections. In the mid-19th century Charcot, in France, intensively studied and described the disease now called “multiple sclerosis”. By the mid-20th century researchers had discovered, in the journal of an obscure member of the British Royal family, a trove of information consistent with MS. Though the man involved lived through the sequelae of this disease in the early 1800s and died nearly 20 years before Charcot’s work, he kept such meticulous notes of his signs and symptoms in his journal that, when reviewed a century later, physicians retrospectively diagnosed him with multiple sclerosis. He became the first known patient with MS. His name was Augustus Frederick D’Este.
A brief background of Augustus D’Este
D’Este was of royal, but tarnished, blood. His father was Prince Augustus Frederick, Duke of Sussex, and his mother, a Catholic, was lady Augusta Murray of Scotland. His parent’s marriage was in stark violation of the 1772 Royal Marriages Act because it did not have the king’s blessing. The king disapproved thereby annulling the marriage and leaving Augustus Frederick an “illegitimate” child. He was given the last name of D’Este, an older European name, but was disinherited by the crown, his grandfather, King George III of Britain.
His disease and treatments
Throughout his lifetime, D’Este struggled with obtaining royal recognition while plagued by his illness. As a young man of 28 years, his MS first manifested as an inability to focus his vision. He then began experiencing “attacks” of “spots” floating about his visual fields. He stated that he had improvement in his symptoms after he began drinking, bathing with and immersing his eyes in a tonic called “steel-water”. But a year or so later he developed diplopia and an odd feeling around the lateral portion of his left eye. His physician treated him with a course of leeches and he noticed some improvement.
However, after a short time he began having problems with periodic falls. He wrote that this was not actual syncope but falling due to profound weakness and fatigue. Soon he couldn’t carry his own weight and required assistance for mobility. He also developed numbness around the lower spine and perineum and bouts of uncontrollable defecation. He changed physicians and his new primary care provider prescribed a course of beef steak consumption concurrent with imbibing either London Porter, sherry or Madeira wine. His legs and back were also rubbed with a liniment. This protocol appeared most tenable, his compliance was very good, and he experienced a short-lived recovery. The response rate seemed, overall, subjectively better than the program of leeches.
Sometime later the lower back and perineal numbness returned but now compounded by urogenital difficulties. He developed urinary retention. A bougie was inserted into the bladder reportedly rupturing a membranous stricture; this procedure was accompanied by a great deal of pain and cold sweats. He was prescribed a tonic of herbs and flowers. Despite all these treatments he was still bothered by a modicum of fatigue which, combined with the back/perineal numbness, made it impossible for him to walk, ride a horse, or even sit in a carriage for long distances. The latter would also provoke a numbness in the legs. To his disfavor, he found himself impotent though his urinary tract was evaluated and found to be faultless. He was given “pills for vigor” with little effect. He was subsequently given a course of medical electricity. Nothing helped.
Death and legacy
In the time leading up to his death D’Este found that his lower extremity numbness continued but now was accompanied by lower abdominal numbness. He also noted a progressive dysfunction in his hands and eventually lost the use of his arms. He suffered from periodic leg spasms which kept him awake at night. During his final years he was totally bedbound. When his father died in 1843 D’Este moved to claim the dukedom of Sussex as his own but the House of Lords dismissed his plea. He died of unknown causes in 1848 at 54 years of age.
In spite of his multiple sclerosis, Augustus D’Este maintained an active, very productive life. He enlisted as an Aide-de-Camp with the British army during the ill-fated Battle of New Orleans in the War of 1812. He served in the 9th Light Dragoons, the 4th Royal Irish Dragoons and, as a colonel, he conducted numerous military inspections. He was a Freemason, a “Knight Commander” of the Hanoverian Guelphic order (a British order of Chivalry) and a Ranger of St. James and Hyde parks. He was an active member of the Aborigines Protection Society with a particular interest in protecting the rights of Native Americans in Canada. D’Este chose to live even with his encumbrances. He served well his country, the crown and the people. His only true defeat, the loss of his birthright, was due to an act of Parliament…NOT to his MS.

   Venous Insufficiency in Multiple Sclerosis
Steven Novella
Link
There is an interesting controversy raging in the Multiple Sclerosis (MS) world that reflects many of the issues we discuss at science-based medicine. Dr. Paolo Zamboni, and Italian vascular surgeon, has now published a series of studies claiming that patients with clinically defined MS have various patterns of chronic cerebrospinal venous insufficiency (CCSVI). Further Dr. Zamboni believes CCSVI is a major cause of MS, not just a clinical side-consequence, and is exploring treatment with venous angioplasty or stenting.
The claims have captured the attention of MS patients, many of whom have a progressive course that is only partially treated by currently available medications. There are centers popping up, many abroad (such as India), providing the “liberation procedure” and anecdotes of miraculous cures and spreading over the internet. There is even a Facebook page dedicated to CCSVI, and you can read the anecdotes for yourself. Many profess dramatic improvement immediately following the procedure, which seems unlikely even if Zamboni’s hypothesis is correct.
Zamboni is also getting attention from neurologists and MS specialists, who remain skeptical because Zamboni’s claims run contrary to years of research and thousands of studies pointing to the current model of MS as an autoimmune disease.
There are at least two stories to follow here. The first is the scientific story – the questions being proposed are answerable with scientific research, and they will be answered. MS remains a serious illness that is inadequately treated (not to downplay the important advances we have made, but we certainly are far from an adequate cure for MS). The potential of a new treatment deserves serious research attention, and CCSVI is getting it. It will probably take another ten years for the research to play itself out adequately for there to be a confident consensus on CCSVI, but eventually we will have a scientific answer.
The other story is the the reaction of the public and the MS community. This has been mixed, but already there are conspiracy theories that the neurology community, the MS society, and Big Pharma (of course) are fighting against CCSVI as part of a misguided turf war. (See the comments to my previous posts on this topic at NeuroLogica for some examples.) Anecdotes are being used to argue against published scientific evidence, and negative studies are being dismissed. If CCSVI is eventually found to be a scientific dead end, I have to wonder if it will survive as just another fringe “alternative” treatment, like Laetrile, psychomotor patterning, and other discarded ideas in medicine.
The Scientific Story
So far there is not much of a scientific story to tell. A PubMed search on CCSVI yields a total of 19 publications (a pittance), indicating how new this concept is. I suspect this number will grow into the hundreds at least before this story plays itself out. If CCSVI is proven to be legitimate then this number will grow into the thousands over the next few decades. If it is disproved, publications will trickle off.
Most of the current research is published by Zamboni’s team. He is building an impressive list of studies, exploring various aspects of CCSVI and MS, but evidence that derives entirely from a single research team is always suspect. The role of bias in research is well documented, and further most new ideas in medicine turn out ultimately to be wrong. Therefore skepticism is the proper approach to bold new claims being supported by a lone research team. Replication will be necessary for the broader scientific community to take CCSVI seriously.
The core claim made by Zamboni is that most patients with MS display 2 or more out of 5 criteria on studies of venous anatomy (using ultrasound or venography) of venous insufficiency. While control patients (healthy subjects or those with other neurological disorders) display 1 or no criteria, and never 2 or more. All other claims (benefit from angioplasty, matching patterns of venous insufficiency with types of MS) derive from this core claim.
I found four independent replications in the literature, three very recently published. The first is by Al-Omari MH, Rousan LA, who found:
“According to the described criteria, 92% of the MS patients showed abnormal findings and 84% of them showed evidence of CCSVI, however; only 24% of controls showed abnormal findings, but none of them showed evidence of CCSVI (OR=7.25, 95% CI 2.92-18.01, P<0.0001).”
These are similar numbers to Zamboni, although the 84% is a little less. This study used only ultrasound, which is a non-invasive technique and therefore good for screening, but the results are very operator dependent. There is no indication in the study that the patients were assessed in a blinded fashion.
The next study by Florian Doepp et al used the following methods:
We performed an extended extra- and transcranial color-coded sonography study including analysis of extracranial venous blood volume flow (BVF), cross-sectional areas, IJV flow analysis during valsalva manoever (VM) as well as ‘CCSVI’ criteria. 56 MS patients and 20 controls were studied.
They found no subjects met the Zamboni critieria for CCSVI – a completely negative replication.
The second was performed by Krogias at al, who found:
The authors conclude that the „chronic cerebrospinal venous insufficiency (CCSVI)“ cannot represent the exclusive pathogenetic factor in the pathogenesis of MS. In our cohort, only 20% of the patients fulfilled the required neurosonological features of CCSVI. So far, the pathogenetic relevance of these findings remains speculative. Thus, based on the current scientific position we cannot justify invasive „therapeutic“ approaches, especially if they are performed outside of clinical trials.
The third study is a Swedish study by SundstrÃm et al (“Venous and cerebrospinal fluid flow in multiple sclerosis – a case-control study.” Peter SundstrÃm, Anders WÃ¥hlin, Khalid Ambarki, Richard Birgander, Anders Eklund and Jan Malm. Annals of Neurology) – not yet available online. This study used MRI scanning to assess blood flow in the internal jugular vein in 21 MS patients and 20 controls, and found no difference
Conclusion
One of four replications found results similar to Zamboni. A second found only 20% of MS patients met Zamboni’s criteria, while two others found that no patients with MS did. Four studies is not a lot – and is not even close to ending this controversy from a scientific point of view. But these early results are not promising and will tend to deepen skepticism within the neurological community.
Clearly there is a need for more research so that both patients and professionals can feel comfortable that CCSVI has been given a thorough investigation and we can say with confidence what role, if any, it plays in MS. The results, also, do not have to be black and white. While it seems unlikely that Zamboni has discovered the sole and ultimate cause of MS in most or all patients, it is possible he has found a significant consequence of MS. Chronic inflammation may result in venous insufficiency in some patients. This venous insufficiency may further play a role in worsening the clinical course in a subset of those patients, who may benefit from treatment. So CCSVI may ultimately play a minor but important role in the management of MS.
Or it may all turn out to be a figment of Zamboni’s imagination, spawned by the sincere hope of finding a cure for MS. Time and research will tell.
My open plea to the MS community, especially those who are going down the rabbit hole of conspiracy theories, is to keep this discussion about the scientific evidence. This is not the place for cheap conspiracy theories. I fear my plea will fall on deaf ears, but it never hurts to ask.

The End for CCSVI
Steven Novella on October 9, 2013
Link

A new study published in The Lancet provides the most definitive evidence to date that chronic cerebrospinal venous insufficiency (CCSVI), a hypothetical syndrome of narrowed veins draining the brain that some believe is the true cause of multiple sclerosis (MS), is not associated with MS.
In a science-based world, this study would be yet one more nail in the coffin of this failed hypothesis. But that’s not the world we live in.
CCSVI background
CCSVI was first proposed in 2009 by Italian vascular surgeon, Dr. Paolo Zamboni – that multiple sclerosis (MS) is caused by chronic blockage of the veins that drain the brain. The current scientific consensus is that MS is a chronic autoimmune disease, and the pathology is caused by primary inflammation. Dr. Zamboni believes that the venous anomalies he has discovered are the primary cause and the inflammation is secondary.
That is a fairly radical hypothesis, up there with the notion that bacterial infection and not stress causes gastric ulcers. Of course the latter hypothesis turned out to be true. As more and more research was done on H. pylori, the evidence pointed increasingly in the direction of a correlation and causation, and the consensus of scientific opinion followed the evidence.
The story for CCSVI has been quite different. The evidence has been mixed at best, and mostly negative. Zamboni initially claimed a nearly 100% correlation between MS and narrowing of the cerebral veins. If true this could potentially change our understanding of MS and lead to new treatments. The MS research community received the claims, as they should, with intense skepticism. Many in the patient community, however, saw the claims as a ray of hope.
The key to any new claim in science is replication – do the results hold up when independently replicated? So far, no one has replicated Zamboni’s near-100% results, but that aside, what has the follow up research shown about CCSVI?
In 2011 I reviewed the major replications to date, nine of them, mostly negative. The largest study at the time did find some correlation between CCSVI and MS, but half of MS patients in the study did not have CCSVI and many subjects with other neurological disease or healthy controls also had CCSVI. So it appears that CCSVI does not always cause MS, and MS patients do not always have CCSVI. While the study left the door open for some relationship, it certainly did not support Zamboni’s claims to have found “the” cause of MS.
Since my 2011 review, additional replications have been devastatingly negative for the CCSVI hypothesis. A 2013 study of 1,767 subjects (with MS, another neurological disease, and healthy controls) was dead negative – no association between MS and CCSVI. This study used ultrasound criteria similar to Zamboni’s.
A recent meta-analysis of 9 studies (included out of 19 identified) did show a correlation between CCSVI using ultrasound criteria and MS, but the data did not establish causation. The results, in my opinion, reveal the weakness in the meta-analysis approach because it can potentially include early false positive data skewing the outcome. A best-evidence analysis is a better approach – looking at the pattern in the research, which clearly shows that later, larger, more rigorous studies (as with the latest one above) tend to be more negative.
The Lancet study
The new Lancet study by Traboulsee et al., including 177 subjects, 79 with multiple sclerosis, 55 siblings, and 43 unrelated controls from three centers in Canada is not the largest study of CCSVI and MS. However the study is large enough, and it does have the advantage of comparing ultrasound investigation of the venous system with full dye catheterization, which is the gold standard.
The results of this study are also completely negative – no correlation between CCSVI and MS. They found that:
Catheter venography criteria for chronic cerebrospinal venous insufficiency were positive for one of 65 (2%) people with multiple sclerosis, one of 46 (2%) siblings, and one of 32 (3%) unrelated controls (p=1.0 for all comparisons). Greater than 50% narrowing of any major vein was present in 48 of 65 (74%) people with multiple sclerosis, 31 of 47 (66%) siblings (p=0.41 for comparison with patients with multiple sclerosis), and 26 of 37 (70%) unrelated controls (p=0.82).
It’s interesting that about 2/3 of people had greater than 50% narrowing, meaning that such narrowing is a common occurrence and it not necessarily correlated with any disease. This study suggests that Zamboni was simply making an incidental finding of a common benign anatomical variant that is neither pathological nor related to MS. Those meeting the strict criteria for CCSVI by catheter examination, on the other hand, were rare – 2-3% of all subjects.
The study also found that ultrasound examination did not correlate well with catheter examination, showing that this technique has poor sensitivity and specificity. This calls into question all previous studies that relied upon ultrasound examination.
Conclusion: CCSVI is still a dubious hypothesis
The notion that CCSVI causes MS has always been a dubious hypothesis. It seems implausible that decades of research showing MS to be an autoimmune disease would all be wrong, and that a vascular surgeon who is not an MS specialist would discover the true vascular cause of MS.
Despite this lack of plausibility, the hypothesis was seriously researched. Early results did not replicate Zamboni’s original claims (calling the quality of the data into question), but did give mixed results with an aggregate small positive correlation. This pattern of results, however, is consistent with the null hypothesis that there is no real phenomenon here.
Furthermore, the largest, highest quality, and most definitive studies tended to be negative. This latest study, while not the largest, is of high quality, using a definitive technique for venous examination. It shows no correlation between CCSVI or venous narrowing with MS, and further shows that ultrasound studies are not reliable, partly explaining the mixed results.
Many patients suffering from MS and not responding to established treatment, however, want CCSVI to be real and to offer them a treatment. This has led to CCSVI taking on a life of its own, separate from the scientific data. Once that occurs, the data loses its ability to convince those caught in the narrative of CCSVI. Any negative data can be dismissed as a conspiracy. There are always convenient villains to be found and plugged into the narrative – Big Pharma, insurance companies, greedy doctors, and in this case, MS doctors protecting their turf.
The story of CCSVI is not yet over, even though it should be. One approach to a new medical hypothesis is to see if the underlying theory is correct – does CCSVI exist and does it correlate with MS? The other approach is to conduct treatment trials to see if treating CCSVI improves outcomes in MS.
There is a procedure of venous angioplasty, called the liberation procedure, for alleged CCSVI. A recent systematic review found:
There is currently no high level evidence to support or refute the efficacy or safety of percutaneous transluminal angioplasty for treatment of CCSVI in people with MS. Clinical practice should be guided by evidence supported by well-designed randomised controlled trials: closure of some of the gaps in the evidence may be feasible at completion of the six ongoing clinical trials.
My summary – the evidence we have so far is mostly negative, consistent with the null hypothesis, but on its own is not iron-clad evidence for lack of efficacy. This is sufficient, in my opinion, to condemn the liberation procedure as a treatment. Being generous, most scientists recommend that the procedure should not be performed outside of a clinical trial.
Further clinical trials are underway, including one by Traboulsee, the lead author in the current Lancet study. So it seems we will have to wait at least two more years for the current clinical trials to conclude before we can officially close the book on CCSVI. This will likely, unfortunately, lead to CCSVI moving to the fringe (much like chelation therapy) rather than fading into history.

Update on CCSVI and Multiple Sclerosis
Steven Novella on October 26, 2016
Link


In 2009 CCSVI was proposed by Italian vascular surgeon, Dr. Paolo Zamboni – that multiple sclerosis (MS) is caused by chronic blockage of the veins that drain the brain. Since that time we have seen the evolution of a medical pseudoscience. It has been a fascinating case study in how science sorts out what works and what doesn’t, and how patients, believers, and the public react to this information. The story is ongoing and there are some interesting updates.
Background on CCSVI
CCSVI stands for chronic cerebrospinal venous insufficiency. Zamboni believes that blockages in the veins that drain blood from the brain cause back pressure in the brain, decreasing blood flow and leading to secondary inflammation, and further that this results in the clinical diseases we collectively known as MS. Zamboni’s interest in MS is not random. His wife has MS, and it is interesting that he is a vascular surgeon and found what he believes is a cause of MS that can be treated by vascular surgeons. This does not mean his ideas are wrong, it just means he has a clear bias and his data needs to be looked at carefully and independently replicated.
His initial study found that 100% of the patients he examined with MS had cranial venous blockage. That is also curious. We rarely find 100% correlations in medicine, even for solid theories. It is a huge red flag for systematic bias.
The MS community was appropriately skeptical. While the exact cause of MS remains unknown, we have been studying it for decades and there is a lot we do know. We know, for example, that MS is primarily an autoimmune disease, and the pathology is largely caused by inflammation. We now, in fact, have a long list of effective treatments for some types of MS that suppress the immune system and inflammation. There are still some types, such as chronic progressive MS, that do not respond to the best treatments.
The idea that MS was caused by vascular blockage was therefore a radical idea that flew in the face of existing research. Occasionally, however, radical ideas turn out to be true, and so some MS researchers set out to test Zamboni’s hypothesis.
Meanwhile, the community of MS patients were extremely interested in this new hypothesis. To them Zamboni’s claims meant hope, especially for the most desperate patients who are not responding to available treatments. Before the basic claim that MS correlates with CCSVI was proven, some doctors (notably in Canada) began treating this hypothetical cause by opening the blocked veins in what became known as the liberation procedure. Many patients wanted this procedure, either open label or experimentally, even though it was unproven.
In an ideal world Zamboni’s new and radical hypothesis would have been objectively tested and replicated, and over the next few years it would either gather support or wither under negative evidence. That is, in fact, what happened within the scientific community – studies failed to replicate Zamboni’s findings, and the hypothesis was essentially disproved.
The largest study was conducted in 2013, involving 1,767 subjects, with either MS, other neurological disease, or healthy controls. They used ultrasound to examine the patients’ blood vessels and found zero correlation between blockage and MS. Another smaller 2013 study involving 177 subjects also used a dye venogram, which is the gold standard, and again found no correlation at all. These two studies signaled the scientific death of the CCSVI hypothesis. It was completely dead at this point. Previously the evidence was mixed but mostly negative, and now it was devastatingly negative.
This should have been the end of the story, but of course the story did not end there, because we do not live in an ideal world.
Recent activity
There continues to be legitimate research into CCSVI, not because it is of scientific interest but because of continued public interest. A 2016 study found no difference in the venous drainage pattern between MS patients and healthy controls. Another 2016 study used “Four-dimensional flow magnetic resonance imaging” and again found no difference between MS patients and controls. Yet another 2016 study found no correlation between CCSVI and MS.
These were all after a 2015 review which concluded that the link between CCSVI and MS was a “failed concept.”
Meanwhile, Zamboni has not conceded the failure of his hypothesis. There is nothing wrong with coming up with a new and even radical idea in medicine. That is the raw material for scientific investigation. It is unacceptable, however, to refuse to abandon your hypothesis in the face of overwhelmingly negative evidence. That is when you pass from the realm of mainstream science into the realm of the crank. In medicine this has direct implications for patients, and therefore there is also a significant ethical dimension.
Also in 2016 Zamboni published another study in which he claims that:
Fixing the flow in the jugulars in patients with chronic cerebrospinal venous insufficiency might significantly reduce brain ventricle volume and improve cerebral perfusion. These changes are more evident in patients in the earlier stages of neurodegenerative disease.
This is a common pattern that we see in many dubious health claims. The first scientific priority is to test the basic claim itself – is there a real correlation between venous blockage and MS? Until that question is settled, asking subsidiary questions is mostly a waste of time and resources. We often find that proponents of “alternative” or dubious claims fail to do this. Rather, they tend to nibble around the edges, doing research that does not address the core question but assumes the core claim and asks tangential questions.
Harriet Hall compared this to Tooth Fairy science. This is like doing research characterizing the amount of money left by the Tooth Fairy, and the relationship between tooth characteristics and money left, but failing to ask the core question – is the Tooth Fairy real?
Zamboni is moving into the realm of Tooth Fairy science, looking at fuzzy outcomes like quality of life or secondary effects like perfusion, rather than addressing the core question.
Despite the fact that CCSVI does not correlate with MS, and is simply a rare finding that appears to have no implications for neurological disease, patients are still seeking the liberation procedure. Again, in an ideal world there is no reason to perform or study the procedure, because the underlying theory has failed. You could make a case for studying it if it had a long tradition of use or there were compelling case reports, but here we are starting from scratch. But, that ideal world eludes us. Some practitioners started offering the liberation procedure, mostly in Canada, leading to medical tourism for CCSVI. For this reason researchers decided to at least quantify the results.
Unsurprisingly, well-controlled studies show that the liberation procedure is of no benefit to patients with MS. A 2015 study concluded:
CCSVI appears to be a poorly reproducible and clinically irrelevant sonographic construct. “Liberation treatment” has no proven efficacy, may exacerbate underlying disease activity and has been complicated with [serious adverse events]. “Liberation treatment” should stop being offered to MS patients even in the settings of RCTs.
That is pretty definitive. The treatment does not work, has significant risks, and may even worsen MS. Stop doing it, and stop even studying it. At some point in medicine we have enough evidence of lack of efficacy or of risk to abandon a treatment. It is not ethical to study something forever.
Disconnect between science and the public
It is likely of no surprise to readers here that there is generally a fairly large disconnect between public perception and the scientific consensus built on solid evidence. The gap seems to correlate with ideology, politics, and motivated reasoning. People accept scientific conclusions when they have no emotional investment in a competing narrative, but will reject science when it conflicts with their beliefs.
If you are a patient with a severe illness, especially one not well managed by accepted treatments, you have a huge motivation to believe any claim that offers hope. Desperate patients, for this reason, represent a vulnerable population. This is why there is potentially so much harm in promoting unscientific medical claims.
The disconnect between science and belief is exacerbated by the internet and social media. This allows for the easy creation of communities that quickly become echo chambers of denial and belief. Such communities are fed by conspiracy theories and anecdotes.
A 2016 review of social media sites and CCSVI found that:
Social media are conveying an anecdotal favorable message about CCSVI treatment for MS. The relative absence of videos offering a negative or more balanced perspective is a concern. Social persuasion through these videos creates a strong positive impression of CCSVI treatment, but the videos do not acknowledge the lack of supporting scientific evidence and the possible role of the placebo effect.
This, of course, is exactly why doctors, academics, scientists, and science communicators need to engage in social media.
Full circle
The claim that MS is caused by CCSVI was never plausible. Despite this, it was quickly tested by MS researchers. It actually only took about 4 years for the clinical research to develop to the point where definitive studies were being done. That is very quick in medical research. The hypothesis was given more than a fair shake. The claims and the criticisms of supporters of the hypothesis were taken into careful consideration and appropriately accounted for.
In the end the research was simply negative. There is no correlation between venous blockage and MS. Further, relieving this blockage is of no benefit for MS patients, and is also a risky procedure.
Zamboni should seriously reconsider his support of this definitively failed hypothesis. He should show the world what a responsible medical scientist does, and concede to the evidence.
I also think that at this point performing the liberation procedure on MS patients is unethical and should completely stop. Otherwise the liberation procedure will join the ranks of many other failed medical hypotheses that continued on as zombie crank treatments, supported only by their originators and their acolytes. Such treatments live on the fringe, exploiting desperate patients, and causing silent harm.
Because of social media, and an increasingly lax regulatory environment thanks to proponents of alternative medicine, these zombie crank treatments do more harm than ever before.

Brian Clement claims Hippocrates treatments “reverse” multiple sclerosis
Jann Bellamy on November 26, 2015
Link


American charlatan Brian Clement made another trip to Canada recently and was caught on audiotape claiming multiple sclerosis could be “reversed” at the Hippocrates Health Institute (HHI), where he serves as Director. This is yet another in a series of his misrepresentations about the effectiveness of the quack treatments offered at HHI. Indeed, Clement calls to mind the old joke about inveterate liars:
Q: Know how can you tell this guy is lying?
A: His lips are moving.
Once again, the Canadian Broadcasting Corporation (CBC), which has done an outstanding job exposing Clement and his mendacity, caught him in this particular fabrication. (The American media, by contrast, has largely ignored the story, even to the point of printing credulous puff pieces about Clement.) According to the CBC, it:
obtained a recording of a lecture Clement gave in September in Montreal where he said, “Last week, we had somebody at the institute that reversed multiple sclerosis.”
He went on to claim that many other people who visited his Florida spa, the Hippocrates Health Institute, saw similar results.
“A nurse that came to us two years ago was crippled, had braces on. By the time she left Hippocrates, she reversed the multiple sclerosis.
“And mainstream medicine, they think it’s remarkable. I’ve seen lots and lots of people over the years did that.”
True to form, when asked by a British Columbian newspaper:
. . . to speak to claims he can reverse MS or cure cancer — widely reported by Canadian media, most notably the CBC [which has a videotape of him making the cancer claims]— Clement said “they fabricated the whole thing.”
And:
asked to confirm if he’s ever claimed he can reverse MS or cure cancer, Clement reiterated, “Never, never have I… All we do is support the body and the body has magic in it, the body can do some amazing things.”
Outlandish claims that cancer could be “reversed” by following HHI’s protocols and that people can “heal themselves,” as well as his later denials, were originally reported by the CBC and other news organizations when Clement stepped into the media spotlight following a court’s ruling that the parents of two Aboriginal Canadian girls suffering from an entirely treatable childhood cancer, lymphoblastic leukemia, could pursue traditional remedies in lieu of conventional treatment. After listening to Clement’s sales pitch, the parents took the girls to HHI, in West Palm Beach, Florida, where it operates under a state license as a massage establishment.
Sadly, thousands of dollars later, one of the girls died. Although the other remained under HHI’s “care” for a while, her cancer recurred. Fortunately, she is now back on conventional treatment and has no contact with HHI. The court’s original decision has been amended to state that, while the rights of Aboriginal Canadians must be respected, the well-being of the child is paramount. Considering the fact that Clement is white and HHI’s cancer treatments are nothing but pure American pseudoscience, it is not clear why the court’s original ruling used Aboriginal tradition as a rationale in the first place.
HHI offers a cornucopia of quack treatments, a favorite being wheatgrass. As our good friend Orac noted over on Respectful Insolence:
if you believe the hype on the HHI website, there’s nothing that wheatgrass can’t do. If the HHI is to be believed, wheatgrass can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many other fantastically beneficial alleged effects. Basically, combine a raw vegan diet with a veritable cornucopia of other kinds of quackery, and you have the HHI.
For all his supposed expertise, Clement is laughably ignorant about science, although plenty full of the sort of babble you’d expect from someone with such a tenuous hold on facts. Orac’s post links to a couple of excruciating videos in which Clement discusses “quantum biology” and other nonsense, nicely demonstrating that “Clement understands neither physics, chemistry, nor biology.” Just for fun, here’s Clement describing, well, something:
All abnormalities that have been labeled as diseases stem from the negative energies that are endured from the poor lifestyle choices and unsustainable environment that we have created on planet earth today.
Our core vulnerability stems from the reduction of bio-frequency that occurs in the cell, which heightens its fragility to make it ineffective in communication and contribution. When these disturbances are critical, they can even cause a cell to mutate.
Odd for someone who claims he has a degree in biochemistry, don’t you think?
Unfortunately, the Canadian girls are not the only victims of HHI and Clement. Others are Stephanie O’Halloran, a young Irish woman, Anael L’Esperance-Nascimentol, a three-year old Canadian boy who went for treatment there, Laurie Ann Prince, Kathyrn Tachell and Kim Curry, also Canadians and all fairly young, and Lajos Tringer. (Lajos also considered treatment by another cancer quack, Stanislaw Burzynski.) Most of these either drained their own resources or raised funds, or both, to pay the considerable expense of going to HHI, as treatments there are not covered by insurance; it is a cash-only operation. Unfortunately, we know that Stephanie, Kathryn, and Kim have died. I have heard that Lajos died in 2014, but I could not confirm that independently.
Yet, Clement was so well greased with his own snake oil that he slithered through the Florida regulatory system, despite three complaints filed with the Board of Medicine and the Agency for Health Care Administration. Although Clement was originally ordered to cease and desist from the practice of medicine, the state backed down, leaving Clement free to pursue the international lecture circuit and continue as HHI’s Director, albeit shedding a few educational degrees of questionable provenance along with way.
Clement has described himself variously as having a PhD and an NMD (Naturopathic Medical Doctor) and has used the honorific “Dr.” These degrees are from schools widely regarded as diploma mills. He is still referred to as an NMD in at least one place on the HHI website, although his bio claims only that he has a degree in biochemistry, without saying where he earned it. His wife and Co-Director of HHI, Anna Maria Gahns-Clement, made similar claims about her education, including that she graduated from the non-existent “Denmark University.” That information has been removed from her bio as well but she, too, is referred to as an NMD elsewhere on HHI’s website.
Fortunately, the bad publicity seems to be catching up with Clement, thanks to skeptical groups who protest his public appearances, the CBC’s and other Canadian media’s extensive coverage, and a growing number of blog posts detailing his nefarious activities. (A list of blog posts can be found here.) In September, he had the dubious, but well-deserved, honor of becoming entry # 1467 in the Encyclopedia of American Loons.
Over this past summer, Clement was scheduled to appear in several European cities, but his events were cancelled in Ireland when his venues discovered his sordid history, thanks to protests by the Cork Skeptics, who were warned of his coming by the UK’s Good Thinking Society. The Society also protested appearances in London and Birmingham. [Tickets for the UK events cost over $100 (US).] According to the Daily Mail:
ticket buyers are promised that diseases including cancer, cardiovascular disease, MS and diabetes can be “altered, prevented and at times conquered”.
On his most recent Canadian tour, he was supposedly scheduled to speak at a Qualicum Beach, B.C., school, although school officials denied his talk had ever been approved. In any event, he was not allowed to speak there. He did give a talk in another B.C. town titled: “The truth they don’t want you to know about vitamins, minerals, and their effects on your health.” Yes, it’s that famous “they” who are constantly working to keep people from learning this or that particular truth.
Right now, HHI’s off-campus events schedule looks a bit thin. Maybe “they” are getting the word out.

Brain Stimulation for Memory
Brain stimulation for memory is interesting science, but don’t believe the premature claims and hype.
Steven Novella on August 24, 2022
Link

There are different kinds of medical pseudoscience that we tackle here at SBM. Some therapies and claims are pseudoscience because they are not conceptually valid – they break the laws of physics, or rely on outdated, superstitious, or just wrong concepts of biology and health. Often they rely on phenomena such as “life force” which don’t seem to exist. Others are based on real scientific phenomena but grossly misapply them. Detox fits into this category. Toxins exist and can cause harm and so removing them can be beneficial, but popular detox treatments are not targeted against actual toxins, there is no evidence the treatments remove any toxins, and there is no evidence of any health benefits.
A third category of medical pseudoscience is perhaps the most pernicious, legitimate cutting-edge medical science that is currently being researched and developed, but unscrupulous gurus make claims for specific treatments that are years or perhaps decades ahead of the science, trying to capitalize on the hype. Stem cell therapy is the poster child for this category – using stem cells to treat serious disease is an active area of research, but we are probably decades away from the sort of applications that people think of, and yet fraudulent stem cell clinics began popping up almost 20 years ago.
Brain stimulation also fits into this third category, using specific frequencies, intensities, and locations of electrical (either direct current or alternating current) or magnetic stimulation to alter brain function. Conceptually I have not problem with this approach and it should be considered perfectly legitimate. The brain is an electrical organ and its function depends on the electrical activity of specific circuits in the brain. Either increasing or decreasing the functional activity of specific brain regions or circuits should therefore be a possible mechanism of intervention.
The hype
As with stem cells, however, it is still early days for this kind of approach. My sense is that it is a bit further along, with some actual approved (if basic) interventions, such as treating seizures, movement disorders, or aborting migraine headaches. But brain stimulation is not a panacea. There is no evidence and no reason to think that it alters the biology of the brain (the health of brain cells), but it can immediately alter the electrical activity of the brain. The challenge is that there are many variables to consider, and so it will take a long time to do the research to dial in which specific interventions will have which specific effects in which populations of people. These variables include the type of stimulation (AC, DC, magnetic), the intensity and duration of stimulation treatments, the targeted part of the brain, and the frequency of the stimulation.
And yet, there are already a number of home brain stimulation devices on the market. What claims are made for these devices? A familiar list of vague and allowable claims, such as improved mood, focus, stress reduction, and improved sleep. Some include the “quack Miranda warning” that they are not intended to treat a disease. Because these are devices, and not drugs, they can easily obtain FDA “clearance” without having to prove efficacy.
Unfortunately, the background of legitimate research into brain stimulation inadvertently feeds this unscrupulous industry, through less-than-skeptical reporting. A recent study shows where the state-of-the-art is for brain stimulation for memory function, and also how lazy reporting can be a problem. The BBC headline reporting on this study is “Brain stimulation boosts memory for a month“. This makes it seem like memory function is improved for a month after treatment, but that is misleading. The study itself is actually quite good, let’s review what it actually shows.
The science
The researchers are extending existing research into brain stimulation to improve working memory (WM) and long term memory (LTM). Previous research has been inconclusive, as the authors of the current study summarize:
Rhythmic activity in the theta and gamma frequency ranges are thought to contribute to both WM and LTM function, particularly during free recall. However, previous attempts at modulating these rhythms to improve memory have yielded inconsistent findings. Although there are some suggestions of improvements in WM with modulation of parietal theta rhythms, changing theta rhythms in the frontal regions and gamma rhythms in the parietal and frontal regions have yielded contradictory results.
Their study design is very thorough. They first look at their hypothesis based on prior research, the use of low frequency stimulation in the parietal cortex and the use of high frequency stimulation in the pre-frontal cortex. They gave the subjects 10 minutes of stimulation per day for four days, and encoded verbal memory for words during stimulation. They studied healthy older adults from 65-88 and tested their immediate recall on the days of stimulation and then recall for the words one month later. They found a statistically significant improved in short term and long term recall for these types of stimulation, and further there seemed to be a dose-response with more successive days of stimulation having a greater effect, and improving in memory on day 4 predicting improving at one month. They used a double-blind sham-controlled protocol.
I like the fact that they then performed two internal controls. They did a second study where they reversed the high and low frequency stimulations, and showed no benefit. This is important to rule out nonspecific effects – for example, perhaps the stimulation (which they could feel) just made subjects overall more alert. This second experiment showed the results are frequency dependent. They then did a third experiment replicating the results of the first study in a fresh sample, again showing significant results. I have mentioned previously that internal replications should become standard, to minimize the publication of false positives.
The limitations
So – this was a nice series of studies suggesting that stimulation using transcranial alternating current stimulation at specific locations and frequencies may improve short and long term recall of words. But any reporting of this, especially in the context of an existing dubious industry of at-home brain stimulation, should carefully point out what this study does not show. First, the effect was only seen for memory during stimulation. The headline suggests a persistent effect over a month, as if brain function improved for a month, rather than just an immediate effect of improved memory for words during stimulation.
This, of course, significantly limits applications of this approach. You would need to be using the device while studying, and your memory outside the window of stimulation would not be affected. We don’t know how long this effect lasts for, and previous research does suggest a declining effect from continued stimulation. We also need to study what the long-term effects are (both longer duration stimulation and greater number of sessions). It’s plausible there could be a negative long-term effect. Might memory function decline between sessions? Does this effect extend beyond memory for words?
Also, it needs to be pointed out that this is not a disease treatment. While Alzheimer’s is mentioned both in the study and the reporting, Alzheimer’s is a biological disease of the brain. At best this would be a symptomatic treatment and would not slow or reverse progression.
We are still early in this kind of research. While I am hopefully for the potential of electrical interventions for brain function, the authors acknowledge that specific applications are likely far in the future. It is certainly too early for home brain hacking through portable devices.

Paralyzed Patient Communicates with Brain Implant
Brain-machine interfaces continue to advance.
Steven Novella on April 20, 2022
Link

While we tend to focus on SBM on exposing and routing out pseudoscience in medicine, it is also important to point out why science-based medicine is so effective. It may not be fashionable to say so, but good ol’ reductionist science is a powerful tool that can have a massive impact in people’s lives.
One story I have been following for years is the incremental advances being made in brain-machine interfaces (BMI), and here I am happy to report on yet another small but significant incremental advance. That is something else worth reminding the public about – science generally advances through accumulated baby steps, and rarely through “stunning breakthroughs”. But breakthroughs are better for headlines, even if they make for sloppy science communication.
A recent study in Nature reports the case of a patient suffering with advanced amyotrophic lateral sclerosis (ALS), which has caused him to be completely paralyzed, enough to be considered in a “locked-in” state. He cannot even move his eyes. ALS is a neurodegenerative disorder that affects motor neurons, causing muscle twitching, weakness, and eventual paralysis. The mind, however, is intact. While there are variable outcomes, in most cases patients get to the point where they are too weak to breath on their own. At that point they may choose to die comfortably or to be placed permanently on a ventilator to breathe for them.
For those with advanced cases of ALS a variety of devices have been developed to allow them to continue to have some function and to communicate, despite losing the ability to speak. Stephen Hawking was perhaps the most famous example of this. He used, by the end, a camera that tracked subtle facial movements to indicate his intentions. Intel actually helped develop a software system to anticipate which words he was trying to communicate and help with error correction. Patients who retain even the tiniest movement in a finger can use that to control a mouse. Some patient blow into a straw to make their desires known.
While these technologies are indispensable, they can be slow and tedious, and some patients do not have the residual muscle movements to use even these techniques. This is why the ultimate communication device would be one that communicates with the brain directly, and does not require any muscle movement at all. This is possible with a brain-machine interface. This technology has been slowly developing over the last few decades.
The good news is that research has already established all the necessary proofs of concept. Electrodes can accurate read brain signals and translate them into intentions. Patients can learn to control their thoughts in order to use the signals to control a mouse cursor or other interface. Brain plasticity allows the interface, with several weeks or months of training, to become progressively easier and quicker. Software has been developed to interpret these brain signals with increasing sophistication.
The primary limiting factor at this time is the hardware technology – the ability to place electrodes in intimate contact with cerebral cortex and to have that connection remain stable (despite the brain’s subtle pulsations) without forming scar tissue that would degrade the connection. Some of the research has been done with scalp electrodes (Hawking tried an electrode cap, but this did not work for him), which is safe and easy, but the resolution of the signals is poor and this limits the communication. Brain surface electrodes work much better, but they are invasive. Long term there is a risk of infection and scaring.
For this reason there are various teams developing the electrode technology, which is now arguably the most important piece of the BMI technology. There are microwire electrodes like thin hairs that can be placed within brain tissue, and there are electrodes that can be placed inside the blood vessels in the brain.
The Nature study used two microelectrode (not wire) arrays on the motor cortex, connected to a percutaneous (through the skin) connector and amplifier. The subject had previously lost all ability to communicate through eye movements or other methods. At first they instructed the patient to imagine moving their hand or doing other movements, but this did not result in any detectable alteration in brain firing. On day 86 after implantation they embarked on a new strategy – using auditory feedback. The brain signals were translated into an auditory tone, and on the first day of trying the patient was able to modulate the tone by voluntarily altering his brain activity.
By day 98 the patient was able to modulate the tone so that it matched a target. By day 106 the patient was able to modulate the tone to freely select letters to form words and sentences. The patient was able to achieve an accuracy of about 90% and was able to spell at 1.08 letters per minute. This is tediously slow, but obvious better than no communication at all.
Again, this is not a breakthrough but another in a long line of incremental advances, inching toward the day when brain-machine interfaces will be robust enough to allow for something approaching normal communication and other applications. The advance here is demonstrating that a patient can communicate through a BMI without any corresponding motor movement at all. This study also reinforces the fact that patients need feedback in order to learn to modulate their brain activity. In this case auditory feedback was used, but in some cases visual feedback can be used (such as seeing a cursor move on a screen).
In short, this technology works. At this point continued incremental advances are all that is necessary – improved electrodes, increased number of electrodes, improved software algorithms, improved robotics, and optimized training techniques. Predictive algorithms can significantly improve the speed of communication. “Self-driving” technology could aid in the control of robotic limbs to manipulate one’s environment and provide some mobility and independence. A computerized environment could allow significant control over lighting, electronic devices, doors, etc. With enough electrodes and connected devices, near normal functionality could be restored. This of course will take decades of research and development, but there does not appear to be any hard obstacles in the way.

Helping the Paralyzed Walk
Steven Novella on September 2, 2015
Link

One of our primary goals at SBM is to advocate for high standards of science in medicine. This means that we spend a lot of our time discussing claims and practices that fall short of this standard. This is very useful – exploring exactly why a claim falls short is a great way to understand what the standard should be and why.
An unfortunate consequence of this approach, however, is that many of our articles tend to be negative. We focus on what doesn’t work, on what needs to be fixed, and on why people fail.
But there is a positive side to the story as well that we should not neglect – science is powerful and it works. That is why we are such enthusiastic advocates of science in medicine and why it is so important to get it right. We shy away from overhyping scientific advances in medicine, because the mainstream media does that so well, but every now and then it’s good to acknowledge awesome medical and scientific advances.
Hacking the nervous system
A new report marks a notable advance in using both robotics technology and electrical stimulation to help a paralyzed man walk. Mark Pollock, described as a blind adventurer, broke his back four years ago after falling out of a window. He was completely paralyzed below the waist, with no voluntary movement. He has been working with the Edgerton Neuromuscular Research Laboratory at the University of California, Los Angeles. Dr. Reggie Edgerton has been working on spinal cord injury research for the past 30 years.
The new research combines two techniques. The first is electrical stimulation of the spinal cord. This is nothing short of a new paradigm in medical intervention for spinal injuries.
There are several broad approaches to intervening in biological function. We can alter problematic anatomy and repair trauma through surgery or compensate with braces, prosthetics, and devices. We can alter physiology and biochemistry through pharmacological intervention. We can adjust physical activity, nutrition, and environmental exposures.
Added to this list is the use of electrical or magnetic stimulation to directly alter nervous system function. Electricity has been used to alter cardiac function, such as with a pacemaker. It has also been used to alter brain function for decades, going back to the beginning of electroconvulsive therapy. But that is a fairly crude and limited application of electrical stimulation. Electrical stimulation has also been used to modulate pain.
The last couple of decades have seen an increase in the sophistication and potential applications for electrical or magnetic stimulation. Combining this technology with computers and robotics has the potential to dramatically increase those applications.
Approaches to paralysis
There are a number of ways we could potentially hack the nervous system in order to repair or replace function lost through injury. Several research teams are working on implanting electrodes onto the surface of the brain, or using scalp surface electrodes, in order to translate thought into computer control. Software interprets the brain signals, which the subject learns to control, enabling them to move a cursor on a screen, or control a robotic arm. This approach has the potential of bypassing any injury or paralysis and giving direct mental control to robotic limbs and devices.
Another approach is to attach electrodes to proximal muscles that are still under voluntary control and then connecting them to more distal muscles that have been paralyzed, or to robotic prosthetic limbs.
The robotics themselves can either take the form of a limb (such as a robotic arm) or an exoskeleton that fits over a patient’s arm or leg.
Edgerton’s team has been working on another approach entirely, specific to spinal cord injury. They use continuous low levels of electrical stimulation below the spinal cord injury to “wake up” the injured spinal network. The theory is that even with complete paralysis, there still may be some surviving connections and if they can be activated that can restore some voluntary control, even after years of total paralysis.
They have been using two methods. The first involves surgically implanting electrodes epidurally – over the membrane that covers the spinal cord. The second is to use transdermal electrical stimulation, which stimulates across the skin and has the advantage of being noninvasive.
A couple years ago they reported on four subjects who were completely paralyzed after spinal cord injury who were able to have some voluntary control of their legs restored. The “holy grail” of spinal cord injury and recovery is voluntary walking, but any movement was a proof of concept.
The new advance
The latest report from Edgerton’s team is the result of a combination of transdermal electrical spinal cord stimulation and a robotic exoskeleton in Mark Polock. The exoskeleton is capable of supporting the patient’s weight and walking. The exoskeleton is also able to monitor any voluntary contribution to movement from the patient.
They were able to demonstrate that Pollock was voluntarily flexing his left knee and hips, contributing a little to the exoskeleton’s movement. He still needed assistance to walk, but this was a significant advance.
The reason it is beneficial for Pollock to contribute to the walking, rather than letting the exoskeleton do all the work, is that there are other health benefits. Paralysis can lead to lack of physical activity and cardiovascular disability. Voluntarily contracting muscles can improve muscle tone and function and improve cardiovascular health.
The Future
Combining robots, computer control, and electrically hacking the nervous system is still relatively new. This is often referred to as brain-machine or brain-machine-brain interface. There are also muscle/nerve-machine interfaces, and now we also have spinal cord-machine interface.
Obviously this is all a very new technology and we need to have realistic expectations of how long it will take for this technology to mature. There is a tendency to overestimate short term technological advances, and then become disappointed when the promised benefits do not manifest quickly. However, there is also a tendency to underestimate longer term advances. Then one day, the world changes rather quickly.
We are still years away from this technology going mainstream – getting it out of the research centers and into hospitals and regular practices. There are still technical issues to be worked out in terms of interfacing with the nervous system. But all of the proofs of concept are now in place. We really just need incremental technological advances.
It may take 10-20 years or even 30-40 years, but it seems likely that in something like that time frame we will see robotics and machine-nervous system interfaces essentially solve the problem of paralysis.

In Animal Study, Nanobots Repair Spinal Cords
Steven Novella on June 3, 2026
Link

For my entire career as a neurologist the ability to repair an injured spinal cord has been one of the holy grails. There has always been promising new research that definitely increases our knowledge but doesn’t lead to an effective treatment. This is not for lack of trying – I also remember the period when Christopher Reeve was a tireless promoter of spinal cord research, following his injury in 1995 (until his death in 2004).
I remain hopeful and find encouragement in new significant breakthroughs, but tempered by the realism that spinal cord repair is an extremely difficult challenge. With that in mind, researchers have recently reported some intriguing results using stem-cell infused nanobots to repair injured spinal cords in zebra fish and mice.
Since the early 2000s it seems stem cells have been the most promising mechanism to repair spinal cord injuries. During the peak of the stem cell hype this seemed highly plausible, leading to many fraudulent clinics claiming they could use stem cells to treat such injuries and many other conditions. But it turns out you can’t just inject stem cells into the site of an injury and have them make meaningful connections, survive, and function. If only it were that easy. Here we are a quarter of a century later and perhaps we are getting closer to the promises of that early hype.
Since 2006 we have been able to create induced pluripotent stem cells. This was an incredible boon to stem cell research, because we could create stem cells on demand, even from the skin cells of the person who would be the ultimate recipient of them (so no problem with rejection). They are not quite as good as embryonic stem cells, but pretty close.
But this only solved one of the technical challenges with stem cell therapies. We also need to get the cells to go where we need them to be, to turn into the types of cells we need, to survive and to function. Neurological applications also require that they make the proper connections. Further, we need the stem cells to not become cancerous. It has taken a couple of decades to work out these issues, to be able to produce large amounts of clinical-grade stem cells, and to demonstrate their safety.
It does seem like we are perhaps finally transitioning to a new phase of stem cell research. While it is still true that the only proven stem cell therapy remains blood-based stem cells, there are many potential treatments currently in late-stage clinical trials. There are also many companies developing stem cell therapies – so they have moved out of the lab into product development (which brings its own corporate hype, but at least around legitimate science rather than fraud). Other technologies, like advanced genetic modification with CRISPR, are also helping.
These stem cell treatments, however, still represent some of the low-hanging fruit, especially for neurological applications. For example, one trial is in Parkinson’s disease. Using stem cells for PD goes back to the 1980s, because it is theoretically simple in that all you need is for the cells to survive and make dopamine. They don’t have to network necessarily with other neurons.
Repairing spinal cord injury is perhaps at the other end of the difficulty spectrum – we need the stem cells to effectively bridge across the site of injury and make robust working connections. Even if we do this it is almost guaranteed there will be some of what we call “abnormal reinervation syndrome” in which the connections don’t go to exactly where they should. The brain has sufficient plasticity, however, that the person can retrain to use their new connections, a process likely to take many months. But this is a minor issue if you can actually repair a damaged spinal cord.
What does the new study accomplish? Researchers have found that using electrical stimulation is an effective way to get stem cells to migrate where we want them to be (at the site of injury) and to differentiate into neural cells and to function. However, this requires the implantation of small wires, an invasive procedure that is disruptive to the healing process. The new approach aims to solve this issue.
Rather than implanted wires, they use magnetic nanobots which are hybridized with the stem cells (called NPCbots for neural progenitor cell bots). They then can use magnetic fields to guide the nanobots and stem cells to the desired location, and to stimulate them electrically to help them differentiate. Once their use is done, the nanobots should eventually just dissolve.
They found that the nanobot-stem cell treatment was fairly effective with zebra fish. Fish that were paralyzed with a spinal cord injury were able to swim and explore. They write: “In a zebrafish spinal cord injury model, alternating magnetic field stimulation of NPCbots induced rapid in vivo neuronal and astrocytic differentiation, enhanced graft integration at the lesion site, and near-complete recovery of swimming and exploratory behaviours within 3 days.”
It needs to be noted that, unlike humans, zebrafish have the ability to spontaneously regenerate their spinal cords. So this study was a proof of concept that their technology works, but cannot be extrapolated to non-regenerating species. They therefore did a follow up with a non-regenerating species – a mouse. Here the stem cells were well tolerated and survived for at least 28 days, were able to move to the site of injury and make connections. The mice had improved movement in walking, coordination, and stride length. There was also no evidence of immune rejection or other issues.
Sounds fairly promising, but of course more research is needed, eventually in human spinal cord injury. We cannot always translate treatments from mice to humans because mice are very small and humans are large. The distance between the two ends of the injured spinal cord may be significant here, so we can’t get too excited until we have some positive human clinical research.
It took over two decades, but we may be finally approaching the time when stem cell therapy reality is catching up to the hype. The technology has proven far more difficult than we had hoped, but relentless progress has gotten us ever closer to actual applications. Still, we must be cautious. We may still need a decade or two before we really start to see the promise of stem cell therapies take off.


Communicating with the Locked In (update)
Researchers have made an incremental advance in using imaging and computers to communicate with patients who are completely locked-in. Let’s review the state of this technology.
Steven Novella on February 1, 2017
Link

Undoubtedly one of the worst neurological syndromes we confront is the locked-in syndrome (LIS). This can result from a stroke or other brain damage in which the thinking part of the brain is intact and functioning – the patient is awake – but the brainstem is damaged so that their brain cannot communicate with the rest of their body. They are essentially paralyzed below the eyes. In LIS some eye movements and blinking are still retained. This may not sound like much but it enables them to communicate yes-and-no answers, which provides some connection to the outside world.
There is also a syndrome known as complete locked-in syndrome (CLIS) in which even eye movements are lacking. This can result from end stage amyotrophic lateral sclerosis (ALS), in which all muscle control is lost. Eventually even the eye muscles are lost and the patient has no motor function. There is currently no way to communicate with people in CLIS, but a new study hopes to change that.
Brain computer interface
The best hope for paralyzed patients is probably advances in brain-computer interface (BCI) technology. There have been some impressive advances in the technology for allowing brains to communicate with computers, and vice-versa. I wrote about such advances here in 2012, and progress has continued since.
Researchers, for example, have been able to train a monkey to operate a robotic arm with its thoughts alone. This advance has been replicated in humans, giving a patient with tetraplegia (complete paralysis of all four limbs) the ability to operate a prosthetic limb. People have also been trained to use the electrical activity of their brains to control a cursor on a computer screen, enabling them to type out full messages.
Computer processing power and software technology is more than up to the task, and will only improve. The real limiting factor technologically is producing a stable physical connection between the computer and the brain. Computer chips tend to get hot and need to be powered. Wires tend to form scar tissue and make infections more likely.
Researchers are experimenting with intravascular electrodes, which may solve some of the problems. Scalp surface electrodes are safer and more convenient, but lose a lot of information resolution because of the skull and other tissue between the electrodes and the brain.
At this point you are probably thinking – OK, if a monkey can control a robotic arm using its brain activity, and a person can control a computer cursor, then conveying a simple yes-no should be a piece of cake. Surprisingly, however, researchers so far have been unable to use BCI to convey such abstract information in subjects who are completely paralyzed.
The possible reasons for this are interesting. It seems to be due to the fact that the learning process requires some motor or sensory feedback. In patients with CLIS, there is no motor feedback. Their motor neurons are completely gone and their muscles have wasted away. Without this motor feedback they cannot learn to operate a BCI.
This is disappointing, but provides useful clues as to how current BCIs are functioning. The brain has plasticity, it can adapt to new inputs and outputs, but it apparently needs them to map its activity to new function. It is much more difficult to adapt to a computer interface using pure thought without the feedback.
The new study
A study published in PLOS Biology looked at four patients with CLIS or entering CLIS due to ALS. They used functional near infrared spectroscopy (fNIS) to measure the oxygenation of blood in the frontal lobes of the brain. When the brain is active the neurons draw more oxygen from the blood, decreasing the oxygen concentration in the blood which can be measured using fNIS.
They trained the subjects using yes-no questions with a known answer, like the name of their spouse. The subjects were told to think “yes, yes, yes” or “no, no, no” for 15 seconds. Computer software then learned how to distinguish their fNIS activity in the two “yes-no” states. They also simultaneously recorded scalp-surface EEG. Once calibrated they tested the accuracy of this system with further yes-no questions with known answers. The authors report that they were able to achieve >70% accuracy with fNIS overall, which was statistically significant.
This is the first time statistically significant results were found in CLIS subjects with a BCI. However, I think the results should be considered preliminary. There were only four subjects, and the results are only modestly above chance. Outcomes varied from 60-70% and there did not appear to be a significant learning curve.
If these results are valid, they can still be useful. You can ask the patient a question 10 times, for example, and if they give one answer 8 out of those 10 times that is probably the answer they intend.
The future
Of course I would like to see these experiments replicated, both exactly and with variations to see if the results can be improved. I would be less suspicious of the outcome if they were able to achieve >90% accuracy. Also, based upon prior studies, it seems that asking the patient to think other things might be more useful. For example, in one study using fMRI scans researchers were able to distinguish when an apparently comatose patient was asked to imagine themselves playing tennis vs walking around their home. But again, asking the patient to imagine a motor task may be problematic if they lack all motor feedback. This needs to be sorted out.
Also, researchers may have better luck with higher resolution imaging, such as brain surface or intravascular electrodes.
Part of the difficulty researchers are having is that they have no way of knowing what is actually happening inside the minds of these patients. Are they paying attention? Are they distracted by some pain or sensation? Maybe they have an itch or an ear worm. It is impossible to know where patients go mentally when they are completely paralyzed.
This is important research, however, and I anticipate how far and how quickly it will advance. We need better physical interfaces to have stable high-resolution connections to the brain. We have also been picking the low hanging fruit, such as motor function or interpreting the activity in the primary visual cortex. We may be able to use this to great effect, but what we really want is to be able to decode the abstract thinking of the brain. I don’t think we are anywhere near this ability. Interpreting abstract thoughts, even yes-no, will probably take much higher resolution and much more sophisticated software and calibration algorithms. We are not entering The Matrix yet.
One possibility, at least with ALS patients, is to begin teaching patients to use such an interface when they are diagnosed, and not waiting until they are near CLIS. They may have a year or two to train their brains, and to train the software, to communicate while they still have motor feedback. By the time they are completely paralyzed they can slide seamlessly into the virtual reality of their BCI.
It’s both exciting and frustrating to be at the dawn of this new technology. There are exciting advances, and we can see the potential, but the real benefits are still out of reach.

Cyborg Therapeutics
Steven Novella on October 31, 2012
Link
It appears that we are near the beginning of a new modality in medicine – the use of computer controlled and powered robotics for therapeutic purposes. At present such technology is in its infancy, but is giving us a glimpse of what it will become.
Recently Vanderbilt University announced that its team at the Center for Intelligent Mechatronics has developed an exoskeleton that paraplegics can wear on their legs to allow them to sit, stand, and walk. This is essentially a mechanized orthotic that paraplegics can wear on their legs. The researchers describe it as a “Segway with legs” – referring to the computer technology that controls the exoskeleton, which responds to the user’s movement. If the user leans forward, then the legs will walk. If they lean back, then they will sit.
Like any technology, you can take either a glass half-full or half-empty view of this device. I will cover both – first the good.
Their system has some advantages over previous systems. It is about half the weight, coming in at 27 pounds while other lower extremity exoskeletons weigh 45 pounds. The exoskeleton is also small enough to fit in a standard wheelchair while being worn, and can be put on and taken off by the user alone. As described above, this system also incorporates intelligent control technology. Users with partial paralysis can have their own movements augmented, while for those with complete plegia the exoskeleton can do all the work.
The exoskeleton allows for a significant increase in independent mobility for the user. This can be significantly helpful in getting paraplegics mobile, which would be advantageous to overall health and reduce the risk of certain complications, like bed sores.
Now for the limitations: The system does not allow for sufficient balance to be used without crutches. This means that users require significant upper body strength and control in order to walks with the legs. There is also a weight limit, so overweight paraplegics, those over 220 pounds, cannot use the device. In short, users need to be fairly physically fit.
The technical specifications indicate that the onboard lithium polymer battery can last for about 1 hour of use between recharges. It does not indicate how long it takes to recharge, but I would guess several hours. It also indicates that the sound generated by the device is 55 dBA, with ambient noise being 38 dBA.
If we consider the various components of these types of systems, it appears that the engineering is fairly solid. The devices are well-engineered, reasonably powerful (although this is still a limitation) and increasingly light and portable. Battery technology to power the device is a limiting factor (as it is with many applications). There is a great deal of research into building a better battery, as so many technologies depend on battery technology (like electric cars, for example). The powered exoskeleton is one more technology that will benefit from general improvements in battery technology.
The computer control seems to be the most advanced aspect of this device. Computers themselves are light and powerful with little energy consumption, and the software to provide intelligent control is already fairly advanced. I’m not sure how close this technology is to providing independent balance (without the need for crutches for stability). Balancing algorithms already exist, such as with the powered wheelchairs that can balance on one set of wheels and climb stairs. There are already robots that can balance and walk on two legs, but nothing small enough to function as an exoskeleton.
There is also the question of how users will adapt to robotics, whether as an exoskeleton (orthotic) or as a replacement for lost limbs (prosthetic). So far the research here is very encouraging. Virtual reality testing indicates that the brain is highly plastic in this regard, and can potentially adapt to new parts so that they feel natural, as if they are part of the body. In other words, it appears to be theoretically possible to neurologically close the loop on orthotics and prosthetics, so that they feel and function like a natural part of the body.
One interesting aspect of this is user control of robotic devices. This exoskeleton uses muscle and movement control – it responds to the user’s own movements. However, other researchers are working methods of more direct brain control. These approaches involve internal or external electrodes that read brain activity and software that can learn to translate the activity into the desired action. There is a learning curve for the user as well, but eventually the user and computer can learn to communicate and robotic limbs may be able to respond naturally to the desires of the user.
Current use of powered limbs is highly limited, but there is a steady stream of incremental advances in every aspect of the devices. What I think we have now is mainly a glimpse of the future. We are nowhere near the Bionic Man level of technology, but we are inching closer to the day when such devices will essentially restore function and mobility to the paralyzed.

Brain-Machine Interface
Steven Novella on December 19, 2012
Link
We spend a great deal of time in the pages of Science-Based Medicine taking down every form of pseudoscience in medicine. Of course, what we see as pseudoscience, proponents often see as emerging or cutting edge science. They are taking advantage of the fact that there is a great deal of legitimate emerging science, and they hope they can sneak past the gates by cloaking themselves in the trappings of real science (jargon, studies, their own journals, etc.). Emerging science, however, no matter how plausible and earnest, still has yet to prove itself (by definition), and has to go through the rigorous process of scientific evaluation to slowly gain acceptance. That process – sorting out what works from what doesn’t, the real from the fake – is where all the action is in SBM.
It is refreshing sometimes to talk about an emerging field that, while still experimental, is legitimate and has the potential to usher in a genuinely revolutionary treatment.
I have been following the research into brain-machine interfaces for some years, and reporting on many of the significant “baby steps” in the advance of this new technology. A recent study published in The Lancet represents another incremental and encouraging advance. Researchers at the University of Pittsburgh implanted two strips of 96 electrodes into the motor cortex of a 52 year-old woman with tetraplegia. The electrodes are capable of detecting the firing of neurons in the motor cortex and transmitting those signals to an external processor that in turn controls a fairly sophisticated robotic arm. The arm is described as having seven degrees of freedom – three dimensions of translation, three dimensions of orientation, and one dimension of grasping.
After two days the subject was able to move the robotic arm with her thoughts alone. Over the course of the 13 week study she progressively gained control of the arm and eventually was able to feed herself with the arm. While this is still very far from a “cure” for paralysis or a restoration of full function, for someone who is tetraplegic (all four limbs are paralyzed) having any independent function is a huge improvement in quality of life.
So where are we with this technology?
There are two basic approaches to such brain-machine interfaces – using scalp electrodes or using implanted brain surface electrodes. The advantage of the scalp electrodes is that they are non-invasive. The subject has to just where a cap or helmet of electrodes. There is, however, a significant disadvantage to this approach – the skull and other tissue between the brain and the electrodes significantly impedes the electrical signals from brain activity. This reduces the resolution of the information that can be read from brain activity.Implanted electrodes have much greater resolution in terms of reading brain activity. You can have a greater number of smaller electrodes, like seeing a picture which far smaller pixels and in focus. The huge disadvantage of implanted electrodes is that they are implanted – this is an invasive procedure, with wires exiting the skull to connect to the external computer. The potential for medical complications, therefore, is far greater than for external electrodes. Research, however, seems to be favoring implanted electrodes as the resolution of scalp surface electrodes is just not sufficient.
How much of a limitation this will have on the application of this technology remains to be seen. As you can see from the picture above, the subject has a device connected to the top of her head that connects to the implanted electrodes. This study took place in the lab. They hope to attach the robotic arm to her wheelchair so she can use it outside the lab, but I do wonder what the long term safety is of having implanted electrodes connected to an external device.
There are analogies in other medical technologies. Pacemakers are fully implanted electronic devices that function safely long term. Perhaps implanted electrodes could be fully internal, and communicate to the external device through blue tooth or a similar wireless technology. Then, however (like a pacemaker) the transmitter will have to be self-powered. Advances are being made on batteries and powering small implanted devices so they don’t have to be recharged, so this is plausible, but not yet available. Patient who have ports or other devices implanted that connect to the outside world are at risk of infection. This can be managed, but it does ultimately limit the life expectancy of such devices. Brain infections, however, are extremely serious, and so any such implant will have to be as safe as possible.
Perhaps a permanent brain implant with an external connector can be devised. The signal processor and any external devices could then be plugged or unplugged from the connector (in a way similar to what was portrayed in the movie, The Matrix). In any case, this is a technical hurdle that needs to be solved for such devices to be safe and effective for long term use outside the laboratory setting.
Some advances are incremental and fairly predictable – increased number of electrodes, more sophisticated computer algorithms for control, and more sophisticated robotic designs. Over the last decade these factors have been steadily improving and can be extrapolated from existing technology. It remains to be seen, however, what the limits of this extrapolation are. How many electrodes can we place on the brain for this purpose?
In summary – researchers have already proven the concept of the brain-machine interface, and the technology has already advanced to the point where functional control of a computer or a robotic device is possible. Now it really is just a matter of further refining the technology.
The next step is the machine-brain interface (and of course closing the loop with a brain-machine-brain interface). What this means is providing feedback from an external machine to the brain. This feedback essentially means artificial sensation, such as having sensors on the hand of a robotic arm that can provide feedback as to the strength of the grip. Researchers have been focusing mainly on the proof of concept of such devices, and so far the results have been very encouraging.
Last year researchers published a study in Nature involving implanted electrodes in a monkey subject. The electrodes were on the motor cortex, and the monkey was able to control a virtual robotic arm. In addition they implanted electrodes on the somatosensory cortex and the monkey was also able to learn to distinguish virtual objects by their feel.
There is further research into brain plasticity and the function of making us feel as if we are inside of, own, and control the parts of our body. These sensations, that we take for granted and may not even be aware of, are specific functions of our brains. The brain uses sensory feedback, which it coordinates with motor intention and movement, to create the sensation that we occupy our bodies. Researchers have been able to reliably trick subjects into feeling as if they occupy a virtual body simply by playing with this sensory feedback. Essentially, if you see a body or limb, and you have a physical sensation that correlates with that body being touched, in many cases that is sufficient for your brain’s processing to conclude that you are that body. Further, if that body or limb moves when and how you intend for it to move your brain will create the sensation that you own and control that body part.
What all of this means is that visual and sensory feedback can be coordinated to make the brain’s inherent wiring create the sensation that a person occupies, owns, and controls either a robotic or even a virtual body or limb. Therefore it is theoretically possible for a robotic arm controlled by implanted electrodes to feel as if it is a person’s natural arm – that it is part of them.
The existing research is very encouraging, indicating that brain-machine-brain interface technology should work well and create direct mental control of virtual or physical external devices, including robotic limbs or even an entire robotic body or exoskeleton. We do not yet know the limits of this technology, however. Brain plasticity – the ability to adapt to new inputs and functions – exists and is crucial for this technology, but it is not unlimited.
Where we are now, therefore, is right on the brink of real-world applications for patients of brain-machine interface devices. Further, by simple extrapolation of existing technology and principles, such devices should become incrementally more powerful and sophisticated. Early research is also promising for truly revolutionary applications of this technology, combined with machine-brain interface technology, to provide neuroprosthetics that can potentially replace lost or paralyzed limbs, and many other potential applications. This is one medical technology that may seem like science fiction, but is rapidly entering the realm of reality.

Adding Sensation to Robotic Limbs
Recently scientists have managed to stimulate the brain in such a way that approximated some of the sensations of a natural limb in a paralyzed subject. No, they did not regain sensation, but the research is a powerful proof of concept. It shows that it is possible to produce natural-feeling sensation through electrical stimulation of the cortex, an important step for brain-machine interface research.
Steven Novella on April 11, 2018
Link

The headlines read, “Paralyzed patient feels sensation again.”
My first reaction was, well that’s like saying a blind man can hear again, since “paralysis” refers to the inability to move, not feel. But I knew what they meant – someone who lost both motor control and sensation from an injury was able to regain sensation.
But that is not what happened either. The patient in the study still cannot feel; they have not regained sensation. Rather, the researchers were able to produce sensation by directly stimulating the sensory cortex of the brain. That’s like physically moving the patient’s arm and saying, “Paralyzed patient moves again.”
The misleading headlines aside, this is an exciting, if incremental, advance. That is often the trick of good science communication – conveying the genuine excitement about an important incremental advance without overhyping it or sowing confusion. Science usually advances by baby steps, while headline writers want “breakthroughs.”
Brain-machine interface
So what is the genuinely interesting science here? This is part of research into brain-machine interface (BMI), the quest to control computers and robotic parts with the brain and to provide sensory information back to the brain.
The ultimate goal is what fiction writers envisioned for The Six Million Dollar Man in the 1970s – a prosthetic limb that can look, feel, and function naturally (with or without the super strength). In order to get there, however, we have to know that we can interface with the brain in such a way as to produce all the necessary phenomena.
This is an important and necessary step, and it was not a foregone conclusion that the idea of BMI could even work theoretically. The brain and body developed together, as a unit, and it was feared that adding an artificial piece to that elaborate network would simply not be able to interface effectively.
There has therefore been a lot of BMI research focusing on proof of concept – can we overcome any theoretical barriers? So far (spoiler) the research has shown that brain machine interfaces can work – the brain is plastic enough to adapt to a new interface, without any theoretical limitations.
So far BMI researchers have shown that subjects (monkeys or humans) can learn to control either a computer or a robotic limb with their brains. The brain can form the pathways necessary to produce functional control. How fine that control can be has yet to be determined, but researchers were able to train a monkey to feed itself Cheerios with a robotic arm.
Motor control has turned out to be the easiest aspect of BMI. The primary limitation is the number and size of the electrodes, and how close they are to the appropriate neurons in the brain. At this point the primary limiting factor is the technology of the electrodes.
Sensation has proved a harder nut to crack, but again all the proof-of-concept signs are positive so far. Sensation is more complex because there are different kinds of sensation, not just touch. The brain needs to feel where the limb is in three-dimensional space (proprioception), and needs feedback from the muscles to indicate that they are moving.
Further, the brain needs to process various sensory streams simultaneously to create the sensation of embodiment (that the limb is part of their body), of ownership (that the person owns the limb), and control (that the person controls the limb).
These more complex sensations are important for motor control. Without them the patient has to look at the robotic limb they want to control. With sensory feedback they don’t have to rely solely on vision, and the feedback improves their brain’s ability to control the limb.
Fortunately it is looking like all of these sensations can be produced artificially through BMI. Recently, for example, researchers were able to reproduce kinesthetic feedback of a robotic limb – the sense that the limb was moving, which added to the sense that it was under the patient’s control.
Where does this new study fit into the overall research? The researchers studied a subject with a C5 spinal cord lesion, resulting in paralysis and lack of sensation in all four extremities. They implanted an intracortical microstimulation (ICMS) array in primary somatosensory cortex (S1). They then looked at various types of stimulation (mainly adjusting frequency and amplitude of the electrical current) to see what sensations resulted.
Previously most subjects having their somatosensory cortex stimulated reported sensations of tingling or buzzing – artificial and not very useful sensations. The researchers wanted to know if they could adjust the stimulation in order to produce more natural sensations.
The subject reported:
It was quite interesting…It was a lot of pinching, squeezing, movements, things like that. Hopefully it helps somebody in the future.
The subject felt as if the limb were moving, or squeezing something, or pinching, not just a non-specific buzzing sensation. That is a pretty small advance when you think of the whole BMI research program, but it is also a very important demonstration of proof of concept. It is possible to produce functional, natural-feeling sensations just by shocking the sensory cortex.
In order for this finding to lead to something practical, however, researchers will need to explore the somatosensory cortex in detail, and create a map of how to simulate that cortex in order to produce certain sensations. This may not only have to be done generally but for each individual. That sensory algorithm would then have to be mapped to specific movements of a robotic limb.
This does seem like the hard way to do it, however. It is all top-down, using brute force to mimic sensory feedback which is painstakingly mapped between the artificial limb and the individual’s brain. It could work, but I have to wonder if there could be an easier way, a way for the mapping to be more automatic.
I suppose that is an area of possible future research.
In any case, it is good to know that we can theoretically produce natural-feeling and functional sensations through BMI. Again – so far all the proofs of concept have worked out. There does not seem to any theoretical limitation to our ability to interface machines and the human brain.
We have made many important baby-step advances in this research, and have to make many more. It’s likely that each encouraging but incremental advance will be announced through overhyped and misleading headlines.

Is there a natural treatment for tinnitus?
Scott Gavura on August 27, 2015
Link


“Why do you bother blogging?” asked a colleague. “You take hours of your personal time to write, and you do it for free. You’re not even getting any citations for all that work.” I admit I found the questions a bit surprising. True, you won’t find SBM posts abstracted in PubMed. But I’m writing for an entirely different audience. I blog for the same reason that I became a pharmacist: to help people use medicines more effectively. Practicing as a pharmacist is one way to do that. In that setting, you’re helping one patient at a time. And seeing how your advice and support can enhance someone’s care is tremendously gratifying.
I see blogging as another form of pharmacy practice, hopefully with similar effects. Yes I do get regular hate mail, and the occasional legal threat, but there’s also gratitude for a post that resonated with someone, or helped them make better decisions about their health. When Google searches don’t give answers, I get questions — too many to answer. Today’s post is based on a request for help from someone seeking advice on natural supplements to treat ringing in their ears. They have tinnitus, and they’re frustrated at the limits of what their physician (and medicine) can do. They sent me an advertisement for a supplement called Ear Tone, a natural health product which is advertised (and approved) to provide tinnitus relief. Can natural supplements do what conventional medicine cannot? 
When buying supplements, the deck is stacked against consumers
One of my recurring (and favourite) blog topics is evaluating the evidence supporting dietary supplements. Not only is it an opportunity to look at a specific medical condition, it’s a tool to illustrate how to use a science-based approach to answer medical questions. Supplements are also the perfect subject to illustrate the consequences of weak, ineffective health regulation, and how this approach harms consumers. Nowhere else in medicine is there an area that’s in such need of consumer advocacy and patient protection. While regulations will differ between countries, supplements tend to get a “pass” by most governments. This pass (which is usually in the form of special regulations), usually excludes supplements from the licensing requirements (and evidence standards) that applies to conventional drug products. It will vary somewhat depending on what country you live in, but in countries like the USA and Canada, this is what you’ll find:
    • There are few limits on what can be legally sold as a supplement or natural health product.
    • There are few limits on the health claims that can be made about these products.
    • There are few, if any, requirements to directly test supplements for safety.
    • There are often no requirements to test supplements for actual effectiveness.
    • Pharmacies and other retailers sell supplements alongside regular drug products, without distinguishing them.
The result is a marketplace that is a boon to supplement makers, but puts consumers at a considerable disadvantage. Worse, many health professionals also give supplements a pass, failing to hold them to the same evidence standards as drug products. Pharmacy shelves are becoming the “Wild West” of healthcare, where evidence-supported products are sold alongside those that are either unproven, or even worse, completely ineffective (e.g. homeopathy).
Supplement manufacturers exploit difficult-to-treat conditions, like tinnitus
When medicine can’t deliver an obvious cure, or where a medical condition is poorly understood, you create the breeding ground for alternative medicine remedies. Steven Novella described their characteristics in a past post:
    • conditions that have subjective symptoms (think fake diseases, like adrenal fatigue)
    • conditions that may vary naturally, over time (e.g. supplements to treat fertility concerns; or pain)
    • illnesses with a substantial psychological condition (e.g. anxiety)
Tinnitus is one of those conditions.
Tinnitus is not just a ringing in the ears
Tinnitus is the perception of noise when there is no external cause. While it’s typically thought of as ringing, it can also be perceived as buzzing or hissing. Tinnitus is common, affecting up to 15% of individuals, depending on your age. While rarely serious, tinnitus can significantly interfere with quality of life. Tinnitus can be caused by age, loud noise (from construction equipment to loud music), ear wax blockage, and ear bone changes. (Sixties rock icon Pete Townsend is a famous tinnitus sufferer, which he attributes to years of listening to headphones.) Many medications are associated with tinnitus, as can other medical conditions, such as cardiovascular disease. Consequently, every tinnitus case needs to be medically evaluated, to search for any underlying causes and to rule out more serious medical conditions. In some cases a clear cause for tinnitus cannot be found, and it becomes a chronic condition. Reducing the impact and effects becomes the treatment goal.
The management of tinnitus focuses first on any underlying causes or conditions. While there is no cure, there are medical treatments that can be effective, including:
    • addressing hearing loss with products like hearing aids
    • treating depression or anxiety which may be identified in patients with tinnitus
    • using behavioral therapies such as tinnitus retraining (reducing awareness of the noise), cognitive behavioural therapy, or masking (low-level noise) to drown out the sound
Overall, these therapies are only modestly effective. There is no magic bullet. While numerous vitamins, minerals and supplements have also been tested, there are no studies that suggest that any supplement provides a meaningful improvement.
What is Ear Tone?
Ear Tone is a combination herbal remedy that’s advertised widely and sold in many pharmacies for the treatment of tinnitus. It’s manufactured by New Nordic, a Swedish supplement manufacturer that has been criticized in the past for making misleading claims about its product. The manufacturer makes the following claim:
Ear Tone is a new product that is based on new research, showing significant results in treating tinnitus naturally. Ear Tone works by supplying the ear with the right nutrients while promoting peripheral blood circulation.
According to the manufacturer’s website, each Ear Tone tablet contains:
    • Ginkgo biloba leaf: [50:1]: 100 mg
        ◦ 24 % Flavonoid glycosides
        ◦ 6 % Terpene lactones
    • Magnesium (as magnesium oxide): 532 mg
    • Pinus pinaster (Maritime pine bark): 50 mg
        ◦ labelled as 95 % Proanthocyanidins
The recommended dose is two tablets per day, which gives a monthly cost of about $30.
Do the ingredients in Ear Tone help tinnitus?
The first ingredient, ginkgo, has a long history of use as a natural medicine, but there’s no clear evidence that ginkgo is effective for any medical condition. Presumably included here to enhance blood circulation in the area, studies have shown mixed results for the treatment of vascular disease and while it has been studied specifically for tinnitus, results have been mixed. Overall, there’s no convincing evidence it actually has any meaningful benefit with tinnitus. A Cochrane review concluded the same, noting:
The limited evidence does not demonstrate that Ginkgo biloba is effective for tinnitus when this is the primary complaint.
The second ingredient is magnesium, supplied as magnesium oxide, and according to the manufacturer is included because it “protects the nerves in the inner ear and promotes an electrolyte balance in its hair cells.” While magnesium is an abundant ion in the body, there is no published evidence with magnesium supplements to suggest it protects nerves or promotes electrolyte balance in hair cells. I found a single open-label study of magnesium supplementation and tinnitus published in 2011 that suggested a modest beneficial effect. Given it was neither randomized nor blinded, it’s hard to see this as evidence as efficacy.
The third ingredient is literally the bark from a pine tree, in this case, the Maritime pine. There’s one study with a branded version of pine bark (“Pycnogenol”) that was evaluated in a pilot study for effectiveness against tinnitus. Over four weeks, patients on the supplement were noted to experience an improvement in symptoms as well as cochlear blood flow. It’s not clear if the study was blinded or randomized, however, and the authors note:
More studies should be planned to better evaluate the pathology and potential applications of Pycnogenol in a larger number of patients who are currently without a real therapeutic solution.
There’s also a 2014 study with Pycnogenol which was a registry — a real-world evaluation that concluded the product may offer benefit in Meniere’s disease and tinnitus. This is nonrandomized, uncontrolled, and therefore unconvincing data. Before we can conclude this product offers actual benefits, it needs to be evaluated in prospective, blinded, and controlled trials.
So there’s little evidence Ear Tone works.
What are the risks of gingko and pine bark?
What about risks? There are few case reports of serious harms with ginkgo or with pine bark, but that’s complicated by poor data collection — since there are few trials and only limited real-world surveillance, the long-term safety is unclear. There is the risk that this combination of products could magnify or interfere with the action of drugs that affect blood coagulation. Its possible effects on other drugs are not well understood.
I don’t see enough evidence of effectiveness here to recommend Ear Tone, but ultimately this is a personal decision. Given what we know (and don’t know) about the efficacy and safety, some may decide it’s worth a try, especially if they’re experiencing poor quality of life from tinnitus. If that was my patient’s choice, I’d want to ensure that their other medications had been reviewed for any possible interactions. I’d also encourage any user to try to objectively measure whether or not they experience any relief. From reports online, many have not found it helpful.
Health Canada’s recommendations aren’t based on evidence
Despite the limited evidence suggesting that Ear Tone has any beneficial effects, Health Canada has approved Ear Tone with the following wording:
Recommended Use or Purpose:Helps to reduce the perception of tinnitus in the ears. Helps to support peripheral circulation.
Health Canada has concluded the product is effective despite the fact that there is no published evidence suggesting this particular combination of ingredients has even been formally tested. This is the double-standard for supplements at work — approval from the regulator without the requirement to actually test your product for safety or effectiveness.
What’s the bottom line for consumers with tinnitus?
Tinnitus is an often-chronic condition for which we lack a good understanding of the causes and treatments. While there are some therapies that can help minimize symptoms, there are no cures.
Despite the hype, the anecdotes, and the marketing, there are no supplements for tinnitus that have been shown to offer any meaningful benefit. It would be wonderful if there really were a magic herb (or combination of herbs and minerals, like Ear Tone) that you could grind up, put in capsules or tablets, and expect relief. But that’s not realistic. This doesn’t stop manufacturers from making claims, or regulators like Health Canada from agreeing, that products like Ear Tone are “effective” because they’ve squeaked over a lowered evidence bar for natural health products.
Learning there are no easy solutions or cures for tinnitus can be difficult to accept, especially when tinnitus significantly impairs your quality of life. Supplement marketers know this all too well, and will likely continue to market unproven supplements for tinnitus that lack good evidence of efficacy.

Daniel and Tana Amen’s Book The Brain Warrior’s Way: Standard Health Advice Mixed with Misinformation and Fanciful Ideas
Daniel Amen, the media-savvy psychiatrist and promoter of SPECT scans, has teamed-up with his wife Tana to write a self-help book that hopelessly muddles good medical advice with misinformation and speculation.
Harriet Hall on February 21, 2017
Link
Dr. Daniel Amen has been called the most popular psychiatrist in America. His main claim to fame is the SPECT (Single Photon Emission Computed Tomography) scans he does on all his patients, for everything from poor school performance to alcoholism, and even marriage counselling. They cost thousands of dollars and expose patients to radiation. He tells patients their disease or lifestyle has created visible holes on the scans where the brain should appear smooth, and he believes showing patients the pretty pictures is instrumental in getting them to understand their problems and cooperate with treatment. He runs a commercial empire of clinics, publishing, media appearances, and other endeavors that have made him a multimillionaire. His latest book, co-authored with his wife Tana Amen, is The Brain Warrior’s Way: Ignite Your Energy and Focus, Attack Illness and Aging, Transform Pain into Purpose. The publisher sent me a review copy of the book. I thought it was worthless and I was not planning to write a review; but when I realized PBS was airing the Amens’ infomercials promoting the book, I felt compelled to offer my own assessment.
It is basically a self-help book. It contains some practical advice about weight, diet, exercise, sleep, stress, etc. – all the things we all know impact our health. It uses the concept of “Brain Warrior” to indicate that commitment to a healthy lifestyle is a mindset requiring us to fight and never give up. It recommends expensive SPECT scans to monitor progress. It recommends dietary supplements; avoidance of gluten, GMOs, artificial sweeteners, and whole categories of foods; and much more, none of it supported by credible scientific evidence. It is larded with lumpy brain pictures from SPECT scans purporting to show “Before, more vulnerable” beside “After, healthier, less vulnerable.” Who knows what the pictures really mean? It is also larded with testimonials that don’t really seem to support its thesis. For instance, John decided he needed to lose weight and after losing 50 pounds and exercising he now feels great. Does that make him a Brain Warrior? Did he get a SPECT scan? If he did, did that change anything?
There is a reason there are so many self-help books. They don’t work. They take a few common-sense ideas, over-simplify them, and prescribe a complicated course of action that is time-consuming and difficult to follow. People read them and are initially enthusiastic, but they rarely follow through, soon lose interest, and are in the market for the next self-help book.
Dr. Amen is not science-based
I am not a fan of Dr. Daniel Amen. I first wrote about him on Quackwatch in 2005, “A Skeptical View of SPECT scans and Dr. Daniel Amen.” In 2007, his lawyers complained that my article was unfair and put him in a negative light. I asked a series of pointed questions and they tried to answer them; I showed that their answers were inadequate. I never heard from the lawyers again. I wrote “SPECT Scans at the Amen Clinic: A New Phrenology” on SBM in 2008 and “Dr. Amen’s Love Affair with SPECT Scans” on SBM in 2013. Others have written articles critical of Dr. Amen for reading too much into SPECT scans; Daniel Carlat called the scans “spectacularly meaningless.” Neely Tucker wrote a critical article in The Washington Post. Neurologist Robert Burton criticized Amen in an article on Salon titled “Brain scam.” Burton and I both formally complained to the PBS ombudsman because airing Amen’s infomercials implied that PBS endorsed his claims as good science; the ombudsman responded that the local stations determine programming and airing a program doesn’t imply endorsement by PBS.
Amen’s Wikipedia page says “Amen’s use of SPECT scans to aid in psychiatric and neurological clinical diagnosis is based on unproven claims and has been criticized by psychiatrists and neuroscientists on ethical and safety grounds”
The power of positive thinking
The Brain Warrior’s Way is for people with problems like addiction, depression, memory problems, obesity, cancer, and many others. It is also for anyone who wants to look and feel their best and who wants to excel at work, school, or relationships.
Much of the book sounds like it is channeling Norman Vincent Peale on the power of positive thinking. Reject negative thoughts. Focus on abundance rather than on deprivation. Repeat affirmations like “I will have better focus” or “I can support my immune system so my cancer won’t come back.” [Ha! Lots of luck with that!]
A typical Brain Warrior testimonial: Kyle is a seventh degree black belt in martial arts. He said he just couldn’t give up Pepsi and bread because it was too hard. Tana pointed out that getting a black belt was much harder than deciding not to open a can of Pepsi. By thinking of it that way, he lost 40 pounds and felt happier and stronger.
Another Brain Warrior story: Dr. Amen ate dinner with a friend who was overweight and diabetic, seemed oblivious to what he ordered, and had to inject insulin at the dinner table. Amen told his friend he was worried about him because he was in the obese range of BMI. The “obese” label got his friend’s attention; he proceeded to lose 53 pounds and was able to cut his insulin dose in half. He reported better focus, energy, memory, and sexual ability. No mention of a SPECT scan, and no reason to think he wouldn’t have done just as well if he had listened to his doctor’s advice.
Questionable statements
    • “Food pollution is killing us.”
    • “Mild traumatic brain injuries are a major cause of psychiatric illness.” [No reference given.]
    • “The greatest danger from antibiotics does not come from those prescribed by your doctor, but rather from the foods you eat.” [No reference given.]
    • “Disorders ranging from ADD, autism, depression, and schizophrenia have been connected to intestinal bacteria imbalances that increased gut permeability.” [No references given. This idea is related to the fad diagnosis of “leaky gut,” a hypothetical condition not recognized by mainstream medicine.]
    • “The constant messaging from the alcohol industry has people feeling they must drink two glasses of wine a day to feel healthy.” [Whaaat? I’ve never seen any such messaging.]
    • “One of our closest friends…told us that our service men and women were offered unlimited Baskin Robbins ice cream during lunch and dinner.” [I seriously doubt that.]
“Brain type” nonsense
“Know your brain type.” (balanced, spontaneous, persistent, sensitive, cautious, and combinations of those, like spontaneous-persistent-sensitive, for a total of 16 types). You can visit the website for a questionnaire as well as specific suggestions to help each type. Amen is big on classifications. He has written about 7 types of ADD, 7 types of anxiety and depression, 6 types of addictions, and 5 types of overeaters. He claims each type requires a different treatment plan. He just made all those types up; they are not recognized by other psychiatrists or scientists.
He also offers a computerized neuropsychological test called Brain Fit WebNeuro that assesses how your brain works in 14 specific areas, scoring each on a scale of 1-10. I took the test, but didn’t get my results because that requires signing up for an account and accepting a barrage of e-mails. It claims to measure things like motor coordination, processing speed, and ability to read faces, but it relies on subjective answers to questions that have nothing to do with those skills. The test has not been validated and is not used elsewhere. In my opinion, the results of such a test are meaningless.
Supplements
The Amens say everyone should take these three essential supplements: multivitamins, omega-3 fatty acids, and vitamin D. That goes way beyond the evidence. They even claim that people who take a multiple vitamin have “younger looking DNA.” [No reference given.] They say researchers at Harvard found that a low level of omega-3 fatty acids is one of the leading preventable causes of death. [Again, no reference given. I think they are talking about this study, which was far from definitive and does not address whether there is any benefit from supplements.]
For most patients, they also recommend gingko, vinpocetine, probiotics, apha lipoic acid, vitamins B, C, and D, huperzine A, choline, phosphatidylserine, and N-acetyl-cysteine. They admit these individual supplements have not worked in large studies, but they think they know how to use smart combinations of supplements effectively to address multiple mechanisms including inflammation, blood flow, blood sugar stabilization, antioxidant support, and nutrient loading. I don’t think they know what they think they know.
Nutrition advice
Diet: 70% plant-based, 30 % high quality protein, with healthy fat mixed in. OK.
Nutrition principles:
     1.  Focus on high-quality calories. [OK]
     2.  Drink plenty of water, half your body weight in ounces (80 ounces of water daily if you weigh 160 pounds). Tana starts the day with 16 oz. warm water with lemon and ginger, which is “cleansing and alkalinizing.” [There’s no evidence to support drinking that much water, or to show a benefit of “cleansing and alkalinizing”]
     3.  Eat high-quality protein in small doses throughout the day. [High quality protein is good, but the evidence doesn’t support the recommendation for small doses throughout the day]
     4.  Eat smart carbohydrates (low glycemic, high fiber). [Makes sense, fills you up so you’re less hungry]
     5.  Focus on healthy fats. [OK]
     6.  Eat from the rainbow. [Colorful foods tend to be healthy, but the Amens’ claims go beyond the evidence, especially when they claim that certain nutrients in colorful foods “aid in detoxification”; Detoxification is an alternative medicine buzzword]
     7.  Cook with brain-healthy herbs and spices. [They go way beyond the evidence here, claiming miraculous benefits from things like turmeric, which was pretty well debunked by a recent systematic review]
     8.  Make sure your food is as clean as possible. Organic, antibiotic-free, hormone-free, pesticide-free, chemical-free, foods that don’t promote inflammation. [More alt-med buzzwords]
     9.  Eliminate any potential allergens or internal attackers like gluten. They say there are scientific reports of people having psychotic episodes when they ingest gluten. [Not supported by any of the three references they give; the referenced studies only show an association of celiac disease with certain mental disorders but do not establish causation]
     10.  Eat healthy during the day, but fast 12 hours at night. [The value of 12-hour fasting has not been established]
They provide a list of 100 best brain-healthy super foods. [There’s no such thing as a super food.] They say certain foods are “clearly weapons of mass destruction” and say we should limit or avoid these altogether: sugar, artificial sweeteners, gluten, soy, corn, and dairy. They say grains turn to sugar in the body and cause obesity, heart disease, diabetes, and cancer.
Demonizing sugar and artificial sweeteners
They recommend avoiding all forms of sugar. They repeat the claims of Robert Lustig that sugar is addictive and “is the PRIMARY cause of obesity, hypertension, heart disease, cholesterol problems, and diabetes – all of which cause brain damage.” They cite a study showing that sugar had the same negative impact on your cells as cigarettes, and was associated with accelerated aging. That’s not what the study showed. It showed a correlation between sugar-sweetened sodas and shorter telomeres, but it also showed a correlation between fruit juices and longer telomeres. Yet the Amens proscribe all fruit juices. They repeat the popular calumnies about the alleged dangers of artificial sweeteners, which have been clearly debunked by the published evidence.
Demonizing gluten
They say gluten-free diets have led to reduction, even full remission, of symptoms in a subset of schizophrenic patients. Again, that’s not what their reference says. It reports an increased incidence of celiac disease in schizophrenics, and improvement (but not full remission) of symptoms when wheat was eliminated from the diet. And the reference points out that other studies had failed to replicate these results. It suggests that individualized dietary modification “might” be a useful adjunct to anti-psychotic medications in a minority of patients.
Other advice
“Avoid anything that hurts your brain.” And there are a lot of those, from smoking to alcohol, from poor decisions to fruit juice(?!), from gadget addiction to unhealthy peer groups.
They make the standard recommendations for sleep hygiene, but add lavender.
“Get key laboratory tests.” CBC, general metabolic panel with fasting blood sugar and lipid panel, Hgb A1C, vitamin D, thyroid panel, C-reactive protein, homocysteine, ferritin, free and total serum testosterone, estrogen and progesterone. Most of these are not indicated as screening tests, and doing unnecessary lab tests is likely to do more harm than good.
They recommend The Great Cholesterol Myth by Steve Sinatra and Jonny Bowden, cholesterol denialists.
They say “Used properly, music is medicine.” They say a brain enhancement playlist will enhance creativity, mood, memory, gratitude, energy, focus, motivation and inspiration. They even suggest specific pieces of music.
They ask readers to keep a detailed journal, helpfully providing pages of elaborate templates with places to record “Things I am grateful for today,” “Read my One Page Miracle,” “Start the day with 16-20 oz. of water,” a list of brain-enhancing foods eaten, ratings of mood, energy, memory, inner peace, etc. on a scale of 1-10, and much more. They list a sample day’s menu, but don’t include recipes. You have to buy a separate book for that, The Brain Warrior’s Way Cookbook.
Conclusion: nothing to see here, move on
There’s nothing new here. Most people already know what they should do to stay healthy: avoid tobacco, control weight, eat a nutritious diet, exercise, avoid stress, get adequate sleep, etc. If thinking of yourself as a warrior helps motivate you to lead a healthy lifestyle, I guess that’s a good thing. If looking at a SPECT scan of your brain frightens you or reassures you, I guess that might help Dr. Amen enlist your cooperation with his treatment plan, but I don’t think it’s worth thousands of dollars and exposing yourself to radiation just to find out something you could have learned without a scan.
Much of the advice in this book is mainstream medical advice, and there are helpful practical hints like putting your food on a smaller plate and not shopping for food when you are hungry. The problem is that the good advice is inextricably mixed with false information and misleading statements, and with detailed recommendations that are not supported by science. I cannot recommend this book.

Mind Over Matter: The Brain’s Way of Healing
Harriet Hall on March 10, 2015
Link
In 2008 I wrote about neuroplasticity as presented in Norman Doidge’s book The Brain That Changes Itself. I urge you to click on the link and read what I wrote there before you continue. The science is fascinating. The brain is far more malleable than we once thought. Areas of the cortex devoted to a sensory input shrink when that input is lost. Neurons from other parts of the brain can be co-opted to take over lost functions. Learning a new skill actually changes the structure and function of the brain: the areas of the cortex devoted to that skill enlarge as the new skill is practiced and perfected.
This is exciting stuff, with potential therapeutic applications in chronic pain, brain damage, and chronic illness. When I reviewed that book, I said I thought Doidge was a bit overenthusiastic; and now he has written a follow-up book that is even more overenthusiastic. In The Brain’s Way of Healing: Stories of Remarkable Recoveries from the Frontiers of Neuroplasticity, he slips into unscientific speculations and relies on anecdotes about patients who have allegedly benefited from practical applications of brain plasticity science. The title is accurate: these are stories, not scientific studies. I continue to find the subject fascinating and to believe that neuroplasticity offers a lot of potential for human healing, but I don’t believe we have learned much about practical ways to accomplish that. Doidge’s book goes beyond the science.
A review in The Guardian says:
Can Parkinson’s be cured by walking, or blindness by “higher judo”? These cures and their emphasis on the patient’s willpower and moral fibre are, at best, bizarre.
A few of the stories
    • A doctor conquered chronic pain by flooding his brain with non-pain stimuli and visualizing brain maps and imagining the areas devoted to pain shrinking.
    • An elderly Parkinson’s patient reversed his worst symptoms with an intensive fast walking program and a special kind of concentration and was able to stop his medication. He had to keep up the exercise to maintain the improvement, which suggests to me that the brain had not re-wired itself very well.
    • A man blind from uveitis stopped all his medications and learned to see again by visualizing (imagining) a blue-black field and doing various exercises.
    • A man with MS used a Portable Neuromodulation Stimulator (PoNS) to stimulate the tongue; it restored his ability to sing and to walk without a cane.
    • A dyslexic boy listened to Mozart and to recordings of his mother’s voice and is now at the top of his class.
The therapies
Doidge is impressed by a number of questionable therapies that have not impressed mainstream scientists.
He tells us light is essential to health. The ancient Chinese knew that each organ system has times of day when it is most and least active, presumably responding to natural light exposure. He says light speeds healing, decreases pain, improves sleep, improves vitamin D levels, and may even decrease cancer risk. He complains that people in our modern world are deprived of natural light and its benefits. He thinks light therapy could repair sick brain cells and make them more receptive to re-wiring.
He sings the praises of low-level laser therapy, which supposedly works by helping the body “marshal its own energy and its own cellular resources to heal itself with no side effects.” He describes near-miraculous successes of laser therapy in healing all kinds of health problems, from wounds to depression. Stephen Barrett of Quackwatch is far less enthusiastic. His skeptical look at low level laser therapy agrees with systematic reviews and health insurance company evaluations and concludes:
At this writing [Feb 2015], the bottom line appears to be that LLLT devices may bring about temporary relief of some types of pain, but there’s no reason to believe that they will influence the course of any ailment or are more effective than other forms of heat delivery.
Doidge praises Feldenkrais’ “holistic insights” about body awareness and his Functional Integration therapy, a somatic educational system. A 2005 systematic review concluded:
The evidence for the Feldenkrais Method is encouraging but, due to the paucity and low quality of studies, by no means compelling.
He calls the tongue “the royal road to the brain” and believes the PoNS tongue stimulator resets the brain and effectively treats MS, stroke, Parkinson’s disease, brain damage from traumatic brain injury, and other conditions.
He praises the Bates system of improving visual acuity with eye exercises, although the American Academy of Ophthalmology and other reviewers have never found evidence that it worked.
He is convinced that the Tomatis method can correct a variety of ailments by stimulating hearing and re-training the brain. That method is controversial, to say the least.
He recommends Matrix Repatterning as a first treatment for patients with head injuries because “if the general flow of energy is blocked, the other treatments may not work nearly as well.” Matrix Repatterning is a hands-on approach developed by a chiropractor/naturopath. It has been claimed to eliminate various kinds of pain and improve a wide variety of other symptoms from erectile dysfunction to snoring; it is supported by testimonials but has never been studied scientifically.
He disparages reductionist Western science and advocates a more holistic, more Eastern approach.
An insight into chronic pain
The part I found most intriguing was the possibility of preventing the development of chronic pain syndromes. Since “nerves that fire together wire together,” experiencing continued pain makes it easier for pain impulses to travel down the pain pathways, so that eventually a small stimulus can cause a large pain. Doidge tells about a pain specialist doctor who is injured and demands a higher dose of morphine than they normally use because of his understanding that adequate early pain relief after an injury ought to help prevent the sensitization of those pathways and reduce the risk of developing chronic pain. Patients with chronic pain have altered brain anatomy: they have been re-wired in a way that exaggerates pain perception and perpetuates the experience of pain (central sensitization). Recognition of this phenomenon might shed light on chronic back pain, on reactions to stress, and on some of those ill-defined painful syndromes like CFS (or SEID) and fibromyalgia. It’s easy to understand how it might be involved in PTSD: the neural circuits that learned to respond appropriately to the sound of gunfire in a war zone produce an inappropriate overreaction to a car backfiring in civilian life.
Treatment to “re-train” those neural pathways would be a welcome addition to the medical toolbox, but I don’t think we have a good handle on how to do that yet.
Caveats
He disparages the reductionism of Western science and tries to conflate neuroplasticity science with ancient Eastern philosophies. His thinking is a bit fuzzy.
I think Doidge is far too gullible about claims for questionable methods to re-wire the brain. He wants them to be true, and confirmation bias kicks in. The methods he recommends have not been adequately tested.
The idea that you can re-wire your own brain is a double-edged sword. It offers hope and empowerment, the sense that you can control your own destiny. But it lends itself to blaming the victim if the treatment is unsuccessful, suggesting the patient didn’t try hard enough. And it comes perilously close to New Age mind-over-matter create-your-own reality woo-woo.
In a sense, the new knowledge about brain plasticity only provides a sophisticated scientific explanation for two simple things we always knew:
     1.  Practice makes perfect.
     2.  Habits are hard to break.
I remember a man who told his children “Do you want to be happy when you grow up? Well, start practicing today!” Words of wisdom.
Conclusion
Brain plasticity is a fascinating field for research, and has great therapeutic potential; but I am skeptical about all the alleged therapeutic achievements in the cases Doidge describes. I applaud his enthusiasm, his passion for his subject, and his desire to help suffering patients; but I think he is holding out false hopes that promise more than is justified by the current evidence. He is recommending some very questionable treatments and he’s asking for a great commitment of time and effort (and sometimes money!) that might not do the patient any good. He’s on the right track, but he’s galloping ahead of the studies that must be done to validate the treatment hypotheses. I await those studies with the greatest interest.

The Limits of Neuroplasticity
Steven Novella on January 8, 2014
Link
I am daily annoyed by overhyped headlines reporting medical and other science news. I think news outlets and the public would be better served if they fired all their headline writers and let the authors and editors craft headlines that actually reflect the story. Of course, often the story is overhyped as well, so this would not be a panacea to annoying science reporting.
Take this headline from The Week (please): “This pill could give your brain the learning powers of a 7-year-old“. The article discusses a recent study (full article here) looking at the effects of a drug, valproic acid, on the ability of young adult male subjects to learn pitch. It might be a good exercise for regular SBM readers to take a look at the full article now and analyze the strengths and weaknesses of the study.
The study found that those subjects taking valproic acid, which is a drug used to treat seizures, migraines, and mood disorders, did slightly better overall in learning to identify the pitch of various tones. The main limitation of the study is that it is very small – 24 participants enrolled, 18 completed. Further, they did not establish a good baseline performance, as the subjects were practicing as they went along.
There are other limitations but these are enough to classify this study as preliminary. It’s an exploratory study that should only be used to decide upon later studies. In my opinion, it should not be reported to the public at all – or if it is, it should be made abundantly clear that these results are so preliminary we cannot conclude anything from them.
If the effect is real, however, what could it mean? It does not mean valproic acid gives you the learning ability of a 7 year old. Perfect pitch is being used as a research paradigm to look at learning windows – periods of time where people have a much greater ability to learn some skill or ability (language, or perfect pitch, for example), and also where later that window closes and learning that skill becomes much more difficult. Researchers are trying to figure out the neurological mechanism of such windows.
If valproic acid has some effect on such learning, it might provide a clue as to the underlying mechanism. The authors of this study conclude:
In sum, our study is the first to show a change in AP with any kind of drug treatment. The finding that VPA can restore plasticity in a fundamental perceptual system in adulthood provides compelling evidence that one of the modes of action for VPA in psychiatric treatment may be to facilitate reorganization and rewiring of otherwise firmly established pathways in the brain and its epigenome
I think they are overstating their conclusions. I would have thrown in at least a “possibly” in there, given the extremely preliminary nature of their results. But again, assuming the results hold up, it is reasonable to speculate about mechanisms.
I would also note that valproic acid is a serious drug with serious side effect, including sedation, weight gain, and foggy mentation. As an anti-seizure drug it also carries the possibility of withdrawal seizures if stopped suddenly. I doubt it would have a net cognitive benefit if taken regularly, which is another reason why I am suspicious of the findings of this study.
This is exactly why I am concerned about the hyped reporting of such preliminary studies to the general public. If this were a supplement rather than a prescribed drug, you bet you would be hearing about it on Dr. Oz, and products would be popping up on health food store shelves.

Neuroplasticity Nonsense Is Full of Red Flags
Adora Winquist offers advice about neuroplasticity, but hers is not the language of science or reality.
Harriet Hall on October 11, 2022
Link

Neuroplasticity is real and is being used in rehabilitation. We have learned that the adult brain can grow new neurons and the brain can be re-wired to function in new ways. In a recent email I was offered an interview with Adora Winquist to learn about neuroplasticity. I declined. There were red flags galore in the invitation and on Winquist’s website, and I realized I could not learn anything useful about the science of neuroplasticity from her.
Her top 5 tips to optimize neuroplasticity are essential oils, meditation, diet, exercise, and music. There is some evidence that some of these can enhance neuroplasticity, but nowhere does she mention evidence or science. She has a new book out: Detox, Nourish, Activate: Plant and Vibrational Medicine for Energy, Mood, and Love. There are already two alternative medicine buzzwords in that title, detox and vibrational medicine, but it gets worse. Adora has managed to pack in an incredible number of red flags. As the Nobel Prizes are being announced, she deserves some kind of prize too, for the most prolific use of the red flags that signal alternative medicine nonsense.
She is the founder of The Soul Institute, an innovator in the field of aromatherapy and energy medicine, and “a visionary in the nascent field of Quantum Alchemy, an evolutionary transformative path for self-mastery which facilitates healing at the DNA level using an amalgamation of plant and vibrational modalities”. Her initial product line, Rhiamon Energy Essentials, was one of the first to combine aromatherapy and energy healing. She went on to create ADORAtherapy, an award-winning aromatherapy brand. She supports women in the awakening journey of the Divine Feminine. She teaches veterans to make their own medicines with herbs, essential oils, and mindfulness techniques. She is a modern alchemist and an expert on crystals. She created Aromatic Neural Repatterning (ANR) to rewire the brain to expect positive experiences.
She makes a number of questionable claims without providing any evidence.
    • Eating blueberries will soak up toxins and can maintain and even grow new brain cells.
    • Tension and stress can rip apart the neurons and release toxins that damage synapses.
    • If you listen to your favorite concerto for 10 minutes a day for a week, you will notice changes in your mental and emotional outlook and response.
    • There are “superfoods” such as turmeric and Goji.
    • Essential oils hold a full spectrum of vibration and sacred geometry.
    • Essential oils are a most potent form of alchemy, encoded with ancient earthly and cosmic frequencies that clear, awaken, align, and activate our innate healing ability throughout the DNA.
    • They work synergistically and holographically with the nervous system to clear trauma.
    • There is an auric field.
    • Eucalyptus oil carries the vibrations of expansion and freedom. It is one of the best oils to clear stagnant energy and emotions.
That’s not the language of science or reality. It’s more than enough to convince any thinking person that she lives outside the universe of science and in a world of fantasy, wishful thinking, and wild imagination. She didn’t hit every possible red flag, but she managed to hit a great many. I advocate science-based medicine, so her only interest to me is as a bad example. If understanding what science-based medicine ISN’T can help people understand what it IS, her example may be useful. She represents the epitome of non-science-based medicine. I wonder if she even knows what science means.
Conclusion: Adora Winquist’s vision of neuroplasticity is not reliable
You may call it fantasy, imagination, or wishful thinking. Whatever it is, it has nothing to do with evidence or science and can’t be trusted.

Stem Cell Stroke Therapy
Steven Novella on September 17, 2025
Link
We have written quite a bit about fraudulent stem cell clinics. They have followed a typical pattern of overhyping new potential therapies, with some clinics going as far as selling fake stem cell treatments. Stem cells were a likely target – they sound extremely advanced, their potential is easy to understand, and you can use them to justify extreme claims of healing.
However, premature hype does not mean a technology will never mature. We often have to balance our criticism of the hype with enthusiasm for the technology itself, but tempered by patience and caution. There is often a 20 year or more delay between the basic science indicating a new potential treatment and seeing that treatment in the clinic. This is why when a new high-tech medical treatment gets approval, I often check to see when the first basic science discovery was made. A 20-30 year gap is typical. (CRISPR is one notable exception, with faster than typical progress to actual therapeutics.)
It has been over 20 years since the stem cell hype hit the public – so how are we doing? As you will see, we are making progress, and getting significantly closer to actual treatments. Stem cell treatments have proven tricky, however. It is difficult to get the stem cells to do what we want, and to not do things we don’t want (like form tumors). The holy grail of stem cell therapy is to be able to inject stem cells into a failing or damaged organ, and have the cells go about repairing and regenerating (and perhaps even rejuvenating) that organ, partly by actually replacing damaged or diseased cells. That goal has proven elusive (other than bone marrow transplant-based treatments).
A recent study, however, perhaps shows a light at the end of the tunnel. This is a mouse study, so that right there should tell you where we are in the research. That puts us still another decade at least from an approved treatment. The researchers took induced pluripotent stem cells (iPSPs) made from human blood cells. They turned these into neural progenitor cells (NPCs). They then injected them into the damaged brains of mice with induced strokes. This group was compared to other mice who had a stroke and were given sham surgery but no stem cells. The results were encouraging.
The NPCs survived, differentiated into neurons, and were functional. They mostly turned into GABA (a type of neurotransmitter) producing neurons, which is interesting because GABA neurons seem to play a role in recovery from stroke. These neurons made connections and were apparently functional. Further, the stem cells contributed to multiple mechanisms of repair – growing new blood vessels, repairing the blood brain barrier, and reducing inflammation.
None of this really matters, however, unless the mice experienced some functional recovery. This can be difficulty to assess in mice, so the researcher employed some AI to help them assess their function. They found that the treatment mice had improved motor function after five weeks – so the treatments produced both structural and functional improvement, persisting for at least five weeks.
The study had a couple of limitations worth pointing out. They did not determine that the neurons made functional connections to other neurons. They did project axons, but we don’t know if they did anything useful. Also, the mice used in the study were immunocompromised. This was done to limit rejection of the xenografts. In humans, allografts or autografts could be used (so not cells from another species, but probably from another person), and so it remains to be seen if an immunocompetent host will receive the grafts.
Still, this is a nice incremental step in the direction of stem cell treatments to enhance recovery after stroke. We have made incredible advanced in the basic technology of stem cells, from 2000 when they first came to public attention. We can take adult cells (like skin or blood cells), and make them into pluripotent stem cells, and then direct them to differentiate into the desired type of cell. This is amazing technology, and there was no guarantee 25 years ago that we would be able to do this.
But the clinical applications have proven trickier than we hoped, so any advance is welcome. We may still be 10-20 years from stem cell therapy for strokes in humans. That would mean 30 plus years from hype to treatment, which is a typical timeframe for a cutting edge treatment. That is at odds with our media-saturated, overhyped, and immediate gratification culture.
    • 

The Bobath Concept for Cerebral Palsy and Stroke Rehabilitation
The Bobath approach, also known as Neurodevelopmental Treatment (NDT) is widely used for cerebral palsy and stroke rehabilitation, but it’s not supported by good evidence.
Harriet Hall on October 18, 2022
Link

In the US, the Bobath Concept is known as Neurodevelopmental Treatment (NDT). Patients with cerebral palsy, stroke, and other central nervous system pathology have dysfunction in posture and movement resulting in limitations of functional activity. The Bobath approach is individualized and continues to evolve. It is based on the brain’s neuroplasticity and is multidisciplinary, involving physical therapy, occupational therapy, and speech and language therapy.
Cerebral palsy
A 2013 systematic review of systematic reviews concluded “Consequently, there are no circumstances where any of the aims of NDT could not be achieved by a more effective treatment. Thus, on the grounds of wanting to do the best for children with CP, it is hard to rationalize a continued place for traditional NDT within clinical care”. They consequently recommended “ceasing provision of the ever-popular NDT”.
A systematic review in 2019 found:
…the effects of neurodevelopmental treatment for children with cerebral palsy are still uncertain. Further studies are required to assess the efficacy and safety of neurodevelopmental treatment for this purpose and until there, current evidence do not support its routinely use in practice.
Small studies have supported it. A small study in 2020 found the Bobath technique more effective than conventional therapy for treatment of cerebral palsy. A small study in 2022 found a correlation between trunk control and oral motor functions in children with CP, with improvement of feeding and swallowing activities.
A protocol for a Cochrane review published in 2015 was developed because “there is no evidence that NDT can promote functional improvement of children with cerebral palsy”.
Stroke rehabilitation
A systematic review from 2009 published in the journal Stroke compared the effectiveness of Bobath therapy to conventional treatments for stroke and found no evidence of the superiority of Bobath therapy over other treatments for stroke for sensorimotor control of the upper and lower limb, dexterity, mobility, ADL, HRQOL, and cost-effectiveness. It found methodological shortcomings in the studies reviewed and called for more research.
Current status
The Bobath approach is widely used for stroke and cerebral palsy, despite the lack of good evidence for its efficacy. The Neuro-Developmental Treatment Association (NDTA) continues to offer certification in NDT. Some European countries consider the Bobath approach obsolete and no longer teach it.
Conclusion
The Bobath approach seemed promising, offering practical, individualized, multidisciplinary interventions to improve function in cerebral palsy and stroke rehabilitation. But the evidence from scientific studies has not validated its superiority over other treatments. More high-quality research is needed.

Mirror Neurons and the Pitfalls of Brain Research
Harriet Hall on October 27, 2014
Link

[Ed. Note: I realize that I normally post on Monday, but thanks to an R21 grant deadline tomorrow, I will not be able to post new material today (although you might have noticed some “familiar” material posted yesterday.) Harriet has graciously agreed to cover for me today, and we have a special guest post for you tomorrow. Fear not. I’ll soon be back. Trying to get the lab funded takes momentary precedence.]
In his new book The Myth of Mirror Neurons: The Real Neuroscience of Communication and Cognition , Gregory Hickok, a professor of cognitive science, challenges current conceptions about mirror neurons. He shows how a complex mythology arose and why it is unwarranted, how experimental results were misinterpreted and disconfirming evidence ignored, and how other interpretations might lead to better insights about how the brain works.
I couldn’t say it any better than Steven Pinker did on the jacket blurb:
Every now and again an idea from science escapes from the lab and takes on a life of its own as an explanation for all mysteries, a validation of our deepest yearnings, and irresistible bait for journalists and humanities scholars…Hickok puts an end to this monkey business by showing that mirror neurons do not, in fact, explain language, empathy, society, and world peace. But this is not a negative exposé—the reader of this book will learn a great deal of the contemporary sciences of language, mind, and brain, and will find that the reality is more exciting than the mythology.
The discovery of mirror neurons: the facts
Mirror neurons were discovered serendipitously during a study of macaque monkeys where researchers were recording the activity of individual brain cells. They found single cells that fired when the monkey grasped an object. Then they happened to notice something they hadn’t expected: the cells also fired as the monkey observed the experimenter grasping an object to set up the next trial.
In all, they recorded data from 184 neurons in the F5 motor area of the brain. Almost all of them fired when the monkey performed some kind of action, just as would be expected from cells in the motor cortex. But 87 of these also responded to some type of visual stimuli: 48 responded to seeing objects and 39 responded to seeing actions; of these, 12 neurons responded most strongly when the monkey grasped an object and also when it observed the researcher performing the same action.
Their initial interpretation: one of the functions of that part of the brain is to retrieve appropriate motor acts in response to sensory stimuli. Monkeys have rich social interactions, so it makes sense that the brain has a mechanism for communicating information about perceived actions of others to motor areas that code self-actions for execution. So far, so good. But they went on to suggest that their findings might have implications for two areas of human research that seemed to show a similar observation/execution correspondence:
    • Limb apraxia, where patients unable to perform an action had been reported to have deficits in understanding the limb gestures of others
    • The motor theory of speech perception, the idea that we perceive speech by reconstructing the motor gestures that generated those sounds
Hickok suggests that the experimental setup had trained the monkeys to associate their own grasp with a reward, and to associate the grasp of the researcher with an upcoming new reward. What the researchers had observed might be merely a reflection of how the brain stores, organizes, and retrieves memories and learned motor patterns. They could have been seeing a generalized phenomenon of association rather than anything mirror-like. If so, the association process itself would be a more promising area for further research.
The findings in monkeys were replicated, but they have never been replicated in humans. Researchers assumed that humans also had a mirror neuron system, but that assumption is supported only by indirect evidence from transcranial magnetic stimulation studies, PET scans, and the observation that patients with damage to Broca’s area had pantomime recognition defects. Hickok points out that those findings are not enough to prove that humans have mirror neurons, and that they might well have non-mirror explanations.
Beyond the facts
Speculation soon ran amok and mirror neurons became wildly popular. Hickok says the idea was seductive because of three factors:
    • You could explain it in one line: “we understand action because the motor representation of that action is activated in our brain.”
    • It promised to bring this simplicity of explanation to many complex problems
    • It was grounded in hardcore animal neurophysiology, providing a neural mechanism for human cognition and revealing an evolutionary pathway.
Mirror neuron research studies proliferated. Mirror neurons were soon implicated in everything from contagious yawning to autism. Hickok lists 37 areas of mirror neuron research and provides citations. I won’t copy the whole list, but it includes schizophrenia, sexual orientation, cigarette smoking, political attitudes, felt presence, the degree of male erection, spectator sport appreciation, drug abuse, and “misattribution of anger in the music of avant-garde jazz saxophonists.” It’s an astonishing body of speculation to have developed from an interpretation of those 12 original macaque neurons, an interpretation that Hickok thinks was probably wrong.
Inconsistencies
He describes a number of anomalies that are inconsistent with mirror neuron theory. You’ll have to read the book for the details, but I’ll just mention one of his points that made me laugh. When a man sees someone kicking another man in the balls, it doesn’t prompt him to mirror the kicking behavior; it prompts him to display a very different behavior, to cringe and protect his own groin. Hickok acknowledges that anomalies don’t necessarily prove a theory wrong, but in this case the sheer number of anomalies is cause for concern and should lead us to explore alternative explanations.
To give one example, mirror neurons seemed to provide a convenient explanation for autism. Autistics appear to lack the ability to understand the goals and intentions of others, to read their emotions, to empathize, and to share attention with others. It is said that they lack a “theory of mind” because of a deficit in mirror neurons. But there is really no good evidence that mirror neurons have anything to do with these abilities, and autistics don’t behave as the mirror theory would predict. There is a false-belief test where children are asked to predict where another person will look for an object when only the child knows it has been moved. Young children who can’t pass the false-belief test lack the ability to understand what is going on in another person’s mind, but they don’t behave as if they are autistic.
Hickok favors another hypothesis: that autism is not a matter of deficits at all, but of hypersensitivity to sensory inputs. This concept has been called “the intense world syndrome.” Maybe they don’t pay attention to human faces because it is painful for them to be flooded with the associated emotional sensations. Maybe the repetitive behaviors, fixations, and other features of autism are protective measures to numb them against the onslaught of overwhelming sensory input. This tallies with Temple Grandin’s invention of an apparatus to squeeze her body to calm her when she felt anxious and overstimulated.
Instead of claiming that he understands autism, Hickok merely proposes a hypothesis for investigation. Perhaps the best thing in the book is this sentence: “I remain a skeptic, even of my own ideas.” The words of a true scientist!
Pitfalls in brain research
The case of autism brings up a point that applies across the board: we must be careful when making inferences about behavior. If an autistic person doesn’t appear to recognize emotions in others, that doesn’t necessarily mean that he can’t recognize them. We can observe a behavior, but we shouldn’t be hasty about assuming we know why the behavior occurs. If a person doesn’t drink milk, we might infer that he doesn’t like it; but it might be that he loves milk but is lactose intolerant. Similarly, when a part of the brain lights up on a PET scan, it indicates increased metabolic activity, but the neurons might be more active because they are working to suppress a response rather than to augment it. Hickok shows in detail how the research on mirror neurons may have gone astray because of false assumptions and jumping to unwarranted conclusions.
Conclusion
The Myth of Mirror Neurons is a fascinating, game-changing book. It explains the details of research studies and its reasoning is thoroughly backed up by citations from the scientific literature. It is not an easy read; some of the concepts are hard to grasp at first, especially for those not familiar with the relevant literature and the terminology. But it offers a valuable lesson in how scientists can be led down the wrong path and how errors can be compounded. It shows how important it is to make sure research data justify the conclusions, to search rigorously for disconfirming evidence, and to make sure alternative explanations have been considered and adequately ruled out. The book accomplishes two goals: it sheds serious doubt on almost everything that has been written about mirror neurons, and it describes cutting edge neuroscience research that may eventually lead us to a better understanding of how communication and cognition really work. No real answers, but plenty of questions. And after all, one of the most important things in science is knowing which questions to ask.

Debunking Sleep Myths
Dispelling common sleep myths is the first step to improving one’s sleep.
Steven Novella on April 17, 2019
Link

It’s always good to see mainstream scientists directly addressing common myths and misconceptions about their specialty. This is especially true in medicine, because of the potential direct consequences of misinformation.
In the current issue of Sleep Health, sleep researchers surveyed websites to find 20 common sleep beliefs, and then did a literature review to find out how backed they were by published evidence. They address these common myths, and also point out questions that are still unresolved in the literature. Here are a few of the more important highlights, with some of my own experience as a physician thrown in.
In recent years, at least within my specialty of neurology, sleep difficulty has been increasingly recognized as comorbid with many of the conditions we treat. Asking patients about their sleep is now (or at least should be) routine. This is especially important because patients often do not even think about sleep as medically relevant. In my experience patients rarely volunteer information about their sleep when asked open-ended questions about their health, any problems they may be having, or anything that might influence whatever neurological problem I am seeing them for. But when I ask directly about sleep, they may tell me that their sleep is horrible and definitely worsens their symptoms. This leads me to suspect that many people just don’t see sleep as a medical issue they should discuss with their doctor, and why it is therefore so important to ask directly.
Perhaps some of the common myths exposed in this study also contribute to this phenomenon. For example, one common myth is that, “Many adults need only 5 or less hours of sleep for general health”. This is critical because some patients may only be getting 3-5 hours of sleep a night, but not perceive this as necessarily a problem. Or they nap during the day or on weekends and think this makes up for it. Perhaps their work and childcare schedule only allows for this duration of sleep and they feel they have no choice.
The reality is that chronic even mild to moderate sleep deprivation is a huge health risk factor. Chronic sleep deprivation becomes the new normal for some people and they don’t realize what an impact it is having. Often they will complain to me about symptoms of chronic sleep deprivation (poor memory, fatigue, weight gain, even excessive daytime sleepiness) and yet not connect these symptoms to their chronic poor sleep.
In reality everyone should get at least 7 hours of sleep per night. Ideally these hours should be continuous, and not interrupted or broken up throughout the day. The timing of sleep should also be as consistent as possible, to keep your brain in a 24 hour circadian rhythm.
The basic recommendations to achieve this are – no electronic devices in bed, low light is better prior to sleep to prepare the brain for sleep, get physical activity and sunlight during the day, avoid eating or drinking right before going to bed, empty your bladder before getting into bed, and address any physical symptoms that might be interfering with sleep onset or maintenance. There is more, but at this point you should probably be consulting your primary care doctor or a specialist.
Where there is enduring controversy is when trade-offs are necessary. What if you did not sleep 7 hours the night before – should you nap? Napping may make up for some lost sleep, but also breaks up your sleep cycle. So this needs to be individualized. Should you sleep in on the weekend? Same dilemma, it does make up some sleep (not completely) but shifts your circadian rhythm.
Another common myth is that a little alcohol before bed can help with sleep onset. The opposite, rather, is true. Alcohol disrupts the sleep cycle. And while we are talking about substances, caffeine is another source of sleep myths. Many people believe that as long as they restrict their caffeine to earlier in the day, caffeine will not affect their sleep.
However, having caffeine even 6 hours prior to bedtime is capable of delaying sleep onset and quality. Caffeine directly disrupts the brain’s circadian rhythm, no matter when you drink it. Further, if you have a lot of caffeine, you may be in withdrawal in the late evening or overnight, and this can cause symptoms that disrupt sleep. A good rule of thumb if you have poor sleep is to restrict caffeine to one 8 oz. beverage in the morning.
The authors also focus on snoring, which many people falsely believe is always benign. It may be, but it may also be a symptom of obstructive sleep apnea (OSA). This is a closing off of the airway due to relaxation of muscles during sleep. The evidence suggests that we are in the middle of an OSA epidemic, being driven partly by the obesity epidemic, as obesity is the major risk factor for OSA. Estimates vary between 14% and 49% of middle-aged males having OSA in the US and Europe.
OSA is a serious health problem. It increases the risk for hypertension, heart disease, and stroke. Often patients do not realize they have OSA, because they do not remember the brief awakenings that the obstructions produce. Their partner will usually know that they snore, but also not realize how severe the problem is. Patients may think they are sleeping through the night, but wake up exhausted as if they haven’t slept and have symptoms of chronic sleep deprivation.
The definitive way to diagnose OSA is with a sleep study. It is also completely treatable. The most common method is to use continuous positive airway pressure (CPAP) to keep the airway open at night. Many patients have difficulty adapting to wearing CPAP at night, but can eventually make it work. There may also be other treatment options, including surgery to widen the airway. Those with OSA are encouraged to follow up with their sleep doctor (or pulmonologist) until they have successfully treated their OSA. Weight loss, of course, may be a cure for some people, but that is a long term solution which is often difficult to achieve.
In my opinion the biggest myth of all is that poor sleep is not a medical issue. It is if it’s impaired sufficiently. There may be other underlying medical conditions causing the poor sleep also, such as OSA or even restless leg syndrome (and yes, this is a real thing). Sometimes medications may be the problem, and this needs to be reviewed with your physician. Chronic poor sleep can also occasionally be an early symptom of a more serious neurological disease.
So if you have poor sleep the first step is to dispel sleep myths. Then adopt good sleep habits. If this does not work, you have questions about what your sleep habits should be, or if you have any concerning symptoms such as severe snoring, then consult your physician.

PET Scans Predict Coma Outcome
Steven Novella on June 1, 2016
Link

A new study shows that 42 really is the answer to life, the universe, and everything. OK, not really, but it does show that 42% of healthy brain activity is the minimum threshold for consciousness.
Disorders of consciousness, also referred to as coma when severe enough, can be a difficult situation to assess sufficiently to make reliable predictions about outcome. Part of the problem is that once someone is not able to maintain consciousness, we lose much of the neurological exam, and therefore it becomes more difficult to assess brain function other than to say that they are not conscious.
Types of coma
Two types of coma in particular are of interest: the persistent vegetative state, also called unresponsive wakefulness syndrome (UWS), and the minimally conscious state (MCS). Both are severe impairments of consciousness. In UWS, by definition, the patient may have sleep-wake cycles, open their eye, have roving eye movements, and grimace, but they do not have any interaction with their environment. They do not respond to voice, look at faces, or move in response to stimuli.
MCS is similar, except that patients give minimal signs of consciousness. They may attend to a face, or move in response to stimuli, but cannot communicate or participate in their care. There is a continuum, of course, from the MCS to a fully conscious state.
Sometimes it can be difficult to distinguish MCS from UWS. In a previous study, 41% of patients who were diagnosed as being in a UWS by standard neurological exam were actually in a MCS when a more thorough neurological exam was conducted.
Later research found that using fMRI scans (which measure blood flow) or quantitative EEGs (which measure electrical activity) were even more sensitive at distinguishing MCS from UWS. However, a 2014 study showed that a PET scan, which measures tissue metabolism, was even better at predicting who had signs of consciousness and also who might recover function a year later.
Of note, this research tends to show that patients who have impaired consciousness due to diffuse anoxic ischemic damage (lack of blood flow to the brain) had poor function and poor prognosis. They tended to really be UWS and not recover. Meanwhile, patients in a coma due to trauma were more variable. Some had more function and more potential to recover. This makes sense as trauma patients may look worse due to focal damage but still have some hidden brain function, while anoxic ischemic patients have damaged their entire brain.
The new PET study
With this background comes the new study, which includes many of the same researchers as the studies I mention above. They looked at PET scanning, because that showed the most potential in previous research, and also looked at trauma patients, because they also showed the most potential in previous research. They examined 131 head trauma patients using [18F]-fluorodeoxyglucose (FDG) PET scanning, and then followed them for a year as they recovered. They found several interesting things.
First, by quantifying overall brain metabolic activity they found that the minimal activity necessary to produce a conscious state was 42% of normal activity (determined by examining healthy controls). Simply put, the brain has to be able to produce a certain minimal amount of activity in order for conscious wakefulness to emerge.
Further, there does not seem to be any part of the brain that was essential for consciousness. There is no “seat of consciousness.” Consciousness is a whole-brain phenomenon, and all parts of the brain contribute their bit to consciousness. This fits with the current science of consciousness, which has failed to find any one piece of the brain that generates consciousness.
Local differences in brain function, however, did predict the return of specific functions. In other words, the activity in the visual cortex predicted the return of vision, while activity in the language cortex predicted the return of language. Therefore, the PET scanning was able to demonstrate not only overall brain activity, but the significance of activity in specific parts of the brain. This helps confirm the lack of a specific part of the brain needed for consciousness, because this study should have been able to show it.
All of this is interesting, but the clinical goal is to determine if such technology can predict overall patient outcome. This study delivered there as well:
Overall, the cerebral metabolic rate accounted for the current level, or imminent return, of awareness in 94% of the patient population, suggesting a global energetic threshold effect, associated with the reemergence of consciousness after brain injury.
PET scan activity specifically predicted the outcome (recovery to consciousness) in 88% of subjects.
Utility
Predicting who is likely to recover from head trauma to the point that they are conscious and able to have some quality of life is extremely useful to family members tasked with making decisions about care.
Patients who are likely to recover based on this type of PET data might benefit from more aggressive care, while patients who have little or no potential to recover can be treated to maximize comfort.
It may seem like it is asking a lot of a diagnostic test to determine the overall care of a patient, but right now those decisions are still being made, just with greater uncertainty as we generally base such decisions on clinical assessment and anatomical imaging. PET scanning, according to this study which also builds upon previous studies, adds another piece of information that can help us make better assessments and predictions.
The fact that this study was able to quantify PET metabolism and consciousness is also extremely helpful. Knowing that there is a threshold, 42%, that is necessary for consciousness is especially useful.
Clearly more research will be necessary to confirm these results and add more details. I would like to see a similar study in patients suffering from other causes of coma, such as diffuse anoxia. The more information we have about PET scanning results and long term outcomes the better.
Families caring for loved-ones in a coma are in a very difficult position. They don’t want to give up if there is hope, but they also don’t want to condemn their loved-one to an existence they may not have wanted if there is no hope. Uncertainty is agonizing, and anything that can reduce uncertainty is extremely useful.

Detecting Consciousness in the Vegetative
Steven Novella on November 6, 2013
Link
People in a vegetative state, usually as a result of brain trauma or anoxia (lack of oxygen) by definition have no signs of conscious awareness or activity. The definition, therefore, is based largely on the absence of evidence for consciousness.
Of course, arguments based upon the absence of evidence are only as compelling as the degree to which evidence has been properly searched for. In recent years technology has advanced to the point that our ability to detect the possible subtle signs of consciousness in those presumed to be vegetative has increased – mainly through functional MRI scans (fMRI) and electroencephalograms (EEGs).
There has been a steady stream of studies demonstrating that a small minority of patients thought to be vegetative actually display some signs of minimal consciousness. The latest such study was recently published in Neuroimage: Clinical by a research team from the University of Cambridge.
But let’s back up a bit first. Even prior to evaluating vegetative patients with fMRI and advanced EEG techniques, several studies showed that a detailed neurological exam specifically designed to detect the most subtle clinical signs of consciousness could find such signs in some patients who were diagnosed as being vegetative by more standard neurological exam. According to one study as many as 41% of patients diagnosed as vegetative were really minimally conscious, meaning they had subtle signs of consciousness, but still cannot wake up, converse, or act purposefully.
Other studies have shown that use of a bedside EEG is a cheap and portable option for properly detecting patients who are minimally conscious rather than vegetative.
Then fMRI began shining an intriguing light into the brains of some of these patients. One early study used fMRI to image the brain activity of an apparently vegetative patient when asked to imagine themselves playing tennis or walking around their home. The researchers were able to show that the patient would demonstrate the appropriate pattern of brain activity (compared to the established baseline) when later asked to repeat the task.
This was a stunning finding, and has later been replicated in other patients. The current study falls into this category. The researcher examined the brains of eight healthy controls while performing the task of listening to a stream of words and counting the number of times the word “yes” or “no” appeared. They then repeated the task with 21 vegetative patients. Of those, 17 showed no brain activity at all, three showed brain activity but it appeared to be random, and one patient displayed brain activity similar to that of the eight healthy controls.
The results of this study suggest that one of the 21 vegetative patients was able to direct their attention at the task in a way that was indistinguishable, by fMRI, from a healthy person.
While extremely interesting, the big question remains – what does all this mean?
The first question we always have to ask is if these results are reliable, or could they be due to an artifact or some error in the protocol. fMRI technology is still very tricky to use, and notoriously produces false positive results when not used carefully.
The results have been replicated enough, however, that at least they should be taken very seriously. There is also another reason to accept the results are probably real. One interesting pattern that has been fairly consistent in the research is that those in a vegetative state from trauma are more likely to demonstrate signs of consciousness than those resulting from anoxia.
This makes sense in that anoxia damages the entire brain, and such diffuse injury does not leave much potential for residual brain activity. Brain trauma, however, can be very non-uniform. There may be parts of the brain relatively spared and still able to participate in consciousness. Further, trauma may cause focal damage resulting in paralysis or sensory impairment that hides signs of consciousness.
Assuming, therefore, that the results are real, what are the implications? From a theoretical point of view, what we want to know is – what is happening inside the mind of those people who appear vegetative but have fMRI activity in these studies? This is the one thing we really want to know, but just can’t at this time.
The fact that the brain is showing activity in response to environmental stimuli, even abstract stimuli such as instructions to pay attention or imagine oneself playing tennis, does not mean that the person is experiencing that activity. We still may only be witnessing some component of attention or information processing without the brain being able to generate sufficient activity to produce anything that can reasonably be considered consciousness.
This is, in fact, what I strongly suspect. Further I believe this is a reasonable default assumption lacking compelling evidence to the contrary.
From a practical point of view, what do the results of this research mean? Is there a difference in prognosis or response to treatment for those who display fMRI activity vs. those who do not? The answer so far is probably not and no, respectively.
While it is true that those in a minimally-conscious state have a very small potential to experience modest neurological recovery, while those who are truly in a vegetative state have no possibility of any meaningful recovery, this difference is slight and has practical implications for only the very rare patient.
There are also currently no effective treatments for those who are vegetative or minimally conscious. The hope is, however, that treatments may be developed. In that case, the minority of vegetative patients who do show brain activity may be the ones to benefit from potential future treatments.
One such treatment involves implanting computer chips (or electrodes attached to computer chips) that enhance the activity of the parts of the brain involved in consciousness and wakefulness. fMRI technology may help us identify the minority of patients who could potentially benefit from such a treatment.
Another potential development that is often discussed in news reports of this fMRI research is the use of the technology to communicate with those who are vegetative but have brain activity. I am highly skeptical of this potential, however. It is certainly reasonable to research this to discover what the potential is, but I would recommend extreme caution.
As I stated above, the fact that the brain can respond to stimuli does not necessarily mean that there is a conscious mind present capable of communication. Further, the risk of such research is that non-specific or random responses will be over interpreted as communication – something we have seen with every research program into communicating with those who cannot communicate normally, including animals and those with cognitive impairments.
No such study has been attempted so far, and I am curious to see the protocols and results.
Conclusion
Using advanced EEG and fMRI technology to study the brains of those who appear to be vegetative is an exciting development that promises to teach us something about brain function and consciousness. This research further holds out the promise of identifying patients who may benefit from yet-to-be-developed technology.
At the very least it can reassure families that their loved-ones have been thoroughly examined and properly diagnosed. For those patients who demonstrate no brain activity at all, the family does not have to worry that they are actually locked in, or that they are prematurely abandoning hope for recovery. Proper diagnosis and prognosis is essential when dealing with the comatose, and this technology will greatly enhance the reliability of diagnosis.
Those patients who do show some brain activity despite appearing vegetative are now in a diagnostic gray zone. There is an indication of brain activity, but we just do not know yet what to really make of it. This is truly an area requiring further research.

A PANDAS Story
Steven Novella on October 17, 2012
Link
One of the skills I try to teach medical students on their journey to becoming experience clinicians is to consider and address the patient’s “narrative.” Patients have a certain understanding of their illness, its cause, and its role in their life. They make sense of their situation as best as they can, resulting in a story they tell themselves. This is how humans generally deal with the complexities of life.
There is a potential problem when the clinical narrative of the health care provider conflicts significantly with the illness narrative of the patient. Patients, for example, often feel that a highly specific diagnosis is necessary for optimal treatment of their condition. Until they are given such a diagnosis they feel they need to keep looking – for better diagnostic tests or different specialists (what I call the “Dr. House” narrative). The appropriate diagnostic and therapeutic algorithm for that patient, however, may not require a specific diagnosis, but rather eliminating certain diagnoses and then treating the probable category or clinical syndrome that remains. The clinical narrative, in other words, may be one of considering risks vs benefits with incomplete and imperfect knowledge.
Increasingly, it seems, the conflict of narratives is taking on a larger scale – not just between one doctor and one patient, but between the medical community and patient communities. Perhaps this is one manifestation of the new social media generation. Take, for example, a recent controversy over a patient diagnosed with PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections).
What is uncontroversial about this story is that Elizabeth Wray is a 16 year old girl who developed the rapid onset of some form of tic or obsessive compulsive disorder. She was diagnosed with PANDAS and treated, for a time, with antibiotics (for the presumed Strep infection). She was recently transferred to Boston Children’s Hospital (BCH) for treatment, but her doctors there apparently disagreed with her previous management. They petitioned the state to take custody of Elizabeth partly so that they can have her transferred to a locked psychiatric unit. A judge recent decided that the state of Massachusetts would take temporary custody of Elizabeth while the case is being sorted out, but did not allow her transfer to the locked unit.
As far as I can tell, those are the basic facts of the case. However these facts are woven into very different narratives. Part of the PANDAS patient community has taken up the call to free Elizabeth Wray. Most are quoting the family’s attorney, such as this report:
“Their daughter Elizabeth was admitted to BCH due to eating issues. This is the second family I have represented within two months regarding BCH with the same fact pattern. In both cases, BCH has immediately told the parents that PANDAS/PANS does not exist, cut off the child’s antibiotics, reported the parents to Mass child protective services, and had the parents trailed by guards at the hospital. In both cases, BCH has actively encouraged children’s services to remove the child from the custody of the parents unless the family signed a voluntary agreement to place the child in a locked psych unit.”
This is sickening. So very sickening.
Please forward this to everyone you know. Parents who are dealing with PANDAS are going through so much. To have their child taken from them, by ignorant doctors who claim the condition doesn’t even exist?
According to this narrative, PANDAS is a very real syndrome that affects many children and responds to treatment. However, most doctors are dismissive, ignorant, and arrogant and “just don’t get it,” so they deny the existence of PANDAS and as a result refuse needed treatment to desperate patients. There are a few mavericks willing to buck the system for their patients, and they are champions of a populist crusade against entrenched professional ignorance. Sometimes insurance companies also get to wear the black hats, or Big Pharma, or government regulators, or all three.
It’s a great story, complete with villains and heroes, and has at its core the hope of a treatment for a serious and frightening illness. It is perhaps naive to think that this powerful narrative can be addressed by something as cold and dry as scientific evidence. The narrative, in fact, shields itself from such evidence.
The medical community, as you might imagine, has a very different narrative, one that you will read here on Science-Based Medicine quite often (yes, we have our own narratives that guide our thinking about often complex topics). According to the SBM or mainstream narrative, medicine is a complex business. It is especially difficult to identify new diseases and clinical entities. The creation of a new diagnosis must be done very carefully, with thoughtful scientific studies used in an open-minded way to explore all the complexities involved. Only when all the ducks are in a row can we confidently conclude that a new diagnosis is, in fact, a distinct entity, and not just a variant or misidentification of existing known diseases. Meanwhile, even before all the diagnostic questions can be answered, we need research to answer the basic question of how patients respond to specific treatments – what clinical features predict what kind of respond to which treatments? This is, as I alluded to above, not necessarily the same question as one of diagnosis.
Often new ideas in medicine are controversial for years, even decades, before a consensus can be reached about this fundamental claims. And most new ideas in medicine turn out to be wrong, but slowly our medical knowledge grinds forward.
How does PANDAS relate to the above narrative? A recent review found:
The relationship between obsessive-compulsive disorder (OCD) or tics/Tourette’s syndrome in childhood to antecedent group A streptococci (GAS) is unclear. One recent prospective cohort study found that more than 85% of clinical exacerbations in OCD/tic behavior in patients who met criteria for PANDAS had no relationship to GAS infection. Another study found no correlation between clinical exacerbations and changes in a variety of markers of brain autoimmunity, the proposed pathogenesis of PANDAS. A third recent study concluded that, compared with specialty clinic diagnoses, patients diagnosed with tics or Tourette’s by physicians in the community were significantly more likely to be diagnosed with PANDAS without meeting the proposed criteria, most lacked supporting laboratory evidence of GAS infection, and they were more likely to be treated with unjustified short-term to chronic antibiotic and/or immunomodulatory therapy.
Despite continued research in the field, the relationship between GAS and specific neuropsychiatric disorders (PANDAS) remains elusive. It is possible that GAS infection may be but one of the many stressors that can exacerbate tic/Tourette’s or OCD in a subset of such patients.
I have to stress that I am not an expert in this area, but reading as much of the published literature as I can, the above is essentially what I found. The syndrome of sudden onset neuropsychiatric symptoms certainly exists, and is reported in the literature. However, the pathogenesis is unclear – specifically its relationship to GAS. GAS may not be a specific cause, it may just be one of many possible triggers of an exacerbation of a syndrome that has another underlying cause or causes. Further, the more specific question of whether or not patients who meet diagnostic criteria for PANDAS respond to antibiotics has not been settled, but certainly those advocating for such treatment have not met their burden of proof that it is safe and effective. One researcher, Singer, has proposed moving to a new diagnostic label, CANS (childhood acute neuropsychiatric syndrome), which has the advantage of not making any assumptions about pathophysiology that are as yet unproven.
The bottom line is that PANDAS remains uncertain and controversial. It’s not implausible and I (I think like most clinicians) remain open minded about this disorder and are just waiting for better evidence to settle the issue. We’re happy to listen to whatever the evidence has to say.
It’s difficult to express all of this complexity to a community of parents of children with a scary neuropsychiatric disorder who are just looking for treatment. The internet narrative of heroes and villains makes the job that much more difficult. BCH seems to be caught in the middle of this controversy. They are not allowed to talk about this case, but a statement from BCH has stated that they do treat PANDAS. This suggests, as I suspected, the notion that they categorically deny the existence of PANDAS is a gross oversimplifcation of their position – suitable for a comic book villain, but not the complexities of modern health care.
Conclusion
Confronting common narrative in the public is critically important for proponents of science-based medicine. I do think this gulf can be bridged, mainly because there is vast common ground. Patient, their families, and the medical community do all want the same thing in the end – to do what is best for patients. Further there is still vast agreement that the scientific evidence is ultimately the best guide to what is best for patients. If we can agree to this common ground, then a much more productive discussion can be had about what the current evidence says, what further studies are needed, and what is the optimum management at present given our state of knowledge.

ADHS

The ADHD Controversy
ADHD was already a controversial diagnosis; are Jerome Kagan’s recent criticisms of it warranted?
Steven Novella on March 1, 2017
Link
Is attention deficit hyperactivity disorder (ADHD) a legitimate diagnosis or is it mostly a fraud? The answer has important implications for many individuals and for society. The diagnosis is accepted as legitimate by the psychiatric profession, but continues to have its vehement critics. Recently, noted psychologist Jerome Kagan has been giving tremendous weight to these criticisms by calling ADHD mostly a fraud. There are significant problems with his criticism, however.
What is ADHD?
ADHD was first described in children in 1902, and was understood as an impulse control disorder. It was not formally recognized as a diagnosis, however, until the second edition of the DSM in 1968. The first approved drug used to treat ADHD was benzedrine in 1936. Ritalin, which is still used to treat the disorder, was approved in 1955.
Here is the official DSM diagnosis:
    • A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development
        ◦ Six or more of the symptoms have persisted for at least six months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities. Please note: The symptoms are not solely a manifestation of oppositional behaviour, defiance, hostility, or failure to understand tasks or instructions. For older adolescents and adults (age 17 and older), five or more symptoms are required
    • Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years
    • Several inattentive or hyperactive-impulsive symptoms are present in two or more settings (e.g. at home, school, or work; with friends or relatives; in other activities)
    • There is clear evidence that the symptoms interfere with, or reduce the quality of, social, academic or occupational functioning
    • The symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better explained by another mental disorder (e.g. mood disorder, anxiety disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal)
There are a few aspects of this diagnosis worth pointing out. First, this is what we call a clinical diagnosis, it is based entirely on signs and symptoms without any objective diagnostic tests. You cannot see ADHD on an MRI scan of the brain, an EEG, or a blood test. This is not unusual in medicine, especially for brain disorders. The same is true, for example, of migraine headaches. It is entirely a clinical diagnosis.
This, by itself, should not call the diagnosis into question. Brain function relies not only on the health of the cells and the absence of identifiable anatomical or gross pathology. It also depends on the pattern of connections among brain cells, the density of their connections, and the details of their biochemistry. We are just starting to be able to image the brain at this level.
As an example, raise someone in a closet for 20 years and I guarantee you they will have a psychological disorder, but you would not be able to tell that from looking at their brain with any tool we currently have.
Because mood, thought, and behavior largely rely on brain function that cannot be imaged, psychiatrists have relied on elaborate schemes of clinical diagnoses to at least have a common language for thinking and talking about mental illness. It is imperfect, and extremely fuzzy around the edges, but it has its utility.
That fuzziness is partly based in the limits of our current technology and understanding. But it is also based in the fact that humans are neurologically heterogeneous and the fact that the brain is an extremely complex system. This means that the same end result (behavior, for example) might result from almost endless permutations of interactions among various systems in the brain and their interaction with the environment.
You can see this in the formal description of ADHD above. There is a sincere attempt to capture a real neurological phenomenon, and to filter out other factors that might contribute to or cause similar symptoms. Signs used to establish the diagnosis cannot be temporary, or isolated to only one environment, or related to other conditions or situations that might provoke them. You need to have many symptoms persistent over a long time without other identifiable causes and to a sufficient degree that they cause demonstrable harm.
There is also an attempt to separate out those who have a real disorder from the typical spectrum of human behavior. This is also a common problem in medicine. Many disorders, like high blood pressure, do not have a sharp demarcation line. The curves for normal blood pressure and hypertension overlap. Experts have to decide where to draw the line, either capturing more people with the disorder but also more people just at the upper range of normal, vs excluding those who are just at the upper range of normal but also then missing more people with the disorder.
Eventually such clinical questions evolve from, “Who has the disorder” to “Who benefits from treatment for the disorder.” That is the real question.
Neuroanatomical Correlates
Despite the fact that ADHD is a fuzzy clinical entity, we have made progress in understanding what is happening in the brain of most people with ADHD. The current consensus is that ADHD is a deficit of executive functions. The frontal lobes carry out many critical functions, some considered executive functions: they include being able to focus your attention, maintain focus, switch among tasks, filter out distractions, and impulse control. Executive function includes the ability to weigh the probable outcomes of your behavior and then make high-level decisions about how you will behave.
As an adult neurologist I see patients with executive function disorder frequently, usually from head trauma. Car accidents in particular result in frontal lobe damage as it is common to hit your head against the windshield during many types of accidents. Patients frequently develop the symptoms of ADHD after frontal head trauma. They have poor focus, and poor impulse control. In one dramatic case a patient’s entire personality changed. She lost all ability to control or moderate her behavior (as have others). Often these patients respond favorably to the same stimulants we use to treat ADHD.
When we look at the brains of those who meet the clinical diagnosis of ADHD with our modern imaging techniques, such as fMRI and EEG, we find a similar pattern of brain dysfunction:
Convergent data from neuroimaging, neuropsychology, genetics and neurochemical studies consistently point to the involvement of the frontostriatal network as a likely contributor to the pathophysiology of ADHD. This network involves the lateral prefrontal cortex, the dorsal anterior cingulate cortex, the caudate nucleus and putamen. Moreover, a growing literature demonstrates abnormalities affecting other cortical regions and the cerebellum.
At this point there is no reasonable disagreement about the fact that ADHD is a disorder of brain function. Children who meet the strict diagnostic criteria are demonstrably different, in consistent and predictable ways, than children who do not (controlling for other possible factors). They have impaired executive functions, and we can see this in changes to the relevant parts of the brain. We still have a lot to learn (again, the brain is complex) but a consistent picture is emerging.
Jerome Kagan’s criticism
Jerome Kagan is a preeminent psychologist. This gives his opinions about a psychological topic a great deal of weight. The press loves him because he has a sensational story to tell and he has impeccable credential. Articles about Kagan often spend an entire paragraph or two touting those credentials.
Unfortunately this is a common mistake that mainstream journalists make when discussing scientific topics. They confuse the expertise of an individual with scientific authority. No individual ever represents the consensus of scientific opinion, they can only represent their own quirky opinions (which may or may not be in line with the consensus).
This is a classic example of this error. Kagan’s opinions do not conform to the current consensus of scientific opinion, but he is presented as an unimpeachable authority. Further, all reporting that I have seen on Kagan’s opinions regarding ADHD fail to put his expertise into a reasonable context. Kagan is a psychologist. He is not a psychiatrist, nor a neuroscientist.
Often related fields covering the same question have different opinions. Geologists and paleontologists disagree about the relative contribution of a meteor impact to the extinction of the dinosaurs at the K-Pg boundary. If a reporter talked only to a geologist they would not capture the true state of the broader scientific opinion.
Many psychologists have opinions about psychiatry that do not reflect the consensus of psychiatric opinion. In essence, even though Kagan has relevant expertise, he is not a clinician, and therefore is an outsider when it comes to the practice of psychiatry. He also does not seem to be up to date on the neuroscience of ADHD.
Yet his recent interview with Spiegel is being widely reports as definitive criticism of the diagnosis and treatment of ADHD. Here are some of the highlights: He says:
Let’s go back 50 years. We have a 7-year-old child who is bored in school and disrupts classes. Back then, he was called lazy. Today, he is said to suffer from ADHD (Attention Deficit Hyperactivity Disorder). That’s why the numbers have soared.
We are familiar with a similar criticism of autism diagnoses. Yes, diagnostic practices have changed. Awareness of the diagnosis has changed. The implication here is that the 1950s diagnosis (a bored child) was better than the current diagnosis of ADHD.
But, if you recall the diagnostic criteria from above, displaying ADHD behavior in school alone is not sufficient to establish the diagnosis. So, Kagan’s example is simply wrong. The child in his example should not be diagnosed with ADHD.
Being generous, he may be implying only that doctors are overdiagnosing ADHD and not following their own diagnostic criteria. This is a real issue, but here is a far more nuanced discussion from an actual clinician:
ADHD is real—it’s not made up. But it exists on a continuum. There’s no marker or white line that says you’re in the “definite” or “highly likely” group. There’s almost unanimous agreement that five or six percent clearly have enough of these symptoms for an ADHD diagnosis. Then there’s the next group, where the diagnosis is more of a judgment call, and for these kids, behavioral therapy might work. And then there’s a third group, on the borderline. These are the ones we’re worried about being pushed into an inaccurate diagnosis.
The real issue is – are schools pushing for more kids in the gray zone to be diagnosed because of funding and regulation issues? Also, there is a real “demarcation problem” with the diagnosis, and we have to carefully consider the risks and benefits of using looser or tighter criteria. These discussions are happening within the profession, and are very evidence-based and nuanced. Kagan’s criticism, by comparison, is shooting from the hip and simplistic. (I will add the caveat that the interview may not reflect the full depth of his opinion, but he is responsible for how he communicates to the public, especially given how widely his opinions have been spread.)
He continues:
SPIEGEL: Experts speak of 5.4 million American children who display the symptoms typical of ADHD. Are you saying that this mental disorder is just an invention?
Kagan: That’s correct; it is an invention. Every child who’s not doing well in school is sent to see a pediatrician, and the pediatrician says: “It’s ADHD; here’s Ritalin.” In fact, 90 percent of these 5.4 million kids don’t have an abnormal dopamine metabolism. The problem is, if a drug is available to doctors, they’ll make the corresponding diagnosis.
That characterization, while you might dismiss it as hyperbole, is irresponsible. “Every” child? Again, this does not meet the official diagnostic criteria for ADHD which requires more than just not doing well in school. His reference to “dopamine metabolism” is just weird. It is true that some studies show some children with ADHD have impaired reward system function. This may be playing a role in some subtypes of ADHD. It is not a core feature of ADHD, however, and the evidence is still very preliminary. Invoking what is essentially a preliminary side point about the neuroanatomical correlates of ADHD as reason to doubt the diagnosis is, to be kind, highly problematic.
Kagan then broadens his criticism to encompass psychiatry in general:
We could get philosophical and ask ourselves: “What does mental illness mean?” If you do interviews with children and adolescents aged 12 to 19, then 40 percent can be categorized as anxious or depressed. But if you take a closer look and ask how many of them are seriously impaired by this, the number shrinks to 8 percent. Describing every child who is depressed or anxious as being mentally ill is ridiculous. Adolescents are anxious, that’s normal. They don’t know what college to go to. Their boyfriend or girlfriend just stood them up. Being sad or anxious is just as much a part of life as anger or sexual frustration.
This is a typical anti-mental illness statement. This is simply a straw man of what psychiatry does.
He is saying that we should not confuse the normal range of behavior with a disorder, as if this is a huge insight. This understanding has already been incorporated into clinical thinking. As I pointed out above – there are great pains taken when defining mental disorders to separate true disorders from the healthy range of human behavior.
Further, being “seriously impaired” is already part of the diagnosis, so what is he talking about?
He goes on to argue that some people are depressed in response to a life event. Right – psychiatrists call this a “reactive depression” because it is already recognized, and not confused with a chronic depression. That is why the diagnosis of clinical depression excludes depression that follows a major trigger, and must continue for greater than six months to be considered a disorder.
From reading the entire interview I am left wondering, exactly what Kagan is criticizing? He is certainly not criticizing the standard of care within psychiatry. He seems to be tilting at a straw man of the worst possible malpractice that deviates from that standard. He is raising issues as if these are not already part of a vigorous evidence-based discussion within psychiatry itself.
A kernel of truth
We often take a sharply critical approach to medical science here at SBM. Self-criticism is critical to improvement. That is the essence of science itself, it is designed for error correction through self-criticism.
Our nuanced position is that science basically works, but there is a lot of room for improvement. Enemies of science, however, or those with a specific ideological axe to grind, use the same evidence to argue that the institution of science is fatally flawed and can be comfortably dismissed or ignored.
I find the same is true of much of the public criticism of psychiatry. There is a lot to criticize in the profession (as in medicine in general), and a lot of room for improvement. Some of that is just the current status of the science. We don’t know everything, and yet medicine (including psychiatry) is an applied science. We have to make important decisions with limited information.
There are also many issues of quality control. Medicine is hard, and keeping quality standards high is challenging.
So there are many legitimate criticisms of ADHD and psychiatry, but that does not mean ADHD is a fraud. The scientific evidence, both clinical and neuroscience, is robust. Kagan’s criticisms are mostly greatly exaggerated, or they are straw men because they are already incorporated into the standard of care.
Unfortunately, you will not be exposed to any of that from reading any of the popular press breathlessly reporting that ADHD is a fraud.

Why Is ADHD On The Rise
Steven Novella on September 18, 2024
Link
Attention-deficit/hyperactivity disorder (ADHD) is one of the most commonly diagnosed neurodevelopment disorders and seems to be on the rise, in both children and adults. The diagnosis in children requires having various symptoms of attention deficit or hyperactivity which is functionally impairing with onset by age 12.
Recognition of the disorder actually goes back farther than you might think – the observation that some children are highly distractible goes back to the late 19th century. The concept was first presented publicly in 1902 by George Frederic Still, who in a lecture discussed an “abnormal defect of moral control in children.” ADHD first appeared as a formal diagnosis in the DSM in 1968.
Since then there has been a steady increase in the incidence and prevalence of ADHD. A 2023 review in JAMA notes:
“An analysis of the National Health Interview Survey (NHIS) reported that the prevalence of ADHD among children increased from 6.1% in 1997 to 1998 to 10.2% in 2015 to 2016. Similarly, the National Survey of Children’s Health showed a 42.0% increase from 2003 to 2011.”
That period, from the 1990s to the 2010s saw perhaps the biggest increase, but the number of diagnoses has crept up further since then. The latest survey, published in May 2024, found:
“Approximately 1 in 9 U.S. children have ever received an ADHD diagnosis (11.4%, 7.1 million children) and 10.5% (6.5 million) had current ADHD. Among children with current ADHD, 58.1% had moderate or severe ADHD, 77.9% had at least one co-occurring disorder, approximately half of children with current ADHD (53.6%) received ADHD medication, and 44.4% had received behavioral treatment for ADHD in the past year; nearly one third (30.1%) did not receive any ADHD-specific treatment.”
ADHD in adults has seen a similar increase, although somewhat trailing the rise in children. The most recent estimates also put the figure at about 10%. This makes sense, since it is now understood that ADHD is a lifelong condition. Children do not outgrow it – they become adults with ADHD.
Of course, this figure depends highly on how the diagnosis is made, and whether you are counting those diagnosed with ADHD or estimates on how many adults may have it, whether formally diagnosed or not. The low-end estimate is closer to 4-5%.
The first question that always arises when a diagnosis is on the increase relates to whether the true incidence is increasing, or is the apparent increase an artifact of how the diagnosis is made. We have had this discussion many times with the autism diagnosis. The two main factors that might result in an artifactual increase are, an expansion of the diagnostic criteria, or increased surveillance – either we have broadened the diagnosis, or we are looking for it more. There is also the possibility of diagnostic substitution – other diagnoses are now shifting to the one apparently increasing.
All of these factors appear relevant to ADHD. We have broadened the diagnostic category to include more symptoms. There is greater surveillance, with increased public awareness, decreased stigma, and greater incentive due to effective treatments.
This does not rule out that there is an actual increase hiding in the data as well, but there is no solid evidence that this is the case. Increased awareness and expanded criteria likely explain the increased numbers. But there are still some lingering questions, which relate to how the diagnosis is made.
ADHD is a clinical diagnosis, which means that it is based on the manifestation of symptoms and observations of behavior. Right now there is no laboratory test for ADHD. What this means is that we are not looking directly at brain function or anatomy to make the diagnosis. This does not mean there are no neuroanatomical correlates – there are. Functional imaging like fMRI scans do show differences in the brains of people with ADHD vs healthy control. They are simply not specific enough to use as a diagnosis.
What this means is that there is an underlying brain condition that then manifests with symptoms and behavior. It’s possible, therefore, that even if the underlying brain condition is static in incidence, manifestations have been increasing because of environmental or societal factors. Some experts hypothesize, for example, that social media and other factors have conditioned children for immediate satisfaction, decreased boredom tolerance, and constant stimulation.
Manifestation is also situation dependent. People with ADHD may do just find in many settings, while finding other setting extremely challenging. Tasks that require prolonged focused attention and inhibition of impulses, like school, tend to manifest ADHD. Increasing diagnosis can therefore result from increasing demands on attention and control.
The other aspect of the diagnosis that is tricky is that ADHD (again, like autism) is part of a spectrum. ADHD is largely understood now as a disorder of executive function, which is essentially our highest level neurological function for strategic planning and control. This is a higher, frontal lobe, largely inhibitory control. Executive function exists on a continuum without a sharp demarcation line between healthy and ADHD. Therefore, where and how we draw the line with affect the number of diagnoses.
This is a challenge for psychiatry in general, not just for ADHD. It is easy to be dismissive by saying – well, all people find executive control challenging at times. All children are impulsive and hyperactive. Are we just “pathologizing” normal behavior? At one end, this is a healthy discussion about exactly where we should draw the line and consider challenges of executive function a “disorder” requiring intervention. This includes discussion if whether or not ADHD is being under or over diagnosed (which also relates to whether or not strict diagnostic criteria are being followed).
At the other end of the spectrum, however, this kind of criticism leads to mental health denial, the notion that ADHD does not even exist as a legitimate diagnosis. Manifestations of ADHD are then spun as normal child behavior, or the result of bad parenting, bad schooling, or whatever your preferred societal scapegoat is. It must be social media and all those electronic devices, right?
The fact is, however, some people objectively have decreased executive function that we can see in their brains using functional imaging. ADHD is also objectively a disorder, meaning that it is not just a set of symptoms and behaviors, those behaviors lead to demonstrable harm. Further, effective interventions reduce the harm and negative outcomes that result from having executive function at the low end of the Bell curve.
The good news is that ADHD denial has been on the wane. The stigma attached to the diagnosis has also been decreasing, and the benefits of effective treatment are increasingly apparent. We still do need to consider the impact of societal factors, like screen time and social media, but that should not be used to either shame or deny those with a real neurological disorder.

More questions about acetaminophen: Does it cause ADHD?
Scott Gavura on March 27, 2014
Link
“Will Tylenol harm my baby?”
Pharmacists are among the most accessible of health professionals, and so we receive a lot of questions from the public. No appointment required, and the advice is free. Among the most frequent sources of questions are women seeking advice on drug use in pregnancy. This is an area where some health professionals are reluctant to tread. Some prefer to redirect all of these questions to physicians. But physicians are not always easily accessible, and few want to make an appointment just to ask what appears to be a simple question: Is it safe, or not? Admittedly, addressing questions about drug use in pregnancy can be challenging. There are no randomized controlled trials we can look to — there’s only messier, less definitive data. Our responses are filled with cautious hedging about risk and benefit, describing what we know (and don’t know) about fetal effects. In the pharmacy, one of the most common questions from pregnant women is about the use of acetaminophen (aka paracetamol aka APAP), more commonly known by the brand name Tylenol. Google “Tylenol and pregnancy” and you get 4.8 million results. Which source should you trust?
It should come as no surprise that acetaminophen has generated several posts over the years at SBM. It’s one of the most commonly-used medicines worldwide, starting in infancy for fever, right through towards end-of-life pain control in the elderly. As an ingredient, acetaminophen is packaged into hundreds of prescription and non-prescription drugs. Acetaminophen has a good safety profile when used appropriately. However it is among the most harmful of drugs in overdose, and the ease at which overdose can occur makes acetaminophen the cause of hundreds of cases of liver failure per year. Given this frequency of use, and a unique risk profile, there are continued questions about its safety and efficacy. Regulators (and manufacturers) continue to experiment with ways to make the drug available, while minimizing the risk of unintentional harm.
Pain in pregnancy, and the desire to treat it, is common. Beyond the non-pregnancy causes everyone can experience, like headaches and colds, the pregnant body is undergoing a rapid transformation that may not be painless. Weight gain of 25 or more pounds leads to posture changes and painful joints from head to toe. Low back pain is common, and it can be worse at night, leading to insomnia. Pelvis pain, knee pain, and hip pain are also common, and can be quite debilitating. While non-drug measures should always be attempted before considering drug treatment, severe or prolonged pregnancy pain may require the consideration of drug treatment.
Acetaminophen is the current go-to drug for pain control in pregnancy. There is good evidence to show that it does not increase the risk of major birth defects above the baseline risk (2-3%) that is inherent to any pregnancy. Acetaminophen can be used throughout pregnancy, and as long as the dosing is appropriate, side effects are remarkably rare. With a safe history of use and a low risk of side effects, acetaminophen is widely used when pain control with drugs is required.
The risks and benefits of drug use in pregnancy can’t be looked at in isolation. There is always an alternative, and the relative risks and benefits must be weighed. Doing nothing is always an alternative for pain, so the consequences of untreated pain need to be considered. But when pain is severe, other drugs might be considered. Stacked up against the alternatives, acetaminophen looks pretty good. Anti-inflammatory drugs like ibuprofen must be avoided in the later stages of pregnancy, due to the concerns about cardiovascular toxicity. Compared to the anti-inflammatory drugs, acetaminophen is unlikely to cause gastrointestinal ulcers, blood disorders, or kidney problems. Nor does acetaminophen appear to increase the risk of cardiovascular events such as heart attacks and strokes. Compared to the anti-inflammatory drugs, acetaminophen also has few interactions with other drugs, so it can safely be used for pain relief in pregnant women on other medications, or with other medical conditions where other pain relievers might have unwanted effects.
Beyond acetaminophen and the anti-inflammatories are the narcotics. The addictive properties of narcotics are well known, and they affect the fetus, too. Compared to a drug like codeine or morphine, acetaminophen provides a non-addictive alternative that may be more appropriate for short-term or long-term pain issues when drug treatment is being considered.
Now there’s a new study suggesting that the risk and benefit of acetaminophen in pregnancy may not be so clear. The paper is from JAMA Pediatrics, and it’s entitled “Acetaminophen Use During Pregnancy, Behavioral Problems, and Hyperkinetic Disorders”. Zeyan Liew and colleagues conducted a study of over 64,000 children and mothers who were enrolled in the Danish National Birth Cohort between 1996 and 2002. The Cohort was established to ask (and answer) questions about pregnancy and early childhood and the relationship to diseases that emerge later in life. Pregnant women were recruited with the intention to conduct long-term studies as these women (and their children) age.
The design of the study was straightforward. Acetaminophen use was assessed through telephone interviews before and after birth. Measurements of ADHD and hyperkinetic disorders after birth were measured by:
    • using a standardized questionnaire in parents once children reached age 7
    • looked for hyperkinetic disorder diagnoses in hospital and psychiatric registries
    • looked for prescriptions for ADHD medications through a national registry
Not surprisingly for a drug that is recommended for use in pregnancy, more than half of all of the study’s participants used acetaminophen at some point during pregnancy. There was a relationship found: Children whose mother used acetaminophen during pregnancy had a higher risk of a hospital diagnosis of HKD (hazard ratio 1.37, confidence intervals 1.19-1.59), receipt of ADHD medication (hazard ratio 1.29, confidence intervals 1.15-1.44) or having ADHD-like behaviors as defined by the standardized questionnaire (hazard ratio 1.01-1.27). There was also a positive relationship with the number of trimesters of use. Numerous confounders were studied and there was no relationship found.
There are a lot of strengths to this study that merit a close consideration of the findings. It’s a big data set that was powerful enough to detect a very subtle difference. The analysis was generally very well done. It was prospective, so the risk of bias due to time and memory (“recall bias”) was minimal. There were three independent data points collected, and two (hospital diagnoses and prescriptions) were objective measurements. There was a consistent trend observed: The risks appeared higher with use in more than one trimester, and when the duration of use (in weeks) increased. This was observed across the different endpoints. We can never say correlation equals causation with a non-randomized study, but does this study suggest it’s time to change the guidance on acetaminophen?
There were a few important limitations. Investigators failed to fully evaluate the family history of behavior disorders in parents. In diseases where there is good evidence for genetics having a substantial role, this is a significant limitation. The use of ADHD-prescriptions may not be a great measure either, given the lack of certainty about the diagnosis of ADHD (although this should have affected both groups equally). It could also be that acetaminophen use is just a signal or proxy for something else — and the acetaminophen is just what we’re noticing, and not the actual cause. It could be another condition or cause that the pregnant women are taking acetaminophen for. Finally there’s considerable uncertainty about the dosing and timing. The measurements of exposure was not ideal — in some cases it had to be estimated for women who could not recall when they took the drug. In addition, the overall dosing (e.g., average number of tablets) wasn’t available).
Probably the biggest fault to the study isn’t actually a flaw — it’s one of how meaningful these results really are. The absolute risks of ADHD remain tiny. Most of the headlines mention the relative risk: (“30% MORE LIKELY TO EXHIBIT ADHD”) when it’s the absolute risk that needs to be considered. The biggest difference as measured at age seven was the variation in the standardized questionnaire: 34 per 1 000 in the group “ever took acetaminophen”, versus 25 per 1 000 in the “never took acetaminophen” group. Recall, that’s a survey result — not a diagnosis. On balance, if the effect is real, it very minor, and the vast majority of the cases of ADHD are being detected in women who took no acetaminophen at all.
Conclusion
I have mixed feelings about these studies. On one hand, these databases give us the ability to evaluate very subtle effects that we could never otherwise identify. They also allow us to make inferences about relationships when randomization isn’t feasible or even ethically possible. And they may lead to further studies to help us better understand risk and benefit. When it comes to acetaminophen and ADHD, we can be reassured that if there is any causal effect from acetaminophen, then the effect is very slight. There’s no evidence to suggest that acetaminophen is driving the perception of growing incidence of ADHD. And studies like these are also a reminder to health professionals that we cannot take anything for granted — we need to look carefully yet critically at any new evidence. But there’s a downside to studies like these. Unwarranted panic is one, often driven by reporting that hypes the “statistically significant” without providing insight and context. Pushing women towards other, less safe alternatives could cause more harm.
Does the study change how we manage pain in pregnancy? It shouldn’t. No drug should be taken in pregnancy unless it’s necessary — acetaminophen is no exception. But there’s no reason for pregnant women to suffer from pain unnecessarily. Acetaminophen remains the drug of choice when pain control is necessary in pregnancy.
References
Liew Z., Ritz B., Rebordosa C., Lee P.C. & Olsen J. Acetaminophen Use During Pregnancy, Behavioral Problems, and Hyperkinetic Disorders, JAMA Pediatrics, DOI: 10.1001/jamapediatrics.2013.4914

Music for ADHD?
In a recent “Ask Me Anything” on Reddit, the CEO of Brain.fm claimed his company’s music can improve concentration and help with ADHD. At the very least I see such claims as highly implausible, and not something we can conclude from the existing basic science research. I have no problem with doing clinical research, and maybe we might learn something about how the brain regulates attention that can be exploited. But marketing products in the meantime based on this dubious support is deceptive and amounts to little more than typical pseudoscientific snake oil.
Steven Novella on March 21, 2018
Link

The CEO of Brain.fm recently had an Ask Me Anything (AMA) on Reddit, which brought their company and claims to my attention. While trying to present themselves as a respectable science-based company, when you strip it down they appear to be just another snake-oil company selling overhyped claims not backed by science. The CEO introduced his AMA beginning:
Hey Reddit! I’m Daniel Clark, CEO of Brain.fm. We use AI to generate music specifically to help people focus, relax and sleep, backed by science. In particular, our popular Focus music is useful for people who must get through a lot of work without distraction, procrastination, or boredom.
After a series of appropriately skeptical questions (good work, all), he had to add an edit to the intro:
We’re getting a lot of questions around our scientific claims. We wanted to clarify that this AMA is to announce our NSF grant and share our excitement around our ongoing research, rather than announcing the publication of a journal article (which would come at the end of the grant). Also, wanted to clarify we are not trying to replace medication but on the track to potentially becoming an alternative for many people–if you have ADHD, I am not claiming that you should stop your current treatment, or that we have the cure, but we are excited for the future and want to share where we are headed.
This is a pattern all-too-familiar to SBM.
The marketing strategy
The strategy for marketing dubious medical devices, services, or products is now well-established. First, target a disease or disorder that is either not well-treated by standard medicine, or there is the perception it is not well-treated. But, to maximize potential sales, also claim the treatment is good for the general population by targeting common everyday symptoms. Who doesn’t want better sleep or focus?
In this case the company, Brain.fm, markets music designed by artificial intelligence to entrain the brain (more on that below). You can choose what you want to target: “Focus, Meditation, Relaxation, Naps, or Night Time Sleep.” They also promise results in, “Within 15 minutes or less.”
It also helps to instill distrust in current treatment. The CEO stated in his AMA intro:
ADHD affects over 8M adults in the U.S. alone, with current solutions causing near-epidemic growth of prescription stimulants. An additional 4M do not meet all the criteria to be diagnosed with ADHD, so they can’t be prescribed medication and have no convenient alternatives for treatment.
He then had to walk that back, as stated in the edit above. That is also very common – stating that the company is not making any “cure” claims, to consult your doctor, do not stop any standard treatment, etc. This is all plausible deniability. With regard to supplements, such statements are FDA mandated.
For those companies trying to market their products with the patina of science, a core aspect of the marketing strategy is to emphasize the science, even when you don’t have any. There are three main ways to do this. The first is to focus on the basic science. As I have discussed many times in these pages, you cannot base clinical claims on basic science. The vast majority of clinical hypotheses we develop from basic science turn out not to work. Biology is simply too complex to make these kinds of extrapolations. We always need to confirm our hypotheses with clinical trials.
The Brain.fm website has a white paper and science FAQ that does just this – talk about the basic science and make simplistic extrapolations to their clinical claims.
The second strategy for seeming scientific is to do in-house or paid-for studies that are designed to show positive results. These can be open-label (meaning not blinded), or may not even be controlled. Or they are simply looking at some outcome that is likely to represent just placebo effects. Or they are looking at biological markers that are non-specific and cannot be used to gauge clinical outcome.
What you rarely see are appropriately designed rigorous clinical trials that are actually capable of showing if the product works or not.
I don’t see any clinical studies touted on the Brain.fm website, and they state they do not have any – yet. Which brings us to strategy 3: play up the fact that you have ongoing research. That is exactly what they were doing in their AMA, hyping the fact that they have a NSF grant to do research. The abstract of the grant does not go into detail about the methods, but they describe it as a phase I study. Phase I is usually just a safety and proof of concept study, and is almost always open label. They are not, generally, efficacy trials. Phase II are preliminary efficacy trials, and phase III are definitive efficacy trials.
Research genuinely takes a long time, and if your goal is to just keep your product and claims in a perpetual state of being studied for marketing purposes, you can easily do that. At the very least you can get 10-20 years of marketing out of the “actively being researched” phase before evidence of lack of efficacy emerges, and the current fad fades, at which time you can move on the next one.
That is the core problematic feature of this (and many) health products. The company is actively selling a product with specific claims, supported with the appearance of having science backing, and being actively studied. But it does not have clinical trials showing efficacy or backing any of their specific claims. In an ideal world they would not be allowed to do that – to make or even imply clinical claims without evidence.
The science
The science behind Brain.fm is not very compelling, in my opinion. It is essentially just another version of the brainwave entrainment claim. I have been writing about this for over a decade. In their science FAQ, Brain.fm gives a decent summary of brain entrainment:
When a temporal regularity is present in the environment, neuronal oscillations can synchronize (i.e. entrain) to this external rhythmic stream. This is operationalized by appropriately biasing the high excitability phases of ongoing neuronal oscillations so that they align with the events in the stream.
Essentially there is a rhythm to the basic electrical activity of the brain, as measured by electroencephalogram (EEG). What exactly causes these baseline rhythms is still a matter of research, but basically it results from synchronized activity in centers in the brain that act as the brain’s “pacemaker.” This, in turn, seems to serve the function of keeping the brain functioning – it is like an alerting signal that keeps pinging the cortex and keeping the stream of activity going.
Further, these rhythms can be driven to some extent by external stimuli. During a routine EEG, for example, patients are exposed to a strobe light at varying frequencies. Often we will see what is called “photic driving” which means the background EEG rhythm synchronizes with the strobe light frequency.
This is part of the basic science that Brain.fm uses to support their claims, and it is all legitimate. They also refer to Dynamic Attention Theory (DAT). This is the notion that our attention is dynamically regulated by the brain based on realtime events and stimuli. Whether this specific formulation is the final answer or not is still being researched, but something like this is surely going on. Attention is a neurological phenomenon unto itself, and it is both an important and complex phenomenon that is certainly dynamic.
But their own FAQ hits upon the key question when they ask:
Does altering brainwaves really mean we are altering mental state?
Yes, that is the 64-thousand-dollar question. It is the same question that has been asked for several decades, so it is not a new question. Companies selling devices to alter brainwaves may still be asking this question in 20 or 100 years.
Their answer to their own question I found to be rambling and confused, without giving a definitive answer but throwing a lot of jargon at the reader (which, it seems, is the point). They conclude:
And specific patterns of neuronal oscillations now start to be seen as fingerprints of cognitive processes. Mental states can thus be altered via neuronal oscillations, but such an alteration has to reach a critical level to be consciously perceived. Indeed, neuronal oscillations are in a constantly fluctuating, while we have a subjective impression of mental stability and continuity.
Got that? I don’t think they actually answered the question, just restated the basic science as if it does.
Having followed these claims and the science for years, I think the answer is – probably not. The essence of the “brainwave entrainment” product claims has always been, that since different mental states correlate with different EEG patterns, if we can force those EEG patterns we will put the brain into the associated state. This has never been a plausible hypothesis, as it is attempting to reverse the arrow of causation in a dubious way.
Looking specifically at attention – it is a complex dynamic process. The brain uses many complex evolved processes to determine how to focus our attention, which is related to how it decides what information to filter out, and what information to bring to our conscious awareness. This complex process is partly responding to external stimuli (of course). So, it is plausible that external stimuli can affect our attention.
Playing music, for example, can be relaxing or distracting. There seems to be great individual variability here as well, as people have different preferences. Further, there are several variables, including type of music, volume, and the specific task one is attempting to engage in.
The notion that some algorithmically designed music can force our brains into a sustainable attentive state enabling us to focus on whatever task we have is implausible to say the least. Individual trial and error would probably be a vastly superior method for determining what kind of music is best to listen to with various tasks.
Further, brain entrainment probably has absolutely nothing to do with the effects of various kinds of music on attention, relaxation, sleep, and other tasks. I have not seen any evidence that external brain entrainment has any exploitable clinical effects. In fact, if there is any attentional affect at all (which I doubt) it would be a coin flip whether it would be a help or hindrance.
This entire approach, which is a “brain hacking” approach, is flawed, in my opinion. There is no simplistic way to hack brain function. You can’t just slap on headphones and improve your attention, precisely because it is a complex evolved function with complex feedback mechanisms. Similarly, you can’t improve your general intelligence by doing a puzzle (even if it is “scientifically designed”). This is the same “brain hacking” fiction that makes for great ad copy, but bad science.
At the very least I see such claims as highly implausible, and not something we can conclude from the existing basic science research. I have no problem with doing clinical research, and maybe we might learn something about how the brain regulates attention that can be exploited. But marketing products in the meantime based on this dubious support is deceptive and amounts to little more than typical pseudoscientific snake oil.
Edit 03/23/2018 – A spokesperson for Brain.fm sent me an e-mail with this notice: “Brain.fm uses AI to generate music that helps people focus, relax and sleep, and so the company does claim to improve concentration. But Brain.fm has not made any claims about ADHD.”
This is exactly the strategy I was detailing above. In the AMA the CEO claims Brain.fm helps people, “focus, relax and sleep, backed by science.” He then has a paragraph about how serious a problem ADHD is, and then another paragraph about their research grant to study its effects, “regardless of whether they meet diagnostic criteria for ADHD.”
In my opinion this is consistent with one deceptive strategy in the marketing of these kinds of treatments – step right up to the line claiming to treat a specific disorder, and create the strong impression that your product can treat the disorder, but never make the claim explicitly for plausible deniability and to be within narrow compliance of FDA regulations.

Redefining Dyslexia
Steven Novella on February 26, 2025
Link

What, exactly, is dyslexia? What causes it, how should it be diagnosed, and stemming from that, how should it be treated? We can even ask a more fundamental question – does it actually exist as a discrete clinical entity?
These questions have existed since dyslexia was first described and named in 1887, by German Opthalmologist, Rudolf Berlin. Not surprisingly, he thought the decreased reading ability was due to “word blindness” – some people had difficulty visually interpreting and therefore decoding written words.
In 1925 Samuel T. Orton, a neuropathologist from the State University of Iowa, advanced his theory that dyslexia was not due to word blindness but rather to a problem with cortical dominance. His theory is was not correct, but it marked the beginning of a shift, from thinking of dyslexia as a visual problem to thinking of it as a neurological problem. The definition moved from opthalmology, to neuropthalmology, and ultimately to neurology.
As an aside, the common misconception (never really a working theory) that those with dyslexia reverse letters stems from the early visual processing theory. However, people with dyslexia do not reverse letters, either letters themselves (like “b” and “d”) or the order of letters in a word. All children as they are learning to read will reverse letters, and those with dyslexia at no higher rate. But it is amazing how much cultural inertia this misconception has.
While dyslexia was being researched and understood as a cognitive issue, not visual, there was still the matter of exactly how to define and diagnosis it clinically. By the 1960s a consensus was emerging that dyslexia is a “specific” learning disability, and that is how it should be diagnosed. What this means is that children with dyslexia have more of a problem with reading that is expected based upon their overall IQ and their learning level.
This definition is very general, and focuses on the disability itself without consideration of cause. It did not answer the question of why some children have difficulty reading out of proportion to their IQ and education. But research continued to address this question.
Another consequence of this general definition was that it fueled denial that dyslexia even exists. Even into the 2000s, UK’s Labour MP Graham Stringer called the condition a “cruel fiction” and stated, “To label children as dyslexic because they’re confused by poor teaching methods is wicked.” Blaming neurological conditions on bad parenting and poor teaching has a long pedigree from ADHD to autism, so this is not surprising.
By the 1990s a new consensus was emerging – that dyslexia is primarily a problem of “phonological awareness”. They have difficulty decoding words because their brains are not good at understanding the relationship between phonemes and words. They don’t assemble the phonemes into words as naturally as the average person. By 1994 this was codified as, “Dyslexia is a specific learning disability that is neurobiological in origin. It is characterized by difficulties with accurate and/or fluent word recognition and by poor spelling and decoding abilities.” In 2002 this was expanded with more complexity and nuance:
“A deficit in processing the phonological component of language resulted directly in difficulty with decoding, spelling, accuracy, and fluency that, in turn, impacted comprehension and reading experience. Impoverished reading experience further impacted the development of vocabulary and background knowledge, which also had a negative influence on comprehension.”
Then in 2009, partly as a response to continued denial that dyslexia is a real neurological disorder, came the Rose Report. This overview of dyslexia reinforced the phonemic awareness theory, that dyslexia is a specific neurodevelopmental disorder with genetic predisposition, and made a number of specific recommendations for interventions based on that understanding. And that is pretty much where the definition of dyslexia has sat until today (while research was ongoing).
Now there is a new attempt to reach an updated consensus of the definition of dyslexia based on the latest research – Toward a consensus on dyslexia: findings from a Delphi study. The conclude:
There was considerable consensus in our expert panel that dyslexia is a difficulty in reading and spelling, associated with multiple factors, and that it frequently co-occurs with other developmental disorders. It was agreed that difficulties in reading fluency and spelling are key markers of dyslexia across different ages and languages. We conclude with a proposed new definition of dyslexia.
And here is that definition, given as a list of consensus statements:
“Dyslexia is a set of processing difficulties that affect the acquisition of reading and spelling.
In dyslexia, some or all aspects of literacy attainment are weak in relation to age, standard teaching and instruction, and level of other attainments.
Across languages and age groups, difficulties in reading fluency and spelling are a key marker of dyslexia.
Dyslexic difficulties exist on a continuum and can be experienced to various degrees of severity.
The nature and developmental trajectory of dyslexia depend on multiple genetic and environmental influences.
Dyslexia can affect the acquisition of other skills, such as mathematics, reading comprehension, or learning another language.
The most commonly observed cognitive impairment in dyslexia is a difficulty in phonological processing (i.e. in phonological awareness, phonological processing speed or phonological memory). However, phonological difficulties do not fully explain the variability that is observed.
Working memory, processing speed, and orthographic skills can contribute to the impact of dyslexia.”
Like many conditions in neurology, dyslexia is a spectrum, with multiple different interactions with other neurological conditions and environmental contexts. Dyslexia is primarily a problem with phonological awareness, but this does not fully explain what we see and the variability of the condition. The full report goes into greater detail if you are interested.
The definition of dyslexia has evolved over time, tracking with the research, and in general has become more specific, nuanced, and complex. This is great for experts and to help guide further research and interventions. It does make it challenging to communicate what dyslexia is to the public, which is partly why simplistic misconception, and even denial, have such cultural staying power.
    • 

TIC’D OFF
Two years ago we discussed the TicTocStop, a dental appliance that the inventors assured us would help mitigate the symptoms of Tourette Syndrome. In the intervening years things have…not gone well. This illustrates the need for skepticism regarding questionable medical claims, and the importance of initiatives like AllTrials to ensure the good, the bad, and the ugly research is available to everyone.
Grant Ritchey on May 4, 2018
Link

This is a follow-up blog post by Clay Jones and Grant Ritchey, who wrote about the use of dental appliances in the management of tourette syndrome way back in the Olden Times (June 2016). Because we will refer to the above post often, and because we make a ton of shillbucks for every click on one of our articles, we encourage you to read (or re-read if you’re a star SBM pupil) our earlier piece multiple times in order to appreciate this post in its entire context.
The story so far
A couple of years ago, we wrote an article about how some dentists claim that they can successfully manage the signs and symptoms of Tourette Syndrome (TS). We covered in some detail the current concepts of the etiology and pathogenesis of the condition; while much is still unknown, we know more than what many outliers would have us believe. That being said, there is no shortage of charlatans willing to take advantage of the gaps in our knowledge by filling them with all manner of pseudoscientific false hope. And while we expressed our wish that dental appliances could benefit those with TS, we registered our skepticism and called for rigorous oversight and accountability for those dentists who claim to treat TS and have called for future research in this area.
Specifically, we singled out a new (at the time) campaign by an organization called TicTocStop, founded by a sports radio personality called Craig Carton. After Carton kicked off the charity with a sizable donation, the organization went into full fundraising mode to sponsor research into a proprietary dental appliance to present to the TS community. This research was to be conducted under the auspices of the highly respected University of Tennessee College of Dentistry, with the Grand Poobah Dean of the school Dr. Timothy Hottel himself acting as the Principal Investigator!
The study design was abysmal. It involved having 65 patients use a placebo device for one week, during which they would rate their tics, then wear the study device for several weeks. You heard that right. All subjects will know that they are wearing the study device, and it wasn’t disclosed what either the placebo device or the therapeutic devices was, or how they differed in their design. The study is uncontrolled and unblinded, practically designed to be positive for the many reasons we discussed in our previous post on the subject.
There was a lot of marketing noise associated with TicTocStop: from Camp Carton (more on that later), to an appearance by Carton and Dr. William Balanoff (then Chief Medical Director of TicTocStop Inc.) on The Doctors TV show, to extravagant celebrity golf tournaments. It struck us as consistent with the kind of marketing commonly seen with bogus free energy machines or juice cleanses, and we wondered if the fundraising was the primary goal and the study just a prop. With all that money rolling in and with some solid scientific research underway, what could possibly go wrong?
Things are possibly going wrong
For over a year after our post, we heard nothing from Drs. Balanoff or Hottel regarding the progress of their research. Accordingly, Grant sent out an email on August 23rd, 2017:
Dear Dr. Hottel and Dr. Balanoff,
I hope this email finds the both of you well. I am writing to follow up on your TicTocStop research project I inquired about 15 months ago. What has transpired since our last correspondence? Has the study begun, and if so, is there any preliminary data or conclusions that you can share at this time?
Thank you for your dedication to helping those with Tourette Syndrome, and I look forward to hearing from you.
Warm regards,
Grant Ritchey
That very day, Dr. Balanoff responded:
Hi Grant,
Thanks for reaching out. The study did start and is now complete. We are in the process of preparing a paper for a peer reviewed journal. I don’t have much more to share but I should have a lot to share very soon.
Thanks,
BillWilliam L. Balanoff, DDS, MS, FICDChief Medical Director TicTocStop, Inc.
Great news! We could only assume that the results were positive, but since we didn’t know the details of the study design (other than they were hoping to enroll 65 participants and any results of improvement would be self-reported), we could only speculate. But regardless, we would hear from them “very soon.”
We waited. Grant learned dental Swahili (thanks Rosetta Stone®-Dental Edition!) and Clay completed the first act of his one-man play (“a triumph of the human spirit!” – Clay’s mom). Still, no news. We waited some more.
Hearing nothing for months, we revisited the situation a couple of weeks ago, wondering what had happened and why the promised study had not yet materialized. Clay first did a little Googling on his Commodore 64 and stumbled upon a New York Post article from September 7, 2017 (two weeks after Grant’s email exchange from a few months ago) which alleged (among other things):
Internal Revenue Service records show the Tic Toc Stop nonprofit has raised more than $1 million since Carton — who was suspended from his sports-talk radio job following his arrest Wednesday — founded it in 2013 to “fight against Tourette Syndrome.”
Intrigued, Grant emailed Drs. Balanoff and Hottel on April 20th of this year.
Dear Dr. Balanoff and Dr. Hottel,
I am writing to follow up on your study on the use of oral appliances in the management of Tourette Syndrome. The last I heard, it sounded like the paper was close to being published, but to date I haven’t seen whether or not it has been. If it has, can you direct me to the article or send me a copy?
As you know, in 2016 my colleague Dr. Clay Jones and I wrote an article on the Science Based Medicine blog about oral appliances and TS in general and the TicTocStop campaign specifically. We were skeptical of the claims made by dentists who treat TS and of the methods of the TicTocStop campaign, but remained hopeful that some good science would be done to add to the body of knowledge of TS management, even if the results were negative.
We are aware of the allegations against TicTocStop founder Craig Carton, and we would like to get your thoughts on how this turn of events affects you and your research. Will you continue with the project? Dr. Hottel, will you need to distance yourself and your University from the project from a public relations standpoint? I realize that the controversy surrounding the charity doesn’t affect the science of whether oral appliance therapy may or may not be effective with TS; there are many layers to it. What are the plans for your research moving forward?
Thank you for your kind attention to this matter. Dr. Jones and I are planning to write a follow up post to our original one and I want to make sure I accurately report all sides of the issue. The blog gets almost two million readers each month, and fair and accurate science reporting is a responsibility we both take very seriously.
Warm regards,
Grant Ritchey
Within the hour, Grant had received a response from Dr. Balanoff (who interestingly no longer had the title of Chief Medical Director, TicTocStop on his signature line).
Hi,
Thanks for reaching out. The research has been submitted for publication. I will be happy to share the article once I know that it has withstood the review process and is ready for publication.
Thanks again for your continued interest.
Dr. Balanoff
William Balanoff, DDS, MS, FICDw********@*****.com9**-683-***3
Full speed ahead! It looks like we’re going to get that groundbreaking paper after all! We were nervous that mentioning the controversy surrounding Craig Carton would cause a defensive reaction in them, but neither did we want to avoid the issue. To his credit, Dr. Balanoff responded quickly and professionally.
We dug further. We stayed up late nights furiously inserting our Fortran punchcards into the Science-Based Medicine mainframe computer that Steve Novella keeps in his basement. We learned that Dean Hottel had been placed on suspension by the Tennessee Board of Dentistry at least a month before Grant’s and Balanoff’s 2017 email exchange, although this was not disclosed by either of them in their correspondence. The notes from the minutes of the Board meeting (on page 7 in the link above if you’re curious) simply stated “Update from School of Dentistry – Dean Hottel was placed on indefinite suspension” with no further explanation. Shortly thereafter, the University of Tennessee announced the appointment of an interim Dean of the College of Dentistry.
We dug even furtherer. It turns out that Dean Hottel has been accused in a blog post of taking money from the TicTocStop charity:
Timothy L. Hottel, Dean of the College of Dentistry at The University of Tennessee Health Science Center reportedly received $340,000 from TicTocStop, Inc., for the ‘Clinical Study on Use of Oral Appliances in Mitigating Severity, Frequency of Motor and Vocal Tics.’
And while we acknowledge that a blog post is not solid evidence by any stretch, and perhaps it was just a grant for the study and he didn’t personally profit from it, it raises serious ethical questions, especially since apparently he is no longer affiliated with the research project. Moreover, the author of the blog also questions whether Camp Carton, a summer camp for kids with TS, even exists at all. That accusation seems a little far-fetched to us, what with all the cool videos and all, but in light of everything else that Craig Carton allegedly did, it’s certainly a story worth pursuing in our opinion.
To summarize, we have a former radio host and a dental school dean who have quietly disappeared from the Tourette’s stage and may be in some sort of legal and ethical hot water. Meanwhile, the former Chief Medical Director of TicTocStop who promised a peer reviewed paper any time now has left us empty handed. Last but not least, the Tourette Syndrome community is left disappointed at yet another empty promise for an effective treatment.
Why did you just tell us all that?
Do you mean apart from gloating and proudly saying “We told you so?”
No, it’s because this highlights an enormous problem with the promotion of medical and dental treatments – whether they are new drugs, procedures, or in this case, a prosthetic intervention. Too often, commercial entities either throw up sham “studies” to support their claims or bypass the scientific process altogether in a rush to get their product to market. Or if they do perform “legitimate” research and don’t get the results they want, they deliberately ignore the results and don’t submit the paper for publication.
While we can’t go on record by saying this is definitely the case with TicTocStop, we were suspicious of them two years ago, and nothing they’ve done since has convinced us otherwise. In fact, the more we look at the whole set up, the shadier it appears to be. Originally on Dr. Balanoff’s website, the focus of the study design didn’t appear to be geared toward an effective treatment for TS, rather it was merely to get the requisite FDA approval for marketing to dentists, dental labs, and potential customers. There is no blinding, the cohort size is too small to be of significance, and the treatment time is only of a few weeks’ duration, hardly enough time to judge efficacy. And as the investigators said on The Doctor’s show, “what we are selling is hope.”
But the really interesting thing is that just as we were writing this post Dr. Balanoff took down all of his references of and associations with TicTocStop as well as the outline of his study design. On his new website (he kept the same URL), he is now promoting an appliance for TS called the T.A.G. appliance. Our hunch is that it is the same appliance as before, but just rebranded. He will probably still use the same shoddy study he has been conducting for years to promote his gadget to dentists, dental labs, and vulnerable people with TS.
This is very suspicious and has a taint about it. The intrigue deepens.
Just like any alternative medicine treatment or therapies not shown to be effective, patients can spend a lot of money chasing hope and they can waste precious time on ineffective cures instead of getting the care they need. There are ways to combat that however, one of which is the AllTrials Initiative.
The AllTrials Initiatve
According to their website, “AllTrials is an international initiative of Ben Goldacre, BMJ, Centre for Evidence-based Medicine, Cochrane Collaboration, James Lind Initiative, PLOS and Sense about Science and is being led in the US by Sense About Science USA, Dartmouth’s Geisel School of Medicine and the Dartmouth Institute for Health Policy & Clinical Practice. The AllTrials petition has been signed by 93310 people and 739 organisations.”
The Declaration of Helsinki codified in a set of ethical principles for human experimentation in 1964. Drafted by the World Medical Association, it asserts that every investigator has an obligation to report the findings of his or her clinical trial, even if those results are negative, unexpected, or is contrary to the interest of the investigator. The AllTrials Initiative supports the registration of any clinical trial prior to the initiation of that trial. Furthermore, trials that have already begun (or are completed) should also be registered retrospectively. This assures that the nature of the experiment cannot be modified during or after the research, and that the investigator(s) cannot move the goalposts after the fact. ClinicalTrials.gov is the world’s largest register for clinical trials, and there is no valid excuse for researchers not to do so.
The next step is to report findings. This is a brief summary of the trial’s results, and becomes part of the public record for all to see. An audit published in 2012 found that only a fifth of trials registered on ClinicalTrials.gov had reported results within one year of completion and different research found that trials which produced negative results are twice as likely to remain unreported than positive trials. According to AllTrials, publication of all results will reduce reporting biases and help researchers and policy-makers produce more reliable systematic reviews of the safety and effectiveness of medical interventions. Following the summary, a full report is submitted. Quoting the AllTrials website:
Full reports sometimes contain narrative descriptions of adverse events experienced by trial participants. This information is important to understanding the trade off between risks and benefits of a treatment. These paragraphs may contain identifiable patient information which may need to be redacted. These paragraphs should be available on request to researchers who provide a protocol of their study plan, with no reasonable request refused by the academic or company who authored the report.
By having these standardized recommendations publicly available, “phantom” research projects, publication biases, and file drawer effects can be reduced. There is transparency and accountability of all researchers, be they corporate, institutional, or governmental. The public is well served, and the body of knowledge in any given area is increased.
Conclusion: Sometimes it’s hard being right
The TicTocStop debacle is a sad lesson in greed, fraud, and the betrayal of trust. When we wrote the original SBM post almost two years ago, we expressed our skepticism and doubts about TS dental appliances due to biological implausibility and a lack of any good evidence in the area of dental appliances and TS. Even so, we assumed the best motives and intentions of the investigators and sent our best wishes to them for their efforts. After all, wouldn’t it be wonderful if a simple dental appliance could manage the symptoms of TS without drugs or surgery? Clay could get some relief from his condition and Grant could help others do the same.
But alas, because of The TicTocStop player’s actions, more money was wasted and more hopes were dashed. Hopefully going forward, researchers will use AllTrials or the ClinicalTrials.gov site to register their research projects. Perhaps Institutional Review Boards (IRBs) and ethics committees will in time require these steps, forcing investigators to be proactively transparent and agree to publish all results, regardless of outcome. This will protect the public in ways that aren’t being done today. As President Ronald Reagan stated: “Trust, but verify.”

Use of Dental Appliances in the Management of Tourette Syndrome
Grant Ritchey, Clay JonesonJune 17, 2016
Link

Editor’s note: This Science Based Medicine blog post is another collaborative effort between Grant Ritchey and Clay Jones. Not only have they previously co-authored an SBM post on fluoride, their partnership has recently expanded into other areas of science journalism. Since the departure of Dr. Jason Luchtefeld as co-host of The Prism Podcast, Clay has joined Grant as the new co-host. To this end, Clay and Grant have added a Science Based Medicine segment to each podcast episode, in which recent SBM blog posts are reviewed and discussed with the authors themselves. Check them out on iTunes or your favorite podcatcher.

One of our primary goals is to promote the concept of scientific skepticism and the importance of prior plausibility when interpreting new research. On the pages of this website, and in extracurricular activities like our various podcasts and personal blogs, we often call upon these two load-bearing pillars of science-based medicine when investigating implausible and unproven claims championed by well-meaning true believers and outright charlatans. What our collective experience has revealed time and time again is that both will often hope that a gullible public will put their trust in a warped version of science, while relying on emotional responses to anecdotes and testimonials.
In our post today, we will walk readers through our investigation of thus far unproven claims involving the treatment of a complex neurological disorder, Tourette syndrome (TS), with a fitted dental appliance aimed at improving the alignment of a patient’s jaw. From the perspective of a dentist (Grant) and a pediatrician (Clay), there aren’t any obvious connections between the jaw and this childhood-onset neuropsychiatric disorder, but proponents believe that there is one and that these appliances can significantly reduce the severity of symptoms. Although impossible to enter into an investigation such as this completely free of emotion or bias, we truly attempted to keep an open mind throughout the process.
First up, a disclaimer:
Clay was diagnosed with Tourette syndrome when he was 7 years old. As both a pediatrician who has now cared for a number of patients with TS and someone who has personally experienced many of the negative physical and social sequelae associated with the condition, this is a topic that Clay takes rather personally. Although his symptoms are now on the milder end of the severity spectrum, and are far from debilitating, they do often serve as a source of frustration in his day-to-day life. The thought of children with Tourette syndrome being taken advantage makes him angrier than that time somebody switched out his regular coffee for Colombian decaffeinated crystals.
Without hesitation, we would love for there to be another effective treatment option for Tourette syndrome in our armamentarium, especially one that would be essentially risk free and relatively inexpensive. Again, as scientific skeptics we are open to new evidence as it emerges. But before we get to the claim and the research being used to back it up, we will give a primer on the scientific consensus on TS so that readers can better assess for themselves the prior plausibility of this proposed treatment.
What is Tourette syndrome?
Tourette syndrome is a complex and historically misunderstood neurological disorder resulting in an astonishing variety of involuntary but transiently-suppressible movements and vocalizations known as tics. TS is also frequently associated with numerous comorbid conditions such as attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) – 60% and 30% respectively. Over the years, our understanding of the incidence of TS has changed considerably. No longer thought to be rare, a recent meta-analysis and systematic review of prior prevalence studies found that TS affects at least 1 out of every 200 children, with boys more likely to be diagnosed than girls by a ratio of 4 to 1.
If that prevalence estimate feels high to you, there is good reason. The severity of TS symptoms is highly variable, ranging from barely noticeable to completely debilitating. Symptoms aren’t even consistent in an individual patient, with significant waxing and waning over the course of a patient’s life being the norm, and shorter periods of acute changes related to stress, distraction, and temporary conscious control. You have almost certainly been around folks with TS and had no idea.
Many people, when conjuring up an image of the typical TS patient, are likely influenced by the numerous inaccurate portrayals in movies and on television. Or their concept of the condition has been biased by countless jokes made at the expense of patients with the disorder, which is often used as a punch line whenever something socially inappropriate occurs. In fact, the only reasonable portrayals we have seen are the movies The Tic Code and Front of the Class, and the documentary I have Tourette’s, But Tourette’s Doesn’t Have Me. Sadly, the lazy jokes (we are looking at you Jimmy Fallon) and terrible film portrayals are considerably more prevalent, and they have contributed to a general public ignorance that increases the risk of misdiagnosis, delayed diagnosis, and bullying.
What are tics?
The most recognizable feature of TS is the tic. These are purposeless movements or noises that occur suddenly, often in bursts, and may seem random to witnesses. But appearances can be deceiving. Although generally considered involuntary, and they can at times take patients by surprise, tics are usually preceded by an intense urge that can usually be suppressed voluntarily with varying degrees of mental effort, a phenomenon that is universally described by patients with the condition. Think of the tic as scratching a sort of internal itch, an itch that might feel good to scratch at times but is a near-constant source of frustration and annoyance for many patients with TS.
Tics can be simple movements, such as eye blinking, grimacing, or jerking of the head or arm, or surprisingly complex behaviors involving multiple muscle groups, such as an unusual gait or a patterned movement of the fingers. They can even be meaningful, ritualistic, or obscene in some cases. Tics can be violent or subtle, easy to conceal or extremely disruptive depending on the setting. Motor tics, in particular severe jerking of the head, can even cause injuries such as cervical disk herniation and dissection of a cervical artery in rare cases.
Vocalizations have a similar categorization into simple and complex vocal tics. Grunting, throat clearing, and sniffing are extremely common, but vocal tics can manifest as words and phrases as well. The most widely known and also misunderstood vocal phenomena associated with TS, thanks to the aforementioned misleading characterizations, is that of coprolalia.
Coprolalia (please read this one) involves the involuntary utterance of obscene words or phrases, although some patients merely think the words or mutter them under their breath. It is believed to occur in 10-40% of patients. But because many patients with mild TS aren’t diagnosed, and studies historically have tended to select for the more severe cases, the prevalence of coprolalia is likely exaggerated.
Coprolalia is fascinating and is a good example of the interplay between TS and OCD, which will make more sense after we’ve discussed the involved neuroanatomy. It is also extremely distressing to patients and often results in extreme social isolation and a severely affected quality of life. It isn’t funny. If you didn’t click on that last link, here it is again.
Here is a list of common tics seen in patients with TS that is not to be used as part of a twisted drinking game at next year’s NECSS.
Although which tics that an individual with TS develops are essentially random, most patients have specific tics that are consistently present. These tics may wax and wane in severity over the years, but they tend to always be there as long as a patient is having tics. Because of this, and the fact that tics in novel anatomic locations do also develop, there is the appearance of a migrating tic pattern. Thankfully in most patients, overall tic severity tends to decrease substantially after adolescence and many adult patients consider themselves to be tic free.
But, and this is very important in the context of evaluating claims of success in treating the condition, more than half of adults who consider themselves to be tic free were not when video evidence was reviewed by a blinded observer. This study didn’t even involve patients undergoing a novel therapy. It was just random adults with a history of TS. There is no reason to assume that adolescents or younger children would be any more accurate.
TS symptom severity is not always easy to assess over any duration of time. When it comes to long term changes, unless someone is secretly videotaping a patient and then carefully counting up tics, it comes down to an easily-biased personal or caregiver assessment. Complicating matters is the waxing and waning nature over long periods of time. If a treatment is started just at the start of what would have been a lull in a patient’s tics, or immediately after an unusually severe period, it can appear to work.
Evaluations of tic frequency for short periods of time, such as immediately before and after an intervention or during an office visit to film a testimonial for your chiropractor, is also prone to error. Severity can increase or decrease significantly from baseline during brief encounters due to stress, relaxation, or suppression, which can be conscious (job interview) or unconscious (increased focus on something else or not wanting to disappoint your parent/chiropractor). TS has historically been difficult to diagnose because kids are notorious for suppressing tics in the doctor’s office. Now caregivers can just use their smartphone to capture tics without the child knowing.
What causes Tourette syndrome?
Although the exact underlying pathophysiology of TS is not completely clear, it is widely considered to be the result of a complex combination of social and environmental factors with genetic abnormalities that alter the structure and function of specific areas of the brain. Although there are some gaps and shadows within which pseudoscientific claims can gather, scientific study has revealed more than what some believers would have us believe.
Environmental and psychosocial variables, while not causative, can play a huge role in the severity of tics in many patients. Stress and anxiety, such as being emotionally upset during an argument or having problems adjusting to a new school, are well known factors in tic exacerbations, as is stress from an acute or chronic illness. From an environmental perspective, there have been links to caffeine and other stimulants as well as maternal smoking, low birth weight, and many more.
There is clearly a genetic component to TS. When thoroughly investigated, TS symptoms can be found in the family history of the vast majority of patients. And the children of a parent with TS have a more than 50% chance of developing tics, with roughly a quarter of them meeting diagnostic criteria for TS. The risk is even higher when TS runs on both sides of the family.
The exact genetic abnormality, or more likely the additive abnormalities in multiple areas of the genome, isn’t known. Over the past several years, multiple candidate regions have been identified, the most interesting so far being a mutation in the SLITRK1 gene on chromosome 13q31.1. This particular gene, which would only explain a small percentage of cases, plays a role in the function of areas in the brain long believed to play a key role in TS, specifically the mesolimbic and frontostriatal pathways.
These areas of the brain, particularly the thalamus, basal ganglia, and frontal cortex, involve connections between movement and behavior and are also implicated in OCD and ADHD, which makes sense considering how frequently these conditions coexist in a TS patient. Although multiple neurotransmitters play a role in the function of these circuits, it is widely believed that a problem with dopamine is the culprit when it comes to TS. Whether there are excess amounts of dopamine or hypersensitive dopamine receptors is unclear.
Gross examination and standard imaging of the brains of TS patients haven’t been helpful, but advanced modalities have increasingly revealed structural and metabolic abnormalities. Patients with TS tend to have decreased volume in the left frontal lobe and overall reduced depth and thickness of gray matter. Metabolic studies have shown increased glucose utilization in the premotor cortex and cerebellum with reduced striatal and orbitofrontal activity. These areas of the brain play a role in the planning and control of movement, as well as in our dopamine-saturated internal reward system, perhaps explaining the urge to tic, the ability to have some temporary control over tics, and the pleasurable feeling when a tic is performed.
Caudate nucleus volume loss as seen on high-resolution MRI is probably the best evidence we have of a clear abnormality in a specific region of the brain. Although still preliminary, it appears that the smaller the caudate volume, the more severe the symptoms of TS and the more likely there will be associated OCD. The caudate nucleus, the activity of which is strongly linked to dopamine activity, plays a key role in the control of movement and in the development of Parkinson’s disease, but also executive function. It’s kind of a big deal.
Of course not knowing all the genetic underpinnings and the exact neuroanatomical abnormalities is not the equivalent of them being unknowable. Clay even recently took part in research at Massachusetts General Hospital, where cutting edge genome-wide association studies are underway. And investigation using advanced neuroimaging techniques is ongoing in numerous research facilities. Stay tuned.
How is Tourette syndrome treated?
Thankfully only a small percentage of those diagnosed with TS will actually require any form of pharmaceutical treatment, although some can’t make it through a day without it. For most, education (patient, family, teacher, employer, etc), reassurance, and monitoring for impairment are all that is necessary. Impairment can come in the form of social upheaval, school or work problems, difficulty with daily living activities, subjective discomfort, pain, or injury.
Patients who present with severe symptoms typically require a prescription as part of their management. For milder cases, although most patients would probably benefit to some degree, only behavioral therapy may be recommended. This typically comes in the form of cognitive behavioral therapy or habit reversal therapy. This can be very helpful alone and as an adjunct to drug therapy, which makes sense considering the significant role that stress plays in overall symptom severity, but it takes a lot of time and effort. And availability is unfortunately limited for many patients.
Historically, the drugs used for TS have blocked dopamine receptors. This is yet another clue to the role of dopamine in the underlying pathophysiology of the condition. The most well-known of these is probably haloperidol, which is better known as an antipsychotic medication but it has a wide variety of uses. Tetrabenazine, a drug that reversibly lowers dopamine levels in the brain, is becoming the treatment of choice because it is equally effective and considerably safer. Most patients experience a 60-80% decrease in tics.
There are other pharmaceutical options, particularly alpha-2 adrenergic stimulators like clonidine which have a general calming effect on the brain. These tend to be less effective but may be better tolerated in some patients and are safer than traditional antipsychotic drugs like haloperidol. In patients with significant behavioral symptoms, like ADHD, these medications play a larger role.
In general, when comorbid conditions are present the drug choice is determined by the aspect of TS that is causing the most problems. Treating severe ADHD with clonidine or even a stimulant medication may actually lead to significant improvement in tics that were exacerbated by the stress caused by the behavioral problems. Treating OCD with behavioral therapy or a selective serotonin reuptake inhibitor may reduce tic severity. Treating problem tics may improve ADHD/OCD symptoms. There is nuance to the management.
Enter the dentists
As was mentioned, TS can have profound physical and psychosocial effects on the individual, as well as creating worry and stress among family members. It is therefore not surprising that some patients or caregivers will go to great lengths to try to obtain relief, either because conventional options aren’t as effective as desired or because they are hesitant to try them. Promises of safe and effective treatments that don’t involve medications may be believed uncritically out of desperation and vain hope.
Parents in particular are a vulnerable population. What parent wouldn’t go to any effort to obtain relief for their suffering child? Sadly, this desperation creates fertile ground in which well-meaning as well as unscrupulous purveyors of alternative medicine plant their unique ideas for management of this condition. Questionable non-scientific treatments for Tourette syndrome run the entire woo gamut – from chiropractic to acupuncture to supplements.
We live in an amazing era of modern dentistry. Gone are the days of Marathon Man and Little Shop of Horror appointments; thanks to measures such as fluoride, sealants, and beautifully lifelike restorations, people can enjoy a level of dental health and aesthetics never before experienced. Relatively recent development such as dental implants allow dentists to restore comfort, function, and appearance in formerly hopeless situations.
One of the most versatile tools in the dentist’s arsenal is the use of acrylic dental appliances to treat or manage a plethora of dental issues. From bite splints to mitigate the effects of bruxism (tooth grinding), to appliances to manage obstructive sleep apnea, to functional orthodontic appliances and retainers – the list goes on and on. There’s almost no problem a patient could have that a hunk of acrylic can’t make better.
There have been a handful of dentists who have claimed that they can alleviate the symptoms of Tourette syndrome and other movement disorders by use of a dental appliance, similar in many ways to the ones used to treat temporomandibular disorders (TMD). Drs. Anthony Sims and Brendan Stack have been at the forefront of this area of study for several years, and have published papers on this subject. Granted, these papers are preliminary and published in low impact journals, but these respected and well-intentioned dentists are trying to support their treatments with a scientific underpinning. Sadly, the science isn’t there yet as we shall see. There is almost nothing in the literature about dental appliances and the management of Tourette syndrome on PubMed or in the Evidence Based Dentistry website at the American Dental Association.
We will take a brief look at two of Dr. Sims’ and Stack’s papers to set the stage for the rest of our discussion. The first is a pilot study of their dental appliance, which has the distinguished if not Spanish Inquisitionish sounding name of Neurocranial Vertical Distractor (NCVD). This paper, published in the Journal of Craniomandibular Practice, outlines the current science on Tourette syndrome. After describing what “mainstream medicine” believes about it, the authors then take a detour, stating:
Many movement disorders are believed to be disjunctions within the thalamus-cortex-substantia nigra connections. However, the authors believe the neuroanatomy of this movement disorder does not rise to the high level of these connections, but is a reflexive disorder that occurs at the spinal cord level within the spinal trigeminal nucleus, specifically the subnucleus caudalis.
They base this hypothesis on their observation that many of the habitual movements of people with TS occur due to reflexive tics of muscles innervated by the trigeminal nerve, or Cranial Nerve V. They then extrapolate this observation to infer that the symptoms of TS and other movement disorders are a function of an “overstimulation” of the neural impulses carried by the trigeminal nerve to the brain due to dysfunction within the temporomandibular (jaw) joint. By treating movement disorders as a TMJ disorder, they reason that a multitude of symptoms can be reduced or eliminated. The NCVD ostensibly reduces this excess neural “noise” by decompressing or distracting the mandibular condyle (head or ball of the lower jaw) from the glenoid fossa (socket), decreasing pressure on the sensitive tissues innervated by the auriculotemporal nerve, a division of the trigeminal nerve. Looking at the device (refer to page 7 in the above article), one can see the thick areas of acrylic on the biting surfaces of the appliance. It is this thickness between the wearer’s teeth, which is determined by the dentist on an individualized basis, which keeps the mandible down and forward in the therapeutic position. The pilot study concludes with a case report of five cases successfully treated with the NCVD.
The other article is an expansion of the first, going more deeply into the proposed neurology and biochemical mechanisms involved in how a dental appliance would reduce or eliminate the symptoms of TS. In the journal Medical Hypotheses, they state:
We hypothesize that the majority of T.S. patients with their various comorbid disorders are due to malposition of the mandible to the patient’s cranial base, resulting in constant stimulation to the trigeminal system that is below the threshold of noxious pain input.
This is indeed an interesting hypothesis, and if true could give hope and relief to millions of people with Tourette syndrome worldwide. No drugs, no surgery – it sounds too good to be true. Adding to the emotional impact of Dr. Sims’ and Stack’s theories, there are many compelling YouTube videos (examples here and here) that purport to show dramatic, almost miraculous responses to the NCVD. These articles are hypothesis-generating and deserve the opportunity to be vetted through rigorous scientific studies and well-controlled trials.
More recently, a new player has entered the game, and this player has barged into the arena boldly and loudly. New York sports radio host Craig Carton, who has Tourette syndrome, has committed $340,000 from his foundation, TicTocStop, to fund device research. Partnering with the University of Tennessee College of Dentistry, Carton wants to help sponsor research in this area. While on the surface this seems an extremely generous and worthwhile endeavor and we certainly don’t want to disparage his intent or actions, there’s a taint about it that we want to address.
First and foremost, anyone who holds a science-based worldview will accept (and hopefully agree) that before a medical product or technique is brought to the public, it must undergo the necessary testing to ensure that it is safe, effective, and better than what is currently available in some way. Basic science research, lab research, and clinical trials are often needed to provide this level of confidence. In this case, however, there is an advertising and branding blitz ahead of the research, and it seems that they are trumpeting the yet-to-be-done research as a marketing tool to infuse some pre-emptive legitimacy to the project.
Their website is heavy on the glitz and light on the science. Their straight to TV campaign on The Doctors show was pure Barnum and Bailey. On it, Mr. Carton stated “…for a hundred years, there’s been not a single advancement in research…” followed by the heart of the message: “We’re selling hope. That’s all we’re selling.”
As responsible health care professionals, that concerns us. We’re neither neurologists nor TS specialists, but we’re pretty sure that there has been at least one scientific advancement in Tourette syndrome research since The Great War. And hope is the only thing they are selling? This appliance will most likely not be covered by medical or dental insurance, so this “hope” that they are selling without proof of efficacy could cost desperate patients and parents thousands of dollars in out-of-pocket expenses.
Grant emailed Timothy L. Hottel, D.D.S., M.S., M.B.A., Dean of the University of Tennessee College of Dentistry and Principal Investigator (PI) of the TicTocStop research project, asking for more information, including study design. Grant informed him that he and Clay were working on an SBM article and wanted his input in order to be “objective and accurate.” His response was as follows:
Dr. Ritchey
Thank you for your interest in our research project. Although I am the PI for this project, it is being completed for TicTocStop. Therefore, I am bound by contract not to release any information on this project….
He then forwarded Grant’s email to Dr. William Balanoff, the medical director for the TicTocStop company (and the guy in the lab coat on the TV show clip), who replied:
Dear Dr. Ritchey,
I read with interest your email to Dr. Hottel. You bring up many good points that need to be addresses [sic] by science in general and dentistry/medicine in particular. Like most research (this included)…it is a journey with no end; only milestones.
As we learn, we will share the information with the world. That is what science does. At this point it is too early to know anything conclusive. I have your contact information and will reach out to you when the research and results achieve some conclusion. I appreciate your zeal to report and comment on this very important study. Let’s stay in touch.
We appreciated both of them responding in a timely and courteous manner; however, we were not given anything of substance. Dr. Balanoff did not respond to a follow up email requesting more information about the proposed study. We understand that in the commercial world, there can be proprietary information that they might not want to reveal – appliance design, materials, what lab they certify to make the appliance, etc. However, in the interest of transparency, why would they not share the experimental details? Are they afraid they will be called out for poor design? Improper blinding? Small sample size?
If the results don’t support their commercial venture, will they move the goalposts or file drawer the study? I guess we won’t know until and unless they publish their data. As staunch supporters of the AllTrials Initiative, we believe that clinical trials should be registered and monitored so that all results are published, not just the ones which have results that benefit the researchers or vested interests. To this end, we challenge Dr. Hottel, Dr. Balanoff, and the TicTocStop research team to register with the AllTrials campaign to ensure that the research is transparent and provides maximum benefit to the scientific community and society at large.
We wish we didn’t have to take such a pessimistic look at this situation, but so far we have seen very little that would lead us to think otherwise. No one is rooting for their success more than we are (especially Clay), but when a venture has all the trappings of a commercial venture, we must raise our eyebrows. Grant has seen this model before in the dental world with a different sort of appliance, and it didn’t end well.
Pulling out his crystal ball, he cynically sees the scenario playing out something like this: TicTocStop will market the hell out of their appliance directly to the consumer via Tourette syndrome support groups, online communities, parenting magazines, and so on. They will be on news shows and all over the web. They want TS patients to ask their physicians and dentists for them, creating a huge demand from the “bottom up”.
They will want to generate some buzz. Moreover, they will mount a huge marketing campaign directly to dentists, informing them of this huge opportunity to help people (and make a lot of money in the process), charging a hefty fee for them to attend TicTocStop’s continuing education courses where they will learn how to properly evaluate and treat the TS patient with their proprietary appliance. Dentists who attend their course will have the privilege of having their name listed on the TicTocStop website as a referral source to drive new patients to their offices, and will have permission to use the TicTocStop logo and promotional materials.
Labs will pay a lot of money to become a TicTocStop “certified lab”, granting them an exclusive license to fabricate the TicTocStop appliance, which will be expensive to fabricate. Meanwhile, we may or may not ever know the results of the study, depending on how well it was done and what they found (or if they accepted our challenge to register with AllTrials). If the study was well designed and carried out properly, taking into account the difficulties in assessing TS symptoms we described above, we predict that the results will be negative, which would be decidedly inconvenient for them. If the study isn’t very robust or well executed, then it will probably be positive, which they will parade around proudly.
Will conflicts of interest be disclosed? Please forgive our pessimism, and we certainly don’t want to impugn the good people at the University of Tennessee or at TicTocStop. Despite our glum prognostication, we would like to go on record to state that we have no doubt that all of the participants and investigators involved in this project sincerely want to help those with Tourette syndrome. And we also recognize that in this age of tight funding, the money for research has to come from somewhere, so we don’t fault them for their fundraising and commercial efforts.
But when profiting from such a situation gets too far ahead of the science and perhaps even trumps it as a priority, it raises our concern and ire. Money has the potential to generate a lot of bias and cognitive blindness, something we call The Daddy Warbucks Fallacy. We earnestly hope that we are proven wrong on all counts.
Parting thoughts
In our opinion, based on the consensus understanding of its underlying pathophysiology there are some major plausibility concerns with the hypothesis that disorders of the temporomandibular joint play a role in the development of TS symptoms. The number of assumptions required certainly violates Occam’s razor, and it raises many questions:
     1.  Tics are present in virtually all muscle groups, not just the muscles of biting and chewing. Why assume that the trigeminal nerve is the culprit? Many assumptions must be made to connect the trigeminal nerve to blinking, let alone shoulder shrugging and coprolalia that don’t make any sense neurologically.
     2.  How does trigeminal “overstimulation” lead to the changes in the brain neuroanatomy seen with advanced imaging, or are those a coincidence? To our knowledge, there are no other medical conditions with a similar pathophysiology. There already is a condition involving chronic injury of the trigeminal nerve called trigeminal neuralgia, however, and it causes severe facial pain but no other neurologic symptoms.
     3.  Assuming “overstimulation” of the trigeminal nerve can result in neurological symptoms, why does it selectively cause tics, ADHD, and OCD and not seizures, schizophrenia, personality changes, or some other neurologic problem? What explains the urge to tic?
     4.  Why is there a clear genetic pattern to TS? TMD does not run in families to anywhere near that degree.
     5.  How does TMD as a factor explain the waxing and waning course of TS and the fact that most patients have significant improvement after puberty? Does malposition of the jaw improve after puberty and as patients age?
In summary, while we can’t yet discount the possibility that a dental appliance, be it a Neurocranial Vertical Distractor or a TicTocStop appliance, can lessen or eliminate the tics that Tourette syndrome patients have, we can conclude that the biological plausibility for such a device is very low. What we know about TS doesn’t jibe with dental hypotheses. YouTube videos and testimonials, as impressive as they may seem, are insufficient because the natural course of TS and the role stress/placebo plays can make absolutely any intervention (and in particular for neurological problems) seem to work in the short run. And the literature on the subject has essentially been a monopoly by two dentists who treat Tourette patients and is scant and of low quality.
Ultimately, readers will need to decide if this is an extraordinary claim or if repositioning of the jaw in an effort to reduce the neuromuscular manifestations of this complex disorder is in line with our basic scientific understanding of neuroanatomy and the consensus pathophysiology of TS. Once a sense of the prior plausibility is determined, the degree of evidence required to make a causal claim can be decided. Then a provisional conclusion can be made that may or may not change if new data is actually published.
At this point, we would caution anyone who has TS, or is the caregiver of someone with the condition, to be wary of these claims until the science can better support it.

More False Hope for People with Tourette Syndrome
After a few years off, this is the third and final installment in a long-running series of posts tackling the claims made by proponents of an oral appliance for the treatment of Tourette Syndrome.
Clay Jones on August 5, 2022
Link

In 2016, celebrity dentist and occasional SBM contributor Grant Ritchey and I wrote a post on claims involving the potential use of a dental appliance for the treatment of tics caused by Tourette syndrome, a complex and fascinating neurological condition that I also happen to have. At the time, we were quite skeptical:
In summary, while we can’t yet discount the possibility that a dental appliance, be it a Neurocranial Vertical Distractor or a TicTocStop appliance, can lessen or eliminate the tics that Tourette syndrome patients have, we can conclude that the biological plausibility for such a device is very low. What we know about TS doesn’t jibe with dental hypotheses. YouTube videos and testimonials, as impressive as they may seem, are insufficient because the natural course of TS and the role stress/placebo plays can make absolutely any intervention (and in particular for neurological problems) seem to work in the short run. And the literature on the subject has essentially been a monopoly by two dentists who treat Tourette patients and is scant and of low quality.
Ultimately, readers will need to decide if this is an extraordinary claim or if repositioning of the jaw in an effort to reduce the neuromuscular manifestations of this complex disorder is in line with our basic scientific understanding of neuroanatomy and the consensus pathophysiology of TS. Once a sense of the prior plausibility is determined, the degree of evidence required to make a causal claim can be decided. Then a provisional conclusion can be made that may or may not change if new data is actually published.
At this point, we would caution anyone who has TS, or is the caregiver of someone with the condition, to be wary of these claims until the science can better support it.
In our initial post, we mentioned that a proper study was being planned under the guidance of Timothy Hottel, the Dean of the College of Dentistry at the University of Tennessee. This study was funded by a $350,000 donation from Tic Toc Stop Inc., a charitable organization founded by radio personality Craig Carton. Carton, and Tic Toc Stop Chief Medical Director William Balanoff, heavily promoted (here on The Doctors in 2016) the study, which as described did not inspire confidence. But we remained hopeful.
A little over a year later, Grant, who at the time was heavily involved in coronavirus gain-of-function research in his basement virology lab, corresponded with Dean Hottel and Dentist Balanoff. We were delighted to learn that the study had been completed and was in preparation for peer review and imminent publication. “Huzzah!”, Grant exclaimed. Unfortunately, Grant’s excitement was premature.
Nearly two years after our original post, we revisited this topic in a May 2018 SBM post because the study had yet to be published and there were some interesting developments behind the scenes. Carton, essentially the money behind the study, had been arrested in September of 2017 on criminal charges of securities fraud and wire fraud, as well as conspiracy to commit those crimes. There were also serious allegations that the Tic Toc Stop foundation didn’t actually do anything to help people with Tourette syndrome.
Grant, I assume using a quill and some parchment paper (because he is very old), had again contacted Hottel and Balanoff. And again, we were reassured. The study had been submitted for publication, though they didn’t reveal to which journal. Balanoff even promised to give us a heads-up just as soon as it was officially accepted. Grant was practically giddy and needed a few extra minutes of nitrous oxide before he could fall asleep that night.
We also wrote at the time that there appeared to have been some kind of upheaval in the University of Tennessee College of Dentistry involving Dean Hottel being placed on “indefinite suspension”. This ended up being a false alarm based on oddly worded minutes from a board meeting. Dean Hottel was simply replaced because he took a position as Director of Statewide Oral Health Initiatives for the University of Tennessee Health Sciences Center.
We noted another interesting tidbit at the time:
But the really interesting thing is that just as we were writing this post Dr. Balanoff took down all of his references of and associations with Tic Toc Stop as well as the outline of his study design. On his new website (he kept the same URL), he is now promoting an appliance for TS called the T.A.G. appliance. Our hunch is that it is the same appliance as before, but just rebranded. He will probably still use the same shoddy study he has been conducting for years to promote his gadget to dentists, dental labs, and vulnerable people with TS.
So here we are in these uncertain times of 2022. Was a study on the use of a dental appliance for the treatment of Tourette syndrome ever published? Or had this merely been a marketing stunt? Grant and I had initially been hopeful, but with the lead researcher at the University of Tennessee’s College of Dentistry leaving his position, the main promoter and money man facing a lengthy prison sentence, and the brains behind the study ghosting the whole operation, we had pretty much given up.
I can’t speak for Grant, but I will readily admit that I put no effort into following up on this over the past 4 years. I honestly never expected this study to see the light of day. I was wrong.
Earlier this week, when looking into similar claims involving a magic wrist buzzer being used to treat Tourette syndrome, I remembered the Tic Toc Stop fiasco and found that the study was actually published in January of 2019 in Compendium of Continuing Education in Dentistry. I’ll briefly break down the study and why it is essentially worthless, as we expected it would be. Better late than never, I suppose.
Improved Yale total tic severity score due to craniofacial manipulation with an oral appliance
In our original post back in 2016, Grant discussed the historical underpinnings of these claims, so I won’t go into detail here. Needless to say, the proposed mechanism given in this study is garbage:
Thus, the action of separating the posterior opposing teeth (typically in excess of 4 mm to 5 mm) causes the condyle to rotate within the condylar fossa of the TMJ and translate down the articulate eminence of the temporal bone. Opening the bite in this way creates neurostimulation of the sensory fibers of the joint capsule to create a shutoff mechanism in the brain to prevent the motor nerves from leaving the brain to fire. The signal received by the brain via the Vth cranial nerve reduces or eliminates the motor signal from the brain to the III, IV, V, VI, VII, IX, and XI cranial nerves.
No evidence exists to support the existence of this “shutoff mechanism”. I could just as easily claim that it actually causes a “boosting mechanism” or, more likely, there is no spoon…I mean mechanism. The mechanism proposed in the study is a bit broader than the claims we addressed back in 2016, specifically because they mention cranial nerves other than just the trigeminal (V). We have the pathways involved in TS fairly mapped out, and though we don’t know everything, this just makes no sense and my earlier response still holds up:
     1.  Tics are present in virtually all muscle groups, not just the muscles of biting and chewing. Why assume that the trigeminal nerve is the culprit? Many assumptions must be made to connect the trigeminal nerve to blinking, let alone shoulder shrugging and coprolalia that don’t make any sense neurologically.
     2.  How does trigeminal “overstimulation” lead to the changes in the brain neuroanatomy seen with advanced imaging, or are those a coincidence? To our knowledge, there are no other medical conditions with a similar pathophysiology. There already is a condition involving chronic injury of the trigeminal nerve called trigeminal neuralgia, however, and it causes severe facial pain but no other neurologic symptoms.
     3.  Assuming “overstimulation” of the trigeminal nerve can result in neurological symptoms, why does it selectively cause tics, ADHD, and OCD and not seizures, schizophrenia, personality changes, or some other neurologic problem? What explains the urge to tic?
     4.  Why is there a clear genetic pattern to TS? TMD does not run in families to anywhere near that degree.
     5.  How does TMD as a factor explain the waxing and waning course of TS and the fact that most patients have significant improvement after puberty? Does malposition of the jaw improve after puberty and as patients age?
The study design, as I mentioned above, renders the result practically meaningless. They did not, as would be necessary to provide any helpful data, randomize the 67 subjects into treatment and control arms with a well thought out sham device. As I’ve explained many times in previous posts, tics associated with Tourette syndrome are significantly affected by environmental and psychological variables. They are highly susceptible to placebo. This is why there are countless examples of various bogus interventions seemingly providing an instant cure.
In the study, they obtained a patient-reported baseline tic severity score and then each subject underwent dental imaging and measurements for a custom oral appliance (Tic Guard). They were then each given a standard mouth guard orthotic. They knew it was a standard mouth guard. There was no blinding.
Tic severity was assessed after a week of wearing the standard mouth guard and then subjects were given their Tic Guard. Again, each subject knew that they were being given a specially-made device. Nobody was blinded. They were almost certainly told that the Tic Guard had already been found effective in “pilot studies” or at the very least had been exposed to the “miraculous” videos where children have dramatic improvements of their tics. There is nothing in the paper that contradicts this assumption.
Tic severity was again assessed one week after subjects were given their custom-made Tic Guard and then again ten weeks later. The study subjects, 3/4 of which were male and the average age was 15 years, were not required to keep a log of how much they wore their Tic Guard. They were just asked at the end. There is no way to now how much they used the devices or even if they did at all. This may come as a surprise, but teenagers (all humans actually) sometimes just tell people in positions of authority what they think they want to hear.
The study found exactly what I would have expected. After a week of using (or not using) a standard mouth guard, subjective tic severity scores were improved when subjects were interviewed by personnel involved with the study. On average, there was a roughly 16% improvement in total tic severity compared to baseline scores at that point.
This doesn’t mean that the standard mouth guard worked. It also doesn’t mean that there was some kind of magical “mind over matter” placebo effect. It means that people in studies who know that they are in studies, who want to improve, who want to please investigators or caregivers, and who are asked to self-report their recall of how they are doing, tend to report that the are doing a bit better. This improvement would have likely been seen even without being asked to wear the standard mouth guard.
After a week of using (nor not using) the custom-made Tic Guard, subjects self-reported an additional 5% improvement, which was deemed to be statistically significant by the study authors. At the final assessment ten weeks later, subjects self-reported an additional 14% improvement in total tic severity. During this time, 9 of the 67 subjects didn’t return to be assessed. We don’t know why 14% of subjects dropped out, but it is certainly possible that this would have made the final numbers look very different.
The authors conclude that both the sham mouth guard and the Tic Guard work, but the Tic Guard works better. A more accurate conclusion is that teenagers with Tourette syndrome are likely to report that their tics are partially improved when they are enrolled in a poorly-designed study, and more so when they are told that an intervention works. There was no effort in this study to actually control for placebo effects.
The authors’ cherry on top:
This study clearly demonstrated that tics in all test subjects were mitigated by optimizing the opening of the vertical dimension. Understanding where the condyle is in relationship to the articulate eminence and fossa will provide guidance as to “why” this works effectively. The long-term implications outpace this study design. Perhaps a treatment modality would be craniofacial surgery to correct a maxilla/mandibular discrepancy. Possibly, interceptive orthodontics might be appropriate on patients with a family history of TS and a propensity toward a class II occlusion; this would be a patient population that would require early screening and treatment.
Research should ideally prove that there is an effect before we talk about how to optimize the proposed underlying mechanism for it. And yes, the authors are throwing out the possibility of surgical intervention and even having kids use Tic Guard oral appliances to potentially prevent the development of Tourette syndrome. Nope.
Tourette syndrome is much more than just a collection of tics. The plausibility that an oral appliance plays any role whatsoever in the pathophysiology that results in tics, however, is extremely low. The evidence in support of such a dental device as a treatment would need to be quite robust in order to warrant acceptance. This ain’t it.
Where are they now?
Tim Hottel is currently an adjunct professor at Lincoln Memorial University and does not appear to be involved in any additional research into dental treatments for neurological conditions. It remains a mystery as to why a respected Dean at a major university would have ever become involved with such a ridiculous study. I don’t think we will ever know what might have been going on behind the scenes.
After his arrest in late 2017, Craig Carton would ultimately be sentenced to 3.5 years in prison and ordered to make restitution of $4.8 million. As of August 2022, he has completed his sentence and is again working very successfully as a radio and television personality. He does not appear to be doing any advocacy or fundraising for Tourette syndrome and the Tic Toc Stop foundation no longer exists. The only person that I can find still touting the device, though under a different name, is William Balanoff.
Balanoff posted a lengthy explanation of this study on his website that is full of nonsense like the following, worthy of it’s own SBM post:
In particular the jaw to brain connection is complex and can have an affect on other parts of our anatomy. Since dentists are experts in head and neck anatomy they are the best qualified to analyze the data provided from research study.
Grant Ritchey continues to practice as a dentist, I think in Nebraska, and has two cats that are both named Gary. He is a smart guy, and has never murdered any lions that I am aware of, so I would love to get his take on whether or not dental school prepared him to evaluate neurological conditions and brain anatomy. I would weigh in myself, but I think I’ve already overstayed my welcome a bit when it comes to this particular issue, and I don’t want to come across as a rabid anti-dentite.

The Parasympathetic State
The claims for an essential oil mixture, Vibrant Blue Parasympathetic, are devoid of science. They are a mixture of pseudoscience, misrepresentation, lies, and imagination.
Harriet Hall on January 7, 2020
Link

Starting a new year. For the past 12 years, I have written an article for the Science-Based Medicine blog every Tuesday. I have often thought that the best way to illustrate the value of science-based medicine is to examine medicine that is not science-based. A bad example can be memorable and instructive. I thought I would start 2020 by writing about a particularly bad example, Vibrant Blue Oils Parasympathetic. I won’t call it the worst ever, because every time I say that, something worse is sure to come along. But it’s a good example of the worst. Vibrant Blue Oils Parasympathetic is about as far from science-based medicine as you can get: a mixture of pseudoscience, misrepresentation, lies, and imagination.
The autonomic nervous system
The Vibrant Blue Oils website explains “How Parasympathetic is Critical to Your Health“. It claims that “digestion, detoxification, and immune functions are only turned on when your body is in a parasympathetic state” and you should optimally be in a parasympathetic state 80% of the time. And “almost all disease and dysfunction result from you not being able to drop into the Parasympathetic state.” What follows is a confused, simplistic discussion of the autonomic nervous system with its two components: the sympathetic branch governs the fight or flight response, and the parasympathetic branch is known as the “Rest, Digest, and Heal” state.
The term “the parasympathetic state” is not recognized by science. The sympathetic and parasympathetic systems work together and neither is ever “turned off.” There is no “parasympathetic state”, but there are ways to increase parasympathetic activity. An article from the Canyon Vista Recovery Center lists ways to activate the parasympathetic nervous system to decrease stress and anxiety. The list includes exercise, meditation, massage, prayer, play, deep breathing, spending time in nature, and doing things you enjoy. It even suggests gently touching the lips to activate the parasympathetic fibers there. Another website lists “12 ways to rest and digest“, repeating many items from the other list and adding acupuncture, yawning, gum chewing, and immersing the face in cold water. One thing these lists do not mention is essential oils.
Essential oils
Vibrant Blue Oils claims that essential oils are a natural way to achieve the parasympathetic state. Their Parasympathetic blend is “a proprietary synergistic combination of two essential oils: clove oil (which is highly stimulatory) and lime oil (which “has super small molecules”). These oils allegedly carry other healing properties, and are said to dull pain, heal infections, purify blood, and balance blood pressure. They claim that lime oil was found to be more effective than antidepressants, but I couldn’t locate any such study. Systematic reviews have concluded that “the evidence is not sufficiently convincing that aromatherapy is an effective therapy for any condition”.
I found one reference to the potential of essential oils for treating irritable bowel syndrome (IBS). Clove oil is one of several essential oils that contain eugenol. The study referred to was in mice that developed gastrointestinal dysfunction when stressed by being restrained. The eugenol was instilled directly into the stomach by gavage. Not aromatherapy, not IBS, and humans are not mice: not relevant.
They recommend applying the Parasympathetic blend to the vagus nerve three times daily, ideally before meals (why?). They incorrectly state that the vagus nerve wraps through almost every organ in the body. The way to apply the oil to the vagus nerve is to apply it to the mastoid bone behind the ear. The vagus nerve does indeed have an auricular branch, but I question whether applying essential oils to skin over the bone of the mastoid process would produce any measurable effect on the vagus nerve or on the parasympathetic nervous system, and they offer no evidence or rationale.
There is a lot of nonsense about vagus nerve toxicity (not a recognized medical condition) and how to recover from it. They offer other essential oil products to support the gallbladder, kidneys, lymph, and liver. “To support the flow of bile and, with it, toxins out of the body, apply Gallbladder™ on the right side of the body under the bra under-wire or along and slightly under the right rib cage two to three times daily”.
You can buy a 5cc (1 teaspoon) bottle of Parasympathetic for $36.95. They also offer essential oil products for circadian rhythm, hypothalamus, sleep, frankincense, and more.
Conclusion: No science here
Vibrant Blue Oils Parasympathetic is a very bad example that mixes pseudoscience, misrepresentation, lies, and imagination. Fantasy-based, not tested, not supported by any scientific evidence.
And yet people will buy it. A typical testimonial:
First time I used your oil, I literally felt my heart lifting. Ever since then, I don’t go anywhere without your parasympathetic oil. Now I’m trying your fertility blend and I’m feeling positive that I will get pregnant. Thank you so much. I really love what you do.
Hope springs eternal, customers have placebo responses, and people who disregard science make money.

Some essential oils may trigger seizures
Some essential oils appear to trigger seizures in people with no history of epilepsy.
Scott Gavura on April 29, 2021
Link

While I’d argue that the only truly essential oil is olive oil, there are dozens of plant-derived “essential oils” that are sold used commercially for health-, beauty-, and food-related purposes. In this case, “essential” refers to the essence of the plant’s aroma, and are not a statement regarding their importance to your health or well-being. Essential oils have been popular for decades but usage has exploded through wellness influencer endorsement combined with multi-level-marketing businesses that have driven awareness and use. While essential oils are generally considered safe, even harmless, by consumers, a number of adverse events have been reported by their use. Vaporizing them, for example, releases volatile organic compounds into the air that can worsen asthma symptoms. Some essential oils contain pro-convulsant compounds, which, when inhaled, have been associated with induced seizures. Now a new study examines the association of essential oil exposure with seizure in patients who presented to hospitals with new or breakthrough seizures.
The study
This was a prospective evaluation of patients by Thomas Mathew and colleagues, examining patients who presented to four Indian hospitals between 2014 and 2018. Participants either needed to present with a first episode of a seizure, or a new seizure in individuals with pre-existing epilepsy who had recent exposure to essential oils. The researchers defined two types of seizures:
    • Essential oil-induced seizures (EOIS) occurred after exposure to an essential oil where there was a temporal relationship, and no previous history of seizure and no recurrence after stopping exposure.
    • Essential oil-provoked seizures (EOPS) occurred in persons with epilepsy or epilepsy syndrome, where the seizure occurred after exposure to an essential oil, and there was no other obvious cause for the seizure (e.g., not taking medication).
Over a four year period, 55 patients were identified out of 350 screened who met the definition of essential oil-related seizure. Twenty-two were EOIS and 33 were EOPS. The group was roughly split male to female, and the age ranged from 8 months to 77 years. Both eucalyptus oil and camphor oil were implicated, and the modes of use included topical (most common), inhalation, and ingestion (least common). Balms containing both camphor and eucalyptus were identified, as well as pure oils containing one or both ingredients. (These are the same active ingredients found in products like Vicks Vapo-Rub, but I have no idea if the products identified in the study were the same.) The paper gives a series of vignettes; here is one so you get the flavour of the cases:
A 12-year-old male was asked by his father to take steam inhalation with a balm containing 4.7 % camphor and 1.2 % eucalyptus for a common cold. Five minutes into inhalation he had a generalized tonic-clonic seizure. His MRI brain and EEG were normal. He was advised to avoid any exposure to essential oil containing products. The boy was followed up for a year with no recurrence of seizure.
The average time to seizure onset varied: 30 minutes to 24 hours after topical application, 2 minutes to 30 minutes after inhalation, and 30 minutes to 6 hours after ingestion. No one in the EOIS group has a subsequent seizure after discontinuing the EO. 94% in the EOPS group remained seizure-free during follow-up, continuing on their existing anti-epileptic medications. Amazingly, some patients in the EOPS who where chronically using essential oils could reduce the number and dosage of their anti-epileptic medications after eliminating exposure to essential oils.
Implications for essential oil users
Plant-derived essential oils may be naturally-sourced, but their concentrated forms can be used in ways and in amounts that are far from “natural”. Essential oils like eucalyptus, camphor, rosemary, thuja, sage, spike lavender, and turpentine have pro-covulsant properties due to their chemical components. In this study, camphor and eucalyptus, commonly used essential oils in India, were found to be associated with seizure occurrence in 55 cases. While cause cannot be definitively proven, it is not likely there will be prospective, blinded trials to further clarify this relationship. In light of these findings, it is probably prudent for those with a history of seizures or epilepsy to avoid use of pro-convulsant essential oils, particularly camphor and eucalyptus. For those without any epilepsy or seizure history, using essential oils with caution, and avoiding ingestion or excessive doses should minimize any risk of these rare but potentially serious adverse events.

Keto Diet for Neurological Disorders
Does the ketogenic diet work for epilepsy or other neurological disorders? While the consensus is that it probably does, the evidence is surprisingly thin.
Steven Novella on February 20, 2019
Link
In the 1992 film, Lorenzo’s Oil, we see the story of Augusto and Michaela Odone, who defied the medical opinions of the time and sought out a treatment for their son Lorenzo’s adrenoleukodystrophy. The notion that a diet could affect a severe neurological disorder was met with skepticism, but the loving parents persisted and finally found what they were looking for.
It is a compelling story, but the reality is more complex. After a few decades of research, we are still left with uncertainty. The diet does prevent the build up of very long chain fatty acids (VLCFA) in the blood, but not in the brain. The evidence does suggest that if the diet is started in asymptomatic individuals with X-linked ALD (but not other disorders) it may delay progression to symptoms. However, once symptoms have started it does not alter the progression of the disease.
We are still at the stage where reviews conclude:
In conclusion, although additional controlled, large, and long-lasting studies are needed to confirm it, Lorenzo’s oil could be effective in preventing neurological manifestations in asymptomatic patients with X-ALD.
Ironically, Lorenzo had significant clinical progression prior to having the special oil (a combination of a 4:1 mix of oleic acid and erucic acid) added to his diet. So while the evidence shows the oil might work in asymptomatic patients, it also shows that it does not work in patients like Lorenzo.
Keto diet for seizures and migraines
Another dietary intervention claimed to be effective for neurological disorders is the ketogenic diet, and again the story is complicated and the evidence short of definitive.
Prior to modern medical treatment, all sorts of interventions were used for patients with epilepsy. Dietary restrictions go back to 500 BCE. The ketogenic diet specifically became popular in the 1920s, but then was largely replaced by modern antiepileptic drugs. In the last 20 years, however, it has seen a resurgence in popularity. So with almost a century of use, where does the evidence stand?
A ketogenic diet is essentially one that is low enough in carbohydrates that the brain becomes starved of glucose. This triggers the production of ketones, which is an alternate fuel source. This results in a host of metabolic changes. It is therefore plausible that there is a real physiological effect from such an extreme diet. But this cuts both ways – there is also the potential for negative effects.
At this point we are still not sure what the potential mechanism is. The production of ketones has been shown to affect the activity of neurotransmitters, which is a plausible mechanism. It also alters antioxidant activity and inflammation in the brain. There are countless studies showing effects on various physiological markers, but nothing tying a specific mechanism to any apparent clinical effect.
The clinical evidence, after almost a century of use, is surprisingly unclear. A 2018 Cochrane review of the ketogenic diet for refractory epilepsy concludes:
The RCTs discussed in this review show promising results for the use of KDs in epilepsy. However, the limited number of studies, small sample sizes and the limited studies in adults, resulted in a low to very low overall quality of evidence.
Most reviews are still concluding that more and better studies are needed. Why is this? Part of the problem is that these studies are hard to do. Subjects need to be placed on an extreme diet, something which is hard to blind and has overall poor compliance. Studies also need to be long term, at least a year if not longer. This is because the effect may take time to occur, may not last, and side effects may start to appear over time.
Studies are plagued by a high drop-out rate, often for lack of benefit. This hugely biases the outcome of studies. But in addition, the high drop-out occurs in clinical practice as well. When a doctor places their own patients on the diet, those who see an apparent benefit are more likely to stick with it. This is a setup for confirmation bias, which might explain why many clinicians are more confident in the treatment than the clinical studies warrant.
I should also point out that the evidence supports effectiveness in children with refractory epilepsy, but not in adults. The reason for this difference is unknown, but it is plausibly due to the different causes of epilepsy between childhood and adult onset.
The side effects of a ketogenic diet are also non-trivial, including gastrointestinal symptoms, increased cholesterol, and long term cardiovascular effects. However, there haven’t been enough long-term studies to really know what the risks are.
So if we do a risk-benefit analysis for the ketogenic diet in childhood refractory epilepsy the result is complex and plagued by unknowns. The diet itself it difficult to adhere to and can have a significant negative impact on quality of life, with significant side effects and some unknown long term risks. There seems to be a benefit in terms of reduction in seizure frequency for some patients, but we still need better quality studies to confirm this.
Because, however, refractory epilepsy is a severe problem that can have a devastating effect on quality of life, many clinicians think it is worth a trial in appropriate patients (the risk is high, but the potential benefit is also high). But clearly the time is ripe for a definitive high quality clinical trial to reduce the uncertainty about this century-old treatment.
What about the ketogenic diet for migraines? Everything I said above about plausibility and side effects applies. The clinical evidence for efficacy is even more preliminary. It consists mainly of case reports and open-label case series. There are no high quality double-blind studies.
The risk-benefit for migraines, in my opinion, is not worth it. What this means is that I would not recommend this intervention outside of an approved clinical trial. I also have concerns about the long-term effects of a ketogenic diet, which have not been adequately studied. Migraines, like seizures, are a chronic condition. We may need to treat patients for decades. That is a major life commitment for an intervention like the ketogenic diet.
There is evidence that milder diets, like the modified Atkin’s diet (MAD) has similar efficacy to the keto diet with fewer side effects and better compliance. This is good, but equivalency to a questionable intervention does not resolve the question of efficacy, and arguably shows a lack of a dose-response effect which could reduce confidence in the treatment.
Further, there are newer migraine interventions coming online, like the recent CGRP antagonists, which are showing great efficacy. I would not recommend the diet until after seeing a headache specialist and exploring all of the established treatments.
The story of dietary interventions for neurological disorders is an instructive one. First, we cannot be dismissive of interventions that seem implausible at first. Similarly, the pop-culture aspect of an intervention, like the keto diet, is not an argument in its favor, but should not cause serious scientists to dismiss it either.
Even more importantly, the controversy over the keto diet shows how important rigorous clinical trials are. We can debate endlessly about the potential risks and benefits of the keto diet, with patients stuck in the middle trying to decide if they should turn their life upside down with an extreme diet, but one that might dramatically improve their lives. The stakes are pretty high for patients.
Unfortunately, the “just try it” approach does not work. It may seem counterintuitive, but the vagaries of chance and the systematic deception of cognitive biases means that unblinded trials are not likely to produce a definitive answer, even for an individual. That last thing you want is for a patient to be convinced that an expensive, difficult, or risky intervention works because of placebo effects, when in fact it is not really helping them. Then they are trapped with a very costly placebo.
We need to know with a higher degree of confidence what the risks and benefits of this intervention are. That requires high quality clinical trials.

Reflex Integration Therapy
Various methods of reflex integration claim benefits for autism, ADHD, brain injuries, pain, and more. They are based on speculative ideas about retained primitive reflexes. They have not been scientifically tested.
Harriet HallonMay 15, 2018
Link


Reflex integration therapy claims to relieve a variety of symptoms of a wide range of neurologic conditions including autism, ADHD, brain injuries, pain, Down Syndrome, cerebral palsy, Parkinson’s, and more. I touched on the subject in a previous article, but there are new developments. Now we have Quantum Reflex Integration with the addition of cold lasers.
What is reflex integration?
According to one description it is:
a novel and non-invasive method of improving developmental delays and central nervous system function in children with a variety of developmental disabilities. This method addresses disorders with a neurologic component, and it is based on the concept that unconditioned reflexes are not static and facilitate adaptation to the external environment, while becoming the foundation for physical, emotional, and cognitive development. Unconditioned reflexes, such as Babkin Palmomental, Babinski, Spinal Galant, and Perez are innate, genetically-based traits that are required for survival by all individuals…An assumption of the NRI therapeutic modality is that if the reflex arc of sensory input, brain processing, and motor response is complete, and the various reflexes are neurologically mature (myelinated), then physical, emotional and cognitive functions will function normally. Alternatively, emotional outbursts, cognitive deficiencies, or atypical movement patterns may occur if there are deficiencies in the interpretation of sensory information or motor responses are abnormal.
Unconditioned or primitive reflexes
Babies are born with a number of special reflexes. I’ll mention just three of the better-known ones.
Moro reflex: If a newborn senses that it is falling, it reacts instinctively by spreading out the arms, then unspreading them. This may have had an evolutionary advantage in helping the infant cling to the mother.
Rooting reflex: When a newborn’s cheek is stroked, it turns to that side and opens its mouth, a reflex that assists in breastfeeding.
Diving reflex: Most (but not all) infants up to six months old, when submerged, will spontaneously block off their airway, hold their breath, and their heart rate will slow down.
These newborn reflexes disappear as the child develops. In older children and adults, the persistence or re-emergence of primitive reflexes beyond the appropriate developmental stage is a sign of serious brain disease or damage.
Advocates of reflex integration treatments claim to find persistent unconditioned reflexes with associated symptoms. They say a persistent Moro reflex is associated with poor impulse control, sensory overload, anxiety, social immaturity, motion sickness, poor balance, poor coordination, distractibility, inability to adapt to change, and mood swings. Retention of the rooting reflex beyond four months is said to cause difficulty with solid foods, poor articulation, and thumb sucking. There are many more unconditioned reflexes with many more claims of associated symptoms.
They say retention of primitive reflexes can be caused by a variety of factors:
The birth process is a key factor in the integration of these reflexes. Therefore a traumatic birth experience or birth by c-section may lead to retained reflexes. Additional causes can include: falls, traumas, lack of tummy time, delayed or skipped creeping or crawling, chronic ear infections, head trauma and vertebral subluxations.
The treatment consists of attempting to integrate these persistent unconditioned reflexes using various exercises and other modalities.
The Masgutova method
One of the best-known reflex integration therapies is the Masgutova Neurosensorymotor Reflex Integration (MNRI) method. Automatic primary motor reflex movements and patterns are its primary focus because they provide protection during infancy and when neurosensorimotor challenges are present (emotional and behavioral regulation issues), and because they are subordinate components of progressively more complex automatic motor reflex schemes, learned motor skills, and advanced motor planning, communication and cognitive development. They say anyone and everyone can potentially benefit.
The method was created by Svetlana Masgutova, a Russian PhD in Developmental and Educational Psychology. She treated children who developed PTSD after the Ufa Train Catastrophe, using movement and tactile activities to draw out “psychologically trapped” children. She was impressed that recovery times were far faster than expected.
The Masgutova website provides a list of scientific articles about MNRI in peer-reviewed journals. They don’t amount to much. The studies are typically poorly designed, without appropriate control groups. In one study of children with autism, the control groups were untreated children with autism and untreated neurotypical children. In studies like these, doing “anything” will always look better than doing “nothing.” They didn’t control for placebo effects or for the natural improvement of autistic symptoms over time. They demonstrated that patients showed improvement during MNRI, but they didn’t ask whether they improved more than they would with any other intervention that provided one-on-one attention, massage, other kinds of exercise, and other nonspecific treatments having nothing to do with primitive reflexes.
A committee of the Wisconsin Department of Health Services reviewed MNRI in 2015 and concluded that it was an untested treatment not supported by any experimental studies.
Quantum Reflex Integration
The word “quantum” immediately raises red flags. The QRI website raises many more. QRI essentially adds sound and light to the mix, with harmonious frequencies and low-level cold lasers. It uses “harmonic laser frequencies for each reflex and acupoint.” Yes, you read that correctly: they invoke the mythical points of acupuncture. Cold lasers stimulate the mitochondria to increase the amount of ATP in the cell. So what? I couldn’t find anything on the website that explained the use of the word “quantum.” The website offers plenty of success stories and testimonials, but not a single scientific study.
Criticism
A blog by a retired neuropsychologist characterizes primitive reflexes as “a new old fad” related to the idea that ontogeny recapitulates phylogeny. He explains that these reflexes become inhibited and disappear in normal development. In cerebral palsy, they may be retained and can sometimes be utilized to induce more reliable and predictable movements. The new fad therapies claim that retained primitive reflexes hinder achievement and can be corrected and “integrated” in short order. Many of them are shotgun approaches that incorporate just about any nonsense.
Conclusion: Long on claims and short on evidence
The various reflex integration therapies are based on speculative ideas about retained primitive reflexes. We can’t know whether any of them are effective, because they haven’t been scientifically tested.

Dubious Autonomic Nervous System Claims
Beware overblown claims that autonomic testing can help almost anything.
Steven Novella on June 14, 2023
Link

The realm of personalized medicine, functional medicine, and of course integrative medicine remains rife with pseudoscience and dubious claims. The claims are often couched in scientific terms, as if this is the next step in scientific medicine, just a bit ahead of its time. This is particularly dangerous, as non-experts will have difficulty parsing the often complex claims being made. This is why it is often necessary for expert communities to regulate themselves to ensure some standard of quality – something that has been eroding within medicine for decades, under relentless and successful assault by the overall CAM community.
One practice that, in my opinion, is a good example of this phenomenon is in-office autonomic nervous system (ANS) testing being offered by some practices. ANS testing and diagnosis itself is legitimate, although this is a very complicated area of neurology. “Boutique” versions of many legitimate medical practices have been cropping up, however, such as questionable thyroid testing, fake allergy testing, and other questionable practices.
This particular practice was brought to my attention because of recent local news stories, which were uncritical and essentially amounted to free advertising for the practitioner. But before I get into that, let me give a little background on the ANS and clinical testing in general.
The ANS is part of the nervous system that regulates our overall nervous system activity in specific ways. The sympathetic nervous system reacts to stress or dangers by increasing blood pressure and cardiac function, dilating the pupils, increasing breathing, and increasing sweating. The parasympathetic nervous system is more active when we are in a calm state, and it increases the activity of our gastrointestinal system and glandular secretions while slowing down the heart and reducing blood pressure. These two systems exist in constant balance, adjusting their relative tone moment to moment in order to, for example, maintain a constant blood flow to the brain. It does this by making constant microadjustments in response to changes in position, muscle tone, and even the varying pressures that result from breathing.
Severe disorders of the ANS can result in dramatic symptoms, such as fainting upon standing up because of insufficient sympathetic activity to raise blood pressure to compensate, or severe constipation even to the point of food failing to move through the GI tract. But ANS disorders can also produce more subtle symptoms, such as just feeling dizzy or light-headed, occasional palpitations, or excessive sweating. Diagnosing ANS disorders can be tricky, especially when they are complex or subtle.
Most medical centers will be able to do basic testing. The most common test is a tilt table test, in which blood pressure and heart rate are measured as head position is altered. For more complex testing there are a few autonomic centers in the US (just a few) that can do extensive testing. Even then sometimes the best we can do is document that there is autonomic dysfunction, but may not be able to localize where the problem is coming from. Treatment is mostly symptomatic as most causes of ANS dysfunction are not curable.
If we are going to introduce a new testing method for ANS function (or really anything in medicine) we need to address a few questions. What, exactly, is it measuring, and what is the measured variable a marker for? What is the sensitivity and specificity of the test? And how useful is the information – does it predict the presence of a specific disease or the response to a specific treatment? Research would need to be done to validate any new test with respect to every condition in which it is used.
With that background I read the reporting of Dr. Plotnikoff who is claiming that his ANS testing device is a “gamechanger” for medicine. I could find no published studies by him or his colleagues regarding ANS testing. I was not reassured by his clinic which boasts personalized, functional, and integrative medicine. On his website he specifically claims that people with the following symptoms or disorders will benefit from testing:
Dizziness, Light-headedness, Fainting, Fatigue, Exercise intolerance, Post-exertional fatigue, Chronic pain including firbromyalgia (sic), Persistent, unexplained weight gain, Sleep disturbances of all types, Anxiousness, Heart palpitations, Depressed mood, “Brain fog”, Brain fatigue, Gastrointestinal (GI) symptoms including constipation, nausea, bloating, diarrhea, constipation, and randomly alternating symptoms, Frequent headaches, Falls or near falls, Urogenital dysfunction including urination difficulties and erectile dysfunction, Difficult to diagnose symptoms, Difficult to control blood pressure, diabetes, or hormonal states, Long COVID, Diabetes, Hypertension, Previous heart attack or heart surgery, Postural orthostatic tachycardia syndrome (POTS), Syncope, Anxiety, dysthymia, and/or depression, Neurologic diagnoses including neuropathies, migraines, and/or seizures, Gastroparesis, Traumatic brain injury (TBI), Post-concussion syndrome, Mast Cell Activation Syndrome (MCAS).
That’s a pretty impressive list, especially without any specific scientific research to back it up. The testing itself seems to be just a poor-man’s basic autonomic test, with cardiac monitoring, respiratory monitoring, and blood pressure testing. This might all be useful as part of a basic medical assessment, but claiming that it can diagnose autonomic dysfunction would require some extensive validative testing. The notion that the results of this testing would help, for example, guide treatment of medical entities and distinct as diabetes and seizures is a stretch.
In addition to incredibly overblown claims of using this testing to guide personalize medicine, they also claim that they can diagnose and treat ANS problems directly:
For those with low parasympathetic status (“rest-and-digest”) or excessive sympathetic status (“fight-or-flight”), we provide access to an FDA-approved parasympathetic system activator called GammaCore.
GammaCore is a device used for vagal nerve stimulation. This is a legitimate treatment for very specific conditions, but Plotnikoff’s clinic seems to think it is a panacea for everything listed above. Also, they falsely stated that the device is “FDA-approved”. “Approval” when it comes to the FDA specifically means that it has been tested and found to be both safe and efficacious for a specific disease. That does not appear to be true – the GammaCore website only says that it is “FDA cleared”, which means that the device itself is safe, without any claims for efficacy. This may have been just a sloppy mistake on their part, but it has significant implications. Falsely claiming FDA approval is not a minor thing.
As we can see, they appear to be taking a kernel of real science and medicine but then turning that into a simplified boutique treatment that is good for just about anything, making extremely overblown claims without sufficient evidence, and presenting themselves as the wave of the future. That’s the “functional medicine” marketing BS in a nutshell.

Gyrostim and the Infrastructure of Quackery
Steven NovellaonJune 5, 2013
Link
It’s frustrating to read yet another story of the process of developing a potential new medical treatment derailed by the current infrastructure of quackery that we have in this and other countries. This is one of the unmeasurable harms that results when pseudoscience is given regulatory, academic, and professional legitimacy. The press then celebrates the nonsense that results.
The basic story is often the same, with a few variations. First, however, let me describe what should happen when someone comes up with an idea for a new medical treatment.
Background research – The first step, whether the innovator is within or without the medical community, is to familiarize oneself with existing research. Is the idea plausible, has it been investigated before, are there any similar treatments that can act as a guide to predicting how this new treatment will work?
Test basic principles – If the idea still makes sense after existing research is taken into account, then new research into the potential treatment is justified. This should start with some basic proofs of concept. Is the treatment safe, does it actually do something, what are the possible mechanisms at work. This level of research may involve in vitro studies (test tubes and petri dishes), and eventually animal research. If the treatment is something that does not have a pre-clinical model (say, for instance, a new therapy technique) then early safety and tolerability studies should be done. If there is any component of the new treatment that involves new or untested scientific principles, they should be studied before they are applied to a treatment (the human energy field and therapeutic touch come to mind).
Preliminary human trials – If the treatment still seems plausible and seems to be safe and supported by basic principles, then some preliminary early human studies are justified. These may be formal FDA phase I trials, or generic pilot studies. These usually involve few subjects, may not be blinded, and are simply intended to get some idea of the effects and safety of the treatment.
Confirmatory trials – Everything so far is simply preliminary and used to determine if large, double-blind, expensive and elaborate studies are justified. These trials are designed to answer, as definitively as possible, if the treatment has specific positive effects and what the risks and negative effects are. These trials may also compare the new treatment to existing standard treatment.
It is only after these confirmatory trials that any health claims can be reasonably justified, that patients should be charged for treatments, that the treatment should be incorporated into medical practice, and insurance companies pay for the treatments. You can make an argument for compassionate use of treatments based on preliminary evidence if there are no other options, but every effort should be made to do this as part of further research.
Press interest in the treatment should also follow this pattern. Only the technical and professional literature and news really should deal with new treatments in the introductory phase. The general lay press should not be trumpeting new treatments that are not even in the preliminary human trial phase. Reporting preliminary human trials should also be done carefully, and put into the proper context. The sensational headlines about a new treatment should be reserved for those that are well established by confirmatory research.
Everything I just described above often does happen when new treatment ideas emerge within the culture of scientific medicine and is handled properly by professionals. Every day medical scientists are sorting out what works from what doesn’t work using some version of this process, and the public usually only hears about new treatments that make it over the finish line.
Alongside this traditional, tested, science-based process there is a growing infrastructure of medical pseudoscience that follows a completely different paradigm. Their process goes something like this:
An innovator comes up with an idea for a new medical treatment (device, supplement, procedure, etc.). They immediately start using the new treatment (if they are a practitioner) or at least trying it out anecdotally on themselves or a few others. Based upon either this limited or no experience, and no actual research, they then market the new treatment directly to the public.
If a pseudoprofessional gets their hands on the treatment, then it is instantly institutionalized. The device is marketed, clinics are established, articles and books are written, and people are treated.
The lay press then give free advertising to the new treatment by writing gullible articles following a predictable narrative – a maverick innovator has come up with a “miracle cure” with dramatic anecdotes. If they developed the treatment in order to treat themselves or, better yet, a loved-one, then that, of course, is the angle. There is token mention of the nasty skeptics, but how could they deny the stunning testimonials?
These two versions of events are simply two ends of a spectrum – science vs. pseudoscience, or legitimate medicine vs. dangerous quackery. I do think that there is a bimodal distribution of new treatments based upon culture. People either function within a culture of science or a culture of pseudo and anti-science, but there is a scattering of treatment across this continuum.
Let’s see where this new treatment, the gyrostim, falls.
GyroStimThe GyroStim was developed by Kevin Maher, who is an engineer, not a medical scientist. He developed the device in order to help his daughter, who suffers from cerebral palsy. He and his wife were told that stimulating the vestibular system, by spinning around or doing somersaults, could help with balance and motor development. Motivated to aggressively treat his daughter to give her the best chance of improvement, they put her through “nearly 1,000 of these spinning motions per day.”
Maher decided to make this process easier by building a robotic chair in which a person can be strapped, and the chair would then spin in every axis. The chair seems to do what it is designed to do – spin a person around in every direction. If your goal is to do this a thousand times a day, this certainly seems like an advantage over doing somersaults. To that extent, the device works.
The deeper question is, however, what are the net risks and benefits of this kind of spinning therapy? But before I get into that, let me finish the story.
A GyroStim machine has apparently been sold to the Mayo Clinic for research, and another to the Air Force Academy for aerospace medical research. So far, so good.
But then Maher apparently was sucked into the rank pseudoscience of chiropractic neurology. His device was purchased by a Richard Turmel, DC, a self-described functional neurologist in Quebec. He says of the machine:
This might be the most amazing machine I’ve ever seen in medicine, and we’re only just at the beginning. I am seeing, quite frankly, new miracles almost every day with this. There are still skeptics out there in the medical community about this, but I’m sure when electricity was first invented, some people said it might be bad.
Hype, anecdotes, and dismissal of legitimate skepticism – the quack trifecta.
Another chiropractic neurologist, Ted Carrick, is also enamored of the GyroStim. I have discussed Carrick before (as has Harriet Hall), he makes many dubious claims and offers only testimonials and poorly-conceived studies as evidence.
The GyroStim is, unfortunately, now associated with the dark underbelly of medicine, the world of pseudoscience. Treatments with the GyroStim cost $2,500 – $6,000 per week, and the claims made for the treatment are expanding – concussion, cerebral palsy, and even autism (of course).
Hopefully the device will at least also go through the standard scientific evaluation. There is some plausibility for this type of treatment for vertigo. In fact, vestibular therapy is already an established and evidence-based treatment for chronic vertigo. Physical therapists develop an exercise program for patients that involve maneuvers to stimulate the vestibular system, which does tend to reduce the vertigo. This probably works through normal brain plasticity.
Vertigo can have many causes, but the common end result is that the brain is not properly integrating various sensory inputs (visual, proprioception, and vestibular) which is necessary for proper cerebellar function (balance and coordination). Forcing the brain to integrate vestibular stimulation may accelerate the process of essentially learning how to establish more normal sensory integration.
One cause of vertigo and poor balance is concussion – the brain is traumatized, which can cause diffuse damage interrupting the amount of connections that the brain makes with itself. This can interrupt sensory integration, causing vertigo. Vestibular therapy is therefore a legitimate treatment for the vertigo that results from head injuries.
The GyroStim is, essentially, automated vestibular therapy. In this regard it is nothing new. The open questions are – is it as or more effective than standard vestibular therapy, and is it cost effective? It’s very expensive, and so the cost-effectiveness question is not trivial. If it is as effective, perhaps there is a niche for it to administer vestibular therapy to patients who cannot physically comply with standard therapy.
Claims that the GyroStim can help with symptoms other than vertigo and balance, however, are not plausible. Existing evidence suggests that the benefits of these types of interventions do not extend beyond the tasks themselves. There is no global brain-training. Training in a task, for example, improves performance on the task, but not general performance.
Likewise – vestibular stimulation can plausibly help with the integration of vestibular sensory information with other sensory information and improve vestibular function, but there is no reason to suspect that it will improve any other aspect of neurological function.
ConclusionThe GyroStim is nothing more than automated vestibular therapy. Before it is mass produced and incorporated into medical treatment, it needs to be tested to see if it is safe, effective, and cost effective for conditions that are already treated by standard vestibular therapy.
If it is effective for vestibular therapy, then it can be studied to see if there are benefits for other conditions. I am skeptical of such benefits, however, because they lack plausibility. Only high quality confirmatory clinical research will be adequate to establish the GyroStim as a legitimate treatment for any such condition. Until then, promoting or using the GryroStim for anything other than vestibular therapy is pure quackery.

Reader’s Digest Promotes Prevagen
Reader’s Digest is advertising a memory aid, Prevagen, that has been tested and shown not to work. Shame on them!
Harriet Hall on December 4, 2018
Link

I am a long-time subscriber to Reader’s Digest. I enjoy the jokes and some of the human interest stories, but I have become increasingly disturbed by some of the questionable health information they present. The most recent issue carried a prominent ad for Prevagen on the back cover. In large print, it says “Healthier Brain. Better Life.” It shows pictures of the product’s box and bottle, both of which say “Improves Memory.” And on the box, you can clearly see the claims that it “supports healthy brain function, sharper mind, and clearer thinking.” The ad claims it is “America’s best-selling brain support supplement and has been clinically shown to help with mild memory problems associated with aging.” This statement has an asterisk leading to a small-print boxed FDA disclaimer: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
The editors of Reader’s Digest have obviously not been reading the Science-Based Medicine blog. In a 2015 article, Steven Novella wrote about the entire class of nootropics, or drugs that are designed to enhance cognitive function. He concluded that they are being abused and hyped without adequate evidence, and he deplored the fact that they are being sold as dietary supplements rather than as drugs. He said some manufacturers cheat by including a stimulant, which can benefit patients diagnosed with certain diseases, but “Current non-stimulant nootropics are likely useless in healthy individuals.”
And earlier this year, Jann Bellamy reviewed the evidence for Prevagen and the lawsuit filed against it by the FTC claiming that the company was making false and misleading statements in labeling and advertisements, that:
(1) there is not “competent and reliable scientific evidence” to support Prevagen’s claims, which is required of health care product advertising, and (2) the claim that Prevagen is “clinically proven” is false.
It was not “clinically proven”. The study they’re referring to found that it didn’t work, but the manufacturer relied on post hoc analyses of subgroups and p-hacking that found some apparently positive results. The FTC explained that:
post-hoc data-dredging is unreliable and can’t rule out ‘statistically significant difference’ as mere noise.
What is Prevagen? What does the evidence show?
It is a dietary supplement whose main ingredient, apoaequorin, is a calcium-binding compound first identified in jellyfish. The company website claims that it is safe and effective for improving memory and supporting brain function. It cites three safety studies and one randomized, double-blinded, placebo-controlled clinical trial in community-dwelling older adults who self-reported memory concerns, the Madison Memory Study. That study was negative: “no statistically significant results were observed over the entire study population.” But the company did some data mining and p-hacking and teased out statistically significant p results for two subgroups of individuals with either minimal or no cognitive impairment. Essentially, they tortured the data to make it confess. Then they used the p-hacked data to speculate that Prevagen would benefit their customers: it would “support people with mild memory loss associated with aging.” That conclusion is not supported by the data. Jann’s articledescribes some of the other problems with the study and with the company’s claims. They claim apoaequorin crosses the blood-brain barrier, but the only evidence they have is in dogs. The safety studies they cite were all in rats. They have no evidence that it crosses the human blood-brain barrier or that it is safe in humans. In fact, there are many consumer complaints and reports of side effects. They are not selling it for dogs or rats, but for humans.
In addition, the American Pharmacists Association website raises some other concerns. They say it “is unlikely to be absorbed to a significant degree; instead it degrades into amino acids.” And they say the tests used in the Madison Memory Study were not validated tests.
Conclusion: Prevagen claims not supported by evidence
There is no evidence that Prevagen is effective or safe in humans. We knew that. The FTC knew that. Mainstream scientific organizations knew that. Why didn’t Reader’s Digest know that? Shame on them! The magazine is widely read and respected, and this Prevagen ad, prominently featured in full color on the back cover, will probably persuade many readers to waste their money on this placebo under the mistaken belief that it will help with the memory problems associated with aging.

Vertigo Voodoo: A Crazy-Sounding Cure That Actually Works
A sequence of positional changes sounds like voodoo, but is actually an effective way to cure benign paroxysmal positional vertigo (BPPV).
Harriet Hall on December 18, 2018
Link

This will not be my typical Science-Based Medicine post.
What it is not
This will not be:
    • About vaccines, diet, pseudoscience, quackery, or alternative medicine
    • A critique of a questionable treatment, claim, or practice
    • A skeptical evaluation of questionable evidence
    • A book review
    • A complaint about celebrities or the media
What it is
    • Information about a diagnosis you may not have heard of
    • Information about a strange set of positional maneuvers that can provide a seemingly miraculous cure with only one or a few treatments
    • A review of the scientific evidence showing that the treatment is effective
    • An example of how science works
    • A cautionary tale
The diagnosis: Benign paroxysmal positional vertigo (BPPV)
Vertigo is a kind of dizziness where a person feels as if they or the objects around them are moving when they are not. Benign paroxysmal positional vertigo (BPPV) is one of the most common types of vertigo. It is an inner ear disorder that produces a spinning sensation with certain changes in the position of the head, such as rolling over in bed. The room seems to jerk repeatedly in the same direction. The episode typically lasts less than a minute; it is sometimes accompanied by nausea. It can be brought on by trauma, but a specific cause is usually not found. The incidence increases with age and it is more common in women. It sometimes resolves spontaneously but can recur.
The gold standard diagnostic test is the Dix-Hallpike maneuver where the examiner lowers the patient from a sitting to a supine position while keeping the head turned to the side and the neck extended. The test is positive if it reproduces the vertigo and produces nystagmus (repetitive jerking of the eyes). The estimated sensitivity (positive results in those who have BPPV) is 79% and the estimated specificity (negative results in those who don’t have it) is 75%, but those estimates are based on a single study with poor methodology.
The symptoms are attributed to “ear rocks”, or otoliths, tiny crystals that are normally attached to the tips of hair cells where their inertia helps the inner ear sense gravity and movement. They can get dislodged and accumulate in the semicircular canals where they can trigger false signals of movement.
The treatment
There are four treatment options:
     1.  Maneuvers by a clinician to reposition the otoliths in a “safe” area where they won’t cause symptoms
     2.  Self-treatment with repositioning maneuvers at home
     3.  No treatment (Not recommended; could lead to falls or other problems)
     4.  Surgery (rarely used in severe recalcitrant cases)
The Epley maneuver
The best-known repositioning treatment is the Epley maneuver, which can be performed by clinicians or by patients themselves. It involves a sequence of positions: sitting with head rotated, lowering to a supine position with neck extended, turning head to the other side, rolling onto the shoulder, and returning to an upright position with head still rotated. It was first described by Epley in 1980; he also applied vibration to stir up the otoliths, but this later proved unnecessary. It is highly successful: it works (stops vertigo and nystagmus) in up to 95% of patients, and sometimes only a single treatment is needed.
The Epley maneuver has been extensively tested. Several systematic reviews have found it effective, including this one from 2006. A 2014 Cochrane review evaluated 11 randomized trials (7 of them blinded) with 745 subjects and determined that it was safe and effective. They thought there was a low risk of bias in the trials. The recurrence rate after treatment was 36%, but the treatment can be repeated. Follow-up measures to limit head movement, including sleeping with head elevated for 1-2 days, are commonly recommended; but a 2005 study found it made no significant difference. After a single Epley maneuver, there was clinical improvement in 96% of those who restricted head movements and 94% of those who didn’t.
Further thoughts
If I had heard about the Epley maneuver in 1980, before any of the studies had been published, I would have been very skeptical. The claim that a single set of positional maneuvers could cure a serious condition like BPPV sounds very improbable. It sounds like so many of those bogus “miracle cure” claims. It sounds more like voodoo than like science. Yes, there is a plausible mechanism, but quacks also think they have plausible mechanisms, like the memory of water to explain homeopathy. And there is no good direct objective evidence of otolith repositioning. But the published clinical evidence is very convincing: the Epley maneuver clearly works for BPPV. This is a good example of science at work. Science accepts good evidence of efficacy even in situations where the underlying mechanism is unclear. It rejects homeopathy not because of its implausibility alone, but because clinical trials do not establish efficacy. If homeopathy were as effective as the Epley maneuver or as penicillin, we might need to re-evaluate our conclusions. It isn’t, so we don’t. And please notice, this is a case of conventional mainstream medicine not relying on pills or surgery but using a simple hands-on procedure that costs nothing and won’t keep the patient coming back. A clear case of doing what’s best for the patient, not for the doctor’s finances.
And the story of the Epley maneuver is a cautionary tale. In 1980, skeptics might have written scathing opinions of what seemed to be a very unlikely treatment; and they would have been wrong. Rather than assuming that an untested treatment doesn’t work, good skeptics and good scientists will withhold judgment pending appropriate testing. Rather than being negative, we should limit ourselves to pointing out that without proper testing, we simply have no way of knowing whether a treatment works or not.
Conclusion: Epley maneuver is not voodoo
Science is really cool; it’s full of surprises. Sometimes what sounds like science turns out to be voodoo, as in the N-ray fiasco. Sometimes what sounds like voodoo turns out to be science. We must keep an open mind and wait for the evidence.

Leaky Brain, Leaky Gut: Are They Real?
First there was leaky gut; now there’s leaky brain. These questionable concepts are being promoted by practitioners of so-called “functional medicine.”
Harriet Hall on November 20, 2018
Link


First there was leaky gut
Three years ago Mark Crislip wrote about leaky gut syndrome for SBM. He said, “because of an almost complete lack of supporting basic science and few therapeutic clinical trials showing no effect, virtually no physician who has an understanding of the gastrointestinal physiology gives the disease credence.” Nothing has changed.
Intestinal permeability is a real thing, but according to this review article “these terms are poorly defined, their assessment is a matter of debate, and their clinical significance is not clearly established.” Leaky gut syndrome, on the other hand, is a fad diagnosis not accepted by mainstream medicine. The Canadian Gastrointestinal Society calls it a myth:
The Myth: According to the proponents of leaky gut syndrome, bacteria and toxins enter the bloodstream through these defective tight junctions and wreak havoc throughout the body, causing bloating, gas, cramps, inflammatory bowel disease (IBD), as well as fatigue, food sensitivities, joint pain, moodiness, irritability, sleeplessness, autism, and skin problems like eczema and psoriasis.
Debunked: This is all speculation, as scientific studies do not validate any of these claims. It is extremely dangerous that a TV doctor personality and some otherwise trusted practitioners are diagnosing and treating this baseless ‘syndrome’.
An article from the NHS agrees:
While it’s true that some conditions and medications can cause a “leaky” gut (what scientists call increased intestinal permeability), there is currently little evidence to support the theory that a porous bowel is the direct cause of any significant, widespread problems.
There is also little evidence that the “treatments” some people claim help to reduce bowel leakiness, such as nutritional supplements and herbal remedies, have any beneficial effect for most of the conditions they supposedly help.
Now there’s “leaky brain”
The same “leaky gut” ideas are now being applied to the brain, blaming all kinds of symptoms on substances leaking through a faulty blood-brain barrier (BBB).
Sometimes I think I have a leaky brain. Memories and facts have leaked out and been lost. And after my recent fall and head injury, a brain CT scan clearly showed that blood had leaked out into the subarachnoid spaces and other areas where it did not belong. But that’s not what functional medicine doctors mean by leaky brain. They are not talking about anything leaking out but rather things leaking into the brain because a defective blood-brain barrier is not doing its job to keep those unwanted things out.
What science says about the blood-brain barrier
An excellent review article explains what science has learned about the BBB and the questions that remain. The small blood vessels of the central nervous system (CNS) have unique properties. They regulate the movement of molecules, ions, and cells between the blood and the CNS. The BBB is a complex regulatory system: some components of the blood (oxygen, some gases, lipid-soluble molecules) diffuse freely into the brain; some molecules that the brain needs (glucose, for example) are actively transported into the brain; some molecules do not pass at all.
The BBB is both a blessing and a curse. A blessing because it regulates brain homeostasis and protects the brain from toxins and pathogens. A curse because it presents an obstacle to drug delivery to the brain.
The review article explains that the BBB is altered with inflammation, injury, and degenerative processes. We know that BBB dysfunction is associated with certain neurologic diseases like multiple sclerosis, Alzheimer’s, and epilepsy; but we don’t know whether the BBB dysfunction is a cause or a result of those diseases. We suspect that some of the changes are healing and others are pathological; we suspect that many different mechanisms are involved. We still don’t understand how alterations in the BBB affect neuronal activity, brain function, and behavior. In neurologic diseases, we don’t know whether BBB changes are due to loss of maintenance signals or to the presence of disruptive signals.
What functional medicine says about leaky brain
In the book Why Isn’t My Brain Working? a chiropractor claims that memory loss, difficulty focusing and concentrating, brain fog, depression, anxiety, fatigue, loss of zest for life, and loss of motivation are all signs that your brain is degenerating. He explains that modern diets, a stressful lifestyle, and environmental toxins are responsible; he tells readers how to properly care for and feed the brain to prevent degenerative diseases like Alzheimer’s, Parkinson’s, and MS. The book is long on speculation and advice but short on evidence.
One alternative medicine website claims that when the BBB is compromised,
the brain is vulnerable to damage from chemicals, inflammatory cytokines, and immune cells. This causes brain fog (cognitive dysfunction), chronic fatigue, anxiety/depression, neurodegenerative diseases, and other neurological conditions.
It recommends how to fix leaky brain at the root causes:
    • An anti-inflammatory diet (avoiding lectin, gluten, high-calorie and high-fat foods)
    • Normalize blood sugar
    • Deal with infections and toxins
    • Reduce stress
    • Avoid sleep loss
    • Healthy brain circulation
    • Reduce homocysteine levels
    • Reduce glutamate levels
    • Lose weight
(Most of these are good general health recommendations; the others are questionable.)
It lists supplements that may help repair a damaged BBB:
    • Acetyl L-carnitine
    • Alpha lipoic acid
    • Alpha GPC
    • Angelica (Dong Quai) extracts
    • Astragalus
    • Astaxanthin
    • Apigenin
    • B12-B6- Folate Mix
    • Berberine
    • Bitter melon
    • Butyrate
    • Chlorogenic acid
    • Citicoline
    • Collagen
    • Curcumin
    • Vitamin D3
    • Ellagic acid
    • Fish oil
    • Ginseng
    • Goji fruit
    • Hydrogen-rich water
    • Licorice
    • Lycopene
    • Myoinositol
    • Magnesium
    • Melatonin
    • Methylene blue
    • Oxaloacetate
    • Feverfew
    • Progesterone
    • Pterostilbene
    • Resveratrol
    • Rosmarinic acid
    • Shilajit
    • Selenium
    • Sulforaphane
    • Ursolic acid
How do they know this? They are mainly extrapolating from mouse and rat studies. There is no evidence from clinical trials to suggest benefits for humans or to determine appropriate dosages. They don’t actually make any recommendations for humans to take any of these.
It lists supplements that may disrupt the BBB in some circumstances: andrographis, L-arginine, nicotine, and zinc. The evidence it offers is from cell culture and rat studies.
It lists drugs that help protect and repair the BBB, but says, “Currently, the only conventional therapy to help improve the blood-brain barrier integrity is glucocorticoids (synthetic cortisone) treatments.”
Another website repeats much of this questionable information and adds a few more very questionable recommendations: take probiotics, drink coffee, avoid alcohol, avoid environmental mold and mycotoxins, reduce exposure to electromagnetic fields (EMFs), and avoid gluten.Yet another website recommends the natural medicines apigenin, baicalein, catechins, curcumin, luteolin, resveratrol, and rutin. It recommends you ask your doctor about getting lab tests to assess your BBB, your microbiome, and yeast overgrowth. Recommended tests include homocysteine, blood sugar, and antibodies against occludin and zonulin. It recommends exercise. Finally, it recommends consulting a functional medicine doctor who will customize diagnostics and natural protocols based on your unique needs.
The notorious functional medicine guru Mark Hyman has a “Broken Brain” video series which I reviewed in a previous SBM article. In that article, I also covered the fallacies of functional medicine. Hyman also has a podcast discussing leaky brain – with a chiropractor!
Conclusion: a questionable concept
While there are documented defects in the BBB associated with some diseases, the concept of “leaky brain syndrome” appears to be a bogus diagnosis created by the functional medicine industry. It attributes all manner of symptoms to a leaky BBB, and claims a leaky brain is the cause of chronic neurodegenerative diseases. These ideas are not supported by acceptable scientific evidence: they rely on questionable evidence from animal and in vitro studies, speculations about basic science, and a lot of imagination. “Leaky brain” gives functional medicine doctors the excuse to read unwarranted conclusions into non-standard lab tests and to play trial-and-error with patients on a long-term basis, experimenting with diet, lifestyle changes, and dietary supplements. The patients may appreciate the attention, but there is no evidence that the functional medicine approach actually heals a defective BBB or provides any objective improvement in clinical outcomes. Or that the symptoms they are treating actually have anything to do with a leaky BBB. Neither leaky gut syndrome nor leaky brain syndrome are recognized by mainstream medicine. They are fantasies from alternative, complementary, integrative, and functional medicine.
s

Zap Your Way to Learning?
Steven Novella on March 23, 2016
Link
The company Halo Neuroscience is now offering a device, the Halo-Sport, which they claim enhances sports performance through “neuropriming.” Their website claims:
Neuropriming uses pulses of energy to increase the excitability of motor neurons, benefiting athletes in two ways: accelerated strength and skill acquisition.
Regular readers of SBM can probably see where this is going.
A proper threshold of evidence
Before I get into the details of this product, I want to back up and discuss some basic principles. There is a clear pattern that has played itself out countless times on SBM or with regular authors on SBM in their other outlets. A person, company, or industry makes a clinical medical claim. We examine the evidence and find it wanting, and state so. Believers in the claim then attack us for being shills, closed minded, and/or failing to do our research.
What they almost never do is confront the actual basis of our analysis – a basis that we have painstakingly and exhaustively explored in the pages of SBM. Just two days ago David Gorski wrote yet another article discussing the fact that there is a huge false positive bias in the medical literature, that there is an ongoing issue of quality control in medical science, and pointing to some of the reasons to be skeptical of premature clinical claims.
Our analyses tend to focus on three identifiable areas – plausibility, pre-clinical evidence, and the clinical evidence. Plausibility refers to all of existing scientific findings and how compatible the new claim is with current science. Some claims, such as homeopathy, are so implausible they should be treated as magic. Other claims are entirely plausible, but plausibility, while important, is an insufficient basis for a clinical claim.
Pre-clinical data is also important but insufficient. The real purpose of pre-clinical studies (test tube, petri dish, and animal studies) is to see if an intervention is likely to be safe and effective before committing to clinical studies in humans. It should not be used as a basis for clinical claims, however.
There are many reasons for this. Biology is complex and it is difficult to impossible to reliably extrapolate from a basic-science phenomenon to a net clinical effect. Even if we properly identify a clinical effect, it is difficult to know what the magnitude of that effect will be in a living biological system (a person). There may be compensatory mechanisms in play, even to the point of having a net harmful effect. There may be unknown side effects or interactions. Finally, disease states may not respond the same way as healthy states.
Clinical evidence is what we need as a proper basis for clinical claims – this intervention will have this net health effect. Clinical evidence is also complex. There are observational studies, experimental studies, meta-analyses, and systematic reviews. Most clinical studies are preliminary (small studies of weak methodological rigor), and most will turn out to be wrong.
The question then becomes – what is the threshold of clinical evidence that must be crossed before a clinical claim should be accepted as probably true and either approved for the market or used by practitioners? This is a complex question, the very question we often explore here at SBM, but our answer can be summarized as – the threshold should be higher than it often is.
The threshold of sufficient clinical evidence should depend in part on plausibility, or prior probability. It should take more clinical evidence to persuade the community that our basic understanding of biology needs to be adjusted than it takes to establish a slightly different use of a medication from the one that is already proven.
However, as a general rule, we like to see multiple independent studies with large sample sizes, rigorous methodology, with consistent results that are both statistically and clinically significant. These studies should be using the proper outcome measures, proper endpoints, proper comparisons, adequate blinding, reasonable dropout rates, controlling for the proper variables, and addressing the appropriate clinical questions. In other words, there are lots of ways for a clinical study to fail, and we don’t put much faith in them until they have gone through the meat grinder of expert review.
The evidence for tDCS and learning
Halo Neuroscience is claiming that using transcranial direct current stimulation (tDCS, which I have discussed before) to stimulate the motor cortex will enhance the results of training.
The plausibility of this claim is moderate – it is reasonable, but not a home run. A 2016 study, published just last month, summarized the current evidence this way:
The effects of transcranial direct current stimulation (tDCS) on brain functions and the underlying molecular mechanisms are yet largely unknown.
This was the preamble to a mouse study in which they found:
Here we report that mice subjected to 20-min anodal tDCS exhibited one-week lasting increases in hippocampal LTP, learning and memory.
Again – reasonable plausibility, but there is still much that is unknown. The unknowns matter. How much current at what frequency do we give to what part of the brain and for how long? These are not trivial questions, they are vital.
Clearly there is stuff happening in the brain that can be plausibly beneficial, but is it beneficial, how long do the effects last, what are the long term effects? We may be enhancing learning in the short term, but burning out those neurons in the long term.
Published clinical research is a mixed bag, the kind of mixed bag that is compatible with no effect, but does not rule out a real effect either. I wrote recently about a study of tDCS and pilot training that was widely reported as positive, but shockingly was an essentially negative study. They specifically looked at motor cortex stimulation during pilot training and found no effect whatsoever.
A 2016 systematic review (which does not include the above study) looking at motor cortex stimulation and learning found:
Therefore, our findings suggest that application of M1 a-tDCS across the three or five consecutive days can be helpful to improve motor sequence learning.
Evidence is preliminary, but encouraging. There are separate studies looking at stimulating the cerebellum, and others looking at stimulating other areas of the brain involved in memory.
Looking at all the evidence, I am hopeful. I think that overall using electrical or magnetic stimulation to affect brain function is highly plausible, and will likely become a new paradigm of neurological intervention into the future.
However, we are in the early stages of clinical research. There are many questions that need to be answered, and we need to fine tune the details of the intervention to optimize any clinical effect.
We are not yet ready, in my opinion, for devices marketed to consumers. We are in a similar stage as with stem cells – plausible, exciting even, and we are making progress but we are not yet there for many potential applications.
Halo Neuroscience claims to have done in-house studies, but they are not peer-reviewed and therefore cannot be used to support claims.
Conclusion: evidence for tDCS is mixed but encouraging
Using tDCS to enhance learning and training is plausible, and the early clinical studies are mixed but encouraging, but in my opinion we are not yet across the threshold of evidence where marketing claims to the public is justified.
There is no mention on the Halo website that they have FDA approval for the device. The company does make another device that is implantable and used to treat epilepsy, and they proclaim that this device is FDA approved, so it seems likely that if their Halo-Sport device were also FDA approved they would say so.
I have found that the FDA has a very low threshold for electronic devices, probably because they are not drugs, especially if they are not implanted. I would not be surprised if the FDA does approve the device, even with very preliminary evidence. But they have apparently not done so yet.
My advice to consumers is to be skeptical of the marketing claims. We are simply not there yet with the clinical evidence. 

Brain Research in the 21st Century
Steven Novella on October 1, 2014
Link
In April 2013 President Obama announced the BRAIN initiative – Brain Research through Advancing Innovative Neurotechnologies – committing 100 million dollars to brain research. The goal of this initiative is to accomplish with the brain what the Human Genome Project accomplished with the human genome.
The BRAIN project came after a similar, and larger, initiative in Europe – the European Union’s Human Brain Project (HBP), which was given 1.3 billion dollars in funding. The HBP came under some controversy this summer when neuroscientists complained about how the money was being awarded.
The serious commitment to brain research on both sides of the Atlantic reflects the general recognition that the brain is an important and complex organ (arguably the most complex thing we know about in the universe) and there is tremendous opportunity to reap benefits from new research.
The comparison to the Human Genome Project is quite deliberate. The HGP is generally perceived to have been incredibly successful, the biological equivalent of announcing that we will send people to the moon by the end of the decade, then doing it.
There is also a PR downside to such big projects, however, and that is premature or unrealistic hype. The HGP came with it the promise (implied or explicit) that once we mapped the human genome countless disease cures would soon follow. That kind of translational research, however, is unpredictable and time consuming. We likely will see the benefits of the HGP, but they will come 1-2 decades later than the expectations created by the hype.
Also, now scientists are talking about mapping the proteome – a list of the proteins that the genes code for. Also, the field of epigenetics is exploding, studying the systems that regulate the expression of all those genes. Reality usually turns out to be more complicated than we think.
Right now we are also in the early-hype phase of the various projects to map the human brain, with most articles mentioning cures for Alzheimer’s and similar diseases. What emerges from efforts to map the brain will depend upon what kind of research is actually done. This was the focus of the recent HBP controversy.
Research might focus, for example, on neuroscientific studies to map specific circuits in the brain, literally mapping the “connectome.” Related to that are efforts to computer model the connectome, essentially creating a virtual human brain. Also related but distinct are efforts to understand human cognition, how those circuits we’re mapping actually function. The BRAIN project includes research focusing on neuroengineering, or machine-brain interfaces for research and to treat neurological injury or disability. Neurophysiology focuses on how the cells of the brain function biologically. Finally, translational research tries to take this basic knowledge and use it to cure diseases or enhance neurological function.
Whenever there are millions or billions of dollars to be awarded, there will be arguments over who is more deserving of the funding. The HBP protest was essentially from neuroscientists who feel that more money should be given to their research into mapping the brain. They felt that too much money was going to computer scientists to create a virtual model of the brain, and that the project was becoming more of an IT project than a neuroscience project.
While they are still working out this controversy, the BRAIN project has taken the approach of spreading out research funding in all of the above areas, including large and small innovating research projects. A recent editorial in Nature praises this approach:
The US BRAIN Initiative has the chance to get the concept back on its feet. Success will probably be down to a careful balance between focused order and innovative chaos — much like the organ itself.
Conclusion
It will probably come as no surprise that I (as a neurologist) am excited about the various brain-mapping initiatives. I also agree that success will depend on striking a careful balance.
In general, more funding for scientific research has a dramatic positive effect. However, there is always a delicate balance between funding research and controlling research. It is obviously reasonable to direct funding toward specific research goals, such as mapping the brain. If the funder, however, tries to micromanage how that goal is achieved, then this can distort the direction of research and actually be counterproductive.
In any massive research project like the various brain mapping initiatives, a balance between top-down order and bottom-up chaos does seem like the best approach. Part of this is balancing basic science and translational science. If research funding shifts research prematurely into finding a cure today, at the expense of basic science, then progress can actually slow. We also do not want to prematurely pick winners and losers, but fund a variety of valuable approaches and let the science sort itself out.
In brain mapping research in particular, I also think there is an interesting synergy between various approaches. Neuroscientists mapping circuits and neuroscientists understanding cognition need each other. We need to understand how the brain is wired up in order to fully understand the basic units and interactions of cognition, and we can only really understand the function of those circuits (which is partly used to map them) if we understand what circuits there are and how they connect. The functions of those circuits are also influenced by many physiological components.
Efforts to create a virtual brain depend largely on neuroscientists mapping the circuits (otherwise the computer scientists will have nothing to model). At the same time, computer simulations can be a valuable tool for mapping and understanding those circuits.
Any one aspect of brain mapping research is dependent on and will be enhanced by all the other aspects of brain research. And of course, at the end of the day we want therapeutic and practical applications, and that requires specific research.
Let the controlled chaos of innovation take hold in as many ways as possible.

The PIED Piper of Nootropics
Steven Novella on May 20, 2015
Link

Nootropics are an emerging class of drugs that are designed to enhance cognitive function. They are part of a broader category of drugs known as performance and image enhancing drugs (PIED) which are used for enhancement of memory and cognition, sexual performance, athletic performance or musculature (also called “lifestyle” drugs).
It will probably come as no surprise to regular readers of SBM that nootropics and PIED are being abused and hyped without adequate evidence. One of the primary problems is that they are sold as supplements or as drugs, often over the internet without adequate regulation. One simple fix is to properly classify these drugs as drugs, and to properly regulate them as drugs.
Many of the cognition-enhancing “supplements” on the market make all the usual claims about “natural” enhancement – meanwhile they predictably contain just vitamins, herbs which have not been shown effective, perhaps nootropics (see below), and often a stimulant, like caffeine. The only drug in the mix which is likely to have a noticeable effect by the user is the stimulant.
The risk of overuse of stimulants in “supplements” is well known.
Meanwhile, what does the science say about the safety and effectiveness of specific nootropics for specific indications? In short, sufficient high-quality studies to make definitive determinations are lacking. For many, however, there is some preliminary and pre-clinical data.
Plausibility
The concept behind nootropics is to target some metabolic or nutritional aspect of brain function, especially a function involved with memory or attention, and then to provide a nutritional precursor to that metabolic pathway, or a drug that enhances the activity of a neurotransmitter, enzyme, or other metabolic factor.
This is not an unreasonable line of research, but tweaking metabolic pathways is not a simple business, and our ability to extrapolate from the petri dish to animals and finally to net clinical effects in humans is very limited. No matter how promising a treatment looks in theory, we need clinical data to see if it has a measurable and lasting clinical effect.
The primary plausibility problem with the PIED category of drugs is that they are further extrapolating from data in disease states to the enhancement of otherwise healthy function. Just because a drug may enhance memory function in someone with Alzheimer’s disease, that does not mean it will enhance memory function to supernormal in a healthy individual.
It is true and likely relevant that the brain is a very metabolically hungry organ. Optimal brain function depends upon most metabolic and physiological parameters functioning well. For this reason the brain is often the canary-in-a-coalmine of biological function – the first thing to go when something is off. Sick hospital patients, for example, are often sleepy or confused because their bodies are simply under stress, or their metabolic parameters are off. It can often be challenging to figure out exactly what is making a patient confused, because so many things can affect brain function.
Further, in everyday healthy life our brain function can be off simply from having insufficient sleep, not eating well, being depressed, or being physically or mentally exhausted.
Given our brain’s sensitivity it does make superficial sense that giving it a specific metabolic boost might help cognitive function. This is essentially what stimulants do. It still needs to be determined, however, that a specific metabolic tweak will have the desired effect. One potential problem with predicting whether a specific intervention will help is determining if that metabolic factor is the limiting factor in brain function.
Enhancing acetycholine (the primary neurotransmitter involved in memory formation) may enhance memory, but what if there is already plenty of acetylcholine and the limiting factor in memory function is something else entirely? This is probably why we cannot extrapolate from a disease state to a healthy state – the limiting factors on function are likely different.
Therefore, from a plausibility standpoint, the idea of nootropics is possible, but very complicated, and we cannot make confident predictions from pre-clinical data alone or extrapolate from one condition to another. We need high-quality clinical studies for each specific clinical claim.
The clinical evidence
One of the most popular nootropics is piracetam. This is actually one of a large and growing class of drugs with many neurological indications, including seizure control and treatment of anxiety and depression. Piracetam has been studied specifically for memory and cognitive enhancement in dementia or cognitive impairment.
A Cochrane systematic review (last updated in 2012) found:
At this stage the evidence available from the published literature does not support the use of piracetam in the treatment of people with dementia or cognitive impairment. Although effects were found on global impression of change, no benefit was shown by any of the more specific measures.
They concluded that the data supports further research, but not current clinical claims or use.
In healthy individuals there are only a couple small studies, and they do not show any significant benefit. Therefore, even though piracetam is a popular “smart drug” the evidence for any significant effect is lacking, especially in healthy individuals.
Another highly popular cognitive enhancer is modafinil. This is a stimulant drug used for narcolepsy, ADHD, and cognitive fatigue resulting from neurological disease or injury. It is a controlled prescription drug, but has still managed to become highly popular as a cognitive enhancer, especially among students.
A recent study, however, highlights the difficulty in extrapolating from disease to healthy states. The researchers compared test performance on healthy subjects taking modafinil vs placebo. They found that the responses were delayed from subjects taking modafinil, but were not more accurate. In hindsight, this result makes sense.
As a stimulant modafinil increases brain function, including frontal lobe executive function. When performing a cognitive task there is often a tradeoff between speed and complexity of processing. Executive function sacrifices speed for complex higher cognitive function. If you have impaired executive function, this tradeoff is worth it. Modafinil can shift the balance back towards a more optimal state.
In the healthy individual, however, you are shifting the balance away from an optimal state, slowing things down without any further gains in accuracy. Therefore modafinil can be a net gain in individuals with ADHD, but a net loss in healthy individuals, and that is what the preliminary clinical data shows.
There are other nootropics but with a similar story – basic science research which is used for marketing hype, but does not establish that the drugs (often sold as supplements) actually work.
Conclusion
Nootropics are an interesting and potentially very useful class of drugs which deserve further research. Their greatest potential is likely in various states of neurological disease or injury. Their use as smart pills, however, is dubious from a plausibility standpoint and lacks sufficient evidence.
Many “smart pill” products on the market cheat by including a regular stimulant, like caffeine. The effects of stimulants on healthy individuals is interesting – while they create the subjective experience of being more alert and higher performance, it is unclear if they actually improve performance, and in fact they may even decrease performance. Even if they do work, their effects typically develop tolerance quickly. Daily use of caffeine, for example, develops tolerance within three weeks, after which regular users are just staving off caffeine withdrawal and experience an overall net negative effect on their alertness.
Stimulant use is therefore potentially useful for alertness in the short term or for intermittent use, but it is unclear if it has a positive effect on cognitive performance. They are good for creating the illusion of cognitive enhancement, however.
Current non-stimulant nootropics are likely useless in healthy individuals.
If you are otherwise healthy and want to optimize your cognitive function, there are some things you can do that are likely to have a dramatically greater benefit than any smart pills on the market:
    • Get enough sleep
    • Get regular exercise
    • Keep mentally active
    • Do not skip meals
    • Avoid alcohol or other recreational drugs

Creatine Supplements for Brain Function
Steven Novella onN ovember 19, 2025
Link

There is a long history of supplements marketed to enhance memory, focus, overall cognitive function, and brain health. None of them are backed by quality scientific evidence, and they seem to go through the typical conveyor belt of claims – by the time one claim is collapsing, such as ginkgo biloba, the industry is happy to move on to the next.
The latest in this brain supplement story is creatine (specifically creatine monohydrate). The story here is a bit more complex than the typical supplement slop. The putative mechanism is reasonably plausible – creatine is converted into phosphocreatine and stored in neurons, which can be broken down into ATP to use as energy. The idea is that when the brain is stressed it can tap into this extra source of energy. At least there is no quantum vibrations or chi energy involved.
With these types of potential mechanisms, however, it is difficult to know if the effect is clinically significant. First, is the availability of ATP a rate-limiting step in brain function? Second, is the amount of ATP made available through phosphocreatine significant enough to affect function? To answer these questions we need clinical research.
A 2024 systematic review goes over all the relevant clinical studies – “Sixteen RCTs involving 492 participants aged 20.8-76.4 years.” That is a modest amount of data, but enough to get a preliminary idea of whether there is any potential here. The review found:
“Creatine supplementation showed significant positive effects on memory (SMD = 0.31, 95% CI: 0.18-0.44, Hedges’s g = 0.3003, 95% CI: 0.1778-0.4228) and attention time (SMD = -0.31, 95% CI: -0.58 to -0.03, Hedges’s g = -0.3004, 95% CI: -0.5719 to -0.0289), as well as significantly improving processing speed time (SMD = -0.51, 95% CI: -1.01 to -0.01, Hedges’s g = -0.4916, 95% CI: -0.7852 to -0.1980). However, no significant improvements were found on overall cognitive function or executive function. Subgroup analyses revealed that creatine supplementation was more beneficial in individuals with diseases, those aged 18-60 years, and females.”
I would characterize these findings as mixed. It seems to help memory, attention, and processing speed, but not overall cognitive function (that seems important) or executive function. Also, the effect was greater in women, those <60, and those with chronic illness. Generally, when we see mixed results like this with preliminary studies, that’s not a good sign.
The authors conclude that there is low to moderate confidence for a beneficial effect which requires “larger robust clinical trials” to validate. That is code for ‘not ready for prime time.’
There is also some evidence that creatine may be helpful for sleep deprivation specifically. This makes sense since a brain under stress, such as sleep deprivation, may make the availability of ATP a rate-limiting step.
Studies generally use a dose of 3-5 grams per day, or even 5-10 grams. For some applications, like sleep deprivation, a loading dose of 20 grams per day for a week is used. These doses are generally safe, but they can stress out the kidneys and should not be used in people with kidney disease. They can also worsen mania in bipolar disorder and worsen Parkinson’s disease when combined with caffeine.
What does all this mean for current recommendations for creatine for brain function? There are currently no published official recommendations from any medical body – so here’s my SBM-orientated take.
The claims for creatine are semi-plausible, and low-dose supplementation is likely safe (with the caveats above). But the clinical evidence is mixed and preliminary. I am especially concerned that the evidence shows no effect for “overall cognitive performance”. Given the overall false positive bias in the medical literature, especially for preliminary studies, the probability that creatine will turn out to be significantly effective is somewhat low, but non-zero.
Clearly, we need larger and more rigorous clinical research to provide more confident answers. There may also be a sub-population or specific indication where it is reasonably effective. That would be similar to melatonin – it is not really an effective general sleep aid, but it can be effective in treating jet lag. Perhaps creatine will turn out to only be effective for acute sleep deprivation.
I would not be surprised either way, but a more confident answer awaits larger clinical trials.
    • 

Brain Wave Pseudoscience
iSynchrony has put together a plausible-sounding bit of bafflegab to justify what it sells. The reality of neurology is against their claims.
Steven Novella on July 12, 2017
Link

Some alternative medicines are essentially magic – like homeopathy, acupuncture, reiki, and straight chiropractic. They purport to work through non-existent “life force” or essence. Sometimes they try to blur the lines by adding a layer of scientific jargon, but in the final analysis they are magic. Other so-called alternative products or treatments are just bad medicine. They have not been properly studied, their plausibility is low, or they have actually been shown not to work. Still others are overtly spiritual, like mind-body new age nonsense (but at least it’s honest).
Some treatments, however, are pure pseudoscience. They purport to work through sophisticated mechanisms understood through cutting-edge modern science. They often exploit hype about the potential of emerging technology, and so are planting their scams in fertile soil. Emerging technology pseudoscience has been a thing for a couple of centuries. It goes back at least to the discovery of electromagnetism and its importance to biological systems. Anton Mesmer’s “animal magnetism” is an example. Magnetic devices were all the rage in the 19th century. There were literally hundreds of magnetic or electrical quack devices in the Victorian age, prompting some mainstream debunking.
At the turn of the 20th century, soon after the discovery of radioactivity, radiation cures were popular. It took the FDA to finally shut down radioactive health products in the mid-20th century. By then radiowave treatments were popular. At the turn of the 21st century we now have stem cell quackery. Stem cells are a legitimate emerging technology, but there is a huge gap between the potential promise and the current reality. This gap is filled by an increasing number of stem cell quack clinics that promise to cure a variety of severe diseases by injecting a mysterious stem cell cocktail somewhere.
I also dare you to find a supplement that does not contain antioxidants (I know they exist, but you get my point).
None of these promising technology-based scam therapies go away entirely (except for radioactive treatments, for obvious reasons). They just get added to the growing list. Magnetic, electrical, and radiowave-based treatments are still popular. 
Neuropseudoscience
The last two decades have seen an explosion in our ability to study and our knowledge of brain function. Neuroscience itself is as old as phrenology, but with new knowledge and techniques comes a new batch of pseudoscientific claims. I was recently pointed (by David Gorski) to one particular company that nicely represents this phenomenon. iSynchrony claims to treat neurological disorders by adjusting your brain waves. They claim:
Using a well-established technology, the electroencephalogram (EEG), we analyze our patients’ brain wave activity to identify the areas that are “out of sync.” With this data, we create a customized plan to treat psychiatric and neurological disorders utilizing individualized Transcranial Magnetic Stimulation (iTMS).
They do a good job, in my opinion, of skimming technological jargon off the top of actual scientific studies, without representing the actual science. The result sounds impressive to a non-expert, while simultaneously sounding like gibberish to a neuroscientist. They further “explain:”
In a person whose brain activity has had its frequency disrupted by a physical or emotional trauma, the brain’s waves may appear imbalanced. iTMS directs short magnetic pulses to the area of the brain in need of stimulation to help synchronize the alpha waves and restore balanced brain wave activity.
The core notion on which they are basing their claims is that brainwaves are normally synchronized or “balanced,” but this balance is disrupted by trauma (emotional or physical), and their treatment restores this balance. All of this is either misleading or untrue. In their promotional material they claim that: “Children with autism have disrupted neural synchronization compared with controls.” They then link to this study for support. This is a great example of distorting the findings of a study to support dubious claims that sound scientific.
The study does purport to show that children with autism have abnormal neural synchronization, but you have to dig deeper to find out what they are actually talking about. We already know that some children with autism have diminished connections among their brain cells. In other words, the brain does not talk to itself as robustly as in neurotypical children.
In healthy brains neurons have a normal resting firing rate at a certain frequency. One core concept in neuroscience is that cells that wire together fire together. So it is also true that clumps of neurons will fire together, they will synchronize their baseline pattern of firing. Further still larger networks of neurons can do the same. Coupled with this is the further basic notion that there is tonic inhibition of neuronal firing at baseline, meaning that at rest the brakes are on so that neurons don’t fire out of control. Neuronal synchronization results from the interconnectedness of brain networks, but also from alternating waves of different amounts of inhibition of those networks.
The result of all this is that, at rest with the eyes closed, an electroencephalogram (EEG) will record what is called the alpha rhythm, an 8-12 Hz smooth sinusoidal wave synchronized throughout the brain (but dominant in the back of the brain). Children with autism have decreased interconnectedness, therefore they have decreased synchronization. No surprise there.
Here is where iSynchrony makes a massive and implausible leap:
Patient-specific treatment with iTMS tailored to each patient’s unique alpha-EEG signal – serves as an effective therapy for autism by normalizing the alpha brain wave oscillation.
There is essentially zero plausibility to this claim. To further explain why we need some additional background on TMS. This technology uses magnetic waves to either increase or decrease the firing rate of a network of neurons. This is a very useful technology for research because it can be tuned to a specific frequency and targeted to a specific brain region. We can say – let’s see what happens when we turn down this part of the brain?
TMS is also an emerging potential therapeutic tool. It may be possible, for example, to stop a seizure or migraine from progressing by using TMS to inhibit neuronal firing. There is absolutely no reason, however, to suspect that TMS alters brain wiring.
In autism the altered EEG pattern is simply a manifestation of the underlying pattern of connections among neurons, which is decreased. Using TMS to change the EEG may have an effect while the TMS is being applied, but its effect is temporary at best and may just be cosmetic when applied to a condition like autism. TMS does not change the underlying condition of decreased brain interconnectedness, and therefore has no plausibility as a treatment for autism. There is no more reason to think it will cure autism than to think that covering over a measles rash with makeup will cure measles.
But the iSynchrony promotional material links to studies about autism, about the EEG, about TMS in order to make it seem like their treatment is scientific. When they make their ultimate claim about treating autism quoted above, however, there is no link. That is because there is no published study showing that it is effective.
They do, however, make this claim:
At the 2014 Autism One conference, the results of a 12-week randomized controlled trial of 24 autistic children, done by Dr. Jeff Bradstreet under the auspices of the Brain Treatment Center, were released showing that an individualized Transcranial Magnetic Stimulation (iTMS) protocol could dramatically improve autism with slightly less than half the children achieving a neuro-typical rating by Child Autism Rating Scale, and another quarter achieving a 30% improvement in their scores. These results open a new frontier for reversing autistic symptoms.
For regular readers of SBM or anyone familiar with the anti-vaccine movement, alarm bells should be ringing. First, Autism One is not a science conference. David Gorski has characterized it as an “anti-vaccine quackfest”. So the results of this study have not been published, peer-reviewed, or even presented at a scientific conference, just a non-scientific conference essentially known for promoting dubious quack treatments for autism.
Even worse, Dr. Jeff Bradstreet is a known promoter of pseudoscientific autism treatments. In 2015 Bradstreet was found dead from an apparent suicide. The regulatory noose was closing in around him – his clinics were being raided and it seemed that his time was up. According to The Washington Post:
Despite scientific consensus to the contrary, Bradstreet believed vaccines could cause autism. And he recommended unorthodox and often unapproved autism treatments including hyperbaric oxygen chambers; hormone injections; stem cell therapy and chelation, a risky chemical procedure Bradstreet believed could remove the mercury supposedly introduced by vaccines.
iSynchrony has essentially tied their scientific validity to a disgraced autism quack who presented one small and likely worthless study at a pseudoscientific conference. I think that puts things into perspective.
Unfortunately iSynchrony is not unique in exploiting “brain wave pseudoscience.” It does sound superficially compelling (if you are not a neuroscientist), the notion of altering the brain waves to alter brain function. The problem is that such claims have the arrow of causation backwards. Brain function determines brain waves, not the other way around. Changing how the brainwaves look on EEG is just cosmetic. At best it might reflect an immediate effect. For example, drugs that affect brain function can certainly change the brain waves – but that is because they are changing brain function. TMS can affect brain function while it is being applied, but it does not rewire the brain or cure anything.
Further still, the notion of “balancing” the brain waves is too simplistic. It does not reflect any real understanding of brain function.
Extending the claims further to psychiatric illness, or just optimizing brain function for the worried well with lots of disposable income, is even more tenuous. I have looked at a lot of EEGs. In a healthy brain they should be symmetrical left to right. We specifically look for asymmetry as a sign of pathology. Emotional trauma, anxiety, depression, and similar conditions should not cause any such changes. A stroke or a tumor would.
Further, EEG is a very noisy medium. It takes a lot of training to see the patterns through all the noise, and to filter out the normal variants and all the things that can affect the EEG (like blinking or facial muscle movement). Noisy systems are ideal for quacks, however, because they provide ample opportunity to make up fake patterns from the noise. If you want to see “individualized imbalance” in an EEG, you can. You can also program an algorithm to mine the EEG noise for similar imbalances.
In the end what we have is just a 21st century version of a phrenology machine.
In short, be very skeptical of any device or treatment that promises to balance your brain waves. Such claims are pseudoscientific nonsense.

Vision Therapy Quackery
Behavioral optometry claims to treat a wide range of disorders, including learning difficulty and attention problems. But these claims are not based on solid scientific ground, and are not supported by rigorous evidence.
Steven Novella on January 31, 2018
Link

There are far too many specific types of medical pseudoscience to address fully, even with a daily blog. It often seems that new ones are created faster than we can address existing dubious treatments, products, and health claims. That is why it is critical that we focus on basic concepts – the red flags that should warn away from probable quackery.
Let’s take a look at vision therapy – the notion that exercises and special glasses can treat a long list of behavioral and learning problems which therapists claim are ultimately caused by vision problems.
A cure for everything
The first red flag or feature of possible quackery that comes up is the claim that there is one cause, and therefore one cure, for a long list of diseases and disorders that do not seem to be connected. Some chiropractors, for example, claim that cracking the back can address just about any medical problem, while medical acupuncturists would treat everything from addiction to cancer by sticking needles in the skin.
The core claim of vision therapists, or behavioral optometrists, is that many children are misdiagnosed with learning and behavior disorders when in fact they have a subtle problem with vision:
According to the American Optometric Association, “studies indicate that 60 percent of children identified as “problem learners” actually suffer from undetected vision problems and in some cases have been inaccurately diagnosed with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD).”
That is a pretty dramatic claim, utterly lacking in evidence. As with many dubious health claims, the scientific evidence has been heading in quite a different direction. It is increasingly clear, for example, that dyslexia is not a problem with vision but with the brain’s processing of language. Attention deficit, likewise, is a problem with the brain’s executive function. These are simply not problems with vision or visual processing.
Historically what often happens with scientifically dubious health practices is that they are based on a core notion that is never validated, or even critically evaluated. Science needs to proceed in a careful and conservative manner – only building on rock solid ground. However, it is easy to elaborate the trappings of science without such solid founding. The core belief becomes a tenet of faith, not questioned or seriously studied, but just taken for granted.
This is especially troublesome in medicine, because outcomes are often subjective, clinical research is extremely difficult, and anecdotes can be highly misleading. In fact it is difficult to interpret clinical evidence without knowing the basic science plausibility. Even when that plausibility is zero, an entire profession can evolve from a spurious basis.
A loose approach to evidence
Looking back over the last century of medical science it is also clear that a rigorous approach to medical evidence is required in order to know what really works. Researcher bias, publication bias, citation bias, placebo effects, statistical errors, and the occasional fraud make it possible to create the false impression that anything works – no matter how absurd. It takes time, care, critical analysis, and methodological rigor to sort out what really works from all this self-deception.
Taking even a slightly loose approach to evidence can create the impression of being evidence-based, even when the truth is very different.
Behavioral optometrists often rely on anecdotal evidence to support their claims. It is no surprise that many of their interventions might seem to subjectively work. First, they are targeting a vulnerable population. Parents and children are often frustrated by learning and behavioral problems, and may be dissatisfied with the range of treatments offered and their effectiveness. The public is also primed with the usual tropes – treat the underlying true cause, not the symptoms, and be wary of “Big Pharma”. Behavioral optometrists are selling what people want, a cure without drugs or surgery.
Further, the outcomes are highly subjective and susceptible to placebo effects. As with any psychological intervention, the very fact that a treatment is being offered may lead to hope, or to greater confidence. There may also be a profound observer effect, and parents will feel pressured to validate the expense of the treatments and their choice to pursue what may seem like an unusual course.
For all these reasons we need to conduct careful clinical research and control for variables as best as we can. When we do that, we find that behavior optometry is not, in fact, based on evidence.
A systematic review of the last thirty years of research found:
The headings selected were: (1) vision therapy for accommodation/vergence disorders; (2) the underachieving child; (3) prisms for near binocular disorders and for producing postural change; (4) near point stress and low-plus prescriptions; (5) use of low-plus lenses at near to slow the progression of myopia; (6) therapy to reduce myopia; (7) behavioural approaches to the treatment of strabismus and amblyopia; (8) training central and peripheral awareness and syntonics; (9) sports vision therapy; (10) neurological disorders and neuro-rehabilitation after trauma/stroke. There is a continued paucity of controlled trials in the literature to support behavioural optometry approaches. Although there are areas where the available evidence is consistent with claims made by behavioural optometrists (most notably in relation to the treatment of convergence insufficiency, the use of yoked prisms in neurological patients, and in vision rehabilitation after brain disease/injury), a large majority of behavioural management approaches are not evidence-based, and thus cannot be advocated.
Essentially there is reasonable evidence for eye exercises to treat convergence insufficiency – which is a disorder of eye movements. This has plausibility, and the evidence is reasonable. There is some evidence for benefit with patients recovering from a stroke or injury, likely due to brain plasticity as it tries to compensate for the damage. However, this literature is plagued with the problem of separating normal recovery from a treatment effect, and also functional recovery (performing specific tasks better because of practice) from neurological recovery (improving the connections in the brain). But being generous, these two areas, where there is the greatest plausibility, show some evidence of efficacy.
All other claims by behavioral optometrists, however, relating to behavior issues and visual problems not caused by eye muscle weakness, lack the kind of evidence necessary to conclude that treatments are effective.
This is also a common pattern that we see in dubious professions – there may be kernels of truth here and there, but the core philosophy is not valid and the majority of the less plausible claims are not true. Often proponents use the kernels to validate the whole, and this is also not legitimate.
Ophthalmologist David Guyton, interviewed about the issue, claims that only about 1% of patients (not the 60% claimed by behavior optometrists) have issues that respond to the exercises. Regarding the implication of this small kernel of validity he notes: “You really can’t validate by association.”
This is similar to chiropractic, in which manipulative therapy may have some benefit for acute uncomplicated lower back strain (a very limited indication at the plausible end of the spectrum) but that does not mean it treats otitis media.
Behavioral optometrists defend their claims by stating that ophthalmologists are being unfair, are overly skeptical, don’t really understand what they do, and are just protecting their turf. Such gratuitous dismissal of criticism is another red flag for quackery. In the end what matters is scientific plausibility and clinical evidence.
Unfortunately behavior optometry is now well embedded in the health care landscape, like many dubious treatments. Some optometrists are trying to expand their scope of practice beyond their true limited area of expertise. This is ultimately a challenge for the regulatory infrastructure. Having good science in health care only matters if practice is actually based on that science.

The Evidence for Rehabilitation Robots
Steven Novella on July 24, 2024
Link

Rehabilitation robots, first introduced in the 1990s, are just what they sound like – robotics used to aid in regaining function through rehabilitation following an injury. The idea sounds compelling, and the technology has been advancing steadily. But still we have to ask ourselves the question – do they actually help, and what is the evidence?
A recent comprehensive meta-analysis and systematic review is likely to spark some discussion and even controversy over this question. The review looked specifically at the use of upper extremity (UE) robotics for post-stroke rehabilitation. Their overall conclusion was this:
“The small significant effects found at the level of motor impairment do not show generalization to clinically meaningful effects at the level of UL-capacity. Meta-regressions suggest that selected participants with some potential of UL-recovery may benefit most from UL-RT, especially earlier poststroke. The robustness and consistency of our findings suggest that the development of the next generation of UL-RT needs to be guided by a better mechanistic understanding about assumed underlying interaction effects between motor learning and motor recovery poststroke.”
They did find statistically significant improvement in some aspects of UE function correlating with the use of rehabilitation robots, but not in other measures of function. But critically the improvements were small (3% in strength, for example) and did not translate into a clinically meaningful difference for the patient. They left the door open, however, for the most favorable cases if robotic intervention is early enough. They also point out (elsewhere, not in that quote) that robotics that use brain-machine interface appear more promising.
Study leader, Gert Kwakkel, is also quoted in the press release as saying:
“Our findings provide robust evidence. This evidence is independent of the type of robot used, the number of weights the robot checks, the cost, and additional features – such as virtual game displays – that have been added to the robot arm. With the data of more than 4,000 patients and thousands of treatments, we would have been able to demonstrate the presence of a positive effect of the arm robots. The fact that this did not happen suggests that the arm robots are more of a hype than an actual solution.”
But in the article and in interviews the researchers are not all negative. The study, they emphasize, does not mean the technology is dead or useless. Rather, the modest results likely reflect the fact that we still do not understand enough about the underlying mechanisms of brain recovery following a stroke, and the rehabilitation factors that enhance recovery.
As a neurologist who has treated many patients and who has followed the rehab literature for decades I have another thought as well. It’s possible that there is simply not that much room for improvement. Specifically, following a stroke for example, brain recovery of function is going to happen mostly as a function of time. Age and health matter, but these are variables that cannot be manipulated by rehab. It does seem to matter that patients engage in some physical and mental activity, and not be sedentary. But if you look at the totality of evidence it is reasonable to conclude that the benefits of activity peak quickly, with further or more specific activity having little room for improvement. In other words, neurological recovery is going to happen as long as there is a minimum of activity, and there’s not much we can do to enhance that.
Perhaps, as the authors suggest, if we understood the actual mechanisms of recovery at a reductionist level we could intervene in a clinically significant positive way, but we are not there yet. Perhaps as robotics improves further, with greater brain-machine interface, we can make recovery quicker and move complete. The authors are not suggesting robotic rehab is a dead-end, rather that we have to realize we are not there yet. We have to think carefully about the path forward, and a lot more research has to be done.
Proponents of robotic rehab point out that there are other advantages to consider. Robotic rehab is often used as an extender of the physical therapist, allowing for far greater rehab time and repetition of activity. Therefore, there may not be much difference between ideal rehab with and without robotics, but robotics allows for more people to get sufficient rehab to maximize recovery. It also saves the physical therapists from extended tedious activity, which may have its own risks, such as repetitive motion injury. Further, the incremental improvements (while not clinically significant) are there, providing a proof-of-concept that we can build on for the future of robotic rehab.
These are all good reasons to continue with the research and development of robotic rehab, and to use them in the appropriate setting. I do think, however, we need to be realistic about the potential for improvement. There may be inherent biological limits on the speed and amount of neurological recovery possible from certain kinds of injuries, and no amount of rehab is going to change those limits.
Unfortunately, we also have to consider the cost effectiveness of such high-tech interventions. Using advanced expensive technology for small incremental clinical improvements may simply not be sustainable, given the challenges of rising health care costs. So future research and development must also consider the cost effectiveness of robotic interventions as well.
Having said all that, and in the context of this recent research, I remain cautiously optimistic for this technology. This is mainly because the underlying technologies – robotics, brain-machine interface, and artificial intelligence – are advancing rapidly and have a tremendous amount of room for improvement. The relevance of past research, therefore may rapidly become obsolete. This creates its own challenge, however, that we have seen in other areas of medicine involving technology – incremental technological advances constantly stay ahead of the research (which takes years to conduct), providing an endless cycle of excuses for past failures and hype over future potential. At some point we need evidence that we are on the right track and that the technology is worth it.
As I often do, I have to point out as a side issue (but one core to science-based medicine) that I think all this hand-wringing about the evidence is healthy and is exactly what we should be doing. But I am often struck by the stark contrast between how we treat evidence in mainstream medicine and how it is treated in the world of “alternative” medicine. If robotic rehab were “alternative” the small incremental improvements would be hailed as proof that the technology not only works, but is entirely worth it. Further, it would be used to justify extreme speculation about underlying mechanisms of action, without any independent evidence. Researchers would have already shifted to studies about how best to implement their treatment, without directly addressing the question of whether or not it actually works.
Alternative medicine proponents have certainly used much weaker evidence to promote much more speculative and even fanciful and “magical” treatments, and never seem to do any hand-wringing about the quality of their evidence or the limitations of their basic science understanding. It’s a different world, with a different culture, and a different set of standards and rules. The alternative medicine world is one we should reject, because it doesn’t work, and because it puts the needs of gurus, manufacturers, and practitioners above patients and the public.
With all the limitations I outlined above, robotic rehabilitation is a plausible technology that does seem to work and provide some incremental improvement. But we still need to determine if it is ultimately worth it, or can be improved enough or better targeted to be worth it.

Parkinson’s Disease: A Detective Story
Harriet Hall on September 20, 2016
Link
I didn’t intend to review Jon Palfreman’s book Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease, but after reading it I decided it was too good not to share. Palfreman is an award-winning science journalist who has Parkinson’s himself. He has done a bang-up job of describing Parkinson’s disease, its impact on patients, and how science is working to understand and treat it.
The disease
Parkinson first described the disease in 1817. It is characterized by shaking, rigidity, slowness of movement, and difficulty with walking. There is a decrease in dopamine in the basal ganglia in the brain. One million Americans have Parkinson’s disease. The incidence increases with age; by age 80 one in fifty people are affected.
Some very strange phenomena have been observed. Parkinson’s disease is less common among smokers and coffee drinkers. When a patient becomes frozen and unable to take the next step, if you draw a line on the floor they will step over the line and walk on. Patients who can’t walk can run, ride a bike, or ice-skate. Some patients appear to have strong responses to placebos, with reversal of symptoms for long periods. Exposure to vibration seems to decrease symptoms; in the late 1800s patients were treated with vibrating chairs until controlled studies showed they didn’t work.
L-dopa
One of the most effective drugs, L-dopa, almost didn’t happen. The first studies showed it didn’t work, but they used small doses. Fortunately, a few scientists persisted and eventually achieved dramatic results by giving a thousand times as much and adding carbidopa to enhance the effect. It changed Parkinson’s disease from a relentless devastating progression to a chronic disease with a gradual decline. But there were serious side effects. We needed better treatments, and we needed to find the cause of the disease.
Practical tricks
Patients have discovered a number of practical tricks to bypass the basal ganglia, like shifting their weight sideways to allow them to go forward. A strenuous exercise program is quite effective: it doesn’t slow the progression of the disease, but it slows the progression of the disability.
Brain surgery
In 1952 a surgeon made a serendipitous mistake. While performing a procedure called a pedunculotomy, his hand slipped and he severed the artery that supplied the basal ganglia. When the patient woke up, his Parkinson’s symptoms were gone! This discovery led to an effective operation that removed part of the thalamus. Other surgical treatments were developed, including implanting an electronic device for deep brain stimulation and implanting fetal cells.
Fetal cell grafts were initially promising, but RCTs with sham surgery showed they didn’t work, and the surgery carries serious risks. Some researchers continue to support it because there’s no doubt that it worked dramatically for two patients; they argue that it works if you do it right, and the different negative studies merely show that there are lots of ways to do it wrong.
Dopamine neurons
Could Parkinson’s be a natural consequence of aging? We lose dopamine neurons as we age; once 70% of them are gone, the symptoms of Parkinson’s kick in. If we all lived to 120 we might all develop Parkinson’s. Animals don’t get it, probably because they have shorter life spans and because they have proportionally more dopamine neurons than humans.
Researchers are looking for a way to protect or revive dopamine neurons. One treatment involves infusing a protective protein directly into the brain by catheter using high pressure. Another approach is gene therapy. Palfreman describes the vicissitudes and the difficulties of that research.
Paradigm shift
We are seeing a paradigm shift. The focus on Parkinson’s as a dopamine disorder was overly simplistic. It appears that dopamine-related symptoms are only the tip of a complex clinical iceberg with many symptoms that have nothing to do with movement, from constipation to sleep disorders, from double vision to dementia. This has been difficult to tease out, because some of these same symptoms are common with aging. Dementia may eventually affect up to 80% of Parkinson’s patients. The major risk factor for dementia is age, so paradoxically the longer we can keep patients alive, the more of them will become demented.
Hope
He quotes a patient’s thoughts on hope that are profound and applicable to other medical conditions like cancer.
…not a naïve hope that I will, by some miracle, have my former self restored, but hope that tomorrow, and the day after, can still be days from which a measure of joy and meaning can be derived.
I applaud that kind of realistic hope and deplore the false hopes that are raised by CAM and quackery.
Environmental or genetic causes?
Years before his diagnosis, the author had produced a Nova documentary titled “The Case of the Frozen Shoulder” about six young drug abusers in San Jose, California who developed the symptoms of Parkinson’s disease after injecting a bad batch of heroin contaminated with a neurotoxic contaminant called MPTP. So we know Parkinson’s can have an environmental cause, but no such cause has been linked to the majority of cases.
Genetic causes were initially dismissed. The fascinating detective story of how a genetic cause was identified is perhaps the best part of the book. It all hinged on a single clinician’s memory. A Parkinson’s patient happened to mention that her ancestors came from a small village in Italy, and the doctor remembered that a family member of another patient had mentioned the same village. He contacted a doctor in that part of Italy and by clever and dogged sleuthing they eventually determined that those two patients were seventh cousins and were two of the 574 descendants of a couple who married in 1700 and that 61 of the recent descendants also had Parkinson’s. They obtained blood samples from family members in both Italy and the US, but they didn’t have the technical skills to take the next step. Years later, researchers at the NIH asked for their blood samples and used linkage studies to roughly localize an area on chromosome 4. By sheer good fortune, one of the researchers was highly familiar with chromosome 4. Also by sheer good luck, an open-access computerized database listed the gene that had mutated. It was called SNCA, and its normal role is to make an obscure brain protein called alpha-synuclein. Researchers had identified that protein in the plaques of Alzheimer’s patients and had put the gene sequences into the database as a public service. It turns out that the characteristic Lewy bodies of Parkinson’s disease consist mainly of alpha-synuclein. This led to promising new avenues of research. Other kindreds were identified that lacked the mutation but that had too many copies of the gene. So far a total of 18 potentially genetic forms of Parkinson’s have turned up.
Cutting edge research
The prospects are exciting: it might be possible to block Alzheimer’s, Parkinson’s, ALS, and a number of other related diseases with a single drug directed at alpha-synuclein. In another development, it appeared that misfolded proteins might play a role, contagiously causing the misfolding of other proteins as in prion diseases like kuru and mad cow disease. The plot thickened when autopsies in Sun City showed that many patients diagnosed with Parkinson’s didn’t actually have the disease. Researchers are looking for biomarkers that may eventually allow early diagnosis and treatment of the disease years before the characteristic symptoms develop. They are investigating so-called “placebo responders.” They are studying the M13 virus, a bacteriophage that acts like a magic elixir with near-miraculous results in rodent studies but that is just now entering human studies. The future looks bright.
I strongly recommend Palfreman’s book
This book is an engaging detective story with edge-of-the-seat excitement that keeps the reader eager to learn what the scientists are going to discover in the next chapter. It’s a good way to learn about a devastating disease that may someday affect you or your family. And it’s a good way to learn how scientific research works, how it progresses by fits and starts, through serendipity and error as well as through well-designed studies. Highly recommended. 

Body Integrity Dysphoria – A Rare and Informative Condition
Steven Novella on September 9, 2026
Link

A fifty year-old man was admitted through the emergency room with extensive dry ice injuries to his left leg. For two days his doctors tried to save the leg, but the damage was too extensive so eventually they had to perform a below-knee amputation. During this time the patient also suffered from small strokes due to fat emboli from the damaged leg.
After the surgery the patient recovered well. He told his doctors that the dry ice injuries were deliberate and that the amputation was the outcome he was hoping for. In fact he was coached throughout the process by people in an online forum, who helped him determine when the damage was extensive enough that amputation would be required.
The initial reaction to such a case is often that this person must be suffering from a kind of mental illness. Perhaps he is psychotic, or this is an extreme version of Munchausen syndrome where people inflict harm on themselves for psychological reasons. This is not the case, but this is similar to the process that the medical profession went through when first encountering these rare cases.
This condition is now known as Body Integrity Dysphoria (BID), previously Body Integrity Disorder or Body Integrity Identity Disorder. But BID was previously described by two psychologists in 1977 in the Journal of Sex Research, in which they named it apotemnophilia. They thought BID was primarily a paraphilia, in which subjects were erotically stimulated by amputations and the thought of themselves being an amputee.
The earliest possible described case, however, goes back to 1785 – French surgeon Jean-Joseph Sue reported a case of a man who paid him to amputate a healthy leg, forcing him to do it at gunpoint, but later reported that this fulfilled his life-long wish. Cases of apparent BID were also described in the 1906 book Pscyopathia Sexualis.
Our understanding of BID has followed a familiar pattern of many complex neurological conditions, first thought to be psychological. This is similar to the once popular theory that autism was caused by a lack of warmth from parents, the so-called “refrigerator mother” theory. We see this today with popular theories regarding gender dysphoria.
This mistake stems in part from that fact that many people do not understand that our experience and sense of self is not a passive result of reality but an active and constructive neurological process. What I mean by this is that you do not feel that you exist inside your body, that you are your body, that you are separate from the rest of the universe, that you own the parts of your body, and control those body part simply because you do. You have these sensations because there are circuits and networks in your brain that actively construct those sensations. We partly know this from cases where these networks fail or are suppressed, resulting in out-of-body experiences, or conditions such as alien-hand syndrome.
There are also cases where the internal body map in the brain does not align with the body itself – phantom limb pain syndrome. In such cases a body part is amputated but the corresponding brain map is still functioning, creating the illusion that the missing limb is still there. There are even cases where patients, after suffering a stroke, experience a supernumerary phantom limb, the sensation that they have an extra limb. Again – this is not a delusion. These patients are not mentally ill. They report a sensation that is at odds with physical reality.
Understanding of phenomena like alien-hand and phantom limb lead to the hypothesis that perhaps BID is also a mismatch between the brain’s internal body map and the body, in this case the offending limb may simply be missing from that map. That would cause the person to feel as if the body part does not belong to them, which can cause distress (dysphoria). They feel they are “overcomplete”, and that they would feel more natural without the body part. These sensations are often recognized from very young (often by age 5), and are persistent throughout their life.
BID was mistaken for a paraphilia likely because many people with BID feel really good when they imagine themselves without the body part they feel does not belong to them, or when they see someone missing that same body part. The relief of the persistent dysphoria can cause a type of euphoria that is some people with BID can cause secondary sexual arousal. This appears to be an epiphenomenon, not what is driving the BID sensations. In the case report above, the subject did not report any associated sexual arousal.
What happens when we turn our modern imaging tools on the brains of those with BID? We can image anatomy and even map connectivity in the brain. What we find aligns well with what we might expect to find. The first relevant study comes from 2011, Xenomelia: a new right parietal lobe syndrome. They studies four subjects with BID using magnetoencephalography while stimulating the unwanted limb and other parts of the body. In all cases the sensation caused the typical response in the sensory parts of the brain. However, only when touching the unwanted body part, the expected activation in the right superior parietal lobule (rSPL) was not activated. What does this mean?
Sensory input in the brain is hierarchical. It begins with primary sensory areas, which then feed to progressively higher brain areas that do more sophisticated processing and incorporate the sensory input into cognitive and emotional processes. The rSPL appears to be involved in incorporating various sensory inputs into a coherent sensation of the whole body. Those networks I discussed above that actively create the sensation of self rely heavily on sensory input. In cases of BID sensations from the unwanted limb do not appear to be incorporated into the body map at higher levels.
A 2013 fMRI study found a similar decrease in activity in the ventral premotor cortex. A 2017 connectivity study found hyperconnectivity in somatosensory areas in subjects with BID. This study suggests that BID may be more complex than a simple mismatch in the body’s internal map and, at least in some cases, may reflect a broader dysfunction in the networks that create the sense of self.
An important 2020 study also focused on the rSPL. They found that this area was atrophied and had hypoconnectivity in subjects with BID. Further, they found that the more intense the feelings of BID the greater the degree of atrophy, which is strong evidence for an actual cause and effect. Many of these findings have been replicated in recent years.
Finally there is a 2025 study that found that sensory activation of the unwanted limb created increased activation of brain centers associated with sensory arousal, pain and reward. These are likely the neuroanatomical correlates of the dysphoria part of BID – the unwanted limb activates distress signals in the brain because it detects that there is something wrong.
To summarize, BID is associated with a mismatch in the internal model of self and the body itself, with general altered function in the networks that generate the sense of self and incorporate sensation into this model, and activation of internal stress due to the mismatch. Clinically BID behaves like a neurological disorder – young onset and lifelong persistence. And now we have the neuroanatomical correlates to back this up.
Further, BID does not respond to talk therapy. Therapy may help with dealing with some of the effects of BID, but does nothing to resolve the BID itself. Medication is likewise ineffective. This leads to a hotly debated ethical dilemma – is it medically ethical to amputate a healthy body part as a treatment for BID? Outcomes do appear to be good, and not taking corrective action often leads to self injury and seeking non-medical amputation. Understanding the neuroscience of BID at the very least can help inform this difficult debate.
The neuroscience of BID is good to keep in mind when considering other conditions that may superficially seem purely psychological. Obviously, there are psychological and psychiatric conditions. I am not saying they don’t exist. It is curious, however, that we (individually and collectively) often assume a psychological cause, even in conditions that are ultimately understood as purely neurological. I suspect this is because it is difficult to think of the core aspects of our sense of reality and sense of self as being constructed by brain networks, rather than a simple recognition of reality. The construction (some might call it an illusion) that our brains create is so compelling we have a hard time recognizing it as a construction.


HEADACHES

CAM and Headaches
Steven Novella on September 3, 2014
Link

A recent editorial entitled “CAM in the Real World: You May Practice Evidence-Based Medicine, But Your Patients Don’t” published in Headache: The Journal of Head and Face Pain by Robert Cowan, a headache specialist, addresses the use of complementary and alternative medicine (CAM) in the treatment of headaches. Unfortunately he propagates many common misconceptions about CAM in the article.
I do agree with one point – physicians need to be more aware of CAM treatments and their patients’ use of them. We should be directly asking our patients about such use, in a non-judgmental way, and we should be familiar enough with common CAM treatments so that we can provide knowledgeable guidance to our patients.
Cowan begins by, in my opinion, grossly exaggerating the current popularity of CAM. He writes:
As much as 82% of headache sufferers use complementary and alternative approaches.
The reference he cites, however, states:
Adults with migraines/severe headaches used CAM more frequently than those without (49.5% vs 33.9%, P < .0001); differences persisted after adjustment (adjusted odds ratio = 1.29, 95% confidence interval [1.15, 1.45]). Mind–body therapies (eg, deep breathing exercises, meditation, yoga) were used most commonly.
Only 4.5% of adults with migraines/severe headaches reported using CAM to specifically treat their migraines/severe headaches.
In order to get the inflated figure you have to include treatments that are, at best, in the gray zone. This is a game proponents of CAM have been playing for years – the definition is vague enough that they can include common practices an inflate the apparent popularity of CAM. Even the lower figure of 49.5% includes people who are simply exercising.
Cowan also did not mention that the same study found that only 4.5% of migraine patients use CAM to treat their migraine. That would have undercut his premise that use is common so that headache doctors need to pay attention.
He continues with perhaps the second most common CAM trope:
There is limited evidence suggesting the vast majority of these treatments are harmful (regardless of the evidence they are helpful), and most have withstood “the test of time,” having been handed down over hundreds, even thousands of years.
“The test of time” has proven to be utterly worthless. Galenic medicine, based on balancing the four humors, survived for a couple thousand years even though its interventions almost certainly caused harm and no benefit. It only faded away in the wake of scientific medicine.
The plural of anecdote is not data, and this includes anecdotes over a long period of time. Long use of treatments can be explained by cultural inertia, in the absence of any real benefit.
Further, lack of evidence of harm is not very compelling. Anecdotal evidence is useful in eliminating immediate obvious harm, such as deadly poisons, but not useful in exposing long term harm or low probability harm.
There are now plenty of example of herbal remedies, used for centuries, that only recently were discovered to have significant toxicity, such as aristolochia and renal failure or kava kava and liver damage. Many herbal supplements also contain heavy metal contaminants, or don’t even have the ingredients on their labels, opening the door for unknown allergic reactions or drug-drug interactions.
Risks are not limited to herbal drugs. Chiropractic neck manipulation has been linked to a rare but serious complication of stroke and even death. A review of acupuncture side effects found they occurred in 11.4% of treatments.
Much of the harm of CAM is also indirect. Patients expending time and limited resources on treatments that are ineffective may delay or even forgo science-based treatments. Even for self-limiting or purely symptomatic syndromes, there is potential harm in patients being convinced that an unscientific treatment is effective due to practitioner recommendation and placebo effects. If a patient feels their migraines are improved due to acupuncture, perhaps they will be more open to using acupuncture to treat their cancer and delay definitive treatment. (Yes – some “medical acupuncturists” advocate using acupuncture to treat cancer.)
It is unreasonable to expect practitioners in an unscientific paradigm to be science-based in the application on their interventions.
I also have to wonder which treatments Dr. Cowan believes have been around for thousands of years. Perhaps some herbs have been in use for that long, and those that work are mostly already incorporated into modern pharmacology. Acupuncture is often claimed to be thousands of years old, but prior to the 20th century acupuncture had more in common with bloodletting than what passes today for acupuncture. Chiropractic and naturopathy are less than two centuries old, and homeopathy is a little over two centuries.
Cowan also does not discuss evidence for lack of efficacy, and like many CAM proponents pretends that this does not exist. There is sufficient evidence, for example, that acupuncture does not work for any specific indication, and specifically does not work for migraine (despite the claims of acupuncturists).
Cowan makes the usual excuse, however:
The most widely used of these are Ayurveda, classical Chinese medicine, homeopathy, chiropractic, and naturopathy. Because these are medical systems rather than discrete interventions, studies are much harder to come by and in general, each has its own internal logic. It is much more difficult to evaluate a system which is based on centuries of trial and error or of an oral tradition.
Why? If any of these interventions work, regardless of their internal logic or history, careful clinical trials should show an effect. I would also point out that astrology has an internal logic. That is not sufficient to make a philosophy legitimate or recommend it as a medical system.
He mentions homeopathy in a few places in the article, without ever pointing out that homeopathy is based purely on magical thinking, that its premises run contrary to modern science, and that a large body of clinical evidence shows that homeopathy does not work for anything.
Here, however, is the worst statement in the entire article:
To summarize, what is presently accepted as conventional medicine came to be so by caveat. Other medical systems have neither been subject to the rigorous vetting that Western medicine approaches have undergone in order to further develop nor have they been demonstrated to be ineffective or dangerous in any systematic way. In other words, there are no scientifically accepted criteria for inclusion or exclusion of specific modalities as CAM or as conventional. Conventional medicine is exactly that – medicine by convention.
He is arguing that scientific medicine won out over competing medical systems because Flexner (a German educator and not a physician) arbitrarily decided that science would be the basis of modern medicine. This is an astounding argument, considering that the application of scientific principles transformed the practice of medicine and has arguably doubled the human life-expectancy since its inception.
Cowan again also ignores the fact that competing systems at the time not only lacked scientific evidence, many of them were demonstrably absurd. Homeopathy was ridiculed long before the Flexner report.
Further, regardless of history, scientific evidence is clearly the best tool we have to determining if a treatment is safe and effective. There is simply no viable alternative. He is also flatly wrong when he argues that CAM systems have not been demonstrated to be ineffective – they largely have, as I pointed out for homeopathy and acupuncture.
Conclusion
Cowan tries very hard to make it seem as if he is being objective and is simply looking out for the best interests of patients. In the end, however, in this article he has simply repeated the misconceptions and distortions typical of CAM proponents.
He makes a false dichotomy between “Western” medicine and alternative medicines. He exaggerates CAM’s popularity, and blurs the line between CAM and scientific medicine by including treatments that are solidly science-based, such as nutrition and exercise.
He pretends that the scientific basis of medicine is just an arbitrary historical choice, rather than the transformational and defining aspect of modern medicine that finally dragged the medical profession out of the era of witch-doctors.
He pretends that we do not already have sufficient evidence for lack of efficacy for most CAM modalities. I would add that a science-based approach would also consider plausibility, which most CAM modalities lack.
In the end Cowan used an elaborate and indirect justification for the same list of magical and disproved therapies that CAM proponents have been promoting for years.
I agree that physicians need to be more familiar with CAM treatments and discuss such issues with patients when appropriate. They should do so, however, from a solid understanding of the actual science and history of such treatments.

Treating Migraines
Steven Novella on January 28, 2015
Link

I am a headache specialist and so I receive many questions, through SBM, NeuroLogica or listeners of the Skeptic’s Guide to the Universe, about how to best treat headaches, or about a specific, often unusual, treatment. Migraines and severe headaches are very common. According to the latest statistics:
14.2% of US adults 18 or older reported having migraine or severe headache in the previous 3 months in the 2012 NHIS. The overall age-adjusted 3-month prevalence of migraine in females was 19.1% and in males 9.0%, but varied substantially depending on age. The prevalence of migraine was highest in females 18-44, where the 3-month prevalence of migraine or severe headache was 23.5%.
That means about 28 million Americans suffer from migraines. Percentages do vary from continent to continent, but not dramatically. Migraine, therefore, is a huge burden. Headaches can be debilitating when severe, and so also are a major source of lost productivity.
This will be a two-part series reviewing some of the options for treating migraines, focusing on science-based treatments in part I, and non-science-based treatments in part II. None of this is intended to give specific medical advice for any individual. If you have severe headaches you should consult your physician. I will simply be reviewing the evidence for various options, focusing on migraine specifically.

Lifestyle factors
The first step in approaching chronic headaches is to identify any lifestyle factors that may be playing a role and can be optimized. The more frequent and severe the migraine, the more important this becomes. This does not necessarily mean that the lifestyle factor is causing the headaches (although it may) but rather it could be triggering headaches or just making them more frequent.
Perhaps the most common trigger I encounter is caffeine. It is possible to have a pure caffeine-withdrawal headache, or for caffeine or caffeine withdrawal to trigger a migraine or increase its frequency. Eliminating caffeine should always be step 1 for reducing a chronic headache. Caffeine is present in coffee, tea, cola and other soft drinks, and chocolate. The recommendation for migraine sufferers is no more than 1 8oz beverage with caffeine per day (that giant 32oz coffee is actually 4 cups), although I prefer for my patients to completely eliminate caffeine when we are trying to maximally-remove triggers. Decaffeinated products should have about 3% of the caffeine normally present, but studies looking at actual products found that some can contain as much as 15% caffeine, enough to be physiologically significant if you drink a lot of decaf coffee.
Clues that caffeine may be playing a role are that your headaches occur in the evening or upon awakening, when it has been the longest since your last dose of caffeine. Weekend headaches, when people sleep in and delay their caffeine drinking, may also be a caffeine-withdrawal pattern. Also, if taking caffeine treats the headache, you are likely treating caffeine withdrawal. It takes at least seven days for the caffeine withdrawal symptoms to go away, but may take several weeks. I like to give my patients a caffeine-free trial for two to three months at least to see what their baseline headaches are like off caffeine.
There are many other possible triggers – red wine or other alcohol, foods with nitrates, aged cheese and deli meats, pickles, and MSG are common. (Studies of MSG do not show any consistent effects, but if an individual finds it is a consistent trigger it’s reasonable to avoid it.) The best way to determine what your triggers are is to keep a headache diary. There are now plenty of apps to help you do this.
Other lifestyle factors include getting regular sleep. Sleep deprivation can trigger a headache or worsen overall headaches. Optimizing sleep is therefore essential, and if you have a full sleep disorder then seek medical attention for that underlying problem. Too often patients don’t make the connection between their poor sleep and other symptoms, and don’t realize that a chronic sleep disorder is a medical condition that requires attention.
Keeping well hydrated and not skipping meals is also important. Don’t overdo the hydration, but make sure you keep well hydrated, especially on long flights, when it is hot or dry, at high altitudes, or when engaging in physical activity. Regular moderate exercise may also help manage migraines.
Nutrition
Several nutritional factors have been linked to migraines or may help with treatment. There is evidence that patients suffering from migraines have a greater chance of being low in magnesium. Evidence for a benefit from routine magnesium supplementation is encouraging but limited at this time, so it is not possible to make a strong recommendation for it. Some experts recommend getting more magnesium in the diet rather than using supplements. I tend to check magnesium levels and supplement when low.
Vitamin B2 (riboflavin) may help reduce migraines, but evidence is limited. The same is true for coenzyme Q10, which has the added disadvantage of being expensive. There is no evidence that a general multivitamin is helpful. As is often the case, the best advice is to have a well-rounded diet. Specific supplements as above may be considered in patients who cannot use medication or want to avoid it, but I have never seen a dramatic response to nutritional interventions alone in severe migraine.
OTC medication
Most migraine patients do not seek medical attention and treat themselves with over-the-counter medication. This is reasonable and there are several good options. NSAIDS (aspirin-like drugs) are a reasonable first line treatment for migraines. They are both anti-inflammatory and analgesic (pain killing). Migraine has an inflammatory component and so the anti-inflammatories may be especially helpful. Acetaminophen, which is not anti-inflammatory, is still effective in many patients.
Taking a medication at the onset of a headache is called an “abortive remedy.” To optimize abortive treatment, take it as soon as you know you are getting a headache. If you have an aura or warning before the headache, take it then. Don’t wait. There is literally a window of opportunity to effectively abort a migraine – don’t miss it. This means having your medication with you at all times. Take the medication with additional hydration. Avoid bright light, loud noise, or anything else that worsens your migraines until it resolves.
Using medication in this way up to once or twice a week should not be an issue for most people (again, consult your physician if you have other chronic conditions that need to be taken into consideration, such as stomach, kidney, or liver problems). If you have more than one to two headaches per week, you probably should be consulting your physician. Taking medication more frequently than that on a long-term basis can cause ulcers or kidney problems for NSAIDS, or liver problems with acetaminophen.
Also, taking any pain medication more than 1-2 times per week can cause what are called rebound headaches, or a medication overuse syndrome. In such cases headaches become more and more frequent, they can become daily, and result in dependence on the pain medication. Definitely seek medical attention before increasing your headache treatments to this extent. It is easier to prevent than to treat a medication overuse syndrome.
Prescription medication
I am not going to give a detailed description of the use of prescription medications for migraine. By definition, you will be seeking medical attention for prescription management. Such a long discussion is also beyond the scope of this article. For professionals there are already thorough reviews out there. The American Headache Society, for example, publishes excellent reviews. Here is a review of the evidence for acute treatment of migraines, and here is one for migraine prevention.
It is good to know, however, what kinds of options are available.
Your doctor can give you prescription strength and other formulations of NSAIDs to optimize their benefit. In addition, there is a class of medications called triptans which can be very effective in aborting migraines, either alone or in combination with NSAIDs.
If you have nausea with your headache to any extent, then treating the nausea can be a very effective method for treating the overall migraine.
There are also many options for migraine preventive therapy. These are medications taken every day in order to reduce the number and severity of migraines or make them more amenable to abortive treatment. These therapies should be carefully individualized, mostly by their side effect profile.
Botulinum toxin is also an approved therapy for migraine prevention in the US. This is given as a series of injections every three months, which some patients may prefer to a daily medication. This can be a very effective option in some patients.
About 60% of women with migraines are responsive to changes in their hormonal status. It may be possible to manage migraines by targeting prevention at high risk times during their cycle, or by adjusting their hormonal therapy.
For many patients who have headaches that are beyond self-treatment, your primary care doctor should be your first stop. They can decide whether or not to refer you to a specialist, which is usually a general neurologist. There are also neurologists who are specialized in headache medicine, and there is now board certification for this specialty. Finally there are some multi-disciplinary headache clinics for the most severe patients.
Conclusion
The purpose of this quick overview is to help individuals with chronic headaches optimize their self-treatment, and have a basic understanding of the options available from health professionals, including the range of experts that are available.
To reiterate – this cannot substitute for specific medical advice, which has to be individualized. Defer to your doctor if you have any questions about your headaches. Also, it is appropriate to seek medical attention for any severe headache syndrome, worsening headaches, new headaches, headaches that are difficult to treat, or any headaches associated with other worrisome symptoms. Acute severe headaches should be seen urgently in an emergency setting.
Next week I will review more speculative treatments for headaches, or those that specifically lack plausibility and/or evidence to support them.

How Not to Treat Migraine
Steven Novella on February 4, 2015
Link


Last week I gave a quick overview of standard treatment options for migraine, a severe form of recurrent headaches. As promised, this week I will address some common treatments for migraine that I don’t think are supported by the evidence.
Acupuncture
Acupuncture is the CAM modality that, it seems to me, has infiltrated the furthest into mainstream medicine, including for the treatment of migraine. In fact the The American Headache Society includes acupuncture on its list of recommended treatments. The reason for this is that acupuncture proponents have been able to change the rules of clinical research so that essentially negative or worthless studies of acupuncture are presented as positive.
I reviewed the evidence for acupuncture and migraine previously, demonstrating the multiple problems with the acupuncture literature in general, and specifically acupuncture in migraines. Most studies suffer from at least one fatal flaw: they are not properly blinded, they do not include a control, they mix acupuncture with non-acupuncture variables (mostly including electrical stimulation in the treatment group), comparison groups are not adequately treated, they make multiple comparisons to maximize chance outcomes, or they are simply too small making them susceptible to all the usual problems of bias in research.
What we don’t see is a consistent and clinically-relevant effect in properly-controlled double-blind trials where the variables of acupuncture are isolated.
As with the rest of acupuncture research, what the results actually show is that when you do properly isolate the variables, the location or insertion of needles do not seem to matter, consistent with the interpretation that acupuncture is an elaborate placebo.
The best demonstration of the persistent positive bias in interpreting acupuncture studies by acupuncture proponents is the 2009 Cochrane review of acupuncture in migraine (the latest version). After saying that acupuncture may work, they acknowledge:
There is no evidence for an effect of ‘true’ acupuncture over sham interventions, though this is difficult to interpret, as exact point location could be of limited importance.
This is not difficult to interpret at all. The properly-blinded comparisons are negative. Only unblinded results are encouraging. This makes acupuncture the equivalent of N-rays – not a real phenomenon.
Electrical stimulation
Using either electrical or magnetic stimulation to alter brain function for therapeutic purposes is an emerging and interesting treatment modality. However, I don’t think we are quite there yet.
Last March the FDA approved the first device for the treatment of migraines with electrical stimulation, the Cephaly device. Approval was based upon two studies, which I reviewed at the time.
The FDA cited two studies in support of the device. The first was an unblinded pilot study looking at patient satisfaction (not efficacy). The second study involved 67 subjects and was placebo controlled. However – the results were negative. There was no statistically-significant difference between the treatment and the control group. The study concluded, however, that the treatment showed a statistically significant difference from baseline while the placebo did not. This is not an appropriate statistical comparison, but it is a very common error. This study should be considered negative, but was used as the basis for FDA approval.
At present I would consider this approach experimental but plausible. Real efficacy still needs to be demonstrated. Further, there are multiple possible stimulation sites (occipital nerve vs. frontal stimulation) and multiple intensities and durations need to be explored, both for acute migraine and prevention. It will likely still be a few years before we can make solid conclusions about this approach.
Chiropractic
Cervical manipulation for migraine headache is commonly offered by chiropractors. The research here is very heterogeneous, partly because there are many subtypes of headaches, some of which involve neck pain, restricted range of motion, or muscle tightness. Physical therapy can be helpful in such cases, but there is no reason to use anything other than the most gentle of interventions, such as massage, or mobilization when necessary.
Studies specifically of chiropractic show, ironically, no benefit for tension headaches. Studies with migraine are of limited rigor. A 2004 Cochrane review (the latest available) concluded:
A few non-invasive physical treatments may be effective as prophylactic treatments for chronic/recurrent headaches. Based on trial results, these treatments appear to be associated with little risk of serious adverse effects. The clinical effectiveness and cost-effectiveness of non-invasive physical treatments require further research using scientifically rigorous methods. The heterogeneity of the studies included in this review means that the results of a few additional high-quality trials in the future could easily change the conclusions of our review.
The old, “More research is needed,” which is essentially a euphemism for, “current research does not demonstrate efficacy.”
The reviews all seem to still rely heavily on one study from 1998 comparing spinal manipulation to amitriptyline, which is considered an accepted treatment for the prevention of migraine. The study, however, was short, only an 8 week treatment period and 4 week follow up. This is often how long it takes for amitriptyline to start working. They also used a low dose of amitriptyline, which is often subtherapeutic. The fact that there was no difference between manipulation and a short course of low dose amitriptyline is not impressive, and likely represents lack of efficacy for both.
At present there is insufficient evidence to recommend manipulation for migraine treatment or prevention. In patients with neck pain or symptoms associated with their headaches, simple physical therapy or massage is a reasonable option, but also has little evidence for efficacy. There are a few small studies of massage with positive results, and “more research is needed.”
Conclusion
There are many other treatments offered for migraines that are of dubious evidence or plausibility, but I can’t cover them all in one article. The three above are the most common.
Reviewing the literature one common theme keeps cropping up – most studies are of such limited scientific rigor that their conclusions of are little or no value. Most such studies are false positives and simply reflect the bias of the researchers. It is unfortunate that so many studies of preliminary design continue to be done even in areas that are far beyond the preliminary stage. We don’t need another pilot study of acupuncture for migraine. What we need are rigorous placebo-controlled trials.
It is disappointing that in some cases definitive trials have not been done even after decades of use.

New Study Questions fMRI Validity
Steven Novella on July 6, 2016
Link

One way to describe our overall editorial stance at SBM is that we are criticizing medical science in a constructive way because we would like to see higher standards more generally applied. Science is complex, medical science especially so because it deals with people who are complex and unique. Getting it right is hard and so we need to take a very careful and thoughtful approach. There are countless ways to get it wrong.
One way to get it wrong is to put too much faith in a new technology or scientific approach when there has not been enough time to adequately validate that approach. It’s tempting to think that the new idea or technology is going to revolutionize science or medicine, but history has taught us to be cautious. For instance, antioxidants, it turns out, are not going to cure a long list of diseases.
One recent technology that is very exciting, but insiders recognize is very problematic, is perhaps even more problematic than we thought –functional MRI scans (fMRI). A new study suggests that the statistical software used to analyse the raw data from fMRIs might be significantly flawed, producing a flood of false positive results.
An fMRI primer
MRI scanning uses powerful magnets to image soft tissue in the body. The magnets (1.5-3 Tesla, typically) align the spin of hydrogen atoms in water molecules with the magnetic field. The time it takes for the atoms to align and then relax depends on the characteristics of the tissue. The MRI scan therefore sees subtle differences in tissue (density, water content) and uses this information to construct detailed images.
Functional MRI takes it one step further – it images blood flow using a technique known as blood oxygenation level dependent (BOLD) imaging. When a part of the brain is active there is an initial dip in blood oxygenation as the neurons consume oxygen, but then blood flow increases bringing more oxygen to the tissue. This peaks at about 6 seconds, then the oxygen level dips below baseline and then back to baseline.
Software analyses the raw data from fMRI scan to create what are called voxels. A voxel is a three-dimensional pixel, representing a tiny cube of brain tissue containing about a million cells. The software determines the activity level of each voxel based upon how closely changes in oxygenation level match the expected pattern that occurs when brain cells are active.
The software will also look for groups of voxels that have the same activity level, a phenomenon known as clustering. Scientists infer from a clustering of voxels showing increased activity which in turn is inferred from how closely it matches the expected pattern of oxygenation, that a part of the brain is undergoing increased activity. Researchers try to correlate such regional activity with specific tasks, and then infer that this part of the brain is involved in that task.
The Black Box
Already we can see that interpreting the results of an fMRI study involves a chain of inference. The chain gets longer, however, because often researchers will need to do multiple trials of multiple individuals and then compare their brain activity statistically.
For example, you might have one control group that is essentially doing nothing, while another group is looking at a specific image. Then you compare the fMRI activity statistically between the two groups, and can conclude that looking at the specific image correlates with increased activity in one part of the brain, and from that you infer that the active part of the brain is involved in visual processing.
To date about 40,000 such studies have been published, adding a tremendous amount to our knowledge of what different parts of the brain are doing and how they connect up and interact.
However, in addition to other problems with fMRI studies, a key link in this long chain of inference has always been a bit of a controversy – the statistical analysis of the raw data to detect clusters of voxels that are active together. Researchers use statistical software packages that they purchase. They need to learn how to use the software, but most neuroscientists are not software engineers and so they have to trust that the software works as advertised. To them the software is a black box that spits out data.
Famously, neuroscientist Craig Bennett scanned a dead salmon using fMRI and found that when the dead salmon was shown pictures, the software detected a statistical cluster of voxel activity in its brain. Bennett won an Ig Nobel prize for his efforts. More importantly, he sounded an alarm bell that fMRI software might have a problem with generating false positives.
The new study
“Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates,” was recently published in PNAS by authors Anders Eklund, Thomas E. Nichols, and Hans Knutsson. This is a follow up study to earlier work with similar results.
In their prior study they set out to conduct validation tests of one popular fMRI statistical software package. They used existing open source data for task-based in individual data, using a null data set (meaning there should be no difference). Given where the thresholds are set in terms of finding a statistical match to a pattern of oxygenation consistent with brain activity, there should be a 5% false positive rate. They found a false positive rate as high as 70%.
The current study expands on their earlier work. First, they are using three of the most common statistical software packages instead of just one, and they are also comparing groups rather than just individuals. They compare two groups each randomly drawn from the same pool of healthy individuals, so there should be no difference. Again, there should be a 5% false positive rate, but they found many statistical tests with much higher false positive rates, between 60-90%. (This depends on the parameters used, like number of subjects and threshold of statistical significance.) They summarize these results:
For a nominal familywise error rate of 5%, the parametric statistical methods are shown to be conservative for voxelwise inference and invalid for clusterwise inference.
There is a lot of statistical jargon in the paper, but basically the voxelwise inference tended to be conservative and have a valid false positive rate less than 5%, while the clusterwise inference tended to have high levels of false positive.
The authors also make two other important points. The first is that they corrected statistically for multiple comparisons when doing their analyses. (In other words, if you roll the dice 20 times, you are likely to get a 5% result once, so you have to adjust the statistical thresholds to account for the fact that you rolled 20 times.) However, in their review of published papers 40% do not correct for multiple comparisons. This means, in those 40% of papers, false positive rates are likely to be even higher.
They also complain that many researchers did not store their raw data in a way that would allow for a reanalysis of the data. We only have the results of the statistical analysis, but cannot run the analysis again with better methods or thresholds.
They also note that a specific software bug was discovered:
Second, a 15-year-old bug was found in 3dClustSim while testing the three software packages (the bug was fixed by the AFNI group as of May 2015, during preparation of this manuscript). The bug essentially reduced the size of the image searched for clusters, underestimating the severity of the multiplicity correction and overestimating significance (i.e., 3dClustSim FWE P values were too low).
What’s the fix?
This type of research is critical to the practice of science – it’s what makes science self-corrective. It also has to do directly with a concept that is critical to science but underappreciated, especially in the general public, that of validity.
Any test or measurement has to be validated, which usually means that the test is used with known data to see that it produces the results it should, that those results are meaningful, and that they are precise and reliable. Until a test has been validated, you don’t know what the results actually mean. They are like the personality tests given is Cosmopolitan Magazine; for entertainment purposes only.
What the authors of the current study are essentially saying is that the statistical software used to tease a signal out of the massive amount of noise generated by fMRI scans have not been properly validated. Prior validation studies were inadequate. Their studies are a better validation paradigm, and they show significant problems with the software that cause at least these three popular packages to generate high percentages of false positives.
The authors conclude:
It is not feasible to redo 40,000 fMRI studies, and lamentable archiving and data-sharing practices mean most could not be reanalyzed either. Considering that it is now possible to evaluate common statistical methods using real fMRI data, the fMRI community should, in our opinion, focus on validation of existing methods.
In other words, we have to dust ourselves off and just move forward. Let’s fix the statistical problems and make sure that fMRI studies going forward are more valid.
I have already had a skeptical eye toward fMRI research given all the crazy results that have been published (the dead salmon study aside). Now I am even more skeptical. Some of the research is clearly very rigorous and high quality, but much of it had many red flags for false positive results (sloppy methods, lack of replication, implausible results).
Hopefully this research and similar validation research will tighten up the field of fMRI research. It is an incredibly powerful tool, but it is tricky to use.

Carotid Artery Stenosis: Surgery, Stent, or Nonsurgical Stroke Prevention?
Harriet Hall on March 29, 2016
Link


The carotid artery in the neck is a common site of atherosclerosis. As plaque builds up, it leaves less room for blood flow and can cause strokes through clotting or embolization. Carotid stenosis is defined as a greater than 70% narrowing of the lumen (the space through which the blood flows in an artery). It can cause symptoms, including transient ischemic attacks (TIAs) and minor strokes; but it is frequently asymptomatic. It can be treated with carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAAS). There has been much discussion about which procedure is better and when it is better not to do either.
What are the risks?
Symptomatic carotid artery stenosis (with TIAs or minor strokes) requires prompt evaluation and triage. After a TIA, the risk of stroke is increased. There is a scoring system using age, blood pressure, clinical features, duration of symptoms, and diabetes. Patients with the lowest score have a 1.2% risk of stroke within 7 days, and those with the highest score have a risk of 11.7%. There is compelling evidence that endarterectomy benefits symptomatic patients. It reduces the risk of a major stroke in the next two years by 80%. Overall, the number needed to treat (NNT) is eight operations to prevent one stroke.
Asymptomatic carotid artery stenosis of 75% or less carries a stroke risk of 1.3% annually. When stenosis is more than 75%, the combined rate for TIA and stroke is 10.5% per year, but some of those strokes are cerebral hemorrhages or lacunar infarcts that would not be expected to benefit from endarterectomy. Early studies found that surgery significantly lowered the risk of stroke, but better subsequent studies found little or no benefit. By one estimate, the number needed to treat to prevent one stroke over 5 years is around 40. Because of the relatively low risk of surgery-preventable strokes, experts have generally called for surgery to be restricted to cases where the peri-operative risk is less than 3%, where the stenosis is greater than 80%, and where the surgeon is experienced.
Surgical risks cover a wide risk of complications ranging from infection to death. Risks are greater in symptomatic patients and in facilities where fewer procedures are done.
Acceptable guidelines for operative risks have been developed: risk of stroke or death of 3% for asymptomatic patients, 5% for patients with TIA, 7% for patients with stroke, and 10% for patients with recurrent stenosis. But these guidelines are being questioned. They were based on studies with selected patients and experienced surgeons, and medical treatment has improved since those studies were done. The annual rate of stroke in asymptomatic carotid stenosis may now be less than 1% with medical treatment. In the real-world setting today, the relative benefit of surgical vs. medical treatment is smaller than the studies indicated, and the risks of surgery seem less reasonable.
What are the treatment options?
There are basically three options: lifestyle modification, medications, and procedures.
Lifestyle modification includes anything that will reduce the risk of a stroke and reduce the progression of arteriosclerosis, including smoking cessation, exercise, and diet. Of course, these preventive measures are advisable for everyone, not just for patients with carotid stenosis.
Medications include antiplatelet medications like aspirin and clopidogrel (Plavix), drugs to reduce blood pressure, and statins, which not only reduce cholesterol levels but also reduce inflammation, reduce the formation of clots, and help stabilize plaques.
Procedures include invasive open surgery and less invasive stent placement.
In carotid endarterectomy (CEA) an incision is made in the neck; the artery is exposed, opened, and plaque is removed.
In carotid angioplasty and stenting (CAAS) an incision is made in the groin. A catheter is threaded into the femoral artery and guided up through the aorta and into the carotid artery, where a balloon is inflated to break up plaque and a wire-mesh stent is left in place to maintain the enlarged space for blood flow.
CEA equivalent to CAAS
Two studies reported in the March 17, 2016 issue of The New England Journal of Medicine by Rosenfield et al. and Brott et al. compared stents to endarterectomy and found no significant differences in long-term outcomes.
Beyond deciding the merits of surgery vs. stenting, the bigger question is whether asymptomatic patients will benefit from either procedure. The accompanying editorial points out that “More than 90% of carotid-artery interventions are performed in asymptomatic patients, even though evidence suggests that up to 90% of them will undergo an ultimately unnecessary and potentially harmful procedure.” In the US, 90%; in Germany and Italy, 60% of surgeries are done on asymptomatic patients; in Canada and Australia, 15%; and in Denmark, 0%. Why such a discrepancy? Doctors in all those countries have access to the same evidence from scientific studies, but apparently they have different opinions about the levels of risk and benefit that justify performing invasive procedures. I can only speculate about other possible reasons such as financial considerations.
What about screening?
The US Preventive Services Task Force (USPSTF) recommends against screening asymptomatic people in the general population for carotid stenosis because screening is likely to do more harm than good. A detailed explanation of their reasoning and the evidence they relied on can be found here.
They point out that “no externally validated risk stratification tools can reliably distinguish between persons who have clinically important carotid artery stenosis and those who do not or those who will experience harm after treatment with CEA or CAAS.” They conclude:
The USPSTF found no evidence that screening for carotid artery stenosis leads to additional treatment and benefit beyond standard preventive treatments based on traditional cardiovascular risk factors. In patients and surgeons similar to those in the RCTs, treatment with CEA for asymptomatic carotid artery stenosis can result in a net absolute reduction in stroke rates, but this benefit has only been shown in selected patients with selected surgeons and must be weighed against a small increase in nonfatal myocardial infarctions. The net benefit of CEA largely depends on patients surviving the perioperative period without complications and living for at least 5 years. The magnitude of these benefits would be smaller in asymptomatic persons in the general population than among patients in RCTs.
For the general primary care population, the magnitude of benefit is small to none. Adequate evidence indicates that both the testing strategy for carotid artery stenosis and treatment with CEA or CAAS can cause serious harms. In selected centers similar to those in the trials, CEA is associated with a 30-day stroke or mortality rate of approximately 2.4%; reported rates are as high as approximately 5% in low-volume centers and 6% in certain states. Myocardial infarctions are reported in 0.8% to 2.2% of patients after CEA. The 30-day stroke or mortality rate after CAAS is approximately 3.1% to 3.8%. The overall magnitude of harms is small to moderate depending on patient population, surgeon, center volume, and geographic location.
Conclusion: Current practice for carotid artery stenosis – more harm than good
Scientific studies have provided us with considerable evidence about carotid artery screening and treatment; but for whatever reason, the evidence has often been disregarded. Carotid endarterectomy and angioplasty/stenting are being done on too many asymptomatic patients in the US. And asymptomatic people in the general population are getting carotid ultrasound screening (often from direct-to-consumer businesses like Lifeline) despite the evidence that it does more harm than good.
I agree with the authors of the NEJM editorial:
Outside clinical trials, endarterectomy and stenting should be reserved for patients with symptomatic severe stenosis or for asymptomatic patients who are shown to be at higher risk for stroke with medical therapy than with intervention. Such patients (approximately 10 to 15% of patients with asymptomatic stenosis of 70 to 99%) may be identified by an algorithm that incorporates information about microemboli detected by means of transcranial Doppler, and in the future by imaging strategies that identify the vulnerable plaque.

Bad Reporting about Uploading Memories
Steven Novella on March 2, 2016
Link

The Mirror declares, ‘Scientists develop Matrix-style technique of ‘feeding’ information directly into your brain.’ Discovery News went with, “Novices ‘Download’ Pilots’ Brainwaves, Learn To Fly.” Most other outlets spoke of ‘uploading’ information to the brain, and learning in seconds.
The one thing I was certain of from reading these headlines is that this was not what was happening. Brain-machine interface technology is progressing rapidly, but we are a long way away from downloading information from or uploading information to the human brain.
The news outlets reported that electrical activity was recorded from pilots and then used to stimulate the subject. They also reported that this enhanced learning by 33%.
What actually happened
Here is the actual study: “Transcranial Direct Current Stimulation Modulates Neuronal Activity and Learning in Pilot Training.”
There were 31 subjects in the study, divided into four groups. One group had transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC), while a second had sham stimulation of this area. Sham stimulation creates the sensation of being stimulated but does not reach the brain. A third group had tDCS to the primary motor cortex (M1) and a fourth group had sham stimulation of M1.
Stimulation of DLPFC has been associated with increasing working memory in prior studies. While this finding is still somewhat controversial, the studies so far are promising. The introduction to the new study gives a thorough review of this research if you want to delve into the details.
Stimulation of M1 is meant to enhance acquiring motor skills, although this finding is less well established with prior research. The 31 subjects were trained on a flight simulator and their performance tracked. The question for the study was whether or not either type of stimulation would aid in learning of this new and fairly complex task.
Here is the main result for DLPFC stimulation:
Neither the initial nor the final behavioral performance were significantly different between DLPFC stimulation and sham groups (Supplementary Table S1). The average trial duration to reach 2-/3-back was not significantly different between stimulation and sham groups. In addition, the average number of trials to reach 2-/3- back and the average 2-/3- back streak durations were not statistically different between groups. Significant differences in online, offline, and combined learning rates were not observed between stimulation and sham groups (see Supplementary Table S1, Figure 4E).
What they did observe is that the variance for the stimulation groups was 33% less than the sham group. So there was less variability in performance, even though overall average performance was no different.
The results for the M1 group were the same – no statistically significant difference in overall learning, and this time no difference in variance either.
The researchers also took many measures of brain activity looking for differences in the stimulation and sham groups, and there were some difference, but these do not directly relate to actual learning.
Journalism failure #1: Turning a negative into a positive
Overall this was a negative study. Stimulation of either brain region did not improve learning in the subjects. The only effect was to reduce the variability in learning in the DLPFC stimulation but not M1 stimulation.
Given the small size of this study and the number of variables they observed it is not a surprise that there would be a few statistically significant outcomes. These could easily be chance outcomes, and should not be considered reliable until they are replicated in larger studies.
More interesting than the outcome of the study itself is how absolutely wrong the mainstream reporting was. There was never any ‘downloading’ or in fact any kind of recording made from pilots. There are no pilots in this study. Further, the brain stimulation was standard, not based at all on activity recorded from pilots.
Finally – the study was essentially negative. There was no improvement in learning in the stimulation group compared to the sham group. The 33% ‘improvement’ reported was not an improvement, but just a decrease in variability.
Journalism failure #2: Stopping at the press release
This is one of the most complete journalistic fails reporting a science news item I have seen in a while. However, in this case it is the press release from HRL Laboratories that is largely to blame (not to suggest that the journalists are off the hook). The press release reports:
Dr. Matthew Phillips and his team of investigators from HRL’s Information & System Sciences Laboratory used transcranial direct current stimulation (tDCS) in order to improve learning and skill retention. ‘We measured the brain activity patterns of six commercial and military pilots, and then transmitted these patterns into novice subjects as they learned to pilot an airplane in a realistic flight simulator,’ he says.
I found that nowhere in the paper itself. It seems that the quote is taken out of context, but it’s hard to imagine the context since it seems to have no relationship to this study.
The press release also states:
The study, published in the February 2016 issue of the journal Frontiers in Human Neuroscience, found that subjects who received brain stimulation via electrode-embedded head caps improved their piloting abilities.
This is true – but then so did the controls. They did not improve their skills more than the controls. Elsewhere the release says that stimulation ‘modulates’ learning (not ‘improves’). It modulated learning only in the decrease in variance. However, then the press release states it outright:
While previous research has demonstrated that tDCS can both help patients more quickly recover from a stroke and boost a healthy person’s creativity, HRL’s study is one of the first to show that tDCS is effective in accelerating practical learning.
But learning was not accelerated.
Conclusion: A press release is not a study
Using tDCS to alter brain function is an interesting area of research. This type of treatment may eventually play a role in recovery from stroke or other brain injury, but it is still too early to tell.
The current study is small, with 31 subjects spread across four groups, and the researchers looked at many variables. This is clearly a preliminary study (one might say a ‘pilot’ study, but not in the way the news reporting indicated), which is useful for guiding further research but lacking the power and specificity to draw any firm conclusions.
What the reporting of this study shows is the massive problem that exists in reporting science news items to the public. The press release and the reporting that flowed from that press release seem to have almost no correlation with the findings of the study itself.

Brain Stimulation for the Masses
Steven Novella on July 10, 2013
Link
In the last decade or so there has been increasing research into non-invasive brain stimulation techniques for a variety of conditions. These include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS), and transcranial magnetic stimulation (TMS). These techniques alter the excitability of neurons in the brain, seem to have an effect on plasticity (the ability to form new connections), and can modulate the activity of brain networks.
Overall the current research is preliminary but encouraging. Many of the details of exactly how to apply this new technology, however, are still being worked out. One recent review summarizes this complexity:
tDCS can be used to manipulate brain excitability via membrane polarisation: cathodal stimulation hyperpolarises, while anodal stimulation depolarises the resting membrane potential, whereby the induced after-effects depend on polarity, duration and intensity of the stimulation. A variety of other parameters influence tDCS effects; co-application of neuropharmacologically active drugs may most impressively prolong or even reverse stimulation effects. Transcranial alternating stimulation (tACS) and random noise stimulation (tRNS) are used to interfere with ongoing neuronal oscillations and also finally produce neuroplastic effects if applied with appropriate parameters.
In other words – exactly where the electrodes are placed on the scalp, how strong the stimulation is, how long it is applied, and the details of the pattern of electrical activity all potentially affect the net effect on brain function. Anodal tDCS stimulated neuronal firing, while cathodal tDCS inhibits function. Further, there are differences in terms of who is receiving the treatment (someone who is neurologically healthy vs. someone who recently had a stroke), and what other treatments are being given concurrently – such as physical therapy and pharmacotherapy.
Overall this does not seem like the kind of treatment that should be given over-the-counter. That is exactly what is happening, however.
For example, a product called foc.us is being sold with the following claims:
foc.us is a tDCS headset for gamersOverclock your head!Overclock your brain using transcranial Direct Current Stimulation (tDCS) to increase the plasticity of your brain. Make your synapses fire faster.Faster Processor, Faster Graphics, Faster Brain!
They also address the question of whether or not the device is regulated:
No. The foc.us gamer headset offers no medical benefits, is not a medical device, and is not regulated by the FDA.
The FDA does regulate medical devices, including some cranial electrotherapy stimulation (CES) devices. But, according to the FDA, “There is no regulation for therapeutic tDCS,” which it does not consider a CES device because it is too different.
It is very problematic to claim that a device that is explicitly medical in nature is “not a medical device” simply because the claims currently being made for it are performance enhancement, rather than treating a disease or condition. This strategy does not work for drugs. I doubt the FDA would buy the argument that amphetamine is not “medical” if used for performance enhancement.
It seems to me that foc.us is exploiting the current holes in FDA regulations, which have not yet dealt with devices such as tDCS.
Regardless of regulation, I would argue that tDCS technology is not ready for the general consumer.
Effects of tDCS are promising, but largely preliminary. There are studies looking at the treatment of depression, rehabilitation from stroke, and pain relief. Results seem most encouraging for stroke recovery, less so for depression, and are leaning negative for pain relief (but again, this does not necessarily apply to all forms of brain stimulation). In all cases results should be considered preliminary.
In terms of cognitive performance, studies are again preliminary with mixed results, some showing little or no benefit.
All of the studies do tend to agree, however, that tDCS is safe. Potential side effects include local itching or tingling, headache, a burning sensation, and discomfort. However, better reporting of adverse events to more thoroughly evaluate potential side effects is also being recommended.
Conclusion
tDCS is an interesting and potentially very useful treatment designed to alter brain activity, with potential applications to depression, motor function, cognitive function, and pain. Its application is complex, however, and researchers are still working out the effects of numerous parameters.
In my opinion, tDCS is not ready for the over-the-counter market, nor the DIY community. Our knowledge base is simply not detailed enough. Further, even if we did have detailed knowledge of optimal placement, frequency, intensity, duration, etc. it would be difficult for the average user to get all these details correct. Even if these parameters could be fully automated, there is still the issue of the individual medical history of each user and how that might impact the safety and usefulness of tDCS. Meanwhile, regulations lag behind the technology and may never be aggressive.
While generally safe (although more safety data is needed), we still do not have enough information about the net effects of using this technology in various conditions for a long period of time.
It is likely that for the foreseeable future consumers will have to protect themselves from companies selling tDCS devices with unsubstantiated claims. At present I recommend caution.

EMDR Is Still Dubious
Steven Novella on October 23, 2024
Link
A recent meta-analysis of eye movement desensitization and reprocessing (EMDR) therapy concludes that the evidence “confirms” EMDR is effective in treating depression. It is a great example of the limitations of meta-analysis, and how easy it is to create essentially a false narrative using poor quality research.
EMDR was “developed” by Dr. Francine Shapiro in 1987. It is the notion that bilateral eye movements stimulate the frontal lobes which alters the processing of memory information. This allows subjects to better process traumatic memories to lessen their negative effects. There are two ways to look at the claims of EMDR, the proposed neurological mechanism and the clinical evidence for efficacy. Both are severely lacking.
The neurological explanation for EMDRs putative effects has always been very hand-wavy – a just-so story without hard evidence in neuroscience. Admittedly it is difficult to reverse engineer the neuroanatomical correlates of complex cognitive entities, and there are many clinically accepted conditions we still do not fully understand.
The difference is that EMDR is a treatment based upon and proposed underlying neurological mechanism, and yet there was never any real basis for proposing such a mechanism. It was always essentially wild speculation. Later research aiming to backfill the evidence for an EMDR mechanism amounts to what I call “stuff happens” evidence. Whenever subjects do anything cognitive stuff is happening in the brain, but that does not mean that whatever brain activity is detected is having the specific effects that are claimed for it, in this case changing how subjects process traumatic or painful memories.
The big problem with the alleged mechanism is that it is very gimicky, like a “brain hack” that alters brain function with “one simple trick”. That’s just not how the brain works. Research on mechanism and clinical efficacy also suffer from the same problem – the research lacks sufficient controls.
This gets to the fundamental question we tackle at SBM – how do we know anything in medicine? We are dealing with complex, messy, and variable systems (humans) with lots of subjective outcomes. In order to truly advance our knowledge of how the human machine works, the mechanism of disease and disorder, and the efficacy of treatments, we need to define, isolate, and control variables as much as possible. Otherwise it is very easy to create the illusion of a real effect that is actually nothing more than a cultural story.
We see this with acupuncture, for example. If we operationally define acupuncture according to acupuncture points and manipulation with needle insertion, it becomes exceedingly clear that acupuncture is not a real phenomenon. The points don’t exist in any genuine scientific way, and it does not seem to matter if or how these fictitious points are manipulated. The entire clinical effect of acupuncture can be explained as a subjective placebo response to the ritual surrounding the administration of acupuncture. It is all smoke and mirrors.
EMDR suffers from the exact same problem. Let’s look at this recent meta-analysis to demonstrate. If you go through the individual studies you will see that none of them are compelling evidence for the efficacy of EMDR, and therefore adding a lot of weak studies together does not create a strong study. This is the perfect example of garbage in-garbage out.
For example, studies like this one have no control intervention. The control group was “watchful waiting” – in other words, nothing. This study used a medication treatment control group, so of course of completely unblinded. You could also argue the duration of medication treatment was too short, and a comparison is meaningless without any therapy intervention in the control. In this study the control group was relaxation therapy. At least this is a somewhat reasonable control, although not completely and not blinded. Also in this study both EMDR and relaxation were effective.
What we don’t see in the EMDR research to any significant degree are studies that actually isolate the variable that is the very definition of EMDR itself. What we are given is excuses – how difficult it is to blind such interventions. Helpful trial are entirely doable, however. You could, for example, have one group in which the practitioner goes through the entire process of EMDR (which includes a lot of actual cognitive therapy) but without the eye movements. You could also substitute some other similar physical intervention, such as having the subjects tap their hands, or perhaps do a task on one side of the body only.
If EMDR researchers were doing what scientists should be doing – trying to prove their hypothesis wrong with studies able to do so, by isolating specific components of EMDR – then we could start to build a case for or against EMDR. We could see if eye movements themselves matter, if bilateral movements matter, if movements matter. This, of course, feeds back to the putative mechanism.
Instead what we have are weak clinical trials that are not properly controlled or blinded and do not isolate specific variables. Just as will acupuncture, this opens the door for non-specific therapeutic effects – the ritual surrounding EMDR. With therapy there are also many real therapeutic effects that come from the bond between therapist and client. In fact, that seems to be the variable that matters most.
It’s tempting to say – why does any of this matter as long as people feel better? But it does matter. Without the ability to determine which specific elements of mental illness intervention (or any intervention) has specific efficacy, then we cannot make real progress. We are stuck chasing nonspecific placebo effects.
Further, not only would a lack of specific knowledge about efficacy hamper our ability to understand how the brain works and what is happening to cause mental disorder, but it can lead to the creation of false narratives or the illusion of knowledge (which is far worse than mere ignorance). That is what we have with things like acupuncture and EMDR – a feedback loop of non-specific or placebo effects being falsely interpreted as specific effects feeding into speculations about underlying mechanisms that are unmoored from reality. We get a cultural narrative pretending to be science.
Then, of course, this false cultural narrative becomes institutionalized. Once we have an “Institute of Fake BS” the fake BS is never going away. Rather we end up with research articles and even entire journals which are dedicated to “cargo cult”, “tooth fairy” (pick your metaphor) fake science. They do studies which are meant to show that their preferred treatment works, and never to examine whether or not it works.
EMDR is therefore not likely going away anytime soon, even though it is a house of card built on nothing.

Dynamic Neural Retraining
Steven Novella on February 6, 2013
Link
Snake oil often resides on the apparent cutting edge of medical advance. This is a marketing strategy – exploiting the media hype that often precedes actual scientific advances (even ones that don’t eventually pan out). The slogan of this approach could be, “Turning tomorrow’s possible cures into today’s pseudoscientific snake oil.”
The strategy works because, to the average person, the claims will sound plausible and scientific and will contain familiar scientific buzz words. There is therefore a proliferation of stem cell clinics, anti-oxidant supplements, and personalized genetic medicine.
We can add to the list of cutting edge pseudoscience, neural plasticity and brain training. Neuroscientists are discovering that even the adult brain has greater capacity for plasticity than was previously thought. Plasticity is the capacity of the brain to rewire itself, to acquire new abilities or compensate for damage. Mostly this is simply a technical description of a very common phenomenon – learning. Shoot a basketball 1000 times and (surprising to no one) you (meaning your brain) will get better at shooting baskets. Some of this is physical, such as developing the necessary strength in the involved muscles, but mostly this is the brain learning how to shoot baskets through plasticity.
One legitimate question that neuroscientists are researching is how generalizable (transferable) such training is. In other words, can learning to shoot baskets make you better at some other similar task, like throwing a baseball? Or – can doing one form of mental task make you smarter in general, or give you cognitive skills that apply outside of the task at hand? This question has not been fully resolved. There is mixed evidence, partly because of variable study techniques but also because there are numerous permutations of this question – which tasks transfer to which abilities. There are also different populations – young, adult, older adult and healthy vs cognitively impaired.
A 2012 review of brain training in general stated:
Sparse evidence coupled with lack of scientific rigor, however, leaves claims concerning the impact and duration of such brain training largely unsubstantiated.
I personally don’t like the term “brain training” as it suggests it is something other than simply learning. What we can conclude from the existing evidence is that performing and practicing mental tasks makes you better at those tasks. It is unclear how much they transfer to other skills or to basic mental ability (like memory or concentration) but the mixed evidence suggests significant limits on such transferability. One large study showed no transferability, even to similar tasks. Other studies do show some general memory enhancement in older adults.
Where there appears to be general agreement is the following – computer-based training programs work as well as traditional programs (pen and paper) and do not require computer savvy, video games may have some benefit (although maybe not as much as computer programs optimized for cognitive benefits), novelty seems to be an important feature, and overall being mentally active is good for mental ability. Open questions include the degree and manner in which cognitive skills transfer, and whether “plasticity-based” programs are better than other training programs.
There are now many companies and products exploiting this complexity, and the fact that this is a relatively new area of research with many open questions, to make specific claims for their products that are not justified by the evidence. One of the worst offenders is a product called Dynamic Neural Retraining (which results in an unfortunate acronym). The website for this product has all the red flags of snake oil. There is a page, for example, for testimonials but none for published research supporting their claims.
They also go way beyond the existing research, claiming that certain disorders (some legitimate, some dubious) are caused by limbic system dysfunction, and their program can change the limbic system through neural plasticity. Not a single link in this chain of claims is scientifically substantiated.
They target vulnerable populations, like those who believe they suffer from multiple chemical sensitivity. This is not a recognized disorder, and so people who believe they have this syndrome are likely responding to popular myths, are likely to be misdiagnosed (meaning they likely have a genuine underlying condition that is being neglected, which may be psychological or physical), and are also likely to respond to a placebo intervention (at least for a time).
Such products also benefit from the non-specific effects of the intervention. Just doing something, anything, to address a chronic problem is likely to make someone feel better. In the case of “brain training” interventions, there are real cognitive benefits to the increased mental activity. The problem is the layer of pseudoscience placed on top of this legitimate but limited intervention. The DNR “system” also employs other interventions, some of which are legitimate therapies, like cognitive behavior therapy. This is what I have called the “part of this complete breakfast” approach – give standard and proven therapy and then add the pseudoscience for marketing purposes.
Conclusion
“Brain training” remains a problematic area. Evidence-based recommendations include basic advice, such as – keep mentally active, keep physically active, and engage in novel activities. Video games and widely available brain training games (cheap or free) are likely as effective as expensive programs with expansive claims. Just do a Google search to see how much is available – here is one example (there, I just saved you $300).
Until there is rigorous research demonstrating specific and significant advantages for a particular “brain training” program, I would not believe the hype.

Does Brain Training Work?
Steven Novella on April 17, 2013
Link
Websites such as Luminosity.com make some bold promises about the effectiveness of computer-based brain-training programs. The site claims:
“Harness your brain’s neuroplasticity and train your way to a brighter life”“Your brain’s abilities are unique. That’s why your Personalized Training Program adapts to fit your brain and your life goals.”“Just 10 hours of Lumosity training can create drastic improvements. Track your own amazing progress with our sophisticated tools.”
Wow – in just 10 hours I can become smarter by playing fun video games personalized to my brain. I’m a huge fan of video games, and I would love to justify this hobby by saying that I’m training my brain while I play, but what does the scientific evidence have to say about such claims?
Not surprisingly, the published evidence is complex and mixed.
Before I summarize that evidence, let me describe the variables with which brain-training research must contend. First there are various target populations who likely will not respond in the same way to brain-training interventions. These include: healthy children, healthy young adults, healthy older adults, children with some form of cognitive impairment or developmental delay, adults with traumatic brain injury, older adults with mild cognitive impairment, and older adults with Alzheimer’s disease or other forms of dementia.
Most studies do indeed pick a target population or two on which to focus. Each of these populations need to be considered separately when reviewing the literature.
The second important variable is the brain function that is being evaluated. There is no single measure of brain function or intelligence. Studies typically identify the following distinct functions:
Memory is the ability to encode, store, and recall information. Memory can be further divided into recognition, recall, verbal, visual, episodic, and working memory. Each type of memory has specific tasks associated with that memory function.
Attention is the ability to focus one’s perception on target visual or auditory stimuli and filter out unwanted distractions.
Executive function is ability to strategically plan one’s actions, abstraction, and cognitive flexibility – the ability to change strategy as needed. A classic test for executive function is trail-making, drawing a line from A-1-B-2, etc., which requires quickly switching from numbers to letters and back again.
Reaction time and processing speed are related functions that deal with how quickly someone can react to stimuli and process information, respectively.
Another very important variable in brain-training studies is generalizability – to what extend does training in one specific task increase performance on other tasks, and how far from the trained task does the effect extend? For example, does training in a visual memory task improve verbal memory, and does any memory training improve executive function?
Intervention types generally break down to three categories – classic training tasks, neuropsychological training (which involves multiple tasks at once), and video games.
Finally, studies need to account for the duration of any training effect. If there is an effect, how long does it last after the period of training ends?
The above variables must be considered in addition to all the generic factors that influence the rigor of any clinical study – number of subjects, randomization, effect size, statistical significance, proper blinding, adequate control group, accounting for multiple comparisons, drop-out rate if any, dose-response (in this case, duration and intensity of training) and replicability.
With all of these variables to account for it will take a great deal of research to understand the true effects of computer-based brain training of each type for various outcomes and on various populations. Not surprisingly, existing research is just scratching the surface of addressing all the potential questions regarding brain-training.
A 2012 systematic review by Kueider et. al. identified 151 computerized training studies published between 1984 and 2011 involving healthy older adults. That is not many studies, resulting in only a few studies for each intervention and target population. Of the 151 studies identified, only 38 met the review’s inclusion criteria.
For the full results of this review, I suggest you read the original article, which is available open-access at the link above. It’s not really possible to summarize the full results in less space than the review itself, so there is no reason to duplicate it here. To give an overview, however, in each category there were only a few studies, and most studies were relatively small. My overall impression, therefore, is that much more research needs to be done.
Studies generally found positive effects from brain-training (not surprising for small preliminary studies), but in most cases results were mixed with some positive and some negative studies. Brain-training was generally found to be as effective as traditional book and pencil training, but less labor intensive.
Effects were strongest for the task that was trained, with highly variable outcomes in terms of generalizability. Overall tasks generalized either not at all or only to closely related tasks, but not across the board or to very different tasks. For example, there seemed to be no cross-over effect between visual spacial cognitive function and verbal cognitive function.
In this review classic training tasks had the biggest effect on working memory, processing speed, and executive function. Neuropsychological tasks had the most improvement on memory and visuospacial ability. Video games had a positive impact on reaction time and processing speed.
A more recent 2013 review and meta-analysis of studies involving healthy children and adults concluded:
…that memory training programs appear to produce short-term, specific training effects that do not generalize. Possible limitations of the review (including age differences in the samples and the variety of different clinical conditions included) are noted. However, current findings cast doubt on both the clinical relevance of working memory training programs and their utility as methods of enhancing cognitive functioning in typically developing children and healthy adults.
A 2013 study of brain-training in older adults with mild cognitive impairment or dementia found no statistically significant difference in the treatment and control groups, but a tendency toward better performance in the treatment group, only for the more mildly affected subjects.
Conclusion
Computer-based brain-training is a promising intervention for maintaining and improving cognitive function in healthy and perhaps mildly impaired individuals, primarily because it is convenient, less labor intensive than traditional methods, and cost effective.
Existing research, however, is inadequate to rigorously address all of the variables of brain-training interventions. There do appear to be a few patterns in the existing research, however.
    • Brain-training is effective, whether designed as classic cognitive tasks, combined tasks, or video games.
    • Effects are mostly restricted to the specific tasks being trained and do not significantly generalize to other tasks or cognitive functions. Effects tend to be short lived, although evidence here is very mixed.
    • Computer-based brain-training does not appear to be significantly different in outcome from traditional pencil and paper-based training, but is less labor intensive.
    • I could find no published evidence to support any claims for individualized programs.
In short, brain-training does not seem to make you smarter, but will make you better at whatever task you perform. This can be simply a training effect – you will get better at anything you do repetitively. This is no more an effect of brain plasticity than any generic learning. Suggestions that such brain-training makes your brain function better in any way other than simply learning the task that is being practiced is not evidence-based.
Another way to look at all this is that the very concept of “brain-training” is probably flawed. It is useful as a marketing slogan, but does not seem to be based in reality. “Brain-training” is just a fancy term for good old-fashioned learning, but is meant to invoke an image of cutting edge neuroscience and brain plasticity which is not supported by evidence. It’s just learning.
The bottom-line recommendations I would make from existing data are this:
    • Engaging in various types of cognitively demanding tasks is probably a good thing.
    • Try to engage in novel and various different types of tasks. These do not have to be computer-based.
    • Find games that you genuinely find fun – don’t make it a chore, and don’t overdo it.
    • Don’t spend lots of money on fancy brain-training programs with dramatic claims.
    • Don’t believe the hype.
Finally, there is a clear need for further research. We need many large rigorous studies that control for multiple variables.

Auditory Integration Training
Steven Novella on June 26, 2013
Link
Finding a simple fix for complex problems is highly appealing, which drives a persistent market in simple fixes, whether or not they are actually effective. The growing “brain training” industry is an example of this – the concept being that performing simple tasks, such as playing particular games, can have wide-ranging cognitive benefits. Unfortunately the evidence has not been kind to this notion.
Related to the brain training concept is auditory integration training. One permutation of this, the Tomatis Method, describes it this way:
The sound message is correctly heard but poorly analyzed in an emotional framework. The brain protects itself by constructing barriers that can result in the development of various disorders.You can do the listening sessions repeatedly by using specially designed devices that stimulate the brain and progressively help it more effectively analyze the sensory message.Your ear is not used only for hearing. It also stimulates your brain and establishes your balance. Well-tuned listening is therefore an essential component for promoting personal development.
This is a common approach to marketing such therapies – argue that one factor is a dominant cause of a host of problems, describe the method for addressing that one factor, which then leads to a happy, healthy, fulfilling life. This marketing formula appears well established.
Plausibility becomes progressively lower as the claims extend to disorders and symptoms that are further removed from the alleged cause. Auditory integration training is a plausible treatment for those with certain language disorders – those caused or contributed to by faulty integration of sensory information.
The Tomatis Method lists the following areas of application:Attention DisordersAffective and Emotional DisordersCommunication DisordersPsychomotor DifficultiesPervasive Developmental Disorder (PDD)Personal Development and Well-BeingImprovement of the Voice and of MusicalityPreparation for ChildbirthIntegration of Foreign Languages
Such lists always look as if they were compiled by marketers, not scientists or clinicians. In any case, what is the evidence they offer for the effectiveness of this method? They summarize the results of one study for auditory processing disorders, three for anxiety, and four for learning disabilities and behavioral problems (one was a meta-analysis of five studies with a total of 225 subjects). That’s it, and they did not provide references.
The studies are all small and uncontrolled or not blinded, many are just case series where Tomatis practitioners followed the progress of their clients. In other words – this is very low grade evidence, barely above testimonials, and completely unreliable, especially since many relied upon subjective outcomes.
In anxiety research, for example, there is a known confounding effect where the introduction of any novel method will cause a non-specific placebo effect. This factor needs to be controlled for in a blinded fashion, or else the results will be uninterpretable.
I could not find much in a PubMed search to support auditory integration training or the Tomatis Method specifically. I did find one review of auditory integration for autism spectrum disorder which concluded that:
There is no evidence that auditory integration therapy or other sound therapies are effective as treatments for autism spectrum disorders. As synthesis of existing data has been limited by the disparate outcome measures used between studies, there is not sufficient evidence to prove that this treatment is not effective.
At present there is insufficient evidence to justify using the therapy for ASD.
I did find preliminary evidence for altered auditory processing in those with panic disorder. It is not clear, however, if this contributes to the anxiety or is simply a result of the anxiety, or if both symptoms are a result of an underlying disorder. It is a huge leap to conclude that training auditory processing will affect the anxiety.
This precise kind of logical leap is common, however, with the marketing of dubious therapies. The fallacy is in assuming that addressing what might be a marker or a superficial manifestation of a deeper issue will somehow address or fix the deeper issue.
Conclusion
Auditory integration therapy may be a reasonable hypothesis for certain language disorders, but there is little plausibility for other symptoms, such as anxiety or developmental disorders. What evidence we do have is either too preliminary and flawed to be of use, or is negative.
The marketing of specific brands of auditory integration therapy goes far beyond the evidence and displays many of the features of a dubious therapy. Chief among these is indication creep – an ever-expanding list of conditions it is alleged to treat, to expand the market for a treatment that has yet to be established even for its more plausible indications.
This therapy is also part of a broader trend of “brain training” therapies, the core notion being that training the brain (i.e. learning and practice) in one area can have wide-ranging cognitive benefits. So far the literature seems to support the opposite conclusion, that the benefits from cognitive tasks do not generalize beyond the specific tasks themselves.

Is There a Treatment for Tinnitus
Steven Novella on November 14, 2012
Link
There are several features of a symptom or illness that make it a convenient target for proponents of unconventional therapies. Subjective symptoms are more likely to be targeted than objective conditions – you don’t see many so-called “alternative” birth control treatments. Symptoms for which placebo effects alone are likely to produce the illusion of effectiveness are good targets for ineffective treatments. Symptoms that vary naturally over time also are good targets – patients are likely to seek treatment when their symptoms are maximal, which means spontaneous regression to the mean will provide an effective illusion of efficacy for any intervention. Illnesses with a substantial psychological component (such as those that are worsened by emotional stress or that are emotional, such as anxiety) are likely to benefit from non-specific effects of the therapeutic interaction, rendering the treatment itself irrelevant.
Finally, any condition or symptom for which there is currently no effective treatment provides a market ripe for exploitation.
Tinnitus has many of these features. Tinnitus describes the subjective experience of spontaneous noise perceived in one or both ears, which can be a buzzing, hiss, tone, or ringing sound. The severity of the tinnitus, its loudness, can vary over time, but perhaps more importantly the degree to which the tinnitus is bothersome can vary considerably. The sound is distracting and can have a significant impact on quality of life. Those with tinnitus can ignore the sound at times (depending on its severity), can be distracted from the sound, and may even learn through cognitive therapy to become accustomed to it. Therefore we might expect that tinnitus is amenable to placebo effects.
Finally, there is no proven effective treatment for tinnitus, which means that those who suffer from tinnitus may be desperate for a treatment. Desperation is a commodity highly prized by snake-oil salesmen.
Not surprisingly, there are a few “alternative” treatments that claim to be effective for tinnitus. There are also some experimental but scientifically legitimate treatments. Neuroscientists are still uncertain about the cause – the pathophysiology – of tinnitus. One theory, however, is that it is caused by insufficient tonic inhibition (the nervous system generally functions by inhibiting the firing of neurons at baseline, until they are activated). GABA is the most common inhibitory neurotransmitter in the brain, so it is possible that decreased GABA activity in the auditory system is one component of tinnitus. Drugs that increase GABA activity in the brain, therefore, would be a plausible treatment for tinnitus.
One GABA agonist drug, vigabatrin, has been tested on an animal model of tinnitus and has shown some effectiveness. We do not yet know, however, how predictive or useful the animal model is, and the drug has not been tested in humans. This is, therefore, extremely preliminary information and not an adequate basis for treatment decisions. Another GABA drug, gabapentin, has been tested in humans. A recent review found only two studies worth considering, both of which concluded that gabapentin was no more effective than placebo. The studies were insufficient, however, to definitively rule out an effect.
There is also preliminary evidence that the drug clonazepam may be effective for tinnitus. This drug, however, also has anti-anxiety effects and the study was open-label, so it is too soon to make any definitive conclusions.
That’s about it for science-based pharmacological therapy for tinnitus. There are other treatments, such as tinnitus retraining therapy (TRT) and tinnitus masking (TM). There is one study showing efficacy of TRT compared to TM (not blinded and not placebo-controlled), with significant effects for severe tinnitus and modest effects for mild to moderate tinnitus. TM involves using earphones (essentially hearing aids) that produce a masking noise meant to cancel out the tinnitus. At present these two interventions appear to be the most effective treatments for tinnitus, but their effectiveness is modest.
I have found three “alternative” treatments recommended for tinnitus. The most common is the herb Ginkgo biloba. Ginkgo is more commonly recommended for dementia or memory difficulty, although the best evidence to date shows that it is completely ineffective for this condition. Ginkgo is also offered as a treatment for tinnitus, with the same hand-waving justification as for memory symptoms. Dr. Weil recommends it for tinnitus and claims:
Ginkgo may help by increasing blood circulation in the head and neck. Give it at least a two months trial.
The evidence, however, is not with Weil – the best study to date shows no effect from Ginkgo:
There were no significant differences in primary or secondary outcome measures between the groups. 34 of 360 participants receiving active treatment reported that their tinnitus was less troublesome after 12 weeks of treatment compared with 35 of 360 participants who took placebo.
Conclusions
50 mg Ginkgo biloba extract LI 1370 given 3 times daily for 12 weeks is no more effective than placebo in treating tinnitus.
A Cochrane systematic review concurs that Gingko is ineffective.
Dr. Weil also recommends craniosacral therapy (CST) from a naturopath for tinnitus. This is a completely unscientific therapy. Mark Crislip does an excellent job of explaining why CST is nonsensical and unscientific – it has something to do with the fact that the bones of the skull are fused and cannot be manipulated in the manner claimed by CST. Just to be thorough, I did a PubMed search for craniosacral therapy and tinnitus and came up with zero results. A recent systematic review of CST for any condition concluded:
This review revealed the paucity of CST research in patients with different clinical pathologies. CST assessment is feasible in RCTs and has the potential of providing valuable outcomes to further support clinical decision making. However, due to the current moderate methodological quality of the included studies, further research is needed.
In other words, there is no evidence that CST works for anything. The ubiquitous conclusion that “further research is needed” is an excellent example of the difference between evidence-based medicine and science-based medicine. The SBM conclusion would be quite different – Considering the extreme scientific implausibility of CST, not one penny or scientific resource should be expended further studying this fanciful notion.
There is also a homeopathic treatment for tinnitus that has been widely marketed recently. The product is known as Quietus (not to be confused with the suicide drug from the excellent movie, Children of Men). The Quietus website proclaims:
Quietus® homeopathic tablets are formulated to homeopathically help support the body’s own healing mechanism that cancels out symptoms such as roaring, buzzing & whizzing, and supports healthy functioning in the inner ear… safely & naturally.
The site does not list the homeopathic “ingredients” of this product. It doesn’t matter, of course, because most homeopathic preparations are diluted to the point that there are no active ingredients left. I say “most” because some products may be only slightly diluted and still contain active ingredients, which is worse because then direct toxicity becomes a possibility.
There is no evidence that Quietus or any homeopathic preparation is effective for tinnitus (or for any indication, for that matter). The marketers of Quietus offer only testimonials, which are worse than useless given that they are cherry picked to give a certain impression. The website does contain the usual CAM disclaimer:
**These results not typical. Individual results will vary. These real testimonials do not represent the typical or ordinary experience of users. Each person’s experience with Quietus® is different, which cannot be determined from these testimonials. These statements have not been evaluated by the Food and Drug Administration. Claims are based on traditional homeopathic principles, which are different than modern scientific testing. For more information on homeopathy, please visit http://nccam.nih.gov/health/homeopathy
If any visitor bothers to follow the link to the NCCAM website they will find this statement about homeopathy:
There is little evidence to support homeopathy as an effective treatment for any specific condition.
Several key concepts of homeopathy are inconsistent with fundamental concepts of chemistry and physics.
Conclusion
Tinnitus is a difficult symptom at present with no clearly effective treatment. Scientific research is increasing our understanding of the cause(s) of tinnitus and there are some plausible treatments being researched.
So called “alternative” therapies, however, have nothing to offer. Herbs are simply drugs that are not purified and are difficult to standardize. If an herb contains an active ingredient that might be effective in treating tinnitus (or any condition) it should be identified, purified, and studied. In any case, the herb Ginkgo which is claimed to be effective for tinnitus is ineffective according to the best available evidence.
Craniosacral therapy and homeopathy are both rank pseudosciences that have no plausibility as treatments and for which there is no evidence of efficacy for anything, including tinnitus.
For now we have to accept the fact that there are no proven therapies that are highly effective for tinnitus. The best chance for developing solutions comes from science-based assessments of plausible treatments, and from not wasting time and resources on fanciful nonsense.

Quantum Neurology
Steven Novella on September 18, 2013
Link
As the resident neurologist on SBM, my ears always prick up when I come across a new neurology-based scam, and my colleagues often send such items my way. In addition the word “quantum” has become a standard marketing term of alt. med quackery. So how could I resist taking a bite out of “quantum neurology”?
One might think (if one were a completely naïve rube) that those claiming to practice quantum neurology have, through diligent research, discovered how certain quantum principles apply to nervous system function and disease, leading to new treatment modalities. On the other hand, a more savvy consumer of such health claims (such as regular readers of SBM) would likely suspect that quantum neurology will turn out to be the same-old mix of nonsense and snake oil in a shiny new package.
Let’s have a look.
According to the Hayden Institute, which appears to be a typical vanity institute of one Chase Hayden, DC:
Quantum Neurology focuses on allowing nerves that may be associated with painful or debilitating injuries, illnesses, or conditions to stabilize so that the body can heal itself. This safe non-invasive technique that allows the doctor to evaluate, strengthen, and rehabilitate every major nerve in the body. This is accomplished with a specific series of upper and lower body muscle strength tests designed to evaluate the entire spinal cord, as well as strengthening the nerves with light therapy, and gentle joint mobilization.
We are also informed that:
Nerves control every function in your body, and when they become dysfunctional, a symptom develops. In order to wiggle your toes, walk, identify temperature changes, breathe, have your heart beat, or any other function in your body, a nerve has to send a message.
In other words, quantum neurology is just straight-chiropractic vitalism by a new name. Straight chiropractic, as imagined by D.D. Palmer, is based on the pre-scientific vitalistic notion that life energy flows through the nerves to the entire body and is essential for health. All illness is caused by blockages to the flow of this life energy, and therefore all illness can be treated by restoring this flow. What blocks this flow are subtle (meaning non-existent) subluxations or misalignments of the spine, which some chiropractors still claim they can correct with manipulations, restoring flow, and allowing the body to heal itself.
This is why straight chiropractors believe they can treat things like asthma, a disease of the lungs.
Above we have the absolute claim that “nerves control every function in your body.” This is demonstrably not true. Not all organs and functions are regulated by nervous control. The liver, for example, functions quite nicely on its own. You could make the strained argument that the autonomic nervous system regulates blood flow, and blood flow is critical to all functions of the body, but that still does not mean that the nerves control liver function. One might as well say that the thyroid “controls” every function in the body.
They also claim that in order for the heart to beat a nerve has to send a message – also not true. The heart has its own internal electrical system and beats all on its own. It is regulated partly by autonomic nerves, but it does not need them to beat. Transplanted hearts, for example, have no nerve supply, and work just fine.
The notion that nerves control everything is chiropractic philosophy, not science.
Under their “services” tab they list applied kinesiology – we have discussed this on SBM before as well. Applied kinesiology is more chiropractic magic, nothing more than self-deception and the ideomotor effect. Practitioners claim they can diagnose illness through muscle strength testing, but it only seems to work when the tester knows the results they want to get (just like dowsing). Applied kinesiology is essentially dowsing with muscles.
They also offer “detoxification” and “functional endocrinology.” Two other topics we have already thoroughly exposed as nonsense on SBM.
They don’t exactly claim they can cure specific diseases, but their website proclaims that, “Patients have reported improvements with the following symptoms and conditions.” That’s a nice dodge. They then provide a long list of conditions and serious diseases, such as epilepsy, multiple sclerosis, high blood pressure, skin rashes, and many more.
Another chiropractor offering “quantum neurology” is George Gonzalez, author of the book Holographic Healing. Gonzalez informs us:
We now understand that the Nervous System is inclusive of every aspect of action and communication available to our body. It includes our physical body and our all aspects of our nonphysical body: also known as our energetic body, Bio-Energetic Field, Aura or LightBody. It includes our mind, our thoughts, our emotions and our Spiritual connection.
He offers something called the GRT LITE (trademarked), which is just light therapy. This is pure snake oil without any scientific plausibility or credible evidence that it does anything. It is a virtual magic wand.
On such websites I always look for references to research to support the amazing claims being made for medical innovations. New medical technology does not just come out of nowhere – there has to be a paper trail of research supporting it. Gonzalez says that research is important, and he requires research of his quantum neurology (trademarked) training seminars. What he considers “research,” however, are case studies. Case reports are useful in medicine – but they are not considered “research.”
He presents, for example, a case study of a patient who suffered a brain aneurysm. The case report is so poorly written, if a medical student handed this in I would seriously question their competency. We are not given any specific details. The report was actually painful for me to read. For example, we are told that the patient had an aneurysm, but we are not told its size and location. We are told he had surgery, but not told which procedure, exactly. Nowhere in the write up of the case is it mentioned that the aneurysm hemorrhaged – it’s as if Gonzalez thinks “aneurysm” means bleed, rather than a defect in an artery that can rupture and bleed. He also states that the “baseball sized” aneurysm was removed “from the patient’s skull.” Aneurysms are not in the skull – from the one image provided the aneurysm was clearly intracranial.
It’s almost as if the case study was written by someone without any medical knowledge at all, let alone specialist neurological knowledge.
Gonzalez is apparently impressed that the patient recovered following the aneurysm bleed, the impressiveness supported by the claim that, “The family was told” that he would be neurologically impaired and need a caregiver. Second-hand information through an emotional family is not exactly a credible source of prognostic information.
In fact, most people who suffer such a bleed will improve significantly. The imaging provided shows only a moderate-sized bleed. Once the swelling goes down and the blood is reabsorbed the patient should recover nicely.
Conclusion
Quantum Neurology displays all the features of pseudoscience – its practitioners use jargon to dress up superstitious pre-scientific beliefs, they make claims not supported by plausibility or evidence, they go through the motions of something they can present as science without any of the substance, and they surround themselves with the trappings of legitimacy.
They lack the true substance of science, however. There is no research to support their claims. They cannot explain their claims in terms that are compatible with existing science. They have not conducted research capable of exploring whether or not their core claims are true, let alone their alleged clinical applications.
Their claims are vacuous but they ride on a magic carpet of slick marketing. “Quantum Neurology” and “Holographic Healing” are just that – marketing terms meant to give the false impression of modernity to crusty pre-scientific nonsense.

Brainwashed: Neuroscience and Its Perversions
Harriet Hall on August 20, 2013
Link
Sally Satel and Scott Lilienfeld have written a new book, Brainwashed: The Seductive Appeal of Mindless Neuroscience. Its purpose is not to critique neuroscience, but to expose and protest its mindless oversimplification, interpretive license, and premature application in the legal, commercial, clinical, and philosophical domains.
The brain is a wondrous thing: “…the three pound universe between our ears has more connections than there are stars in the Milky Way.” Trying to understand how it works and how it generates conscious awareness and subjective feelings is a daunting task. Neuroimaging is one of the tools we are using to study it. Unfortunately, people get so enthusiastic about its possibilities that they are constantly tempted to read more into the images than is really there. This has given rise to a new phrenology that interprets our mental characteristics with pretty colored pictures. We are easily impressed by pictures; after all, a picture is worth a thousand words.
Brain imaging can’t show us what is going on in the mind of the person. It shows areas that have increased oxygen consumption. A spot lights up when a person thinks or acts, but that doesn’t tell us much. Single blobs that light up in the brain have been interpreted as centers for things like love, rewards, hate, and belief in God. This is sometimes referred to as “blobology.” They found an area in one person that lit up when he thought about an actress he loved. That area was thought to be a “reward” center. But it also lit up when he thought of Ahmadinejad! So they did some fancy footwork and rationalized that he believed that the Jewish people would endure and therefore he derived pleasure from the idea that Ahmadinejad would fail. That’s pretty far-fetched. Occam’s razor would suggest that maybe the area that lit up was reacting not to pleasure, but to something else. People tend to read what they want to see into ambiguous patterns like a Rorschach test. Mental functions are rarely limited to a single spot in the brain; multiple areas are involved and interconnected. Researchers are increasingly moving away from blobology and towards pattern analysis where they look at the patterns of activation across the entire brain.
Neuroscience is one of the great intellectual achievements of modern science, and it’s sad to see it perverted and hyped in spasms of “premature extrapolation.” The mind is a result of the actions of neurons, but one can’t use the physical rules of the cellular level to predict activity at the psychological level. Neurobiology deals with brains and physical causes; psychology deals with the mind, with thoughts and motives. This might sound superficially like dualism, but it isn’t; the mind is solely the product of a physical brain, but there is an explanatory ladder with many levels, and it can be counterproductive to put too much emphasis on the lower levels. A marriage counselor could try to improve his understanding of a couple’s problems by doing fMRI scans of their brains, but that would only draw attention away from their thoughts, feelings, and interactions with each other at a level where intervention could be helpful.
Neurodeterminism may replace Freudian determinism (unconscious conflicts and drives determine our thoughts and actions) and Skinnerian determinism (rewards and punishments) to become the next grand narrative of human behavior. The authors ask, “Can we ever fully comprehend the psychological by referring to the neural?” Some people (among them Sam Harris and Michael Gazzaniga) think we can, even hoping that knowledge of the brain will solve all our political and ethical problems, and that government bureaucrats might some day be replaced by neurocrats.
There is a tendency to grant brain-based explanations superiority over all other ways of accounting for human behavior. Understanding the biological basis of pleasure has led some addiction experts to fundamentally rethink the moral and legal aspects of addiction. In the legal world, there is a temptation to shift from blame to biology, relieving the criminal of responsibility for his actions.
Whenever you see a headline “Brain Scans Show…” you should be skeptical. Scans don’t reveal causes, only correlations. In teenagers, there is increased activity in regions associated with aggression when they play violent video games. That doesn’t mean video games trigger violence. Maybe aggressive teenagers enjoy those games more. Maybe parental inattentiveness leads to both more video game playing and more aggressive tendencies. Maybe those areas also light up with excitement and competition. Or maybe there’s another explanation altogether.
Functional magnetic resonance imaging (fMRI) measures oxygen consumption as a proxy for increased neuronal activity. It uses a subtraction technique to compare oxygen consumption during a task to baseline consumption. The data are collected as voxels, a volume designation analogous to the pixels of a 2 dimensional display. A computer filters out background noise and generates an image with color gradations to reflect the likelihood that the results of the subtraction process were not due to chance. The pictures we usually see of scans are not of a single person, but a composite averaging the results of everyone in a study. Defining the task is critical: having teenagers look at color pictures of people rather than black and white completely reversed the findings of one experiment. There are other complications. There is a 2-5 second delay between the activation of neurons and the increase in blood flow. The amygdala lights up in situations of fear but it also lights up in situations of anger, happiness, and even sexual arousal. An area may light up because its neurons are stimulating other neurons, or it might light up because it is inhibiting the activity of other neurons. Sometimes the voxel is too large to register tiny clusters of neurons that have a critical function. There is also the practice factor, where brain circuits operate more efficiently and use less oxygen as the person becomes skilled at a task. Additional mischief comes from statistical errors, as in the famous fMRI scan of a dead salmon “thinking.” And researchers may home in on tiny areas of activation and inadvertently concentrate on chance fluctuations in the data, drawing conclusions that will not be replicable. Another problem is when researchers “learn” something from brain imaging that we already knew by other means; this might be called “neuroredundancy.”
Neuromarketing capitalizes on the fact that consumers are seldom consciously aware of the motives behind their own choices. The more brazen promoters of brain scanning to get insights into consumer behavior are pulling off a “brain scam” on the companies that hire them. Clinicians scan the brains of addicts with the good intention of putting addiction on an equal footing with diseases like Alzheimer’s. But they ignore the reality that quitting is the rule rather than the exception. A survey found that 77% of former drug addicts and 86% of former alcoholics reported no substance abuse problems during the year before the survey. Identifying addiction as a brain disease tends to remove personal responsibility and depicts addicts as helpless.
Neuroscience has made us question the very concept of free will: the unconscious processes of the brain register our decisions before we are conscious of deciding. It has raised questions about individual responsibility and about the morality of blaming or punishing people in a deterministic world. But those are moral and philosophical issues that neuroscience itself can’t resolve.
Daniel Amen
Satel and Lilienfeld briefly mention Dr. Daniel Amen and his Amen Clinic empire. He is a prime example of someone who reads far more into brain scans than is warranted. He thinks single photon emission computed tomography (SPECT) scans are essential to diagnose and treat mental illnesses, addiction, ADHD, and other conditions (a claim not accepted by mainstream psychiatrists and psychologists). He charges patients thousands of dollars to inject them with radioactive compounds and show them pretty colored pictures of their brains, without any credible evidence that it adds to the diagnostic or treatment processes. I have written about him here and here.
Here’s an example of his “proof.” Are you impressed?

His latest endeavor is a new book, Unleash the Power of the Female Brain. He reviewed 26,000 SPECT scans of men and women, and concluded that the female brain was more active in 112 of the 128 brain regions he looked at. From the differences in those regions, he concluded that women make better bosses and leaders, are better at memory, empathy, intuition, collaboration, self-control, and “appropriate” worry. Men are only better in 9 areas associated with visual perception, form recognition and object representation; they are better at tracking objects in space. He thinks his findings explain why women have a lower incidence of ADHD, antisocial personality disorder, substance abuse, and incarceration. He offers advice to help women love their brain, overcome mood disorders, optimize brain function, and supercharge it for better health, energy, mood, and sex.
Being a woman, I’d love to believe women are superior to men in so many ways, but I won’t let my wishes interfere with my judgment. I have never found any of Amen’s work credible. He has a great imagination and a lot of enthusiasm, but he’s not much of a scientist.
Conclusion
Neuroimaging is frequently misunderstood and overhyped. Amen’s book belongs in the fantasy and science fiction section of the bookstore. Satel and Lilienfeld’s book belongs in the science-based medicine section. It offers keen insights into what neuroscience can and can’t do, and much food for thought.

Conscious Discipline – More Dubious Neuroscience
Steven Novella on August 21, 2013
Link
I did not coordinate my topic for today with Harriet’s excellent review yesterday of Satel and Lilienfeld’s excellent book; the timing is just fortuitous. Harriet discussed popular abuses of neuroscience, which often amount to an oversimplification and hyperreductionism of a complex area of study. I was recently asked to comment on a claim that I feel falls squarely into this realm – so-called conscious discipline.
From the conscious discipline website:
It surpasses behavioral approaches that teach specific behaviors, and offers a neurodevelopmental model of the brain…
The Conscious Discipline Brain State Model becomes a frame for us to understand the internal brain-body states that are most likely to produce certain behaviors in children and in ourselves. With this awareness, we learn to consciously manage our own thoughts and emotions so we can help children learn to do the same.
They even offer a helpful picture of the brain to illustrate their model (above).
I am a huge advocate of reductionist science – understanding how something works by understanding its component parts and how they work, as deep down as we can go. Hyperreductionism, however, is the misguided notion that higher order interactions can be understood solely on the basis of the function of their component parts.
For example, trying to understand all the complexity of life as a reproductive struggle among genes is a tad hyperreductionist. This form of reductionism also leads to a “hard science bias.” For example – claiming that biology is just applied chemistry and chemistry is just applied physics are ultimately hyperreductionist arguments. There are biological interactions that cannot be understood simply by applying the principles of physics.
The hyperreductionist temptation in neuroscience is to reduce all of the complexity of human thought, mood, and behavior to the biological functioning of the brain. This temptation is partly rooted in our more general desire for simplification and control. We like to break the world down into bite-sized pieced and organize them into a simple scheme we can grasp and work with.
Rather, we need to look at human behavior on a cultural, social, psychological and neuroscientific level simultaneously. Further – neuroscience is very complex, and we are far from having a complete model of how the brain functions. We do know that any simplistic model of one piece of the brain having a single function and lighting up when that function is active is hopelessly inadequate.
Getting back to conscious discipline – here is a good example of how it is trying to impose a simplistic system onto the complexity of human behavior:
Similarly, an emotional state is triggered by the world not going our way. It limits our ability to see from another’s point of view. This unconscious state keeps us on autopilot so our words and tone match those of key authority figures from our childhood. We revert to disciplining the same ways we were disciplined, even if we know these behaviors to be ineffective or hurtful.
The only way to soothe the emotional state is through connection.
“The emotional state,” as if there is one emotional state, or that all emotions have the same basic purpose and effect. Humans, rather, are a complex tapestry of emotions that are a complex mixture of adaptive and maladaptive, depending on degree and context.
Emotions such as empathy, for example, actually help us to see from another’s point of view. Emotions can provide a powerful intuitive insight, especially into social interaction. When people or situations make us feel a certain way, that can be very useful information provided by millions of years of evolution.
There are slivers of truth in this model. It does seem that our brain is basically organized into a primitive “lizard” brain dedicated to basic physiological function, a more advanced mammalian brain involving emotion and instinct, and then the most recently evolved neocortex which contains our executive function. This model is not wrong – it’s just incomplete and oversimplistic.
This approach represents another common neuroscience folly – taking some basic psychological principles and then packaging them into a nicely gift-wrapped system. The system, however, does not add anything new or unique. In other words – the concept of conscious discipline does not seem to add anything to our understanding of neuroscience or human behavior.
The same criticism has been leveled against other popular psychological systems, such as neurolinguistic programming. There does not appear to be anything unique to this system, it’s just cobbling together psychological factors that can deceive or influence behavior.
The conscious discipline website has a section on research. This is typically thin and uninformative. The few studies presented that actually test conscious discipline as an intervention are ultimately useless. They are very small and do not contain proper controls. They simply introduce conscious discipline as an intervention and see that behavior changes. Since they do not compare it to other interventions controlling for observation bias, novelty bias, etc. we have no way of knowing if it is anything specific about conscious discipline that is having the effect, or simply the fact that something – anything – is being introduced and observed.
Conclusion
Ultimately it is not clear what conscious discipline is, other than an oversimplification of some basic neuroscience models of brain function. The evidence for it is virtually non-existent – worthless uncontrolled studies, commentary, or basic psychology that does not specifically support anything that can meaningfully be defined as conscious discipline.
The system is likely to be highly counterproductive, in fact, because it encourages (in fact formalizes) an oversimplification of our understanding of human thought, mood, and behavior. This system exemplifies many of the features of neuro-pseudoscience that Satel and Lilienfeld describe in their new book.

Frontal Lobotomy: Zombies Created by One of Medicine’s Greatest Mistakes
Frontal lobotomies have a dramatic, thankfully rather brief, history in the treatment of mental illness. Janet Sternburg has written an illuminating, and humanizing, book on the history of lobotomies, both personal and societal.
Harriet Hall on September 15, 2015
Link

It’s not clear who first quipped “I’d rather have a bottle in front of me than a frontal lobotomy,” but it’s not just a joke. Almost anything would be preferable to a frontal lobotomy. It was a barbarous procedure with catastrophic consequences, and yet it was once widely accepted and even earned a Portuguese doctor a Nobel Prize. In the annals of medical history, it stands out as one of medicine’s biggest mistakes and an example of how disastrously things can go wrong when a treatment is put into widespread use before it has been adequately tested.
A new book by Janet Sternburg, White Matter: A Memoir of Family and Medicine, puts a human face on the suffering of mentally ill patients and their families, and helps us understand why they agreed to lobotomies. It is the affecting story of how her relatives made the difficult but misinformed decision to lobotomize two of her mother’s five siblings, one for schizophrenia and the other for depression, and the consequences of that decision.
She says “even as a child I had a slight awareness, compounded from fear and pity, that something wrong had been done, that it couldn’t be right for people to be this way, expressionless and indifferent to anything around them.” As an adult, she questioned how good, kind people like her aunts could have done this to their siblings, and how they could have authorized a lobotomy on a second family member after they had seen its effects on the first. She did extensive research, interviewed family members, and tried to understand what had happened. She was shocked when her one surviving aunt denied that Sternburg’s uncle was ever mentally ill, claiming the other sisters had lied about him when they had told the author he had tried to kill people, and that he would have grown out of it if they hadn’t insisted on the surgery. The family was dysfunctional; other members had mental health problems, and there was animosity between the sisters. What had really happened? The truth proved elusive.
As best the author could piece the story together, her uncle Bennie developed schizophrenia as a teenager and became a danger to his family, attacking his sisters with knives and anything else that might serve as a weapon. He was properly diagnosed, but every time he was locked up in an asylum, his mother literally howled in protest at the conditions, rescued him, and took him home…until the next time he tried to kill someone and had to be locked up again. His sisters lived in fear.
At the time, there was no real alternative to locking psychotic patients up; there were no anti-psychotic drugs yet. Mental illness was a stigma that made families try to hide the existence of their mentally ill members and made potential spouses hesitant to marry into a tainted family. There was a eugenics movement with the philosophy that some people didn’t deserve to live. That attitude probably made it more acceptable to experiment on patients.
The origins of frontal lobotomy

In 1935 a Portuguese doctor, Egas Moniz, attended a conference where he learned of an experiment where the frontal lobes of two chimpanzees were removed and they changed from violent and difficult to handle to docile and compliant. It gave him the idea that mental illness in humans might be treated surgically. He devised a leucotome, an instrument for dividing the white matter in the brain, and he experimented on 11 female patients from the Lisbon insane asylum (no informed consent in those days!). He found that they became more docile and seemingly content, just like the chimpanzees. He rushed to publish a paper proclaiming his procedure a success. Several months later, many of his patients relapsed, as did one of the chimpanzees; this follow-up information was not publicized.
An article that re-evaluated Moniz’s research pointed out numerous flaws (for instance, inaccurate description of the technical parameters, lacking angle values and variable depths of insertion).
It said:
If we believe in the summary published by Moniz of the first 20 operations, the results look promising: “35% (seven cases) healed, 35% (seven cases) improved, 30% (six cases) unchanged, no worsening, no cases of death.” [But after many more procedures had been done, a surgical mortality of 5% was reported.] Categorized according to diagnoses, of the group of 5 cases of “Mélancolie anxieuse,” 4 cases resolved and 1 improved. However, of the 7 cases of schizophrenia, only 2 improved and 5 were unchanged. Although undesirable effects arose in almost every intervention, they were only described as temporary. These were, in particular, increased temperature, vomiting, bladder and bowel incontinence, diarrhea, and ocular affections such as ptosis and nystagmus, as well as psychological effects such as apathy, akinesia, lethargy, timing and local disorientation, kleptomania, and abnormal sensations of hunger. Moniz did not admit to having detected a decrease in intelligence and memory performance, whereby it is unclear how he could have come to this conclusion.
Moniz displayed unconscionable haste, presenting his results at a conference only 4 weeks after the first operation and publishing them a few weeks later. And other doctors around the world displayed equally ill-advised haste in adopting the operation based on this very preliminary evidence.
Lobotomies flourish and Moniz wins a Nobel Prize

In 1942, Walter Freeman and a colleague wrote the book Psychosurgery: Intelligence, Emotion and Social Behavior Following Prefrontal Lobotomy for Mental Disorders. Lobotomy became increasingly popular, from 150 operations in 1945 to 2,000 in 1947. In 1949 Egas Moniz was awarded the Nobel Prize in Medicine for his discovery of lobotomy. They called it:
…one of the most important discoveries ever made in psychiatric therapy because through its use a great number of suffering people and total invalids have recovered and have been socially rehabilitated.
Bennie didn’t exactly “recover” or become “socially rehabilitated,” but the validation of lobotomy by the Nobel committee had an impact. After the award, more people were lobotomized in the three following years than in the previous fourteen years. The number of lobotomies jumped to 18,000.
Dr. Walter Freeman acknowledged that “Every patient probably loses something by this operation, some spontaneity, some sparkle, some flavor of the personality.” (An understatement if there ever was one!) But he claimed that the operation’s benefits were greater than the downsides, offering “freedom” to both patient and family. And it reduced costs: instead of the state paying $35,000 a year to keep an insane patient in an asylum, they could lobotomize him for $250 and send him home. Freeman wasn’t a surgeon, so he came up with an operation that didn’t require drilling holes in the skull or even a sterile operating room; it was simpler but even more barbaric. To put it bluntly, he stabbed the patient’s brain with an icepick through the eye socket.
Some of his colleagues were horrified by the icepick method, and they denounced it. So Freeman became his own PR agent, traveling around the country in a van he called the Lobotomobile, assaulting patients with icepicks and spreading the gospel of lobotomy like a sort of modern Johnny Appleseed. He got to the point that he could do a lobotomy in 12 minutes. Instead of anesthesia, he used an electroconvulsive shock box, even though it sometimes resulted in broken bones from convulsions.
He inflated his statistics. He called his surgeries a success if the patient could return to work, but there was a double standard. For men, work was defined as engaging in activity outside the home; for women, it was performing simple household tasks within the home. Of the 241 lobotomies carried out at Stockton State Hospital, 85% were on women.
Bennie’s operation
A psychiatrist named Myerson presented lobotomy to the Sternburg family as a way for them to keep Bennie at home. He explained that it would disconnect the signal from Bennie’s emotional centers that told him someone was dangerous, so he would no longer be violent. After much discussion, they bowed to the authority of the expert and authorized the surgery.
Here is what was done to Bennie: holes were drilled in his skull; the blade of an instrument was inserted through the holes, its handle swung as far and deep as possible.
He was no longer violent, and the family no longer had to fear him; but he didn’t speak a word, he barely moved, and he didn’t react to anything or anyone. He was incapable of taking care of himself and required constant supervision. He had eruptions of inappropriate sexual behavior with family members. He would do odd things in public like whirling on the sidewalk like a dervish in a slow trance. He even had to be reminded not to swallow food whole without chewing. After 15 years he suddenly recovered the ability to speak but then subjected the family to a surrealistic nonstop flood of fragmented thoughts. He had become “a head without the czar inside.”
Dejá vu
Later, one of the sisters, Francie, became severely depressed and even developed auditory hallucinations. She was hospitalized after a suicide attempt, but some time later she was found lying half-conscious on the streetcar tracks. Medication and electric shock treatments had been unavailing. The doctors offered an improved “mini-lobotomy” procedure that they promised would enable her to live alone and care for herself. They told her family that without the surgery she would “weep for the rest of her life.” Seeing it as a last resort, and after much agonized discussion, they agreed to the surgery.
After surgery, she could indeed live alone and care for herself, but she was reduced to a person who would phone her mother with pride to announce that she had made a TV dinner all by herself. She compulsively gulped down any pills she could find and tried to destroy the evidence of what she had done; they couldn’t tell whether she was trying to kill herself or not. She was apathetic and unreactive. Like Bennie, she had been “erased” and turned into a sort of zombie. She had not wanted the operation, but after it was done she never even mentioned it.
Lobotomy is discredited
Bennie died at the age of 59 in a nursing home. He had been twirling in the hallway until an attendant turned him toward the dining room for lunch. At lunch, he tried to swallow a handful of peanuts all at once and choked to death. That same year, Walter Freeman performed a third lobotomy on one of his earliest patients who had relapsed for the second time. He tore a blood vessel in her brain and she hemorrhaged to death. His surgical privileges were taken away.
There was an increasing backlash against lobotomy, with publicity about prominent victims like JFK’s sister Rosemary, described as “just a bit slow, a bit difficult.” She came out of her lobotomy permanently disabled, paralyzed on one side, incontinent, and unable to speak coherently. She required constant care by a private nurse for the rest of her life. Lobotomy began to be perceived as an inappropriate means of social control. The movie One Flew Over the Cuckoo’s Nest became a classic. Lawsuits were filed. Legislation was enacted against it in various states. Even though the USSR was notorious for making bogus psychiatric diagnoses of political dissidents and incarcerating them in insane asylums to control them, it set an example by prohibiting lobotomies in 1950 on moral grounds. Effective antipsychotic drugs were discovered, offering a better way to handle these patients.
Is life without feeling ever acceptable?
Sternburg started her investigation with the assumption that the operation turned everyone into zombies, but she learned otherwise: “[It] sometimes provided genuine relief to people who, to my surprise, were able to be aware of their situations, even to compare them with the past and say how much better they were. One trade-off, though, remained constant: the lobotomized remained indifferent.” She describes Bennie as “a person at the farthest reaches of not being at home in the world, in the midst of a tribe that had damaged him and also kept him safe.”
That raises serious philosophical and ethical questions. Is a life without feeling preferable to one spent in torment? Who is to decide? Can psychotic patients give informed consent? In a modern world concerned about terrorism, “the possibility of dehumanizing people is always with us, at least as great a terror.”
Conclusion: A cautionary tale we hope never to be repeated
Frontal lobotomy was one of the most regrettable chapters in the history of medicine. Sternburg’s book gives us insight into its impact on its victims and on their entire extended families. It tells a cautionary tale that we should know about and remember so that kind of thing will never happen again. Its most important lesson is the one we keep stressing on SBM: before a proposed treatment is put into widespread use it must be submitted to rigorous scientific testing to evaluate it for safety, effectiveness, and unexpected consequences.

Different Strokes for Different Folks: Assessing Risk in Women
Harriet Hall on March 4, 2014
Link
You may have noticed that men and women are different. I hope you have noticed. As the French say, vive la différence! It’s not just that one has dangly bits and the other has bumpy chests. Or that one has to shave a beard and doesn’t like to ask for directions while the other has menstrual periods and likes to discuss feelings. There are differences in physiology and in the incidence of various diseases. For instance, normal lab values for hemoglobin are higher for men than for women, and autism is more prevalent in males while multiple sclerosis is more prevalent in females.
In the past, women have been underrepresented in clinical studies; when the first studies of aspirin for cardiovascular prevention came out, we knew it was effective for men, but we didn’t have enough evidence to recommend it for women. This is changing; researchers today are more aware of the need to include women in their studies. Now the American Heart Association/American Stroke Association (AHA/ASA) has issued the first evidence-based guidelines for reducing the risk of stroke in women.
Previous guidelines were for all adults, without specifying any differences by sex. Interestingly, those guidelines said stroke was more prevalent in men than in women, directly contradicting what the new guidelines for women say. They say the lifetime risk of stroke in women is higher than in men (20% vs. 17%). In 2009, 60% of stroke-related deaths were in women. Women are different: genetic differences in immunity, coagulation, hormonal factors, reproductive factors, and social factors can influence the risk of stroke and impact stroke outcomes. The new guidelines were needed to reflect risk factors that are unique to women.
They identify 6 sex-specific risk factors:
    • pregnancy
    • pre-eclampsia
    • gestational diabetes
    • oral contraceptive use
    • postmenopausal hormone use
    • changes in hormonal status
There are also four risk factors that are stronger or more prevalent in women:
    • migraine with aura
    • atrial fibrillation
    • diabetes
    • high blood pressure
Here are the new recommendations:
    • Women with a history of high blood pressure before pregnancy should be considered for low-dose aspirin and/or calcium supplement therapy to lower preeclampsia risks.
    • Women who have preeclampsia have twice the risk of stroke and a four-fold risk of high blood pressure later in life. Therefore, preeclampsia should be recognized as a risk factor well after pregnancy, and other risk factors such as smoking, high cholesterol, and obesity in these women should be treated early.
    • Pregnant women with moderately high blood pressure (150-159 mmHg/100-109 mmHg) may be considered for blood pressure medication, whereas expectant mothers with severe high blood pressure (160/110 mmHg or above) should be treated.
    • Women should be screened for high blood pressure before taking birth control pills because the combination raises stroke risks.
    • Women who have migraine headaches with aura should stop smoking to avoid higher stroke risks.
    • Women over age 75 should be screened for atrial fibrillation due to its link to higher stroke risk.
Women generally have lower blood pressure levels than men, but that changes with age. Intervention (treatment of hypertension) in women over 55 reduced strokes by 38% and heart attacks by 25%. The benefit of treatment is even greater in younger and black women. There is no evidence for sex differences in response to medications, and treatment recommendations are the same for both sexes; but in practice, there is a difference in the drugs men and women are given, and fewer women achieve good BP control.
In December 2013 a report from The Eighth Joint National Committee published in The Journal of the American Medical Association found that treatment goals for patients over 60 could be changed from 140/90 to 150/90 without changing outcomes. For patients under 60, they found insufficient evidence to support any systolic BP threshold for drug treatment. There was evidence to support a diastolic goal of less than 90 in those over 30. As with the recent cholesterol guidelines, clinicians are encouraged to make treatment decisions for individuals based on their overall risk status rather than treating to reach a specific BP or cholesterol level. They also stress the importance of prevention: “For all persons with hypertension, the potential benefits of a healthy diet, weight control, and regular exercise cannot be overemphasized.”
Mainstream medicine has always preferred prevention to treatment. For those who accuse doctors of just throwing pills at patients, here’s a quotation from the 2002 guidelines:
The continuing message is that adoption of healthy life habits remains the cornerstone of primary prevention, including the avoidance of tobacco (including secondhand smoke), healthy dietary patterns, weight control, and regular, appropriate exercise. An important role of healthcare providers is to support and reinforce these public health recommendations for all patients.
In the male-dominated fields of science and medicine, women have too often been given short shrift. The situation is radically different today from what it was when the women’s lib movement first started to raise our consciousness of gender inequities. As the Virginia Slims slogan said, “You’ve come a long way, baby” but we need to go still further. The new guidelines point out that risk assessment tables for cardiovascular disease are based largely on data from men; better data and new tables are needed to predict risk in women. I hope these new sex-specific guidelines will be the first of many such efforts, not just in cardiovascular disease but in every aspect of medicine.

Premature Claims for Neurotrophic Factors
Steven Novella on November 9, 2011
Link
Scientific medicine is not easy. By this point we have largely picked the low hanging fruit, and continued improvements are mostly incremental and hard won. In order to get the most out of our limited research dollars, and optimize medical practice with the safest and most effective treatments, we need to use all available scientific evidence in the proper way. That is the essence of SBM.
There are those, however, that misuse or abuse the scientific evidence — whether to promote an ideology, out of innocent ignorance, or for nefarious purposes. In order to be truly science-based a medical intervention should be plausible, or at least not implausible, based upon basic science evidence, and it should actually be safe and effective when tested in people. Therefore, medical practices can fail to be scientific for one of two broad reasons: they can be scientifically implausible, or they can lack proper clinical evidence for safety and efficacy (or even have evidence for lack of efficacy). Some modalities (like homeopathy) fail on both counts.
The more pernicious medical claims are those that seem highly plausible, that can be extrapolated from basic science, but simply lack adequate clinical evidence. Stem cell clinics are an example — they can easily dazzle desperate patients with scientific descriptions of how stem cells work, and even cite published basic-science papers showing the potential of this technology. But what they cannot do is provide clinical evidence that the specific intervention they are offering is safe and effective for the specific disease or condition they are treating.
I recently came across another example of this type of failure — the promotion of neurotrophic factors for autism and other neurodevelopmental disorders. One center, the Neurorecovery Center Edelfo, specializes in this claim.
Neurotrophic factors are generally proteins that bind to cells and cause them to grow, proliferate, or just maintain their functionality. Some nervous system cells would die without a steady supply of the needed neurotrophic factors. The discovery of neurotrophic factors and their role in nervous system function was certainly very important to our understanding of neurological diseases. This knowledge has also led to a great deal of speculation about the potential of neurotrophic factors in treating neurological diseases.
After a couple decades of clinical research, however, the reality has not lived up to the promise. As is often the case, highly plausible ideas do not pan out in clinical research. Several neurotrophic factors, for example have been studied in diseases like ALS without any measurable clinical benefit. They are just another reminder that the body is complex, and even when we have a very compelling picture of why a treatment should work, that picture is almost certainly incomplete. We cannot know what the net effect will be of a treatment until we do rigorous clinical trials.
Another way to look at this is that the body has evolved complex mechanisms of self-regulation. It is not easy to push or pull on one piece of this complex system and predict the net effect. There are many reasons why a treatment that we predict should work, doesn’t.
Edelfo is doing what many similar clinics or supplement marketers do — making simplistic extrapolations from the basic science to clinical claims, without supporting those claims with clinical evidence. They cite basic science research to give the false impression they are science-based. For example, they write on their website:
BDNF has shown to have a neurotrophic effect in serotoninergic and dopaminergic neurons, but also in glutamatergic neurons of the hippocampus and the sensory regions like pain, touch and hearing. BDNF also contributes to the maturation of GABAergic neurons, so it can also be useful in bipolar disorders, schizophrenia, ADD, memory, neuronal deficits that affect audition, sensitivity, etc.GDNF has shown a specific effect in dopaminergic neurons and secondly in motor neurons, so it can be very useful in ADD, where a hypo development of the dopaminergic circuit has been shown, although there are other types of ADD that are generated by alterations in other regions like the frontal lobe, basal ganglia, etc. GDNF can also be useful in Parkinson’s, where there is a severe loss of the dopaminergic neurons of the substantia nigra and in motor problems, where experimental studies performed in rodents with motor damage have shown that the GDNF favors the axonal growth of motor neurons and improves the functional recovery.
Edelfo uses a diagnostic method based upon EEG to then design a nutritional supplement for their specific customers. The claims above are an excellent example of the type of pseudoscientific deception I am describing.  There is indeed a great deal of interest in GDNF for Parkinson’s disease. Animals studies have shown promise, but human studies have been negative. The problem is probably due to getting the GDNF to the target tissue.
GDNF is a protein. If you eat a protein it will be broken down into amino acids and used as food — it will not get into the bloodstream unaltered. This is why protein-based drugs typically need to be given intravenously, to bypass the stomach. GDNF has even more difficulty, however, since it also needs to cross the blood brain barrier — a protective barrier around blood vessels in the brain evolved to specifically regulate what gets into the brain. To overcome this issue researchers have used one of two methods — they either use gene therapy to insert GDNF producing genes into brain cells, or they use a continuous infusion of GDNF into the cerebrospinal fluid (CSF).
There are rather extreme methods of introducing a drug to the body, but they are necessary. And even still, researchers speculate that the CSF infusions used in human trials were not sufficient to get GDNF to the cells in the brain that are the target of treatment.
It is with these types of issues that pseudoscientific treatments often fail — bioavailability and pharmacokinetics. Does the substance get into the body, and what happens to it once it does? Basing claims for a nutritional supplement on the activity of BDNF is highly deceptive. It certainly can sound compelling to a non-expert, but the claims utterly fail when closely examined. The same, by the way, can be said for BDNF, which is also a protein.
Edelfo’s use of EEG (electroencephalogram), visual and auditory evoked potentials (VEP, AEP) is also questionable. These modalities are all legitimate methods of research and diagnosis, but they need to be specifically validated for each specific clinical use. They are therefore ripe for exploitation — they can be used inappropriately to give the impression of high-tech diagnostic procedure without the evidence to support the specific application.
The published research in this area is complex and mixed. In autism, for example, studies do show that there is a statistical difference in AEPs between autistic and typical children. This does not mean, however, that the test has specificity or sensitivity in the diagnosis of an individual. This is a common misuse of scientific evidence: using group comparisons and applying them to the individual. A different kind of study is necessary to see what predictive value the test has when applied to an individual. There are therefore many diagnostic modalities that are useful for research, but are not used clinically for this reason.
To further bolster their claims Edelfo does publish a few in-house studies. The quality of these studies is so low, however, that they are useless for anything but marketing. In a study of another neurotrophic factor, FGF2, in autism, the study was published in Defeat Autism Now (DAN), which is a dubious site dedicated to biological treatments for autism and notorious for making pseudoscientific claims. That aside, the study itself is fatally flawed in numerous ways, including using very low subject numbers and not describing any blinding. These types of studies are almost guaranteed to generate false positive results — again, useful for marketing, but not doing good science.
Conclusion
The public needs to be aware of the types of misleading claims that are made by clinics, centers, and marketers of health products that can seem very scientific when they are not. The use of pre-clinical evidence to make clinical claims, the use of research methods for clinical diagnosis, and the use of supplements without any consideration of bioavailability are chief among them. Patients and their families are cautioned to be skeptical of any clinic or center that claims to offer a unique service. Further, any clinical claims being made should be backed by well-designed clinical trials of the specific claims published in respected peer-reviewed journals.
Anything less than this is likely to be selling false hope, not a legitimate treatment.

Irlen Syndrome
Is Irlen syndrome real? Probably not, and likely represents yet another form of zombie alternative medicine, immune to science and evidence and almost impossible to stop.
Steven Novella on August 7, 2013
Link
Those who cannot remember the past are condemned to repeat it. – George Santayana
Science-based medicine is more than a set of methods or certain philosophy of medicine – it is an entire approach to what should be the core questions for any interventionist profession: is it real and does it work?
These are often deceptively difficult questions to answer. Fortunately we have at least a century of experience applying systematic methods to answering these questions within the context of medicine. This is a wealth of history from which to learn, full of cautionary tales and enlightening examples.
However, as Winston Churchill lamented, we tend to forget the lessons of the past leading to, “…the most thoughtless of ages. Every day headlines and short views.”
Part of the mission of science-based medicine (and skepticism in general) is to remember the lessons of the past as they relate to science and pseudoscience, and to constantly remind the public and our colleagues of these lessons.
The history of medicine is littered with ideas that did not pan out, worthless treatments, non-existent diseases, and frequent error. That is unavoidable, and acceptable as long as we constantly strive to correct and minimize those errors.
The primary lesson of the history of medicine is that new ideas need to go through a rigorous process of evaluation before they should be generally accepted and implemented. We are constantly examining and refining those rigorous methods. They include careful evaluation of possible mechanisms and overall scientific plausibility, coupled with clinical evidence designed to eliminate all forms of bias and illusion.
The alternative is to be overwhelmed by bias and illusion, which tends to lead us to false positives – confirmation of our cherished guesses, and even to entire systems of medicine based on fairy tales and imagination.
Many of these medical treatments or systems, after being discarded by science because they failed in rigorous evaluation, continue on as scientific zombies – unkillable, immune to evidence and reason, going through the motions of life without actually being alive.
Irlen syndrome
In my opinion, Irlen syndrome is one such scientific zombie. The idea was created in the early 1980s by Helen Irlen, a therapist. Some people also give credit for co-developing the idea to New Zealander Olive Meares, a teacher. As described on Irlen.com:
The Irlen Method has been used for over 25 years to identify and help people with a type of processing problem called Irlen Syndrome, formerly known as Scotopic Sensitivity Syndrome (SSS). Irlen Syndrome is not an optical problem. It is a problem with the brain’s ability to process visual information. This problem tends to run in families and is not currently identified by other standardized educational or medical tests.
The notion is that the brain in some people with learning disabilities and other related problems has difficulty processing visual information, causing eye strain, mental fatigue, and poor performance on visual tasks, such as reading. This difficulty, however, is worse with certain frequencies of light, and if they can be filtered out with colored lenses the brain would have an easier time processing visual information, relieving symptoms.
It’s a bit of a far-fetched idea, but not a priori impossible. It does sound like the kind of overly simplistic idea a non-neuroscientist would think of. Regardless, sometimes naive guesses turn out to be correct, or at least contain a kernel of truth. We have had 25 years to test this idea scientifically – how has it fared?
Not very well, as you may have guessed. Reading through the literature, by 1990 the scientific community went from skeptical to outright rejection of Irlen syndrome. It never crossed the threshold of proving that it exists as a distinct entity. In medicine this can be tricky, as different diseases and disorders can overlap in their signs and symptoms. It is also easy to mistake many different disorders for one far-reaching disorder (which appears to be the case here).
The question is – is there anything unique to what is alleged to be Irlen syndrome? Does the concept add anything to our understanding of patients and how to treat them? Are there specific findings or tests that predict something about how a patient will respond to a treatment or the natural history of their illness? Without a specific feature, test result, or predictive value, it is likely that the alleged syndrome is an illusion rather than a genuine pathophysiological entity.
A 1990 critique concludes:
Furthermore, in the absence of any evidence that it is a separate and distinct entity, it appears that the scotopic sensitivity syndrome is, in fact, a symptom complex which results primarily from various refractive, binocular, and accommodative disorders. Some of the papers which support Irlen’s hypotheses provide reason to believe that there is a strong placebo effect.
Existing known eye disorders (listed above) explain the findings in patients diagnosed with Irlen syndrome. Further, when treated for these known eye conditions with established therapies, the patients improved and the findings used to diagnose Irlen syndrome resolved.
A 1991 review was not kind to the proponents:
Research on this is reviewed, and is also shown to have procedural irregularities which preclude firm conclusions. Owing to the poor quality of much of this research the claims of the protagonists of these therapies cannot be proved or disproved. A proposed new therapy is normally preceded by a valid theoretical hypothesis; this has been lacking in the present topic.
Another 1990 review focusing on treatments concluded:
Recent experimental evaluations of the lenses do not support the use of the lenses as a useful intervention for children with reading disabilities.
So – the syndrome does not appear to exist, the research is shoddy, and the specific treatments (colored lenses) do not appear to work. In a science-based world Irlen syndrome would have been pronounced dead in the early 1990s. The other possibility is that Irlen syndrome exists but the research was just inadequate, in which case the proper response would have been to do large rigorous trials to settle the question once and for all. We can jump ahead a decade to a 2002 review:
However, very little objective evidence has been provided to support anecdotal reports of improvements in visual performance. Many studies are flawed in that they lack controls for investigator bias, and placebo, learning and fatigue effects. Therefore, the use of tinted lenses in low vision remains controversial and eye care practitioners will have to continue to rely on anecdotal evidence to assist them in their prescribing decisions.
The research largely dries up there, except for some small physiological studies that I find unconvincing. One efficacy trial appears in PubMed after the 2002 review, a 2011 study:
RESULTS:The Irlen diagnostician diagnosed Irlen syndrome in 77% of our poor readers. We found no evidence for any immediate benefit of Irlen colored overlays as measured by the reading-rate test or the global reading measure.CONCLUSIONS:Our data suggest that Irlen colored overlays do not have any demonstrable immediate effect on reading in children with reading difficulties.
Conclusion: Ilren syndrome lacks scientific support
Irlen syndrome is yet another example of a medical diagnosis and treatment that was promoted prior to adequate scientific evidence to establish that it is real, and treatments based upon the diagnosis are effective. A quarter of a century later evidence is still lacking, and what evidence we do have that is reasonably rigorous is negative.
The most parsimonious interpretation is that Irlen syndrome is not real. The label is being applied to a heterogeneous group of patient who have many other conditions. Colored lens therapy does not appear to work.
In my opinion, given that this is the status of Irlen syndrome after 25 years it is unethical to continue to promote and offer this as a treatment. The burden rests heavily on proponents to conduct large rigorous studies if they wish to persist in their claims, and then to abide by the results of those studies.
Otherwise Irlen syndrome (by its various names) will continue to exist as a medical zombie, alongside homeopathy, psychomotor patterning, acupuncture, subluxation theory, and other unkillable nonsense.

Why the Brain is the Most Interesting Organ
I mean it’s not even close.
Jonathan Howard on August 8, 2025
Link
One of the biggest mysteries of medicine is why medical students choose to study anything besides the brain. Here are some of the most fascinating neurological syndromes:
    • Neglect syndrome is due to large right-sided injuries, almost always a stroke. These patients are paralyzed on the left side and blind to the left side of the world. Moreover, they are often unaware of their deficits (anosognosia), and some patients can even be completely unaware the left side of the world even exists. One patient of mine was completely confident in her ability to clap, though she could not move her left side. Even after her right hand met only air in response, she insisted she was able to clap, but simply did not “want to”. You could put her left arm in front of her face and she would insist it belonged to someone else. As her condition improved, she gained intellectual awareness of her inability to move her left side, but described it as a “bother” rather than the tragedy it was (anosodiaphoria). These patients also lack prosody, which refers to the pitch and tone of a sentence. Their speech may sound very robotic, without any feeling.
    • Patients with apraxia lose learned motor skills.  These patients have intact strength, sensation, and coordination, yet they may have trouble with simple tasks such as dressing themselves. They approach everyday items the way I’d approach an airplane’s cockpit. I could physically turn all the knobs, but I wouldn’t know where to begin.
    • Alien limb syndrome is a rare condition, a patient’s limb may take on a life of its own. One woman, with a parietal lobe stroke, said her arm moved a plate across her table for no reason. As I was speaking to her, her hand constantly picked at her blanket without her intending to do this. She felt like her arm didn’t belong to her.
    • Patients with Wernicke’s aphasia can speak in sentences that are grammatically correct, but are utterly devoid of meaning. For example they may say, “He went to the thing there that they were all going to do about it after the thing.” To anyone who doesn’t speak English, they sound completely normal, and patients have no insight into their deficit. They can’t understand anything you say, nor can they understand why you can’t understand them. Since they are unaware of their own deficits, they can become frustrated when no one understands them, and they may try to leave the hospital. They may have limited deficits otherwise, and I’ve seen at least several patients be admitted to a psychiatric ward.
    • Broca’s aphasia is essentially the inverse of Wernicke’s aphasia. These patients can understand language quite well, but have deficits in speech production. These patients are aware of their deficits, and it’s awful to watch their suffering. They are almost always weak on the right-side of their body.
    • Patients alexia without agraphia are unable to read (alexia), but they are able to write (without agraphia). This occurs due to an injury to the occipital (visual) cortex on the left hemisphere, which contains the language areas for most people. Patients can speak and write just fine, however their visual cortex on the left is functionally blind. When they look at a words, only their right brain perceives it. Since this part of the brain has no language, they can’t read what they just wrote. These patients are also blind to the right-half of the world.
    • Patients with injuries to both occipital lobes are blind, but can be unaware of it (Anton’s syndrome). The last patient I met with this was admitted to the trauma service after she fell down a flight of stairs. It took several days before someone noticed she couldn’t see. She didn’t complain about it to anyone and denied it when asked.
    • Patients with masses in their occipital lobes can have interesting hallucinations.  One woman with a tumor of her right occipital lobe reported seeing “fields of checkerboards” and brilliant flashing colors on the left side of her world.  Another man with a similar tumor described seeing all sorts of animals on the left. 
    • Prosopagnosia is a more subtle visual deficit, where patients lose the ability to recognize faces. One woman I met went to lunch with friends and was convinced a stranger sat down when her friend returned from the bathroom. Later, she described calling out to a woman on the street, who she thought was her cousin. These sorts of problems with facial recognition can also be seen in psychiatric disorders, where patients are convinced a loved one is an imposter (Capras delusion) or that a stranger is someone close to them (Fregoli delusion).
    • Patients with simultanagnosia can only view one object in their visual field at a time. If you saw the letter H made up of a bunch of small Ts, you’d be able to see both the big and small letters. These patients will see just a few scattered Ts, but can’t see the overall picture. It is due to lesions of both parietal lobes.
    • I’ve met patients with transient global amnesia. As the name implies, these patients have an episode, less than 24 hours, where they are unable to remember anything. This usually occurs in older people, sometimes during strenuous activities. They may ask you why they are in the ER a dozen times, as they are unable to remember your answer. Patients are usually better by the next day, though they don’t remember what happened the day before. The condition rarely recurs.
    • I’ve met patients with limbic encephalitis, who may also have profound memory deficits, combined with severe psychosis, agitation, and seizures. This condition most often occurs in young women, often with ovarian teratomas. I’ve seen perfectly healthy women develop severe delusions over the course of a few days. These patients can be admitted to psychiatric units before their disease is properly diagnosed. Alternatively, they can be ill enough to need mechanical ventilation in an ICU. If the tumor is removed early enough and patients are given immunotherapy, the eventual outcome can be good.
    • I’ve seen patients with frontal lobe injuries who can walk and talk perfectly fine. They seem mostly normal in formal neurological tests. Yet, they just can’t make good decisions in the real world, navigating the hundreds of small social encounters we all have daily. They can be short-tempered and inappropriate, or inappropriately jocular. They have no boundaries or filters and can get in big trouble. Their deficits may be hard to pinpoint during a conversation, but they can’t function well in the world.
Having said all this, it’s important to remember these patients are not there for our fascination.  Nearly all of them had devastating brain injuries, some of which we are currently powerless to treat.  Multiple branches of neurology, such as stroke, MS, and migraines have had significant advances over the past decade. Yet, significant progress for other conditions remains stubbornly out of reach, and it’s no secret what’s happening to medical research today.

